FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU MacDonald, SM
Patel, SA
Hickey, S
Specht, M
Isakoff, SJ
Gadd, M
Smith, BL
Yeap, BY
Adams, J
DeLaney, TF
Kooy, H
Lu, HM
Taghian, AG
AF MacDonald, Shannon M.
Patel, Sagar A.
Hickey, Shea
Specht, Michelle
Isakoff, Steven J.
Gadd, Michele
Smith, Barbara L.
Yeap, Beow Y.
Adams, Judith
DeLaney, Thomas F.
Kooy, Hanne
Lu, Hsiao-Ming
Taghian, Alphonse G.
TI Proton Therapy for Breast Cancer After Mastectomy: Early Outcomes of a
Prospective Clinical Trial
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID RADIATION-THERAPY; RANDOMIZED-TRIAL; RADIOTHERAPY; HEART; MORTALITY;
RISK; CHEMOTHERAPY; PNEUMONITIS
AB Purpose: Dosimetric planning studies have described potential benefits for the use of proton radiation therapy (RT) for locally advanced breast cancer. We report acute toxicities and feasibility of proton delivery for 12 women treated with postmastectomy proton radiation with or without reconstruction.
Methods and Materials: Twelve patients were enrolled in an institutional review board-approved prospective clinical trial. The patients were assessed for skin toxicity, fatigue, and radiation pneumonitis during treatment and at 4 and 8 weeks after thecompletion of therapy. All patients consented to have photographs taken for documentation of skin toxicity.
Results: Eleven of 12 patients had left-sided breast cancer. One patient was treated for right-sided breast cancer with bilateral implants. Five women had permanent implants at the time of RT, and 7 did not have immediate reconstruction. All patients completed proton RT to a dose of 50.4 Gy (relative biological effectiveness [RBE]) to the chest wall and 45 to 50.4 Gy (RBE) to the regional lymphatics. No photon or electron component was used. The maximum skin toxicity during radiation was grade 2, according to the Common Terminology Criteria for Adverse Events (CTCAE). The maximum CTCAE fatigue was grade 3. There have been no cases of RT pneumonitis to date.
Conclusions: Proton RT for postmastectomy RT is feasible and well tolerated. This treatment may be warranted for selected patients with unfavorable cardiac anatomy, immediate reconstruction, or both that otherwise limits optimal RT delivery using standard methods. (C) 2013 Elsevier Inc.
C1 [MacDonald, Shannon M.; Patel, Sagar A.; Hickey, Shea; Adams, Judith; DeLaney, Thomas F.; Kooy, Hanne; Lu, Hsiao-Ming; Taghian, Alphonse G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Specht, Michelle; Gadd, Michele; Smith, Barbara L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg Oncol, Boston, MA USA.
[Isakoff, Steven J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol & Oncol, Boston, MA USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP MacDonald, SM (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Yawkey 117,54 Fruit St, Boston, MA 02114 USA.
EM smacdonald@partners.org
FU Massachusetts General Hospital [C06 CA059267]; Proton Therapy Research
and Treatment Center
FX Supported by the federal share of program income earned by Massachusetts
General Hospital on C06 CA059267, Proton Therapy Research and Treatment
Center.
NR 20
TC 33
Z9 34
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 1
PY 2013
VL 86
IS 3
BP 484
EP 490
DI 10.1016/j.ijrobp.2013.01.038
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 152AE
UT WOS:000319500700020
PM 23523326
ER
PT J
AU Hamstra, DA
Conlon, ASC
Daignault, S
Dunn, RL
Sandler, HM
Hembroff, AL
Zietman, AL
Kaplan, I
Ciezki, J
Kuban, DA
Wei, JT
Sanda, MG
Michalski, JM
AF Hamstra, Daniel A.
Conlon, Anna S. C.
Daignault, Stephanie
Dunn, Rodney L.
Sandler, Howard M.
Hembroff, A. Larry
Zietman, Anthony L.
Kaplan, Irving
Ciezki, Jay
Kuban, Deborah A.
Wei, John T.
Sanda, Martin G.
Michalski, Jeff M.
CA PROSTQA Consortium Study Grp
TI Multi-institutional Prospective Evaluation of Bowel Quality of Life
After Prostate External Beam Radiation Therapy Identifies Patient and
Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA
Experience
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID LATE RECTAL TOXICITY; RANDOMIZED-TRIAL; CONFORMAL RADIOTHERAPY; RADICAL
PROSTATECTOMY; CANCER SURVIVORS; DOSE-RESPONSE; BRACHYTHERAPY; MEN
AB Purpose: To evaluate patients treated with external beam radiation therapy as part of the multicenter Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment (PROST-QA), to identify factors associated with posttreatment patient-reported bowel health-related quality of life (HRQOL).
Methods and Materials: Pretreatment characteristics and treatment details among 292 men were evaluated using a general linear mixed model for their association with measured HRQOL by the Expanded Prostate Cancer Index Composite instrument through 2 years after enrollment.
Results: Bowel HRQOL had a median score of 100 (interquartile range 91.7-100) pretreatment and 95.8 (interquartile range 83.3-100) at 2 years, representing new moderate/big problems in 11% for urgency, 7% for frequency, 4% for bloody stools, and 8% for an overall bowel problems. Baseline bowel score was the strongest predictor for all 2-year endpoints. In multivariable models, a volume of rectum >= 25% treated to 70 Gy (V70) yielded a clinically significant 9.3-point lower bowel score (95% confidence interval [CI] 16.8-1.7, P = .015) and predicted increased risks for moderate to big fecal incontinence (P = .0008). No other radiation therapy treatment-related variables influenced moderate to big changes in rectal HRQOL. However, on multivariate analyses V70 >= 25% was associated with increases in small, moderate, or big problems with the following: incontinence (3.9-fold; 95% CI 1.1-13.4, P = .03), rectal bleeding (3.6-fold; 95% CI 1.3-10.2, P = .018), and bowel urgency (2.9-fold; 95% CI 1.1-7.6, P = .026). Aspirin use correlated with a clinically significant 4.7-point lower bowel summary score (95% CI 9.0-0.4, P = .03) and an increase in small, moderate, or big problems with bloody stools (2.8-fold; 95% CI 1.2-6.4, P = .018). Intensity modulated radiation therapy was associated with higher radiation therapy doses to the prostate and lower doses to the rectum but did not independently correlate with bowel HRQOL.
Conclusion: After contemporary dose-escalated external beam radiation therapy up to 11% of patients have newly identified moderate/big problems with bowel HRQOL 2 years after treatment. Bowel HRQOL is related to baseline function, rectal V70, and aspirin use. Finally, our findings validate the commonly utilized cut-point of rectal V70 >= 25% as having significant impact on patient-reported outcomes. (C) 2013 Elsevier Inc.
C1 [Hamstra, Daniel A.] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 40185 USA.
[Conlon, Anna S. C.; Daignault, Stephanie] Univ Michigan, Dept Biostat, Ctr Comprehens Canc, Ann Arbor, MI 40185 USA.
[Dunn, Rodney L.; Wei, John T.] Univ Michigan, Med Ctr, Dept Urol, Ann Arbor, MI 40185 USA.
[Sandler, Howard M.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Los Angeles, CA 90048 USA.
[Hembroff, A. Larry] Michigan State Univ, Off Survey Res, E Lansing, MI 48824 USA.
[Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Kaplan, Irving] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Ciezki, Jay] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
[Kuban, Deborah A.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Sanda, Martin G.] Emory Univ, Med Ctr, Dept Urol, Atlanta, GA 30322 USA.
[Michalski, Jeff M.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA.
RP Hamstra, DA (reprint author), Univ Michigan, Med Ctr, Dept Radiat Oncol, 1500 Med Ctr Dr, Ann Arbor, MI 40185 USA.
EM dhamm@med.umich.edu
RI Sanda, Martin/B-2023-2015; Wei, John/E-8967-2012
FU National Institutes of Health [R01 CA 95662, CA083654, 1RC1CA146596];
Sanofi Aventis
FX Funding was provided by National Institutes of Health grants R01 CA
95662, CA083654, and 1RC1CA146596.; M.G.S. reports grant funding from
the National Institutes of Health and payment from Sanofi Aventis for
speaking engagements. H.M.S. reports working as a consultant for
Astellas, Bayer, and Millennium Pharmaceuticals.
NR 23
TC 17
Z9 17
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD JUL 1
PY 2013
VL 86
IS 3
BP 546
EP 553
DI 10.1016/j.ijrobp.2013.01.036
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 152AE
UT WOS:000319500700030
PM 23561651
ER
PT J
AU Brauns, S
Gollub, RL
Walton, E
Hass, J
Smolka, MN
White, T
Wassink, TH
Calhoun, VD
Ehrlich, S
AF Brauns, Stefan
Gollub, Randy L.
Walton, Esther
Hass, Johanna
Smolka, Michael N.
White, Tonya
Wassink, Thomas H.
Calhoun, Vince D.
Ehrlich, Stefan
TI Genetic variation in GAD1 is associated with cortical thickness in the
parahippocampal gyrus
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Cortical thickness; Single nucleotide polymorphism; GAD1; COMT Val/Met
polymorphism; Schizophrenia
ID CATECHOL-O-METHYLTRANSFERASE; ANTERIOR CINGULATE CORTEX; HUMAN
CEREBRAL-CORTEX; CHILDHOOD-ONSET SCHIZOPHRENIA; GLUTAMIC-ACID
DECARBOXYLASE; 1ST EPISODE SCHIZOPHRENIA; TASK-INDUCED DEACTIVATION;
SURFACE-BASED ANALYSIS; DEFAULT MODE NETWORK; GRAY-MATTER
AB Patients with schizophrenia show widespread cortical thickness reductions throughout the brain. Likewise, reduced expression of the gamma-Aminobutyric acid (GABA) synthesizing enzyme glutamic acid decarboxylase (GAD1) and a single nucleotide polymorphism (SNP) rs3749034 in the corresponding gene have been associated with schizophrenia. We tested whether this SNP is associated with reduced cortical thickness, an intermediate phenotype for schizophrenia. Because of the well known interactions between the GABAergic and dopaminergic systems, we examined whether associations between GAD1 rs3749034 and cortical thickness are modulated by the catechol-O-methyltransferase (COMT) Val158Met genotype. Structural MRI and genotype data was obtained from 94 healthy subjects enrolled in the Mind Clinical Imaging Consortium study to examine the relations between GAD1 genotype and cortical thickness. Our data show a robust reduction of cortical thickness in the left parahippocampal gyrus (PUG) in G allele hornozygotes of GAD1 rs3749034. When we stratified our analyses according to the COMT Val158Met genotype, cortical thickness reductions of G allele homozygotes were only found in the presence of the Val allele. Genetic risk variants of schizophrenia in the GABAergic system might interact with the dopaminergic system and impact brain structure and functioning. Our findings point to the importance of the GABAergic system in the pathogenesis of schizophrenia. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Brauns, Stefan; Walton, Esther; Hass, Johanna; Ehrlich, Stefan] Tech Univ Dresden, Dept Child & Adolescent Psychiat, Dresden, Germany.
[Brauns, Stefan; Gollub, Randy L.; Walton, Esther; Ehrlich, Stefan] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Brauns, Stefan] Charite, Dept Psychiat, D-13353 Berlin, Germany.
[Gollub, Randy L.; Ehrlich, Stefan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Smolka, Michael N.] Tech Univ Dresden, Dept Psychiat, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany.
[White, Tonya] Erasmus MC Sophia, Dept Child Psychiat, Rotterdam, Netherlands.
[Wassink, Thomas H.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[Calhoun, Vince D.] Mind Res Network, Albuquerque, NM USA.
[Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
RP Ehrlich, S (reprint author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, Translat Dev Neurosci Sect, Fetscherstr 74, D-01307 Dresden, Germany.
EM transden.lab@uniklinikum-dresden.de
RI Calhoun, Vince/H-7146-2013; Smolka, Michael/B-4865-2011;
OI Calhoun, Vince/0000-0001-9058-0747; Smolka, Michael/0000-0001-5398-5569;
Ehrlich, Stefan/0000-0003-2132-4445; Walton, Esther/0000-0002-0935-2200;
Gollub, Randy L./0000-0002-9434-4044
FU NIH/NCRR [P41RR14075]; Department of Energy [DE-FG02-99ER62764]; MIND
Research Network [Morphometry BIRN 1U24, RR021382A, Function BIRN
U24RR021992-01, NIH.NCRR MO1 RR025758-01]; Department of Energy for the
Mental Illness and Neuroscience Discovery (MIND) Research Network
[DE-FG02-99ER62764]; Deutsche Forschungsgemeinschaft; NARSAD; Biomedical
Science Exchange Program; Deutscher Akademischer Austausch Dienst;
Friedrich-Ebert-Stiftung
FX This research was supported by grants from NIH/NCRR P41RR14075,
Department of Energy DE-FG02-99ER62764, MIND Research Network,
Morphometry BIRN 1U24, RR021382A, Function BIRN U24RR021992-01, NIH.NCRR
MO1 RR025758-01, the Department of Energy for the Mental Illness and
Neuroscience Discovery (MIND) Research Network [DE-FG02-99ER62764], the
Deutsche Forschungsgemeinschaft and the NARSAD Young Investigator Award
(Research Fellowship and Grant to S Ehrlich), the Biomedical Science
Exchange Program (scholarship to S Brauns), the Deutscher Akademischer
Austausch Dienst and the Friedrich-Ebert-Stiftung (scholarships to E
Walton). These sources had no further role in the study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication.
NR 101
TC 4
Z9 4
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUL
PY 2013
VL 47
IS 7
BP 872
EP 879
DI 10.1016/j.jpsychires.2013.03.010
PG 8
WC Psychiatry
SC Psychiatry
GA 152RR
UT WOS:000319549300004
PM 23566421
ER
PT J
AU Malone, JC
Cohen, S
Liu, SR
Vaillant, GE
Waldinger, RJ
AF Malone, Johanna C.
Cohen, Shiri
Liu, Sabrina R.
Vaillant, George E.
Waldinger, Robert J.
TI Adaptive midlife defense mechanisms and late-life health
SO PERSONALITY AND INDIVIDUAL DIFFERENCES
LA English
DT Article
DE Personality; Defense mechanisms; Defense maturity; Coping; Social
support; Physical health
ID MALE PSYCHOLOGICAL HEALTH; SOCIAL SUPPORT; EGO MECHANISMS;
NATURAL-HISTORY; PHYSICAL HEALTH; COPING STYLES; OLDER-ADULTS;
PERSONALITY; PSYCHOPATHOLOGY; MORTALITY
AB A growing body of research suggests that personality characteristics relate to physical health; however, this relationship has primarily been tested in cross-sectional studies that have not followed the participants into old age. The present study utilizes data from a 70-year longitudinal study to prospectively examine the relationship between the adaptive defense mechanisms in midlife and objectively assessed physical health in late life. In addition to examining the direct effect, we test whether social support mediates this relationship. The sample consisted of 90 men who were followed for over seven decades beginning in late adolescence. Health ratings from medical records were made at three time points (ages 70, 75, and 80). Defense mechanisms were coded from narratives by trained independent raters (Vaillant, Bond, & Vaillant, 1986). Independent raters assessed social supports between ages 50 and 70. More adaptive defenses in midlife were associated with better physical health at all three time points in late life. These relationships were partially mediated by social support. Findings are consistent with the theory that defense maturity is important for building social relationships, which in turn contribute to better late-life physical health. Psychological interventions aimed at improving these domains may be beneficial for physical health. (C) 2013 Elsevier Ltd. All rights reserved.
C1 Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Malone, JC (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,701, Boston, MA 02114 USA.
EM johanna.malone@gmail.com
FU NIA NIH HHS [R01 AG034554]
NR 41
TC 9
Z9 9
U1 3
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0191-8869
J9 PERS INDIV DIFFER
JI Pers. Individ. Differ.
PD JUL
PY 2013
VL 55
IS 2
BP 85
EP 89
DI 10.1016/j.paid.2013.01.025
PG 5
WC Psychology, Social
SC Psychology
GA 146LF
UT WOS:000319091900001
PM 24031102
ER
PT J
AU Vandenberg, LN
Colborn, T
Hayes, TB
Heindel, JJ
Jacobs, DR
Lee, DH
Myers, JP
Shioda, T
Soto, AM
vom Saal, FS
Welshons, WV
Zoeller, RT
AF Vandenberg, Laura N.
Colborn, Theo
Hayes, Tyrone B.
Heindel, Jerrold J.
Jacobs, David R., Jr.
Lee, Duk-Hee
Myers, John Peterson
Shioda, Toshi
Soto, Ana M.
vom Saal, Frederick S.
Welshons, Wade V.
Zoeller, R. Thomas
TI Regulatory decisions on endocrine disrupting chemicals should be based
on the principles of endocrinology
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Review
DE Weight of evidence; Organizational; Adaptive effect; Hormesis; Human
exposure; Epidemiology; Flare
ID ORGANIZATIONAL-ACTIVATIONAL HYPOTHESIS; PRENATAL PHTHALATE EXPOSURE;
NUCLEAR RECEPTOR SUPERFAMILY; NONMONOTONIC DOSE-RESPONSES; GOOD
LABORATORY PRACTICES; BISPHENOL-A EXPOSURE; OF-EVIDENCE ANALYSIS;
BREAST-CANCER CELLS; ANOGENITAL DISTANCE; RISK-ASSESSMENT
AB For years, scientists from various disciplines have studied the effects of endocrine disrupting chemicals (EDCs) on the health and wellbeing of humans and wildlife. Some studies have specifically focused on the effects of low doses, i.e. those in the range that are thought to be safe for humans and/or animals. Others have focused on the existence of non-monotonic dose response curves. These concepts challenge the way that chemical risk assessment is performed for EDCs. Continued discussions have clarified exactly what controversies and challenges remain. We address several of these issues, including why the study and regulation of EDCs should incorporate endocrine principles; what level of consensus there is for low dose effects; challenges to our understanding of non-monotonicity; and whether EDCs have been demonstrated to produce adverse effects. This discussion should result in a better understanding of these issues, and allow for additional dialog on their impact on risk assessment. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Vandenberg, Laura N.] Tufts Univ, Ctr Regenerat & Dev Biol, Medford, MA 02155 USA.
[Vandenberg, Laura N.] Tufts Univ, Dept Biol, Medford, MA 02155 USA.
[Colborn, Theo] Endocrine Disrupt Exchange, Paonia, CO USA.
[Hayes, Tyrone B.] Univ Calif Berkeley, Museum Vertebrate Zool, Energy & Resources Grp, Grp Endocrinol,Lab Integrat Studies Amphibian Bio, Berkeley, CA 94720 USA.
[Hayes, Tyrone B.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.
[Heindel, Jerrold J.] NIEHS, Div Extramural Res & Training, NIH DHHS, Res Triangle Pk, NC 27709 USA.
[Jacobs, David R., Jr.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN USA.
[Lee, Duk-Hee] Kyungpook Natl Univ, Sch Med, Dept Prevent Med, Taegu, South Korea.
[Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc Res, Mol Profiling Lab, Charlestown, MA USA.
[Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat & Cell Biol, Medford, MA 02155 USA.
[vom Saal, Frederick S.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.
[Welshons, Wade V.] Univ Missouri, Dept Biomed Sci, Columbia, MO USA.
[Zoeller, R. Thomas] Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.
RP Vandenberg, LN (reprint author), Tufts Univ, Ctr Regenerat & Dev Biol, 200 Boston Ave,Suite 4600, Medford, MA 02155 USA.
EM laura.vandenberg@tufts.edu
FU NIH [GM 087107, ES 08314, ES 010026, ES 018764, HL 53560, UMC
MO-VMFC0018]; Susan G. Komen for Cure grant [FAS0703860]; Mitchell Kapor
Foundation; Cornell-Douglas Foundation; Wallace Global Fund; Kendeda
Foundation
FX The authors gratefully acknowledge the following funding sources: NIH
grants GM 087107 (to LNV), ES 08314 (to AMS), ES 010026 (to RTZ), ES
018764 (to FSvS), HL 53560 (to DRJ), UMC MO-VMFC0018 (to WVW), a Susan
G. Komen for Cure grant FAS0703860 (to TS), grants from the Mitchell
Kapor Foundation, the Cornell-Douglas Foundation, and the Wallace Global
Fund (to TBH) and a grant from the Kendeda Foundation (to JPM). The
funders had no role in the preparation of this manuscript.
NR 216
TC 54
Z9 58
U1 10
U2 108
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD JUL
PY 2013
VL 38
BP 1
EP 15
DI 10.1016/j.reprotox.2013.02.002
PG 15
WC Reproductive Biology; Toxicology
SC Reproductive Biology; Toxicology
GA 152MG
UT WOS:000319535200001
PM 23411111
ER
PT J
AU Antebi, B
Cheng, XG
Harris, JN
Gower, LB
Chen, XD
Ling, J
AF Antebi, Ben
Cheng, Xingguo
Harris, Jeffrey N.
Gower, Laurie B.
Chen, Xiao-Dong
Ling, Jian
TI Biomimetic Collagen-Hydroxyapatite Composite Fabricated via a Novel
Perfusion-Flow Mineralization Technique
SO TISSUE ENGINEERING PART C-METHODS
LA English
DT Article
ID APATITE FORMATION; IN-VITRO; BONE; SCAFFOLDS; BIOMINERALIZATION; MATRIX;
REGENERATION; MECHANISM; REPAIR; CELLS
AB Prevalent three-dimensional scaffolds for bone tissue engineering are mineralized collagen-hydroxyapatite (Col/HA) composites. Conventional mineralization techniques are either to coat collagen scaffold surfaces with minerals or to simply mix collagen and mineral nanoparticles together. These conventional in vitro collagen mineralization methods are different from the in vivo bone formation process and often result in scaffolds that are not suitable for bone tissue engineering. In this study, a unique perfusion-flow (i.e., dynamic) in conjunction with a previously described polymer-induced liquid-precursor (PILP) method was used to fabricate a porous Col/HA composite. The dynamic flow emulated the physiological extracellular fluid flow containing the mineralization ions, while the PILP method facilitated the deposition of the HA crystals within the collagen fibrils (i.e., intrafibrillar mineralization). By utilizing a dynamic PILP technique to mimic the in vivo bone formation process, the resultant Col/HA composite has a similar structure and compositions like human trabecular bone. A comparison of the dynamic and static mineralization methods revealed that the novel dynamic technique facilitates more efficient and homogenous mineral deposition throughout the Col/HA composite. The dynamic intrafibrillar mineralization method generated stiff Col/HA composites with excellent surface property for cell attachment and growth. The human mesenchymal stem cells cultured on the Col/HA composites quickly remodeled the scaffolds and resulted in constructs with an extensive cell-derived extracellular matrix network.
C1 [Antebi, Ben; Cheng, Xingguo; Harris, Jeffrey N.; Ling, Jian] SW Res Inst, Dept Microencapsulat & Nanomat, San Antonio, TX 78238 USA.
[Antebi, Ben; Ling, Jian] Univ Texas Hlth Sci Ctr San Antonio, Univ Texas San Antonio, Biomed Engn Program, San Antonio, TX 78229 USA.
[Gower, Laurie B.] Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
[Chen, Xiao-Dong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA.
[Chen, Xiao-Dong] South Texas Vet Hlth Care Syst, Audie L Murphy Div Hosp, San Antonio, TX USA.
RP Ling, J (reprint author), SW Res Inst, Dept Microencapsulat & Nanomat, 6220 Culebra Rd, San Antonio, TX 78238 USA.
EM jling@swri.org
RI Gower, Laurie/A-5947-2008
OI Gower, Laurie/0000-0003-2927-5406
FU National Heart, Lung, and Blood Institute [1R21 HL102775-01]
FX This work was supported by the National Heart, Lung, and Blood
Institute: 1R21 HL102775-01.
NR 38
TC 21
Z9 22
U1 8
U2 66
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3384
J9 TISSUE ENG PART C-ME
JI Tissue Eng. Part C-Methods
PD JUL
PY 2013
VL 19
IS 7
BP 487
EP 496
DI 10.1089/ten.tec.2012.0452
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 150PY
UT WOS:000319404500001
PM 23157544
ER
PT J
AU Unawane, AV
Patel, K
Bhullar, JS
Subhas, G
Mittal, VK
Cheung, LY
AF Unawane, Amruta V.
Patel, Kashyap
Bhullar, Jasneet S.
Subhas, Gokulakkrishna
Mittal, Vijay K.
Cheung, Laurence Y.
TI Success of Reminder Systems in Reducing Catheter-associated Urinary
Tract Infections
SO AMERICAN SURGEON
LA English
DT Article; Proceedings Paper
CT Annual Scientific Meeting and Postgraduate Course Program of the
Southeastern-Surgical-Congress
CY FEB 09-12, 2013
CL Jacksonville, FL
SP SE Surg Congress
C1 [Unawane, Amruta V.; Patel, Kashyap; Bhullar, Jasneet S.; Subhas, Gokulakkrishna; Mittal, Vijay K.; Cheung, Laurence Y.] Providence Hosp & Med Ctr, Dept Gen Surg, Southfield, MI USA.
RP Unawane, AV (reprint author), Massachusetts Gen Hosp, Dept Gen Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA.
EM amu0385@gmail.com
NR 4
TC 1
Z9 1
U1 0
U2 2
PU SOUTHEASTERN SURGICAL CONGRESS
PI CUMMING
PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA
SN 0003-1348
EI 1555-9823
J9 AM SURGEON
JI Am. Surg.
PD JUL
PY 2013
VL 79
IS 7
BP 745
EP 746
PG 2
WC Surgery
SC Surgery
GA AI6ED
UT WOS:000336962600023
PM 23816012
ER
PT J
AU Dranoff, G
AF Dranoff, Glenn
TI A Message from the Founding Editor-in-Chief
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Editorial Material
C1 [Dranoff, Glenn] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dranoff, Glenn] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA USA.
RP Dranoff, G (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD JUL
PY 2013
VL 1
IS 1
BP 2
EP 4
DI 10.1158/2326-6066.CIR-13-0017
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA AM7FC
UT WOS:000340029100001
PM 24777243
ER
PT J
AU Hacohen, N
Fritsch, EF
Carter, TA
Lander, ES
Wu, CJ
AF Hacohen, Nir
Fritsch, Edward F.
Carter, Todd A.
Lander, Eric S.
Wu, Catherine J.
TI Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID TUMOR-SPECIFIC ANTIGENS; CYTOLYTIC T-LYMPHOCYTES; SOMATIC POINT
MUTATION; LUNG-CARCINOMA; HUMAN-MELANOMA; COLORECTAL-CANCER;
HIGH-FREQUENCY; CELL EPITOPES; VACCINATION; PEPTIDES
AB Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells. (C)2013 AACR.
C1 [Hacohen, Nir; Fritsch, Edward F.; Carter, Todd A.; Lander, Eric S.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Fritsch, Edward F.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA.
[Wu, Catherine J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Wu, CJ (reprint author), Harvard Inst Med, Dana Farber Canc Inst, Rm 420,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM cwu@partners.org
FU Blavatnik Family Foundation; NIH [NHLBI:5 R01 HL103532-03,
NCI:1R01CA155010-02]
FX We acknowledge the generous support of the Blavatnik Family Foundation
and the NIH (NHLBI:5 R01 HL103532-03; NCI:1R01CA155010-02) for our work
on neoepitope-based vaccines.
NR 38
TC 41
Z9 41
U1 1
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD JUL
PY 2013
VL 1
IS 1
BP 11
EP 15
DI 10.1158/2326-6066.CIR-13-0022
PG 5
WC Oncology; Immunology
SC Oncology; Immunology
GA AM7FC
UT WOS:000340029100003
PM 24777245
ER
PT J
AU De Raedt, T
Beert, E
Pasmant, E
Bradner, JE
Wolkenstein, P
Legius, E
Cichowski, K
AF De Raedt, Thomas
Beert, Eline
Pasmant, Eric
Bradner, James E.
Wolkenstein, Pierre
Legius, Eric
Cichowski, Karen
TI SUZ12: A novel tumor suppressor and potential biomarker for efficacy of
BRD4 inhibition
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [De Raedt, Thomas; Cichowski, Karen] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Beert, Eline; Legius, Eric] Katholieke Univ Leuven, Leuven, Belgium.
[Pasmant, Eric] Univ Paris 05, Paris, France.
[Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wolkenstein, Pierre] Univ Paris Est Creteil, Creteil, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2013
VL 73
SU 13
MA PR15
DI 10.1158/1538-7445.CEC13-PR15
PG 1
WC Oncology
SC Oncology
GA V40RU
UT WOS:000209496500109
ER
PT J
AU Clemons, JL
Weinstein, M
Guess, MK
Alperin, M
Moalli, P
Gregory, WT
Lukacz, ES
Sung, VW
Chen, BH
Bradley, CS
AF Clemons, Jeffrey L.
Weinstein, Milena
Guess, Marsha K.
Alperin, Marianna
Moalli, Pamela
Gregory, William Thomas
Lukacz, Emily S.
Sung, Vivian W.
Chen, Bertha H.
Bradley, Catherine S.
CA AUGS Res Committ
TI Impact of the 2011 FDA Transvaginal Mesh Safety Update on AUGS Members'
Use of Synthetic Mesh and Biologic Grafts in Pelvic Reconstructive
Surgery
SO FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY
LA English
DT Article
DE mesh; pelvic organ prolapse; surgery; sling
AB Objective: To describe the frequency of use and recent change in use of synthetic mesh and biologic grafts in pelvic organ prolapse (POP) and stress urinary incontinence surgery by American Urogynecology Society (AUGS) members.
Methods: An electronic survey of AUGS members was conducted between December 2011 and January 2012. Frequency of graft use in POP (overall and by transvaginal and transabdominal approaches) and stress urinary incontinence surgery was queried relative to the timing of the 2011 Food and Drug Administration (FDA) safety update. Rates of materials' use before and after the statement were compared using Wilcoxon signed rank test.
Results: Fifty-three percent (507/962) of AUGS members responded and were included in analysis; 79% were urogynecologists. Before the FDA warning, in POP surgery, most (90%) used synthetic mesh and fewer (34%) used biologic grafts; 99% used synthetic mesh slings. After the FDA statement, respondents reported an overall decrease in the percent of POP cases in which they used synthetic mesh (P < 0.001) but no change in biologic graft use for POP (P = 0.37) or synthetic mesh sling use (P = 0.10). Specifically, transvaginal mesh use decreased: 40% reported decreased use and 12% stopped use. However, transvaginal mesh was still used by 61% of respondents in at least some cases. No change (62%) or increased use (12%) of mesh was reported for transabdominal POP procedures.
Conclusions: Synthetic mesh use in transvaginal POP surgery decreased after the 2011 FDA safety update, but synthetic mesh use for transabdominal POP repair and sling procedures and overall biologic graft use in POP surgery did not decrease.
C1 [Clemons, Jeffrey L.] MultiCare Hlth Syst, Tacoma, WA USA.
[Weinstein, Milena] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Guess, Marsha K.] Yale Univ, New Haven, CT USA.
[Alperin, Marianna] Univ Calif San Diego, San Diego, CA 92103 USA.
[Moalli, Pamela] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA.
[Gregory, William Thomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Lukacz, Emily S.] UC San Diego Hlth Syst, San Diego, CA USA.
[Sung, Vivian W.] Brown Univ, Women & Infants Hosp, Brown Med Sch, Providence, RI USA.
[Chen, Bertha H.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Bradley, Catherine S.] Iowa City VA Hlth Care Syst, Iowa City, IA USA.
[Bradley, Catherine S.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
RP Clemons, JL (reprint author), 1901 S Union Ave,Suite B-2006, Tacoma, WA 98405 USA.
EM drclemons@yahoo.com
NR 10
TC 20
Z9 21
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2151-8378
J9 FEMALE PELVIC MED RE
JI Female Pelvic Med. Reconstr. Surg.
PD JUL-AUG
PY 2013
VL 19
IS 4
BP 191
EP 198
DI 10.1097/SPV.0b013e31829099c1
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA V35XR
UT WOS:000209179000002
PM 23797515
ER
PT J
AU Greenhawt, M
Weiss, C
Conte, ML
Doucet, M
Engler, A
Camargo, CA
AF Greenhawt, Matthew
Weiss, Christopher
Conte, Marisa L.
Doucet, Marlie
Engler, Amy
Camargo, Carlos A., Jr.
TI Racial and Ethnic Disparity in Food Allergy in the United States: A
Systematic Review
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Review
DE Food allergy; Food sensitization; 95% Predictive Decision Points; Serum
IgE; Race; Ethnicity; Children; Prevalence; Anaphylaxis; Disparity;
Epinephrine; Black; African American
AB BACKGROUND: The prevalence of food allergy is rising among US children. Little is known about racial/ethnic disparities in food allergy.
OBJECTIVE: We performed a systematic literature review to understand racial/ethnic disparities in food allergy in the United States.
METHODS: We searched PubMed/MEDLINE, Embase, and Scopus for original data about racial/ethnic disparities in the diagnosis, prevalence, treatment, or clinical course of food allergy or sensitization, with a particular focus on black (African American) race. Articles were analyzed by study methodology, racial/ethnic composition, food allergy definition, outcomes, summary statistic used, and covariate adjustment.
RESULTS: Twenty of 645 identified articles met inclusion criteria. The studies used multiple differing criteria to define food allergy, including self-report, sensitization assessed by serum food-specific IgE to selected foods without corroborating history, discharge codes, clinic chart review, and event-reporting databases. None used oral food challenge. In 12 studies, black persons (primarily children) had significantly increased adjusted odds of food sensitization or significantly higher proportion or odds of food allergy by self-report, discharge codes, or clinic-based chart review than white children. Major differences in study methodology and reporting precluded calculation of a pooled estimate of effect.
CONCLUSION: Sparse and methodologically limited data exist about racial/ethnic disparity in food allergy in the United States. Available data lack a common definition for food allergy and use indirect measures of allergy, not food challenge. Although data suggest an increased risk of food sensitization, self-reported allergy, or clinic-based diagnosis of food allergy among black children, no definitive racial/ethnic disparity could be found among currently available studies. (C) 2013 American Academy of Allergy, Asthma & Immunology
C1 [Greenhawt, Matthew] Univ Michigan, Sch Med, Dept Internal Med, Div Allergy & Clin Immunol, Ann Arbor, MI USA.
[Greenhawt, Matthew] Univ Michigan Hlth Syst, Ann Arbor, MI 48106 USA.
[Weiss, Christopher] Global Food Protect Inst, Battle Creek, MI USA.
[Conte, Marisa L.] Univ Michigan, Taubman Hlth Sci Lib, Ann Arbor, MI 48109 USA.
[Doucet, Marlie] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ Fellow, Div Adolescent, Atlanta, GA USA.
[Doucet, Marlie] Ctr Dis Control & Prevent, Sch Hlth, Atlanta, GA USA.
[Engler, Amy] Stanford Univ, Dept Human Biol, Palo Alto, CA 94304 USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Rheumatol Allergy & Immunol, Boston, MA USA.
RP Greenhawt, M (reprint author), Univ Michigan Hlth Syst, Div Allergy & Clin Immunol, 24 Frank Lloyd Wright Dr Lobby H-2100,Box 442, Ann Arbor, MI 48106 USA.
EM mgreenha@med.umich.edu
OI Greenhawt, Matthew/0000-0002-2365-9372; Conte,
Marisa/0000-0001-7377-163X
FU Centers for Disease Control and Prevention [214-2010-M-37396]; Food
Allergy Research and Education; Michigan Institute for Clinical and
Health Research; NIH [UL1RR024986]
FX Supported by the Centers for Disease Control and Prevention contract
214-2010-M-37396 with the Food Allergy & Anaphylaxis Network (now the
Food Allergy Research and Education) and the Michigan Institute for
Clinical and Health Research, NIH UL1RR024986 (M.L.C. and M.G.). The
findings and conclusions in this paper are those of the authors and do
not necessarily represent the official positions of the Centers for
Disease Control and Prevention (CDC) or Food Allergy Research and
Education.
NR 42
TC 10
Z9 10
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2013
VL 1
IS 4
BP 378
EP 386
DI 10.1016/j.jaip.2013.04.009
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA V38WW
UT WOS:000209374500009
PM 24565543
ER
PT J
AU Rauh-Hain, JA
Shoni, M
Schorge, JO
Goodman, A
Horowitz, NS
del Carmen, MG
AF Rauh-Hain, J. Alejandro
Shoni, Melina
Schorge, John O.
Goodman, Annekathryn
Horowitz, Neil S.
del Carmen, Marcela G.
TI Prognostic Determinants in Patients with Uterine and Ovarian
Carcinosarcoma
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE carcinosarcoma; ovarian cancer; uterine cancer
AB OBJECTIVE: To analyze and compare the demographics, treatment, recurrence, and survival rates in patients with carcinosarcoma of the uterus and ovary.
STUDY DESIGN: All patients with uterine and ovarian carcinosarcoma who underwent surgical staging at the 2 participating institutions between 1995 and 2007 were identified. The Kaplan Meier method was used to generate overall survival (OS) data. Factors predictive of outcome were compared using the Cox proportional hazards model.
RESULTS: Analysis of 87 women with uterine carcino-" sarcoma and 71 with ovarian carcinosarcoma was performed. Of those, 47% of the patients with uterine carcinosarcoma, compared to 14% of the patients with ovarian carcinosarcoma, were diagnosed with localized disease (p <0.001). Age > 65 years old (p < 0.001), tumor extension (local versus regional versus distant, p <0.001), and platinum -based chemotherapy (p = 0.05) were all independent predictors of survival. In a multivariate Cox regression model, age > 65 years old (hazard ratio [HR] = 2.5, p <0.001), tumor extension (locoregional versus distant, HR= 3.9, p =0.006), and uterine versus ovarian carcinosarcoma (HR = 2.2, p = 0.009) were identified as independent predictors of OS.
CONCLUSION: Uterine carcinosarcoma presents at an earlier stage than does ovarian carcinosarcoma. In the multivariate analysis uterine carcinosarcoma demonstrated shorter survival than did ovarian carcinosarcoma after adjustment for extent of disease spread, age, and platinum -based chemotherapy.
C1 Harvard Univ, Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Div Gynecol Oncol,Med Sch, Boston, MA USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gynecol Oncol, Boston, MA USA.
RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 21
TC 4
Z9 5
U1 0
U2 0
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
EI 1943-3565
J9 J REPROD MED
JI J. Reprod. Med.
PD JUL-AUG
PY 2013
VL 58
IS 7-8
BP 297
EP 304
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA V43RA
UT WOS:000209697300004
PM 23947079
ER
PT J
AU Puntil, C
York, J
Limandri, B
Greene, P
Arauz, E
Hobbs, D
AF Puntil, Cheryl
York, Janet
Limandri, Barbara
Greene, Pamela
Arauz, Eric
Hobbs, Deborah
TI Competency-Based Training for PMH Nurse Generalists: Inpatient
Intervention and Prevention of Suicide
SO JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION
LA English
DT Article
DE suicide prevention; self-directed violence (SDV); psychiatric nursing;
inpatient intervention; competencies; consumer perspective
ID CONTROLLED-TRIAL; ATTEMPTERS; EDUCATION; PROGRAMS; VETERANS
AB Suicide is the tenth leading cause of death in the United States. Approximately 90,000 psychiatric mental health (PMH) nurse generalists work in hospitals in the United States, mostly on inpatient psychiatric units where the most acutely suicidal patients are hospitalized. Although competencies have been developed for mental health clinicians in assessing and managing suicide risk, there are no standard competencies for PMH nurse generalists. Widely accepted nursing practices do not meet suicide-specific standards of care or evidence-based criteria. Although both the Commission on Collegiate Nursing Education Essentials for Baccalaureate Education and the Quality and Safety Education for Nurses competencies stress the necessity for comprehensive assessment, safe clinical practices, patient-centered care, evidence-based interventions, and interprofessional communication and collaboration, there are no specific requirements for suicide prevention training in educational and clinical programs. The American Psychiatric Nurses Association has an opportunity to provide leadership in developing, implementing, and evaluating competency-based training for nurses and partner with the national effort to increase the competencies in suicide prevention in the behavioral health workforce.
C1 [Puntil, Cheryl] Univ Calif Los Angeles, Resnick Neuropsychiat Hosp, Los Angeles, CA 90095 USA.
[York, Janet] Ralph H Johnson VAMC, Charleston, SC USA.
[Limandri, Barbara] Linfield Coll, Mcminnville, OR USA.
[Greene, Pamela] Menninger Clin, Houston, TX USA.
[Arauz, Eric] Arauz Inspirat Enterprises LLC, East Brunswick, NJ USA.
[Hobbs, Deborah] Amer Psychiat Nurses Assoc, Falls Church, VA USA.
RP Puntil, C (reprint author), Univ Calif Los Angeles, Resnick Neuropsychiat Hosp, 195 Med Plaza, Los Angeles, CA 90095 USA.
EM cpuntil@mednet.ucla.edu
NR 42
TC 8
Z9 8
U1 2
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1078-3903
EI 1532-5725
J9 J AM PSYCHIAT NURSES
JI J. Am. Psych. Nurses Assoc.
PD JUL-AUG
PY 2013
VL 19
IS 4
BP 205
EP 210
DI 10.1177/1078390313496275
PG 6
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA AJ5KK
UT WOS:000337720900007
PM 23950543
ER
PT J
AU Muller, M
Cassonnet, P
Favre, M
Jacob, Y
Demeret, C
AF Muller, Mandy
Cassonnet, Patricia
Favre, Michel
Jacob, Yves
Demeret, Caroline
TI A Comparative Approach to Characterize the Landscape of Host-Pathogen
Protein-Protein Interactions
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Immunology; Issue 77; Genetics; Microbiology; Biochemistry; Molecular
Biology; Cellular Biology; Biomedical Engineering; Infection; Cancer
Biology; Virology; Medicine; Host-Pathogen Interactions; Host-Pathogen
Interactions; Protein-protein interaction; High-throughput screening;
Luminescence; Yeast two-hybrid; HT-GPCA; Network; protein; yeast; cell;
culture
AB Significant efforts were gathered to generate large-scale comprehensive protein-protein interaction network maps. This is instrumental to understand the pathogen-host relationships and was essentially performed by genetic screenings in yeast two-hybrid systems. The recent improvement of protein-protein interaction detection by a Gaussia luciferase-based fragment complementation assay now offers the opportunity to develop integrative comparative interactomic approaches necessary to rigorously compare interaction profiles of proteins from different pathogen strain variants against a common set of cellular factors.
This paper specifically focuses on the utility of combining two orthogonal methods to generate protein-protein interaction datasets: yeast two-hybrid (Y2H) and a new assay, high-throughput Gaussia princeps protein complementation assay (HT-GPCA) performed in mammalian cells.
A large-scale identification of cellular partners of a pathogen protein is performed by mating-based yeast two-hybrid screenings of cDNA libraries using multiple pathogen strain variants. A subset of interacting partners selected on a high-confidence statistical scoring is further validated in mammalian cells for pair-wise interactions with the whole set of pathogen variants proteins using HT-GPCA. This combination of two complementary methods improves the robustness of the interaction dataset, and allows the performance of a stringent comparative interaction analysis. Such comparative interactomics constitute a reliable and powerful strategy to decipher any pathogen-host interplays.
C1 [Muller, Mandy; Cassonnet, Patricia; Favre, Michel; Jacob, Yves; Demeret, Caroline] Inst Pasteur, Unite Genet Papillomavirus & Canc Humain GPCH, Paris, France.
[Muller, Mandy] Univ Sorbonne Paris Cite, Paris, France.
[Jacob, Yves] Harvard Univ, Sch Med, Dana Farber Canc Inst, CCSB,Dept Canc Biol, Cambridge, MA 02138 USA.
RP Demeret, C (reprint author), Inst Pasteur, Unite Genet Papillomavirus & Canc Humain GPCH, Paris, France.
EM caroline.demeret@pasteur.fr
FU Institut Pasteur; Ligue nationale contre le Cancer [R05/75-129,
RS07/75-75]; Association pour la Recherche sur le Cancer [ARC
A09/1/5031, 4867]; Agence Nationale de la Recherche [ANR07 MIME 009 02,
ANR09 MIEN 026 01]; M.E.N.R.T fellowship
FX This work was supported in part by funding from the Institut Pasteur and
by grants from the Ligue nationale contre le Cancer (grants R05/75-129
and RS07/75-75), the Association pour la Recherche sur le Cancer (grants
ARC A09/1/5031 and 4867), and the Agence Nationale de la Recherche
(ANR07 MIME 009 02 and ANR09 MIEN 026 01). M.M was a recipient of a
M.E.N.R.T fellowship.
NR 15
TC 2
Z9 2
U1 1
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2013
IS 77
AR UNSP e50404
DI 10.3791/50404
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RG
UT WOS:000209227900017
PM 23893119
ER
PT J
AU Villamar, MF
Volz, MS
Bikson, M
Datta, A
DaSilva, AF
Fregni, F
AF Villamar, Mauricio F.
Volz, Magdalena Sarah
Bikson, Marom
Datta, Abhishek
DaSilva, Alexandre F.
Fregni, Felipe
TI Technique and Considerations in the Use of 4x1 Ring High-definition
Transcranial Direct Current Stimulation (HD-tDCS)
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 77; Neurobiology; Neuroscience; Physiology; Anatomy;
Biomedical Engineering; Biophysics; Neurophysiology; Nervous System
Diseases; Diagnosis; Therapeutics; Anesthesia and Analgesia;
Investigative Techniques; Equipment and Supplies; Mental; Disorders;
Transcranial direct current stimulation; tDCS; High-definition
transcranial direct current stimulation; HD-tDCS; Electrical brain
stimulation; Transcranial electrical stimulation (tES); Noninvasive
Brain Stimulation; Neuromodulation; non-invasive; brain; stimulation;
clinical techniques
AB High-definition transcranial direct current stimulation (HD-tDCS) has recently been developed as a noninvasive brain stimulation approach that increases the accuracy of current delivery to the brain by using arrays of smaller " high-definition" electrodes, instead of the larger padelectrodes of conventional tDCS. Targeting is achieved by energizing electrodes placed in predetermined configurations. One of these is the 4x1ring configuration. In this approach, a center ring electrode (anode or cathode) overlying the target cortical region is surrounded by four return electrodes, which help circumscribe the area of stimulation. Delivery of 4x1-ring HD-tDCS is capable of inducing significant neurophysiological and clinical effects in both healthy subjects and patients. Furthermore, its tolerability is supported by studies using intensities as high as 2.0 milliamperes for up to twenty minutes. Even though 4x1 HD-tDCS is simple to perform, correct electrode positioning is important in order to accurately stimulate target cortical regions and exert its neuromodulatory effects. The use of electrodes and hardware that have specifically been tested for HD-tDCS is critical for safety and tolerability. Given that most published studies on 4x1 HD-tDCS have targeted the primary motor cortex (M1), particularly for pain-related outcomes, the purpose of this article is to systematically describe its use for M1 stimulation, as well as the considerations to be taken for safe and effective stimulation. However, the methods outlined here can be adapted for other HD-tDCS configurations and cortical targets.
C1 [Villamar, Mauricio F.; Volz, Magdalena Sarah; Datta, Abhishek; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil,Lab Neuromodulat, Cambridge, MA 02138 USA.
[Villamar, Mauricio F.; Volz, Magdalena Sarah; Datta, Abhishek; Fregni, Felipe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Villamar, Mauricio F.] Pontifical Catholic Univ Ecuador, Sch Med, Quito, Ecuador.
[Volz, Magdalena Sarah] Charite Univ Med Berlin, Berlin, Germany.
[Bikson, Marom; Datta, Abhishek] CUNY City Coll, New York, NY 10031 USA.
[DaSilva, Alexandre F.] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA.
RP Bikson, M (reprint author), CUNY City Coll, New York, NY 10031 USA.
EM bikson@ccny.cuny.edu
NR 28
TC 17
Z9 17
U1 1
U2 8
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2013
IS 77
AR UNSP e50309
DI 10.3791/50309
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RG
UT WOS:000209227900009
PM 23893039
ER
PT J
AU Dransfield, MT
Lettis, S
Barnhart, F
Crim, C
Calverley, PMA
AF Dransfield, Mark T.
Lettis, Sally
Barnhart, Frank
Crim, Courtney
Calverley, Peter M. A.
TI Fluticasone furoate and vilanterol for COPD Reply
SO LANCET RESPIRATORY MEDICINE
LA English
DT Letter
ID OBSTRUCTIVE PULMONARY-DISEASE; PROPIONATE/SALMETEROL 250/50;
EXACERBATIONS; SALMETEROL
C1 [Dransfield, Mark T.] Univ Alabama Birmingham, AB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
[Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Barnhart, Frank; Crim, Courtney] GlaxoSmithKline, Res Triangle Pk, NC USA.
[Lettis, Sally] GlaxoSmithKline, London, England.
[Calverley, Peter M. A.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England.
RP Dransfield, MT (reprint author), Univ Alabama Birmingham, AB Lung Hlth Ctr, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA.
EM mdransfield99@msn.com
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD JUL
PY 2013
VL 1
IS 5
BP E21
EP E22
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AQ3JS
UT WOS:000342689300002
PM 24429207
ER
PT J
AU Besselink, M
van Santvoort, H
Freeman, M
Gardner, T
Mayerle, J
Vege, SS
Werner, J
Banks, P
Mckay, C
Fernandez-Del Castillo, C
French, J
Gooszen, H
Johnson, C
Sarr, M
Takada, T
Windsor, J
Saluja, A
Liddle, R
Papachristou, G
Singh, V
Runzi, M
Wu, B
Singh, V
Bollen, T
Morgan, D
Mortele, K
Mittal, A
En-Qiang, M
de Waele, J
Petrov, M
Dellinger, P
Lerch, MM
Anderson, R
McClave, S
Hartwig, W
Bruno, M
Oria, A
Baron, T
Fagenholz, P
Horvath, K
van Baal, M
Nealon, W
Andren-Sandberg, A
Bakker, O
Bassi, C
Buchler, M
Boermeester, M
Bradley, E
Chari, S
Charnley, R
Connor, S
Dervenis, C
Deviere, J
Dudeja, V
Fockens, P
Forsmark, C
Friess, H
Isaji, S
Isenmann, R
Klar, E
Levy, P
Lillemoe, K
Liu, X
Lohr, CM
Mayumi, T
Mossner, J
Neoptolemos, J
Nordback, I
Olah, A
Padbury, R
Parks, R
Radenkovic, D
Rau, B
Rebours, V
Seewald, S
Seifert, H
Shimosegawa, T
Siriwardena, A
Steinberg, W
Sutton, R
Tanaka, M
Takeda, K
Tse, F
van Goor, H
Warshaw, A
Wang, C
Whitcomb, D
Zhao, Y
Zyromski, N
AF Besselink, Marc
van Santvoort, Hjalmar
Freeman, Martin
Gardner, Timothy
Mayerle, Julia
Vege, Santhi Swaroop
Werner, Jens
Banks, Peter
McKay, Colin
Fernandez-del Castillo, Carlos
French, Jeremy
Gooszen, Hein
Johnson, Colin
Sarr, Mike
Takada, Tadahiro
Windsor, John
Saluja, Ashok
Liddle, Rodger
Papachristou, Georgios
Singh, Vijay
Ruenzi, Michael
Wu, Bechien
Singh, Vikesh
Bollen, Thomas
Morgan, Desiree
Mortele, Koenraad
Mittal, Anubhav
En-qiang, Mao
de Waele, Jan
Petrov, Maxim
Dellinger, Patchen
Lerch, Markus M.
Anderson, Roland
McClave, Stephen
Hartwig, Werner
Bruno, Marco
Oria, Alejandro
Baron, Todd
Fagenholz, Peter
Horvath, Karen
van Baal, Mark
Nealon, William
Andren-Sandberg, Ake
Bakker, Olaf
Bassi, Claudio
Buchler, Markus
Boermeester, Marja
Bradley, Ed
Chari, Suresh
Charnley, Richard
Connor, Saxon
Dervenis, Christos
Deviere, Jacques
Dudeja, Vikas
Fockens, Paul
Forsmark, Chris
Friess, Helmut
Isaji, Shuji
Isenmann, Rainer
Klar, Ernst
Levy, Philippe
Lillemoe, Keith
Liu, Xubao
Loehr, Chengdu Matthias
Mayumi, Toshihiko
Mossner, Joachim
Neoptolemos, John
Nordback, Isto
Olah, Attila
Padbury, Roy
Parks, Rowan
Radenkovic, Dejan
Rau, Bettina
Rebours, Vinciane
Seewald, Stefan
Seifert, Hans
Shimosegawa, Tooru
Siriwardena, Ajith
Steinberg, William
Sutton, Robert
Tanaka, Masao
Takeda, Kazunori
Tse, Francis
van Goor, Harry
Warshaw, Andrew
Wang, Chunyou
Whitcomb, David
Zhao, Yupei
Zyromski, Nicholas
CA Working Grp IAP APA Acute
TI IAP/APA evidence-based guidelines for the management of acute
pancreatitis
SO PANCREATOLOGY
LA English
DT Article
DE Acute pancreatitis; Pancreas; Guidelines; Diagnosis; Prediction;
Prevention; Treatment; Intervention; Nutrition; Surgery; Radiology;
Gastroenterology
AB Background: There have been substantial improvements in the management of acute pancreatitis since the publication of the International Association of Pancreatology (IAP) treatment guidelines in 2002. A collaboration of the IAP and the American Pancreatic Association (APA) was undertaken to revise these guidelines using an evidence-based approach.
Methods: Twelve multidisciplinary review groups performed systematic literature reviews to answer 38 predefined clinical questions. Recommendations were graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The review groups presented their recommendations during the 2012 joint IAP/APA meeting. At this one-day, interactive conference, relevant remarks were voiced and overall agreement on each recommendation was quantified using plenary voting.
Results: The 38 recommendations covered 12 topics related to the clinical management of acute pancreatitis: A) diagnosis of acute pancreatitis and etiology, B) prognostication/predicting severity, C) imaging, D) fluid therapy, E) intensive care management, F) preventing infectious complications, G) nutritional support, H) biliary tract management, I) indications for intervention in necrotizing pancreatitis, J) timing of intervention in necrotizing pancreatitis, K) intervention strategies in necrotizing pancreatitis, and L) timing of cholecystectomy. Using the GRADE system, 21 of the 38 (55%) recommendations, were rated as 'strong' and plenary voting revealed 'strong agreement' for 34 (89%) recommendations.
Conclusions: The 2012 IAP/APA guidelines provide recommendations concerning key aspects of medical and surgical management of acute pancreatitis based on the currently available evidence. These recommendations should serve as a reference standard for current management and guide future clinical research on acute pancreatitis. Copyright (C) 2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd.
C1 UNSW Clin Sch, Int Assoc Pancreatol, Liverpool BC, NSW 1871, Australia.
[Working Grp IAP APA Acute] Amer Pancreat Assoc, Minneapolis, MN 55414 USA.
[Besselink, Marc] AMC Amsterdam, Amsterdam, Netherlands.
[van Santvoort, Hjalmar] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Freeman, Martin] Univ Minnesota, Minneapolis, MN 55455 USA.
[Gardner, Timothy] Dartmouth Hitchcock Med Ctr, Lebanon, NH USA.
[Mayerle, Julia] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany.
[Vege, Santhi Swaroop; Sarr, Mike] Mayo Clin, Rochester, MN USA.
[Werner, Jens] Heidelberg Univ, Bergheimer Str 58, D-69115 Heidelberg, Germany.
[Banks, Peter] Brigham & Womens Hosp, Boston, MA 02115 USA.
[McKay, Colin] Glasgow Royal Infirmary, Glasgow, Lanark, Scotland.
[Fernandez-del Castillo, Carlos] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[French, Jeremy] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England.
[Gooszen, Hein] Univ Med Ct St Radboud, Nijmegen, Netherlands.
[Johnson, Colin] Southampton Gen Hosp, Southampton, Hants, England.
[Takada, Tadahiro] Teikyo Univ, Sch Med, Tokyo, Japan.
[Windsor, John] Univ Auckland, Auckland 1, New Zealand.
RP Besselink, M (reprint author), AMC Amsterdam, Amsterdam, Netherlands.
EM besselink@amc.nl; h.vansantvoort@umcutrecht.nl;
werner@med.uni-heidelberg.de
RI Sutton, Robert/I-3587-2016; Connor, Saxon/N-7641-2013;
OI Sutton, Robert/0000-0001-6600-562X; Connor, Saxon/0000-0002-5788-2185;
Lerch, Markus M./0000-0002-9643-8263
FU IAP/APA
FX The IAP/APA provided organizational support for the development of these
guidelines. No external funding was provided, and there was no financial
support for anyone involved with the development of these guidelines.
NR 96
TC 107
Z9 107
U1 1
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1424-3903
EI 1424-3911
J9 PANCREATOLOGY
JI Pancreatology
PD JUL-AUG
PY 2013
VL 13
IS 4
SU 2
BP E1
EP E15
DI 10.1016/j.pan.2013.07.063
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA V41QK
UT WOS:000209560500001
ER
PT J
AU Culpepper, L
Fried, R
AF Culpepper, Larry
Fried, Ronna
TI Attention-Deficit/Hyperactivity Disorder in a Chronic Care Paradigm
SO POSTGRADUATE MEDICINE
LA English
DT Article
DE attention-deficit/hyperactivity disorder; life span disorder; chronic
care models; primary care physician; integrated health care team
ID DEFICIT-HYPERACTIVITY DISORDER; EXECUTIVE FUNCTION IMPAIRMENTS;
RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE; ADULT ADHD; MEDICATION
ADHERENCE; SUBTHRESHOLD DIAGNOSES; LATE-ONSET; LIFE-SPAN; MANAGEMENT
AB The prevalence and disease burden of adult attention-deficit/hyperactivity disorder (ADHD) suggests that primary care physicians (PCPs) have an opportunity to improve the functioning and quality of life of a significant number of adult patients. The American Academy of Pediatrics provides evidence-based clinical practice guidelines that recognize ADHD as a chronic condition, and a large proportion of children with ADHD continue to meet diagnostic criteria as adults. Therefore, the management of ADHD should incorporate principles common to the management of other chronic conditions, including proactive planning for continuity of treatment across the life span and integrated, multidisciplinary health care teams for optimal disease management. This article describes a clinical approach whereby adult ADHD is treated within a chronic care paradigm that prominently features the involvement of the PCP. If PCPs envision ADHD as a chronic illness, similar to asthma or diabetes, they may be less likely to refer individuals to be managed by specialists, and more likely to see their role in coordinating and monitoring adult ADHD care, knowing when and how to bring other resources into play, and when and how to educate patients.
C1 [Culpepper, Larry] Boston Univ, Dept Family Med, Boston, MA 02215 USA.
[Fried, Ronna] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Culpepper, L (reprint author), Boston Univ, Dept Family Med, Boston, MA 02215 USA.
OI Culpepper, Larry/0000-0002-7655-0477
NR 87
TC 3
Z9 3
U1 1
U2 5
PU JTE MULTIMEDIA
PI WEST CONSHOHOCKEN
PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD JUL
PY 2013
VL 125
IS 4
BP 78
EP 86
DI 10.3810/pgm.2013.07.2680
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX2SQ
UT WOS:000346795000008
PM 23933896
ER
PT J
AU Andresen, EM
Peterson-Besse, JJ
Krahn, GL
Walsh, ES
Horner-Johnson, W
Iezzoni, LI
AF Andresen, Elena M.
Peterson-Besse, Jana J.
Krahn, Gloria L.
Walsh, Emily S.
Horner-Johnson, Willi
Iezzoni, Lisa I.
TI Pap, Mammography, and Clinical Breast Examination Screening Among Women
with Disabilities: A Systematic Review
SO WOMENS HEALTH ISSUES
LA English
DT Review
ID HEALTH-CARE ACCESS; PREVENTIVE MEDICAL-SERVICES; MOBILITY IMPAIRMENTS;
INTERVIEW SURVEY; MENTAL-ILLNESS; RECEIPT; BARRIERS; BENEFICIARIES;
DISPARITIES; PEOPLE
AB Background: Research has found some disparities between U. S. women with and without disabilities in receiving clinical preventive services. Substantial differences may also exist within the population of women with disabilities. The current study examined published research on Pap smears, mammography, and clinical breast examinations across disability severity levels among women with disabilities.
Methods: Informed by an expert panel, we followed guidelines for systematic literature reviews and searched MEDLINE, PsycINFO, and Cinahl databases. We also reviewed in-depth four disability- or preventive service-relevant journals. Two reviewers independently extracted data from all selected articles.
Findings: Five of 74 reviewed publications of met all our inclusion criteria and all five reported data on Pap smears, mammography, and clinical breast examination. Articles classified disability severity groups by functional and/or activity levels. Associations between disability severity and Pap smear use were inconsistent across the publications. Mammography screening fell as disability level increased according to three of the five studies. Results demonstrated modestly lower screening, but also were inconsistent for clinical breast examinations across studies.
Conclusion: Evidence is inconsistent concerning disparities in these important cancer screening services with increasing disability levels. Published studies used differing methods and definitions, adding to concerns about the evidence for screening disparities rising along with increasing disability. More focused research is required to determine whether significant disparities exist in cancer screening among women with differing disability levels. This information is essential for national and local public health and health care organizations to target interventions to improve care for women with disabilities. Copyright (C) 2013 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Andresen, Elena M.; Horner-Johnson, Willi] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Peterson-Besse, Jana J.] Univ Pacific, Dept Publ Hlth, Forest Grove, OR USA.
[Krahn, Gloria L.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
[Walsh, Emily S.] Kaiser Permanente, Kaiser Permanente Res Affiliates Evidence Based P, Portland, OR USA.
[Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
RP Andresen, EM (reprint author), Oregon Hlth & Sci Univ, Inst Dev & Disabil, Dept Publ Hlth & Prevent Med, 707 SE Gaines St, Portland, OR 97239 USA.
EM andresee@ohsu.edu
OI Horner-Johnson, Willi/0000-0003-3568-1400
FU Intramural CDC HHS [CC999999]
NR 42
TC 18
Z9 18
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD JUL-AUG
PY 2013
VL 23
IS 4
BP E205
EP E214
DI 10.1016/j.whi.2013.04.002
PG 10
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AO1WW
UT WOS:000341107200002
PM 23816150
ER
PT J
AU Toh, WS
Foldager, CB
Olsen, BR
Spector, M
AF Toh, Wei Seong
Foldager, Casper Bindzus
Olsen, Bjorn Reino
Spector, Myron
TI Basement membrane molecule expression attendant to chondrogenesis by
nucleus pulposus cells and mesenchymal stem cells
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE laminin; type IV collagen; cartilage; nucleus pulposus; mesenchymal stem
cells
ID COLLAGEN-GAG SCAFFOLDS; INTERVERTEBRAL DISC; IN-VITRO; CARTILAGE
FORMATION; DIFFERENTIATION; LAMININ; IMMUNOLOCALIZATION; RECEPTORS;
PROTEINS; PERLECAN
AB Bone marrow-derived mesenchymal stem cells (MSCs) represent an autologous cell source for nucleus pulposus (NP) tissue engineering and regeneration. Although studies have demonstrated the ability of MSCs to differentiate to NP-like chondrocytic cells, few have comparatively studied the matrix synthesis and composition of the cartilaginous tissue formed in vitro from both cell types, particularly with respect to the expression of basement membrane (BM) molecules. The objective of this study was to evaluate chondrogenesis and expression of BM molecules, laminin and type IV collagen, in monolayer and in pellet cultures of caprine NP cells and MSCs. Both cell types demonstrated comparable levels of chondrogenesis, indicated by the percentage of chondrocytic cells, and the amounts of glycosaminoglycan and type II collagen. Laminin and type IV collagen were expressed intracellularly by NP cells and MSCs cultured in monolayer. During chondrogenesis in pellet cultures, the deposition of BM molecules in NP and MSC pellets followed an orderly spatiotemporal shift in pattern from a diffuse territorial and interterritorial distribution to a defined pericellular localization, as seen in normal adult NP. These results inform the use of MSCs for NP regeneration and suggest the possible involvement of certain BM molecules in chondrogenesis and cartilage regeneration. (c) 2013 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 31:11361143, 2013
C1 [Toh, Wei Seong; Foldager, Casper Bindzus; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn, Boston, MA 02130 USA.
[Toh, Wei Seong; Foldager, Casper Bindzus; Spector, Myron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02115 USA.
[Olsen, Bjorn Reino] Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
RP Spector, M (reprint author), VA Boston Healthcare Syst, Tissue Engn, 150 South Huntington Ave,MS 151, Boston, MA 02130 USA.
EM mspector@rics.bwh.harvard.edu
RI Toh, Wei Seong/K-7720-2013
OI Toh, Wei Seong/0000-0001-9147-6423
FU Department of Veterans Affairs, Veterans Health Administration,
Rehabilitation Research and Development Service; A*STAR International
Fellowship, Singapore; Danish Minister of Science, Technology and
Innovation; Department of Veterans Affairs
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Rehabilitation Research and
Development Service. W.S.T. is supported by A*STAR International
Fellowship, Singapore. C.B.F. is supported by an Elite Research
Scholarship from the Danish Minister of Science, Technology and
Innovation. M.S. is supported by a Research Career Scientist Award from
the Department of Veterans Affairs.
NR 23
TC 8
Z9 8
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2013
VL 31
IS 7
BP 1136
EP 1143
DI 10.1002/jor.22330
PG 8
WC Orthopedics
SC Orthopedics
GA 149VW
UT WOS:000319350500021
PM 23508654
ER
PT J
AU Elshihawy, H
Hammad, M
AF Elshihawy, Hosam
Hammad, Mohamed
TI Molecular modeling studies and synthesis of novel quinoxaline
derivatives with potential anti-cancer activity as inhibitors of
methionine synthase
SO MEDICINAL CHEMISTRY RESEARCH
LA English
DT Article
DE Cobalamin; MCF-7 cells; Methionine; Methionine synthase; PC-3;
Quinoxaline derivatives and tumor
ID CELLS; DEPENDENCE
AB Methionine synthase (MetS) catalyses the transfer of a methyl group from the methyltetrahydrofolate (MTHF) to homocysteine to produce methionine and tetrahydrofolate. MetS is over-expressed in the cytosol of certain breast and prostate tumor cells. In this article, we designed, synthesized, and evaluated the biological activity of a series of substituted quinoxaline derivatives that mimic the MTHF in the structure. The main aim was to develop inhibitors that could inhibit the enzyme reaction by blocking the binding of MTHF. These inhibitors were docked into the MTHF binding domain in such the same way as MTHF in its binding domain. Compound 4-({(6-nitro-quinoxalin-2-yl)methylamino}methyl)benzoic acid showed the lowest free energy of the binding (-152.62 kJ/mol) and showed the lowest IC50 values of 45 +/- A 9 and 53 +/- A 9 mu M against two types of cancer cell lines PC-3 and MCF-7, respectively.
C1 [Elshihawy, Hosam] Suez Canal Univ, Sch Pharm, Div Organ Chem, Ismailia 41522, Egypt.
[Hammad, Mohamed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Boston, MA USA.
RP Elshihawy, H (reprint author), Suez Canal Univ, Sch Pharm, Div Organ Chem, Ismailia 41522, Egypt.
EM h.elshihawy@uea.ac.uk
NR 12
TC 1
Z9 1
U1 2
U2 19
PU SPRINGER BIRKHAUSER
PI NEW YORK
PA 233 SPRING STREET, 6TH FLOOR, NEW YORK, NY 10013 USA
SN 1054-2523
EI 1554-8120
J9 MED CHEM RES
JI Med. Chem. Res.
PD JUL
PY 2013
VL 22
IS 7
BP 3405
EP 3415
DI 10.1007/s00044-012-0307-4
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 149ZK
UT WOS:000319359800036
ER
PT J
AU Tang, MH
AF Tang, Michael H.
TI The lance armstrong story: Should we find another hero?
SO PEDIATRIC BLOOD & CANCER
LA English
DT Editorial Material
C1 [Tang, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tang, Michael H.] Harvard Univ, Sch Med, Boston, MA USA.
RP Tang, MH (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 6A, Boston, MA 02114 USA.
EM mhtang@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUL
PY 2013
VL 60
IS 7
BP 1071
EP 1072
DI 10.1002/pbc.24513
PG 2
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 149ZZ
UT WOS:000319361300011
PM 23483728
ER
PT J
AU Skapek, SX
Anderson, JR
Hill, DA
Henry, D
Spunt, SL
Meyer, W
Kao, S
Hoffer, FA
Grier, HE
Hawkins, DS
Raney, RB
AF Skapek, Stephen X.
Anderson, James R.
Hill, D. Ashley
Henry, David
Spunt, Sheri L.
Meyer, William
Kao, Simon
Hoffer, Fredric A.
Grier, Holcombe E.
Hawkins, Douglas S.
Raney, R. Beverly
TI Safety and efficacy of high-dose tamoxifen and sulindac for desmoid
tumor in children: Results of a Children's Oncology Group (COG) Phase II
Study
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE chemotherapy; desmoid-type fibromatosis; sulindac; tamoxifen
ID FAMILIAL ADENOMATOUS POLYPOSIS; NONCYTOTOXIC DRUG-THERAPY; AGGRESSIVE
FIBROMATOSIS; MUTATIONS; METHOTREXATE; VINBLASTINE; GENE
AB Background Desmoid fibromatosis (desmoid tumor, DT) is a soft tissue neoplasm prone to recurrence despite complete surgical resection. Numerous small retrospective reports suggest that non-cytotoxic chemotherapy using tamoxifen and sulindac may be effective for DT. We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children's Oncology Group. Procedures Eligible patients were <19 years of age who had measurable DT that was recurrent or not amenable to surgery or radiation. The primary objective was to estimate progression-free survival (PFS). Patients received tamoxifen and sulindac daily for 12 months or until disease progression or intolerable toxicity occurred. Response was assessed by magnetic resonance imaging. Results Fifty-nine eligible patients were enrolled from 2004 to 2009; 78% were 1018 years old. Twenty-two (38%) were previously untreated; 15 (41%) of the remaining 37 enrolling with recurrent DT had prior systemic chemotherapy and six (16%) had prior radiation. No life-threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2-year PFS and survival rates were 36% (95% confidence interval: 0.230.48) and 96%, respectively. All three deaths were due to progressive DT. Conclusions Tamoxifen and sulindac caused few serious side effects in children with DT, although ovarian cysts were common. However, the combination showed relatively little activity as measured by response and PFS rates. Pediatr Blood Cancer 2013; 60: 11081112. (c) 2012 Wiley Periodicals, Inc.
C1 [Skapek, Stephen X.] Univ Texas SW Med Ctr Dallas, Div Pediat Hematol Oncol, Dallas, TX 75390 USA.
[Skapek, Stephen X.] Childrens Med Ctr, Ctr Canc & Blood Disorders, Dallas, TX 75235 USA.
[Anderson, James R.] Univ Nebraska, Coll Publ Hlth, Med Ctr, Dept Biostat, Omaha, NE USA.
[Hill, D. Ashley] Childrens Natl Med Ctr, Dept Pathol, Washington, DC 20010 USA.
[Hill, D. Ashley] Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA.
[Hill, D. Ashley] George Washington Univ, Dept Integrat Syst Biol, Washington, DC USA.
[Henry, David] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Spunt, Sheri L.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Spunt, Sheri L.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA.
[Meyer, William] Univ Oklahoma, Hlth Sci Ctr, Jimmy Everest Sect Pediat Hematol Oncol, Oklahoma City, OK USA.
[Kao, Simon] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
[Hoffer, Fredric A.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Hoffer, Fredric A.] Qual Assurance Review Ctr, Providence, RI USA.
[Grier, Holcombe E.] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA 02115 USA.
[Grier, Holcombe E.] Childrens Hosp, Boston, MA 02115 USA.
[Hawkins, Douglas S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Raney, R. Beverly] UT MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX USA.
[Raney, R. Beverly] UT MD Anderson Canc Ctr, Div Pediat, Houston, TX USA.
RP Skapek, SX (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Hematol Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM stephen.skapek@UTSouthwestern.edu
FU National Cancer Institute, Bethesda, Maryland [CA-24507, CA-29511,
CA-72989, CA-98543]
FX Grant sponsor: National Cancer Institute, Bethesda, Maryland; Grant
numbers: CA-24507, CA-29511, CA-72989, CA-98543.
NR 31
TC 20
Z9 22
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUL
PY 2013
VL 60
IS 7
BP 1108
EP 1112
DI 10.1002/pbc.24457
PG 5
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 149ZZ
UT WOS:000319361300016
PM 23281268
ER
PT J
AU Reeve, BB
Withycombe, JS
Baker, JN
Hooke, MC
Lyons, JC
Mowbray, C
Wang, JC
Freyer, DR
Joffe, S
Sung, L
Tomlinson, D
Gold, SH
Hinds, PS
AF Reeve, Bryce B.
Withycombe, Janice S.
Baker, Justin N.
Hooke, Mary C.
Lyons, Jessica C.
Mowbray, Catriona
Wang, Jichuan
Freyer, David R.
Joffe, Steven
Sung, Lillian
Tomlinson, Deborah
Gold, Stuart H.
Hinds, Pamela S.
TI The first step to integrating the child's voice in adverse event
reporting in oncology trials: A content validation study among pediatric
oncology clinicians
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE adverse events; cancer; clinical trials; patient-reported outcomes;
pediatric; validity
ID QUALITY-OF-LIFE; CANCER; ADOLESCENTS; CHEMOTHERAPY; SYMPTOMS; HEALTH;
QUESTIONNAIRE; FATIGUE; PATIENT; VALIDITY
AB Purpose Children with cancer experience significant toxicities while undergoing treatment. Documentation of adverse events (AEs) in clinical trials is mandated by federal agencies. Although many AEs are subjective, the current standard is clinician reporting. Our long-term goal is to create and validate a self-report measure of subjective AEs for children aged 7 years and older that will inform AE reporting for the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). This content validation study aimed to identify which of the AEs in the current CTCAE should be included in a pediatric self-report measure. Methods We sought expert panel review and consensus among 187 pediatric clinicians from seven Children's Oncology Group institutions to determine which of the 790 AEs are amenable to child self-report. Two survey iterations were used to identify suitable AEs, and clinician agreement estimated by the content-validity ratio (CVR) was assessed. Results Response rates for surveys 1 and 2 were 72% and 67%, respectively. After the surveys, 64 CTCAE terms met the criteria of being subjective, relevant for use in pediatric cancer trials, and amenable to self-report by a child. The most frequent reasons for removal of CTCAE terms were that they relied on laboratory or clinical measures or were not applicable to children. Conclusion The 64 CTCAE terms will be translated into child-friendly terms as the basis of the child-report toxicity measure. Ultimately, systematic collection of these data will improve care by enhancing the accuracy and completeness of treatment toxicity reports for childhood cancer. Pediatr Blood Cancer 2013; 60: 12311236. (c) 2013 Wiley Periodicals, Inc.
C1 [Reeve, Bryce B.; Lyons, Jessica C.; Gold, Stuart H.] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Withycombe, Janice S.] Palmetto Hlth Childrens Hosp, Columbia, SC USA.
[Baker, Justin N.] St Jude Childrens Res Hosp, Memphis, NC USA.
[Hooke, Mary C.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA.
[Mowbray, Catriona; Wang, Jichuan; Hinds, Pamela S.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Wang, Jichuan; Hinds, Pamela S.] George Washington Univ, Sch Med, Washington, DC USA.
[Freyer, David R.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Freyer, David R.] Univ So Calif, Los Angeles, CA USA.
[Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Joffe, Steven] Boston Childrens Hosp, Boston, MA USA.
[Sung, Lillian; Tomlinson, Deborah] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
RP Reeve, BB (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101-D McGavran Greenberg Bldg,135 Dauer Dr,CB 74, Chapel Hill, NC 27599 USA.
EM bbreeve@email.UNC.edu
OI Joffe, Steven/0000-0002-0667-7384
FU Alex's Lemonade Stand Foundation; American Lebanese Syrian Associated
Charities
FX Grant sponsor: Alex's Lemonade Stand Foundation; Grant sponsor: American
Lebanese Syrian Associated Charities.
NR 37
TC 8
Z9 8
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUL
PY 2013
VL 60
IS 7
BP 1231
EP 1236
DI 10.1002/pbc.24463
PG 6
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 149ZZ
UT WOS:000319361300037
PM 23335328
ER
PT J
AU Sakai, N
Tager, AM
AF Sakai, Norihiko
Tager, Andrew M.
TI Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary
fibrosis
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
DE Pulmonary fibrosis; Epithelial cells; Apoptosis; Fibroblasts;
Myofibroblasts; Extracellular matrix
ID TISSUE GROWTH-FACTOR; INTERSTITIAL LUNG-DISEASE; PROSTAGLANDIN E-2
RESISTANCE; ENDOPLASMIC-RETICULUM STRESS; BLEOMYCIN-INDUCED APOPTOSIS;
TGF-BETA ACTIVATION; SONIC HEDGEHOG SHH; MYOFIBROBLAST DIFFERENTIATION;
TRANSCRIPTIONAL ACTIVATION; MESENCHYMAL INTERACTIONS
AB Idiopathic pulmonary fibrosis (IPF) is characterized by the progressive and ultimately fatal accumulation of fibroblasts and extracellular matrix in the lung that distorts its architecture and compromises its function. IPF is now thought to result from wound-healing processes that, although initiated to protect the host from injurious environmental stimuli, lead to pathological fibrosis due to these processes becoming aberrant or over-exuberant. Although the environmental stimuli that trigger IPF remain to be identified, recent evidence suggests that they initially injure the alveolar epithelium. Repetitive cycles of epithelial injury and resultant alveolar epithelial cell death provoke the migration, proliferation, activation and myofibroblast differentiation of fibroblasts, causing the accumulation of these cells and the extracellular matrix that they synthesize. In turn, these activated fibroblasts induce further alveolar epithelial cell injury and death, thereby creating a vicious cycle of pro-fibrotic epithelial cell-fibroblast interactions. Though other cell types certainly make important contributions, we focus here on the "pas de deux" (steps of two), or perhaps more appropriate to IPF pathogenesis, the "folie a deux" (madness of two) of epithelial cells and fibroblasts that drives the progression of pulmonary fibrosis. We describe the signaling molecules that mediate the interactions of these cell types in their "fibrosis of two", including transforming growth factor-beta, connective tissue growth factor, sonic hedgehog, prostaglandin E-2, angiotensin II and reactive oxygen species. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to human disease. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Sakai, Norihiko; Tager, Andrew M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Sakai, Norihiko; Tager, Andrew M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Tager, Andrew M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Tager, AM (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, 149 13th St,Room 8301, Charlestown, MA 02129 USA.
EM amtager@partners.org
FU NIH [R01-HL095732, R01-HL108975]; Scleroderma Research Foundation;
Coalition for Pulmonary Fibrosis; Pulmonary Fibrosis Foundation;
Nirenberg Center for Advanced Lung Disease; Japan Society for the
Promotion of Science (JSPS)
FX The authors gratefully acknowledge support from NIH R01-HL095732 and
R01-HL108975, and Scleroderma Research Foundation, Coalition for
Pulmonary Fibrosis, Pulmonary Fibrosis Foundation and Nirenberg Center
for Advanced Lung Disease Grants to A.M.T., and from the Japan Society
for the Promotion of Science (JSPS) Excellent Young Researcher Overseas
Visit Program to N.S. The authors have no conflicting financial
interests.
NR 175
TC 41
Z9 46
U1 1
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUL
PY 2013
VL 1832
IS 7
SI SI
BP 911
EP 921
DI 10.1016/j.bbadis,2013.03.001
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 143SC
UT WOS:000318887500008
PM 23499992
ER
PT J
AU Thomas, JJ
Hartmann, AS
Killgore, WDS
AF Thomas, Jennifer J.
Hartmann, Andrea S.
Killgore, William D. S.
TI Non-fat-phobic eating disorders: Why we need to investigate implicit
associations and neural correlates
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
C1 [Thomas, Jennifer J.; Hartmann, Andrea S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Thomas, Jennifer J.; Hartmann, Andrea S.] Massachusetts Gen Hosp, Eating Disorders Clin & Res Program, Boston, MA 02114 USA.
[Thomas, Jennifer J.; Hartmann, Andrea S.] McLean Hosp, Klarman Eating Disorders Ctr, Belmont, MA 02178 USA.
[Killgore, William D. S.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02178 USA.
RP Thomas, JJ (reprint author), Massachusetts Gen Hosp, Eating Disorders Clin & Res Program, WAC 816D,15 Parkman St, Boston, MA 02114 USA.
EM jjthomas@partners.org
OI Killgore, William/0000-0002-5328-0208
FU Hilda and Preston Davis Foundation; Klarman Family Foundation; Swiss
National Science Foundation [PBSKP1_134330/1, PBSKP1_140040]
FX Supported by Hilda and Preston Davis Foundation, Klarman Family
Foundation, and Swiss National Science Foundation post-doctoral
fellowship (PBSKP1_134330/1, PBSKP1_140040).
NR 6
TC 5
Z9 5
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2013
VL 46
IS 5
SI SI
BP 416
EP 419
DI 10.1002/eat.22098
PG 4
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA 142EJ
UT WOS:000318779000008
PM 23658082
ER
PT J
AU Katzman, DK
Misra, M
AF Katzman, Debra K.
Misra, Madhusmita
TI Bone health in adolescent females with anorexia nervosa: What is a
clinician to do?
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Article
DE anorexia nervosa; adolescence; bone mineral density; estrogen;
insulin-like growth factor-1
ID MINERAL DENSITY; YOUNG-WOMEN; VITAMIN-D; GROWTH-HORMONE; DOUBLE-BLIND;
GIRLS; CHILDREN; OSTEOPOROSIS; INCREASES; FRACTURE
AB The objective of this case report is to present a pharmacologic strategy for treatment of adolescents with anorexia nervosa (AN) and low bone mineral density (BMD). We present a 17.5-year-old girl with a 3-year history of AN and longstanding inability to optimize nutrition and gain weight, and a decrease over time in her already low BMD. A year after treatment with the 17- estradiol patch (100 mcg twice weekly) with cyclic oral progesterone (2.5 mg medroxyprogesterone acetate daily for days 110 of every month), her spine and hip BMD Z-scores improved, and a further decrease was prevented. This novel treatment is a consideration for girls with AN at greatest risk for low BMD. Adolescents with AN are at risk for low BMD, and the most effective treatment is weight and menses restoration, which can be difficult to attain and to sustain. Recent studies have shown promising results with pharmacological therapy for low BMD in AN. This article discusses current concepts related to bone loss in AN, and new pharmacologic considerations for adolescents at greatest risk for low BMD. (c) 2013 by Wiley Periodicals, Inc.
C1 [Katzman, Debra K.] Hosp Sick Children, Dept Pediat, Div Adolescent Med, Toronto, ON M5G 1X8, Canada.
[Katzman, Debra K.] Univ Toronto, Toronto, ON, Canada.
[Misra, Madhusmita] Massachusetts Gen Hosp, Div Pediat Endocrinol, Dept Pediat, Boston, MA 02114 USA.
[Misra, Madhusmita] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Katzman, DK (reprint author), Hosp Sick Children, Dept Pediat, Div Adolescent Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM debra.katzman@sickkids.ca
FU NICHD NIH HHS [R01 HD060827]
NR 27
TC 3
Z9 3
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2013
VL 46
IS 5
SI SI
BP 456
EP 460
DI 10.1002/eat.22102
PG 5
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA 142EJ
UT WOS:000318779000017
PM 23658091
ER
PT J
AU Becker, AE
AF Becker, Anne E.
TI Introduction
SO INTERNATIONAL JOURNAL OF EATING DISORDERS
LA English
DT Editorial Material
C1 [Becker, Anne E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Becker, Anne E.] Massachusetts Gen Hosp, Dept Psychiat, Eating Disorders Clin & Res Program, Boston, MA 02114 USA.
RP Becker, AE (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.
EM anne_becker@hms.harvard.edu
NR 0
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0276-3478
J9 INT J EAT DISORDER
JI Int. J. Eating Disord.
PD JUL
PY 2013
VL 46
IS 5
SI SI
BP 507
EP 507
DI 10.1002/eat.22125
PG 1
WC Psychology, Clinical; Nutrition & Dietetics; Psychiatry; Psychology
SC Psychology; Nutrition & Dietetics; Psychiatry
GA 142EJ
UT WOS:000318779000027
PM 23658101
ER
PT J
AU Pretz, JL
Wo, JY
Mamon, HJ
Kachnic, LA
Hong, TS
AF Pretz, Jennifer L.
Wo, Jennifer Y.
Mamon, Harvey J.
Kachnic, Lisa A.
Hong, Theodore S.
TI Chemoradiation Therapy Localized Esophageal, Gastric, and Pancreatic
Cancer
SO SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Gastrointestinal; Cancer; Chemoradiation; Surgery; Targeted therapy
ID PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; HER2-POSITIVE
BREAST-CANCER; COOPERATIVE-ONCOLOGY-GROUP; COMBINED-MODALITY THERAPY;
ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; PREOPERATIVE CHEMORADIATION;
STEREOTACTIC RADIOSURGERY; SURGERY
AB Chemoradiation plays an important role in management of locally advanced gastrointestinal tumors. This article reviews data regarding chemoradiation for tumors of the upper gastrointestinal tract. For esophageal and gastroesophageal junction cancers, chemoradiation is standard of care in the preoperative setting. In gastric cancer, two standards have emerged: definitively treating with perioperative chemotherapy alone and using chemoradiation postoperatively. For pancreatic cancer, the benefit of radiation is less well-defined. The future of treatment sites lies in trials evaluating new chemotherapy regimens, alternative systemic therapies, and different radiation fractionation schema. Because care of these patients is complex, multimodality team evaluation before treatment is encouraged.
C1 [Pretz, Jennifer L.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA.
[Wo, Jennifer Y.; Hong, Theodore S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Mamon, Harvey J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiat Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kachnic, Lisa A.] Boston Univ, Sch Med, Boston Med Ctr, Dept Radiat Oncol, Boston, MA 02118 USA.
RP Hong, TS (reprint author), Massachusetts Gen Hosp, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM tshong1@partners.org
NR 66
TC 5
Z9 5
U1 0
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1055-3207
J9 SURG ONCOL CLIN N AM
JI Surg. Oncol. Clin. N. Am.
PD JUL
PY 2013
VL 22
IS 3
BP 511
EP +
DI 10.1016/j.soc.2013.02.005
PG 16
WC Oncology; Surgery
SC Oncology; Surgery
GA 146IQ
UT WOS:000319085200009
PM 23622077
ER
PT J
AU Thomas, CP
Garnick, DW
Horgan, CM
Miller, K
Harris, AHS
Rosen, MM
AF Thomas, Cindy Parks
Garnick, Deborah W.
Horgan, Constance M.
Miller, Kay
Harris, Alex H. S.
Rosen, Melissa M.
TI Establishing the feasibility of measuring performance in use of
addiction pharmacotherapy
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Performance measurement; Pharmacotherapy; Addiction medication; Veterans
health; Medicaid
ID ALCOHOL-DEPENDENT PATIENTS; SUBSTANCE-ABUSE TREATMENT; RANDOMIZED
CONTROLLED TRIAL/; USE DISORDERS; HEALTH-CARE; MEDICATION COMPLIANCE;
COST-EFFECTIVENESS; OPIOID DEPENDENCE; MEASURING QUALITY; MENTAL-HEALTH
AB This paper presents the rationale and feasibility of standardized performance measures for use of pharmacotherapy in the treatment of substance use disorders (SUD), an evidence-based practice and critical component of treatment that is often underused. These measures have been developed and specified by the Washington Circle, to measure treatment of alcohol and opioid dependence with FDA-approved prescription medications for use in office-based general health and addiction specialty care. Measures were pilot tested in private health plans, the Veterans Health Administration (VHA), and Medicaid. Testing revealed that use of standardized measures using administrative data for overall use and initiation of SUD pharmacotherapy is feasible and practical. Prevalence of diagnoses and use of pharmacotherapy vary widely across health systems. Pharmacotherapy is generally used in a limited portion of those for whom it might be indicated. An important methodological point is that results are sensitive to specifications, so that standardization is critical to measuring performance across systems. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Thomas, Cindy Parks; Garnick, Deborah W.; Horgan, Constance M.; Rosen, Melissa M.] Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA 02454 USA.
[Harris, Alex H. S.] US Dept Vet Affairs, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Miller, Kay] Truven Hlth Analyt, Santa Barbara, CA 93111 USA.
RP Thomas, CP (reprint author), Brandeis Univ, Schneider Inst Hlth Policy, Waltham, MA 02454 USA.
EM cthomas@brandeis.edu
RI Thomas, Cindy/L-3204-2015; Garnick, Deborah/I-9009-2012
OI Thomas, Cindy/0000-0001-5855-1196;
FU NIDA NIH HHS [R01 DA029316]
NR 72
TC 9
Z9 9
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JUL
PY 2013
VL 45
IS 1
BP 11
EP 18
DI 10.1016/j.jsat.2013.01.004
PG 8
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 141VU
UT WOS:000318755400002
PM 23490233
ER
PT J
AU Hagedorn, HJ
Noorbaloochi, S
Simon, AB
Bangerter, A
Stitzer, ML
Stetler, CB
Kivlahan, D
AF Hagedorn, Hildi J.
Noorbaloochi, Siamak
Simon, Alisha Baines
Bangerter, Ann
Stitzer, Maxine L.
Stetler, Cheryl B.
Kivlahan, Daniel
TI Rewarding early abstinence in Veterans Health Administration addiction
clinics
SO JOURNAL OF SUBSTANCE ABUSE TREATMENT
LA English
DT Article
DE Alcohol dependence; Stimulant dependence; Contingency management;
Substance use disorders treatment; Effectiveness
ID SUBSTANCE USE DISORDERS; COST CONTINGENCY MANAGEMENT; COCAINE
ABSTINENCE; REINFORCEMENT THERAPY; RANDOMIZED-TRIAL; MAINTAINED
PATIENTS; METHADONE PATIENTS; FOLLOW-UP; INCENTIVES; DEPENDENCE
AB This study investigates the addition of a contingency management (CM) intervention to Veterans Health Administration substance use disorders treatment on during- and post-treatment outcomes for Veterans diagnosed with alcohol dependence only (n = 191) or stimulant dependence (n = 139). Participants were randomly assigned to 8 weeks of usual care or usual care plus CM. Follow-up assessments occurred at 2, 6 and 12 months. In the alcohol dependent subgroup, CM participants submitted significantly more negative samples (13 versus 11 samples, Cohen's d = 0.54), were retained significantly longer (7 versus 6 weeks, d = 0.47), achieved significantly longer median durations of abstinence (16 versus 9 consecutive visits; median difference = 7, 95% CI = 4-8), and submitted significantly more negative samples at follow-ups (unstandardized effect size = 0.669, se = 0.2483) compared to usual care participants. Intervention effects were nonsignificant for the stimulant dependent subgroup. The study provides support for the effectiveness of CM interventions for alcohol dependent patients. Published by Elsevier Inc.
C1 [Hagedorn, Hildi J.] Minneapolis VA Healthcare Syst, Vet Hlth Adm Subst Use Disorder Qual Enhancement, Minneapolis, MN 55417 USA.
[Hagedorn, Hildi J.; Noorbaloochi, Siamak; Simon, Alisha Baines; Bangerter, Ann] Minneapolis VA Healthcare Syst, Vet Hlth Adm Hlth Serv Res & Dev Ctr Excellence, Minneapolis, MN 55417 USA.
[Hagedorn, Hildi J.; Noorbaloochi, Siamak] Univ Minnesota, Minneapolis, MN 55455 USA.
[Stitzer, Maxine L.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA.
[Stetler, Cheryl B.] Boston Univ, Sch Hlth & Independent Consultant, Dept Hlth Serv, Amherst, MA 01002 USA.
[Kivlahan, Daniel] VA Puget Sound Healthcare Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA.
[Kivlahan, Daniel] Univ Washington, Sch Med, Seattle, WA 98185 USA.
RP Hagedorn, HJ (reprint author), Minneapolis VA Healthcare Syst, 1 Vet Dr, Minneapolis, MN 55417 USA.
EM hildi.hagedorn@va.gov
NR 30
TC 5
Z9 5
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0740-5472
J9 J SUBST ABUSE TREAT
JI J. Subst. Abus. Treat.
PD JUL
PY 2013
VL 45
IS 1
BP 109
EP 117
DI 10.1016/j.jsat.2013.01.006
PG 9
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 141VU
UT WOS:000318755400014
PM 23453480
ER
PT J
AU Rakvongthai, Y
Oraintara, S
AF Rakvongthai, Yothin
Oraintara, Soontorn
TI Estimating the relative phase parameters of complex wavelet coefficients
in noise
SO SIGNAL PROCESSING
LA English
DT Article
DE Complex Gaussian scale mixtures; Complex wavelet phase; Relative phase;
Parameter estimation in noise
ID TRANSFORM; SIGNALS
AB This paper proposes a method to estimate the parameters of the relative phase probability density function (RP pdf) of the complex coefficients when an image is corrupted by additive white Gaussian noise. With the complex Gaussian scale mixture (CGSM) assumption of the clean coefficients, we first introduce the relative phase mixture (RPM) pdf by deriving the pdf of the relative phase of the noisy coefficients. Along with the derived pdf, a parameter estimation method based on the maximum likelihood approach is proposed by exploiting the relationships between the pdfs parameters and the complex covariance matrix of the corresponding complex coefficient vector. Simulation studies using simulated data are performed to show the effectiveness of the estimation method. Moreover, we use the proposed estimation method in the application of texture retrieval in a noisy environment. The results show that the proposed method can estimate the parameters of the clean vector well in the case of simulated data and that the proposed estimation method improves the retrieval accuracy rate. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Rakvongthai, Yothin; Oraintara, Soontorn] Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA.
RP Rakvongthai, Y (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med & Mol, 55 Fruit St, Boston, MA 02114 USA.
EM yothin.rakvongthai@mavs.uta.edu; oraintar@uta.edu
NR 19
TC 1
Z9 1
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1684
J9 SIGNAL PROCESS
JI Signal Process.
PD JUL
PY 2013
VL 93
IS 7
BP 1738
EP 1747
DI 10.1016/j.sigpro.2013.01.012
PG 10
WC Engineering, Electrical & Electronic
SC Engineering
GA 135ZT
UT WOS:000318329900004
ER
PT J
AU Shaw, ME
Hamalainen, MS
Gutschalk, A
AF Shaw, Marnie E.
Hamalainen, Matti S.
Gutschalk, Alexander
TI How anatomical asymmetry of human auditory cortex can lead to a
rightward bias in auditory evoked fields
SO NEUROIMAGE
LA English
DT Article
DE Asymmetry; Signal; Cortical curvature; Signal cancelation;
Nonuniformity; Dipole amplitude
ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; HUMAN-BRAIN; PLANUM
TEMPORALE; SPEECH REGION; ORGANIZATION; RESPONSES; FMRI; MEG
AB Auditory evoked fields and potentials, such as the N-1 or the 40-Hz steady state response, are often stronger in the right compared to the left auditory cortex. Here we investigated whether a greater degree of cortical folding in left auditory cortex could result in increased MEG signal cancelation and a subsequent bias in MEG auditory signals toward the right hemisphere. Signal cancelation, due to non-uniformity of the orientations of underlying neural currents, affects MEG and EEG signals generated by any neuronal activity of reasonable spatial extent. We simulated MEG signals in patches of auditory cortex in seventeen subjects, and measured the relationships between underlying activity distribution, cortical non-uniformity, signal cancelation and resulting (fitted) dipole strength and position.
Our results suggest that the cancelation of MEG signals from auditory cortex is asymmetric, due to underlying anatomy, and this asymmetry may result in a rightward bias in measurable dipole amplitudes. The effect was significant across all auditory areas tested, with the exception of planum temporale. Importantly, we also show how the rightward bias could be partially or completely offset by increased cortical area, and therefore increased cortical activity, on the left side. We suggest that auditory researchers are aware of the impact of cancelation and its resulting rightward bias in signal strength from auditory cortex. These findings are important for studies seeking functional hemispheric specialization in the auditory cortex with MEG as well as for integration of MEG with other imaging modalities. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Shaw, Marnie E.; Gutschalk, Alexander] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany.
[Hamalainen, Matti S.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Hamalainen, Matti S.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA.
RP Gutschalk, A (reprint author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM Alexander.Gutschalk@med.uni-heidelberg.de
RI Hamalainen, Matti/C-8507-2013
FU Bundesministerium fur Bildung und Forschung (BMBF) [01EV0712]
FX This study was supported by Bundesministerium fur Bildung und Forschung
(BMBF, grant 01EV0712 to A.G.).
NR 43
TC 20
Z9 22
U1 2
U2 37
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD JUL 1
PY 2013
VL 74
BP 22
EP 29
DI 10.1016/j.neuroimage.2013.02.002
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 124CL
UT WOS:000317441300003
PM 23415949
ER
PT J
AU Das, F
Ghosh-Choudhury, N
Bera, A
Kasinath, BS
Choudhury, GG
AF Das, Falguni
Ghosh-Choudhury, Nandini
Bera, Amit
Kasinath, Balakuntalam S.
Choudhury, Goutam Ghosh
TI TGF-induced PI 3 kinase-dependent Mnk-1 activation is necessary for
Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID INITIATION-FACTOR 4E; PROTEIN-KINASE; MESSENGER-RNA; TRANSLATION
INITIATION; AKT KINASE; BETA; EXPRESSION; DISEASE; GROWTH; TUMORIGENESIS
AB Transforming growth factor (TGF)-induced canonical signal transduction is involved in glomerular mesangial cell hypertrophy; however, the role played by the noncanonical TGF signaling remains largely unexplored. TGF time-dependently stimulated eIF4E phosphorylation at Ser-209 concomitant with enhanced phosphorylation of Erk1/2 (extracellular signal regulated kinase1/2) and MEK (mitogen-activated and extracellular signal-regulated kinase kinase) in mesangial cells. Inhibition of Erk1/2 by MEK inhibitor or by expression of dominant negative Erk2 blocked eIF4E phosphorylation, resulting in attenuation of TGF-induced protein synthesis and mesangial cell hypertrophy. Expression of constitutively active (CA) MEK was sufficient to induce protein synthesis and hypertrophy similar to those induced by TGF. Pharmacological or dominant negative inhibition of phosphatidylinositol (PI) 3 kinase decreased MEK/Erk1/2 phosphorylation leading to suppression of eIF4E phosphorylation. Inducible phosphorylation of eIF4E at Ser-209 is mediated by Mnk-1 (mitogen-activated protein kinase signal-integrating kinase-1). Both PI 3 kinase and Erk1/2 promoted phosphorylation of Mnk-1 in response to TGF. Dominant negative Mnk-1 significantly inhibited TGF-stimulated protein synthesis and hypertrophy. Interestingly, inhibition of mTORC1 activity, which blocks dissociation of eIF4E-4EBP-1 complex, decreased TGF-stimulated phosphorylation of eIF4E without any effect on Mnk-1 phosphorylation. Furthermore, mutant eIF4E S209D, which mimics phosphorylated eIF4E, promoted protein synthesis and hypertrophy similar to TGF. These results were confirmed using phosphorylation deficient mutant of eIF4E. Together our results highlight a significant role of dissociation of 4EBP-1-eIF4E complex for Mnk-1-mediated phosphorylation of eIF4E. Moreover, we conclude that TGF-induced noncanonical signaling circuit involving PI 3 kinase-dependent Mnk-1-mediated phosphorylation of eIF4E at Ser-209 is required to facilitate mesangial cell hypertrophy. J. Cell. Physiol. 228: 16171626, 2013. (c) 2013 Wiley Periodicals, Inc.
C1 [Das, Falguni; Bera, Amit; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA.
[Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU NIH [RO1 DK50190, RO1 AR52425, RO1 DK077295, RC2A 036613]; VA Merit
Review grants; VA Senior Research Career Scientist Award; VA Research
Service
FX Contract grant sponsor: NIH;; Contract grant numbers: RO1 DK50190, RO1
AR52425, RO1 DK077295, RC2A 036613.; Contract grant sponsor: VA Merit
Review grants.; Contract grant sponsor: VA Senior Research Career
Scientist Award.; Contract grant sponsor: VA Research Service.
NR 29
TC 9
Z9 9
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2013
VL 228
IS 7
BP 1617
EP 1626
DI 10.1002/jcp.24327
PG 10
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA 113PX
UT WOS:000316681100029
PM 23359369
ER
PT J
AU Seif, AE
Naranjo, A
Baker, DL
Bunin, NJ
Kletzel, M
Kretschmar, CS
Maris, JM
McGrady, PW
von Allmen, D
Cohn, SL
London, WB
Park, JR
Diller, LR
Grupp, SA
AF Seif, A. E.
Naranjo, A.
Baker, D. L.
Bunin, N. J.
Kletzel, M.
Kretschmar, C. S.
Maris, J. M.
McGrady, P. W.
von Allmen, D.
Cohn, S. L.
London, W. B.
Park, J. R.
Diller, L. R.
Grupp, S. A.
TI A pilot study of tandem high-dose chemotherapy with stem cell rescue as
consolidation for high-risk neuroblastoma: Children's Oncology Group
study ANBL00P1
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
DE pediatric; neuroblastoma; tandem transplant; hematopoietic SCT
ID PERIPHERAL-BLOOD; LYMPHOPROLIFERATIVE DISEASE; INTENSIVE CHEMOTHERAPY;
SOLID TUMORS; TRANSPLANTATION; THERAPY; MEGATHERAPY; DEPLETION;
SURVIVAL; PATIENT
AB Increasing treatment intensity has improved outcomes for children with neuroblastoma. We performed a pilot study in the Children's Oncology Group to assess the feasibility and toxicity of a tandem myeloablative regimen without TBI supported by autologous CD34-selected peripheral blood stem cells. Forty-one patients with high-risk neuroblastoma were enrolled; eight patients did not receive any myeloablative consolidation procedure and seven received only one. Two patients out of 41 (4.9%) experienced transplant-related mortality. CD34 selection was discontinued after subjects were enrolled due to serious viral illness. From the time of study enrollment, the overall 3-year EFS and OS were 44.8 +/- 9.6% and 59.2 +/- 9.2% (N = 41). These results demonstrate that tandem transplantation in the cooperative group setting is feasible and support a randomized comparison of single vs tandem myeloablative consolidation with PBSC support for high-risk neuroblastoma.
C1 [Seif, A. E.; Bunin, N. J.; Maris, J. M.; Grupp, S. A.] Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, Philadelphia, PA 19104 USA.
[Seif, A. E.; Bunin, N. J.; Maris, J. M.; Grupp, S. A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Naranjo, A.; McGrady, P. W.] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL USA.
[Naranjo, A.; McGrady, P. W.] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Biostat, Gainesville, FL USA.
[Naranjo, A.; McGrady, P. W.] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA.
[Baker, D. L.] Princess Margaret Hosp Children, Dept Haematol & Oncol, Perth, WA, Australia.
[Kletzel, M.] Childrens Mem Hosp, Dept Pediat, Div Hematol Oncol & Stem Cell Transplant, Chicago, IL 60614 USA.
[Kletzel, M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[von Allmen, D.] Cincinnati Childrens Hosp, Med Ctr, Div Gen & Thorac Surg, Dept Surg, Cincinnati, OH USA.
[Cohn, S. L.] Comer Childrens Hosp, Dept Pediat, Div Hematol Oncol, Chicago, IL USA.
[London, W. B.; Diller, L. R.] Childrens Hosp, Dana Farber Canc Inst, Div Hematol Oncol, Dept Pediat, Boston, MA 02115 USA.
[Park, J. R.] Seattle Childrens Hosp, Dept Pediat, Div Oncol, Seattle, WA USA.
[Park, J. R.] Univ Washington, Sch Med, Seattle, WA USA.
[Grupp, S. A.] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA.
RP Grupp, SA (reprint author), Childrens Hosp Philadelphia, Dept Pediat, Div Oncol, 3501 Civ Ctr Blvd,CTRB 3006, Philadelphia, PA 19104 USA.
EM grupp@email.chop.edu
RI Seif, Alix/B-9918-2013;
OI Seif, Alix/0000-0002-1799-2582; Cohn, Susan/0000-0001-5749-7650
FU WW Smith Charitable Trust; Foerderer-Murray, Weinberg; Sanford Funds of
the Children's Hospital of Philadelphia (S.A. Grupp); Robert A.
Good/ASBMT New Investigator Award; NIH [U10 CA98413, U10 CA98543]
FX Supported in part by the WW Smith Charitable Trust, and the
Foerderer-Murray, Weinberg and Sanford Funds of the Children's Hospital
of Philadelphia (S.A. Grupp); the Robert A. Good/ASBMT New Investigator
Award (A.E. Seif); NIH grants U10 CA98413 (COG SDC grant) and U10
CA98543 (COG Chair's grant). We would also like to thank Danniel
Gaidula, MFA, for assistance in preparing Figure 1.
NR 33
TC 9
Z9 10
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2013
VL 48
IS 7
BP 947
EP 952
DI 10.1038/bmt.2012.276
PG 6
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 176KF
UT WOS:000321302300011
PM 23334272
ER
PT J
AU Garfall, A
Kim, HT
Sun, L
Ho, VT
Armand, P
Koreth, J
Alyea, EP
Soiffer, RJ
Antin, JH
Ritz, J
Cutler, C
AF Garfall, A.
Kim, H. T.
Sun, L.
Ho, V. T.
Armand, P.
Koreth, J.
Alyea, E. P.
Soiffer, R. J.
Antin, J. H.
Ritz, J.
Cutler, C.
TI KIR ligand incompatibility is not associated with relapse reduction
after double umbilical cord blood transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Letter
ID STEM-CELL TRANSPLANTATION; LEUKEMIA; ALLOREACTIVITY; RECEPTORS; OUTCOMES
C1 [Garfall, A.; Ho, V. T.; Armand, P.; Koreth, J.; Alyea, E. P.; Soiffer, R. J.; Antin, J. H.; Ritz, J.; Cutler, C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kim, H. T.; Sun, L.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Ho, V. T.; Armand, P.; Koreth, J.; Alyea, E. P.; Soiffer, R. J.; Antin, J. H.; Ritz, J.; Cutler, C.] Dana Farber Canc Inst, Div Hematol Malignancies, Dept Med Oncol, Boston, MA 02115 USA.
RP Garfall, A (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
EM corey_cutler@dfci.harvard.edu
NR 15
TC 7
Z9 7
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD JUL
PY 2013
VL 48
IS 7
BP 1000
EP 1002
DI 10.1038/bmt.2012.272
PG 3
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 176KF
UT WOS:000321302300023
PM 23318536
ER
PT J
AU Thomas, ML
Brown, GG
Thompson, WK
Voyvodic, J
Greve, DN
Turner, JA
Mathalon, DH
Ford, J
Wible, CG
Potkin, SG
AF Thomas, Michael L.
Brown, Gregory G.
Thompson, Wesley K.
Voyvodic, James
Greve, Douglas N.
Turner, Jessica A.
Mathalon, Daniel H.
Ford, Judith
Wible, Cynthia G.
Potkin, Steven G.
CA FBIRN
TI An application of item response theory to fMRI data: Prospects and
pitfalls
SO PSYCHIATRY RESEARCH-NEUROIMAGING
LA English
DT Article
DE Functional MRI; Item response theory; Bayesian analysis; Task design
ID WORKING-MEMORY; SCHIZOPHRENIA; INFORMATION; MODEL
AB When using functional brain imaging to study neuropsychiatric patients an important challenge is determining whether the imaging task assesses individual differences with equal precision in healthy control and impaired patient groups. Classical test theory (CTT) requires separate reliability studies of patients and controls to determine equivalent measurement precision with additional studies to determine measurement precision for different levels of disease severity. Unlike CTT, item response theory (IRT) provides estimates of measurement error for different levels of ability, without the need for separate studies, and can determine if different tests are equivalently difficult when investigating differential deficits between groups. To determine the potential value of IRT in functional brain imaging, IRT was applied to behavioral data obtained during a multi-center functional MRI (fMRI) study of working memory (WM). Average item difficulty was approximately one standard deviation below the ability scale mean, supporting the task's sensitivity to individual differences within the ability range of patients with WM impairment, but not within the range of most controls. The correlation of IRT estimated ability with fMRI activation during the task recognition period supported the linkage of the latent IRT scale to brain activation data. IRT can meaningfully contribute to the design of fMRI tasks. Published by Elsevier Ireland Ltd.
C1 [Thomas, Michael L.; Brown, Gregory G.; Thompson, Wesley K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA.
[Brown, Gregory G.] VA San Diego Healthcare Syst, VISN 22, Mental Illness Res Educ & Clin Ctr, San Diego, CA 92161 USA.
[Voyvodic, James] Duke Univ, Med Ctr, Brain Imaging & Anal Ctr, Durham, NC 27710 USA.
[Greve, Douglas N.] Massachusetts Gen Hosp, Dept Radiol, Cambridge, MA 02114 USA.
[Turner, Jessica A.] Mind Res Network, Albuquerque, NM 87106 USA.
[Mathalon, Daniel H.; Ford, Judith] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Mathalon, Daniel H.; Ford, Judith] San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Wible, Cynthia G.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02301 USA.
[Wible, Cynthia G.] Brockton VAMC, Cambridge, MA 02301 USA.
[Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat, Irvine, CA 92697 USA.
RP Brown, GG (reprint author), VA San Diego Healthcare Syst, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.
EM gbrown@ucsd.edu
RI Turner, Jessica/H-7282-2015;
OI Turner, Jessica/0000-0003-0076-8434; Potkin, Steven/0000-0003-1028-1013;
Mathalon, Daniel/0000-0001-6090-4974
FU National Center for Research Resources (National Institutes of Health)
[1 U24 RR021992]; VA Grant
FX This research was supported by a grant from the National Center for
Research Resources to the Function Biomedical Informatics Research
Network (National Institutes of Health grant 1 U24 RR021992) and by a VA
Grant to Desert Pacific Mental Illness, Research, Education, and
Clinical Center. The authors have no conflict of interest to declare.
NR 44
TC 1
Z9 1
U1 1
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0925-4927
EI 1872-7506
J9 PSYCHIAT RES-NEUROIM
JI Psychiatry Res. Neuroimaging
PD JUN 30
PY 2013
VL 212
IS 3
BP 167
EP 174
DI 10.1016/j.pscychresns.2013.01.009
PG 8
WC Clinical Neurology; Neuroimaging; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 169DD
UT WOS:000320756500001
PM 23642468
ER
PT J
AU Uno, H
Tian, L
Cai, TX
Kohane, IS
Wei, LJ
AF Uno, Hajime
Tian, Lu
Cai, Tianxi
Kohane, Isaac S.
Wei, L. J.
TI A unified inference procedure for a class of measures to assess
improvement in risk prediction systems with survival data
SO STATISTICS IN MEDICINE
LA English
DT Article
DE area under the receiver operating characteristic curve; C-statistic;
Cox's regression; integrated discrimination improvement; net
reclassification improvement; risk prediction
ID GENE-EXPRESSION SIGNATURE; C-REACTIVE PROTEIN; BREAST-CANCER; INTEGRATED
DISCRIMINATION; CARDIOVASCULAR RISK; ROC CURVE; MODELS;
RECLASSIFICATION; MARKER; AREA
AB Risk prediction procedures can be quite useful for the patient's treatment selection, prevention strategy, or disease management in evidence-based medicine. Often, potentially important new predictors are available in addition to the conventional markers. The question is how to quantify the improvement from the new markers for prediction of the patient's risk in order to aid cost-benefit decisions. The standard method, using the area under the receiver operating characteristic curve, to measure the added value may not be sensitive enough to capture incremental improvements from the new markers. Recently, some novel alternatives to area under the receiver operating characteristic curve, such as integrated discrimination improvement and net reclassification improvement, were proposed. In this paper, we consider a class of measures for evaluating the incremental values of new markers, which includes the preceding two as special cases. We present a unified procedure for making inferences about measures in the class with censored event time data. The large sample properties of our procedures are theoretically justified. We illustrate the new proposal with data from a cancer study to evaluate a new gene score for prediction of the patient's survival. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Uno, Hajime] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Uno, Hajime; Cai, Tianxi; Wei, L. J.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
[Tian, Lu] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.
[Kohane, Isaac S.] Harvard Univ, Div Hlth Sci & Technol, Cambridge, MA 02138 USA.
[Kohane, Isaac S.] MIT, Cambridge, MA 02139 USA.
RP Uno, H (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, 450 Brookline Ave, Boston, MA 02115 USA.
EM huno@jimmy.harvard.edu
FU NCI NIH HHS [P30 CA124435, RC4 CA155940]; NIAID NIH HHS [R01 AI024643];
NIGMS NIH HHS [R01 GM079330]; NLM NIH HHS [U54 LM008748]
NR 33
TC 65
Z9 65
U1 0
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
J9 STAT MED
JI Stat. Med.
PD JUN 30
PY 2013
VL 32
IS 14
BP 2430
EP 2442
DI 10.1002/sim.5647
PG 13
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA 157FA
UT WOS:000319880100008
PM 23037800
ER
PT J
AU Paschalis, EI
Chodosh, J
Sperling, RA
Salvador-Culla, B
Dohlman, C
AF Paschalis, Eleftherios I.
Chodosh, James
Sperling, Ralph A.
Salvador-Culla, Borja
Dohlman, Claes
TI A Novel Implantable Glaucoma Valve Using Ferrofluid
SO PLOS ONE
LA English
DT Article
ID AQUEOUS-HUMOR; SURGERY; SHUNTS
AB Purpose: To present a novel design of an implantable glaucoma valve based on ferrofluidic nanoparticles and to compare it with a well-established FDA approved valve.
Setting: Massachusetts Eye & Ear Infirmary, Boston, USA.
Methods: A glaucoma valve was designed using soft lithography techniques utilizing a water-immiscible magnetic fluid (ferrofluid) as a pressure-sensitive barrier to aqueous flow. Two rare earth micro magnets were used to calibrate the opening and closing pressure. In-vitro flow measurements were performed to characterize the valve and to compare it to Ahmed (TM) glaucoma valve. The reliability and predictability of the new valve was verified by pressure/flow measurements over a period of three months and X-ray diffraction (XRD) analysis over a period of eight weeks. In vivo assessment was performed in three rabbits.
Results: In the in vitro experiments, the opening and closing pressures of the valve were 10 and 7 mmHg, respectively. The measured flow/pressure response was linearly proportional and reproducible over a period of three months (1.8 mu l/min at 12 mmHg; 4.3 mu l/min at 16 mmHg; 7.6 mu l/min at 21 mmHg). X-ray diffraction analysis did not show oxidization of the ferrofluid when exposed to water or air. Preliminary in vivo results suggest that the valve is biocompatible and can control the intraocular pressure in rabbits.
Conclusions: The proposed valve utilizes ferrofluid as passive, tunable constriction element to provide highly predictable opening and closing pressures while maintaining ocular tone. The ferrofluid maintained its magnetic properties in the aqueous environment and provided linear flow to pressure response. Our in-vitro tests showed reliable and reproducible results over a study period of three months. Preliminary in-vivo results were very promising and currently more thorough investigation of this device is underway.
C1 [Paschalis, Eleftherios I.; Chodosh, James; Salvador-Culla, Borja; Dohlman, Claes] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
[Sperling, Ralph A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Paschalis, EI (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
EM Eleftherios_paschalis@meei.harvard.edu
RI Sperling, Ralph /I-7050-2013;
OI Sperling, Ralph /0000-0002-8027-0697; Paschalis,
Eleftherios/0000-0002-4544-4452
FU Boston Keratoprosthesis Fund; Massachusetts Eye and Ear Infirmary,
Boston, USA
FX This work was funded by the Boston Keratoprosthesis Fund, Massachusetts
Eye and Ear Infirmary, Boston, USA. The authors would like to
acknowledge the contribution of Dr. Kuldip Raj and Ms. Vanessa Rene from
Ferrotec (USA) Corporation for providing the custom fluorophilic
ferrofluid material.
NR 21
TC 6
Z9 6
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 28
PY 2013
VL 8
IS 6
AR e67404
DI 10.1371/journal.pone.0067404
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IH
UT WOS:000321148400075
PM 23840691
ER
PT J
AU Wilson, PC
Lee, MH
Appleton, KM
El-Shewy, HM
Morinelli, TA
Peterson, YK
Luttrell, LM
Jaffa, AA
AF Wilson, Parker C.
Lee, Mi-Hye
Appleton, Kathryn M.
El-Shewy, Hesham M.
Morinelli, Thomas A.
Peterson, Yuri K.
Luttrell, Louis M.
Jaffa, Ayad A.
TI The Arrestin-selective Angiotensin AT(1) Receptor Agonist
[Sar(1),Ile(4),Ile(8)]-AngII Negatively Regulates Bradykinin B-2
Receptor Signaling via AT(1)-B-2 Receptor Heterodimers
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID KALLIKREIN-KININ SYSTEM; OXIDE-GENERATING VASODILATORS; VASCULAR
SMOOTH-MUSCLE; G-PROTEIN; BETA-ARRESTIN; NITRIC-OXIDE; IN-VIVO;
DIABETIC-NEPHROPATHY; HEART-FAILURE; BIASED LIGAND
AB The renin-angiotensin and kallikrein-kinin systems are key regulators of vascular tone and inflammation. Angiotensin II, the principal effector of the renin-angiotensin system, promotes vasoconstriction by activating angiotensin AT(1) receptors. The opposing effects of the kallikrein-kinin system are mediated by bradykinin acting on B-1 and B-2 bradykinin receptors. The renin-angiotensin and kallikrein-kinin systems engage in cross-talk at multiple levels, including the formation of AT(1)-B-2 receptor heterodimers. In primary vascular smooth muscle cells, we find that the arrestin pathway-selective AT(1) agonist, [Sar(1),Ile(4),Ile(8)]-AngII, but not the neutral AT(1) antagonist, losartan, inhibits endogenous B-2 receptor signaling. In a transfected HEK293 cell model that recapitulates this effect, we find that the actions of [Sar(1), Ile(4), Ile(8)]-AngII require the AT(1) receptor and result from arrestin-dependent co-internalization of AT(1)-B-2 heterodimers. BRET50 measurements indicate that AT(1) and B-2 receptors efficiently heterodimerize. In cells expressing both receptors, pretreatment with [Sar(1),Ile(4),Ile(8)]-AngII blunts B-2 receptor activation of G(q/11)-dependent intracellular calcium influx and G(i/o)-dependent inhibition of adenylyl cyclase. In contrast, [Sar(1),Ile(4),Ile(8)]-AngII has no effect on B-2 receptor ligand affinity or bradykinin-induced arrestin3 recruitment. Both radioligand binding assays and quantitative microscopy-based analysis demonstrate that [Sar(1),Ile(4),Ile(8)]-AngII promotes internalization of AT(1)-B-2 heterodimers. Thus, [Sar(1),Ile(4),Ile(8)]-AngII exerts lateral allosteric modulation of B-2 receptor signaling by binding to the orthosteric ligand binding site of the AT(1) receptor and promoting co-sequestration of AT(1)-B-2 heterodimers. Given the opposing roles of the renin-angiotensin and kallikrein-kinin systems in vivo, the distinct properties of arrestin pathway-selective and neutral AT(1) receptor ligands may translate into different pharmacologic actions.
C1 [Wilson, Parker C.; Lee, Mi-Hye; El-Shewy, Hesham M.; Morinelli, Thomas A.; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Coll Med, Dept Med, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Med Univ S Carolina, Coll Med, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Appleton, Kathryn M.; Peterson, Yuri K.] Med Univ S Carolina, Coll Pharm, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA.
[Luttrell, Louis M.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
[Jaffa, Ayad A.] Amer Univ Beirut, Dept Biochem, Beirut 11072020, Lebanon.
[Jaffa, Ayad A.] Amer Univ Beirut, Dept Mol Genet, Beirut 11072020, Lebanon.
RP Luttrell, LM (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Diabet & Med Genet, 96 Jonathan Lucas St,Suite 816CSB,MSC624, Charleston, SC 29425 USA.
EM luttrell@musc.edu
FU National Institutes of Health [R01 HL087986, HL077192, R01 DK55524, F30
DK083208]; National Center for Research Resources [S10 RR027777];
Research Service of the Ralph H. Johnson Veterans Affairs Medical Center
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01 HL087986 and HL077192 (to A. A. J.), R01 DK55524 (to
L. M. L.), and F30 DK083208 (to P. C. W.) and National Center for
Research Resources Grant S10 RR027777 (to T. A. M. and L. M. L.). This
work was also supported by the Research Service of the Ralph H. Johnson
Veterans Affairs Medical Center.
NR 56
TC 15
Z9 15
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 28
PY 2013
VL 288
IS 26
BP 18872
EP 18884
DI 10.1074/jbc.M113.472381
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 176WB
UT WOS:000321335800025
PM 23661707
ER
PT J
AU Prasad, R
Katiyar, SK
AF Prasad, Ram
Katiyar, Santosh K.
TI Grape seed proanthocyanidins inhibit migration potential of pancreatic
cancer cells by promoting mesenchymal-to-epithelial transition and
targeting NF-kappa B
SO CANCER LETTERS
LA English
DT Article
DE NF-kappa B; Epithelial-to-mesenchymal transition; Pancreatic cancer
cells; Cancer cell migration; Grape seed proanthocyanidins
ID REPRESSES E-CADHERIN; BREAST-CANCER; TUMOR PROGRESSION; EXPRESSION;
TRANSCRIPTION; INFLAMMATION; SNAIL; SLUG; METASTASIS; ALPHA
AB Here we explore the effect of grape seed proanthocyanidins (GSPs) on pancreatic cancer cell migration and the molecular mechanisms underlying these effects. Treatment of human pancreatic cancer cell lines Miapaca-2, PANC-1 and AsPC-1 with GSPs resulted in inhibition of cell migration (19-82%, P < 0.01-0.001), which was associated with decreased phosphorylation of ERK1/2 and inactivation of NF-kappa B. Treatment of cells with UO126, an inhibitor of MEK, and caffeic acid phenethyl ester, an inhibitor of NE-kappa B, also inhibited the migration of cells (40-80%, P < 0.01-0.001). Inhibition of cell migration by GSPs was associated with reversal of the epithelial-to-mesenchymal transition. This was associated with upregulation of E-cadherin and desmoglein-2 and down-regulation of fibronectin, N-cadherin and vimentin. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Sch Publ Hlth, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
[Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Katiyar, SK (reprint author), Univ Alabama Birmingham, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA.
EM skatiyar@uab.edu
FU Veterans Administration Merit Review Award
FX This work was supported partially by the funds from the Veterans
Administration Merit Review Award (SKK). Grateful thanks to Dr. Fiona
Hunter for editorial assistance. The content of this article does not
necessarily reflect the views or policies of the funding sources, and
also the funders had no role in study design, data analysis and
preparation of the manuscript.
NR 35
TC 7
Z9 11
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3835
J9 CANCER LETT
JI Cancer Lett.
PD JUN 28
PY 2013
VL 334
IS 1
SI SI
BP 118
EP 126
DI 10.1016/j.canlet.2012.08.003
PG 9
WC Oncology
SC Oncology
GA 164MF
UT WOS:000320413500018
PM 22902508
ER
PT J
AU Jones, JC
Freeman, GJ
AF Jones, Jennifer C.
Freeman, Gordon J.
TI Costimulatory Genes: Hotspots of Conflict between Host Defense and
Autoimmunity
SO IMMUNITY
LA English
DT Editorial Material
C1 [Jones, Jennifer C.] NCI, Vaccine Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Freeman, GJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM Gordon_Freeman@dfci.harvard.edu
RI Jones, Jennifer/C-8691-2015
OI Jones, Jennifer/0000-0002-9488-7719
FU NIAID NIH HHS [R01 AI089955, P01 AI056299, P01 AI080192, U19 AI082630]
NR 10
TC 2
Z9 2
U1 1
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD JUN 27
PY 2013
VL 38
IS 6
BP 1083
EP 1085
DI 10.1016/j.immuni.2013.06.008
PG 4
WC Immunology
SC Immunology
GA AA2TR
UT WOS:000330947500002
PM 23809156
ER
PT J
AU Heesters, BA
Chatterjee, P
Kim, YA
Gonzalez, SF
Kuligowski, MP
Kirchhausen, T
Carroll, MC
AF Heesters, Balthasar A.
Chatterjee, Priyadarshini
Kim, Young-A.
Gonzalez, Santiago F.
Kuligowski, Michael P.
Kirchhausen, Tomas
Carroll, Michael C.
TI Endocytosis and Recycling of Immune Complexes by Follicular Dendritic
Cells Enhances B Cell Antigen Binding and Activation
SO IMMUNITY
LA English
DT Article
ID ALPHA-DEFICIENT MICE; GERMINAL-CENTERS; AFFINITY MATURATION; LYMPHOTOXIN
BETA; HUMORAL IMMUNITY; CYTOCHALASIN-D; STROMAL CELLS; IGG RESPONSES;
FOLLICLES; RECEPTOR
AB Stromal-derived follicular dendritic cells (FDCs) are a major reservoir for antigen that are essential for formation of germinal centers, the site where memory and effector B cells differentiate. A long-standing question is how FDCs retain antigen in its native form for extended periods and how they display it to specific B cells. Here we found that FDCs acquired complement-coated immune complexes (ICs) from noncognate B cells via complement receptors 1 and 2 (CD35 and CD21, respectively) and rapidly internalized them by an actin-dependent pathway. ICs were retained intact within a nondegradative cycling compartment and were displayed periodically on the cell surface where they were accessible to antigen-specific B cells. This would explain how antigens are protected from damage and retained over long periods of time, while remaining accessible for B cells.
C1 [Heesters, Balthasar A.; Chatterjee, Priyadarshini; Kim, Young-A.; Gonzalez, Santiago F.; Kuligowski, Michael P.; Kirchhausen, Tomas; Carroll, Michael C.] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Kirchhausen, Tomas] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Carroll, Michael C.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Heesters, Balthasar A.] Univ Med Ctr Utrecht, Dept Med Microbiol, NL-3584 CX Utrecht, Netherlands.
RP Carroll, MC (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA.
EM michael.carroll@childrens.harvard.edu
FU National Institutes of Health [RO1 AI039246-16, R37 AI054636, PO1
AI078897-04]; New England Regional Center of Excellence in Biodefense
and Emerging Infectious Diseases [GM-075252, U54 AI057159]; Glaxo-Smith
Kline [GSK-P-11-02]; Marie Curie International Outgoing Fellowship for
Career Development [220044]
FX The authors thank all members of the M.C.C. lab and P. Reeves of the
T.K. lab for suggestions and help with experiments. We acknowledge the
valuable technical assistance with live cell and confocal imaging from
E. Marino and H. Leung, respectively, and help by M. Coughlin for
preparation of EM sections. Supported by the National Institutes of
Health (RO1 AI039246-16, R37 AI054636, and PO1 AI078897-04 to M.C.C.),
New England Regional Center of Excellence in Biodefense and Emerging
Infectious Diseases (GM-075252 and U54 AI057159 to T.K.), Glaxo-Smith
Kline (GSK-P-11-02 to M.C.C. and GSK postdoctoral fellowship to P.C.),
and Marie Curie International Outgoing Fellowship for Career Development
(220044 to S.F.G.).
NR 39
TC 65
Z9 65
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD JUN 27
PY 2013
VL 38
IS 6
BP 1164
EP 1175
DI 10.1016/j.immuni.2013.02.023
PG 12
WC Immunology
SC Immunology
GA AA2TR
UT WOS:000330947500012
PM 23770227
ER
PT J
AU Le Page, AK
Jager, MM
Kotton, CN
Simoons-Smit, A
Rawlinson, WD
AF Le Page, Amelia K.
Jager, Mischa M.
Kotton, Camille N.
Simoons-Smit, Alberdina
Rawlinson, William D.
TI International Survey of Cytomegalovirus Management in Solid Organ
Transplantation After the Publication of Consensus Guidelines
SO TRANSPLANTATION
LA English
DT Article
DE Cytomegalovirus; Transplantation; Survey; Prophylaxis; Guidelines
ID LUNG TRANSPLANTATION; DISEASE; RECIPIENTS; VALGANCICLOVIR; PROPHYLAXIS;
EFFICACY; KIDNEY
AB Background. The Transplantation Society published guidelines on cytomegalovirus (CMV) management after solid organ transplantation in 2010, which provide recommendations on prevention, treatment, diagnostics, and resistance. We aimed to survey international clinicians on their posttransplantation CMV management practices with reference to these guidelines to see if they altered the management of clinicians caring for transplant patients.
Methods. The members of The Transplantation Society were emailed an electronic survey 12 months after the guideline publication.
Results. A total of 155 clinicians responded, representing 126 centers in 41 countries. Overall, there was a high uptake of usage of the guidelines. High rates of initial CMV prevention were used (93%), with 46% using only universal prophylaxis, 21% only preemptive therapy, and 33% a hybrid combination dependent on recipient risk for CMV. Socioeconomic and geographic influence was evident, with 26% of respondents from developing countries using no CMV prevention, and more preemptive therapy used in Asia. Valganciclovir was the most common antiviral used, with dosing often below recommendations (33% in infection). Molecular monitoring was used by 84% of clinicians. Management of antiviral-associated neutropenia commonly included antiviral dose reduction or withdrawal (51%).
Conclusions. We conclude that there is significant geographic variation in CMV management after solid organ transplantation. Although the majority of clinicians adhere to consensus guidelines, opportunity exists to encourage better guideline uptake.
C1 [Le Page, Amelia K.; Rawlinson, William D.] Prince Wales Hosp, POWH & UNSW Res Labs, Randwick, NSW 2031, Australia.
[Le Page, Amelia K.; Rawlinson, William D.] Univ New S Wales, Fac Med, Sch Med Sci, Sydney, NSW, Australia.
[Jager, Mischa M.; Rawlinson, William D.] Prince Wales Hosp, Div Virol, SEALS Microbiol, Randwick, NSW 2031, Australia.
[Jager, Mischa M.; Simoons-Smit, Alberdina] Vrije Univ Amsterdam, Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands.
[Kotton, Camille N.; Rawlinson, William D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA.
RP Rawlinson, WD (reprint author), Prince Wales Hosp, Div Virol, SEALS Microbiol, Barker St, Randwick, NSW 2031, Australia.
EM w.rawlinson@unsw.edu.au
OI Rawlinson, William/0000-0003-0988-7827
NR 16
TC 23
Z9 23
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUN 27
PY 2013
VL 95
IS 12
BP 1455
EP 1460
DI 10.1097/TP.0b013e31828ee12e
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299EF
UT WOS:000330377600010
PM 23640298
ER
PT J
AU Leen, AM
Bollard, CM
Mendizabal, AM
Shpall, EJ
Szabolcs, P
Antin, JH
Kapoor, N
Pai, SY
Rowley, SD
Kebriaei, P
Dey, BR
Grilley, BJ
Gee, AP
Brenner, MK
Rooney, CM
Heslop, HE
AF Leen, Ann M.
Bollard, Catherine M.
Mendizabal, Adam M.
Shpall, Elizabeth J.
Szabolcs, Paul
Antin, Joseph H.
Kapoor, Neena
Pai, Sung-Yun
Rowley, Scott D.
Kebriaei, Partow
Dey, Bimalangshu R.
Grilley, Bambi J.
Gee, Adrian P.
Brenner, Malcolm K.
Rooney, Cliona M.
Heslop, Helen E.
TI Multicenter study of banked third-party virus-specific T cells to treat
severe viral infections after hematopoietic stem cell transplantation
SO BLOOD
LA English
DT Article
ID LYMPHOPROLIFERATIVE DISEASE; CLINICAL-TRIALS; CYTOMEGALOVIRUS;
RECIPIENTS; IMMUNOTHERAPY; THERAPY; ADENOVIRUS; MORTALITY; LYMPHOMAS;
CRITERIA
AB Virus-specific T cell (VST) lines could provide useful antiviral prophylaxis and treatment of immune-deficient patients if it were possible to avoid the necessity of generating a separate line for each patient, often on an emergency basis. We prepared a bank of 32 virus-specific lines from individuals with common HLA polymorphisms who were immune to Epstein-Barr virus (EBV), cytomegalovirus, or adenovirus. A total of 18 lines were administered to 50 patients with severe, refractory illness because of infection with one of these viruses after hematopoietic stem cell transplant. The cumulative rates of complete or partial responses at 6 weeks postinfusion were 74.0% (95% CI, 58.5%-89.5%) for the entire group (n = 50), 73.9% (95% CI, 51.2%-96.6%) for cytomegalovirus (n = 23), 77.8% for adenovirus (n = 18), and 66.7% (95% CI, 36.9%-96.5%) for EBV (n = 9). Only 4 responders had a recurrence or progression. There were no immediate infusion-elated adverse events, and de novo graft-versus-host disease developed in only 2 patients. Despite the disparity between the lines and their recipients, the mean frequency of VSTs increased significantly postinfusion, coincident with striking decreases in viral DNA and resolution of clinical symptoms. The use of banked third-party VSTs is a feasible and safe approach to rapidly treat severe or intractable viral infections after stem cell transplantation. This study is registered at www.clinicaltrials.gov as NCT00711035.
C1 [Leen, Ann M.; Bollard, Catherine M.; Grilley, Bambi J.; Gee, Adrian P.; Brenner, Malcolm K.; Rooney, Cliona M.; Heslop, Helen E.] Methodist Hosp, Ctr Cell & Gene Therapy, Baylor Coll Med, Texas Childrens Hosp, Houston, TX 77030 USA.
[Mendizabal, Adam M.; Kebriaei, Partow] EMMES Corp, Rockville, MD USA.
[Shpall, Elizabeth J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Szabolcs, Paul] Duke Univ, Med Ctr, Durham, NC USA.
[Antin, Joseph H.; Pai, Sung-Yun] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kapoor, Neena] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA.
[Pai, Sung-Yun] Boston Childrens Hosp, Boston, MA USA.
[Rowley, Scott D.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Dey, Bimalangshu R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gee, Adrian P.; Rooney, Cliona M.] Baylor Coll Med, Prod Assistance Cell Therapy Ctr, Houston, TX 77030 USA.
RP Heslop, HE (reprint author), Ctr Cell & Gene Therapy, 1102 Bates St,Suite 1640, Houston, TX 77030 USA.
EM hheslop@bcm.edu
FU National Institutes of Health-NHLBI [U54HL08100]; Specialized Centers
for Cellular Therapy; [P30CA125123]
FX The clinical trial was supported by National Institutes of Health-NHLBI
grant U54HL08100, Specialized Centers for Cellular Therapy, and the
manufacture of VSTs by NHLBI Production Assistance for Cellular Therapy.
The authors also appreciate the support of shared resources by cancer
center support grant P30CA125123.
NR 28
TC 130
Z9 137
U1 5
U2 16
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 27
PY 2013
VL 121
IS 26
BP 5113
EP 5123
DI 10.1182/blood-2013-02-486324
PG 11
WC Hematology
SC Hematology
GA 184OJ
UT WOS:000321900700005
PM 23610374
ER
PT J
AU Qu, J
Jakobs, TC
AF Qu, Juan
Jakobs, Tatjana C.
TI The Time Course of Gene Expression during Reactive Gliosis in the Optic
Nerve
SO PLOS ONE
LA English
DT Article
ID ELEVATED INTRAOCULAR-PRESSURE; AXONAL-TRANSPORT; RAT GLAUCOMA; MOUSE
RETINA; ASTROCYTES; HEAD; INJURY; MODEL; BRAIN; NEURONS
AB Reactive gliosis is a complex process that involves changes in gene expression and morphological remodeling. The mouse optic nerve, where astrocytes, microglia and oligodendrocytes interact with retinal ganglion cell axons and each other, is a particularly suitable model for studying the molecular mechanisms of reactive gliosis. We triggered gliosis at the mouse optic nerve head by retro orbital nerve crush. We followed the expression profiles of 14,000 genes from 1 day to 3 months, as the optic nerve formed a glial scar. The transcriptome showed profound changes. These were greatest shortly after injury; the numbers of differentially regulated genes then dropped, returning nearly to resting levels by 3 months. Different genes were modulated with very different time courses, and functionally distinct groups of genes responded in partially overlapping waves. These correspond roughly to two quick waves of inflammation and cell proliferation, a slow wave of tissue remodeling and debris removal, and a final stationary phase that primarily reflects permanent structural changes in the axons. Responses from astrocytes, microglia and oligodendrocytes were distinctively different, both molecularly and morphologically. Comparisons to other models of brain injury and to glaucoma indicated that the glial responses depended on both the tissue and the injury. Attempts to modulate glial function after axonal injuries should consider different mechanistic targets at different times following the insult.
C1 [Qu, Juan; Jakobs, Tatjana C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02138 USA.
RP Jakobs, TC (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02138 USA.
EM tatjana_jakobs@meei.harvard.edu
OI Jakobs, Tatjana/0000-0002-8104-9206
FU National Institutes of Health (NIH) [EY019703, EY14104]; Research to
Prevent Blindness; Massachusetts Lions Eye Research Fund
FX This project was funded by National Institutes of Health (NIH) grant
EY019703, core grant EY14104, and grants from Research to Prevent
Blindness and the Massachusetts Lions Eye Research Fund. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 47
TC 30
Z9 30
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2013
VL 8
IS 6
AR e67094
DI 10.1371/journal.pone.0067094
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 174IX
UT WOS:000321150000024
PM 23826199
ER
PT J
AU Smith, AK
White, DB
Arnold, RM
AF Smith, Alexander K.
White, Douglas B.
Arnold, Robert M.
TI Uncertainty - The Other Side of Prognosis
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA.
[White, Douglas B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA.
[Arnold, Robert M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
FU NIA NIH HHS [K23 AG040772]
NR 5
TC 33
Z9 34
U1 1
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 27
PY 2013
VL 368
IS 26
BP 2448
EP 2450
DI 10.1056/NEJMp1303295
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 171KQ
UT WOS:000320926900004
PM 23802514
ER
PT J
AU Puig, A
Dighe, AS
AF Puig, Alberto
Dighe, Anand S.
TI Case 20-2013: A 29-Year-Old Man with Anemia and Jaundice
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID DEFICIENCY
C1 [Puig, Alberto] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Dighe, Anand S.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Puig, Alberto] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Dighe, Anand S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Puig, A (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 27
PY 2013
VL 368
IS 26
BP 2502
EP 2509
DI 10.1056/NEJMcpc1302333
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 171KQ
UT WOS:000320926900012
PM 23802518
ER
PT J
AU Mannstadt, M
Harris, M
Bravenboer, B
Chitturi, S
Dreijerink, KMA
Lambright, DG
Lim, ET
Daly, MJ
Gabriel, S
Juppner, H
AF Mannstadt, Michael
Harris, Mark
Bravenboer, Bert
Chitturi, Sridhar
Dreijerink, Koen M. A.
Lambright, David G.
Lim, Elaine T.
Daly, Mark J.
Gabriel, Stacey
Jueppner, Harald
TI Germline Mutations Affecting G alpha(11) in Hypoparathyroidism
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Mannstadt, Michael; Daly, Mark J.; Jueppner, Harald] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Harris, Mark] Univ Queensland, Mater Childrens Hosp, Brisbane, Qld 4101, Australia.
[Bravenboer, Bert] Catharina Hosp, Eindhoven, Netherlands.
[Chitturi, Sridhar] Royal Darwin Hosp, Tiwi, NT, Australia.
[Dreijerink, Koen M. A.] Univ Med Ctr, Utrecht, Netherlands.
[Lambright, David G.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Lim, Elaine T.; Gabriel, Stacey] Broad Inst, Cambridge, MA USA.
RP Mannstadt, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM hjueppner@partners.org
OI Dreijerink, Koen/0000-0002-3140-3502
FU NHGRI NIH HHS [X01 HG006062-01]; NHLBI NIH HHS [RC2 HL103010, HL103010,
UC2 HL103010, HL102923-26, RC2 HL102923, UC2 HL102923]; NIDDK NIH HHS
[P01 DK011794, P01DK11794, K08DK081669-01, R01DK46718-20, R01 DK046718,
K08 DK081669]
NR 5
TC 31
Z9 31
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 27
PY 2013
VL 368
IS 26
BP 2532
EP 2534
DI 10.1056/NEJMc1300278
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 171KQ
UT WOS:000320926900033
PM 23802536
ER
PT J
AU Park, E
Kim, H
Kim, JM
Primack, B
Vidal-Cardenas, S
Xu, Y
Price, BD
Mills, AA
D'Andrea, AD
AF Park, Eunmi
Kim, Hyungjin
Kim, Jung Min
Primack, Benjamin
Vidal-Cardenas, Sofia
Xu, Ye
Price, Brendan D.
Mills, Alea A.
D'Andrea, Alan D.
TI FANCD2 Activates Transcription of TAp63 and Suppresses Tumorigenesis
SO MOLECULAR CELL
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; FANCONI-ANEMIA PATHWAY; HOLLIDAY JUNCTION
RESOLVASE; ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE; KNOCKOUT MICE; P63;
SLX4; REPAIR; PROTEIN
AB Fanconi anemia (FA) is a rare genetic disorder characterized by an increased susceptibility to squamous cell cancers. Fifteen FA genes are known, and the encoded proteins cooperate in a common DNA repair pathway. A critical step is the monoubiquitination of the FANCD2 protein, and cells from most FA patients are deficient in this step. How monoubiquitinated FANCD2 suppresses squamous cell cancers is unknown. Here we show that Fancd2-deficient mice are prone to Ras-oncogene-driven skin carcinogenesis, while Usp1-deficient mice, expressing elevated cellular levels of Fancd2-Ub, are resistant to skin tumors. Moreover, Fancd2-Ub activates the transcription of the tumor suppressor TAp63, thereby promoting cellular senescence and blocking skin tumorigenesis. For FA patients, the reduction of FANCD2-Ub and TAp63 protein levels may account for their susceptibility to squamous cell neoplasia. Taken together, Usp1 inhibition may be a useful strategy for upregulating TAp63 and preventing or treating squamous cell cancers in the general non-FA population.
C1 [Park, Eunmi; Kim, Hyungjin; Kim, Jung Min; Primack, Benjamin; Vidal-Cardenas, Sofia; Xu, Ye; Price, Brendan D.; D'Andrea, Alan D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[D'Andrea, Alan D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA.
[Mills, Alea A.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
RP D'Andrea, AD (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM alan_dandrea@dfci.harvard.edu
FU Susan G. Komen Foundation [KG101186]; ASCO-Gianni Bonadonna Fellowship;
NIH [R01DK43889, R01HL52725, P01HL048546]
FX We thank Youngeun Choi for help in real-time PCR analysis and Jason T.
Tsichlis for technical assistance. We thank Markus Grompe, K.J. Patel,
Alec Kimmelman, David Pellman, Dipanjan Chowdhury, Geoffrey Shapiro,
Kalindi Parmar, David Kozono, Younghoon Kee, Min Huang, and other
members of the D'Andrea Laboratory for helpful discussions. E.P. is
supported by postdoctoral fellowships from the Susan G. Komen Foundation
(KG101186) and the ASCO-Gianni Bonadonna Fellowship. This study was also
supported by NIH grants R01DK43889, R01HL52725, and P01HL048546 to
A.D.D. E.P and A.D.D conceived and designed the study. E.P. performed
all experiments and analyzed the data. J.M.K. was involved in the
establishment of mouse models and animal experiments. H.K. contributed
to the xenograft study, and B.P. provided technical assistance during
animal experiments. Y.X. and B.P. contributed to the elucidation of the
transcriptional activity of the FANCD2-Ub protein. E.P., J.M.K., H.K.,
A.M., and A.D.D. participated in discussions and interpretations of the
experiments. E.P., J.M.K., and A.D.D. wrote the manuscript.
NR 45
TC 27
Z9 27
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD JUN 27
PY 2013
VL 50
IS 6
BP 908
EP 918
DI 10.1016/j.molcel.2013.05.017
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 176QT
UT WOS:000321319900013
PM 23806336
ER
PT J
AU Amatruda, JF
Ross, JA
Christensen, B
Fustino, NJ
Chen, KS
Hooten, AJ
Nelson, H
Kuriger, JK
Rakheja, D
Frazier, AL
Poynter, JN
AF Amatruda, James F.
Ross, Julie A.
Christensen, Brock
Fustino, Nicholas J.
Chen, Kenneth S.
Hooten, Anthony J.
Nelson, Heather
Kuriger, Jacquelyn K.
Rakheja, Dinesh
Frazier, A. Lindsay
Poynter, Jenny N.
TI DNA methylation analysis reveals distinct methylation signatures in
pediatric germ cell tumors
SO BMC CANCER
LA English
DT Article
DE Germ Cell Tumor; Teratoma; DNA Methylation; Imprinting
ID YOLK-SAC TUMOR; IMPRINTING ANALYSIS; OVARIAN TERATOMAS; TESTICULAR
CANCER; GENES; H19; HYPERMETHYLATION; PROMOTER; DIFFERENTIATION;
RESISTANCE
AB Background: Aberrant DNA methylation is a prominent feature of many cancers, and may be especially relevant in germ cell tumors (GCTs) due to the extensive epigenetic reprogramming that occurs in the germ line during normal development.
Methods: We used the Illumina GoldenGate Cancer Methylation Panel to compare DNA methylation in the three main histologic subtypes of pediatric GCTs (germinoma, teratoma and yolk sac tumor (YST); N = 51) and used recursively partitioned mixture models (RPMM) to test associations between methylation pattern and tumor and demographic characteristics. We identified genes and pathways that were differentially methylated using generalized linear models and Ingenuity Pathway Analysis. We also measured global DNA methylation at LINE1 elements and evaluated methylation at selected imprinted loci using pyrosequencing.
Results: Methylation patterns differed by tumor histology, with 18/19 YSTs forming a distinct methylation class. Four pathways showed significant enrichment for YSTs, including a human embryonic stem cell pluripotency pathway. We identified 190 CpG loci with significant methylation differences in mature and immature teratomas (q < 0.05), including a number of CpGs in stem cell and pluripotency-related pathways. Both YST and germinoma showed significantly lower methylation at LINE1 elements compared with normal adjacent tissue while there was no difference between teratoma (mature and immature) and normal tissue. DNA methylation at imprinted loci differed significantly by tumor histology and location.
Conclusion: Understanding methylation patterns may identify the developmental stage at which the GCT arose and the at-risk period when environmental exposures could be most harmful. Further, identification of relevant genetic pathways could lead to the development of new targets for therapy.
C1 [Amatruda, James F.; Fustino, Nicholas J.; Chen, Kenneth S.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
[Amatruda, James F.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
[Rakheja, Dinesh] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
[Amatruda, James F.; Fustino, Nicholas J.; Chen, Kenneth S.] Childrens Med Ctr, Ctr Canc & Blood Disorders, Dallas, TX 75390 USA.
[Ross, Julie A.; Poynter, Jenny N.] Div Pediat Epidemiol & Clin Res, Dept Pediat, Minneapolis, MN 55455 USA.
[Ross, Julie A.; Hooten, Anthony J.; Nelson, Heather; Kuriger, Jacquelyn K.; Poynter, Jenny N.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
[Nelson, Heather; Kuriger, Jacquelyn K.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA.
[Christensen, Brock] Dartmouth Med Sch, Sect Biostat & Epidemiol, Dept Community & Family Med, Hanover, NH 03755 USA.
[Frazier, A. Lindsay] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Amatruda, JF (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
EM james.amatruda@utsouthwestern.edu
FU National Institutes of Health [R01 CA135731, R03 CA141481, K05
CA157439]; Minnesota Medical Foundation; Cancer Prevention and Research
Institute of Texas [RP110394]; Amon G. Carter Foundation, Fort Worth,
TX; Children's Cancer Research Fund, Minneapolis, MN
FX The authors would like to acknowledge the Biomedical Genomics Center at
the University of Minnesota for performing the DNA methylation analysis.
Supported by grants from the National Institutes of Health (R01 CA135731
to J.F.A., R03 CA141481 to J.N.P., K05 CA157439 toJ.A.R.); the Minnesota
Medical Foundation; the Cancer Prevention and Research Institute ofTexas
(RP110394 to J.F.A.); the Amon G. Carter Foundation, Fort Worth,
TX;andtheChildren's Cancer Research Fund, Minneapolis, MN.
NR 40
TC 16
Z9 16
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 27
PY 2013
VL 13
AR 313
DI 10.1186/1471-2407-13-313
PG 13
WC Oncology
SC Oncology
GA 176MH
UT WOS:000321308300001
PM 23806198
ER
PT J
AU Gerszten, PC
Sahgal, A
Sheehan, JP
Kersh, R
Chen, S
Flickinger, JC
Quader, M
Fahim, D
Grills, I
Shin, JH
Winey, B
Oh, K
Sweeney, RA
Guckenberger, M
AF Gerszten, Peter C.
Sahgal, Arjun
Sheehan, Jason P.
Kersh, Ronald
Chen, Stephanie
Flickinger, John C.
Quader, Mubina
Fahim, Daniel
Grills, Inga
Shin, John H.
Winey, Brian
Oh, Kevin
Sweeney, Reinhart A.
Guckenberger, Matthias
TI A multi-national report on methods for institutional credentialing for
spine radiosurgery
SO RADIATION ONCOLOGY
LA English
DT Article
DE Spine Radiosurgery; Stereotactic Body Radiotherapy; Credentialing; Spine
Tumors
ID INTENSITY-MODULATED RADIOTHERAPY; STEREOTACTIC BODY RADIOTHERAPY; ACR
PRACTICE GUIDELINES; RADIATION-THERAPY; QUALITY-ASSURANCE;
CLINICAL-TRIALS; CONFORMAL RADIOTHERAPY; ADVANCED TECHNOLOGY; CYBERKNIFE
RADIOSURGERY; PARASPINAL TUMORS
AB Background: Stereotactic body radiotherapy and radiosurgery are rapidly emerging treatment options for both malignant and benign spine tumors. Proper institutional credentialing by physicians and medical physicists as well as other personnel is important for the safe and effective adoption of spine radiosurgery. This article describes the methods for institutional credentialing for spine radiosurgery at seven highly experienced international institutions.
Methods: All institutions (n = 7) are members of the Elekta Spine Radiosurgery Research Consortium and have a dedicated research and clinical focus on image-guided spine radiosurgery. A questionnaire consisting of 24 items covering various aspects of institutional credentialing for spine radiosurgery was completed by all seven institutions.
Results: Close agreement was observed in most aspects of spine radiosurgery credentialing at each institution. A formal credentialing process was believed to be important for the implementation of a new spine radiosurgery program, for patient safety and clinical outcomes. One institution has a written policy specific for spine radiosurgery credentialing, but all have an undocumented credentialing system in place. All institutions rely upon an in-house proctoring system for the training of both physicians and medical physicists. Four institutions require physicians and medical physicists to attend corporate sponsored training. Two of these 4 institutions also require attendance at a non-corporate sponsored academic society radiosurgery course. Corporate as well as non-corporate sponsored training were believed to be complimentary and both important for training. In 5 centers, all cases must be reviewed at a multidisciplinary conference prior to radiosurgery treatment. At 3 centers, neurosurgeons are not required to be involved in all cases if there is no evidence for instability or spinal cord compression. Backup physicians and physicists are required at only 1 institution, but all institutions have more than one specialist trained to perform spine radiosurgery. All centers believed that credentialing should also be device specific, and all believed that professional societies should formulate guidelines for institutions on the requirements for spine radiosurgery credentialing. Finally, in 4 institutions radiation therapists were required to attend corporate-sponsored device specific training for credentialing, and in only 1 institution were radiation therapists required to also attend academic society training for credentialing.
Conclusions: This study represents the first multi-national report of the current practice of institutional credentialing for spine radiosurgery. Key methodologies for safe implementation and credentialing of spine radiosurgery have been identified. There is strong agreement among experienced centers that credentialing is an important component of the safe and effective implementation of a spine radiosurgery program.
C1 [Gerszten, Peter C.; Chen, Stephanie; Flickinger, John C.; Quader, Mubina] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.
[Sahgal, Arjun] Univ Toronto, Toronto, ON, Canada.
[Sheehan, Jason P.] Univ Virginia, Charlottesville, VA USA.
[Kersh, Ronald] Riverside Med Ctr, Newport News, VA USA.
[Fahim, Daniel; Grills, Inga] Oakland Univ, William Beaumont Sch Med, Royal Oak, MI USA.
[Shin, John H.; Winey, Brian; Oh, Kevin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sweeney, Reinhart A.; Guckenberger, Matthias] Univ Hosp Wurzburg, Wurzburg, Germany.
[Gerszten, Peter C.] Presbyterian Univ Hosp, Dept Neurol Surg, Pittsburgh, PA 15213 USA.
RP Gerszten, PC (reprint author), Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.
EM gersztenpc@upmc.edu
OI Flickinger, John/0000-0001-6900-1384; Guckenberger,
Matthias/0000-0002-7146-9071
FU Elekta Stereotactic research grant
FX This research was partially supported through an Elekta Stereotactic
research grant with all institutions being members of the Elekta Spine
Radiosurgery Research Consortium. This work and these data, however, are
the intellectual property of the individual group members and their
sponsoring institutions.
NR 45
TC 4
Z9 4
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-717X
J9 RADIAT ONCOL
JI Radiat. Oncol.
PD JUN 27
PY 2013
VL 8
AR 158
DI 10.1186/1748-717X-8-158
PG 8
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 176VK
UT WOS:000321333900003
PM 23806078
ER
PT J
AU Nayak, BK
Feliers, D
Sudarshan, S
Friedrichs, WE
Day, RT
New, DD
Fitzgerald, JP
Eid, A
DeNapoli, T
Parekh, DJ
Gorin, Y
Block, K
AF Nayak, B. K.
Feliers, D.
Sudarshan, S.
Friedrichs, W. E.
Day, R. T.
New, D. D.
Fitzgerald, J. P.
Eid, A.
DeNapoli, T.
Parekh, D. J.
Gorin, Y.
Block, K.
TI Stabilization of HIF-2 alpha through redox regulation of mTORC2
activation and initiation of mRNA translation
SO ONCOGENE
LA English
DT Article
DE mTOR; Nox oxidase; Rictor; p22(phox); HIF-2 alpha; renal cancer
ID TUMOR-SUPPRESSOR PROTEIN; CANCER; PHOSPHORYLATION; EXPRESSION;
CARCINOMA; COMPLEX; EIF4E; AKT; TRANSFORMATION; CONTRIBUTES
AB Hypoxia inducible factor-2 alpha (HIF-2 alpha) has a critical role in renal tumorigenesis. HIF-2 alpha is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation. Mammalian target of rapamycin (mTOR) functions in two distinct complexes: Raptor-associated mTORC1 and Rictor-associated mTORC2. Rictor-associated mTORC2 complex has been linked to maintaining HIF-2 alpha protein in the absence of VHL; however, the mechanisms remain to be elucidated. Although Raptor-associated mTORC1 is a known key upstream regulator of mRNA translation, initiation and elongation, the role of mTORC2 in regulating mRNA translation is not clear. Complex assembly of the mRNA cap protein, eukaryotic translation initiation factor 4 (eIF4)E, with activators (eIF4 gamma (eIF4G)) and inhibitors (eIF4E-binding protein 1 (4E-BP1)) are rate-limiting determinants of mRNA translation. Our laboratory has previously demonstrated that reactive oxygen species, mediated by p22(phox)-based Nox oxidases, are enhanced in VHL-deficient cells and have a role in the activation of Akt on S473, a site phosphorylated by the mTORC2 complex. In this study, we examined the role of Rictor-dependent regulation of HIF-2 alpha through eIF4E-dependent mRNA translation and examined the effects of p22(phox)-based Nox oxidases on TORC2 regulation. We demonstrate for the first time that mTORC2 complex stability and activation is redox sensitive, and further defined a novel role for p22(phox)-based Nox oxidases in eIF4E-dependent mRNA translation through mTORC2. Furthermore, we provide the first evidence that silencing of p22(phox) reduces HIF-2 alpha-dependent gene targeting in vitro and tumor formation in vivo. The clinical relevance of these studies is demonstrated.
C1 [Nayak, B. K.; Feliers, D.; Friedrichs, W. E.; Day, R. T.; New, D. D.; Eid, A.; Gorin, Y.; Block, K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Sudarshan, S.; Fitzgerald, J. P.; Parekh, D. J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA.
[DeNapoli, T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Block, K.] South Texas Vet Hlth Care Syst, Audie L Murphy Mem Hosp Div, San Antonio, TX USA.
RP Block, K (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM block@uthscsa.edu
FU Veterans Administration; NIH [R01 NCI CA131272, K08 CA138774]; Voelcker
Fund Young Investigator Award; Cancer Center Support Grant, National
Cancer Institute [5 P30 CA054174-18]
FX We acknowledge Dr Goutam Gosh-Choudhury for the HRE responsive element,
Cynthia Galindo for technical contributions and Dr Hanna E. Abboud for
helpful discussions and critical reading of the manuscript. This study
was supported by the Veterans Administration Career Development Award
and NIH R01 NCI CA131272 (KB), and NIH K08 CA138774 and Voelcker Fund
Young Investigator Award (SS). This study was also supported in part by
the Cancer Center Support Grant, National Cancer Institute, 5 P30
CA054174-18 (DJP).
NR 28
TC 18
Z9 19
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUN 27
PY 2013
VL 32
IS 26
BP 3147
EP 3155
DI 10.1038/onc.2012.333
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 172LL
UT WOS:000321004600005
PM 22869144
ER
PT J
AU Yang, Q
Liao, L
Deng, X
Chen, R
Gray, NS
Yates, JR
Lee, JD
AF Yang, Q.
Liao, L.
Deng, X.
Chen, R.
Gray, N. S.
Yates, J. R., III
Lee, J. D.
TI BMK1 is involved in the regulation of p53 through disrupting the
PML-MDM2 interaction
SO ONCOGENE
LA English
DT Article
DE BMK1; PML; p53
ID HUMAN-PAPILLOMAVIRUS TYPE-16; MAMMALIAN MAP KINASE; PREMATURE
SENESCENCE; SIGNAL-TRANSDUCTION; CUTANEOUS MELANOMA; CELL-PROLIFERATION;
GENE-EXPRESSION; E6 ONCOPROTEIN; ONCOGENIC RAS; GROWTH-FACTOR
AB Promyelocytic leukemia protein (PML) modulates the p53 tumor suppressor through its interaction with p53 and MDM2. We found that activated big MAP kinase 1 (BMK1) preferentially associates with PML isoform IV and disrupts PML-MDM2 interaction. Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated p53 activation in part by promoting PML-dependent MDM2 nucleolar sequestration. We discovered that BMK1 deactivation coupled with doxorubicin synergistically enhanced MDM2 nucleolar sequestration and, consequently, promoted PML-mediated p53 upregulation leading to tumor cell apoptosis in vitro and tumor regression in vivo. Collectively, these results not only suggest that BMK1 activity has a role in suppressing p53 by blocking the interaction between PML and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy.
C1 [Yang, Q.; Chen, R.; Lee, J. D.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Liao, L.; Yates, J. R., III] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
[Deng, X.; Gray, N. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Lee, JD (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.
EM jdlee@scripps.edu
FU National Institutes of Health [CA079871, CA114059]; University of
California [19XT-0084]
FX We thank Dr Giovanni Blandino, Dr Myung Kim and Dr Pier Paolo Pandolfi
for generously providing the PML null and control cell lines. This work
was supported by the National Institutes of Health [CA079871 and
CA114059 to JDL] and by the funds from the Tobacco-Related Disease,
Research Program of the University of California [19XT-0084 to JDL].
NR 37
TC 14
Z9 17
U1 1
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUN 27
PY 2013
VL 32
IS 26
BP 3156
EP 3164
DI 10.1038/onc.2012.332
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 172LL
UT WOS:000321004600006
PM 22869143
ER
PT J
AU Haeno, H
Maruvka, YE
Iwasa, Y
Michor, F
AF Haeno, Hiroshi
Maruvka, Yosef E.
Iwasa, Yoh
Michor, Franziska
TI Stochastic Tunneling of Two Mutations in a Population of Cancer Cells
SO PLOS ONE
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; COLORECTAL-CANCER; EVOLUTIONARY DYNAMICS;
MUTATOR PHENOTYPE; STEM-CELLS; INSTABILITY; INITIATION; RETINOBLASTOMA;
THERAPY; MODEL
AB Cancer initiation, progression, and the emergence of drug resistance are driven by specific genetic and/or epigenetic alterations such as point mutations, structural alterations, DNA methylation and histone modification changes. These alterations may confer advantageous, deleterious or neutral effects to mutated cells. Previous studies showed that cells harboring two particular alterations may arise in a fixed-size population even in the absence of an intermediate state in which cells harboring only the first alteration take over the population; this phenomenon is called stochastic tunneling. Here, we investigated a stochastic Moran model in which two alterations emerge in a cell population of fixed size. We developed a novel approach to comprehensively describe the evolutionary dynamics of stochastic tunneling of two mutations. We considered the scenarios of large mutation rates and various fitness values and validated the accuracy of the mathematical predictions with exact stochastic computer simulations. Our theory is applicable to situations in which two alterations are accumulated in a fixed-size population of binary dividing cells.
C1 [Haeno, Hiroshi; Iwasa, Yoh] Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 812, Japan.
[Maruvka, Yosef E.; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Maruvka, Yosef E.; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Iwasa, Y (reprint author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 812, Japan.
EM yohiwasa@kyudai.jp; michor@jimmy.harvard.edu
RI Iwasa, Yoh/G-5368-2010
OI Iwasa, Yoh/0000-0003-0691-1852
FU NCI
FX This work was supported by NCI. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 44
TC 2
Z9 2
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2013
VL 8
IS 6
AR e65724
DI 10.1371/journal.pone.0065724
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 178DN
UT WOS:000321424400011
PM 23840359
ER
PT J
AU Trudeau, MB
Catalano, PJ
Jindrich, DL
Dennerlein, JT
AF Trudeau, Matthieu B.
Catalano, Paul J.
Jindrich, Devin L.
Dennerlein, Jack T.
TI Tablet Keyboard Configuration Affects Performance, Discomfort and Task
Difficulty for Thumb Typing in a Two-Handed Grip
SO PLOS ONE
LA English
DT Article
ID MOBILE PHONE USE; TRAPEZIOMETACARPAL JOINT; FEASIBILITY; MOTION; VARIES
AB When holding a tablet computer with two hands, the touch keyboard configuration imposes postural constraints on the user because of the need to simultaneously hold the device and type with the thumbs. Designers have provided users with several possible keyboard configurations (device orientation, keyboard layout and location). However, potential differences in performance, usability and postures among these configurations have not been explored. We hypothesize that (1) the narrower standard keyboard layout in the portrait orientation leads to lower self-reported discomfort and less reach than the landscape orientation; (2) a split keyboard layout results in better overall outcomes compared to the standard layout; and (3) the conventional bottom keyboard location leads to the best outcomes overall compared to other locations. A repeated measures laboratory experiment of 12 tablet owners measured typing speed, discomfort, task difficulty, and thumb/wrist joint postures using an active marker system during typing tasks for different combinations of device orientation (portrait and landscape), keyboard layout (standard and split), and keyboard location (bottom, middle, top). The narrower standard keyboard with the device in the portrait orientation was associated with less discomfort (least squares mean (and S.E.) 2.9 +/- 0.6) than the landscape orientation (4.5 +/- 0.7). Additionally, the split keyboard decreased the amount of reaching required by the thumb in the landscape orientation as defined by a reduced range of motion and less MCP extension, which may have led to reduced discomfort (2.7 +/- 0.6) compared to the standard layout (4.5 +/- 0.7). However, typing speed was greater for the standard layout (127 +/- 5 char./min.) compared to the split layout (113 +/- 4 char./min.) regardless of device orientation and keyboard location. Usage guidelines and designers can incorporate these findings to optimize keyboard design parameters and form factors that promote user performance and usability for thumb interaction.
C1 [Trudeau, Matthieu B.; Catalano, Paul J.; Dennerlein, Jack T.] Harvard Sch Publ Hlth, Boston, MA USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jindrich, Devin L.] Calif State Univ San Marcos, San Marcos, TX USA.
[Dennerlein, Jack T.] Harvard Univ, Sch Med, Boston, MA USA.
[Dennerlein, Jack T.] Northeastern Univ, Boston, MA 02115 USA.
RP Dennerlein, JT (reprint author), Harvard Sch Publ Hlth, Boston, MA USA.
EM j.dennerlein@neu.edu
OI Dennerlein, Jack/0000-0001-7703-643X
FU NIOSH [R01 OH008373]; Harvard-NIOSH Education and Research Center [2 T42
OH008416-07]; National Science Foundation [0964220]
FX This study was funded in part by NIOSH R01 OH008373, a pilot project
grant awarded by the Harvard-NIOSH Education and Research Center under
Grant No. 2 T42 OH008416-07, and the National Science Foundation grant
0964220. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 21
TC 5
Z9 5
U1 2
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2013
VL 8
IS 6
AR e67525
DI 10.1371/journal.pone.0067525
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 178DN
UT WOS:000321424400109
PM 23840730
ER
PT J
AU Tso, FY
Abrahamyan, L
Hu, SL
Ruprecht, RM
Wood, C
AF Tso, For Yue
Abrahamyan, Levon
Hu, Shiu-Lok
Ruprecht, Ruth M.
Wood, Charles
TI Variations in the Biological Functions of HIV-1 Clade C Envelope in a
SHIV-Infected Rhesus Macaque during Disease Progression
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; NEUTRALIZATION
SENSITIVITY; MULLER RATCHET; FITNESS; GP120; ENV; R5; CCR5; CD4
AB A better understanding of how the biological functions of the HIV-1 envelope (Env) changes during disease progression may aid the design of an efficacious anti-HIV-1 vaccine. Although studies from patient had provided some insights on this issue, the differences in the study cohorts and methodology had make it difficult to reach a consensus of the variations in the HIV-1 Env functions during disease progression. To this end, an animal model that can be infected under controlled environment and reflect the disease course of HIV-1 infection in human will be beneficial. Such an animal model was previously demonstrated by the infection of macaque with SHIV, expressing HIV-1 clade C Env V1-V5 region. By using this model, we examined the changes in biological functions of Env in the infected animal over the entire disease course. Our data showed an increase in the neutralization resistance phenotype over time and coincided with the decrease in the net charges of the V1-V5 region. Infection of PBMC with provirus expressing various Env clones, isolated from the infected animal over time, showed a surprisingly better replicative fitness for viruses expressing the Env from early time point. Biotinylation and ELISA data also indicated a decrease of cell-surface-associated Env and virion-associated gp120 content with disease progression. This decrease did not affect the CD4-binding capability of Env, but were positively correlated with the decrease of Env fusion ability. Interestingly, some of these changes in biological functions reverted to the pre-AIDS level during advance AIDS. These data suggested a dynamic relationship between the Env V1-V5 region with the host immune pressure. The observed changes of biological functions in this setting might reflect and predict those occurring during natural disease progression in human.
C1 [Tso, For Yue; Abrahamyan, Levon; Wood, Charles] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA.
[Tso, For Yue; Abrahamyan, Levon; Wood, Charles] Univ Nebraska, Sch Biol Sci, Lincoln, NE USA.
[Hu, Shiu-Lok] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
[Hu, Shiu-Lok] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA.
[Ruprecht, Ruth M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Wood, C (reprint author), Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA.
EM cwood1@unl.edu
RI Hu, Shiu-Lok/A-3196-2008
OI Hu, Shiu-Lok/0000-0003-4336-7964
FU Public Health Service [CA75903, TW001429]; National Institute of Medical
Sciences, Center for Biomedical Research Excellence [P30 GM103509, R01
AI076170, P01 AI48240]; American Recovery and Reinvestment Act [3P01
AI048240-08S1]
FX This work was supported by Public Health Service grants, CA75903,
TW001429 and the National Institute of Medical Sciences, Center for
Biomedical Research Excellence grant P30 GM103509 to C. W; R01 AI076170
to S. L. H; P01 AI48240 to R. M. R., S. L. H and C. W.; American
Recovery and Reinvestment Act funding 3P01 AI048240-08S1 to R. M. R., C.
W. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 52
TC 0
Z9 0
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2013
VL 8
IS 6
AR e66973
DI 10.1371/journal.pone.0066973
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 178DN
UT WOS:000321424400060
PM 23840566
ER
PT J
AU Liu, H
Rose, ME
Miller, TM
Li, WJ
Shinde, SN
Pickrell, AM
Poloyac, SM
Graham, SH
Hickey, RW
AF Liu, Hao
Rose, Marie E.
Miller, Tricia M.
Li, Wenjin
Shinde, Sunita N.
Pickrell, Alicia M.
Poloyac, Samuel M.
Graham, Steven H.
Hickey, Robert W.
TI COX2-derived primary and cyclopentenone prostaglandins are increased
after asphyxial cardiac arrest
SO BRAIN RESEARCH
LA English
DT Article
DE Prostaglandin; Cyclopentenone; Hypoxic-ischemia; Cardiac arrest;
Cyclooxygenase
ID CEREBRAL-ISCHEMIA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2);
BRAIN-INJURY; PPAR-GAMMA; CYCLOOXYGENASE-2; INHIBITION; ELECTROPHILE;
MECHANISMS; RAT
AB Background: Cyclopentenone prostaglandins have been identified as potential neurotoxic agents in the setting of hypoxia-ischemia. Cyclooxygenase-2 (COX-2), the upstream enzyme responsible for prostaglandin production is upregulated following hypoxic-ischemic brain injury. However, the temporal production and concentration of cyclopentenone prostaglandins has not been described following global brain ischemia. Methods Global brain ischemia was induced in rats by asphyxial cardiac arrest (ACA) followed by resuscitation. Rats were sacrificed between 24 h and 7 days following resuscitation and their brains removed. Western blot, immunohistochemistry, and mass spectroscopy were performed. A cohort of rats was pretreated with the COX-2 inhibitor SC58125. Results COX-2 is induced in hippocampus at 24 h following ACA. Multiple prostaglandins, including cyclopentenone prostaglandin species, are increased in hippocampus as 24 h following ACA. Prostaglandin and cyclopentenone prostaglandin concentrations are returned to baseline at 3 and 7 days post-ischemia. The COX-2 inhibitor SC58125 completely abrogates the post-ischemic increase in prostaglandins and cyclopentenone prostaglandins. Conclusions Prostaglandins, including cyclopentenone prostaglandins, are increased in ischemic brain, peak at 24 h and can be attenuated by the COX-2 inhibitor SC58125. These data establish the presence of potentially neurotoxic cyclopentenone prostaglandins in post-ischemic brains, thus identifying a target and therapeutic window for neuroprotective therapies. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Liu, Hao; Rose, Marie E.; Li, Wenjin; Graham, Steven H.] VA Pittsburgh Healthcare, Geriatr Res Educ & Clin Ctr GR H 00, Pittsburgh, PA USA.
[Liu, Hao; Rose, Marie E.; Li, Wenjin; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15260 USA.
[Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA.
[Shinde, Sunita N.; Pickrell, Alicia M.; Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.
RP Hickey, RW (reprint author), Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.
EM Robert.hickey@chp.edu
FU National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH) [5UL1 RR024153-05]; NIH Roadmap for
Medical Research; [R21HD058846]; [R01NS37459]
FX We would like to thank Li Wang, MS for her help with statistical
support. Supported by R21HD058846 (RWH), R01NS37459 (SHG). Statistical
support was provided by the Clinical Translational Science Institute of
the University of Pittsburgh: Grant number 5UL1 RR024153-05 from the
National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), and NIH Roadmap for Medical
Research.
NR 27
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JUN 26
PY 2013
VL 1519
BP 71
EP 77
DI 10.1016/j.brainres.2013.04.029
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 178US
UT WOS:000321473500008
PM 23624225
ER
PT J
AU Shah, NJ
Hyder, MN
Moskowitz, JS
Quadir, MA
Morton, SW
Seeherman, HJ
Padera, RF
Spector, M
Hammond, PT
AF Shah, Nisarg J.
Hyder, Md. Nasim
Moskowitz, Joshua S.
Quadir, Mohiuddin A.
Morton, Stephen W.
Seeherman, Howard J.
Padera, Robert F.
Spector, Myron
Hammond, Paula T.
TI Surface-Mediated Bone Tissue Morphogenesis from Tunable Nanolayered
Implant Coatings
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID POLYELECTROLYTE MULTILAYER FILMS; LAYER-BY-LAYER; BIOMEDICAL
APPLICATIONS; TITANIUM IMPLANTS; ELASTIC-MODULUS; REVISION; BMP-2;
REGENERATION; PERFORMANCE; PROTEINS
AB The functional success of a biomedical implant critically depends on its stable bonding with the host tissue. Aseptic implant loosening accounts for more than half of all joint replacement failures. Various materials, including metals and plastic, confer mechanical integrity to the device, but often these materials are not suitable for direct integration with the host tissue, which leads to implant loosening and patient morbidity. We describe a self-assembled, osteogenic, polymer-based conformal coating that promotes stable mechanical fixation of an implant in a surrogate rodent model. A single modular, polymer-based multilayered coating was deposited using a water-based layer-by-layer approach, by which each element was introduced on the surface in nanoscale layers. Osteoconductive hydroxyapatite (HAP) and osteoinductive bone morphogenetic protein-2 (BMP-2) contained within the nanostructured coating acted synergistically to induce osteoblastic differentiation of endogenous progenitor cells within the bone marrow, without indications of a foreign body response. The tuned release of BMP-2, controlled by a hydrolytically degradable poly(beta-amino ester), was essential for tissue regeneration, and in the presence of HAP, the modular coating encouraged the direct deposition of highly cohesive trabecular bone on the implant surface. In vivo, the bone-implant interfacial tensile strength was significantly higher than standard bioactive bone cement, did not fracture at the interface, and had long-term stability. Collectively, these results suggest that the multilayered coating system promotes biological fixation of orthopedic and dental implants to improve surgical outcomes by preventing loosening and premature failure.
C1 [Shah, Nisarg J.; Hyder, Md. Nasim; Moskowitz, Joshua S.; Quadir, Mohiuddin A.; Morton, Stephen W.; Hammond, Paula T.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Shah, Nisarg J.; Hyder, Md. Nasim; Quadir, Mohiuddin A.; Morton, Stephen W.; Hammond, Paula T.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Seeherman, Howard J.] Restituo LLC, Cambridge, MA 02138 USA.
[Padera, Robert F.; Spector, Myron] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Padera, Robert F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA.
[Spector, Myron] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Spector, Myron] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hammond, Paula T.] MIT, Inst Soldier Nanotechnol, Cambridge, MA 02139 USA.
RP Hammond, PT (reprint author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM hammond@mit.edu
FU NIH [R01 AG029601]; Institute for Soldier Nanotechnologies; U.S. Army
Research Office [W911NF-07-D-0004]; Koch Institute at MIT; National
Cancer Institute [P30 CA014051]; Natural Sciences and Engineering
Research Council of Canada; NSF
FX Funding: This work was supported by the NIH (R01 AG029601), in part by
the Institute for Soldier Nanotechnologies (supported by the U.S. Army
Research Office under contract W911NF-07-D-0004), and the Koch Institute
(supported by the National Cancer Institute under grant P30 CA014051) at
MIT. M.N.H. and S. W. M. acknowledge fellowships from the Natural
Sciences and Engineering Research Council of Canada and the NSF,
respectively. P. T. H. acknowledges the David H. Koch (1962) Chair
Professorship in Engineering.
NR 38
TC 19
Z9 19
U1 6
U2 65
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 26
PY 2013
VL 5
IS 191
AR 191ra83
DI 10.1126/scitranslmed.3005576
PG 10
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 171KX
UT WOS:000320928000004
PM 23803705
ER
PT J
AU Nishihara, R
Lochhead, P
Kuchiba, A
Jung, S
Yamauchi, M
Liao, XY
Imamura, Y
Qian, ZR
Morikawa, T
Wang, ML
Spiegelman, D
Cho, E
Giovannucci, E
Fuchs, CS
Chan, AT
Ogino, S
AF Nishihara, Reiko
Lochhead, Paul
Kuchiba, Aya
Jung, Seungyoun
Yamauchi, Mai
Liao, Xiaoyun
Imamura, Yu
Qian, Zhi Rong
Morikawa, Teppei
Wang, Molin
Spiegelman, Donna
Cho, Eunyoung
Giovannucci, Edward
Fuchs, Charles S.
Chan, Andrew T.
Ogino, Shuji
TI Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation
Status
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY;
COLON-CANCER; MICROSATELLITE INSTABILITY; LINE-1 HYPOMETHYLATION; PIK3CA
MUTATION; FAMILY-HISTORY; KRAS MUTATION; LIFE-STYLE; SURVIVAL
AB Importance Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells.
Objective To examine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation.
Design and Setting We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer mortality. Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios (HRs) for colorectal carcinoma incidence according to BRAF mutation status.
Main Outcomes and Measures Incidence of colorectal cancer cases according to tumor BRAF mutation status.
Results Among 127 865 individuals, with 3 165 985 person-years of follow-up, we identified 1226 incident rectal and colon cancers with available molecular data. Compared with nonuse, regular aspirin use was associated with lower BRAF-wild-type cancer risk (multivariable HR, 0.73; 95% CI, 0.64 to 0.83; age-adjusted incidence rate difference [RD], -9.7; 95% CI, -12.6 to -6.7 per 100 000 person-years). This association was observed irrespective of status of tumor PTGS2 expression or PIK3CA or KRAS mutation. In contrast, regular aspirin use was not associated with a lower risk of BRAF-mutated cancer (multivariable HR, 1.03; 95% CI, 0.76 to 1.38; age-adjusted, incidence RD, 0.7; 95% CI, -0.3 to 1.7 per 100 000 person-years: P for heterogeneity = .037, between BRAF-wild-type vs BRAF-mutated cancer risks). Compared with no aspirin use, aspirin use of more than 14 tablets per week was associated with a lower risk of BRAF-wild-type cancer (multivariable HR, 0.43; 95% CI, 0.25 to 0.75; age-adjusted incidence RD, -19.8; 95% CI, -26.3 to -13.3 per 100 000 person-years). The relationship between the number of aspirin tablets per week and colorectal cancer risk differed significantly by BRAF mutation status (P for heterogeneity = .005).
Conclusions and Relevance Regular aspirin use was associated with lower risk of BRAF-wild-type colorectal cancer but not with BRAF-mutated cancer risk. These findings suggest that BRAF-mutant colon tumor cells may be less sensitive to the effect of aspirin. Given the modest absolute risk difference, further investigations are necessary to determine clinical implications of our findings.
C1 [Nishihara, Reiko; Lochhead, Paul; Kuchiba, Aya; Yamauchi, Mai; Liao, Xiaoyun; Imamura, Yu; Qian, Zhi Rong; Morikawa, Teppei; Fuchs, Charles S.; Ogino, Shuji] Brigham & Womens Hosp, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jung, Seungyoun; Wang, Molin; Spiegelman, Donna; Cho, Eunyoung; Giovannucci, Edward; Fuchs, Charles S.; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
[Nishihara, Reiko; Kuchiba, Aya; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Wang, Molin; Spiegelman, Donna; Giovannucci, Edward; Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Wang, Molin; Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Lochhead, Paul] Univ Aberdeen, Gastrointestinal Res Grp, Inst Med Sci, Aberdeen, Scotland.
[Morikawa, Teppei] Tokyo Univ Hosp, Dept Pathol, Tokyo 113, Japan.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
RP Chan, AT (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St, Boston, MA 02114 USA.
EM achan@partners.org; shuji_ogino@dfci.harvard.edu
OI Qian, Zhi rong/0000-0003-1633-4120
FU National Institutes of Health (NIH) [P01 CA87969, P01 CA55075, UM1
CA167552, P50 CA127003, R01 CA137178, K24 DK098311, R01 CA151993];
Bennett Family Fund for Targeted Therapies Research; National Colorectal
Cancer Research Alliance; Harvard University
FX This work was supported by grants P01 CA87969 to Dr Hankinson; P01
CA55075 and UM1 CA167552 to Dr Willett; P50 CA127003 to Dr Fuchs.; R01
CA137178 and K24 DK098311 to Dr Chan; and R01 CA151993 to Dr Ogino from
the National Institutes of Health (NIH); the Bennett Family Fund for
Targeted Therapies Research; and the National Colorectal Cancer Research
Alliance. Dr Lochhead is a Scottish Government Clinical Academic Fellow
and was supported by a Harvard University Frank Knox Memorial
Fellowship. Dr Chan is a Damon Runyon Clinical Investigator.
NR 43
TC 65
Z9 66
U1 5
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 26
PY 2013
VL 309
IS 24
BP 2563
EP 2571
DI 10.1001/jama.2013.6599
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170KD
UT WOS:000320848100026
PM 23800934
ER
PT J
AU Joynt, KE
Gawande, AA
Orav, EJ
Jha, AK
AF Joynt, Karen E.
Gawande, Atul A.
Orav, E. John
Jha, Ashish K.
TI Contribution of Preventable Acute Care Spending to Total Spending for
High-Cost Medicare Patients
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID EMERGENCY-DEPARTMENT VISITS; SENSITIVE CONDITIONS; HEALTH-CARE;
HOSPITALIZATIONS; BENEFICIARIES; PROGRAMS
AB Importance A small proportion of patients account for the majority of US health care spending, and understanding patterns of spending among this cohort is critical to reducing health care costs. The degree to which preventable acute care services account for spending among these patients is largely unknown.
Objective To quantify preventable acute care services among high-cost Medicare patients.
Design, Setting, and Participants We summed standardized costs for each inpatient and outpatient service contained in standard 5% Medicare files from 2009 and 2010 across the year for each patient in our sample, and defined those in the top decile of spending in 2010 as high-cost patients and those in the top decile in both 2009 and 2010 as persistently high-cost patients. We used standard algorithms to identify potentially preventable emergency department (ED) visits and acute care inpatient hospitalizations. A total of 1 114 469 Medicare fee-for-service beneficiaries aged 65 years or older were included.
Main Outcomes and Measures Proportion of acute care hospital and ED costs deemed preventable among high-cost patients.
Results The 10% of Medicare patients in the high-cost group were older, more often male, more often black, and had more comorbid illnesses than non-high-cost patients. In 2010, 32.9% (95% CI, 32.9%-32.9%) of total ED costs were incurred by high-cost patients. Based on validated algorithms, 41.0% (95% CI, 40.9%-41.0%) of these costs among high-cost patients were potentially preventable compared with 42.6% (95% CI, 42.6%-42.6%) among non-high-cost patients. High-cost patients accounted for 79.0% (95% CI, 79.0%-79.0%) of inpatient costs, 9.6% (95% CI, 9.6%-9.6%) of which were due to preventable hospitalizations; 16.8% (95% CI, 16.8%-16.8%) of costs within the non-high-cost group were due to preventable hospitalizations. Comparable proportions of ED spending (43.3%; 95% CI, 43.3%-43.3%) and inpatient spending (13.5%; 95% CI, 13.5%-13.5%) were preventable among persistently high-cost patients. Regions with high primary care physician supply had higher preventable spending for high-cost patients.
Conclusions and Relevance Among a sample of patients in the top decile of Medicare spending in 2010, only a small percentage of costs appeared to be related to preventable ED visits and hospitalizations. The ability to lower costs for these patients through better outpatient care may be limited.
C1 [Joynt, Karen E.; Gawande, Atul A.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Orav, E. John; Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Gawande, Atul A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Gawande, Atul A.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA.
RP Joynt, KE (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM kjoynt@partners.org
OI Gawande, Atul/0000-0002-1824-9176
FU Rx Foundation; West Wireless Foundation
FX This study was funded by the Rx Foundation and the West Wireless
Foundation.
NR 21
TC 46
Z9 46
U1 1
U2 18
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 26
PY 2013
VL 309
IS 24
BP 2572
EP 2578
DI 10.1001/jama.2013.7103
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170KD
UT WOS:000320848100027
PM 23797716
ER
PT J
AU Carroll, AE
Frakt, AB
AF Carroll, Aaron E.
Frakt, Austin B.
TI New Evidence Supports, Challenges, and Informs the Ambitions of Health
Reform
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID CARE
C1 [Carroll, Aaron E.] Indiana Univ Sch Med, Ctr Hlth Policy & Professionalism Res, Childrens Hlth Serv Res, Indianapolis, IN 46202 USA.
[Frakt, Austin B.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.
[Frakt, Austin B.] Boston Univ, Sch Publ Hlth, VA Boston Healthcare Syst, Boston, MA USA.
[Frakt, Austin B.] Univ Penn, Leonard Davis Inst, Philadelphia, PA 19104 USA.
RP Carroll, AE (reprint author), Indiana Univ Sch Med, Childrens Hlth Serv Res, 410 W 10th St,HITS Bldg,Ste 1020, Indianapolis, IN 46202 USA.
EM aaecarro@iupui.edu
NR 7
TC 1
Z9 1
U1 0
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 26
PY 2013
VL 309
IS 24
BP 2600
EP 2601
DI 10.1001/jama.2013.7685
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170KD
UT WOS:000320848100032
PM 23797767
ER
PT J
AU Lee, TR
Choi, M
Kopacz, AM
Yun, SH
Liu, WK
Decuzzi, P
AF Lee, Tae-Rin
Choi, Myunghwan
Kopacz, Adrian M.
Yun, Seok-Hyun
Liu, Wing Kam
Decuzzi, Paolo
TI On the near-wall accumulation of injectable particles in the
microcirculation: smaller is not better
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FINITE-ELEMENT-METHOD; BLOOD-CELL AGGREGATION; MACROMOLECULAR
THERAPEUTICS; TUMORITROPIC ACCUMULATION; SHEAR FLOWS; CANCER; DESIGN;
TUMORS; SHAPE; SIZE
AB Although most nanofabrication techniques can control nano/micro particle (NMP) size over a wide range, the majority of NMPs for biomedical applications exhibits a diameter of similar to 100 nm. Here, the vascular distribution of spherical particles, from 10 to 1,000 nm in diameter, is studied using intravital microscopy and computational modeling. Small NMPs (<= 100 nm) are observed to move with Red Blood Cells (RBCs), presenting an uniform radial distribution and limited near-wall accumulation. Larger NMPs tend to preferentially accumulate next to the vessel walls, in a size-dependent manner (similar to 70% for 1,000 nm NMPs). RBC-NMP geometrical interference only is responsible for this behavior. In a capillary flow, the effective radial dispersion coefficient of 1,000 nm particles is similar to 3-fold larger than Brownian diffusion. This suggests that sub-micron particles could deposit within diseased vascular districts more efficiently than conventional nanoparticles.
C1 [Lee, Tae-Rin; Decuzzi, Paolo] Methodist Hosp, Res Inst, Dept Translat Imaging, Houston, TX 77030 USA.
[Lee, Tae-Rin; Decuzzi, Paolo] Methodist Hosp, Res Inst, Dept Nanomed, Houston, TX 77030 USA.
[Lee, Tae-Rin; Kopacz, Adrian M.; Liu, Wing Kam] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA.
[Choi, Myunghwan; Yun, Seok-Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Choi, Myunghwan; Yun, Seok-Hyun] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Liu, Wing Kam] Sungkyunkwan Univ, Sch Mech Engn, Suwon, Kyonggi Do, South Korea.
[Liu, Wing Kam] King Abdulaziz Univ, Distinguished Scientists Program Comm, Jeddah 21413, Saudi Arabia.
[Decuzzi, Paolo] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, I-88100 Catanzaro, Italy.
RP Liu, WK (reprint author), Northwestern Univ, Dept Mech Engn, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM liu@northwestern.edu; pdecuzzi@tmhs.org
RI Liu, Wing/B-7599-2009; Decuzzi, Paolo/F-1899-2016;
OI Decuzzi, Paolo/0000-0001-6050-4188; Choi, Myunghwan/0000-0002-4235-7003
FU Cancer Prevention Research Institute of Texas [CPRIT RP110262]; U.S.
National Institutes of Health [U54CA143837, U54CA151668]; Office of
Science of the U.S. Department of Energy [DE-AC02-06CH11357]; World
Class University Program through the National Research Foundation of
Korea (NRF); Ministry of Education, Science and Technology [R33-10079];
[CMMI-0856492]; [CMMI-0856333]
FX PD acknowledges partial support from the Cancer Prevention Research
Institute of Texas through (grant CPRIT RP110262); the U.S. National
Institutes of Health (grants U54CA143837 and U54CA151668). WKL
acknowledges the support of CMMI-0856492 and CMMI-0856333 and this
research used resources of the QUEST cluster at Northwestern University
and the Argonne Leadership Computing Facility at Argonne National
Laboratory, which is supported by the Office of Science of the U.S.
Department of Energy under contract DE-AC02-06CH11357. WKL also
acknowledges the support of the World Class University Program through
the National Research Foundation of Korea (NRF) funded by the Ministry
of Education, Science and Technology (R33-10079). SHY acknowledges
support from the U.S. National Institutes of Health (grant U54CA143837).
NR 41
TC 29
Z9 29
U1 2
U2 38
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 26
PY 2013
VL 3
AR 2079
DI 10.1038/srep02079
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 171IQ
UT WOS:000320919800001
PM 23801070
ER
PT J
AU Natasha, G
Tan, A
Farhatnia, Y
Rajadas, J
Hamblin, MR
Khaw, PT
Seifalian, AM
AF Natasha, G.
Tan, Aaron
Farhatnia, Yasmin
Rajadas, Jayakumar
Hamblin, Michael R.
Khaw, Peng T.
Seifalian, Alexander M.
TI Channelrhodopsins: visual regeneration and neural activation by a light
switch
SO NEW BIOTECHNOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; EMBRYONIC STEM-CELLS; IN-VIVO;
GENE-TRANSFER; PHOTORECEPTOR DEGENERATION; RETINITIS-PIGMENTOSA;
TRANSGENIC MICE; OPTICAL CONTROL; RCS RATS; MILLISECOND-TIMESCALE
AB The advent of optogenetics provides a new direction for the field of neuroscience and biotechnology, serving both as a refined investigative tool and as potential cure for many medical conditions via genetic manipulation. Although still in its infancy, recent advances in optogenetics has made it possible to remotely manipulate in vivo cellular functions using light. Coined Nature Methods' 'Method of the Year' in 2010, the optogenetic toolbox has the potential to control cell, tissue and even animal behaviour. This optogenetic toolbox consists of light-sensitive proteins that are able to modulate membrane potential in response to light. Channelrhodopsins (ChR) are light-gated microbial ion channels, which were first described in green algae. ChR2 (a subset of ChR) is a seven transmembrane a helix protein, which evokes membrane depolarization and mediates an action potential upon photostimulation with blue (470 nm) light. By contrast to other seven-transmembrane proteins that require second messengers to open ion channels, ChR2 form ion channels themselves, allowing ultrafast depolarization (within 50 milliseconds of illumination). It has been shown that integration of ChR2 into various tissues of mice can activate neural circuits, control heart muscle contractions, and even restore breathing after spinal cord injury. More compellingly, a plethora of evidence has indicated that artificial expression of ChR2 in retinal ganglion cells can reinstate visual perception in mice with retinal degeneration.
C1 [Natasha, G.; Tan, Aaron; Farhatnia, Yasmin; Seifalian, Alexander M.] UCL, UCL Div Surg & Intervent Sci, Ctr Nanotechnol & Regenerat Med, London, England.
[Natasha, G.; Tan, Aaron] UCL, UCL Med Sch, London, England.
[Rajadas, Jayakumar] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Biomat & Adv Drug Delivery Lab, Stanford, CA 94305 USA.
[Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
[Khaw, Peng T.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
[Khaw, Peng T.] UCL, UCL Inst Ophthalmol, London, England.
[Khaw, Peng T.] UCL, UCL Partners AHSC, London, England.
[Seifalian, Alexander M.] Royal Free London NHS Fdn Trust, London, England.
RP Seifalian, AM (reprint author), UCL, UCL Div Surg & Intervent Sci, Ctr Nanotechnol & Regenerat Med, London, England.
EM a.seifalian@ucl.ac.uk
RI Seifalian, Alexander/I-6028-2013;
OI Seifalian, Alexander/0000-0002-1180-3322; G,
Natasha/0000-0002-9262-4595; Hamblin, Michael/0000-0001-6431-4605
NR 90
TC 1
Z9 2
U1 4
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1871-6784
EI 1876-4347
J9 NEW BIOTECHNOL
JI New Biotech.
PD JUN 25
PY 2013
VL 30
IS 5
BP 461
EP 474
DI 10.1016/j.nbt.2013.04.007
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 181US
UT WOS:000321695200006
ER
PT J
AU Truong, QA
Hayden, D
Woodard, PK
Kirby, R
Chou, ET
Nagurney, JT
Wiviott, SD
Fleg, JL
Schoenfeld, DA
Udelson, JE
Hoffmann, U
AF Truong, Quynh A.
Hayden, Douglas
Woodard, Pamela K.
Kirby, Ruth
Chou, Eric T.
Nagurney, John T.
Wiviott, Stephen D.
Fleg, Jerome L.
Schoenfeld, David A.
Udelson, James E.
Hoffmann, Udo
TI Sex Differences in the Effectiveness of Early Coronary Computed
Tomographic Angiography Compared With Standard Emergency Department
Evaluation for Acute Chest Pain The Rule-Out Myocardial Infarction With
Computer-Assisted Tomography (ROMICAT)-II Trial
SO CIRCULATION
LA English
DT Article
DE acute coronary syndrome; chest pain; emergency service, hospital; sex;
tomography; x-ray computed
ID AMERICAN-HEART-ASSOCIATION; CT ANGIOGRAPHY; ARTERY-DISEASE;
CARDIOVASCULAR-RADIOLOGY; DIAGNOSTIC PERFORMANCE; CLINICAL-CARDIOLOGY;
DOSE REDUCTION; RADIATION; RISK; INTERVENTION
AB Background
We evaluate sex-based differences in the effectiveness of early cardiac computed tomographic angiography (CCTA) and standard emergency department (ED) evaluation in patients with acute chest pain.
Methods and Results
In the Rule-Out Myocardial Infarction With Computer-Assisted Tomography (ROMICAT)-II multicenter, controlled trial, we randomized 1000 patients (47% women) 40 to 74 years of age with symptoms suggestive of acute coronary syndrome to an early CCTA or standard ED evaluation. In this prespecified analysis, women in the CCTA arm had a greater reduction in length of stay, lower hospital admission rates, and lesser increased cumulative radiation dose than men in a comparison of ED strategies (P for interaction 0.02). Although women had lower acute coronary syndrome rates than men (3% versus 12%; P<0.0001), sex differences in length of stay persisted after adjustment for baseline differences, including acute coronary syndrome rate (P for interaction <0.03). Length of stay was similar between sexes with normal CCTA findings (P=0.11). There was no missed acute coronary syndrome for either sex. No difference was observed in major adverse cardiac events between sexes and ED strategies (P for interaction =0.39). Women had more normal CCTA examinations than men (58% versus 37%; P<0.0001), less obstructive coronary disease by CCTA (5% versus 17%; P=0.0001), but similar normalcy rates for functional testing (P=0.65). Men in the CCTA arm had the highest rate of invasive coronary angiography (18%), whereas women had comparable low 5% rates regardless of ED strategy.
Conclusions
This trial provides data supporting an early CCTA strategy as an attractive option in women presenting to the ED with symptoms suggestive of acute coronary syndrome. The findings may be explained by lower CAD prevalence and severity in women than men.
C1 [Truong, Quynh A.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program,Div Cardiol, Boston, MA 02114 USA.
[Truong, Quynh A.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Nagurney, John T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Emergency Dept, Boston, MA 02114 USA.
[Hayden, Douglas; Schoenfeld, David A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Woodard, Pamela K.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA.
[Kirby, Ruth; Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Chou, Eric T.] Kaiser Permanente Fontana Med Ctr, Fontana, CA USA.
[Wiviott, Stephen D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02114 USA.
[Udelson, James E.] Tufts Med Ctr, Div Cardiol, Boston, MA USA.
[Udelson, James E.] Tufts Med Ctr, Ctr Cardiovasc, Boston, MA USA.
RP Truong, QA (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, Div Cardiol, 165 Cambridge St,Ste 400, Boston, MA 02114 USA.
EM qtruong@partners.org
FU National Institutes of Health/National Heart, Lung, and Blood Institute
[U01HL092040, U01HL092022, K23HL098370, L30HL093896]; Qi Imaging; St.
Jude Medical; American College of Radiology Imaging Network; Duke
Clinical Research Institute
FX The study was supported by the National Institutes of Health/National
Heart, Lung, and Blood Institute (U01HL092040 and U01HL092022). Dr
Truong was supported by the National Institutes of Health/National
Heart, Lung, and Blood Institute (K23HL098370 and L30HL093896).; Dr
Truong receives grant support from Qi Imaging, St. Jude Medical,
American College of Radiology Imaging Network, and Duke Clinical
Research Institute. The other authors report no conflicts.
NR 22
TC 9
Z9 9
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 25
PY 2013
VL 127
IS 25
BP 2494
EP 2502
DI 10.1161/CIRCULATIONAHA.113.001736
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 171HU
UT WOS:000320916900013
PM 23685743
ER
PT J
AU Bangalore, S
Bhatt, DL
AF Bangalore, Sripal
Bhatt, Deepak L.
TI Coronary Intravascular Ultrasound
SO CIRCULATION
LA English
DT Article
ID FRACTIONAL FLOW RESERVE; ARTERY-DISEASE; INTRACORONARY ULTRASOUND;
MYOCARDIAL-INFARCTION; ANGIOGRAPHIC DETERMINATION; INTEROBSERVER
VARIABILITY; STENOSIS; ATHEROSCLEROSIS; SAFETY; ANGIOPLASTY
C1 [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, Boston, MA USA.
EM dlbhattmd@post.harvard.edu
OI Bangalore, Sripal/0000-0001-9485-0652
FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic;
Sanofi Aventis; Medicines Company
FX Dr Bhatt discloses the following relationships - Advisory Board:
Elsevier Practice Update Cardiology, Medscape Cardiology; Board of
Directors: Boston VA Research Institute, Society of Chest Pain Centers;
Chair: American Heart Association Get With The Guidelines Science
Subcommittee; Honoraria: American College of Cardiology (Editor,
Clinical Trials, Cardiosource), Duke Clinical Research Institute
(clinical trial steering committees), Slack Publications (Chief Medical
Editor, Cardiology Today's Intervention), WebMD (CME steering
committees); Other: Senior Associate Editor, Journal of Invasive
Cardiology; Data Monitoring Committees: Duke Clinical Research
Institute, Population Health Research Institute; Research Grants:
Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic,
Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx
Pharma, Takeda. Dr Bangalore reports no conflicts.
NR 34
TC 3
Z9 3
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 25
PY 2013
VL 127
IS 25
BP E868
EP E874
DI 10.1161/CIRCULATIONAHA.113.003534
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 171HU
UT WOS:000320916900002
PM 23797744
ER
PT J
AU Woodell, A
Coughlin, B
Kunchithapautham, K
Casey, S
Williamson, T
Ferrell, WD
Atkinson, C
Jones, BW
Rohrer, B
AF Woodell, Alex
Coughlin, Beth
Kunchithapautham, Kannan
Casey, Sarah
Williamson, Tucker
Ferrell, W. Drew
Atkinson, Carl
Jones, Bryan W.
Rohrer, Baerbel
TI Alternative Complement Pathway Deficiency Ameliorates Chronic
Smoke-Induced Functional and Morphological Ocular Injury
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; FACTOR-H
POLYMORPHISM; CAUSES OXIDATIVE DAMAGE; MACULAR DEGENERATION;
CIGARETTE-SMOKE; BRUCHS MEMBRANE; FACTOR-B; CHOROIDAL
NEOVASCULARIZATION; MITOCHONDRIAL DYSFUNCTION
AB Background: Age-related macular degeneration (AMD), a complex disease involving genetic variants and environmental insults, is among the leading causes of blindness in Western populations. Genetic and histologic evidence implicate the complement system in AMD pathogenesis; and smoking is the major environmental risk factor associated with increased disease risk. Although previous studies have demonstrated that cigarette smoke exposure (CE) causes retinal pigment epithelium (RPE) defects in mice, and smoking leads to complement activation in patients, it is unknown whether complement activation is causative in the development of CE pathology; and if so, which complement pathway is required.
Methods: Mice were exposed to cigarette smoke or clean, filtered air for 6 months. The effects of CE were analyzed in wildtype (WT) mice or mice without a functional complement alternative pathway (AP; CFB-/-) using molecular, histological, electrophysiological, and behavioral outcomes.
Results: CE in WT mice exhibited a significant reduction in function of both rods and cones as determined by electroretinography and contrast sensitivity measurements, concomitant with a thinning of the nuclear layers as measured by SD-OCT imaging and histology. Gene expression analyses suggested that alterations in both photoreceptors and RPE/choroid might contribute to the observed loss of function, and visualization of complement C3d deposition implies the RPE/Bruch's membrane (BrM) complex as the target of AP activity. RPE/BrM alterations include an increase in mitochondrial size concomitant with an apical shift in mitochondrial distribution within the RPE and a thickening of BrM. CFB-/- mice were protected from developing these CE-mediated alterations.
Conclusions: Taken together, these findings provide clear evidence that ocular pathology generated in CE mice is dependent on complement activation and requires the AP. Identifying animal models with RPE/BrM damage and verifying which aspects of pathology are dependent upon complement activation is essential for developing novel complement-based treatment approaches for the treatment of AMD.
C1 [Woodell, Alex; Rohrer, Baerbel] Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
[Coughlin, Beth; Kunchithapautham, Kannan; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Casey, Sarah; Williamson, Tucker; Atkinson, Carl] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
[Ferrell, W. Drew; Jones, Bryan W.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
[Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
EM rohrer@musc.edu
OI Jones, Bryan/0000-0001-5527-6643
FU Department for Veterans Affairs [RX000444]; Research to Prevent
Blindness (RPB), New York, NY; Foundation Fighting Blindness, Columbia,
MD; NIH NHLBI [RO1 091944]; NIH [C06RR015455]
FX This work was supported in part by a Department for Veterans Affairs
merit award RX000444 (BR), unrestricted grant to MUSC from Research to
Prevent Blindness (RPB), New York, NY and Foundation Fighting Blindness,
Columbia, MD, and NIH NHLBI RO1 091944 (CA). Animal studies were
conducted in a facility constructed with support from the NIH
(C06RR015455). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 93
TC 9
Z9 9
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2013
VL 8
IS 6
AR e67894
DI 10.1371/journal.pone.0067894
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175IB
UT WOS:000321223000122
PM 23825688
ER
PT J
AU Kaymakcalan, MD
Je, Y
Sonpavde, G
Galsky, M
Nguyen, PL
Heng, DYC
Richards, CJ
Choueiri, TK
AF Kaymakcalan, M. D.
Je, Y.
Sonpavde, G.
Galsky, M.
Nguyen, P. L.
Heng, D. Y. C.
Richards, C. J.
Choueiri, T. K.
TI Risk of infections in renal cell carcinoma (RCC) and non-RCC patients
treated with mammalian target of rapamycin inhibitors
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE renal cell carcinoma; mTOR inhibitors; temsirolimus; everolimus;
infections; meta-analysis
ID CANCER-TREATMENT-GROUP; PHASE-III TRIAL; NEUROENDOCRINE TUMORS;
INTERFERON-ALPHA; CLINICAL-TRIALS; EVEROLIMUS; TEMSIROLIMUS; PLACEBO;
THERAPY; METAANALYSIS
AB Background: Mammalian target of rapamycin (mTOR) inhibitors are used in a variety of malignancies. Infections have been reported with these drugs. We performed an up-to-date meta-analysis to further characterise the risk of infections in cancer patients treated with these agents.
Methods: Pubmed and oncology conferences' proceedings were searched for studies from January 1966 to June 2012. Studies were limited to phase II and III randomised controlled trials (RCTs) of everolimus or temsirolimus reporting on cancer patients with adequate safety profiles. Summary incidences, relative risks (RRs), and 95% confidence intervals (CIs) were calculated.
Results: A total of 3180 patients were included. The incidence of all-grade and high-grade infections due to mTOR inhibitors was 33.1% (95% CI, 24.5-43.0%) and 5.6% (95% CI, 3.8-8.3%), respectively. Compared with controls, the RR of all-grade and high-grade infections due to mTOR inhibitors was 2.00 (95% CI, 1.76-2.28, P<0.001) and 2.60 (95% CI, 1.54-4.41, P<0.001), respectively. Subgroup analysis found no difference in incidences or risks between everolimus and temsirolimus or between different tumour types (renal cell carcinoma (RCC) vs non-RCC). Infections included respiratory tract (61.7%), genitourinary (29.4%), skin/soft tissue (4.2%), and others (4.9%).
Conclusion: Treatment with mTOR inhibitors is associated with a significant increase in risk of infections. Close monitoring for any signs of infections is warranted.
C1 [Kaymakcalan, M. D.; Nguyen, P. L.] Dana Farber Canc Inst, Dept Pharm, Boston, MA 02215 USA.
[Je, Y.] Kyung Hee Univ, Dept Food & Nutr, Seoul 130701, South Korea.
[Sonpavde, G.] UAB, Ctr Comprehens Canc, Dept Med Oncol, Birmingham, AL 35205 USA.
[Galsky, M.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA.
[Nguyen, P. L.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Heng, D. Y. C.] Tom Baker Canc Clin, Dept Med Oncol, Calgary, AB T2N 4N2, Canada.
[Heng, D. Y. C.] Univ Alberta, Calgary, AB T2N 4N2, Canada.
[Richards, C. J.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Richards, C. J.; Choueiri, T. K.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Choueiri, T. K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP Choueiri, TK (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Toni_Choueiri@dfci.harvard.edu
FU Trust Family Research Fund for Kidney Cancer
FX This study was supported by Trust Family Research Fund for Kidney
Cancer.
NR 40
TC 13
Z9 13
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUN 25
PY 2013
VL 108
IS 12
BP 2478
EP 2484
DI 10.1038/bjc.2013.278
PG 7
WC Oncology
SC Oncology
GA 172LD
UT WOS:000321003700010
PM 23736025
ER
PT J
AU Salanitro, AH
Kripalani, S
Resnic, J
Mueller, SK
Wetterneck, TB
Haynes, KT
Stein, J
Kaboli, PJ
Labonville, S
Etchells, E
Cobaugh, DJ
Hanson, D
Greenwald, JL
Williams, MV
Schnipper, JL
AF Salanitro, Amanda H.
Kripalani, Sunil
Resnic, JoAnne
Mueller, Stephanie K.
Wetterneck, Tosha B.
Haynes, Katherine Taylor
Stein, Jason
Kaboli, Peter J.
Labonville, Stephanie
Etchells, Edward
Cobaugh, Daniel J.
Hanson, David
Greenwald, Jeffrey L.
Williams, Mark V.
Schnipper, Jeffrey L.
TI Rationale and design of the Multicenter Medication Reconciliation
Quality Improvement Study (MARQUIS)
SO BMC HEALTH SERVICES RESEARCH
LA English
DT Article
DE Medication reconciliation; Hospitalization; Quality improvement; Care
transitions
ID PATIENT SAFETY RESEARCH; ADVERSE DRUG EVENTS; HEALTH-CARE; EPISTEMOLOGY;
FRAMEWORK; DISCREPANCIES; ADMISSION; ERRORS; TRIAL; INTERVENTIONS
AB Background: Unresolved medication discrepancies during hospitalization can contribute to adverse drug events, resulting in patient harm. Discrepancies can be reduced by performing medication reconciliation; however, effective implementation of medication reconciliation has proven to be challenging. The goals of the Multi-Center Medication Reconciliation Quality Improvement Study (MARQUIS) are to operationalize best practices for inpatient medication reconciliation, test their effect on potentially harmful unintentional medication discrepancies, and understand barriers and facilitators of successful implementation.
Methods: Six U. S. hospitals are participating in this quality improvement mentored implementation study. Each hospital has collected baseline data on the primary outcome: the number of potentially harmful unintentional medication discrepancies per patient, as determined by a trained on-site pharmacist taking a "gold standard" medication history. With the guidance of their mentors, each site has also begun to implement one or more of 11 best practices to improve medication reconciliation. To understand the effect of the implemented interventions on hospital staff and culture, we are performing mixed methods program evaluation including surveys, interviews, and focus groups of front line staff and hospital leaders.
Discussion: At baseline the number of unintentional medication discrepancies in admission and discharge orders per patient varies by site from 2.35 to 4.67 (mean=3.35). Most discrepancies are due to history errors (mean 2.12 per patient) as opposed to reconciliation errors (mean 1.23 per patient). Potentially harmful medication discrepancies averages 0.45 per patient and varies by site from 0.13 to 0.82 per patient. We discuss several barriers to implementation encountered thus far. In the end, we anticipate that MARQUIS tools and lessons learned have the potential to decrease medication discrepancies and improve patient outcomes.
C1 [Salanitro, Amanda H.] VA Tennessee Valley Healthcare Syst, Ctr Geriatr Res Educ & Clin, Nashville, TN USA.
[Salanitro, Amanda H.; Kripalani, Sunil] Vanderbilt Univ, Dept Med, Sect Hosp Med, Div Gen Internal Med & Publ Hlth, Nashville, TN USA.
[Resnic, JoAnne] Soc Hosp Med, Ctr Hosp Innovat & Improvement, Philadelphia, PA USA.
[Mueller, Stephanie K.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA.
[Mueller, Stephanie K.; Greenwald, Jeffrey L.; Schnipper, Jeffrey L.] Harvard Univ, Sch Med, Boston, MA USA.
[Wetterneck, Tosha B.] UW Madison, Ctr Qual & Prod Improvement, Madison, WI USA.
[Wetterneck, Tosha B.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
[Haynes, Katherine Taylor] Vanderbilt Univ, Peabody Coll, Nashville, TN 37203 USA.
[Stein, Jason] Emory Univ, Dept Med, Qual Program, Atlanta, GA 30322 USA.
[Kaboli, Peter J.] Univ Iowa, Ctr Comprehens Access & Delivery Res & Evaluat CA, Iowa City VA Healthcare Syst, Carver Coll Med, Iowa City, IA USA.
[Labonville, Stephanie] Brigham & Womens Hosp, Dept Pharm Serv, Boston, MA 02115 USA.
[Etchells, Edward] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
[Cobaugh, Daniel J.] Amer Soc Hlth Syst Pharmacists Res & Educ Fdn, Bethesda, MD USA.
[Hanson, David] Amer Assoc Crit Care Nurses, Aliso Viejo, CA USA.
[Greenwald, Jeffrey L.] Massachusetts Gen Hosp, Inpatient Clinician Educ Serv, Boston, MA 02114 USA.
[Williams, Mark V.] Northwestern Univ, Div Hosp Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Schnipper, Jeffrey L.] Brigham & Womens Hosp, Div Gen Med, BWH Hospitalist Serv, Boston, MA 02115 USA.
RP Salanitro, AH (reprint author), VA Tennessee Valley Healthcare Syst, Ctr Geriatr Res Educ & Clin, Nashville, TN USA.
EM Amanda.Salanitro@Vanderbilt.Edu
FU Agency for Healthcare Research and Quality (AHRQ) [R18HS019598-01]
FX Grant support: Agency for Healthcare Research and Quality (AHRQ)
R18HS019598-01 to the Society of Hospital Medicine (SHM) with Dr.
Schnipper as principle investigator.
NR 34
TC 9
Z9 9
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6963
J9 BMC HEALTH SERV RES
JI BMC Health Serv. Res.
PD JUN 25
PY 2013
VL 13
AR 230
DI 10.1186/1472-6963-13-230
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 174JQ
UT WOS:000321151900001
PM 23800355
ER
PT J
AU Wessler, JD
Grip, LT
Mendell, J
Giugliano, RP
AF Wessler, Jeffrey D.
Grip, Laura T.
Mendell, Jeanne
Giugliano, Robert P.
TI The P-Glycoprotein Transport System and Cardiovascular Drugs
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Review
DE adverse drug event(s); drug-drug interaction; P-glycoprotein;
pharmacology
ID FACTOR XA INHIBITOR; MULTIDRUG-RESISTANCE; IN-VITRO; ORAL
ANTICOAGULANTS; ATRIAL-FIBRILLATION; CLINICAL-RELEVANCE; CARDIAC
GLYCOSIDE; HEALTHY-SUBJECTS; DIGOXIN; CLOPIDOGREL
AB Permeability glycoprotein (P-gp) mediates the export of drugs from cells located in the small intestine, blood-brain barrier, hepatocytes, and kidney proximal tubule, serving a protective function for the body against foreign substances. Intestinal absorption, biliary excretion, and urinary excretion of P-gp substrates can therefore be altered by either the inhibition or induction of P-gp. A wide spectrum of drugs, such as anticancer agents and steroids, are known P-gp substrates and/or inhibitors, and many cardiovascular drugs have recently been observed to have clinically relevant interactions as well. We review the interactions among commonly prescribed cardiovascular drugs that are P-gp substrates and observe interactions involving P-gp that may be relevant to clinical practice. Cardiovascular drugs with narrow therapeutic indexes (e.g., antiarrhythmic agents, anticoagulant agents) have demonstrated large increases in concentrations when coadministered with potent P-gp inhibitors, thus increasing the risk for drug toxicity. Therefore, dose adjustment or use of alternative agents should be considered when strong P-gp-mediated drug-drug interactions are present. Finally, interactions between novel drugs and known P-gp inhibitors are now being systematically evaluated during drug development, and recommended guidelines for the administration of P-gp substrate drugs will be expanded. (C) 2013 by the American College of Cardiology Foundation
C1 [Wessler, Jeffrey D.] Harvard Univ, Sch Med, Boston, MA USA.
[Grip, Laura T.; Giugliano, Robert P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,TIMI Study Grp, Boston, MA USA.
[Mendell, Jeanne] Daiichi Sankyo Pharma Dev, Edison, NJ USA.
RP Giugliano, RP (reprint author), TIMI Study Grp, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU Daiichi Sankyo
FX The ENGAGE AF-TIMI 48 trial is funded by Daiichi Sankyo. Dr. Mendell is
an employee of and has stock options with Daiichi Sankyo. All other
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
NR 52
TC 57
Z9 59
U1 2
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUN 25
PY 2013
VL 61
IS 25
BP 2495
EP 2502
DI 10.1016/j.jacc.2013.02.058
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167AO
UT WOS:000320602700001
PM 23563132
ER
PT J
AU Jung, M
AF Jung, Minsoo
TI Sexual Behavior and Condom Use among Gay Men, Female Sex Workers, and
Their Customers: Evidence from South Korea
SO PLOS ONE
LA English
DT Article
ID RISK BEHAVIOR; DETERMINANTS; VIETNAM; WOMEN
AB Background: Despite the significance for sexually transmitted diseases (STD) control in East Asia, few studies have examined the relationship between high-risk sexual behavior and condom use. We investigated how three sexually vulnerable groups for STDs show differences in condom use behaviors (CUBs) depending on their STD infection.
Methods: The source of data came from the National Survey for STD Prevalence Rate and Sexual Behavior of the High-Risk Sexual Community. The effects of behavioral determinants on CUBs were estimated by using path analysis models. An 11-item questionnaire assessing subjects' health risk behaviors, sexual beliefs, sexual risk behaviors, and condom use.
Results: Condom use was higher for men who have sex with men (MSM; n = 108) when they were bisexuals and had high self-efficacy, for Johns (Johns; n = 118) when they had experience of STD infection, and for female sex workers (FSWs; n = 1,083) when they had high self-efficacy, did not engage in drunken sex, and were anxious about infection. Regardless of whether they were infected with STDs, FSWs always used condom when they had high sexual beliefs. On the contrary, Johns exhibited a negative relationship between sexual risk behavior and condom use when they had experience of STD infection. The variable commonly significant to all three groups was the number of sex partners; but it exhibited a positive relationship with MSMs and Johns, and a negative one with FSWs.
Conclusions: CUBs were related to sexual beliefs as well as sexual risk behavior. At the same time, the experience of STD infection mediated the relationship between the two. Therefore, we need to draw social attention to promote safer sex among STD-vulnerable groups.
C1 [Jung, Minsoo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Seoul, South Korea.
RP Jung, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM minsoo_jung@dfci.harvard.edu
OI Jung, Minsoo/0000-0003-3317-6507
FU National Research Foundation of Korea; Korean Government
[NRF-2007-E00049-00]
FX This work was supported by the National Research Foundation of Korea
Grant funded by the Korean Government (NRF-2007-E00049-00). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 39
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 24
PY 2013
VL 8
IS 6
AR e66867
DI 10.1371/journal.pone.0066867
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 182JP
UT WOS:000321738400072
PM 23950786
ER
PT J
AU Simon, SR
Keohane, CA
Amato, M
Coffey, M
Cadet, B
Zimlichman, E
Bates, DW
AF Simon, Steven R.
Keohane, Carol A.
Amato, Mary
Coffey, Michael
Cadet, Bismarck
Zimlichman, Eyal
Bates, David W.
TI Lessons learned from implementation of computerized provider order entry
in 5 community hospitals: a qualitative study
SO BMC MEDICAL INFORMATICS AND DECISION MAKING
LA English
DT Article
DE Quality of care; Clinical decision support; Meaningful use;
Transformation
ID HEALTH INFORMATION-TECHNOLOGY; ADOPTION; SYSTEMS; IMPACT; CARE;
CONSEQUENCES; INNOVATIONS
AB Background: Computerized Provider Order Entry (CPOE) can improve patient safety, quality and efficiency, but hospitals face a host of barriers to adopting CPOE, ranging from resistance among physicians to the cost of the systems. In response to the incentives for meaningful use of health information technology and other market forces, hospitals in the United States are increasingly moving toward the adoption of CPOE. The purpose of this study was to characterize the experiences of hospitals that have successfully implemented CPOE.
Methods: We used a qualitative approach to observe clinical activities and capture the experiences of physicians, nurses, pharmacists and administrators at five community hospitals in Massachusetts (USA) that adopted CPOE in the past few years. We conducted formal, structured observations of care processes in diverse inpatient settings within each of the hospitals and completed in-depth, semi-structured interviews with clinicians and staff by telephone. After transcribing the audiorecorded interviews, we analyzed the content of the transcripts iteratively, guided by principles of the Immersion and Crystallization analytic approach. Our objective was to identify attitudes, behaviors and experiences that would constitute useful lessons for other hospitals embarking on CPOE implementation.
Results: Analysis of observations and interviews resulted in findings about the CPOE implementation process in five domains: governance, preparation, support, perceptions and consequences. Successful institutions implemented clear organizational decision-making mechanisms that involved clinicians (governance). They anticipated the need for education and training of a wide range of users (preparation). These hospitals deployed ample human resources for live, in-person training and support during implementation. Successful implementation hinged on the ability of clinical leaders to address and manage perceptions and the fear of change. Implementation proceeded smoothly when institutions identified and anticipated the consequences of the change.
Conclusions: The lessons learned in the five domains identified in this study may be useful for other community hospitals embarking on CPOE adoption.
C1 [Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Simon, Steven R.; Keohane, Carol A.; Amato, Mary; Zimlichman, Eyal; Bates, David W.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Amato, Mary] Massachusetts Coll Pharm & Hlth Sci Boston, Boston, MA USA.
[Coffey, Michael] North Shore Phys Grp, Saugus, MA USA.
[Cadet, Bismarck] Winchester Hosp, Winchester, MA USA.
RP Simon, SR (reprint author), VA Boston Healthcare Syst, Boston, MA USA.
EM Steven.simon2@va.gov
FU Rx Foundation; Commonwealth Fund
FX The Rx Foundation and Commonwealth Fund supported the study. They
commented on its design, but were not involved in data collection, data
management, analysis, interpretation, or writing of the manuscript. The
authors thank Mr. Max Stewart for editorial assistance.
NR 29
TC 13
Z9 13
U1 4
U2 26
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6947
J9 BMC MED INFORM DECIS
JI BMC Med. Inform. Decis. Mak.
PD JUN 24
PY 2013
VL 13
AR 67
DI 10.1186/1472-6947-13-67
PG 10
WC Medical Informatics
SC Medical Informatics
GA 172JD
UT WOS:000320998100001
PM 23800211
ER
PT J
AU Toteberg-Harms, M
Hanson, JVM
Funk, J
AF Toeteberg-Harms, Marc
Hanson, James V. M.
Funk, Jens
TI Cataract Surgery combined with excimer laser trabeculotomy to lower
intraocular pressure: effectiveness dependent on preoperative IOP
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Cataract; Cataract surgery; Extracapsular cataract extraction;
Phacoemulsification; Glaucoma; Glaucoma surgery; Excimer laser
trabeculotomy; Excimer laser trabeculostomy; Trabecular meshwork;
Primary open angle glaucoma; Ocular hypertension
ID CHAMBER LENS IMPLANTATION; NORMAL-TENSION GLAUCOMA; OPEN-ANGLE GLAUCOMA;
TERM-FOLLOW-UP; VISUAL-ACUITY; AB-INTERNO; 308 NM; PHACOEMULSIFICATION;
TRABECULECTOMY; PROGRESSION
AB Background: Cataract surgery combined with excimer laser trabeculotomy (phaco-ELT) can reduce intraocular pressure (IOP). The aim of this study was to evaluate the effect of phaco-ELT on IOP in patients as a function of preoperative IOP.
Methods: Patients with open-angle glacuoma or ocular hypertension who received phaco-ELT between 01/2008 and 10/2009 were included. Patients were assigned based on preoperative IOP either to the study group (<= 21 mmHg) or control group (>21 mmHg) in this IRB-approved, prospective, consecutive case series. Visual Acuity, IOP, and number of anti-glaucoma drugs (AGD) were recorded at baseline and 12 months after phaco-ELT. Any postoperative complications were also recorded.
Results: 64 eyes of 64 patients (76.5 +/- 9.4 years) were included. Baseline IOP was 19.8 +/- 5.3 mmHg (AGD 2.4 +/- 1.1) for all eyes, 16.5 +/- 2.9 mmHg (AGD 2.5 +/- 1.0) for the study group, and 25.8 +/- 2.9 mmHg (AGD 2.2 +/- 1.4) for the control group. Across the two groups, IOP was reduced by 4.5 +/- 5.9 mmHg (-23.0%, p < 0.001) and AGD by 0.9 +/- 1.5 (-38.9%, p < 0.001). For the study group IOP was reduced by 1.9 +/- 4.4 mmHg (-11. 5 %, p = 0.012) and AGD by 1.1 +/- 1.4 (-42.9%, p < 0.001), and for the control group by 9.5 +/- 5.4 mmHg (-36.6%, p < 0.001) and AGD by 0.7 +/- 1.6 (-29.5%, p = 0.085). There were no serious postoperative complications such as endophthalmitis, significant hyphema, or a severe fibrinous reaction of the anterior chamber.
Conclusions: IOP remained significantly reduced from baseline 12 months after phaco-ELT regardless of preoperative IOP levels, with no major complications. The IOP reduction remained constant over the entire follow-up. Hence, phaco-ELT can be considered in glaucoma and ocular hypertensive patients whenever cataract surgery is performed, in order to further reduce IOP or to reduce the requirement for IOP-reducing medications.
C1 [Toeteberg-Harms, Marc] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
[Toeteberg-Harms, Marc; Hanson, James V. M.; Funk, Jens] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
RP Toteberg-Harms, M (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM MarcToeteberg@aol.com
RI Toteberg-Harms, Marc/J-4954-2013
OI Toteberg-Harms, Marc/0000-0002-2134-1336
NR 41
TC 2
Z9 3
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUN 24
PY 2013
VL 13
AR UNSP 24
DI 10.1186/1471-2415-13-24
PG 9
WC Ophthalmology
SC Ophthalmology
GA 175DC
UT WOS:000321209000001
PM 23799932
ER
PT J
AU Stickrath, C
Noble, M
Prochazka, A
Anderson, M
Griffiths, M
Manheim, J
Sillau, S
Aagaard, E
AF Stickrath, Chad
Noble, Melissa
Prochazka, Allan
Anderson, Mel
Griffiths, Megan
Manheim, Jonathan
Sillau, Stefan
Aagaard, Eva
TI Attending Rounds in the Current Era What Is and Is Not Happening
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID DUTY-HOUR REGULATIONS; INTERNAL-MEDICINE; EDUCATION; BEDSIDE; FACULTY;
MODEL
AB Importance: General medicine rounds by attending physicians provide the foundation for patient care and education in teaching hospitals. However, the detailed activities of these rounds in the current era are not well characterized.
Objective: To describe the characteristics of attending rounds for internal medicine inpatients in a large teaching hospital system.
Design: A cross-sectional observational study of attending rounds in internal medicine. Rounds were observed directly by research assistants.
Setting: Four teaching hospitals associated with a large public medical school.
Participants: Fifty-six attending physicians and 279 trainees treating 807 general medicine inpatients.
Main Outcomes and Measures: Duration and location of rounds, composition of teams, and frequency of 19 potential activities during rounds.
Results: We observed 90 days of rounds. A typical rounding day consisted of 1 attending with 3 trainees visiting a median of 9 (range, 2-18 [SD, 2.9]) patients for a median of 2.0 hours (range, 25-241 [SD, 2.7] minutes). On rounds, teams most frequently discussed the patient care plan (96.7% of patients), reviewed diagnostic studies (90.7%), communicated with patients (73.4%), and discussed the medication list (68.8%). Teams infrequently discussed invasive lines or tubes (9.3%) or nursing notes (6.2%) and rarely communicated with nurses (12.0%) or taught physical examination skills (14.6%), evidence-based medicine topics (7.2%), or learner-identified topics (3.2%). Many commonly performed activities occurred infrequently at the bedside.
Conclusions and Relevance: Most activities on attending rounds do not take place at the bedside. The teams discuss patient care plans and test results most of the time but fail to include many items that may be of significant value, including specific aspects of patient care, interprofessional communication, and learner-centered education. Future studies are needed to further assess the implications of these observations.
C1 [Stickrath, Chad; Prochazka, Allan; Anderson, Mel; Manheim, Jonathan; Sillau, Stefan; Aagaard, Eva] Univ Colorado, Sch Med, Dept Med, Denver, CO 80220 USA.
[Stickrath, Chad; Prochazka, Allan; Anderson, Mel] Denver Vet Affairs Med Ctr, Med Serv, Denver, CO USA.
[Noble, Melissa; Griffiths, Megan] Univ Colorado, Sch Med, Denver, CO 80220 USA.
RP Stickrath, C (reprint author), Univ Colorado, Sch Med, Med Serv, Denver VA Med Ctr, 1055 Clermont St,Box 111, Denver, CO 80220 USA.
EM Chad.stickrath@va.gov
FU University of Colorado Academy of Medical Educators Rymer Family
Endowment Grant
FX This study was supported by the University of Colorado Academy of
Medical Educators Rymer Family Endowment Grant.
NR 20
TC 22
Z9 22
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 24
PY 2013
VL 173
IS 12
BP 1084
EP 1089
DI 10.1001/jamainternmed.2013.6041
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170OE
UT WOS:000320861700012
PM 23649040
ER
PT J
AU Schwartz, JAT
Pearson, SD
AF Schwartz, Jennifer A. T.
Pearson, Steven D.
TI Cost Consideration in the Clinical Guidance Documents of Physician
Specialty Societies in the United States
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID PRACTICE GUIDELINES; AMERICAN-COLLEGE; TASK-FORCE; HEART-ASSOCIATION;
MEDICINE; ALLOCATION; CARDIOLOGY; ISSUES; CARE
AB Importance: Despite increasing concerns regarding the cost of health care, the consideration of costs in the development of clinical guidance documents by physician specialty societies has received little analysis.
Objective: To evaluate the approach to consideration of cost in publicly available clinical guidance documents and methodological statements produced between 2008 and 2012 by the 30 largest US physician specialty societies.
Design: Qualitative document review.
Main Outcomes and Measures: Whether costs are considered in clinical guidance development, mechanism of cost consideration, and the way that cost issues were used in support of specific clinical practice recommendations.
Results: Methodological statements for clinical guidance documents indicated that 17 of 30 physician societies (57%) explicitly integrated costs, 4 (13%) implicitly considered costs, 3 (10%) intentionally excluded costs, and 6 (20%) made no mention. Of the 17 societies that explicitly integrated costs, 9 (53%) consistently used a formal system in which the strength of recommendation was influenced in part by costs, whereas 8 (47%) were inconsistent in their approach or failed to mention the exact mechanism for considering costs. Among the 138 specific recommendations in these guidance documents that included cost as part of the rationale, the most common form of recommendation (50 [36%]) encouraged the use of a specific medical service because of equal effectiveness and lower cost.
Conclusions and Relevance: Slightly more than half of the largest US physician societies explicitly consider costs in developing their clinical guidance documents; among these, approximately half use an explicit mechanism for integrating costs into the strength of recommendations. Many societies remain vague in their approach. Physician specialty societies should demonstrate greater transparency and rigor in their approach to cost consideration in documents meant to influence care decisions.
C1 [Schwartz, Jennifer A. T.; Pearson, Steven D.] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA.
[Pearson, Steven D.] Massachusetts Gen Hosp, Inst Clin & Econ Review, Inst Technol Assessment, Boston, MA 02114 USA.
RP Pearson, SD (reprint author), NIH, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA.
EM pearsonsd@cc.nih.gov
NR 39
TC 19
Z9 19
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 24
PY 2013
VL 173
IS 12
BP 1091
EP 1097
DI 10.1001/jamainternmed.2013.817
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170OE
UT WOS:000320861700014
PM 23649494
ER
PT J
AU Balboni, TA
Balboni, M
Enzinger, AC
Gallivan, K
Paulk, E
Wright, A
Steinhauser, K
VanderWeele, TJ
Prigerson, HG
AF Balboni, Tracy A.
Balboni, Michael
Enzinger, Andrea C.
Gallivan, Kathleen
Paulk, Elizabeth
Wright, Alexi
Steinhauser, Karen
VanderWeele, Tyler J.
Prigerson, Holly G.
TI Provision of Spiritual Support to Patients With Advanced Cancer by
Religious Communities and Associations With Medical Care at the End of
Life
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; TREATMENT PREFERENCES; ETHNIC-DIFFERENCES; NEAR-DEATH;
PALLIATIVE CARE; PHYSICIANS; ACKNOWLEDGMENT; QUESTIONNAIRE;
BENEFICIARIES; VALIDITY
AB Importance: Previous studies report associations between medical utilization at the end-of-life (EoL) and religious coping and spiritual support from the medical team. However, the influence of clergy and religious communities on EoL outcomes is unclear.
Objective: To determine whether spiritual support from religious communities influences terminally ill patients' medical care and quality of life (QoL) near death.
Design, Setting, and Participants: A US-based, multisite cohort study of 343 patients with advanced cancer enrolled from September 2002 through August 2008 and followed up (median duration, 116 days) until death. Baseline interviews assessed support of patients' spiritual needs by religious communities. End-of-life medical care in the final week included the following: hospice, aggressive EoL measures (care in an intensive care unit [ICU], resuscitation, or ventilation), and ICU death.
Main Outcomes and Measures: End-of-life QoL was assessed by caregiver ratings of patient QoL in the last week of life. Multivariable regression analyses were performed on EoL care outcomes in relation to religious community spiritual support, controlling for confounding variables, and were repeated among high religious coping and racial/ethnic minority patients.
Results: Patients reporting high spiritual support from religious communities (43%) were less likely to receive hospice (adjusted odds ratio [AOR], 0.37; 95% CI, 0.20-0.70 [P=.002]), more likely to receive aggressive EoL measures (AOR, 2.62; 95% CI, 1.14-6.06 [P=.02]), and more likely to die in an ICU (AOR, 5.22; 95% CI, 1.71-15.60 [P=.004]). Risks of receiving aggressive EoL interventions and ICU deaths were greater among high religious coping (AOR, 11.02; 95% CI, 2.83-42.89 [P<.001]; and AOR, 22.02; 95% CI, 3.24-149.58 [P=.002]; respectively) and racial/ethnic minority patients (AOR, 8.03; 95% CI, 2.04-31.55 [P=.003]; and AOR, 11.21; 95% CI, 2.29-54.88 [P=.003]; respectively). Among patients well-supported by religious communities, receiving spiritual support from the medical team was associated with higher rates of hospice use (AOR, 2.37; 95% CI, 1.03-5.44 [P=.04]), fewer aggressive interventions (AOR, 0.23; 95% CI, 0.06-0.79 [P=.02]) and fewer ICU deaths (AOR, 0.19; 95% CI, 0.05-0.80 [P=.02]); and EoL discussions were associated with fewer aggressive interventions (AOR, 0.12; 95% CI, 0.02-0.63 [P=.01]).
Conclusions and Relevance: Terminally ill patients who are well supported by religious communities access hospice care less and aggressive medical interventions more near death. Spiritual care and EoL discussions by the medical team may reduce aggressive treatment, highlighting spiritual care as a key component of EoL medical care guidelines.
C1 [Balboni, Tracy A.; Balboni, Michael; Enzinger, Andrea C.; Wright, Alexi; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.
[Balboni, Tracy A.; Balboni, Michael; Enzinger, Andrea C.; Wright, Alexi; Prigerson, Holly G.] Dana Farber Canc Inst, McGraw Patterson Ctr Populat Sci, Boston, MA 02115 USA.
[Balboni, Tracy A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Balboni, Tracy A.; Balboni, Michael; Enzinger, Andrea C.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
[Wright, Alexi] Dana Farber Canc Inst, Div Womens Cancers, Boston, MA 02115 USA.
[Enzinger, Andrea C.; Wright, Alexi] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Balboni, Tracy A.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA.
[Balboni, Michael; Prigerson, Holly G.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Wright, Alexi] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Enzinger, Andrea C.] Harvard Univ, Sch Med, Boston, MA USA.
[Balboni, Michael] Harvard Univ, Sch Divin, Cambridge, MA 02138 USA.
[Gallivan, Kathleen] Brigham & Womens Hosp, Dept Chaplaincy, Boston, MA 02115 USA.
[Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Paulk, Elizabeth] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
[Steinhauser, Karen] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[VanderWeele, Tyler J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[VanderWeele, Tyler J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Balboni, TA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA.
EM tbalboni@lroc.harvard.edu
FU National Institute of Mental Health [MH63892]; National Cancer Institute
[CA 106370, CA 156732]; Fetzer Foundation; American Society of Clinical
Oncology Young Investigator Award; Career Development Award; Healthcare
Chaplaincy/John Templeton Foundation Award; University of Chicago
Program in Religion and Medicine Faculty Scholars Award; John Templeton
Foundation grant
FX This research was supported by grant MH63892 from the National Institute
of Mental Health and grants CA 106370 and CA 156732 from the National
Cancer Institute (Dr Prigerson); by the Fetzer Foundation (Drs Prigerson
and Paulk); by an American Society of Clinical Oncology Young
Investigator Award and Career Development Award and a Healthcare
Chaplaincy/John Templeton Foundation Award (Dr T. A. Balboni); by a
University of Chicago Program in Religion and Medicine Faculty Scholars
Award (Dr M. Balboni); and by a John Templeton Foundation grant (Dr
VanderWeele).
NR 36
TC 46
Z9 46
U1 3
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 24
PY 2013
VL 173
IS 12
BP 1109
EP 1117
DI 10.1001/jamainternmed.2013.903
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170OE
UT WOS:000320861700018
PM 23649656
ER
PT J
AU Lee, BY
Sonnenberg, A
AF Lee, Brent Y.
Sonnenberg, Amnon
TI Time Trends of Mortality From Colorectal Cancer in the United States: A
Birth-Cohort Analysis
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
ID HELICOBACTER-PYLORI INFECTION; PEPTIC-ULCER; RISK; METAANALYSIS
C1 [Lee, Brent Y.; Sonnenberg, Amnon] Portland VA Med Ctr, Div Gastroenterol & Hepatol, Portland, OR USA.
[Lee, Brent Y.; Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Div Gastroenterol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 6
TC 1
Z9 1
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 24
PY 2013
VL 173
IS 12
BP 1148
EP 1150
DI 10.1001/jamainternmed.2013.656
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170OE
UT WOS:000320861700029
PM 23700085
ER
PT J
AU Ishida, JH
McCulloch, CE
Dudley, RA
Grimes, BA
Johansen, KL
AF Ishida, Julie H.
McCulloch, Charles E.
Dudley, R. Adams
Grimes, Barbara A.
Johansen, Kirsten L.
TI Dialysis Facility Profit Status and Compliance With a Black Box Warning
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Ishida, Julie H.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA 94143 USA.
[Dudley, R. Adams] Univ Calif San Francisco, Dept Med, Div Pulm Dis & Crit Care Med, San Francisco, CA 94143 USA.
[McCulloch, Charles E.; Dudley, R. Adams; Grimes, Barbara A.; Johansen, Kirsten L.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Dudley, R. Adams] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.
[Johansen, Kirsten L.] San Francisco VA Med Ctr, Dept Med, Div Nephrol, San Francisco, CA USA.
RP Ishida, JH (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, 521 Parnassus Ave,Clin Sci C443,Box 0532, San Francisco, CA 94143 USA.
EM julie.ishida@ucsf.edu
FU NIDDK NIH HHS [K24DK085153, N01-DK-7-0005, T32 DK007219, K24 DK085153]
NR 6
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 24
PY 2013
VL 173
IS 12
BP 1152
EP 1153
DI 10.1001/jamainternmed.2013.979
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 170OE
UT WOS:000320861700031
PM 23699967
ER
PT J
AU Zhu, JQ
Zhu, JH
Springer, TA
AF Zhu, Jieqing
Zhu, Jianghai
Springer, Timothy A.
TI Complete integrin headpiece opening in eight steps
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID X-RAY-SCATTERING; I-LIKE DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS;
HYBRID DOMAIN; EXTRACELLULAR SEGMENT; OUTSIDE-IN; TGF-BETA; A-DOMAIN;
ACTIVATION
AB Carefully soaking crystals with Arg-Gly-Asp (RGD) peptides, we captured eight distinct RGD-bound conformations of the alpha(IIb)beta(3) integrin headpiece. Starting from the closed beta I domain conformation, we saw six intermediate beta I conformations and finally the fully open beta I with the hybrid domain swung out in the crystal lattice. The beta 1-alpha 1 backbone that hydrogen bonds to the Asp side chain of RGD was the first element to move followed by adjacent to metal ion-dependent adhesion site Ca2+, alpha 1 helix, alpha 1' helix, beta 6-alpha 7 loop, alpha 7 helix, and hybrid domain. We define in atomic detail how conformational change was transmitted over long distances in integrins, 40 angstrom from the ligand binding site to the opposite end of the beta I domain and 80 angstrom to the far end of the hybrid domain. During these movements, RGD slid in its binding groove toward alpha(IIb), and its Arg side chain became ordered. RGD concentration requirements in soaking suggested a >200-fold higher affinity after opening. The thermodynamic cycle shows how higher affinity pays the energetic cost of opening.
C1 [Zhu, Jieqing; Zhu, Jianghai; Springer, Timothy A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Program Cellular & Mol Med,Childrens Hosp Boston, Boston, MA 02115 USA.
RP Springer, TA (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Program Cellular & Mol Med,Childrens Hosp Boston, Boston, MA 02115 USA.
EM timothy.springer@childrens.harvard.edu
RI Zhu, Jianghai/B-7339-2014
FU National Institutes of Health [HL-103526]; American Heart Association;
American Society of Hematology
FX This work was supported by National Institutes of Health grant
HL-103526. Jieqing Zhu is a recipient of a Scientist Development Grant
from the American Heart Association and an ASH Scholar Award for junior
faculty from the American Society of Hematology.
NR 55
TC 47
Z9 47
U1 1
U2 17
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD JUN 24
PY 2013
VL 201
IS 7
BP 1053
EP 1068
DI 10.1083/jcb.201212037
PG 16
WC Cell Biology
SC Cell Biology
GA 169IK
UT WOS:000320773500009
PM 23798730
ER
PT J
AU Guha, M
Castellanos-Rizaldos, E
Makrigiorgos, GM
AF Guha, Minakshi
Castellanos-Rizaldos, Elena
Makrigiorgos, G. Mike
TI DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m
Mutation
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; GROWTH-FACTOR-RECEPTOR; REAL-TIME PCR; COLD-PCR;
ACQUIRED-RESISTANCE; GENE-MUTATIONS; GEFITINIB; ERLOTINIB;
IDENTIFICATION; ENRICHMENT
AB Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20. These mutations may originate from small subclonal populations in the primary tumor that become dominant later on during treatment. In order to detect these low-level DNA variations in the primary tumor or to monitor their progress in plasma, it is important to apply reliable and sensitive mutation detection methods. Here, we combine two recently developed methodologies, Differential Strand Separation at Critical Temperature (DISSECT), with peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) for the detection of T790M EGFR mutation. DISSECT pre-enriches low-abundance T790M EGFR mutations from target DNA prior to implementing PNA-LNA PCR, a method that can detect 1 mutant allele in a background of 100-1000 wild type alleles. The combination of DISSECT and PNA-LNA PCR enables the detection of 1 mutant allele in a background of 10,000 wild type alleles. The combined DISSECT-PNA-LNA PCR methodology is amenable to adaptation for the sensitive detection of additional emerging resistance mutations in cancer.
C1 [Guha, Minakshi; Castellanos-Rizaldos, Elena; Makrigiorgos, G. Mike] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, Boston, MA 02115 USA.
[Makrigiorgos, G. Mike] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Div Med Phys & Biophys,Dept Radiat Oncol,Sch Med, Boston, MA 02115 USA.
RP Makrigiorgos, GM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div DNA Repair & Genome Stabil,Dept Radiat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM mmakrigiorgos@lroc.harvard.edu
FU Innovative Molecular Analysis Technologies Program of National Cancer
Institute [CA-111994]
FX This work was supported in part by grant CA-111994 of the Innovative
Molecular Analysis Technologies Program of National Cancer Institute.
The contents of this manuscript do not necessarily represent the
official views of the National Cancer Institute or the National
Institutes of Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. No additional external funding received for this study.
NR 22
TC 9
Z9 10
U1 3
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2013
VL 8
IS 6
AR e67782
DI 10.1371/journal.pone.0067782
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 170JP
UT WOS:000320846500155
PM 23805327
ER
PT J
AU Hass, J
Walton, E
Kirsten, H
Liu, JY
Priebe, L
Wolf, C
Karbalai, N
Gollub, R
White, T
Roessner, V
Muller, KU
Paus, T
Smolka, MN
Schumann, G
Scholz, M
Cichon, S
Calhoun, V
Ehrlich, S
AF Hass, Johanna
Walton, Esther
Kirsten, Holger
Liu, Jingyu
Priebe, Lutz
Wolf, Christiane
Karbalai, Nazanin
Gollub, Randy
White, Tonya
Roessner, Veit
Mueller, Kathrin U.
Paus, Tomas
Smolka, Michael N.
Schumann, Gunter
Scholz, Markus
Cichon, Sven
Calhoun, Vince
Ehrlich, Stefan
CA IMAGEN Consortium
TI A Genome-Wide Association Study Suggests Novel Loci Associated with a
Schizophrenia-Related Brain-Based Phenotype
SO PLOS ONE
LA English
DT Article
ID HUMAN CEREBRAL-CORTEX; DATA QUALITY-CONTROL; HIPPOCAMPAL ATROPHY;
PSYCHOTIC DISORDERS; ALZHEIMERS-DISEASE; QUANTITATIVE TRAIT; BIPOLAR
DISORDER; STRUCTURAL MRI; VERBAL MEMORY; GENE
AB Patients with schizophrenia and their siblings typically show subtle changes of brain structures, such as a reduction of hippocampal volume. Hippocampal volume is heritable, may explain a variety of cognitive symptoms of schizophrenia and is thus considered an intermediate phenotype for this mental illness. The aim of our analyses was to identify single-nucleotide polymorphisms (SNP) related to hippocampal volume without making prior assumptions about possible candidate genes. In this study, we combined genetics, imaging and neuropsychological data obtained from the Mind Clinical Imaging Consortium study of schizophrenia (n = 328). A total of 743,591 SNPs were tested for association with hippocampal volume in a genome-wide association study. Gene expression profiles of human hippocampal tissue were investigated for gene regions of significantly associated SNPs. None of the genetic markers reached genome-wide significance. However, six highly correlated SNPs (rs4808611, rs35686037, rs12982178, rs1042178, rs10406920, rs8170) on chromosome 19p13.11, located within or in close proximity to the genes NR2F6, USHBP1, and BABAM1, as well as four SNPs in three other genomic regions (chromosome 1, 2 and 10) had p-values between 6.75x10(-6) and 8.3x10(-7). Using existing data of a very recently published GWAS of hippocampal volume and additional data of a multicentre study in a large cohort of adolescents of European ancestry, we found supporting evidence for our results. Furthermore, allelic differences in rs4808611 and rs8170 were highly associated with differential mRNA expression in the cis-acting region. Associations with memory functioning indicate a possible functional importance of the identified risk variants. Our findings provide new insights into the genetic architecture of a brain structure closely linked to schizophrenia. In silico replication, mRNA expression and cognitive data provide additional support for the relevance of our findings. Identification of causal variants and their functional effects may unveil yet unknown players in the neurodevelopment and the pathogenesis of neuropsychiatric disorders.
C1 [Hass, Johanna; Walton, Esther; Roessner, Veit; Ehrlich, Stefan] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, Dresden, Germany.
[Kirsten, Holger; Scholz, Markus] Univ Leipzig, IMISE, D-04109 Leipzig, Germany.
[Kirsten, Holger; Scholz, Markus] Univ Leipzig, LIFE Leipzig Interdisciplinary Res Cluster Genet, D-04109 Leipzig, Germany.
[Liu, Jingyu; Calhoun, Vince] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA.
[Liu, Jingyu; Calhoun, Vince] MIND Res Network, Albuquerque, NM USA.
[Priebe, Lutz] Univ Bonn, Life & Brain Ctr, Dept Genom, Bonn, Germany.
[Priebe, Lutz; Cichon, Sven] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Wolf, Christiane; Karbalai, Nazanin; Cichon, Sven] Max Planck Inst Psychiat, RG Stat Genet, D-80804 Munich, Germany.
[Gollub, Randy] Massachusetts Gen Hosp, MGH MIT HMS Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Gollub, Randy; Ehrlich, Stefan] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[White, Tonya; Ehrlich, Stefan] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA.
[White, Tonya; Ehrlich, Stefan] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA.
[Mueller, Kathrin U.; Smolka, Michael N.] Tech Univ Dresden, Dept Psychiat, Univ Hosp Carl Gustav Carus, Dresden, Germany.
[Paus, Tomas] Univ Toronto, Rotman Res Inst, Toronto, ON, Canada.
[Paus, Tomas] Univ Nottingham, Brain & Body Ctr, Nottingsham, England.
[Paus, Tomas] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
[Schumann, Gunter] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Cichon, Sven] Res Ctr Juelich, Inst Neurosci & Med INM 1, Julich, Germany.
RP Ehrlich, S (reprint author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, Dresden, Germany.
EM transden.lab@uniklinikum-dresden.de
RI Cichon, Sven/H-8803-2013; Cichon, Sven/B-9618-2014; Smolka,
Michael/B-4865-2011;
OI Cichon, Sven/0000-0002-9475-086X; Cichon, Sven/0000-0002-9475-086X;
Smolka, Michael/0000-0001-5398-5569; Ehrlich,
Stefan/0000-0003-2132-4445; Gollub, Randy L./0000-0002-9434-4044;
Walton, Esther/0000-0002-0935-2200; Liu, Jingyu/0000-0002-1724-7523
FU National Institutes of Health [NIH/NCRR P41RR14075]; Department of
Energy [DE-FG02-99ER62764]; MIND Research Network; Morphometry
Biomedical Informatics Research Network (BIRN) [1U24, RR021382A];
Function BIRN [U24RR021992-01, NIH.NCRR MO1 RR025758-01]; NARSAD;
Deutsche Forschungsgemeinschaft; German Federal Ministry of Education
and Research (BMBF), within the context of the National Genome Research
Network plus (NGFNplus) [PtJ-Bio 0313909]; German Federal Ministry of
Education and Research (BMBF), within the Integrated Genome Research
Network (IG) MooDS [01GS08144]; Leipzig Interdisciplinary Research
Cluster of Genetic Factors, Clinical Phenotypes and Environment (LIFE
Center, Universitat Leipzig); European Union; European Regional
Development Fund (ERDF); Free State of Saxony within the framework of
the excellence initiative; European Commission Framework Programme 6
(FP-6) Integrated Project IMAGEN [PL037286]; European Commission
Framework Programme 7 (FP-7) Project Alzheimer's Disease, Alcoholism,
Memory, Schizophrenia (ADAMS); FP-7 Innovative Medicine Initiative
Project European Autism Interventions (AIMS); UK Department of Health
National Institute of Health Research (NIHR)-Biomedical Research Centre
Mental Health program; MRC programme grant Developmental Pathways into
Adolescent Substance Abuse [93558]; Eli Lilly; Janssen-Cilag; Medice;
Novartis
FX This work was supported by the National Institutes of Health (NIH/NCRR
P41RR14075), Department of Energy (DE-FG02-99ER62764), MIND Research
Network, Morphometry Biomedical Informatics Research Network (BIRN)
(1U24, RR021382A), Function BIRN (U24RR021992-01, NIH.NCRR MO1
RR025758-01), NARSAD Young Investigator Grant (SE), and the Deutsche
Forschungsgemeinschaft (Research Fellowship to SE). Further funding came
from the German Federal Ministry of Education and Research (BMBF, grant
PtJ-Bio 0313909 to HK), within the context of the National Genome
Research Network plus (NGFNplus), and the Integrated Genome Research
Network (IG) MooDS (grant 01GS08144 to SC). HK and MS are supported by
the Leipzig Interdisciplinary Research Cluster of Genetic Factors,
Clinical Phenotypes and Environment (LIFE Center, Universitat Leipzig).
LIFE is funded by the European Union, the European Regional Development
Fund (ERDF) and the Free State of Saxony within the framework of the
excellence initiative. IMAGEN is funded by the European Commission
Framework Programme 6 (FP-6) Integrated Project IMAGEN (PL037286), the
European Commission Framework Programme 7 (FP-7) Project Alzheimer's
Disease, Alcoholism, Memory, Schizophrenia (ADAMS), the FP-7 Innovative
Medicine Initiative Project European Autism Interventions (AIMS), the UK
Department of Health National Institute of Health Research
(NIHR)-Biomedical Research Centre Mental Health program and the MRC
programme grant Developmental Pathways into Adolescent Substance Abuse
(93558). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.; Veit
Roessner has received lecture fees from Eli Lilly, Janssen-Cilag,
Medice, and Novartis and was a member of advisory boards of Eli Lilly,
Novartis. All other authors declare no biomedical financial interests or
other potential conflict of interests. This does not alter the authors'
adherence to all the PLOS ONE policies on sharing data and materials.
NR 83
TC 6
Z9 6
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2013
VL 8
IS 6
AR e64872
DI 10.1371/journal.pone.0064872
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 170JP
UT WOS:000320846500007
PM 23805179
ER
PT J
AU Lewinsohn, DM
Swarbrick, GM
Cansler, ME
Null, MD
Rajaraman, V
Frieder, MM
Sherman, DR
McWeeney, S
Lewinsohn, DA
AF Lewinsohn, David M.
Swarbrick, Gwendolyn M.
Cansler, Meghan E.
Null, Megan D.
Rajaraman, Veena
Frieder, Marisa M.
Sherman, David R.
McWeeney, Shannon
Lewinsohn, Deborah A.
TI Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified
by a Proteomic Peptide Library
SO PLOS ONE
LA English
DT Article
ID PROTECTIVE IMMUNITY; DENDRITIC CELLS; INFECTED-CELLS; HIV-INFECTION;
HLA-B; LYMPHOCYTES; VACCINES; ANTIGEN; MICE; VACCINATION
AB Identification of CD8(+) T cell antigens/epitopes expressed by human pathogens with large genomes is especially challenging, yet necessary for vaccine development. Immunity to tuberculosis, a leading cause of mortality worldwide, requires CD8(+) T cell immunity, yet the repertoire of CD8 antigens/epitopes remains undefined. We used integrated computational and proteomic approaches to screen 10% of the Mycobacterium tuberculosis (Mtb) proteome for CD8 Mtb antigens. We designed a weighting schema based upon a Multiple Attribute Decision Making: framework to select 10% of the Mtb proteome with a high probability of containing CD8(+) T cell epitopes. We created a synthetic peptide library consisting of 15-mers overlapping by 11 aa. Using the interferon-gamma ELISPOT assay and Mtb-infected dendritic cells as antigen presenting cells, we screened Mtb-specific CD8(+) T cell clones restricted by classical MHC class I molecules (MHC class Ia molecules), that were isolated from Mtb-infected humans, against this library. Three novel CD8 antigens were unambiguously identified: the EsxJ family (Rv1038c, Rv1197, Rv3620c, Rv2347c, Rv1792), PE9 (Rv1088), and PE_PGRS42 (Rv2487c). The epitopes are B5701-restricted EsxJ(24-34), B3905-restricted PE9(53-67), and B3514-restricted PE_PGRS42(48-56), respectively. The utility of peptide libraries in identifying unknown epitopes recognized by classically restricted CD8(+) T cells was confirmed, which can be applied to other intracellular pathogens with large size genomes. In addition, we identified three novel Mtb epitopes/antigens that may be evaluated for inclusion in vaccines and/or diagnostics for tuberculosis.
C1 [Lewinsohn, David M.; Frieder, Marisa M.] Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
[Lewinsohn, David M.; Rajaraman, Veena; Frieder, Marisa M.] Portland VA Med Ctr, Portland, OR USA.
[Swarbrick, Gwendolyn M.; Cansler, Meghan E.; Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA.
[Rajaraman, Veena; McWeeney, Shannon] Oregon Hlth & Sci Univ, Oregon Canc Inst, Portland, OR 97201 USA.
[Sherman, David R.] Seattle Biomed Res Inst, Seattle, WA 98109 USA.
RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
EM lewinsde@ohsu.edu
RI Lewinsohn, David/I-4936-2013
OI McWeeney, Shannon/0000-0001-8333-6607; Lewinsohn,
David/0000-0001-9906-9494
FU VA Merit Review Grant; Portland VA Medical Center, US National
Institutes of Health [HHSN266200400081C (NO1-A1-400081), R01AI48090]
FX This work was supported by a VA Merit Review Grant and the Portland VA
Medical Center, US National Institutes of Health HHSN266200400081C
(NO1-A1-400081), and R01AI48090. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 41
TC 13
Z9 14
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 21
PY 2013
VL 8
IS 6
AR e67016
DI 10.1371/journal.pone.0067016
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 170JP
UT WOS:000320846500117
PM 23805289
ER
PT J
AU Liu, XH
Wu, Y
Yao, S
Levine, AC
Kirschenbaum, A
Collier, L
Bauman, WA
Cardozo, CP
AF Liu, Xin-Hua
Wu, Yong
Yao, Shen
Levine, Alice C.
Kirschenbaum, Alexander
Collier, Lauren
Bauman, William A.
Cardozo, Christopher P.
TI Androgens Up-regulate Transcription of the Notch Inhibitor Numb in C2C12
Myoblasts via Wnt/beta-Catenin Signaling to T Cell Factor Elements in
the Numb Promoter
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BETA-CATENIN; MYOGENIC DIFFERENTIATION; SKELETAL-MUSCLE; POSTNATAL
MYOGENESIS; WNT; ACTIVATION; RECEPTOR; FATE; TESTOSTERONE; PATHWAY
AB Androgen signaling via the androgen receptor is a key pathway that contributes to development, cell fate decisions, and differentiation, including that of myogenic progenitors. Androgens and synthetic steroids have well established anabolic actions on skeletal muscle. Wnt and Notch signaling pathways are also essential to myogenic cell fate decisions during development and tissue repair. However, the interactions among these pathways are largely unknown. Androgenic regulation of Wnt signaling has been reported. Nandrolone, an anabolic steroid, has been shown to inhibit Notch signaling and up-regulate Numb, a Notch inhibitor. To elucidate the mechanisms of interaction between nandrolone and Wnt/Notch signaling, we investigated the effects of nandrolone on Numb expression and Wnt signaling and determined the roles of Wnt signaling in nandrolone-induced Numb expression in C2C12 myoblasts. Nandrolone increased Numb mRNA and protein levels and T cell factor (Tcf) transcriptional activity via inhibition of glycogen synthase kinase 3 beta. Up-regulation of Numb expression by nandrolone was blocked by the Wnt inhibitors, sFRP1 and DKK1, whereas Wnt3a increased Numbm RNA and protein expression. In addition, we observed that the proximal promoter of the Numb gene had functional Tcf binding elements to which beta-catenin was recruited in a manner enhanced by both nandrolone and Wnt3a. Moreover, site-directed mutagenesis indicated that the Tcf binding sites in the Numb promoter are required for the nandrolone-induced Numb transcriptional activation in this cell line. These results reveal a novel molecular mechanism underlying up-regulation of Numb transcription with a critical role for increased canonical Wnt signaling. In addition, the data identify Numb as a novel target gene of the Wnt signaling pathway by which Wnts would be able to inhibit Notch signaling.
C1 [Liu, Xin-Hua; Wu, Yong; Collier, Lauren; Bauman, William A.; Cardozo, Christopher P.] James J Peter Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA.
[Yao, Shen; Levine, Alice C.; Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Kirschenbaum, Alexander] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA.
[Bauman, William A.; Cardozo, Christopher P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.
RP Cardozo, CP (reprint author), James J Peter Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM chris.cardozo@mssm.edu
FU Veterans Health Administration, Rehabilitation Research and Development
Service [B4162C, F7756R, F6997R]
FX This work was supported by the Veterans Health Administration,
Rehabilitation Research and Development Service Grants B4162C, F7756R,
and F6997R.
NR 47
TC 7
Z9 7
U1 1
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 21
PY 2013
VL 288
IS 25
BP 17990
EP 17998
DI 10.1074/jbc.M113.478487
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 168QZ
UT WOS:000320721900006
PM 23649620
ER
PT J
AU Buck, TM
Plavchak, L
Roy, A
Donnelly, BF
Kashlan, OB
Kleyman, TR
Subramanya, AR
Brodsky, JL
AF Buck, Teresa M.
Plavchak, Lindsay
Roy, Ankita
Donnelly, Bridget F.
Kashlan, Ossama B.
Kleyman, Thomas R.
Subramanya, Arohan R.
Brodsky, Jeffrey L.
TI The Lhs1/GRP170 Chaperones Facilitate the Endoplasmic
Reticulum-associated Degradation of the Epithelial Sodium Channel
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ER-ASSOCIATED DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR;
NUCLEOTIDE-EXCHANGE FACTOR; HEAT-SHOCK PROTEINS; NA+ CHANNEL; MOLECULAR
CHAPERONES; MISFOLDED GLYCOPROTEINS; HSP70 CHAPERONES; QUALITY-CONTROL;
MECHANISTICALLY DISTINCT
AB The epithelial sodium channel, ENaC, plays a critical role in maintaining salt and water homeostasis, and not surprisingly defects in ENaC function are associated with disease. Like many other membrane-spanning proteins, this trimeric protein complex folds and assembles inefficiently in the endoplasmic reticulum (ER), which results in a substantial percentage of the channel being targeted for ER-associated degradation (ERAD). Because the spectrum of factors that facilitates the degradation of ENaC is incomplete, we developed yeast expression systems for each ENaC subunit. We discovered that a conserved Hsp70-like chaperone, Lhs1, is required for maximal turnover of the ENaC alpha subunit. By expressing Lhs1 ATP binding mutants, we also found that the nucleotide exchange properties of this chaperone are dispensable for ENaC degradation. Consistent with the precipitation of an Lhs1-alpha ENaC complex, Lhs1 holdase activity was instead most likely required to support the ERAD of alpha ENaC. Moreover, a complex containing the mammalian Lhs1 homolog GRP170 and alpha ENaC co-precipitated, and GRP170 also facilitated ENaC degradation in human, HEK293 cells, and in a Xenopus oocyte expression system. In both yeast and higher cell types, the effect of Lhs1 on the ERAD of alpha ENaC was selective for the unglycosylated form of the protein. These data establish the first evidence that Lhs1/Grp170 chaperones can act as mediators of ERAD substrate selection.
C1 [Buck, Teresa M.; Plavchak, Lindsay; Brodsky, Jeffrey L.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.
[Roy, Ankita; Donnelly, Bridget F.; Kashlan, Ossama B.; Kleyman, Thomas R.; Subramanya, Arohan R.] Univ Pittsburgh, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA.
[Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15261 USA.
RP Brodsky, JL (reprint author), Univ Pittsburgh, Dept Biol Sci, A320 Langley Hall,4249 5th Ave, Pittsburgh, PA 15260 USA.
EM jbrodsky@pitt.edu
FU National Institutes of Health [K01DK090195, DK65161, GM75061, DK79307];
United States Department of Veterans Affairs; University of Pittsburgh
George O'Brien Kidney Research Center; American Heart Association
[10BGIA3890010]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants K01DK090195 (to T. M. B.), DK65161 (to T. K.), GM75061 (to
J. L. B.), and DK79307 (to the University of Pittsburgh George O'Brien
Kidney Research Center).; Supported by a Mid-level Career Development
Award from the United States Department of Veterans Affairs, pilot funds
from the University of Pittsburgh George O'Brien Kidney Research Center,
and by James A. Shaver Fund of the American Heart Association Grant
10BGIA3890010.
NR 116
TC 17
Z9 17
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 21
PY 2013
VL 288
IS 25
BP 18366
EP 18380
DI 10.1074/jbc.M113.469882
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 168QZ
UT WOS:000320721900040
PM 23645669
ER
PT J
AU Wei, SC
Tsao, PN
Weng, MT
Cao, ZF
Wong, JM
AF Wei, Shu-Chen
Tsao, Po-Nien
Weng, Meng-Tzu
Cao, Zhifang
Wong, Jau-Min
TI Flt-1 in colorectal cancer cells is required for the tumor invasive
effect of placental growth factor through a p38-MMP9 pathway
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Colorectal cancer; Flt-1; PlGF; Invasion; Migration; MMP9
ID FACTOR RECEPTOR-1; PROGNOSTIC-SIGNIFICANCE; MICROVESSEL DENSITY;
ENDOTHELIAL-CELLS; ANGIOGENESIS; EXPRESSION; VEGF; METASTASIS; SURVIVAL;
MACROPHAGES
AB Background: Placenta growth factor (PlGF), a dimeric glycoprotein with 53% homology to VEGF, binds to VEGF receptor-1 (Flt-1), but not to VEGF receptor-2 (Flk-1), and may function by modulating VEGF activity. We previously have showed that PlGF displays prognostic value in colorectal cancer (CRC) but the mechanism remains elucidated.
Results: Overexpression of PlGF increased the invasive/migration ability and decreased apoptosis in CRC cells showing Flt-1 expression. Increased migration was associated with increasing MMP9 via p38 MAPK activation. Tumors grew faster, larger; with higher vascularity from PlGF over-expression cells in xenograft assay. In two independent human CRC tissue cohorts, PlGF, MMP9, and Flt-1 expressions were higher in the advanced than the localized disease group. PlGF expression correlated with MMP9, and Flt-1 expression. CRC patients with high PlGF and high Flt-1 expression in tissue had poor prognosis.
Conclusion: PlGF/Flt-1 signaling plays an important role in CRC progression, blocking PlGF/Flt-1 signaling maybe an alternative therapy for CRC.
C1 [Wei, Shu-Chen; Wong, Jau-Min] Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei 100, Taiwan.
[Tsao, Po-Nien] Natl Taiwan Univ Hosp & Coll Med, Dept Pediat, Taipei 100, Taiwan.
[Weng, Meng-Tzu] Far Eastern Mem Hosp, Dept Internal Med, Taipei 100, Taiwan.
[Cao, Zhifang] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Wong, JM (reprint author), Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei 100, Taiwan.
EM jmwong@ntu.edu.tw
OI TSAO, PO-NIEN/0000-0002-6114-1769
FU National Science Council of Taiwan [100-2314-B-002-071-]; Liver Disease
Prevention & Treatment Research Foundation
FX We thank the second Core Laboratory of the Department of Medical
Research of the National Taiwan University Hospital for technical
assistance, Dr. Hwai-I Yang for his kind help in statistical analysis,
Prof. Wen-Fang Cheng and Min-Hung Hsu for technical support in tumor
xenograft experiment. We thank the critical review and comments from Dr.
Ji Luo (Medical Oncology Branch, Center for Cancer Research, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland,
USA). The in vitro work was supported partially by the National Science
Council of Taiwan (100-2314-B-002-071-), and others by the Liver Disease
Prevention & Treatment Research Foundation.
NR 39
TC 11
Z9 12
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1021-7770
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD JUN 21
PY 2013
VL 20
AR 39
DI 10.1186/1423-0127-20-39
PG 12
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 179GD
UT WOS:000321506900001
PM 23799978
ER
PT J
AU Brown, MC
Lee, DJ
Benson, TE
AF Brown, M. Christian
Lee, Daniel J.
Benson, Thane E.
TI Ultrastructure of spines and associated terminals on brainstem neurons
controlling auditory input
SO BRAIN RESEARCH
LA English
DT Article
DE Olivocochlear; Stapedius; Tensor tympani; Middle ear muscle; Vesicle
morphometry; Electron microscopy
ID MEDIAL OLIVOCOCHLEAR NEURONS; TENSOR TYMPANI MOTONEURONS; POSTEROVENTRAL
COCHLEAR NUCLEUS; MIDDLE-EAR MUSCLES; DENDRITIC SPINES; GUINEA-PIG;
HORSERADISH-PEROXIDASE; REFLEX PATHWAYS; INFERIOR COLLICULUS; SYNAPTIC
PLASTICITY
AB Spines are unique cellular appendages that isolate synaptic input to neurons and play a role in synaptic plasticity. Using the electron microscope, we studied spines and their associated synaptic terminals on three groups of brainstem neurons: tensor tympani motoneurons, stapedius motoneurons, and medial olivocochlear neurons, all of which exert reflexive control of processes in the auditory periphery. These spines are generally simple in shape; they are infrequent and found on the somata as well as the dendrites. Spines do not differ in volume among the three groups of neurons. In all cases, the spines are associated with a synaptic terminal that engulfs the spine rather than abuts its head. The positions of the synapses are variable, and some are found at a distance from the spine, suggesting that the isolation of synaptic input is of diminished importance for these spines. Each group of neurons receives three common types of synaptic terminals. The type of terminal associated with spines of the motoneurons contains pleomorphic vesicles, whereas the type associated with spines of olivocochlear neurons contains large round vesicles. Thus, spine-associated terminals in the motoneurons appear to be associated with inhibitory processes but in olivocochlear neurons they are associated with excitatory processes. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Brown, M. Christian; Lee, Daniel J.; Benson, Thane E.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Brown, M. Christian; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
RP Brown, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM Chris_Brown@meei.harvard.edu; Daniel_Lee@meei.harvard.edu;
Thane_Benson@meei.harvard.edu
FU National Institutes of Health-NIDCD [DC01089, DC06285]
FX National Institutes of Health-NIDCD, grant numbers DC01089 (to M.C.B.)
and DC06285 (to D.J.L.).
NR 67
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JUN 21
PY 2013
VL 1516
BP 1
EP 10
DI 10.1016/j.brainres.2013.04.020
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 173OV
UT WOS:000321089700001
ER
PT J
AU Bachler, BC
Humbert, M
Lakhashe, SK
Rasmussen, RA
Ruprecht, RM
AF Bachler, Barbara C.
Humbert, Michael
Lakhashe, Samir K.
Rasmussen, Robert A.
Ruprecht, Ruth M.
TI Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1
antibody repertoire in the absence of viremia
SO RETROVIROLOGY
LA English
DT Article
DE Macaque model; Recombinant protein vaccine; Heterologous R5 SHIV clade C
challenge; Complete protection; Subtractive peptide phage display; V3
crown; Boosting of vaccine-induced Ab titers after multiple challenges;
Neo-antigen reactivity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ORIGINAL ANTIGENIC SIN; T-CELL RESPONSES;
HIV-1 VACCINE; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSE; RHESUS
MACAQUES; PEPTIDE LIBRARIES; CHIMERIC VIRUS; PHAGE DISPLAY
AB Background: We addressed the question whether live-virus challenges could alter vaccine-induced antibody (Ab) responses in vaccinated rhesus macaques (RMs) that completely resisted repeated exposures to R5-tropic simian-human immunodeficiency viruses encoding heterologous HIV clade C envelopes (SHIV-Cs).
Results: We examined the Ab responses in aviremic RMs that had been immunized with a multi-component protein vaccine (multimeric HIV-1 gp160, HIV-1 Tat and SIV Gag-Pol particles) and compared anti-Env plasma Ab titers before and after repeated live-virus exposures. Although no viremia was ever detected in these animals, they showed significant increases in anti-gp140 Ab titers after they had encountered live SHIVs. When we investigated the dynamics of anti-Env Ab titers during the immunization and challenge phases further, we detected the expected, vaccine-induced increases of Ab responses about two weeks after the last protein immunization. Remarkably, these titers kept rising during the repeated virus challenges, although no viremia resulted. In contrast, in vaccinated RMs that were not exposed to virus, anti-gp140 Ab titers declined after the peak seen two weeks after the last immunization. These data suggest boosting of pre-existing, vaccine-induced Ab responses as a consequence of repeated live-virus exposures. Next, we screened polyclonal plasma samples from two of the completely protected vaccinees by peptide phage display and designed a strategy that selects for recombinant phages recognized only by Abs present after - but not before - any SHIV challenge. With this "subtractive biopanning" approach, we isolated V3 mimotopes that were only recognized after the animals had been exposed to live virus. By detailed epitope mapping of such anti-V3 Ab responses, we showed that the challenges not only boosted pre-existing binding and neutralizing Ab titers, but also induced Abs targeting neo-antigens presented by the heterologous challenge virus.
Conclusions: Anti-Env Ab responses induced by recombinant protein vaccination were altered by the multiple, live SHIV challenges in vaccinees that had no detectable viral loads. These data may have implications for the interpretation of "vaccine only" responses in clinical vaccine trials.
C1 [Bachler, Barbara C.; Humbert, Michael; Lakhashe, Samir K.; Rasmussen, Robert A.; Ruprecht, Ruth M.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Bachler, Barbara C.] Univ Vet Med, VetCore Facil Res, A-1210 Vienna, Austria.
[Humbert, Michael; Lakhashe, Samir K.; Rasmussen, Robert A.; Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
RP Ruprecht, RM (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
EM ruth_ruprecht@dfci.harvard.edu
RI Lakhashe, Samir/F-1150-2014
FU National Institutes of Health [P01 AI048240, R37 AI034266]; NCRR [P51
DRR00016500]
FX This work was supported by National Institutes of Health grants P01
AI048240 and R37 AI034266 to R. M. R., and NCRR P51 DRR00016500 to
Yerkes.
NR 55
TC 1
Z9 1
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JUN 21
PY 2013
VL 10
AR 63
DI 10.1186/1742-4690-10-63
PG 13
WC Virology
SC Virology
GA 172PZ
UT WOS:000321017900001
PM 23800339
ER
PT J
AU Puli, SR
Kalva, N
Bechtold, ML
Pamulaparthy, SR
Cashman, MD
Estes, NC
Pearl, RH
Volmar, FH
Dillon, S
Shekleton, MF
Forcione, D
AF Puli, Srinivas R.
Kalva, Nikhil
Bechtold, Matthew L.
Pamulaparthy, Smitha R.
Cashman, Micheal D.
Estes, Norman C.
Pearl, Richard H.
Volmar, Fritz-Henry
Dillon, Sonu
Shekleton, Michael F.
Forcione, David
TI Diagnostic accuracy of endoscopic ultrasound in pancreatic
neuroendocrine tumors: A systematic review and meta analysis
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Endoscopic ultrasound; Ultrasound; Endosonography; Pancreatic mass;
Neuroendocrine tumors; Sensitivity; Specificity; Positive predictive
value; Negative predictive value
ID SOMATOSTATIN RECEPTOR SCINTIGRAPHY; FINE-NEEDLE-ASPIRATION; ENDOCRINE
TUMORS; PREOPERATIVE LOCALIZATION; CONTROLLED-TRIALS; ULTRASONOGRAPHY;
INSULINOMAS; METAANALYSIS; EUS; GASTRINOMAS
AB AIM: To detect pancreatic neuroendocrine tumors (PNETs) has been varied. This study is undertaken to evaluate the accuracy of endoscopic ultrasound (EUS) in detecting PNETs.
METHODS: Only EUS studies confirmed by surgery or appropriate follow-up were selected. Articles were searched in Medline, Ovid journals, Medline nonindexed citations, and Cochrane Central Register of Controlled Trials and Database of Systematic Reviews. Pooling was conducted by both fixed and random effects model).
RESULTS: Initial search identified 2610 reference articles, of these 140 relevant articles were selected and reviewed. Data was extracted from 13 studies (n = 456) which met the inclusion criteria. Pooled sensitivity of EUS in detecting a PNETs was 87.2% (95% CI: 82.2-91.2). EUS had a pooled specificity of 98.0% (95% CI: 94.3-99.6). The positive likelihood ratio of EUS was 11.1 (95% CI: 5.34-22.8) and negative likelihood ratio was 0.17 (95% CI: 0.13-0.24). The diagnostic odds ratio, the odds of having anatomic PNETs in positive as compared to negative EUS studies was 94.7 (95% CI: 37.9-236.1). Begg-Mazumdar bias indicator for publication bias gave a Kendall's tau value of 0.31 (P = 0.16), indication no publication bias. The P for chi(2) heterogeneity for all the pooled accuracy estimates was > 0.10.
CONCLUSION: EUS has excellent sensitivity and specificity to detect PNETs. EUS should be strongly considered for evaluation of PNETs. (C) 2013 Baishideng. All rights reserved.
C1 [Puli, Srinivas R.; Pamulaparthy, Smitha R.; Cashman, Micheal D.; Volmar, Fritz-Henry; Dillon, Sonu; Shekleton, Michael F.] Univ Illinois, Div Gastroenterol & Hepatol, OSF St Francis Med Ctr, Peoria, IL 61637 USA.
[Kalva, Nikhil] Univ Illinois, Dept Internal Med, OSF St Francis Med Ctr, Peoria, IL 61637 USA.
[Bechtold, Matthew L.] Univ Missouri, Div Gastroenterol & Hepatol, Columbia, MO 65212 USA.
[Estes, Norman C.; Pearl, Richard H.] Univ Illinois, Dept Surg, OSF St Francis Med Ctr, Peoria, IL 61637 USA.
[Forcione, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Intervent Endoscopy Serv,Gastrointestinal Unit, Boston, MA 02114 USA.
RP Puli, SR (reprint author), Univ Illinois, Div Gastroenterol & Hepatol, OSF St Francis Med Ctr, Peoria Campus,100 NE Randolph Ave, Peoria, IL 61637 USA.
EM srinivaspuli@yahoo.com
NR 37
TC 19
Z9 23
U1 2
U2 6
PU BAISHIDENG PUBL GRP CO LTD
PI WANCHAI
PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG
100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUN 21
PY 2013
VL 19
IS 23
BP 3678
EP 3684
DI 10.3748/wjg.v19.i23.3678
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 167ZV
UT WOS:000320675100020
PM 23801872
ER
PT J
AU Dowdell, S
Grassberger, C
Sharp, GC
Paganetti, H
AF Dowdell, S.
Grassberger, C.
Sharp, G. C.
Paganetti, H.
TI Interplay effects in proton scanning for lung: a 4D Monte Carlo study
assessing the impact of tumor and beam delivery parameters
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID PARTICLE BEAMS; STATISTICAL-ANALYSIS; DOSIMETRIC IMPACT; MOVING TARGETS;
MOTION; THERAPY; RADIOTHERAPY; SIMULATION; IRRADIATION; DESIGN
AB Relative motion between a tumor and a scanning proton beam results in a degradation of the dose distribution (interplay effect). This study investigates the relationship between beam scanning parameters and the interplay effect, with the goal of finding parameters that minimize interplay. 4D Monte Carlo simulations of pencil beam scanning proton therapy treatments were performed using the 4DCT geometry of five lung cancer patients of varying tumor size (50.4-167.1 cc) and motion amplitude (2.9-30.1 mm). Treatments were planned assuming delivery in 35 x 2.5 Gy(RBE) fractions. The spot size, time to change the beam energy (tau(es)), time required for magnet settling (tau(ss)), initial breathing phase, spot spacing, scanning direction, scanning speed, beam current and patient breathing period were varied for each of the five patients. Simulations were performed for a single fraction and an approximation of conventional fractionation. For the patients considered, the interplay effect could not be predicted using the superior-inferior motion amplitude alone. Larger spot sizes (sigma similar to 9-16 mm) were less susceptible to interplay, giving an equivalent uniform dose (EUD) of 99.0 +/- 4.4% (1 standard deviation) in a single fraction compared to 86.1 +/- 13.1% for smaller spots (sigma similar to 2-4 mm). The smaller spot sizes gave EUD values as low as 65.3% of the prescription dose in a single fraction. Reducing the spot spacing improved the target dose homogeneity. The initial breathing phase can have a significant effect on the interplay, particularly for shorter delivery times. No clear benefit was evident when scanning either parallel or perpendicular to the predominant axis of motion. Longer breathing periods decreased the EUD. In general, longer delivery times led to lower interplay effects. Conventional fractionation showed significant improvement in terms of interplay, giving a EUD of at least 84.7% and 100.0% of the prescription dose for the small and larger spot sizes respectively. The interplay effect is highly patient specific, depending on the motion amplitude, tumor location and the delivery parameters. Large degradations of the dose distribution in a single fraction were observed, but improved significantly using conventional fractionation.
C1 [Dowdell, S.; Grassberger, C.; Sharp, G. C.; Paganetti, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Dowdell, S.; Grassberger, C.; Sharp, G. C.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Grassberger, C.] Paul Scherrer Inst, Ctr Proton Radiotherapy, CH-5232 Villigen, Switzerland.
RP Dowdell, S (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM sdowdell@partners.org
FU NCI [CA111590]
FX This work was funded by NCI grant CA111590. The authors would like to
thank Partners Research Computing, particularly Jon Jackson, for
maintenance of the computing cluster.
NR 41
TC 26
Z9 26
U1 1
U2 17
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JUN 21
PY 2013
VL 58
IS 12
BP 4137
EP 4156
DI 10.1088/0031-9155/58/12/4137
PG 20
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 158JP
UT WOS:000319966100013
PM 23689035
ER
PT J
AU Rottmann, J
Keall, P
Berbeco, R
AF Rottmann, J.
Keall, P.
Berbeco, R.
TI Markerless EPID image guided dynamic multi-leaf collimator tracking for
lung tumors
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID BODY RADIATION-THERAPY; RESPIRATORY MOTION; INTRAFRACTION MOTION; MLC
TRACKING; PHASE-II; RADIOTHERAPY; CANCER; FEASIBILITY; MANAGEMENT;
PREDICTION
AB Compensation of target motion during the delivery of radiotherapy has the potential to improve treatment accuracy, dose conformity and sparing of healthy tissue. We implement an online image guided therapy system based on soft tissue localization (STiL) of the target from electronic portal images and treatment aperture adaptation with a dynamic multi-leaf collimator (DMLC). The treatment aperture is moved synchronously and in real time with the tumor during the entire breathing cycle. The system is implemented and tested on a Varian TX clinical linear accelerator featuring an AS-1000 electronic portal imaging device (EPID) acquiring images at a frame rate of 12.86 Hz throughout the treatment. A position update cycle for the treatment aperture consists of four steps: in the first step at time t = t(0) a frame is grabbed, in the second step the frame is processed with the STiL algorithm to get the tumor position at t = t(0), in a third step the tumor position at t = t(i) + delta t is predicted to overcome system latencies and in the fourth step, the DMLC control software calculates the required leaf motions and applies them at time t = t(i) + delta t. The prediction model is trained before the start of the treatment with data representing the tumor motion. We analyze the system latency with a dynamic chest phantom (4D motion phantom, Washington University). We estimate the average planar position deviation between target and treatment aperture in a clinical setting by driving the phantom with several lung tumor trajectories (recorded from fiducial tracking during radiotherapy delivery to the lung). DMLC tracking for lung stereotactic body radiation therapy without fiducial markers was successfully demonstrated. The inherent system latency is found to be delta t = (230 +/- 11) ms for a MV portal image acquisition frame rate of 12.86 Hz. The root mean square deviation between tumor and aperture position is smaller than 1 mm. We demonstrate the feasibility of real-time markerless DMLC tracking with a standard LINAC-mounted (EPID).
C1 [Rottmann, J.; Berbeco, R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rottmann, J.; Berbeco, R.] Harvard Univ, Sch Med, Boston, MA USA.
[Keall, P.] Univ Sydney, Sydney Med Sch, Radiat Phys Lab, Sydney, NSW 2006, Australia.
RP Rottmann, J (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM jrottmann@lroc.harvard.edu
FU National Cancer Institute [R21CA156068, R01CA93626]; NHMRC Australia
Fellowship
FX This work was supported by awards R21CA156068 and R01CA93626 from the
National Cancer Institute and NHMRC Australia Fellowship. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Cancer Institute or the
National Institutes of Health. Also, we would like to thank Varian
Medical Systems, Inc. for providing us with the frame grabber soft- and
hardware.
NR 30
TC 11
Z9 11
U1 0
U2 12
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JUN 21
PY 2013
VL 58
IS 12
BP 4195
EP 4204
DI 10.1088/0031-9155/58/12/4195
PG 10
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 158JP
UT WOS:000319966100016
PM 23715431
ER
PT J
AU D'Souza, G
Gross, ND
Pai, SI
Haddad, RI
Gillison, ML
Posner, MR
AF D'Souza, Gypsyamber
Gross, Neil D.
Pai, Sara I.
Haddad, Robert I.
Gillison, Maura L.
Posner, Marshall R.
TI Oral HPV infection in HPV-positive oropharyngeal cancer cases and their
spouses.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
SU S
MA CRA6031
PG 1
WC Oncology
SC Oncology
GA AG6YC
UT WOS:000335564000009
ER
PT J
AU Hodi, FS
Lee, SJ
McDermott, DF
Rao, UNM
Butterfield, LH
Tarhini, AA
Leming, PD
Puzanov, I
Kirkwood, JM
AF Hodi, F. Stephen
Lee, Sandra J.
McDermott, David F.
Rao, Uma N. M.
Butterfield, Lisa H.
Tarhini, Ahmad A.
Leming, Philip D.
Puzanov, Igor
Kirkwood, John M.
CA Eastern Cooperative Oncology Grp
TI Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab
(Ipi) versus Ipi alone in metastatic melanoma: E1608.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Pittsburgh Phys, Pittsburgh, PA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Cincinnati Hematol Oncol Inc, Cincinnati, OH USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
SU S
MA CRA9007
PG 1
WC Oncology
SC Oncology
GA AG6YC
UT WOS:000335564000014
ER
PT J
AU Kang, YK
Ryu, MH
Ryoo, BY
Kim, HJ
Lee, JJ
Yoo, C
Nam, BH
Ramaiya, N
Jagannathan, JP
Demetri, GD
AF Kang, Yoon-Koo
Ryu, Min-Hee
Ryoo, Baek-Yeol
Kim, Hyun Jin
Lee, Jong Jin
Yoo, Changhoon
Nam, Byung-Ho
Ramaiya, Nikhil
Jagannathan, Jyothi Priya
Demetri, George D.
TI Randomized phase III trial of imatinib (IM) rechallenge versus placebo
(PL) in patients (pts) with metastatic and/or unresectable
gastrointestinal stromal tumor (GIST) after failure of at least both IM
and sunitinib (SU): RIGHT study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea.
Natl Canc Ctr, Goyang, South Korea.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
SU S
MA LBA10502
PG 1
WC Oncology
SC Oncology
GA AG6YC
UT WOS:000335564000016
ER
PT J
AU Stupp, R
Hegi, ME
Gorlia, T
Erridge, S
Grujicic, D
Steinbach, JP
Wick, W
Tarnawski, R
Nam, DH
Weyerbrock, A
Hau, P
Taphoorn, MJB
Nabors, LB
Reardon, DA
Van den Bent, MJ
Perry, JR
Hong, YK
Hicking, C
Picard, M
Weller, M
AF Stupp, Roger
Hegi, Monika E.
Gorlia, Thierry
Erridge, Sara
Grujicic, Danica
Steinbach, Joachim Peter
Wick, Wolfgang
Tarnawski, Rafal
Nam, Do-Hyun
Weyerbrock, Astrid
Hau, Peter
Taphoorn, Martin J. B.
Nabors, Louis B.
Reardon, David A.
Van den Bent, Martin J.
Perry, James R.
Hong, Yong Kil
Hicking, Christine
Picard, Martin
Weller, Michael
CA EORTC
Canadian Brain Tumor Consortium
CENTRIC Study Team
TI Cilengitide combined with standard treatment for patients with newly
diagnosed glioblastoma and methylated O-6-methylguanine-DNA
methyltransferase (MGMT) gene promoter: Key results of the multicenter,
randomized, open-label, controlled, phase III CENTRIC study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 CHU Vaudois, CH-1011 Lausanne, Switzerland.
Eortc Data Ctr, Brussels, Belgium.
Edinburgh Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Clin Ctr Serbia, Inst Neurosurg, Belgrade, Serbia.
Klinikum JW Goethe Univ Frankfurt, Dr Senkenberg Inst Neuroonkol, Frankfurt, Germany.
Univ Klinikum Heidelberg, Heidelberg, Germany.
Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland.
Inst Oncol, Gliwice Branch, Radiotherapy & Chemotherapy Clin, Gliwice, Poland.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Univ Klinikum Freiburg, Freiburg, Germany.
Univ Klinikum Regensburg, Regensburg, Germany.
Med Ctr Haaglanden, The Hague, Netherlands.
Univ Alabama Birmingham, Birmingham, AL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Erasmus MC, Rotterdam, Netherlands.
Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada.
Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
Merck KGaA, Darmstadt, Germany.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
RI Tarnawski, Rafal/N-7526-2016
NR 0
TC 0
Z9 0
U1 1
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
SU S
MA LBA2009
PG 1
WC Oncology
SC Oncology
GA AG6YC
UT WOS:000335564000019
ER
PT J
AU Sznol, M
Kluger, HM
Hodi, FS
McDermott, DF
Carvajal, RD
Lawrence, DP
Topalian, SL
Atkins, MB
Powderly, JD
Sharfman, WH
Puzanov, I
Smith, DC
Wigginton, JM
Kollia, G
Gupta, AK
Sosman, JA
AF Sznol, Mario
Kluger, Harriet M.
Hodi, F. Stephen
McDermott, David F.
Carvajal, Richard D.
Lawrence, Donald P.
Topalian, Suzanne Louise
Atkins, Michael B.
Powderly, John D.
Sharfman, William Howard
Puzanov, Igor
Smith, David C.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Sosman, Jeffrey Alan
TI Survival and long-term follow-up of safety and response in patients
(pts) with advanced melanoma (MEL) in a phase I trial of nivolumab
(anti-PD-1; BMS-936558; ONO-4538).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Canc Ctr, New Haven, CT USA.
Yale Univ, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
SU S
MA CRA9006
PG 1
WC Oncology
SC Oncology
GA AG6YC
UT WOS:000335564000013
ER
PT J
AU Chen, XL
Lei, YH
Liu, CF
Yang, QF
Zuo, PY
Liu, CY
Chen, CZ
Liu, YW
AF Chen, Xing-Lin
Lei, Ying-Hong
Liu, Cun-Fei
Yang, Qun-Fang
Zuo, Pei-Yuan
Liu, Cheng-Yun
Chen, Chang-Zhong
Liu, Yu-Wei
TI Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart
Disease Associated with Chemotherapy: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID METASTATIC COLORECTAL-CANCER; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL
CARCINOMA; PHASE-III; CARDIOVASCULAR COMPLICATIONS; 1ST-LINE
CHEMOTHERAPY; SYSTEMATIC REVIEWS; RANDOMIZED-TRIAL; CLINICAL-TRIALS;
DOUBLE-BLIND
AB Concerns have arisen regarding the risk of ischemic heart disease with the novel antiangiogenic agent bevacizumab, a recombinant humanised monoclonal antibody to the vascular endothelial growth factor that is widely used in cancer treatment. Currently, the role of bevacizumab in ischemic heart disease is controversial. This meta-analysis was therefore performed to assess the overall risk of ischemic heart disease associated with the use of bevacizumab. The databases of PubMed, EMBASE and Web of Science were searched for English language studies of randomised controlled trials comparing bevacizumab with control therapy published through October 25, 2012. Summary incidence rates, relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models based on the heterogeneity of the included studies. A total of 4,617 patients from 7 randomised controlled trials were identified and included for analysis. Among those patients receiving bevacizumab, the summary incidence of ischemic heart disease was 1.0% (95% CI, 0.6%-1.4%). Patients treated with bevacizumab had a significantly increased risk of ischemic heart disease with an RR of 2.49 (95% CI, 1.37-4.52) compared with controls. In addition, both high doses and low doses of bevacizumab increased the risk of cardiac ischemia (low dose at 2.5 mg/kg per week: RR, 2.14 [95% CI, 1.09-4.19]; high dose at 5 mg/kg per week: RR, 4.81 [95% CI, 1.03-22.42]). Bevacizumab was also found to significantly increase the risk of cardiac ischemia in patients with colorectal cancer (RR, 2.13; 95% CI, 1.11-4.06) compared with controls. This meta-analysis shows the use of bevacizumab was associated with an increased risk of developing ischemic heart disease in colorectal cancer patients receiving this drug. Our conclusions are limited by the available data. Further evaluations of high-quality RCTs are needed.
C1 [Chen, Xing-Lin; Lei, Ying-Hong; Zuo, Pei-Yuan; Liu, Cheng-Yun; Liu, Yu-Wei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Key Lab Geriatr,Hlth Minist,Dept Geriatr, Wuhan 430074, Peoples R China.
[Liu, Cun-Fei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Geriatr, Shanghai 200030, Peoples R China.
[Yang, Qun-Fang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Hyperbar Oxygen Ctr, Wuhan 430074, Peoples R China.
[Chen, Chang-Zhong] Dana Farber Canc Inst, Microarray Core Facil, Boston, MA 02115 USA.
RP Liu, CY (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Key Lab Geriatr,Hlth Minist,Dept Geriatr, Wuhan 430074, Peoples R China.
EM lcyun@medmail.com.cn
FU Health Department of Hubei Province [JX4C47]
FX This study was supported by a grant from Health Department of Hubei
Province (No. JX4C47). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 14
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2013
VL 8
IS 6
AR e66721
DI 10.1371/journal.pone.0066721
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 190LY
UT WOS:000322342800099
PM 23818962
ER
PT J
AU Parker, NH
Donninger, H
Birrer, MJ
Leaner, VD
AF Parker, Nina Holderness
Donninger, Howard
Birrer, Michael J.
Leaner, Virna D.
TI p21-Activated Kinase 3 (PAK3) Is an AP-1 Regulated Gene Contributing to
Actin Organisation and Migration of Transformed Fibroblasts
SO PLOS ONE
LA English
DT Article
ID ANCHORAGE-INDEPENDENT GROWTH; C-JUN ACTIVATION; CELL-MIGRATION;
PROTEIN-KINASE; MENTAL-RETARDATION; FOCAL COMPLEXES; STRESS FIBERS;
RAT-1A CELLS; EXPRESSION; CANCER
AB Activating Protein 1 (AP-1) plays a vital role in cell proliferation, differentiation and apoptosis. While de-regulation of AP-1 has been linked to many cancers, little is known regarding its downstream transcriptional targets that associate with cellular transformation. Previous studies identified PAK3, a serine/threonine kinase, as a potential AP-1 target gene. PAK3 has been implicated in a variety of pathological disorders and over-expression of other PAK-family members has been linked to cancer. In this study, we investigate AP-1 regulation of PAK3 expression and the role of PAK3 in cJun/AP-1-associated cellular transformation. Our results showed elevated PAK3 expression at both the mRNA and protein level in cJun-over-expressing Rat1a fibroblasts, as well as in transformed human fibroblasts. Elevated PAK3 expression in cJun/AP-1 over-expressing cells associated with a significant increase in PAK3 promoter activation. This increased promoter activity was lost when a single putative Jun binding site, which can bind AP-1 directly both in vitro and in vivo, was mutated. Further, inhibition of PAK3 using siRNA showed a regression in the cell morphology, migratory potential and actin organisation associated with AP-1 transformed cells. Our study is a first to describe a role for AP-1 in regulating PAK3 expression and suggest that PAK3 is an AP-1 target required for actin organization and migration observed in transformed cells.
C1 [Parker, Nina Holderness; Leaner, Virna D.] Univ Cape Town, Div Med Biochem, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Donninger, Howard] Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40292 USA.
[Birrer, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Gillette Ctr Gynecol Oncol, Gynecol Canc Res Program,Med Sch, Boston, MA 02115 USA.
RP Leaner, VD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Gillette Ctr Gynecol Oncol, Gynecol Canc Res Program,Med Sch, Boston, MA 02115 USA.
EM Virna.Leaner@uct.ac.za
FU University of Cape Town/Carnegie Corporation of New York Development
Grants; Medical Research Council (SA)
FX This work is supported by grants from the University of Cape
Town/Carnegie Corporation of New York Development Grants, the Medical
Research Council (SA). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 46
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2013
VL 8
IS 6
AR e66892
DI 10.1371/journal.pone.0066892
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 190LY
UT WOS:000322342800107
ER
PT J
AU Neuberg, D
Arceci, RJ
AF Neuberg, Donna
Arceci, Robert J.
TI When "rare" is no excuse for progress
SO BLOOD
LA English
DT Editorial Material
ID LANGERHANS CELL HISTIOCYTOSIS; LONG-TERM SURVIVORS; MUTATIONS
C1 [Neuberg, Donna] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Arceci, Robert J.] Phoenix Childrens Hosp, Ron Matricaria Inst Mol Med, Phoenix, AZ USA.
RP Neuberg, D (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 9
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 20
PY 2013
VL 121
IS 25
BP 4970
EP 4972
DI 10.1182/blood-2013-05-498675
PG 5
WC Hematology
SC Hematology
GA 184NR
UT WOS:000321898500003
PM 23788022
ER
PT J
AU Olenchock, BA
Vander Heiden, MG
AF Olenchock, Benjamin A.
Vander Heiden, Matthew G.
TI Pyruvate as a Pivot Point for Oncogene-Induced Senescence
SO CELL
LA English
DT Editorial Material
ID CANCER
C1 [Olenchock, Benjamin A.; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Olenchock, Benjamin A.; Vander Heiden, Matthew G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Olenchock, Benjamin A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA.
RP Vander Heiden, MG (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM mvh@mit.edu
FU NCI NIH HHS [R01 CA168653]; NHLBI NIH HHS [K08 HL119355, T32 HL007604]
NR 9
TC 3
Z9 3
U1 0
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUN 20
PY 2013
VL 153
IS 7
BP 1429
EP 1430
DI 10.1016/j.cell.2013.06.001
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 168RA
UT WOS:000320722000011
PM 23791173
ER
PT J
AU Sun, S
Del Rosario, BC
Szanto, A
Ogawa, Y
Jeon, Y
Lee, JT
AF Sun, Sha
Del Rosario, Brian C.
Szanto, Attila
Ogawa, Yuya
Jeon, Yesu
Lee, Jeannie T.
TI Jpx RNA Activates Xist by Evicting CTCF
SO CELL
LA English
DT Article
ID X-CHROMOSOME INACTIVATION; EMBRYONIC STEM-CELLS; DOSAGE COMPENSATION;
SEX DETERMINATION; MOUSE; TSIX; GENE; TRANSCRIPTION; SWITCH; BINDING
AB In mammals, dosage compensation between XX and XY individuals occurs through X chromosome inactivation (XCI). The noncoding Xist RNA is expressed and initiates XCI only when more than one X chromosome is present. Current models invoke a dependency on the X-to-autosome ratio (X:A), but molecular factors remain poorly defined. Here, we demonstrate that molecular titration between an X-encoded RNA and an autosomally encoded protein dictates Xist induction. In pre-XCI cells, CTCF protein represses Xist transcription. At the onset of XCI, Jpx RNA is upregulated, binds CTCF, and extricates CTCF from one Xist allele. We demonstrate that CTCF is an RNA-binding protein and is titrated away from the Xist promoter by Jpx RNA. Thus, Jpx activates Xist by evicting CTCF. The functional antagonism via molecular titration reveals a role for long noncoding RNA in epigenetic regulation.
C1 [Sun, Sha; Del Rosario, Brian C.; Szanto, Attila; Ogawa, Yuya; Jeon, Yesu; Lee, Jeannie T.] Howard Hughes Med Inst, Boston, MA 02114 USA.
[Sun, Sha; Del Rosario, Brian C.; Szanto, Attila; Ogawa, Yuya; Jeon, Yesu; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sun, Sha; Del Rosario, Brian C.; Szanto, Attila; Ogawa, Yuya; Jeon, Yesu; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
RP Lee, JT (reprint author), Howard Hughes Med Inst, Boston, MA 02114 USA.
EM lee@molbio.mgh.harvard.edu
FU National Institutes of Health [RO1-GM58839]
FX We are grateful to R. Jaenisch for the gift of F1-2.1 ES cells and G.
Daley for Ainv15. We thank S. Pinter for sharing unpublished data, J.
Ahn for sharing ChIP primers, B. Payer and D. Lessing for critically
reading the manuscript, and all lab members for engaging discussions.
This work is supported by a grant from the National Institutes of Health
(RO1-GM58839 to J.T.L.). J.T.L. is an Investigator of the Howard Hughes
Medical Institute.
NR 53
TC 98
Z9 99
U1 1
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUN 20
PY 2013
VL 153
IS 7
BP 1537
EP 1551
DI 10.1016/j.cell.2013.05.028
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 168RA
UT WOS:000320722000021
PM 23791181
ER
PT J
AU Shaw, AT
Kim, DW
Nakagawa, K
Seto, T
Crino, L
Ahn, MJ
De Pas, T
Besse, B
Solomon, BJ
Blackhall, F
Wu, YL
Thomas, M
O'Byrne, KJ
Moro-Sibilot, D
Camidge, DR
Mok, T
Hirsh, V
Riely, GJ
Iyer, S
Tassell, V
Polli, A
Wilner, KD
Janne, PA
AF Shaw, Alice T.
Kim, Dong-Wan
Nakagawa, Kazuhiko
Seto, Takashi
Crino, Lucio
Ahn, Myung-Ju
De Pas, Tommaso
Besse, Benjamin
Solomon, Benjamin J.
Blackhall, Fiona
Wu, Yi-Long
Thomas, Michael
O'Byrne, Kenneth J.
Moro-Sibilot, Denis
Camidge, D. Ross
Mok, Tony
Hirsh, Vera
Riely, Gregory J.
Iyer, Shrividya
Tassell, Vanessa
Polli, Anna
Wilner, Keith D.
Jaenne, Pasi A.
TI Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID EML4-ALK FUSION GENE; CLINICAL-TRIALS; OPEN-LABEL; PHASE-III; LYMPHOMA;
ONCOLOGY; EGFR; REARRANGEMENT; GEFITINIB; DOCETAXEL
AB Background
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown.
Methods
We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen. Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a separate study. The primary end point was progression-free survival.
Results
The median progression-free survival was 7.7 months in the crizotinib group and 3.0 months in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001). The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001). An interim analysis of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54). Common adverse events associated with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea. Patients reported greater reductions in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.
Conclusions
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.
C1 [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
[Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
[Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
[Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Nakagawa, Kazuhiko] Kinki Univ, Fac Med, Osakasayama City, Osaka, Japan.
[Seto, Takashi] Kyushu Natl Canc Ctr, Fukuoka, Japan.
[Crino, Lucio] Azienda Osped Perugia, Perugia, Italy.
[De Pas, Tommaso] European Inst Oncol, Milan, Italy.
[Polli, Anna] Pfizer Italia, Milan, Italy.
[Besse, Benjamin] Inst Gustave Roussy, Villejuif, France.
[Moro-Sibilot, Denis] CHU Grenoble, Thorac Oncol Unit, F-38043 Grenoble, France.
[Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Blackhall, Fiona] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England.
[Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China.
[Thomas, Michael] Univ Klinikum Heidelberg, Thoraxklinik, Heidelberg, Germany.
[Thomas, Michael] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany.
[O'Byrne, Kenneth J.] St James Hosp, Dublin, Ireland.
[Camidge, D. Ross] Univ Colorado, Aurora, CO USA.
[Mok, Tony] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
[Hirsh, Vera] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Iyer, Shrividya] Pfizer Oncol, New York, NY USA.
[Tassell, Vanessa; Wilner, Keith D.] Pfizer Oncol, La Jolla, CA USA.
RP Shaw, AT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Yawkey 7B,32 Fruit St, Boston, MA 02114 USA.
EM ashaw1@partners.org
RI MORO-SIBILOT, denis/N-6493-2013; Blackhall, Fiona/N-2186-2015;
OI Blackhall, Fiona/0000-0001-8716-3395; MORO-SIBILOT,
Denis/0000-0001-6776-8610; Wu, Yi-Long/0000-0002-3611-0258
FU Pfizer
FX Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.
NR 30
TC 1089
Z9 1149
U1 20
U2 136
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 20
PY 2013
VL 368
IS 25
BP 2385
EP 2394
DI 10.1056/NEJMoa1214886
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167AE
UT WOS:000320601700008
PM 23724913
ER
PT J
AU Awad, MM
Katayama, R
McTigue, M
Liu, W
Deng, YL
Brooun, A
Friboulet, L
Huang, DH
Falk, MD
Timofeevski, S
Wilner, KD
Lockerman, EL
Khan, TM
Mahmood, S
Gainor, JF
Digumarthy, SR
Stone, JR
Mino-Kenudson, M
Christensen, JG
Iafrate, AJ
Engelman, JA
Shaw, AT
AF Awad, Mark M.
Katayama, Ryohei
McTigue, Michele
Liu, Wei
Deng, Ya-Li
Brooun, Alexei
Friboulet, Luc
Huang, Donghui
Falk, Matthew D.
Timofeevski, Sergei
Wilner, Keith D.
Lockerman, Elizabeth L.
Khan, Tahsin M.
Mahmood, Sidra
Gainor, Justin F.
Digumarthy, Subba R.
Stone, James R.
Mino-Kenudson, Mari
Christensen, James G.
Iafrate, A. John
Engelman, Jeffrey A.
Shaw, Alice T.
TI Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CELL LUNG-CANCER; GEFITINIB; EML4-ALK; SAFETY; GENE; INHIBITOR;
EFFICACY; THERAPY; KINASE
AB Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently shown efficacy in the treatment of lung cancers with ROS1 translocations. Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. We performed a biopsy of a resistant tumor and identified an acquired mutation leading to a glycine-to-arginine substitution at codon 2032 in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. The same resistance mutation was observed at all the metastatic sites that were examined at autopsy, suggesting that this mutation was an early event in the clonal evolution of resistance.
C1 [Awad, Mark M.; Katayama, Ryohei; Friboulet, Luc; Lockerman, Elizabeth L.; Khan, Tahsin M.; Mahmood, Sidra; Gainor, Justin F.; Engelman, Jeffrey A.; Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Boston, MA 02114 USA.
[Digumarthy, Subba R.] Massachusetts Gen Hosp, Ctr Canc, Dept Radiol, Boston, MA 02114 USA.
[Stone, James R.; Mino-Kenudson, Mari; Iafrate, A. John] Massachusetts Gen Hosp, Ctr Canc, Dept Pathol, Boston, MA 02114 USA.
[McTigue, Michele; Liu, Wei; Deng, Ya-Li; Brooun, Alexei; Huang, Donghui; Falk, Matthew D.; Timofeevski, Sergei; Wilner, Keith D.; Christensen, James G.] Pfizer Worldwide Res & Dev, La Jolla, CA USA.
RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA.
EM jengelman@partners.org; ashaw1@partners.org
RI friboulet, luc/N-7276-2015
OI friboulet, luc/0000-0002-1129-4978
FU Pfizer; National Cancer Institute [5R01CA164273-02, R01CA137008, Lung
SPORE P50CA090578, a1R21CA161590-01]; V Foundation Translational
Research Grant; Be a Piece of the Solution; Evan Spirito Memorial
Foundation
FX Supported by Pfizer, by grants from the National Cancer Institute
(5R01CA164273-02, to Drs. Shaw and Engelman; R01CA137008 and Lung SPORE
P50CA090578, to Dr. Engelman; and a1R21CA161590-01, to Dr. Iafrate), by
a V Foundation Translational Research Grant (to Drs. Shaw and Engelman),
by Be a Piece of the Solution, and by the Evan Spirito Memorial
Foundation.
NR 25
TC 96
Z9 97
U1 4
U2 20
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 20
PY 2013
VL 368
IS 25
BP 2395
EP 2401
DI 10.1056/NEJMoa1215530
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167AE
UT WOS:000320601700009
PM 23724914
ER
PT J
AU Alexander, EK
Chan-Smutko, G
Saksena, MA
Popa, I
AF Alexander, Erik K.
Chan-Smutko, Gayun
Saksena, Mansi A.
Popa, Ion
TI Case 19-2013: A 35-Year-Old Woman with Recurrent Goiter and Ductal
Carcinoma of the Breast
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID THYROID-NODULES; RADIATION; CANCER
C1 [Alexander, Erik K.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Chan-Smutko, Gayun] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Saksena, Mansi A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Popa, Ion] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Alexander, Erik K.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Saksena, Mansi A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Popa, Ion] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Alexander, EK (reprint author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
NR 16
TC 1
Z9 1
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 20
PY 2013
VL 368
IS 25
BP 2416
EP 2424
DI 10.1056/NEJMcpc1209273
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167AE
UT WOS:000320601700013
PM 23782181
ER
PT J
AU Wilfond, BS
Magnus, D
Antommaria, AH
Appelbaum, P
Aschner, J
Barrington, KJ
Beauchamp, T
Boss, RD
Burke, W
Caplan, AL
Capron, AM
Cho, M
Clayton, EW
Cole, FS
Darlow, BA
Diekema, D
Faden, RR
Feudtner, C
Fins, JJ
Fost, NC
Frader, J
Hester, DM
Janvier, A
Joffe, S
Kahn, J
Kass, NE
Kodish, E
Lantos, JD
McCullough, L
McKinney, R
Meadow, W
O'Rourke, PP
Powderly, KE
Pursley, DM
Ross, LF
Sayeed, S
Sharp, RR
Sugarman, J
Tarnow-Mordi, WO
Taylor, H
Tomlinson, T
Truog, RD
Unguru, YT
Weise, KL
Woodrum, D
Youngner, S
AF Wilfond, Benjamin S.
Magnus, David
Antommaria, Armand H.
Appelbaum, Paul
Aschner, Judy
Barrington, Keith J.
Beauchamp, Tom
Boss, Renee D.
Burke, Wylie
Caplan, Arthur L.
Capron, Alexander M.
Cho, Mildred
Clayton, Ellen Wright
Cole, F. Sessions
Darlow, Brian A.
Diekema, Douglas
Faden, Ruth R.
Feudtner, Chris
Fins, Joseph J.
Fost, Norman C.
Frader, Joel
Hester, D. Micah
Janvier, Annie
Joffe, Steven
Kahn, Jeffrey
Kass, Nancy E.
Kodish, Eric
Lantos, John D.
McCullough, Laurence
McKinney, Ross, Jr.
Meadow, William
O'Rourke, P. Pearl
Powderly, Kathleen E.
Pursley, DeWayne M.
Ross, Lainie Friedman
Sayeed, Sadath
Sharp, Richard R.
Sugarman, Jeremy
Tarnow-Mordi, William O.
Taylor, Holly
Tomlinson, Tom
Truog, Robert D.
Unguru, Yoram T.
Weise, Kathryn L.
Woodrum, David
Youngner, Stuart
TI The OHRP and SUPPORT
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Wilfond, Benjamin S.; Diekema, Douglas] Univ Washington, Sch Med, Dept Pediat, Div Bioeth, Seattle, WA 98195 USA.
[Wilfond, Benjamin S.; Diekema, Douglas; Woodrum, David] Seattle Childrens Res Inst, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA.
[Magnus, David; Cho, Mildred] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
[Magnus, David] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Magnus, David; Cho, Mildred] Stanford Univ, Stanford Ctr Biomed Eth, Stanford, CA 94305 USA.
[Antommaria, Armand H.] Cincinnati Childrens Hosp Med Ctr, Eth Ctr, Cincinnati, OH 45229 USA.
[Antommaria, Armand H.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA.
[Appelbaum, Paul] Columbia Univ, Dept Psychiat, New York, NY USA.
[Aschner, Judy] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
[Aschner, Judy] Childrens Hosp Montefiore, Bronx, NY USA.
[Barrington, Keith J.; Janvier, Annie] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada.
[Barrington, Keith J.; Janvier, Annie] St Justine Univ Hlth Ctr, Montreal, PQ, Canada.
[Beauchamp, Tom] Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA.
[Boss, Renee D.] Johns Hopkins Sch Med, Dept Pediat, Div Neonatol, Baltimore, MD USA.
[Boss, Renee D.; Faden, Ruth R.; Kahn, Jeffrey; Kass, Nancy E.; Taylor, Holly; Unguru, Yoram T.] Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA.
[Burke, Wylie] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA USA.
[Caplan, Arthur L.] NYU, Div Med Eth, Langone Med Ctr, New York, NY USA.
[Capron, Alexander M.] Univ So Calif, Keck Sch Med, Gould Sch Law, Los Angeles, CA 90033 USA.
[Capron, Alexander M.] Univ So Calif, Pacific Ctr Hlth Policy & Eth, Los Angeles, CA USA.
[Clayton, Ellen Wright] Vanderbilt Univ, Sch Med, Ctr Biomed Eth & Soc, Nashville, TN 37212 USA.
[Clayton, Ellen Wright] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA.
[Clayton, Ellen Wright] Vanderbilt Law Sch, Nashville, TN USA.
[Cole, F. Sessions] Washington Univ, Sch Med, St Louis Childrens Hosp, Div Newborn Med, St Louis, MO USA.
[Cole, F. Sessions] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.
[Darlow, Brian A.] Univ Otago, Dept Pediat, Christchurch, New Zealand.
[Feudtner, Chris] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Feudtner, Chris] Childrens Hosp Philadelphia, Dept Med Eth, Philadelphia, PA 19104 USA.
[Fins, Joseph J.] Cornell Univ, Weill Med Coll, Dept Med, Div Med Eth, New York, NY 10021 USA.
[Fins, Joseph J.] NewYork Presbyterian Hosp, Weill Cornell Med Ctr, Div Med Eth, New York, NY USA.
[Fost, Norman C.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA.
[Fost, Norman C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Hist & Bioeth, Madison, WI USA.
[Frader, Joel] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA.
[Frader, Joel] Northwestern Univ, Dept Med Humanities & Bioeth, Chicago, IL 60611 USA.
[Hester, D. Micah] Univ Arkansas Med Sci, Div Med Humanities, Little Rock, AR 72205 USA.
[Hester, D. Micah] Arkansas Childrens Hosp, Little Rock, AR 72202 USA.
[Joffe, Steven] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Joffe, Steven] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kahn, Jeffrey; Kass, Nancy E.; Taylor, Holly] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
[Kodish, Eric] Cleveland Clin, Lerner Coll Med, Dept Bioeth, Cleveland, OH 44106 USA.
[Kodish, Eric] Cleveland Clin, Lerner Coll Med, Dept Pediat, Cleveland, OH 44106 USA.
[Lantos, John D.] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA.
[Lantos, John D.] Childrens Mercy Hosp Bioeth Ctr, Kansas City, MO USA.
[McCullough, Laurence] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
[McKinney, Ross, Jr.] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA.
[McKinney, Ross, Jr.] Duke Univ, Sch Med, Trent Ctr Bioeth Humanities & Hist Med, Durham, NC USA.
[Meadow, William] Univ Chicago, Dept Pediat, Div Neonatol, Chicago, IL 60637 USA.
[O'Rourke, P. Pearl] Partners HealthCare, Human Res Affairs, Boston, MA USA.
[Powderly, Kathleen E.] Suny Downstate Med Ctr, John Conley Div Med Eth & Humanities, Brooklyn, NY 11203 USA.
[Pursley, DeWayne M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Pursley, DeWayne M.] Beth Israel Deaconess Med Ctr, Dept Neonatol, Boston, MA 02215 USA.
[Ross, Lainie Friedman] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA.
[Ross, Lainie Friedman] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Ross, Lainie Friedman] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
[Ross, Lainie Friedman] Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA.
[Sayeed, Sadath] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Sayeed, Sadath] Boston Childrens Hosp, Boston, MA USA.
[Sharp, Richard R.; Weise, Kathryn L.] Cleveland Clin, Dept Bioeth, Cleveland, OH 44106 USA.
[Sharp, Richard R.] Cleveland Clin, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44106 USA.
[Sugarman, Jeremy] Johns Hopkins Berman Inst Bioeth, Dept Med, Div Gen Internal Med, Baltimore, MD USA.
[Tarnow-Mordi, William O.] Univ Sydney, Dept Pediat, Sydney, NSW 2006, Australia.
[Tarnow-Mordi, William O.] Westmead Hosp, Sydney, NSW, Australia.
[Tomlinson, Tom] Michigan State Univ, Coll Human Med, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA.
[Truog, Robert D.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Div Med Eth, Boston, MA USA.
[Truog, Robert D.] Boston Childrens Hosp, Div Crit Care Med, Boston, MA USA.
[Unguru, Yoram T.] Herman & Walter Samuelson Childrens Hosp Sinai, Div Pediat Hematol Oncol, Baltimore, MD USA.
[Woodrum, David] Univ Washington, Sch Med, Dept Pediat, Div Neonatol, Seattle, WA 98195 USA.
[Youngner, Stuart] Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH USA.
RP Wilfond, BS (reprint author), Univ Washington, Sch Med, Dept Pediat, Div Bioeth, Seattle, WA 98195 USA.
OI Barrington, Keith/0000-0001-9669-5094; Clayton,
Ellen/0000-0002-0308-4110; Joffe, Steven/0000-0002-0667-7384
NR 0
TC 28
Z9 28
U1 1
U2 9
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 20
PY 2013
VL 368
IS 25
BP E36
EP +
DI 10.1056/NEJMc1307008
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167AE
UT WOS:000320601700038
PM 23738513
ER
PT J
AU Ng, AK
Garber, JE
Diller, LR
Birdwell, RL
Feng, Y
Neuberg, DS
Silver, B
Fisher, DC
Marcus, KJ
Mauch, PM
AF Ng, Andrea K.
Garber, Judy E.
Diller, Lisa R.
Birdwell, Robyn L.
Feng, Yang
Neuberg, Donna S.
Silver, Barbara
Fisher, David C.
Marcus, Karen J.
Mauch, Peter M.
TI Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging
and Mammographic Screening in Survivors of Hodgkin Lymphoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID LONG-TERM SURVIVORS; HIGH FAMILIAL RISK; CANCER-RISK; 2ND MALIGNANCY;
BRCA2 MUTATION; YOUNG-WOMEN; FOLLOW-UP; DISEASE; SURVEILLANCE; RADIATION
AB Purpose
Current guidelines recommend breast magnetic resonance imaging (MRI) as an adjunct to mammography for breast cancer screening in female cancer survivors treated with chest irradiation at a young age, beginning 8 to 10 years after treatment. Prospective data evaluating its efficacy in female cancer survivors are lacking. This study sought to compare the sensitivity and specificity of breast MRI with those of mammography in women who received chest irradiation for Hodgkin lymphoma (HL).
Patients and Methods
We enrolled 148 women treated with chest irradiation for HL at age <= 35 years who were > 8 years beyond treatment. Yearly breast MRI and mammogram were performed over a 3-year period. Sensitivity and specificity of the two screening modalities were compared.
Results
With the screening, 63 biopsies were performed in 45 women; 18 (29%) showed a malignancy. All but one of the screen-detected malignancies were preinvasive or subcentimeter node-negative breast cancers. After excluding first-screen MRI and mammogram, mammogram sensitivity was 68% as compared with 67% for MRI (P = 1.0). Sensitivity increased to 94% using both screening modalities. The specificities of mammogram alone, MRI alone, and both were 93%, 94%, and 90%, respectively.
Conclusion
In contrast to women with genetic or familial risk, in HL survivors breast MRI was not more sensitive than mammogram for breast cancer detection. However, the two screening modalities complement each other in the detection of early cases of disease. Early diagnosis is particularly important in these patients, given the breast cancer treatment challenges in patients who have received prior cancer therapy. (C) 2013 by American Society of Clinical Oncology
C1 [Ng, Andrea K.; Birdwell, Robyn L.; Silver, Barbara; Marcus, Karen J.; Mauch, Peter M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ng, Andrea K.; Garber, Judy E.; Diller, Lisa R.; Feng, Yang; Neuberg, Donna S.; Silver, Barbara; Fisher, David C.; Marcus, Karen J.; Mauch, Peter M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Ng, AK (reprint author), 75 Francis St,ASB1-L2, Boston, MA 02115 USA.
EM ang@lroc.harvard.edu
FU Lance Armstrong Foundation; Susan G. Komen Foundation [BCTR0600221]
FX Supported by an Issues of Cancer Survivorship Research Grant from the
Lance Armstrong Foundation and Grant No. BCTR0600221 from the Susan G.
Komen Foundation.
NR 38
TC 30
Z9 30
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
BP 2282
EP U91
DI 10.1200/JCO.2012.46.5732
PG 8
WC Oncology
SC Oncology
GA 164XV
UT WOS:000320446700013
PM 23610104
ER
PT J
AU Terpos, E
Morgan, G
Dimopoulos, MA
Drake, MT
Lentzsch, S
Raje, N
Sezer, O
Garcia-Sanz, R
Shimizu, K
Turesson, I
Reiman, T
Jurczyszyn, A
Merlini, G
Spencer, A
Leleu, X
Cavo, M
Munshi, N
Rajkumar, SV
Durie, BGM
Roodman, GD
AF Terpos, Evangelos
Morgan, Gareth
Dimopoulos, Meletios A.
Drake, Matthew T.
Lentzsch, Suzanne
Raje, Noopur
Sezer, Orhan
Garcia-Sanz, Ramon
Shimizu, Kazuyuki
Turesson, Ingemar
Reiman, Tony
Jurczyszyn, Artur
Merlini, Giampaolo
Spencer, Andrew
Leleu, Xavier
Cavo, Michele
Munshi, Nikhil
Rajkumar, S. Vincent
Durie, Brian G. M.
Roodman, G. David
TI International Myeloma Working Group Recommendations for the Treatment of
Multiple Myeloma-Related Bone Disease
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SPINAL-CORD COMPRESSION; RANDOMIZED CONTROLLED-TRIAL; CLINIC CONSENSUS
STATEMENT; SKELETAL-RELATED EVENTS; VITAMIN-D DEFICIENCY; ZOLEDRONIC
ACID; UNDETERMINED SIGNIFICANCE; MONOCLONAL GAMMOPATHY; DOUBLE-BLIND;
VERTEBRAL AUGMENTATION
AB Purpose
The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.
Methodology
An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members.
Recommendations
Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability. (C) 2013 by American Society of Clinical Oncology
C1 [Terpos, Evangelos; Dimopoulos, Meletios A.] Univ Athens, Sch Med, Athens 11528, Greece.
[Morgan, Gareth] Royal Marsden Hosp, London SW3 6JJ, England.
[Drake, Matthew T.; Rajkumar, S. Vincent] Mayo Clin, Rochester, MN USA.
[Lentzsch, Suzanne] Columbia Univ, New York, NY USA.
[Raje, Noopur; Munshi, Nikhil] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sezer, Orhan] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
[Garcia-Sanz, Ramon] Univ Salamanca, E-37008 Salamanca, Spain.
[Shimizu, Kazuyuki] Nagoya City Midori Gen Hosp, Nagoya, Aichi, Japan.
[Turesson, Ingemar] Malmo Univ, Malmo, Sweden.
[Reiman, Tony] Univ New Brunswick, St John, NB E2L 4L5, Canada.
[Jurczyszyn, Artur] Univ Hosp, Krakow, Poland.
[Merlini, Giampaolo] Univ Pavia, I-27100 Pavia, Italy.
[Cavo, Michele] Univ Bologna, Sch Med, Bologna, Italy.
[Spencer, Andrew] Monash Univ, Melbourne, Vic 3004, Australia.
[Leleu, Xavier] Ctr Hosp Reg Univ, Hop Claude Huriez, Lille, France.
[Durie, Brian G. M.] Samuel Oschin Canc Ctr, Los Angeles, CA USA.
[Roodman, G. David] Indiana Univ, Sch Med, Indianapolis, IN USA.
RP Terpos, E (reprint author), Univ Athens, Sch Med, Dept Clin Therapeut, 80 Vas Sofias Ave, Athens 11528, Greece.
EM eterpos@med.uoa.gr
RI Garcia-Sanz, Ramon/B-7986-2017;
OI Garcia-Sanz, Ramon/0000-0003-4120-2787; CAVO,
MICHELE/0000-0003-4514-3227; Merlini, Giampaolo/0000-0001-7680-3254
FU NIAMS NIH HHS [R01 AR059679]
NR 90
TC 75
Z9 78
U1 2
U2 14
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 20
PY 2013
VL 31
IS 18
BP 2347
EP U179
DI 10.1200/JCO.2012.47.7901
PG 13
WC Oncology
SC Oncology
GA 164XV
UT WOS:000320446700020
PM 23690408
ER
PT J
AU Tobwala, S
Zhang, XS
Zheng, YY
Wang, HJ
Banks, WA
Ercal, N
AF Tobwala, Shakila
Zhang, Xinsheng
Zheng, Youyou
Wang, Hsiu-Jen
Banks, William A.
Ercal, Nuran
TI Disruption of the integrity and function of brain microvascular
endothelial cells in culture by exposure to diesel engine exhaust
particles
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Diesel engine exhaust; Diesel exhaust particles; Oxidative stress;
Reactive oxygen species; Glutathione
ID PARTICULATE AIR-POLLUTION; TERT-BUTYL HYDROPEROXIDE; OXIDATIVE STRESS;
IN-VITRO; GLUTATHIONE METABOLISM; DOPAMINERGIC-NEURONS; ULTRAFINE
PARTICLES; LIPID-PEROXIDATION; BARRIER; DAMAGE
AB Diesel exhaust particles (DEPs), a by-product of diesel engine exhaust (DEE), are known to produce pro-oxidative and pro-inflammatory effects, thereby leading to oxidative stress-induced damage. Given the key role of DEPs in inducing oxidative stress, we investigated the role of DEPs in disrupting the integrity and function of immortalized human brain microvascular endothelial cells (HBMVEC). To study this, HBMVEC cells were exposed to media containing three different concentrations of DEPs or plain media for 24 h. Those exposed to DEPs showed significantly higher oxidative stress than the untreated group, as indicated by the glutathione (GSH) and malondialdehyde (MDA) levels, and the glutathione peroxidase and glutathione reductase activities. DEPs also induced oxidative stress-related disruption of the HBMVEC cells monolayer, as measured by trans-epithelial electrical resistance. Taken together, these data suggest that DEPs induce cell death and disrupt the function and integrity of HBMVEC cells, indicating a potential role of DEPs in neurotoxicities. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Tobwala, Shakila; Zhang, Xinsheng; Zheng, Youyou; Wang, Hsiu-Jen; Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO 65409 USA.
[Banks, William A.] Univ Washington, Sch Med, GRECC, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
[Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
RP Ercal, N (reprint author), Missouri Univ Sci & Technol, Dept Chem, 400 West 11th St,142 Schrenk Hall, Rolla, MO 65409 USA.
EM nercal@mst.edu
FU NIDA, NIH [1 R15DA023409-01A2]
FX Dr. Ercal was supported by 1 R15DA023409-01A2 from the NIDA, NIH and the
contents of this paper are solely the responsibility of the authors and
do not necessarily represent official views of the NIDA or NIH. The
authors appreciate the editorial efforts of Barbara Harris.
NR 58
TC 9
Z9 9
U1 1
U2 17
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-4274
J9 TOXICOL LETT
JI Toxicol. Lett.
PD JUN 20
PY 2013
VL 220
IS 1
BP 1
EP 7
DI 10.1016/j.toxlet.2013.03.023
PG 7
WC Toxicology
SC Toxicology
GA 151GS
UT WOS:000319449300001
PM 23542817
ER
PT J
AU Yehia, BR
Kangovi, S
Frank, I
AF Yehia, Baligh R.
Kangovi, Shreya
Frank, Ian
TI Patients in transition: avoiding detours on the road to HIV treatment
success
SO AIDS
LA English
DT Article
DE behavioral model; care transitions; health outcomes; HIV; quality of
care
ID HEALTH-CARE TRANSITION; ANTIRETROVIRAL THERAPY; YOUTH; PERSPECTIVES;
PREVENTION; RELEASE; SYSTEM; ADULTS; PRISON
C1 [Yehia, Baligh R.; Kangovi, Shreya; Frank, Ian] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Kangovi, Shreya] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Yehia, BR (reprint author), Univ Penn, Perelman Sch Med, 1309 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM byehia@upenn.edu
FU Penn Center for AIDS Research [P30 AI 045008]; National Institutes of
Health [K23-MH097647-01A1]
FX This work was support, in part, by the Penn Center for AIDS Research,
P30 AI 045008. B.R.Y. was supported by the National Institutes of Health
(K23-MH097647-01A1).
NR 20
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 19
PY 2013
VL 27
IS 10
BP 1529
EP 1533
DI 10.1097/QAD.0b013e328360104e
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 250HG
UT WOS:000326840700001
PM 23435297
ER
PT J
AU Manchia, M
Adli, M
Akula, N
Ardau, R
Aubry, JM
Backlund, L
Banzato, CEM
Baune, BT
Bellivier, F
Bengesser, S
Biernacka, JM
Brichant-Petitjean, C
Bui, E
Calkin, CV
Cheng, ATA
Chillotti, C
Cichon, S
Clark, S
Czerski, PM
Dantas, C
Del Zompo, M
DePaulo, JR
Detera-Wadleigh, SD
Etain, B
Falkai, P
Frisen, L
Frye, MA
Fullerton, J
Gard, S
Garnham, J
Goes, FS
Grof, P
Gruber, O
Hashimoto, R
Hauser, J
Heilbronner, U
Hoban, R
Hou, LP
Jamain, S
Kahn, JP
Kassem, L
Kato, T
Kelsoe, JR
Kittel-Schneider, S
Kliwicki, S
Kuo, PH
Kusumi, I
Laje, G
Lavebratt, C
Leboyer, M
Leckband, SG
Jaramillo, CAL
Maj, M
Malafosse, A
Martinsson, L
Masui, T
Mitchell, PB
Mondimore, F
Monteleone, P
Nallet, A
Neuner, M
Novak, T
O'Donovan, C
Osby, U
Ozaki, N
Perlis, RH
Pfennig, A
Potash, JB
Reich-Erkelenz, D
Reif, A
Reininghaus, E
Richardson, S
Rouleau, GA
Rybakowski, JK
Schalling, M
Schofield, PR
Schubert, OK
Schweizer, B
Seemuller, F
Grigoroiu-Serbanescu, M
Severino, G
Seymour, LR
Slaney, C
Smoller, JW
Squassina, A
Stamm, T
Steele, J
Stopkova, P
Tighe, SK
Tortorella, A
Turecki, G
Wray, NR
Wright, A
Zandi, PP
Zilles, D
Bauer, M
Rietschel, M
McMahon, FJ
Schulze, TG
Alda, M
AF Manchia, Mirko
Adli, Mazda
Akula, Nirmala
Ardau, Raffaella
Aubry, Jean-Michel
Backlund, Lena
Banzato, Claudio E. M.
Baune, Bernhard T.
Bellivier, Frank
Bengesser, Susanne
Biernacka, Joanna M.
Brichant-Petitjean, Clara
Bui, Elise
Calkin, Cynthia V.
Cheng, Andrew Tai Ann
Chillotti, Caterina
Cichon, Sven
Clark, Scott
Czerski, Piotr M.
Dantas, Clarissa
Del Zompo, Maria
DePaulo, J. Raymond
Detera-Wadleigh, Sevilla D.
Etain, Bruno
Falkai, Peter
Frisen, Louise
Frye, Mark A.
Fullerton, Jan
Gard, Sebastien
Garnham, Julie
Goes, Fernando S.
Grof, Paul
Gruber, Oliver
Hashimoto, Ryota
Hauser, Joanna
Heilbronner, Urs
Hoban, Rebecca
Hou, Liping
Jamain, Stephane
Kahn, Jean-Pierre
Kassem, Layla
Kato, Tadafumi
Kelsoe, John R.
Kittel-Schneider, Sarah
Kliwicki, Sebastian
Kuo, Po-Hsiu
Kusumi, Ichiro
Laje, Gonzalo
Lavebratt, Catharina
Leboyer, Marion
Leckband, Susan G.
Lopez Jaramillo, Carlos A.
Maj, Mario
Malafosse, Alain
Martinsson, Lina
Masui, Takuya
Mitchell, Philip B.
Mondimore, Frank
Monteleone, Palmiero
Nallet, Audrey
Neuner, Maria
Novak, Tomas
O'Donovan, Claire
Osby, Urban
Ozaki, Norio
Perlis, Roy H.
Pfennig, Andrea
Potash, James B.
Reich-Erkelenz, Daniela
Reif, Andreas
Reininghaus, Eva
Richardson, Sara
Rouleau, Guy A.
Rybakowski, Janusz K.
Schalling, Martin
Schofield, Peter R.
Schubert, Oliver K.
Schweizer, Barbara
Seemueller, Florian
Grigoroiu-Serbanescu, Maria
Severino, Giovanni
Seymour, Lisa R.
Slaney, Claire
Smoller, Jordan W.
Squassina, Alessio
Stamm, Thomas
Steele, Jo
Stopkova, Pavla
Tighe, Sarah K.
Tortorella, Alfonso
Turecki, Gustavo
Wray, Naomi R.
Wright, Adam
Zandi, Peter P.
Zilles, David
Bauer, Michael
Rietschel, Marcella
McMahon, Francis J.
Schulze, Thomas G.
Alda, Martin
TI Assessment of Response to Lithium Maintenance Treatment in Bipolar
Disorder: A Consortium on Lithium Genetics (ConLiGen) Report
SO PLOS ONE
LA English
DT Article
ID MAPPING SUSCEPTIBILITY GENES; PROPHYLACTIC LITHIUM; OBSERVER AGREEMENT;
MOOD DISORDERS; ONSET; ASSOCIATION; RELIABILITY; MORTALITY; ILLNESS; AGE
AB Objective: The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length of treatment, unpredictable clinical course, and often inconsistent compliance. Prospective and retrospective methods of assessment of lithium response have been proposed in the literature. In this study we report the key phenotypic measures of the "Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder" scale currently used in the Consortium on Lithium Genetics (ConLiGen) study.
Materials and Methods: Twenty-nine ConLiGen sites took part in a two-stage case-vignette rating procedure to examine inter-rater agreement [Kappa (kappa)] and reliability [intra-class correlation coefficient (ICC)] of lithium response. Annotated first-round vignettes and rating guidelines were circulated to expert research clinicians for training purposes between the two stages. Further, we analyzed the distributional properties of the treatment response scores available for 1,308 patients using mixture modeling.
Results: Substantial and moderate agreement was shown across sites in the first and second sets of vignettes (kappa = 0.66 and kappa = 0.54, respectively), without significant improvement from training. However, definition of response using the A score as a quantitative trait and selecting cases with B criteria of 4 or less showed an improvement between the two stages (ICC1 = 0.71 and ICC2 = 0.75, respectively). Mixture modeling of score distribution indicated three subpopulations (full responders, partial responders, non responders).
Conclusions: We identified two definitions of lithium response, one dichotomous and the other continuous, with moderate to substantial inter-rater agreement and reliability. Accurate phenotypic measurement of lithium response is crucial for the ongoing ConLiGen pharmacogenomic study.
C1 [Manchia, Mirko; Calkin, Cynthia V.; Garnham, Julie; O'Donovan, Claire; Slaney, Claire; Alda, Martin] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada.
[Adli, Mazda; Stamm, Thomas] Charite, Dept Psychiat & Psychotherapy, D-13353 Berlin, Germany.
[Akula, Nirmala; Bui, Elise; Detera-Wadleigh, Sevilla D.; Hou, Liping; Kassem, Layla; Laje, Gonzalo; Richardson, Sara; Steele, Jo; McMahon, Francis J.; Schulze, Thomas G.] NIMH, Human Genet Branch, Div Intramural Res Programs, NIH, Bethesda, MD 20892 USA.
[Ardau, Raffaella; Chillotti, Caterina; Del Zompo, Maria] Univ Hosp Cagliari, Clin Pharmacol Unit, Cagliari, Italy.
[Aubry, Jean-Michel; Malafosse, Alain; Nallet, Audrey] Hop Univ Geneve, Dept Mental Hlth & Psychiat, Geneva, Switzerland.
[Backlund, Lena; Frisen, Louise; Martinsson, Lina] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
[Banzato, Claudio E. M.; Dantas, Clarissa] Univ Estadual Campinas, Dept Psychiat, Campinas, Brazil.
[Baune, Bernhard T.; Clark, Scott; Schubert, Oliver K.] Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia.
[Bellivier, Frank; Brichant-Petitjean, Clara] Grp Hosp Lariboisiere F Widal, AP HP, Paris, France.
[Bengesser, Susanne; Reininghaus, Eva] Med Univ Graz, Dept Psychiat, Graz, Austria.
[Biernacka, Joanna M.; Frye, Mark A.; Seymour, Lisa R.] Mayo Clin, Dept Psychiat, Rochester, MN USA.
[Cheng, Andrew Tai Ann] Acad Sinica, Inst Biomed Sci, Div Epidemiol & Genet, Taipei, Taiwan.
[Cichon, Sven] Univ Bonn, Life & Brain Ctr, Dept Genom, Bonn, Germany.
[Cichon, Sven] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Czerski, Piotr M.] Poznan Univ Med Sci, Psychiat Genet Unit, Poznan, Poland.
[Del Zompo, Maria; Severino, Giovanni; Squassina, Alessio] Univ Cagliari, Dept Biomed Sci, Sect Neurosci & Clin Pharmacol, Cagliari, Italy.
[DePaulo, J. Raymond; Goes, Fernando S.; Mondimore, Frank; Potash, James B.; Schweizer, Barbara; Tighe, Sarah K.; Schulze, Thomas G.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Etain, Bruno; Jamain, Stephane; Leboyer, Marion] Fac Med, Equipe 15, Inst Mondor Rech Biomed, INSERM,Unite 955, Creteil, France.
[Falkai, Peter; Seemueller, Florian] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany.
[Fullerton, Jan; Schofield, Peter R.] Neurosci Res Australia Genet Mental Illness & Bra, Sydney, NSW, Australia.
[Gard, Sebastien] Hop Charles Perrens, Psychiat Serv, Bordeaux, France.
[Grof, Paul] Mood Disorders Ctr Ottawa, Ottawa, ON, Canada.
[Grof, Paul] Univ Toronto, Dept Psychiat, Toronto, ON, Canada.
[Gruber, Oliver; Heilbronner, Urs; Reich-Erkelenz, Daniela; Zilles, David; Schulze, Thomas G.] Univ Gottingen, Dept Psychiat & Psychotherapy, D-37073 Gottingen, Germany.
[Hashimoto, Ryota] Osaka Univ, Grad Sch Med, Osaka, Japan.
[Hauser, Joanna] Poznan Univ Med Sci, Psychiat Genet Unit, Poznan, Poland.
[Hoban, Rebecca; Kelsoe, John R.; Leckband, Susan G.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Hoban, Rebecca; Kelsoe, John R.] Vet Affairs San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA.
[Kahn, Jean-Pierre] Ctr Hosp Univ Nancy, Serv Psychiat & Psychol Clin, Nancy, France.
[Kato, Tadafumi; Kusumi, Ichiro] RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Saitama, Japan.
[Kittel-Schneider, Sarah; Neuner, Maria; Reif, Andreas] Univ Wurzburg, Dept Psychiat Psychosomat & Psychotherapy, D-97070 Wurzburg, Germany.
[Kliwicki, Sebastian; Rybakowski, Janusz K.] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland.
[Kuo, Po-Hsiu] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan.
[Kusumi, Ichiro; Masui, Takuya] Hokkaido Univ, Grad Sch Med, Dept Psychiat, Sapporo, Hokkaido, Japan.
[Lavebratt, Catharina; Osby, Urban; Schalling, Martin] Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
[Lavebratt, Catharina; Osby, Urban; Schalling, Martin] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden.
[Leckband, Susan G.] Vet Affairs San Diego Healthcare Syst, Dept Pharm, San Diego, CA USA.
[Leckband, Susan G.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA.
[Lopez Jaramillo, Carlos A.] Univ Antioquia, Dept Psychiat, Medellin, Colombia.
[Maj, Mario; Monteleone, Palmiero; Tortorella, Alfonso] Univ Naples Federico II, Dept Psychiat, Naples, Italy.
[Mitchell, Philip B.; Wright, Adam] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia.
[Mitchell, Philip B.; Wright, Adam] Black Dog Inst, Sydney, NSW, Australia.
[Novak, Tomas; Stopkova, Pavla] Univ Prague, Prague Psychiat Ctr, Prague, Czech Republic.
[Ozaki, Norio] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi 47011, Japan.
[Ozaki, Norio] Nagoya Univ, Grad Sch Med, Dept Psychiat, Nagoya, Aichi 4648601, Japan.
[Perlis, Roy H.; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Perlis, Roy H.; Smoller, Jordan W.] Harvard Univ, Sch Med, Boston, MA USA.
[Pfennig, Andrea; Bauer, Michael] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Dresden, Germany.
[Potash, James B.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.
[Rouleau, Guy A.] Univ Montreal, Ctr Hosp Univ Montreal, Ctr Excellence Neurosci, Montreal, PQ, Canada.
[Rouleau, Guy A.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada.
[Grigoroiu-Serbanescu, Maria] Alexandru Obregia Psychiat Hosp, Biometr Psychiat Genet Res Unit, Bucharest, Romania.
[Turecki, Gustavo] Douglas Mental Hlth Univ Inst, McGill Grp Suicide Studies, Montreal, PQ, Canada.
[Wray, Naomi R.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia.
[Zandi, Peter P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Rietschel, Marcella; Schulze, Thomas G.] Heidelberg Univ, Univ Med Ctr Mannheim, Cent Inst Mental Hlth Mannheim, Dept Genet Epidemiol Psychiat, Mannheim, Germany.
RP Schulze, TG (reprint author), NIMH, Human Genet Branch, Div Intramural Res Programs, NIH, Bethesda, MD 20892 USA.
EM thomas.schulze@med.uni-goettingen.de; malda@dal.ca
RI Banzato, Claudio/B-2517-2008; Cichon, Sven/H-8803-2013; Cichon,
Sven/B-9618-2014; Ozaki, Norio/M-8908-2014; Hou, Liping/G-1648-2011;
BELLIVIER, FRANK/H-5197-2012; Novak, Tomas/B-8008-2017; Kato,
Tadafumi/J-3583-2014; Serbanescu, Maria/D-4306-2011; Hashimoto,
Ryota/P-8572-2014; Wray, Naomi/C-8639-2015
OI Kuo, Po-Hsiu/0000-0003-0365-3587; Jamain, Stephane/0000-0002-4321-4100;
McMahon, Francis/0000-0002-9469-305X; Backlund,
Lena/0000-0001-9399-5024; Banzato, Claudio/0000-0002-8556-3982; Manchia,
Mirko/0000-0003-4175-6413; Lavebratt, Catharina/0000-0003-4987-2718;
Reininghaus, Eva/0000-0001-5964-4087; Kittel-Schneider,
Sarah/0000-0003-3057-6150; Mitchell, Philip/0000-0002-7954-5235; Lopez,
Carlos/0000-0002-1875-1369; Cichon, Sven/0000-0002-9475-086X; Cichon,
Sven/0000-0002-9475-086X; Ozaki, Norio/0000-0002-7360-4898; Hou,
Liping/0000-0003-3972-245X; Novak, Tomas/0000-0001-9156-9654; Kato,
Tadafumi/0000-0001-7856-3952; Serbanescu, Maria/0000-0002-1304-6687;
Hashimoto, Ryota/0000-0002-5941-4238; Wray, Naomi/0000-0001-7421-3357
FU Canadian Institutes of Health Research [64410]; Unitatea Executiva
pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si
Inovarii (UEFISCDI), Bucharest, Romania [89/2012]; Swiss National
Foundation [32003B_125469/1]; National Institute of Mental Health (NIMH)
at the National Institutes of Health (NIH), Department of Health and
Human Services, United States Government; Deutsche
Forschungsgemeinschaft [RI 908/7-1]
FX The work on assessment of lithium response has been supported by a grant
from Canadian Institutes of Health Research #64410 to MA. MG-S was
supported by Unitatea Executiva pentru Finantarea Invatamantului
Superior, a Cercetarii, Dezvoltarii si Inovarii (UEFISCDI), Bucharest,
Romania (grant no. 89/2012). JMA and AN were supported by a grant from
the Swiss National Foundation (#32003B_125469/1 to JM Aubry). ConLiGen
is in part supported by funds from the Intramural Research Program of
the National Institute of Mental Health (NIMH) at the National
Institutes of Health (NIH), Department of Health and Human Services,
United States Government. It is further supported by a grant from the
Deutsche Forschungsgemeinschaft to MR, MB, and TGS (RI 908/7-1). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 44
TC 25
Z9 26
U1 7
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2013
VL 8
IS 6
AR e65636
DI 10.1371/journal.pone.0065636
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 190ST
UT WOS:000322361200028
PM 23840348
ER
PT J
AU Konadhode, RR
Pelluru, D
Blanco-Centurion, C
Zayachkivsky, A
Liu, M
Uhde, T
Glen, WB
van den Pol, AN
Mulholland, PJ
Shiromani, PJ
AF Konadhode, Roda Rani
Pelluru, Dheeraj
Blanco-Centurion, Carlos
Zayachkivsky, Andrew
Liu, Meng
Uhde, Thomas
Glen, W. Bailey, Jr.
van den Pol, Anthony N.
Mulholland, Patrick J.
Shiromani, Priyattam J.
TI Optogenetic Stimulation of MCH Neurons Increases Sleep
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MELANIN-CONCENTRATING HORMONE; LOCUS-COERULEUS; OREXIN NEURONS; RAT;
MICE; HYPOTHALAMUS; HYPOCRETIN; NUCLEUS; BRAIN; GENE
AB Melanin concentrating hormone (MCH) is a cyclic neuropeptide present in the hypothalamus of all vertebrates. MCH is implicated in a number of behaviors but direct evidence is lacking. To selectively stimulate the MCH neurons the gene for the light-sensitive cation channel, channelrhodopsin-2, was inserted into the MCH neurons of wild-type mice. Three weeks later MCH neurons were stimulated for 1 min every 5 min for 24 h. A 10 Hz stimulation at the start of the night hastened sleep onset, reduced length of wake bouts by 50%, increased total time in non-REM and REM sleep at night, and increased sleep intensity during the day cycle. Sleep induction at a circadian time when all of the arousal neurons are active indicates that MCH stimulation can powerfully counteract the combined wake-promoting signal of the arousal neurons. This could be potentially useful in treatment of insomnia.
C1 [Shiromani, Priyattam J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA.
[Konadhode, Roda Rani; Pelluru, Dheeraj; Blanco-Centurion, Carlos; Liu, Meng; Uhde, Thomas; Mulholland, Patrick J.; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Glen, W. Bailey, Jr.; Mulholland, Patrick J.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
[Zayachkivsky, Andrew; van den Pol, Anthony N.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
RP Shiromani, PJ (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Psychiat, 114 Doughty St,MSC404 STB 404, Charleston, SC 29425 USA.
EM shiroman@musc.edu
FU NIH [AA017922, MH055772, NS052287, NS079940, NS48476]; Medical Research
Service of the Department of Veterans Affairs
FX This work was supported by NIH grants AA017922, MH055772, NS052287,
NS079940, and NS48476 and the Medical Research Service of the Department
of Veterans Affairs. We thank Dr. Mahesh Thakkar for helpful comments
during the writing of this manuscript, and Sundaravadivel
Balasubramanian for assistance with the confocal microscope.
NR 23
TC 71
Z9 73
U1 0
U2 16
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 19
PY 2013
VL 33
IS 25
BP 10257
EP 10263
DI 10.1523/JNEUROSCI.1225-13.2013
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 166YF
UT WOS:000320596400008
PM 23785141
ER
PT J
AU Burra, N
Hervais-Adelman, A
Kerzel, D
Tamietto, M
de Gelder, B
Pegna, AJ
AF Burra, Nicolas
Hervais-Adelman, Alexis
Kerzel, Dirk
Tamietto, Marco
de Gelder, Beatrice
Pegna, Alan J.
TI Amygdala Activation for Eye Contact Despite Complete Cortical Blindness
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PERCEIVED GAZE DIRECTION; EMOTIONAL FACES; BRAIN; PERCEPTION; CORTEX;
FEAR; RECOGNITION; RESPONSES; SIGNALS; SYSTEM
AB Cortical blindness refers to the loss of vision that occurs after destruction of the primary visual cortex. Although there is no sensory cortex and hence no conscious vision, some cortically blind patients show amygdala activation in response to facial or bodily expressions of emotion. Here we investigated whether direction of gaze could also be processed in the absence of any functional visual cortex. A well-known patient with bilateral destruction of his visual cortex and subsequent cortical blindness was investigated in an fMRI paradigm during which blocks of faces were presented either with their gaze directed toward or away from the viewer. Increased right amygdala activation was found in response to directed compared with averted gaze. Activity in this region was further found to be functionally connected to a larger network associated with face and gaze processing. The present study demonstrates that, in human subjects, the amygdala response to eye contact does not require an intact primary visual cortex.
C1 [Pegna, Alan J.] Univ Hosp Geneva, Dept Clin Neurosci & Dermatol, Neurol Clin, Lab Expt,Neuropsychol Unit, CH-1211 Geneva 4, Switzerland.
[Burra, Nicolas; Kerzel, Dirk; Pegna, Alan J.] Univ Geneva, Fac Psychol & Educ Sci, CH-1211 Geneva, Switzerland.
[Burra, Nicolas; Hervais-Adelman, Alexis; Kerzel, Dirk; Pegna, Alan J.] Univ Geneva, Neurosci Ctr, CH-1211 Geneva, Switzerland.
[Hervais-Adelman, Alexis] Univ Geneva, Sch Med, Brain & Language Lab, CH-1211 Geneva, Switzerland.
[Tamietto, Marco; de Gelder, Beatrice] Tilburg Univ, Cognit & Affect Neurosci Lab, NL-5000 AB Tilburg, Netherlands.
[de Gelder, Beatrice] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Tamietto, Marco] Univ Turin, Dept Psychol, I-10126 Turin, Italy.
RP Pegna, AJ (reprint author), Univ Hosp Geneva, Lab Expt Neuropsychol, Neuropsychol Unit, Neurol Clin, 4 Gabrielle Perret Gentil, CH-1211 Geneva 4, Switzerland.
EM alan.pegna@hcuge.ch
RI Pegna, Alan/D-1297-2017;
OI Pegna, Alan/0000-0001-9920-9290; Hervais-Adelman,
Alexis/0000-0002-5232-626X; Tamietto, Marco/0000-0002-8815-8499
FU Swiss National Science Foundation [320030144187, PDFMP1_129459]
FX This work was supported by the Swiss National Science Foundation for
Scientific Research Grants 320030144187 and PDFMP1_129459.
NR 37
TC 34
Z9 35
U1 3
U2 17
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 19
PY 2013
VL 33
IS 25
BP 10483
EP 10489
DI 10.1523/JNEUROSCI.3994-12.2013
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 166YF
UT WOS:000320596400027
PM 23785160
ER
PT J
AU Beissner, F
Meissner, K
Bar, KJ
Napadow, V
AF Beissner, Florian
Meissner, Karin
Baer, Karl-Juergen
Napadow, Vitaly
TI The Autonomic Brain: An Activation Likelihood Estimation Meta-Analysis
for Central Processing of Autonomic Function
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID HEART-RATE-VARIABILITY; RESTING-STATE CONNECTIVITY; PREFRONTAL CORTEX;
SKIN-CONDUCTANCE; NERVOUS-SYSTEM; CINGULATE CORTEX;
INDIVIDUAL-DIFFERENCES; NEURAL ACTIVITY; FEAR RESPONSES; HUMAN AMYGDALA
AB The autonomic nervous system (ANS) is of paramount importance for daily life. Its regulatory action on respiratory, cardiovascular, digestive, endocrine, and many other systems is controlled by a number of structures in the CNS. While the majority of these nuclei and cortices have been identified in animal models, neuroimaging studies have recently begun to shed light on central autonomic processing in humans. In this study, we used activation likelihood estimation to conduct a meta-analysis of human neuroimaging experiments evaluating central autonomic processing to localize (1) cortical and subcortical areas involved in autonomic processing, (2) potential subsystems for the sympathetic and parasympathetic divisions of the ANS, and (3) potential subsystems for specific ANS responses to different stimuli/tasks. Across all tasks, we identified a set of consistently activated brain regions, comprising left amygdala, right anterior and left posterior insula and midcingulate cortices that form the core of the central autonomic network. While sympathetic-associated regions predominate in executive-and salience-processing networks, parasympathetic regions predominate in the default mode network. Hence, central processing of autonomic function does not simply involve a monolithic network of brain regions, instead showing elements of task and division specificity.
C1 [Beissner, Florian; Baer, Karl-Juergen] Jena Univ Hosp, Dept Psychiat & Psychotherapy, D-07743 Jena, Germany.
[Meissner, Karin] Univ Munich, Inst Med Psychol, D-80336 Munich, Germany.
[Beissner, Florian; Napadow, Vitaly] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
RP Beissner, F (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, 149 13th St,Room 2316, Charlestown, MA 02129 USA.
EM florian@nmr.mgh.harvard.edu
FU German Research Foundation [BE4677/1-1]; National Center for
Complementary and Alternative Medicine [R01-AT004714, R01-AT005280,
P01-AT006663]; NIDDK [R21-DK097499]
FX This work was supported by German Research Foundation Grant BE4677/1-1
(F.B.) and National Center for Complementary and Alternative Medicine
Grants R01-AT004714, R01-AT005280, and P01-AT006663 and NIDDK Grant
R21-DK097499 (V.N.).
NR 98
TC 96
Z9 96
U1 11
U2 44
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 19
PY 2013
VL 33
IS 25
BP 10503
EP +
DI 10.1523/JNEUROSCI.1103-13.2013
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 166YF
UT WOS:000320596400029
PM 23785162
ER
PT J
AU Kullgren, JT
Duey, KA
Werner, RM
AF Kullgren, Jeffrey T.
Duey, Katia A.
Werner, Rachel M.
TI A Census of State Health Care Price Transparency Websites
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Kullgren, Jeffrey T.] Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
[Duey, Katia A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
EM jkullgre@med.umich.edu
NR 6
TC 10
Z9 10
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 19
PY 2013
VL 309
IS 23
BP 2437
EP 2438
DI 10.1001/jama.2013.6557
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 165SW
UT WOS:000320505100019
PM 23780454
ER
PT J
AU Saver, JL
Fonarow, GC
Smith, EE
Reeves, MJ
Grau-Sepulveda, MV
Pan, WQ
Olson, DM
Hernandez, AF
Peterson, ED
Schwamm, LH
AF Saver, Jeffrey L.
Fonarow, Gregg C.
Smith, Eric E.
Reeves, Mathew J.
Grau-Sepulveda, Maria V.
Pan, Wenqin
Olson, DaiWai M.
Hernandez, Adrian F.
Peterson, Eric D.
Schwamm, Lee H.
TI Time to Treatment With Intravenous Tissue Plasminogen Activator and
Outcome From Acute Ischemic Stroke
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID GUIDELINES-STROKE; THROMBOLYSIS; CARE; ASSOCIATION; SYSTEMS;
IMPROVEMENT; EXPERIENCE; MANAGEMENT; ALTEPLASE; THERAPY
AB Importance Randomized clinical trials suggest the benefit of intravenous tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent. However, modest sample sizes have limited characterization of the extent to which onset to treatment (OTT) time influences outcome; and the generalizability of findings to clinical practice is uncertain.
Objective To evaluate the degree to which OTT time is associated with outcome among patients with acute ischemic stroke treated with intraveneous tPA.
Design, Setting, and Patients Data were analyzed from 58 353 patients with acute ischemic stroke treated with tPA within 4.5 hours of symptom onset in 1395 hospitals participating in the Get With The Guidelines-Stroke Program, April 2003 to March 2012.
Main Outcomes and Measures Relationship between OTT time and in-hospital mortality, symptomatic intracranial hemorrhage, ambulatory status at discharge, and discharge destination.
Results Among the 58 353 tPA-treated patients, median age was 72 years, 50.3% were women, median OTT time was 144 minutes (interquartile range, 115-170), 9.3% (5404) had OTT time of 0 to 90 minutes, 77.2% (45 029) had OTT time of 91 to 180 minutes, and 13.6% (7920) had OTT time of 181 to 270 minutes. Median pretreatment National Institutes of Health Stroke Scale documented in 87.7% of patients was 11 (interquartile range, 6-17). Patient factors most strongly associated with shorter OTT included greater stroke severity (odds ratio [ OR], 2.8; 95% CI, 2.5-3.1 per 5-point increase), arrival by ambulance (OR, 5.9; 95% CI, 4.5-7.3), and arrival during regular hours (OR, 4.6; 95% CI, 3.8-5.4). Overall, there were 5142 (8.8%) in-hospital deaths, 2873 (4.9%) patients had intracranial hemorrhage, 19 491 (33.4%) patients achieved independent ambulation at hospital discharge, and 22 541 (38.6%) patients were discharged to home. Faster OTT, in 15-minute increments, was associated with reduced in-hospital mortality (OR, 0.96; 95% CI, 0.95-0.98; P < .001), reduced symptomatic intracranial hemorrhage (OR, 0.96; 95% CI, 0.95-0.98; P < .001), increased achievement of independent ambulation at discharge (OR, 1.04; 95% CI, 1.03-1.05; P < .001), and increased discharge to home (OR, 1.03; 95% CI, 1.02-1.04; P < .001).
Conclusions and Relevance In a registry representing US clinical practice, earlier thrombolytic treatment was associated with reduced mortality and symptomatic intracranial hemorrhage, and higher rates of independent ambulation at discharge and discharge to home following acute ischemic stroke. These findings support intensive efforts to accelerate hospital presentation and thrombolytic treatment in patients with stroke.
C1 [Saver, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA.
[Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Grau-Sepulveda, Maria V.; Pan, Wenqin; Olson, DaiWai M.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Ctr, Durham, NC USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Saver, JL (reprint author), Univ Calif Los Angeles, Comprehens Stroke Ctr, 710 Westwood Plaza, Los Angeles, CA 90095 USA.
EM jsaver@mednet.ucla.edu
RI Smith, Eric/C-5443-2012; Hernandez, Adrian F./A-7818-2016
OI Smith, Eric/0000-0003-3956-1668; Saver, Jeffrey/0000-0001-9141-2251;
Schwamm, Lee/0000-0003-0592-9145; Hernandez, Adrian
F./0000-0003-3387-9616
FU Boehringer-Ingelheim; Merck; Bristol-Myers Squib/Sanofi Pharmaceutical
Partnership; AHA Pharmaceutical Roundtable
FX The GWTG-Stroke Program is provided by the AHA/American Stroke
Association. The GWTG-Stroke Program is currently supported in part by a
charitable contribution from Janssen Pharmaceutical Companies of Johnson
& Johnson. The GWTG-Stroke Program has been funded in the past through
support from Boehringer-Ingelheim, Merck, Bristol-Myers Squib/Sanofi
Pharmaceutical Partnership, and the AHA Pharmaceutical Roundtable.
NR 31
TC 196
Z9 201
U1 3
U2 21
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 19
PY 2013
VL 309
IS 23
BP 2480
EP 2488
DI 10.1001/jama.2013.6959
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 165SW
UT WOS:000320505100029
PM 23780461
ER
PT J
AU Thompson, GR
Kontoyiannis, DP
Patterson, TF
AF Thompson, George R., III
Kontoyiannis, Dimitrios P.
Patterson, Thomas F.
TI Real-world Experience in the Midst of an Exserohilum Meningitis Outbreak
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID FUNGAL-INFECTIONS
C1 [Thompson, George R., III] Univ Calif Davis, Div Infect Dis, Dept Med Microbiol & Immunol, Davis, CA 95616 USA.
[Thompson, George R., III] Univ Calif Davis, Dept Internal Med, Div Infect Dis, Davis, CA 95616 USA.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Control, Houston, TX 77030 USA.
[Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Employee Hlth, Houston, TX 77030 USA.
[Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Patterson, TF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Room 5-035R,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM patterson@uthscsa.edu
NR 8
TC 2
Z9 2
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 19
PY 2013
VL 309
IS 23
BP 2493
EP 2495
DI 10.1001/jama.2013.6294
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 165SW
UT WOS:000320505100032
PM 23780464
ER
PT J
AU Seo, JH
Li, QY
Fatima, A
Eklund, A
Szallasi, Z
Polyak, K
Richardson, AL
Freedman, ML
AF Seo, Ji-Heui
Li, Qiyuan
Fatima, Aquila
Eklund, Aron
Szallasi, Zoltan
Polyak, Kornelia
Richardson, Andrea L.
Freedman, Matthew L.
TI Deconvoluting complex tissues for expression quantitative trait
locus-based analyses
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Article
DE expression quantitative trait locus; heterogeneous tissue; breast cancer
risk single nucleotide polymorphisms
ID BREAST-CANCER RISK; GENE-EXPRESSION; FGFR2 EXPRESSION; NONCODING RNA;
DISEASE; DNA; AKR1C1
AB Breast cancer genome-wide association studies have pinpointed dozens of variants associated with breast cancer pathogenesis. The majority of risk variants, however, are located outside of known protein-coding regions. Therefore, identifying which genes the risk variants are acting through presents an important challenge. Variants that are associated with mRNA transcript levels are referred to as expression quantitative trait loci (eQTLs). Many studies have demonstrated that eQTL-based strategies provide a direct way to connect a trait-associated locus with its candidate target gene. Performing eQTL-based analyses in human samples is complicated because of the heterogeneous nature of human tissue. We addressed this issue by devising a method to computationally infer the fraction of cell types in normal human breast tissues. We then applied this method to 13 known breast cancer risk loci, which we hypothesized were eQTLs. For each risk locus, we took all known transcripts within a 2 Mb interval and performed an eQTL analysis in 100 reduction mammoplasty cases. A total of 18 significant associations were discovered (eight in the epithelial compartment and 10 in the stromal compartment). This study highlights the ability to perform large-scale eQTL studies in heterogeneous tissues.
C1 [Seo, Ji-Heui; Li, Qiyuan; Polyak, Kornelia; Freedman, Matthew L.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Dept Med Oncol, Boston, MA 02215 USA.
[Fatima, Aquila; Richardson, Andrea L.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Li, Qiyuan; Freedman, Matthew L.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Li, Qiyuan; Eklund, Aron; Szallasi, Zoltan] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Szallasi, Zoltan] Harard MIT Div Hlth Sci & Technol CHIP HST, Childrens Hosp Informat Program, Boston, MA USA.
[Szallasi, Zoltan; Polyak, Kornelia; Richardson, Andrea L.; Freedman, Matthew L.] Harvard Univ, Sch Med, Boston, MA USA.
[Richardson, Andrea L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Freedman, ML (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Dept Med Oncol, Boston, MA 02215 USA.
EM freedman@broadinstitute.org
OI Szallasi, Zoltan/0000-0001-5395-7509; Eklund, Aron
Charles/0000-0003-0861-1001
NR 28
TC 4
Z9 4
U1 1
U2 9
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD JUN 19
PY 2013
VL 368
IS 1620
AR 20120363
DI 10.1098/rstb.2012.0363
PG 6
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 139WD
UT WOS:000318614800007
PM 23650637
ER
PT J
AU Kerenyi, MA
Shao, Z
Hsu, YJ
Guo, GJ
Luc, S
O'Brien, K
Fujiwara, Y
Peng, C
Nguyen, M
Orkin, SH
AF Kerenyi, Marc A.
Shao, Zhen
Hsu, Yu-Jung
Guo, Guoji
Luc, Sidinh
O'Brien, Kassandra
Fujiwara, Yuko
Peng, Cong
Nguyen, Minh
Orkin, Stuart H.
TI Histone demethylase Lsd1 represses hematopoietic stem and progenitor
cell signatures during blood cell maturation
SO ELIFE
LA English
DT Article
ID BONE-MARROW-CELLS; GENE-EXPRESSION; DNA METHYLATION; HUMAN GENOME;
DIFFERENTIATION; ENHANCERS; CHROMATIN; LEUKEMIA; TRANSCRIPTION;
PLURIPOTENT
AB Here, we describe that lysine-specific demethylase 1 (Lsd1/KDM1a), which demethylates histone H3 on Lys4 or Lys9 (H3K4/K9), is an indispensible epigenetic governor of hematopoietic differentiation. Integrative genomic analysis, combining global occupancy of Lsd1, genome-wide analysis of its substrates H3K4 monomethylation and dimethylation, and gene expression profiling, reveals that Lsd1 represses hematopoietic stem and progenitor cell (HSPC) gene expression programs during hematopoietic differentiation. We found that Lsd1 acts at transcription start sites, as well as enhancer regions. Loss of Lsd1 was associated with increased H3K4me1 and H3K4me2 methylation on HSPC genes and gene derepression. Failure to fully silence HSPC genes compromised differentiation of hematopoietic stem cells as well as mature blood cell lineages. Collectively, our data indicate that Lsd1-mediated concurrent repression of enhancer and promoter activity of stem and progenitor cell genes is a pivotal epigenetic mechanism required for proper hematopoietic maturation.
C1 [Kerenyi, Marc A.; Shao, Zhen; Hsu, Yu-Jung; Guo, Guoji; Luc, Sidinh; O'Brien, Kassandra; Fujiwara, Yuko; Peng, Cong; Nguyen, Minh; Orkin, Stuart H.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Kerenyi, Marc A.; Shao, Zhen; Hsu, Yu-Jung; Guo, Guoji; Luc, Sidinh; O'Brien, Kassandra; Fujiwara, Yuko; Peng, Cong; Nguyen, Minh; Orkin, Stuart H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Orkin, Stuart H.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA.
RP Orkin, SH (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
EM orkin@bloodgroup.tch.harvard.edu
FU NIH National Heart, Lung and Blood Institute [R01HL075735]; Howard
Hughes Medical Institute; Austrian Science Fund (FWF) [J 2948-B19]
FX NIH National Heart, Lung and Blood Institute R01HL075735 Marc A Kerenyi;
Howard Hughes Medical Institute Stuart H Orkin; Austrian Science Fund
(FWF) J 2948-B19 Marc A Kerenyi
NR 63
TC 63
Z9 63
U1 0
U2 9
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUN 18
PY 2013
VL 2
AR e00633
DI 10.7554/eLife.00633
PG 23
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 274PR
UT WOS:000328619000003
PM 23795291
ER
PT J
AU Hudson, NE
Ding, F
Bucay, I
O'Brien, ET
Gorkun, OV
Superfine, R
Lord, ST
Dokholyan, NV
Falvo, MR
AF Hudson, Nathan E.
Ding, Feng
Bucay, Igal
O'Brien, E. Timothy, III
Gorkun, Oleg V.
Superfine, Richard
Lord, Susan T.
Dokholyan, Nikolay V.
Falvo, Michael R.
TI Submillisecond Elastic Recoil Reveals Molecular Origins of Fibrin Fiber
Mechanics
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID BETA-SHEET TRANSITION; ALPHA-C REGION; DYNAMICS SIMULATIONS;
COILED-COILS; CLOT; PROTEINS; EXTENSIBILITY; NETWORKS; MODULUS; FORCE
AB Fibrin fibers form the structural scaffold of blood clots. Thus, their mechanical properties are of central importance to understanding hemostasis and thrombotic disease. Recent studies have revealed that fibrin fibers are elastomeric despite their high degree of molecular ordering. These results have inspired a variety of molecular models for fibrin's elasticity, ranging from reversible protein unfolding to rubber-like elasticity. An important property that has not been explored is the timescale of elastic recoil, a parameter that is critical for fibrin's mechanical function and places a temporal constraint on molecular models of fiber elasticity. Using high-frame-rate imaging and atomic force microscopy-based nanomanipulation, we measured the recoil dynamics of individual fibrin fibers and found that the recoil was orders of magnitude faster than anticipated from models involving protein refolding. We also performed steered discrete molecular-dynamics simulations to investigate the molecular origins of the observed recoil. Our results point to the unstructured alpha C regions of the otherwise structured fibrin molecule as being responsible for the elastic recoil of the fibers.
C1 [Hudson, Nathan E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Immune Dis Inst, Boston, MA USA.
[Hudson, Nathan E.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Hudson, Nathan E.; Bucay, Igal; O'Brien, E. Timothy, III; Superfine, Richard; Falvo, Michael R.] Univ N Carolina, Dept Phys & Astron, Ctr Computat & Syst Biol, Program Cellular & Mol Biophys, Chapel Hill, NC 27515 USA.
[Gorkun, Oleg V.; Lord, Susan T.] Univ N Carolina, Dept Pathol & Lab Med, Program Cellular & Mol Biophys, Ctr Computat & Syst Biol, Chapel Hill, NC USA.
[Dokholyan, Nikolay V.] Univ N Carolina, Dept Biochem & Biophys, Program Cellular & Mol Biophys, Ctr Computat & Syst Biol, Chapel Hill, NC USA.
[Ding, Feng] Clemson Univ, Dept Phys & Astron, Clemson, SC 29634 USA.
RP Falvo, MR (reprint author), Univ N Carolina, Dept Phys & Astron, Ctr Computat & Syst Biol, Program Cellular & Mol Biophys, Chapel Hill, NC 27515 USA.
EM falvo@physics.unc.edu
RI Ding, Feng/G-6029-2011;
OI Ding, Feng/0000-0003-1850-6336; GORKUN, OLEG/0000-0002-3068-3389;
Dokholyan, Nikolay/0000-0002-8225-4025; Hudson,
Nathan/0000-0003-0573-7661
FU National Institutes of Health [GM080742, HL31048, P41-EB002025];
National Science Foundation [CMMI-1030640, DMR-0705977]
FX This work was supported by National Institutes of Health grants
GM080742, HL31048, and P41-EB002025, and National Science Foundation
grants CMMI-1030640 and DMR-0705977.
NR 63
TC 6
Z9 6
U1 1
U2 21
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JUN 18
PY 2013
VL 104
IS 12
BP 2671
EP 2680
DI 10.1016/j.bpj.2013.04.052
PG 10
WC Biophysics
SC Biophysics
GA 169DI
UT WOS:000320757100012
PM 23790375
ER
PT J
AU Pardee, AB
AF Pardee, Arthur B.
TI Francois Jacob memorial
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT News Item
ID EXPRESSION; PROTEINS
C1 Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA.
RP Pardee, AB (reprint author), Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA.
EM arthur_pardee@dfci.harvard.edu
NR 12
TC 1
Z9 2
U1 2
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 18
PY 2013
VL 110
IS 25
BP 10053
EP 10054
DI 10.1073/pnas.1309173110
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 179DU
UT WOS:000321500200016
ER
PT J
AU Tolstorukov, MY
Sansam, CG
Lu, P
Koellhoffer, EC
Helming, KC
Alver, BH
Tillman, EJ
Evans, JA
Wilson, BG
Park, PJ
Roberts, CWM
AF Tolstorukov, Michael Y.
Sansam, Courtney G.
Lu, Ping
Koellhoffer, Edward C.
Helming, Katherine C.
Alver, Burak H.
Tillman, Erik J.
Evans, Julia A.
Wilson, Boris G.
Park, Peter J.
Roberts, Charles W. M.
TI Swi/Snf chromatin remodeling/tumor suppressor complex establishes
nucleosome occupancy at target promoters
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID RHABDOID TUMORS; GENE-REGULATION; HUMAN GENOME; CANCER; TRANSCRIPTION;
SNF5; MUTATIONS; LANDSCAPE; MICE; INI1
AB Precise nucleosome-positioning patterns at promoters are thought to be crucial for faithful transcriptional regulation. However, the mechanisms by which these patterns are established, are dynamically maintained, and subsequently contribute to transcriptional control are poorly understood. The switch/sucrose non-fermentable chromatin remodeling complex, also known as the Brg1 associated factors complex, is a master developmental regulator and tumor suppressor capable of mobilizing nucleosomes in biochemical assays. However, its role in establishing the nucleosome landscape in vivo is unclear. Here we have inactivated Snf5 and Brg1, core subunits of the mammalian Swi/Snf complex, to evaluate their effects on chromatin structure and transcription levels genomewide. We find that inactivation of either subunit leads to disruptions of specific nucleosome patterning combined with a loss of overall nucleosome occupancy at a large number of promoters, regardless of their association with CpG islands. These rearrangements are accompanied by gene expression changes that promote cell proliferation. Collectively, these findings define a direct relationship between chromatin-remodeling complexes, chromatin structure, and transcriptional regulation.
C1 [Tolstorukov, Michael Y.; Alver, Burak H.; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Tolstorukov, Michael Y.; Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Sansam, Courtney G.; Lu, Ping; Koellhoffer, Edward C.; Helming, Katherine C.; Tillman, Erik J.; Evans, Julia A.; Wilson, Boris G.; Roberts, Charles W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Sansam, Courtney G.; Lu, Ping; Koellhoffer, Edward C.; Helming, Katherine C.; Tillman, Erik J.; Evans, Julia A.; Wilson, Boris G.; Roberts, Charles W. M.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Sansam, Courtney G.; Lu, Ping; Koellhoffer, Edward C.; Helming, Katherine C.; Tillman, Erik J.; Evans, Julia A.; Wilson, Boris G.; Roberts, Charles W. M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Park, PJ (reprint author), Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
EM peter_park@harvard.edu; charles_roberts@dfci.harvard.edu
OI Koellhoffer, Edward/0000-0002-7260-9507; Tillman,
Erik/0000-0003-3599-0297; Alver, Burak/0000-0002-5019-7652
FU Ruth L. Kirschstein National Research Service Award Fellowship from the
National Cancer Institute [5F32 CA123776]; Ruth L. Kirschstein National
Research Service Award Fellowship [U01HG004258, R01GM082798,
R01CA113794]; Innovative Research Grant from Stand Up 2 Cancer; U01 NCI
Mouse Models of Cancer Consortium Award; Sloan Research Fellowship;
Garrett B. Smith Foundation; Miles for Mary; foundation Cure AT/RT Now
FX We thank Xi Wang for critical review of the manuscript and Lee Whale for
the artwork in Figs. 1A and 5. This work was supported in part by a Ruth
L. Kirschstein National Research Service Award Fellowship 5F32 CA123776
from the National Cancer Institute (to C. G. S.), U01HG004258 (to
M.Y.T.), R01GM082798 (to P.J.P.), R01CA113794 (to C. W. M. R.); an
Innovative Research Grant from Stand Up 2 Cancer (to C. W. M. R.); and a
U01 NCI Mouse Models of Cancer Consortium Award (to C. W. M. R.). The
Sloan Research Fellowship (P.J.P.), Garrett B. Smith Foundation, Miles
for Mary, and the foundation Cure AT/RT Now (C. W. M. R.) provided
additional support.
NR 52
TC 62
Z9 62
U1 0
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 18
PY 2013
VL 110
IS 25
BP 10165
EP 10170
DI 10.1073/pnas.1302209110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 179DU
UT WOS:000321500200039
PM 23723349
ER
PT J
AU Li, XH
Burnight, ER
Cooney, AL
Malani, N
Brady, T
Sander, JD
Staber, J
Wheelan, SJ
Joung, JK
McCray, PB
Bushman, FD
Sinn, PL
Craig, NL
AF Li, Xianghong
Burnight, Erin R.
Cooney, Ashley L.
Malani, Nirav
Brady, Troy
Sander, Jeffry D.
Staber, Janice
Wheelan, Sarah J.
Joung, J. Keith
McCray, Paul B., Jr.
Bushman, Frederic D.
Sinn, Patrick L.
Craig, Nancy L.
TI piggyBac transposase tools for genome engineering
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE GULOP; ROSA26; protein-DNA interaction; induced pluripotent stem cell
production
ID MAMMALIAN-CELLS; SLEEPING-BEAUTY; STEM-CELLS; SACCHAROMYCES-CEREVISIAE;
GENE-EXPRESSION; SITE SELECTION; IN-VIVO; DNA; MICE; MUTAGENESIS
AB The transposon piggyBac is being used increasingly for genetic studies. Here, we describe modified versions of piggyBac transposase that have potentially wide-ranging applications, such as reversible transgenesis and modified targeting of insertions. piggyBac is distinguished by its ability to excise precisely, restoring the donor site to its pretransposon state. This characteristic makes piggyBac useful for reversible transgenesis, a potentially valuable feature when generating induced pluripotent stem cells without permanent alterations to genomic sequence. To avoid further genome modification following piggyBac excision by reintegration, we generated an excision competent/integration defective (Exc(+)Int(-)) transposase. Our findings also suggest the position of a target DNA-transposase interaction. Another goal of genome engineering is to develop reagents that can guide transgenes to preferred genomic regions. Others have shown that piggyBac transposase can be active when fused to a heterologous DNA-binding domain. An Exc(+)Int(-) transposase, the intrinsic targeting of which is defective, might also be a useful intermediate in generating a transposase whose integration activity could be rescued and redirected by fusion to a site-specific DNA-binding domain. We show that fusion to two designed zinc finger proteins rescued the Int(-) phenotype. Successful guided transgene integration into genomic DNA would have broad applications to gene therapy and molecular genetics. Thus, an Exc(+)Int(-) transposase is a potentially useful reagent for genome engineering and provides insight into the mechanism of transposase-target DNA interaction.
C1 [Li, Xianghong; Craig, Nancy L.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA.
[Li, Xianghong; Craig, Nancy L.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
[Burnight, Erin R.; McCray, Paul B., Jr.] Univ Iowa, Carver Coll Med, Genet Program, Iowa City, IA 52242 USA.
[Cooney, Ashley L.; Staber, Janice; McCray, Paul B., Jr.; Sinn, Patrick L.] Univ Iowa, Dept Pediat, Carver Coll Med, Iowa City, IA 52242 USA.
[Malani, Nirav; Brady, Troy; Bushman, Frederic D.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
[Sander, Jeffry D.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Mol Pathol Unit, Boston, MA 02129 USA.
[Sander, Jeffry D.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02129 USA.
[Sander, Jeffry D.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Wheelan, Sarah J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Biostat & Bioinformat, Baltimore, MD 21205 USA.
RP Sinn, PL (reprint author), Univ Iowa, Dept Pediat, Carver Coll Med, Iowa City, IA 52242 USA.
EM patrick-sinn@uiowa.edu; ncraig@jhmi.edu
OI Bushman, Frederic/0000-0003-4740-4056
FU Maryland Stem Cell Research Fund; National Institutes of Health (NIH)
[T32 CA009216, DP1 GM105378, R01 GM088040, R01 HL-105821]; University of
Iowa Center for Gene Therapy [NIH P30 DK-54759]; [AI 052845];
[AI082020]
FX We thank Dr. Rupak Mitra and Dr. Courtney Busch for many discussions
about piggyBac; Benjamin Brett, Dr. Todd Scheetz, and Dr. Tom Bair for
their expert consultation; and Maureen R. Regan for technical
assistance. This work was supported by a grant from the Maryland Stem
Cell Research Fund (to N.L.C.). N.L.C. is an investigator of the Howard
Hughes Medical Institute. This work was supported by Grants AI 052845
and AI082020 (to F. D. B.). J.D.S. was supported by National Institutes
of Health (NIH) Grant T32 CA009216. J.K.J. was supported by NIH
Director's Pioneer Award DP1 GM105378 and by NIH Grant R01 GM088040.
This work was supported by the NIH Grant R01 HL-105821 (to P. L. S. and
J.K.J.) and partially supported by the University of Iowa Center for
Gene Therapy (NIH P30 DK-54759).
NR 29
TC 40
Z9 44
U1 1
U2 29
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 18
PY 2013
VL 110
IS 25
BP E2279
EP E2287
DI 10.1073/pnas.1305987110
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 179DU
UT WOS:000321500200009
PM 23723351
ER
PT J
AU Peng, J
Li, QL
Wigglesworth, K
Rangarajan, A
Kattamuri, C
Peterson, RT
Eppig, JJ
Thompson, TB
Matzuk, MM
AF Peng, Jia
Li, Qinglei
Wigglesworth, Karen
Rangarajan, Adithya
Kattamuri, Chandramohan
Peterson, Randall T.
Eppig, John J.
Thompson, Thomas B.
Matzuk, Martin M.
TI Reply to Mottershead et al.: GDF9:BMP15 heterodimers are potent
regulators of ovarian functions
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Letter
ID MORPHOGENETIC PROTEIN 15; DIFFERENTIATION FACTOR-9; GROWTH
C1 [Peng, Jia; Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Peng, Jia; Matzuk, Martin M.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Rangarajan, Adithya; Matzuk, Martin M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA.
[Li, Qinglei] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
[Wigglesworth, Karen; Eppig, John J.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Kattamuri, Chandramohan; Thompson, Thomas B.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA.
[Peterson, Randall T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Peterson, Randall T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Matzuk, MM (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
EM mmatzuk@bcm.edu
FU NICHD NIH HHS [R01 HD023839, R37 HD033438, R01 HD033438]
NR 6
TC 1
Z9 1
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 18
PY 2013
VL 110
IS 25
BP E2258
EP E2258
DI 10.1073/pnas.1304497110
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 179DU
UT WOS:000321500200004
PM 23940843
ER
PT J
AU Kluk, MJ
Ashworth, T
Wang, HF
Knoechel, B
Mason, EF
Morgan, EA
Dorfman, D
Pinkus, G
Weigert, O
Hornick, JL
Chirieac, LR
Hirsch, M
Oh, DJ
South, AP
Leigh, IM
Pourreyron, C
Cassidy, AJ
DeAngelo, DJ
Weinstock, DM
Krop, IE
Dillon, D
Brock, JE
Lazar, AJF
Peto, M
Cho, RJ
Stoeck, A
Haines, BB
Sathayanrayanan, S
Rodig, S
Aster, JC
AF Kluk, Michael J.
Ashworth, Todd
Wang, Hongfang
Knoechel, Birgit
Mason, Emily F.
Morgan, Elizabeth A.
Dorfman, David
Pinkus, Geraldine
Weigert, Oliver
Hornick, Jason L.
Chirieac, Lucian R.
Hirsch, Michelle
Oh, David J.
South, Andrew P.
Leigh, Irene M.
Pourreyron, Celine
Cassidy, Andrew J.
DeAngelo, Daniel J.
Weinstock, David M.
Krop, Ian E.
Dillon, Deborah
Brock, Jane E.
Lazar, Alexander J. F.
Peto, Myron
Cho, Raymond J.
Stoeck, Alexander
Haines, Brian B.
Sathayanrayanan, Sriram
Rodig, Scott
Aster, Jon C.
TI Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry
SO PLOS ONE
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; SQUAMOUS-CELL CARCINOMA; MARGINAL ZONE
LYMPHOMA; GENE AMPLIFICATION; OVARIAN-CANCER; BREAST-CANCER; CODING
GENOME; STEM-CELLS; B-CLL; T-ALL
AB Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been lacking. Here, we bridge this gap by developing an immunohistochemical (IHC) stain that detects a neoepitope created by the proteolytic cleavage event that activates NOTCH1. Following validation using xenografted cancers and normal tissues with known patterns of NOTCH1 activation, we applied this test to tumors linked to dysregulated Notch signaling by mutational studies. As expected, frequent NICD1 staining was observed in T lymphoblastic leukemia/lymphoma, a tumor in which activating NOTCH1 mutations are common. However, when IHC was used to gauge NOTCH1 activation in other human cancers, several unexpected findings emerged. Among B cell tumors, NICD1 staining was much more frequent in chronic lymphocytic leukemia than would be predicted based on the frequency of NOTCH1 mutations, while mantle cell lymphoma and diffuse large B cell lymphoma showed no evidence of NOTCH1 activation. NICD1 was also detected in 38% of peripheral T cell lymphomas. Of interest, NICD1 staining in chronic lymphocytic leukemia cells and in angioimmunoblastic lymphoma was consistently more pronounced in lymph nodes than in surrounding soft tissues, implicating factors in the nodal microenvironment in NOTCH1 activation in these diseases. Among carcinomas, diffuse strong NICD1 staining was observed in 3.8% of cases of triple negative breast cancer (3 of 78 tumors), but was absent from 151 non-small cell lung carcinomas and 147 ovarian carcinomas. Frequent staining of normal endothelium was also observed; in line with this observation, strong NICD1 staining was also seen in 77% of angiosarcomas. These findings complement insights from genomic sequencing studies and suggest that IHC staining is a valuable experimental tool that may be useful in selection of patients for clinical trials.
C1 [Kluk, Michael J.; Ashworth, Todd; Wang, Hongfang; Mason, Emily F.; Morgan, Elizabeth A.; Dorfman, David; Pinkus, Geraldine; Hornick, Jason L.; Chirieac, Lucian R.; Hirsch, Michelle; Oh, David J.; Dillon, Deborah; Brock, Jane E.; Rodig, Scott; Aster, Jon C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Kluk, Michael J.; Ashworth, Todd; Wang, Hongfang; Mason, Emily F.; Morgan, Elizabeth A.; Dorfman, David; Pinkus, Geraldine; Hornick, Jason L.; Chirieac, Lucian R.; Hirsch, Michelle; Oh, David J.; Dillon, Deborah; Brock, Jane E.; Rodig, Scott; Aster, Jon C.] Harvard Univ, Sch Med, Boston, MA USA.
[Knoechel, Birgit; Weigert, Oliver; DeAngelo, Daniel J.; Weinstock, David M.; Krop, Ian E.] Dana Farber Canc Inst, Dept Pediat Hematol, Boston, MA 02115 USA.
[Knoechel, Birgit; Weigert, Oliver; DeAngelo, Daniel J.; Weinstock, David M.; Krop, Ian E.] Dana Farber Canc Inst, Dept Oncol & Med Oncol, Boston, MA 02115 USA.
[South, Andrew P.; Leigh, Irene M.; Pourreyron, Celine; Cassidy, Andrew J.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Div Canc Res, Dundee DD1 9SY, Scotland.
[South, Andrew P.; Leigh, Irene M.; Pourreyron, Celine; Cassidy, Andrew J.] Univ Dundee, Ninewells Hosp & Med Sch, Med Res Inst, Genet Core Serv Unit, Dundee DD1 9SY, Scotland.
[Lazar, Alexander J. F.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
[Peto, Myron] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Cho, Raymond J.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Stoeck, Alexander; Haines, Brian B.; Sathayanrayanan, Sriram] Merck Oncol, Boston, MA USA.
RP Aster, JC (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
EM jaster@rics.bwh.harvard.edu
RI Lazar, Alexander/A-3416-2008;
OI Lazar, Alexander/0000-0002-6395-4499; Cassidy,
Andrew/0000-0003-4309-6981; Morgan, Elizabeth/0000-0001-5880-9337
FU NIH; Leukemia and Lymphoma Society; BWH Department of Pathology Robbins
Award
FX Supported by grants from the NIH and Leukemia and Lymphoma Society (JCA)
and the BWH Department of Pathology Robbins Award (MJK). The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 57
TC 37
Z9 38
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2013
VL 8
IS 6
AR UNSP e67306
DI 10.1371/journal.pone.0067306
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 166SA
UT WOS:000320576400182
PM 23825651
ER
PT J
AU Nakaya, T
Ishiguro, K
Belzil, C
Rietsch, AM
Yu, QY
Mizuno, S
Bronson, RT
Geng, Y
Nguyen, MD
Akashi, K
Sicinski, P
Nakatani, Y
AF Nakaya, Takeo
Ishiguro, Kei-ichiro
Belzil, Camille
Rietsch, Anna M.
Yu, Qunyan
Mizuno, Shin-ichi
Bronson, Roderick T.
Geng, Yan
Minh Dang Nguyen
Akashi, Koichi
Sicinski, Piotr
Nakatani, Yoshihiro
TI p600 Plays Essential Roles in Fetal Development
SO PLOS ONE
LA English
DT Article
ID END RULE PATHWAY; FOCAL ADHESION KINASE; AUXIN TRANSPORT; E7
ONCOPROTEIN; PROTEIN; MOUSE; IDENTIFICATION; TRANSFORMATION; GENES;
HEART
AB p600 is a multifunctional protein implicated in cytoskeletal organization, integrin-mediated survival signaling, calcium-calmodulin signaling and the N-end rule pathway of ubiquitin-proteasome-mediated proteolysis. While push, the Drosophila counterpart of p600, is dispensable for development up to adult stage, the role of p600 has not been studied during mouse development. Here we generated p600 knockout mice to investigate the in vivo functions of p600. Interestingly, we found that homozygous deletion of p600 results in lethality between embryonic days 11.5 and 13.5 with severe defects in both embryo and placenta. Since p600 is required for placental development, we performed conditional disruption of p600, which deletes selectively p600 in the embryo but not in the placenta. The conditional mutant embryos survive longer than knockout embryos but ultimately die before embryonic day 14.5. The mutant embryos display severe cardiac problems characterized by ventricular septal defects and thin ventricular walls. These anomalies are associated with reduced activation of FAK and decreased expression of MEF2, which is regulated by FAK and plays a crucial role in cardiac development. Moreover, we observed pleiotropic defects in the liver and brain. In sum, our study sheds light on the essential roles of p600 in fetal development.
C1 [Nakaya, Takeo; Ishiguro, Kei-ichiro; Rietsch, Anna M.; Yu, Qunyan; Geng, Yan; Sicinski, Piotr; Nakatani, Yoshihiro] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Nakaya, Takeo; Ishiguro, Kei-ichiro; Rietsch, Anna M.; Yu, Qunyan; Mizuno, Shin-ichi; Geng, Yan; Akashi, Koichi; Sicinski, Piotr; Nakatani, Yoshihiro] Harvard Univ, Sch Med, Boston, MA USA.
[Nakaya, Takeo] Tokyo Med Univ, Translat Res Unit, Shinjuku Ku, Tokyo 1608402, Japan.
[Nakaya, Takeo] Tokyo Med Univ, Dept Mol Pathol, Shinjuku Ku, Tokyo 1608402, Japan.
[Ishiguro, Kei-ichiro] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan.
[Belzil, Camille; Minh Dang Nguyen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Mizuno, Shin-ichi; Akashi, Koichi] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Mizuno, Shin-ichi; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 812, Japan.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Boston, MA USA.
RP Nakatani, Y (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
EM yoshihiro_nakatani@dfci.harvard.edu
FU National Institutes of Health [R01CA138866, R01CA108950]; Uehara
foundation; Japan Society for the Promotion of Science; AIHS
FX This work was supported by National Institutes of Health grants
(R01CA138866 to YN and R01CA108950 to PS). TN was supported by Uehara
foundation fellowship for research abroad. KI was supported by Japan
Society for the Promotion of Science fellowship for research abroad, the
Grant-in-Aid for Scientific Research on Priority Areas, a Grant in-Aid
for Scientific Research on Innovative Areas and Grant in-Aid for Young
Scientists. CB was supported by an AIHS doctoral scholarship. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 32
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2013
VL 8
IS 6
AR e66269
DI 10.1371/journal.pone.0066269
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 166SA
UT WOS:000320576400075
PM 23824717
ER
PT J
AU Hayes, JH
Ollendorf, DA
Pearson, SD
Barry, MJ
Kantoff, PW
Lee, PA
McMahon, PM
AF Hayes, Julia H.
Ollendorf, Daniel A.
Pearson, Steven D.
Barry, Michael J.
Kantoff, Philip W.
Lee, Pablo A.
McMahon, Pamela M.
TI Observation Versus Initial Treatment for Men With Localized, Low-Risk
Prostate Cancer A Cost-Effectiveness Analysis
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ACTIVE SURVEILLANCE; RADICAL PROSTATECTOMY; CONTROLLED-TRIAL;
MANAGEMENT; OUTCOMES; MORTALITY; THERAPY; RADIATION; BIOPSY; GRADE
AB Background: Observation is underutilized among men with localized, low-risk prostate cancer.
Objective: To assess the costs and benefits of observation versus initial treatment.
Design: Decision analysis simulating treatment or observation.
Data Sources: Medicare schedules, published literature.
Target Population: Men aged 65 and 75 years who had newly diagnosed low-risk prostate cancer (prostate-specific antigen level <10 mu g/L, stage <= T2a, Gleason score <= 3 + 3).
Time Horizon: Lifetime.
Perspective: Societal.
Intervention: Treatment (brachytherapy, intensity-modulated radiation therapy, or radical prostatectomy) or observation (active surveillance [AS] or watchful waiting [WW]).
Outcome Measures: Quality-adjusted life expectancy and costs.
Results of Base-Case Analysis: Observation was more effective and less costly than initial treatment. Compared with AS, WW provided 2 additional months of quality-adjusted life expectancy (9.02 vs. 8.85 years) at a savings of $15 374 ($24 520 vs. $39 894) in men aged 65 years and 2 additional months (6.14 vs. 5.98 years) at a savings of $11 746 ($18 302 vs. $30 048) in men aged 75 years. Brachytherapy was the most effective and least expensive initial treatment.
Results of Sensitivity Analysis: Treatment became more effective than observation when it led to more dramatic reductions in prostate cancer death (hazard ratio, 0.47 vs. WW and 0.64 vs. AS). Active surveillance became as effective as WW in men aged 65 years when the probability of progressing to treatment on AS decreased below 63% or when the quality of life with AS versus WW was 4% higher in men aged 65 years or 1% higher in men aged 75 years. Watchful waiting remained least expensive in all analyses.
Limitation: Results depend on outcomes reported in the published literature, which is limited.
Conclusion: Among these men, observation is more effective and costs less than initial treatment, and WW is most effective and least expensive under a wide range of clinical scenarios.
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst,Inst Technol Assessment, Lank Ctr Genitourinary Oncol,Inst Clin & Econ Rev, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hayes, JH (reprint author), Dana Farber Canc Inst, Dana 1230,450 Brookline Ave, Boston, MA 02115 USA.
EM Julia_Hayes@dfci.harvard.edu
FU National Cancer Institute; U.S. Department of Defense
[W81XWH-09-1-0512]; Prostate Cancer Foundation; Institute for Clinical
and Economic Review; National Cancer Institute at the National
Institutes of Health [R25 CA92203-08]; Blue Shield of California
Foundation; Agency for Healthcare Research and Quality; Health Dialog
FX National Cancer Institute, U.S. Department of Defense, Prostate Cancer
Foundation, and Institute for Clinical and Economic Review.; By grant
R25 CA92203-08 (National Cancer Institute at the National Institutes of
Health), grant W81XWH-09-1-0512 (U.S. Department of Defense), a Young
Investigators Award to Dr. Hayes (Prostate Cancer Foundation), and
funding to the Institute for Clinical and Economic Review from the Blue
Shield of California Foundation.; Dr. Hayes: Grants (money to
institution): U.S. Department of Defense, Prostate Cancer Foundation;
Royalties: UpToDate. Dr. Ollendorf: Grants (money to institution): Blue
Shield of California Foundation. Dr. Pearson: Consultancy: National
Institutes of Health, Yale University; Employment: Massachusetts General
Hospital; Grants/grants pending (money to institution): Agency for
Healthcare Research and Quality. Dr. Barry: Board membership: Informed
Medical Decisions Foundation; Employment: Informed Medical Decisions
Foundation; Royalties (money to institution): Health Dialog. Dr.
McMahon: Grants (money to institution): Blue Shield of California
Foundation, Harvard Community Health Plan. All other authors have no
disclosures. Disclosures can also be viewed at
www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-085
7.
NR 39
TC 42
Z9 42
U1 1
U2 13
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 18
PY 2013
VL 158
IS 12
BP 853
EP +
DI 10.7326/0003-4819-158-12-201306180-00002
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167PW
UT WOS:000320645000013
PM 23778902
ER
PT J
AU Mahaffey, KW
Wojdyla, D
Hankey, GJ
White, HD
Nessel, CC
Piccini, JP
Patel, MR
Berkowitz, SD
Becker, RC
Halperin, JL
Singer, DE
Califf, RM
Fox, KAA
Breithardt, G
Hacke, W
AF Mahaffey, Kenneth W.
Wojdyla, Daniel
Hankey, Graeme J.
White, Harvey D.
Nessel, Christopher C.
Piccini, Jonathan P.
Patel, Manesh R.
Berkowitz, Scott D.
Becker, Richard C.
Halperin, Jonathan L.
Singer, Daniel E.
Califf, Robert M.
Fox, Keith A. A.
Breithardt, Guenter
Hacke, Werner
TI Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin
K Antagonist Therapy A Subgroup Analysis of a Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ATRIAL-FIBRILLATION; WARFARIN; ANTICOAGULATION; PREVENTION; DABIGATRAN;
HEMORRHAGE; RISK
AB Background: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation.
Objective: To determine the efficacy and safety of rivaroxaban compared with warfarin among vitamin K antagonist (VKA)-naive and VKA-experienced patients.
Design: Prespecified subgroup analysis. (ClinicalTrials.gov: NCT00403767)
Setting: Global.
Patients: 14 264 persons with atrial fibrillation.
Measurements: Interaction of the relative treatment effect of rivaroxaban and warfarin on stroke or systemic embolism among VKA-naive and VKA-experienced patients.
Results: Overall, 7897 (55.4%) patients were VKA-experienced and 6367 (44.6%) were VKA-naive. The effect of rivaroxaban versus warfarin on stroke or systemic embolism was consistent: Rates per 100 patient-years of follow-up were 2.32 versus 2.87 for VKA-naive patients (hazard ratio [HR], 0.81 [95% CI, 0.64 to 1.03]) and 1.98 versus 2.09 for VKA-experienced patients (HR, 0.94 [CI, 0.75 to 1.18]; interaction P = 0.36). During the first 7 days, rivaroxaban was associated with more bleeding than warfarin (HR in VKA-naive patients, 5.83 [CI, 3.25 to 10.44], and in VKA-experienced patients, 6.66 [CI, 3.83 to 11.58]; interaction P = 0.53). After 30 days, rivaroxaban was associated with less bleeding than warfarin in VKA-naive patients (HR, 0.84 [CI, 0.74 to 0.95]) and similar bleeding in VKA-experienced patients (HR, 1.06 [CI, 0.96 to 1.17]; interaction P = 0.003).
Limitation: The trial was not designed to detect differences in these subgroups.
Conclusion: The efficacy of rivaroxaban in VKA-experienced and VKA-naive patients was similar to that of the overall trial. There were more bleeding events within 7 days of study drug initiation with rivaroxaban, but after 30 days, rivaroxaban was associated with less bleeding in VKA-naive patients and similar bleeding in VKA-experienced patients. This information may be useful to clinicians considering a transition to rivaroxaban for patients receiving VKA therapy.
C1 Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA.
Royal Perth Hosp, Perth, WA, Australia.
Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1030, New Zealand.
Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
Bayer HealthCare Pharmaceut, Montville, NJ 07045 USA.
Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Edinburgh, Edinburgh, Midlothian, Scotland.
Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
Hosp Univ Munster, Munster, Germany.
Heidelberg Univ, Heidelberg, Germany.
RP Mahaffey, KW (reprint author), Duke Clin Res Inst, Room 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.
EM kenneth.mahaffey@dm.duke.edu
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson Johnson; Bayer HealthCare; Johnson & Johnson Pharmaceutical
Research and Development
FX Johnson & Johnson and Bayer HealthCare.; By Johnson & Johnson
Pharmaceutical Research and Development and Bayer HealthCare.
NR 13
TC 19
Z9 20
U1 0
U2 5
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 18
PY 2013
VL 158
IS 12
BP 861
EP +
DI 10.7326/0003-4819-158-12-201306180-00003
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167PW
UT WOS:000320645000014
PM 23778903
ER
PT J
AU Fu, RW
Selph, S
McDonagh, M
Peterson, K
Tiwari, A
Chou, R
Helfand, M
AF Fu, Rongwei
Selph, Shelley
McDonagh, Marian
Peterson, Kimberly
Tiwari, Arpita
Chou, Roger
Helfand, Mark
TI Effectiveness and Harms of Recombinant Human Bone Morphogenetic
Protein-2 in Spine Fusion A Systematic Review and Meta-analysis
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Review
ID LUMBAR INTERBODY FUSION; ANTERIOR CERVICAL DISKECTOMY; OFF-LABEL USE;
RADIOGRAPHIC OUTCOMES; RETROGRADE EJACULATION; INTEGRATED ANALYSIS;
RHBMP-2; SURGERY; AUTOGRAFT; ALLOGRAFT
AB Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is used as a bone graft substitute in spinal fusion, which unites (fuses) bones in the spine. The accuracy and completeness of journal publications of industry-sponsored trials on the effectiveness and harms of rhBMP-2 has been called into question.
Purpose: To independently assess the effectiveness and harms of rhBMP-2 in spinal fusion and reporting bias in industry-sponsored journal publications.
Data Sources: Individual-patient data (IPD) from 17 industry-sponsored studies; related internal documents; and searches of MEDLINE (1996 to August 2012), other databases, and reference lists.
Study Selection: Randomized, controlled trials (RCTs) and cohort studies of rhBMP-2 versus any control and uncontrolled studies of harms.
Data Extraction: Effectiveness outcomes in IPD were recalculated using consistent definitions. Study characteristics and results were abstracted by 1 investigator and confirmed by another. Two investigators independently assessed quality using predefined criteria.
Data Synthesis: Thirteen RCTs and 31 cohort studies were included. For lumbar spine fusion, rhBMP-2 and iliac crest bone graft were similar in overall success, fusion, and other effectiveness measures and in risk for any adverse event, although rates were high across interventions (77% to 93% at 24 months from surgery). For anterior lumbar interbody fusion, rhBMP-2 was associated with nonsignificantly increased risk for retrograde ejaculation and urogenital problems. For anterior cervical spine fusion, rhBMP-2 was associated with increased risk for wound complications and dysphagia. At 24 months, the cancer risk was increased with rhBMP-2 (risk ratio, 3.45 [95% CI, 1.98 to 6.00]), but event rates were low and cancer was heterogeneous. Early journal publications misrepresented the effectiveness and harms through selective reporting, duplicate publication, and underreporting.
Limitations: Outcome assessment was not blinded, and ascertainment of harms in trials was poor. No trials were truly independent of industry sponsorship.
Conclusion: In spinal fusion, rhBMP-2 has no proven clinical advantage over bone graft and may be associated with important harms, making it difficult to identify clear indications for rhBMP-2. Earlier disclosure of all relevant data would have better informed clinicians and the public than the initial published trial reports did.
C1 [Fu, Rongwei] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon State Univ, Corvallis, OR 97331 USA.
RP Fu, RW (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code CSB669, Portland, OR 97239 USA.
EM fur@ohsu.edu
FU Yale University; Medtronic; Oregon Health & Science University
FX Yale University and Medtronic.; By a research subcontract to Oregon
Health & Science University under a sponsored research agreement between
Yale University and Medtronic.
NR 82
TC 151
Z9 152
U1 2
U2 20
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 18
PY 2013
VL 158
IS 12
BP 890
EP +
DI 10.7326/0003-4819-158-12-201306180-00006
PG 23
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167PW
UT WOS:000320645000017
PM 23778906
ER
PT J
AU Roush, GC
Holford, TR
Guddati, AK
AF Roush, George C.
Holford, Theodore R.
Guddati, Achuta K.
TI Chlorthalidone Versus Hydrochlorothiazide
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Roush, George C.] Univ Connecticut Sch Med, Bridgeport, CT USA.
[Roush, George C.] St Vincents Med Ctr, Bridgeport, CT USA.
[Holford, Theodore R.] Yale Univ Sch Publ Hlth, New Haven, CT USA.
[Guddati, Achuta K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Roush, GC (reprint author), Univ Connecticut Sch Med, Bridgeport, CT USA.
NR 5
TC 3
Z9 3
U1 1
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 18
PY 2013
VL 158
IS 12
BP 920
EP 920
DI 10.7326/0003-4819-158-12-201306180-00014
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 167PW
UT WOS:000320645000023
PM 23778913
ER
PT J
AU Braunwald, E
Morrow, DA
AF Braunwald, Eugene
Morrow, David A.
TI Unstable Angina: Is It Time for a Requiem?
SO CIRCULATION
LA English
DT Article
DE angina, unstable; troponin
ID ACUTE CORONARY SYNDROMES; CARDIAC TROPONIN-I; ELEVATION
MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; MEDICINE PRACTICE
GUIDELINES; CLINICAL BIOCHEMISTRY; MINOR ELEVATIONS; NATIONAL ACADEMY;
DECISION-MAKING; SENSITIVE ASSAY
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Braunwald, E (reprint author), TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA.
EM ebraunwald@partners.org
FU Accumetrics; Amgen; Athera; AstraZeneca; Beckman Coulter; BG Medicine;
Bristol-Myers Squibb; Buhlmann Diagnostics; CV Therapeutics; Daiichi
Sankyo Co Ltd; Eli Lilly and Co; GlaxoSmithKline; Integrated
Therapeutics; Johnson Johnson; Merck and Co; Merck-Schering Plow Joint
Venture; Nanosphere; Novartis Pharmaceuticals; Nuvelo; Ortho-Clinical
Diagnostics; Pfizer; Roche Diagnostics; Sanofi-Aventis;
Sanofi-Synthelabo; Schering-Plow; Siemens; Singulex; Daiichi Sankyo;
Genzyme; Amorcyte; Medicines Company; MC Communications; Ikaria;
CardioRentis; Sanofi Aventis; Beckman-Coulter; Critical Diagnostics;
Genentech; Gilead; Instrumentation Laboratories; Merck; Servier
FX The TIMI Study Group has received significant research grant support
from Accumetrics, Amgen, Athera, AstraZeneca, Beckman Coulter, BG
Medicine, Bristol-Myers Squibb, Buhlmann Diagnostics, CV Therapeutics,
Daiichi Sankyo Co Ltd, Eli Lilly and Co, GlaxoSmithKline, Integrated
Therapeutics, Johnson & Johnson, Merck and Co, Merck-Schering Plow Joint
Venture, Nanosphere, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical
Diagnostics, Pfizer, Roche Diagnostics, Sanofi-Aventis,
Sanofi-Synthelabo, Schering-Plow, Siemens, and Singulex. Dr Braunwald
has received consulting fees from Daiichi Sankyo, Genzyme, Amorcyte, The
Medicines Company, MC Communications, Ikaria, CardioRentis, and Sanofi
Aventis. Dr Morrow has received consulting fees from Beckman-Coulter, BG
Medicine, Critical Diagnostics, Genentech, Gilead, Instrumentation
Laboratories, Johnson & Johnson, Merck, Roche Diagnostics, and Servier.
NR 45
TC 36
Z9 39
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 18
PY 2013
VL 127
IS 24
BP 2452
EP 2457
DI 10.1161/CIRCULATIONAHA.113.001258
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 168IM
UT WOS:000320699100024
PM 23775194
ER
PT J
AU Clark, D
McGiffin, DC
Dell'Italia, LJ
Ahmed, MI
AF Clark, Donald, III
McGiffin, David C.
Dell'Italia, Louis J.
Ahmed, Mustafa I.
TI Submassive Pulmonary Embolism: Where's the Tipping Point?
SO CIRCULATION
LA English
DT Article
DE pulmonary embolism
ID RIGHT-VENTRICULAR DYSFUNCTION; VENOUS THROMBOEMBOLISM;
SURGICAL-TREATMENT; CONSECUTIVE PATIENTS; PROGNOSTIC VALUE;
RISK-FACTORS; RIGHT HEART; EMBOLECTOMY; MANAGEMENT; HYPERTENSION
C1 [Clark, Donald, III; Dell'Italia, Louis J.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Div Cardiovasc Dis, Dept Med, Birmingham, AL 35294 USA.
[McGiffin, David C.] Univ Alabama Birmingham, Div Cardiothorac Surg, Dept Surg, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Ahmed, MI (reprint author), Univ Alabama Birmingham, Div Cardiol, Dept Med, 434 BMR2,901 19th St South, Birmingham, AL 35294 USA.
EM mahmed@uab.edu
FU NIDDK NIH HHS [P30 DK079626]
NR 36
TC 0
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 18
PY 2013
VL 127
IS 24
BP 2458
EP 2464
DI 10.1161/CIRCULATIONAHA.112.000859
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 168IM
UT WOS:000320699100025
PM 23775195
ER
PT J
AU Dake, MD
Ansel, GM
Jaff, MR
Ohki, T
Saxon, RR
Smouse, HB
Snyder, SA
O'Leary, EE
Tepe, G
Scheinert, D
Zeller, T
AF Dake, Michael D.
Ansel, Gary M.
Jaff, Michael R.
Ohki, Takao
Saxon, Richard R.
Smouse, H. Bob
Snyder, Scott A.
O'Leary, Erin E.
Tepe, Gunnar
Scheinert, Dierk
Zeller, Thomas
CA Zilver PTX Investigators
TI Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for
Femoropopliteal Lesions 2-Year Follow-Up From the Zilver PTX Randomized
and Single-Arm Clinical Studies
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE angioplasty; drug-eluting stent(s); paclitaxel-eluting stent(s);
peripheral arterial disease
ID SUPERFICIAL FEMORAL-ARTERY; BARE NITINOL STENTS; BALLOON ANGIOPLASTY;
POPLITEAL ARTERIES; TRIAL; IMPLANTATION; DISEASE; CLAUDICATION;
PERFORMANCE; RESTENOSIS
AB Objectives A prospective, multinational randomized controlled trial (RCT) and a complementary single-arm study evaluated the 2-year safety and effectiveness of a paclitaxel-coated drug-eluting stent (DES) in patients with superficial femoral artery lesions. The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-metal stent (BMS) placement.
Background Local drug delivery for superficial femoral artery lesions has been investigated with the intent of limiting restenosis similarly to DES for the coronary arteries. One-year outcomes of DES in the superficial femoral artery are promising, but longer-term benefits have not been established.
Methods In the RCT, patients were randomly assigned to primary DES implantation (n = 236) or PTA (n = 238). Acute PTA failure occurred in 120 patients, who underwent secondary randomization to DES (n = 61) or BMS (n = 59) placement. The single-arm study enrolled 787 patients with DES treatment.
Results Compared with the control group, the primary DES group demonstrated significantly superior 2-year event-free survival (86.6% vs. 77.9%, p = 0.02) and primary patency (74.8% vs. 26.5%, p < 0.01). In addition, the provisional DES group exhibited superior 2-year primary patency compared with the provisional BMS group (83.4% vs. 64.1%, p < 0.01) and achieved higher sustained clinical benefit (83.9% vs. 68.4%, p = 0.05). Two-year freedom from target lesion revascularization with primary DES placement was 80.5% in the single-arm study and 86.6% in the RCT.
Conclusions Two-year outcomes with the paclitaxel-eluting stent support its sustained safety and effectiveness in patients with femoropopliteal artery disease, including the long-term superiority of the DES to PTA and to provisional BMS placement. (Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery; NCT00120406; Zilver (R) PTX (TM) Global Registry; NCT01094678) (C) 2013 by the American College of Cardiology Foundation
C1 [Dake, Michael D.] Stanford Univ, Med Ctr, Dept Cardiothorac Surg, Stanford, CA 94305 USA.
[Ansel, Gary M.] Riverside Methodist Hosp, Ctr Crit Limb Care, Columbus, OH 43214 USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, Vasc Ctr, Boston, MA 02114 USA.
[Ohki, Takao] Jikei Univ Hosp, Dept Surg, Tokyo, Japan.
[Saxon, Richard R.] Tricity Med Ctr, Dept Diagnost Imaging & Intervent Radiol, Oceanside, CA USA.
[Smouse, H. Bob] OSF St Francis Med Ctr, Dept Radiol, Peoria, IL USA.
[Snyder, Scott A.; O'Leary, Erin E.] MED Inst Inc, W Lafayette, IN USA.
[Tepe, Gunnar] Klinikum Rosenheim, Dept Radiol, Rosenheim, Germany.
[Scheinert, Dierk] Pk Hosp, Dept Radiol, Ctr Vasc Med, Leipzig, Germany.
[Zeller, Thomas] Herz Zentrum, Dept Angiol, Bad Krozingen, Germany.
RP Dake, MD (reprint author), Stanford Univ, Sch Med, Dept Cardiothorac Surg, Falk Cardiovasc Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.
EM mddake@stanford.edu
FU Cook Medical; Flexible Stenting Solutions; Cordis Endovascular;
Sanofi-Aventis
FX These studies were sponsored by Cook Medical. Dr. Dake is a member of
the advisory boards of Abbott Vascular, W. L. Gore, TriVascular, and
Vortex Medical and is a member of the board of directors of VIVA
Physicians, a not-for-profit 501(c)(3) education and research
organization, and has received speaking honoraria from Cook Medical. Dr.
Ansel is a consultant for Cook Medical, Cordis Endovascular, C. R. Bard,
W. L. Gore, and Flexible Stenting Solutions; has financial ownership in
Flexible Stenting Solutions; has received payments for speakers' bureau
appointments from Cook Medical, Cordis Endovascular, and W. L. Gore; and
has received research grants from Cook Medical. Dr. Jaff is a member of
the board of directors of VIVA Physicians. Dr. Ohki has received
speaking honoraria from Cook Medical. Dr. Saxon is a member of the
advisory board of Abbott Vascular and serves as a consultant for W. L.
Gore; has received speaking honoraria from W. L. Gore; has received
research grants from Cook Medical, W. L. Gore, Covidien, and Lutonix/C.
R. Bard; and was an expert witness for a device unrelated to this study.
Dr. Smouse is a consultant for Cook Medical. Drs. Snyder and O'Leary are
paid employees of MED Institute, Inc., a contract research organization
and Cook Group company. Dr. Tepe is a consultant for Cook Medical. Dr.
Zeller is a member of the advisory boards of Medtronic-Invatec, W. L.
Gore, Angioslide, Medtronic-Ardian, and Covidien; has received
consulting fees or speaking honoraria from Sanofi-Aventis, C. R. Bard,
Johnson & Johnson Cordis, Covidien, Boston Scientific Corporation,
Straub Medical, Cook Medical, Invatec, Biotronik, Optimed, Pathway
Medical, and W. L. Gore; and has received research grants from Cook
Medical, Krauth Medical, Pathway Medical, Abbott Vascular, Johnson &
Johnson Cordis, Angioslide, Ardian, Biotronik, Invatec, InnoRa, and W.
L. Gore. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
NR 19
TC 141
Z9 147
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUN 18
PY 2013
VL 61
IS 24
BP 2417
EP 2427
DI 10.1016/j.jacc.2013.03.034
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167AJ
UT WOS:000320602200005
PM 23583245
ER
PT J
AU Weinrauch, LA
Desai, AS
Skali, H
D'Elia, JA
AF Weinrauch, Larry A.
Desai, Akshay S.
Skali, Hicham
D'Elia, John A.
TI Risk Stratification of Resistant Hypertension in Chronic Kidney Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE ambulatory blood pressure monitoring; chronic kidney disease; resistant
hypertension
ID RENAL SYMPATHETIC DENERVATION; HIGH-BLOOD-PRESSURE; CONTROLLED-TRIAL;
ARTERY STENOSIS; THERAPY; RECOMMENDATIONS; MANAGEMENT; DIAGNOSIS; HOME
C1 [Weinrauch, Larry A.; D'Elia, John A.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Weinrauch, Larry A.; Desai, Akshay S.; Skali, Hicham] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
RP Weinrauch, LA (reprint author), Harvard Univ, Sch Med, 521 Mt Auburn St, Watertown, MA 02472 USA.
EM lweinrauch@hms.harvard.edu
OI Skali, Hicham/0000-0002-5629-4138; Weinrauch, Larry/0000-0003-1357-9528
NR 19
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUN 18
PY 2013
VL 61
IS 24
BP 2468
EP 2470
DI 10.1016/j.jacc.2013.03.048
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 167AJ
UT WOS:000320602200012
PM 23623913
ER
PT J
AU Cook, AJ
Gold, DR
Li, Y
AF Cook, Andrea J.
Gold, Diane R.
Li, Yi
TI Spatial Cluster Detection for Longitudinal Outcomes Using Administrative
Regions
SO COMMUNICATIONS IN STATISTICS-THEORY AND METHODS
LA English
DT Article
DE Asthma; Cluster detection; Cumulative residuals; Repeated measures;
Wheeze
ID CHILDREN
AB This article proposes a new spatial cluster detection method for longitudinal outcomes that detects neighborhoods and regions with elevated rates of disease while controlling for individual level confounders. The proposed method, CumResPerm, utilizes cumulative geographic residuals through a permutation test to detect potential clusters which are defined as sets of administrative regions, such as a town or group of administrative regions. Previous cluster detection methods are not able to incorporate individual level data including covariate adjustment, while still being able to define potential clusters using informative neighborhood or town boundaries. Often, it is of interest to detect such spatial clusters because individuals residing in a town may have similar environmental exposures or socioeconomic backgrounds due to administrative reasons, such as zoning laws. Therefore, these boundaries can be very informative and more relevant than arbitrary clusters such as the standard circle or square. Application of the CumResPerm method will be illustrated by the Home Allergens and Asthma prospective cohort study analyzing the relationship between area or neighborhood residence and repeated measured outcome, occurrence of wheeze in the last six months, while taking into account mobile locations.
C1 [Cook, Andrea J.] Grp Hlth Res Inst, Biostat Unit, Seattle, WA 98101 USA.
[Cook, Andrea J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Gold, Diane R.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Gold, Diane R.] Harvard Univ, Sch Med, Boston, MA USA.
[Gold, Diane R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Li, Yi] Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
[Li, Yi] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Cook, AJ (reprint author), Grp Hlth Res Inst, Biostat Unit, Seattle, WA 98101 USA.
EM cook.aj@ghc.org
FU National Institutes of Health [RO1 AI/EHS 35786, RO1 CA95747]
FX This work was supported by National Institutes of Health [RO1 AI/EHS
35786 to DRG; RO1 CA95747 to YL and AJC].
NR 18
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0361-0926
J9 COMMUN STAT-THEOR M
JI Commun. Stat.-Theory Methods
PD JUN 18
PY 2013
VL 42
IS 12
BP 2105
EP 2117
DI 10.1080/03610926.2011.605234
PG 13
WC Statistics & Probability
SC Mathematics
GA 135IK
UT WOS:000318281600001
PM 23847392
ER
PT J
AU Danovitch, GM
Chapman, J
Capron, AM
Levin, A
Abbud, M
Al Mousawi, M
Bennett, W
Budiani-Saberi, D
Couser, W
Dittmer, I
Jha, V
Lavee, J
Martin, D
Masri, M
Naicker, S
Takahara, S
Tibell, A
Shaheen, F
Anantharaman, V
Delmonico, FL
AF Danovitch, Gabriel M.
Chapman, Jeremy
Capron, Alexander M.
Levin, Adeera
Abbud-Filho, Mario
Al Mousawi, Mustafa
Bennett, William
Budiani-Saberi, Debra
Couser, William
Dittmer, Ian
Jha, Vivek
Lavee, Jacob
Martin, Dominique
Masri, Marwan
Naicker, Saraladevi
Takahara, Shiro
Tibell, Annika
Shaheen, Faissal
Anantharaman, Vathsala
Delmonico, Francis L.
TI Organ Trafficking and Transplant Tourism: The Role of Global
Professional Ethical Standards-The 2008 Declaration of Istanbul
SO TRANSPLANTATION
LA English
DT Article
DE Declaration of Istanbul; Organ trafficking; Transplant tourism
ID DONATION; POLICY; CHINA; LAW; SOCIETY; ISRAEL; TRADE; INDIA
AB By 2005, human organ trafficking, commercialization, and transplant tourism had become a prominent and pervasive influence on transplantation therapy. The most common source of organs was impoverished people in India, Pakistan, Egypt, and the Philippines, deceased organ donors in Colombia, and executed prisoners in China. In response, in May 2008, The Transplantation Society and the International Society of Nephrology developed the Declaration of Istanbul on Organ Trafficking and Transplant Tourism consisting of a preamble, a set of principles, and a series of proposals. Promulgation of the Declaration of Istanbul and the formation of the Declaration of Istanbul Custodian Group to promote and uphold its principles have demonstrated that concerted, strategic, collaborative, and persistent actions by professionals can deliver tangible changes. Over the past 5 years, the Declaration of Istanbul Custodian Group organized and encouraged cooperation among professional bodies and relevant international, regional, and national governmental organizations, which has produced significant progress in combating organ trafficking and transplant tourism around the world. At a fifth anniversary meeting in Qatar in April 2013, the DICG took note of this progress and set forth in a Communique a number of specific activities and resolved to further engage groups from many sectors in working toward the Declaration's objectives.
C1 [Danovitch, Gabriel M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Chapman, Jeremy] Westmead Hosp, Westmead, NSW 2145, Australia.
[Capron, Alexander M.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Levin, Adeera] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Abbud-Filho, Mario] FAMERP HB FUNFARME, Inst Urol & Nephrol, Sao Paulo, Brazil.
[Abbud-Filho, Mario] FAMERP HB FUNFARME, Sch Med, Sao Paulo, Brazil.
[Al Mousawi, Mustafa] Hamed Al Essa Organ Transplant Ctr, Safat, Kuwait.
[Bennett, William] Legacy Good Samaritan Hosp & Hlth Ctr, Portland, OR USA.
[Budiani-Saberi, Debra] Coalit Organ Failure Solut, Bethesda, MD USA.
[Couser, William] Univ Washington, Sch Med, Woodinville, WA USA.
[Dittmer, Ian] Auckland City Hosp, Dept Renal Med, Auckland, New Zealand.
[Jha, Vivek] Postgrad Inst Med Educ & Res, Dept Nephrol, Chandigarh 160012, India.
[Lavee, Jacob] Tel Aviv Univ, Sackler Fac Med, Heart Transplantat Unit, Leviev Heart Ctr,Sheba Med Ctr, IL-69978 Tel Aviv, Israel.
[Martin, Dominique] Univ Melbourne, Ctr Hlth & Soc, Carlton, Vic 3053, Australia.
[Masri, Marwan] Transmed Life Res Inst, Beirut, Lebanon.
[Naicker, Saraladevi] Univ Witwatersrand, Dept Internal Med, Johannesburg, South Africa.
[Takahara, Shiro] Osaka Univ, Grad Sch Med, Dept Adv Technol Transplantat, Osaka, Japan.
[Tibell, Annika] Karolinska Univ Hosp, Div Transplantat Surg, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.
[Shaheen, Faissal] Saudi Ctr Organ Transplantat, Riyadh, Saudi Arabia.
[Anantharaman, Vathsala] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
[Delmonico, Francis L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA.
RP Danovitch, GM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10833 Le Conte Blvd, Los Angeles, CA 90095 USA.
EM gdanovitch@mednet.ucla.edu
OI Lavee, Jacob/0000-0002-3641-1114; Abbud-Filho, Mario/0000-0002-5079-9813
NR 29
TC 31
Z9 32
U1 2
U2 21
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
EI 1534-6080
J9 TRANSPLANTATION
JI Transplantation
PD JUN 15
PY 2013
VL 95
IS 11
BP 1306
EP 1312
DI 10.1097/TP.0b013e318295ee7d
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 299EE
UT WOS:000330377400004
PM 23644753
ER
PT J
AU Zurowski, M
McDonald, WM
Fox, S
Marsh, L
AF Zurowski, Mateusz
McDonald, William M.
Fox, Susan
Marsh, Laura
TI Psychiatric comorbidities in dystonia: Emerging concepts
SO MOVEMENT DISORDERS
LA English
DT Review
DE dystonia; psychiatry; depression; anxiety; social phobia
ID QUALITY-OF-LIFE; PRIMARY FOCAL DYSTONIA; IDIOPATHIC CERVICAL DYSTONIA;
SPASMODIC TORTICOLLIS; GENERALIZED DYSTONIA; ANXIETY DISORDERS; MUTATION
CARRIERS; DEPRESSION; MANAGEMENT; RECOGNITION
AB Psychiatric disorders are highly prevalent in patients with dystonia and have a profound effect on quality of life. Patients with dystonia frequently meet criteria for anxiety disorders, especially social phobia, and major depressive disorder. Deficits in emotional processing have also been demonstrated in some dystonia populations. Onset of psychiatric disturbances in patients with dystonia often precedes onset of motor symptoms, suggesting that the pathophysiology of dystonia itself contributes to the genesis of psychiatric disturbances. This article examines the hypothesis that mood and anxiety disorders are intrinsic to the neurobiology of dystonia, citing the available literature, which is derived mostly from research on focal isolated dystonias. Limitations of studies are identified, and the role of emotional reactivity, especially in the context of pain secondary to dystonia, is recognized. Available evidence underscores the need to develop dystonia assessment tools that incorporate psychiatric measures. Such tools would allow for a better understanding of the full spectrum of dystonia presentations and facilitate research on the treatment of dystonia as well as the treatment of psychiatric illnesses in the context of dystonia. This article, solicited for a special Movement Disorders issue on novel research findings and emerging concepts in dystonia, addresses the following issues: (1) To what extent are psychiatric disturbances related to the pathophysiology of dystonia? (2) What is the impact of psychiatric disturbances on outcome measures of current assessment tools for dystonia? (3) How do psychiatric comorbidities influence the treatment of dystonia? Answers to these questions will lead to an increased appreciation of psychiatric disorders in dystonia, a better understanding of brain physiology, more nuanced research questions pertaining to this population, better clinical scales that can be used to further patient management and research, and improved patient outcomes. (C) 2013 Movement Disorder Society
C1 [Zurowski, Mateusz] Univ Toronto, Dept Psychiat, Univ Hlth Network, Toronto, ON, Canada.
[McDonald, William M.] Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
[Fox, Susan] Univ Toronto, Div Neurol, Univ Hlth Network, Toronto, ON, Canada.
[Marsh, Laura] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA.
[Marsh, Laura] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
RP Zurowski, M (reprint author), Univ Hlth Network, Dept Psychiat, Toronto Western Hosp, 7 Main,399 Bathurst St, Toronto, ON M5T 2S8, Canada.
EM mateusz.zurowski@uhn.ca
RI zurowski, mateusz/D-1536-2010
OI zurowski, mateusz/0000-0002-6407-4629
FU Dystonia Coalition [U54 NS065701, NS065701]
FX This work was supported by the Dystonia Coalition U54 NS065701 (to
Mateusz Zurowski) and by Dystonia Coalition grant NS065701 (William M.
McDonald).
NR 45
TC 13
Z9 13
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN 15
PY 2013
VL 28
IS 7
BP 914
EP 920
DI 10.1002/mds.25501
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 188ZH
UT WOS:000322235700009
PM 23893448
ER
PT J
AU Tsytsarev, V
Rao, B
Maslov, KI
Li, L
Wang, LHV
AF Tsytsarev, Vassiliy
Rao, Bin
Maslov, Konstantin I.
Li, Li
Wang, Lihong V.
TI Photoacoustic and optical coherence tomography of epilepsy with high
temporal and spatial resolution and dual optical contrasts
SO JOURNAL OF NEUROSCIENCE METHODS
LA English
DT Article
DE Photoacoustic microscopy; Optical coherence tomography; Epileptic
seizures; 4-Aminopyridine
ID CEREBRAL-BLOOD-FLOW; IN-VIVO; HEMODYNAMIC-CHANGES; MICROSCOPY; SEIZURES;
CORTEX; BRAIN; ACTIVATION; SIGNAL; FOCI
AB Epilepsy mapping with high spatial and temporal resolution has great significance for both fundamental research on epileptic neurons and the clinical management of epilepsy. In this communication, we demonstrate for the first time in vivo epilepsy mapping with high spatial and temporal resolution and dual optical contrasts in an animal model. Through the variations of a depthresolved optical coherence tomography signal with optical scattering contrast, we observed that epileptic neuron activities modulated the optical refractive index of epileptic neurons and their surrounding tissue. Simultaneously, through neurovasculature coupling mechanisms and optical absorption contrast, we used photoacoustic signals to document the hemodynamic changes of the microvasculature surrounding the epileptic neurons. The epilepsy mapping results were confirmed by a simultaneously recorded electroencephalogram signal during epileptic seizure. Our new epilepsy mapping tool, with high temporal and spatial resolution and dual optical contrasts, may find many applications, such as drug development and epilepsy surgery. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Tsytsarev, Vassiliy; Rao, Bin; Maslov, Konstantin I.; Li, Li; Wang, Lihong V.] Washington Univ, Dept Biomed Engn, Opt Imaging Lab, St Louis, MO 63130 USA.
[Tsytsarev, Vassiliy] Univ Maryland, Dept Anat & Neurobiol, Sch Med, Baltimore, MD 21201 USA.
[Li, Li] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Wang, LHV (reprint author), Washington Univ, Dept Biomed Engn, 1 Brookings Dr, St Louis, MO 63130 USA.
EM tsytsarev@umaryland.edu; raob@seas.wustl.edu; kimaslov@biomed.wustl.edu;
li.li@mgh.harvard.edu; lhwang@seas.wustl.edu
RI Rao, Bin/C-2499-2015; Wang, Lihong/A-7147-2009
OI Wang, Lihong/0000-0001-9783-4383
FU National Institutes of Health [R01 EB008085, R01 CA134539, U54 CA136398,
R01 CA157277, R01 CA159959, DP1 EB016986]
FX This work was sponsored in part by National Institutes of Health grants
R01 EB008085, R01 CA134539, U54 CA136398, R01 CA157277, R01 CA159959,
DP1 EB016986 (NIH Director's Pioneer Award). L.W. has a financial
interest in Microphotoacoustics, Inc. and Endra, Inc., which, however,
did not support this work. K.M. has a financial interest in
Microphotoacoustics, Inc., which, however, did not support this work.
NR 44
TC 14
Z9 14
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0270
J9 J NEUROSCI METH
JI J. Neurosci. Methods
PD JUN 15
PY 2013
VL 216
IS 2
BP 142
EP 145
DI 10.1016/j.jneumeth.2013.04.001
PG 4
WC Biochemical Research Methods; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 174PP
UT WOS:000321168200009
PM 23603664
ER
PT J
AU Duraiswamy, J
Kaluza, KM
Freeman, GJ
Coukos, G
AF Duraiswamy, Jaikumar
Kaluza, Karen M.
Freeman, Gordon J.
Coukos, George
TI Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively
Restores T-Cell Rejection Function in Tumors
SO CANCER RESEARCH
LA English
DT Article
ID CHRONIC VIRAL-INFECTION; SYNGENEIC MOUSE MODEL; HUMAN OVARIAN-CANCER;
REGULATORY T; PROGRAMMED DEATH-1; DISTINCT MECHANISMS;
ANTITUMOR-ACTIVITY; MYELOID-LEUKEMIA; IMMUNE ESCAPE; GROWTH-FACTOR
AB Tumor progression is facilitated by regulatory T cells (Treg) and restricted by effector T cells. In this study, we document parallel regulation of CD8(+) T cells and Foxp3(+) Tregs by programmed death-1 (PD-1, PDCD1). In addition, we identify an additional role of CTL antigen-4 (CTLA-4) inhibitory receptor in further promoting dysfunction of CD8(+) T effector cells in tumor models (CT26 colon carcinoma and ID8-VEGF ovarian carcinoma). Two thirds of CD8(+) tumor-infiltrating lymphocytes (TIL) expressed PD-1, whereas one third to half of CD8(+) TIL coexpressed PD-1 and CTLA-4. Double-positive (PD-1(+)CTLA-4(+)) CD8(+) TIL had characteristics of more severe dysfunction than single-positive (PD-1(+) or CTLA-4(+)) TIL, including an inability to proliferate and secrete effector cytokines. Blockade of both PD-1 and CTLA-4 resulted in reversal of CD8(+) TIL dysfunction and led to tumor rejection in two thirds of mice. Double blockade was associated with increased proliferation of antigen-specific effector CD8(+) and CD4(+) T cells, antigen-specific cytokine release, inhibition of suppressive functions of Tregs, and upregulation of key signaling molecules critical for T-cell function. When used in combination with GVAX vaccination (consisting of granulocyte macrophage colony-stimulating factor-expressing irradiated tumor cells), inhibitory pathway blockade induced rejection of CT26 tumors in 100% of mice and ID8-VEGF tumors in 75% of mice. Our study indicates that PD-1 signaling in tumors is required for both suppressing effector T cells and maintaining tumor Tregs, and that PD-1/PD-L1 pathway (CD274) blockade augments tumor inhibition by increasing effector T-cell activity, thereby attenuating Treg suppression. (c) 2013 AACR.
C1 [Duraiswamy, Jaikumar; Kaluza, Karen M.; Coukos, George] Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.
[Duraiswamy, Jaikumar; Kaluza, Karen M.; Coukos, George] Univ Penn, Dept Obstet & Gynecol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Coukos, George] Univ Lausanne Hosp, Ludwig Ctr Canc Res, Dept Oncol, Lausanne, Switzerland.
RP Coukos, G (reprint author), Ludwig Ctr Canc Res, Ch Boveresses 155, CH-1066 Lausanne, Switzerland.
EM George.Coukos@chuv.ch
FU NIH grant [2P50-CA083638]; SPORE-Pilot grant; [NIH-P01 AI056299]
FX This work was supported by NIH grant 2P50-CA083638 (G. Coukos),
SPORE-Pilot grant (to J. Duraiswamy), and NIH-P01 AI056299 (G.J.
Freeman).
NR 67
TC 187
Z9 196
U1 8
U2 57
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUN 15
PY 2013
VL 73
IS 12
BP 3591
EP 3603
DI 10.1158/0008-5472.CAN-12-4100
PG 13
WC Oncology
SC Oncology
GA 164AE
UT WOS:000320380300012
PM 23633484
ER
PT J
AU Rice, WL
Hou, S
Kumar, ATN
AF Rice, William L.
Hou, Steven
Kumar, Anand T. N.
TI Resolution below the point spread function for diffuse optical imaging
using fluorescence lifetime multiplexing
SO OPTICS LETTERS
LA English
DT Article
ID TOMOGRAPHY; DOMAIN; CONTRAST; SYSTEM
AB We show that asymptotic lifetime-based fluorescence tomography can localize multiple-lifetime targets separated well below the diffuse point spread function of a turbid medium. This is made possible due to a complete diagonalization of the time domain forward problem in the asymptotic limit. We also show that continuous wave or direct time gate approaches to fluorescence tomography are unable to achieve this separation, indicating the unique advantage of a decay-amplitude-based approach for tomographic lifetime multiplexing with time domain data. (c) 2013 Optical Society of America
C1 [Rice, William L.; Hou, Steven; Kumar, Anand T. N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
RP Kumar, ATN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
EM ankumar@nmr.mgh.harvard.edu
FU National Institutes of Health [R01 EB015325]
FX This work was supported by the National Institutes of Health Grant R01
EB015325.
NR 14
TC 7
Z9 7
U1 0
U2 11
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
J9 OPT LETT
JI Opt. Lett.
PD JUN 15
PY 2013
VL 38
IS 12
BP 2038
EP 2040
DI 10.1364/OL.38.002038
PG 3
WC Optics
SC Optics
GA 163VX
UT WOS:000320366500013
PM 23938969
ER
PT J
AU Singh, JA
AF Singh, J. A.
TI Intraarticular botulinum toxin reduced joint pain in patients with
painful total knee or shoulder arthroplasty
SO TOXICON
LA English
DT Meeting Abstract
CT 7th International Conference on Basic and Therapeutic Aspects of
Botulinum and Tetanus Toxins (TOXINS)
CY OCT 02-05, 2011
CL Santa Fe, NM
C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
EM jasvinder.md@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD JUN 15
PY 2013
VL 68
BP 121
EP 121
DI 10.1016/j.toxicon.2012.07.164
PG 1
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 159VN
UT WOS:000320075500152
ER
PT J
AU Pallin, DJ
Binder, WD
Allen, MB
Lederman, M
Parmar, S
Filbin, MR
Hooper, DC
Camargo, CA
AF Pallin, Daniel J.
Binder, William D.
Allen, Matthew B.
Lederman, Molly
Parmar, Siddharth
Filbin, Michael R.
Hooper, David C.
Camargo, Carlos A., Jr.
TI Clinical Trial: Comparative Effectiveness of Cephalexin Plus
Trimethoprim-Sulfamethoxazole Versus Cephalexin Alone for Treatment of
Uncomplicated Cellulitis: A Randomized Controlled Trial
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE cellulitis; community-associated methicillin-resistant Staphylococcus
aureus; comparative effectiveness; trimethoprim-sulfamethoxazole;
cephalexin
ID RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS;
EMERGENCY-DEPARTMENT; ANTIMICROBIAL THERAPY; SKIN INFECTIONS; RISK;
COLONIZATION; GUIDELINES; CHILDREN
AB Background. Community-associated methicillin-resistant S. aureus (CA-MRSA) is the most common organism isolated from purulent skin infections. Antibiotics are usually not beneficial for skin abscess, and national guidelines do not recommend CA-MRSA coverage for cellulitis, except purulent cellulitis, which is uncommon. Despite this, antibiotics targeting CA-MRSA are prescribed commonly and increasingly for skin infections, perhaps due, in part, to lack of experimental evidence among cellulitis patients. We test the hypothesis that antibiotics targeting CA-MRSA are beneficial in the treatment of cellulitis.
Methods. We performed a randomized, multicenter, double-blind, placebo-controlled trial from 2007 to 2011. We enrolled patients with cellulitis, no abscesses, symptoms for <1 week, and no diabetes, immunosuppression, peripheral vascular disease, or hospitalization (clinicaltrials.gov NCT00676130). All participants received cephalexin. Additionally, each was randomized to trimethoprim-sulfamethoxazole or placebo. We provided 14 days of antibiotics and instructed participants to continue therapy for >= 1 week, then stop 3 days after they felt the infection to be cured. Our main outcome measure was the risk difference for treatment success, determined in person at 2 weeks, with telephone and medical record confirmation at 1 month.
Results. We enrolled 153 participants, and 146 had outcome data for intent-to-treat analysis. Median age was 29, range 3-74. Of intervention participants, 62/73 (85%) were cured versus 60/73 controls (82%), a risk difference of 2.7% (95% confidence interval, -9.3% to 15%; P = .66). No covariates predicted treatment response, including nasal MRSA colonization and purulence at enrollment.
Conclusions. Among patients diagnosed with cellulitis without abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not improve outcomes overall or by subgroup.
C1 [Pallin, Daniel J.; Allen, Matthew B.; Lederman, Molly; Parmar, Siddharth] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA.
[Pallin, Daniel J.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA.
[Binder, William D.; Filbin, Michael R.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Allen, Matthew B.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lederman, Molly] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Hooper, David C.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
RP Pallin, DJ (reprint author), 75 Francis St,Neville House 304-D, Boston, MA 02115 USA.
EM dpallin@partners.org
RI Pallin, Daniel/H-6382-2013
OI Pallin, Daniel/0000-0002-8517-9702
FU Brigham and Women's Hospital Department of Emergency Medicine; Harvard
University, Boston, MA; Department of Emergency Medicine of
Massachusetts General Hospital
FX This work was supported by a grant from the Eleanor and Miles Shore
Fellowship Program of the Brigham and Women's Hospital Department of
Emergency Medicine; by the Milton Fund of Harvard University, Boston,
MA; and by seed funding from the Department of Emergency Medicine of
Massachusetts General Hospital.
NR 30
TC 35
Z9 35
U1 0
U2 16
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2013
VL 56
IS 12
BP 1754
EP 1762
DI 10.1093/cid/cit122
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 151NG
UT WOS:000319466600012
PM 23457080
ER
PT J
AU Jena, AB
AF Jena, Anupam B.
TI Balancing Disease Eradication With the Emergence of Multidrug-Resistant
HIV in Test-and-Treat Policies
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE human immunodeficiency virus; drug resistance; test and treat
ID ANTIRETROVIRAL THERAPY; PREEXPOSURE PROPHYLAXIS; INFECTION;
TRANSMISSION; PREVENTION; INITIATION; EPIDEMIC; COHORT
C1 [Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Jena, Anupam B.] Massachusetts Gen Hosp Boston, Dept Med, Boston, MA USA.
[Jena, Anupam B.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
RP Jena, AB (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM jena.anupam@mgh.harvard.edu
NR 19
TC 1
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUN 15
PY 2013
VL 56
IS 12
BP 1797
EP 1799
DI 10.1093/cid/cit159
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 151NG
UT WOS:000319466600019
PM 23487380
ER
PT J
AU Shyh-Chang, N
Daley, GQ
Cantley, LC
AF Shyh-Chang, Ng
Daley, George Q.
Cantley, Lewis C.
TI Stem cell metabolism in tissue development and aging
SO DEVELOPMENT
LA English
DT Review
DE Blastocyst metabolism; Pluripotent stem cells; Hematopoietic
progenitors; Reprogramming; Metabolomics
ID MITOCHONDRIAL PHOSPHATASE PTPMT1; HEMATOPOIETIC PROGENITORS; MOUSE
EMBRYOS; SOMATIC-CELLS; PREIMPLANTATION EMBRYOS; CAENORHABDITIS-ELEGANS;
MAMMALIAN DEVELOPMENT; GLUCOSE TRANSPORTERS; ANTIOXIDANT ENZYMES;
ENERGY-METABOLISM
AB Recent advances in metabolomics and computational analysis have deepened our appreciation for the role of specific metabolic pathways in dictating cell fate. Once thought to be a mere consequence of the state of a cell, metabolism is now known to play a pivotal role in dictating whether a cell proliferates, differentiates or remains quiescent. Here, we review recent studies of metabolism in stem cells that have revealed a shift in the balance between glycolysis, mitochondrial oxidative phosphorylation and oxidative stress during the maturation of adult stem cells, and during the reprogramming of somatic cells to pluripotency. These insights promise to inform strategies for the directed differentiation of stem cells and to offer the potential for novel metabolic or pharmacological therapies to enhance regeneration and the treatment of degenerative disease.
C1 [Shyh-Chang, Ng; Daley, George Q.] Childrens Hosp, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Shyh-Chang, Ng; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shyh-Chang, Ng; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Shyh-Chang, Ng; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, Boston, MA 02115 USA.
[Cantley, Lewis C.] Cornell Weill Med Coll, Dept Med, New York, NY 10065 USA.
RP Cantley, LC (reprint author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, Boston, MA 02115 USA.
EM lewis_cantley@hms.harvard.edu
RI Cantley, Lewis/D-1800-2014;
OI Cantley, Lewis/0000-0002-1298-7653; Shyh-Chang, Ng/0000-0003-3138-9525
FU NSS Scholarship from the Agency for Science, Technology and Research,
Singapore; National Institutes of Health (NIH); Ellison Medical
Foundation; Alex's Lemonade Stand Foundation; Howard Hughes Medical
Institute; NIH
FX N.S.C. is supported by the NSS Scholarship from the Agency for Science,
Technology and Research, Singapore. G.Q.D. is supported by the National
Institutes of Health (NIH), the Ellison Medical Foundation and Alex's
Lemonade Stand Foundation and is an investigator of the Howard Hughes
Medical Institute. L.C.C. is supported by a grant from the NIH.
Deposited in PMC for release after 12 months.
NR 127
TC 122
Z9 126
U1 7
U2 79
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
J9 DEVELOPMENT
JI Development
PD JUN 15
PY 2013
VL 140
IS 12
BP 2535
EP 2547
DI 10.1242/dev.091777
PG 13
WC Developmental Biology
SC Developmental Biology
GA 154EY
UT WOS:000319655800013
PM 23715547
ER
PT J
AU Kote-Jarai, Z
Saunders, EJ
Leongamornlert, DA
Tymrakiewicz, M
Dadaev, T
Jugurnauth-Little, S
Ross-Adams, H
Al Olama, AA
Benlloch, S
Halim, S
Russel, R
Dunning, AM
Luccarini, C
Dennis, J
Neal, DE
Hamdy, FC
Donovan, JL
Muir, K
Giles, GG
Severi, G
Wiklund, F
Gronberg, H
Haiman, CA
Schumacher, F
Henderson, BE
Le Marchand, L
Lindstrom, S
Kraft, P
Hunter, DJ
Gapstur, S
Chanock, S
Berndt, SI
Albanes, D
Andriole, G
Schleutker, J
Weischer, M
Canzian, F
Riboli, E
Key, TJ
Travis, RC
Campa, D
Ingles, SA
John, EM
Hayes, RB
Pharoah, P
Khaw, KT
Stanford, JL
Ostrander, EA
Signorello, LB
Thibodeau, SN
Schaid, D
Maier, C
Vogel, W
Kibel, AS
Cybulski, C
Lubinski, J
Cannon-Albright, L
Brenner, H
Park, JY
Kaneva, R
Batra, J
Spurdle, A
Clements, JA
Teixeira, MR
Govindasami, K
Guy, M
Wilkinson, RA
Sawyer, EJ
Morgan, A
Dicks, E
Baynes, C
Conroy, D
Bojesen, SE
Kaaks, R
Vincent, D
Bacot, F
Tessier, DC
Easton, DF
Eeles, RA
AF Kote-Jarai, Zsofia
Saunders, Edward J.
Leongamornlert, Daniel A.
Tymrakiewicz, Malgorzata
Dadaev, Tokhir
Jugurnauth-Little, Sarah
Ross-Adams, Helen
Al Olama, Ali Amin
Benlloch, Sara
Halim, Silvia
Russel, Roslin
Dunning, Alison M.
Luccarini, Craig
Dennis, Joe
Neal, David E.
Hamdy, Freddie C.
Donovan, Jenny L.
Muir, Ken
Giles, Graham G.
Severi, Gianluca
Wiklund, Fredrik
Gronberg, Henrik
Haiman, Christopher A.
Schumacher, Fredrick
Henderson, Brian E.
Le Marchand, Loic
Lindstrom, Sara
Kraft, Peter
Hunter, David J.
Gapstur, Susan
Chanock, Stephen
Berndt, Sonja I.
Albanes, Demetrius
Andriole, Gerald
Schleutker, Johanna
Weischer, Maren
Canzian, Federico
Riboli, Elio
Key, Tim J.
Travis, Ruth C.
Campa, Daniele
Ingles, Sue A.
John, Esther M.
Hayes, Richard B.
Pharoah, Paul
Khaw, Kay-Tee
Stanford, Janet L.
Ostrander, Elaine A.
Signorello, Lisa B.
Thibodeau, Stephen N.
Schaid, Dan
Maier, Christiane
Vogel, Walther
Kibel, Adam S.
Cybulski, Cezary
Lubinski, Jan
Cannon-Albright, Lisa
Brenner, Hermann
Park, Jong Y.
Kaneva, Radka
Batra, Jyotsna
Spurdle, Amanda
Clements, Judith A.
Teixeira, Manuel R.
Govindasami, Koveela
Guy, Michelle
Wilkinson, Rosemary A.
Sawyer, Emma J.
Morgan, Angela
Dicks, Ed
Baynes, Caroline
Conroy, Don
Bojesen, Stig E.
Kaaks, Rudolf
Vincent, Daniel
Bacot, Francois
Tessier, Daniel C.
Easton, Douglas F.
Eeles, Rosalind A.
CA COGS-CRUK GWAS-ELLIPSE Part
UK Genetic Prostate Canc
UK ProtecT Study Collaborators
PRACTICAL Consortium
TI Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one
of which associates with TERT expression
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TELOMERE LENGTH; TERT-CLPTM1L LOCUS; WIDE ASSOCIATION; BREAST-CANCER;
LUNG-CANCER; VARIANTS; HTERT; PROMOTER
AB Associations between single nucleotide polymorphisms (SNPs) at 5p15 and multiple cancer types have been reported. We have previously shown evidence for a strong association between prostate cancer (PrCa) risk and rs2242652 at 5p15, intronic in the telomerase reverse transcriptase (TERT) gene that encodes TERT. To comprehensively evaluate the association between genetic variation across this region and PrCa, we performed a fine-mapping analysis by genotyping 134 SNPs using a custom Illumina iSelect array or Sequenom MassArray iPlex, followed by imputation of 1094 SNPs in 22 301 PrCa cases and 22 320 controls in The PRACTICAL consortium. Multiple stepwise logistic regression analysis identified four signals in the promoter or intronic regions of TERT that independently associated with PrCa risk. Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease.
C1 [Kote-Jarai, Zsofia; Saunders, Edward J.; Leongamornlert, Daniel A.; Tymrakiewicz, Malgorzata; Dadaev, Tokhir; Jugurnauth-Little, Sarah; Govindasami, Koveela; Guy, Michelle; Wilkinson, Rosemary A.; Sawyer, Emma J.; Morgan, Angela; Eeles, Rosalind A.] Inst Canc Res, Oncogenet Team, Sutton SM2 5NG, Surrey, England.
[Ross-Adams, Helen; Halim, Silvia; Russel, Roslin] Cambridge Res Inst, Li Ka Shing Ctr, Canc Res UK, Cambridge CB2 0RE, England.
[Al Olama, Ali Amin; Benlloch, Sara; Dunning, Alison M.; Luccarini, Craig; Dennis, Joe; Pharoah, Paul; Dicks, Ed; Baynes, Caroline; Conroy, Don; Easton, Douglas F.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Strangeways Lab, Cambridge CB1 8RN, England.
[Neal, David E.] Univ Cambridge, Addenbrookes Hosp, Surg Oncol Uro Oncol S4, Cambridge CB2 2QQ, England.
[Neal, David E.] Cambridge Res Inst, Li Ka Shing Ctr, Canc Res UK, Cambridge CB2 2QQ, England.
[Hamdy, Freddie C.] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.
[Hamdy, Freddie C.] Univ Oxford, Fac Med Sci, John Radcliffe Hosp, Oxford OX3 9DU, England.
[Donovan, Jenny L.] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England.
[Muir, Ken] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
[Giles, Graham G.; Severi, Gianluca] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia.
[Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia.
[Wiklund, Fredrik; Gronberg, Henrik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Haiman, Christopher A.; Schumacher, Fredrick; Henderson, Brian E.; Ingles, Sue A.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
[Lindstrom, Sara; Kraft, Peter; Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Gapstur, Susan] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Chanock, Stephen; Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Albanes, Demetrius] NCI, Nutr Epidemiol Branch, NIH, Bethesda, MD 20892 USA.
[Andriole, Gerald] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA.
[Schleutker, Johanna; Campa, Daniele] Univ Turku, Dept Medic Biochem & Genet, Inst Biomed Technol, Turku, Finland.
[Schleutker, Johanna; Campa, Daniele] Univ Tampere, BioMediTech, FIN-33101 Tampere, Finland.
[Schleutker, Johanna; Campa, Daniele] FimLab Labs, Tampere, Finland.
[Weischer, Maren; Bojesen, Stig E.] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-230 Herlev, Denmark.
[Canzian, Federico; Kaaks, Rudolf] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany.
[Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London SW7 2AZ, England.
[Key, Tim J.] Univ Oxford, Nuffield Dept Clin Med, Canc Epidemiol Unit, Oxford, England.
[Travis, Ruth C.; John, Esther M.] Canc Prevent Inst Calif, Fremont, CA USA.
[Travis, Ruth C.; John, Esther M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Hayes, Richard B.] NYU, Inst Canc, Langone Med Ctr, Div Epidemiol,Dept Environm Med, New York, NY USA.
[Khaw, Kay-Tee] Univ Cambridge, Clin Gerontol Unit, Cambridge, England.
[Stanford, Janet L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98195 USA.
[Stanford, Janet L.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Ostrander, Elaine A.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Signorello, Lisa B.] Int Epidemiol Inst, Rockville, MD USA.
[Signorello, Lisa B.] Vanderbilt Univ, Sch Med, Div Epidemiol, Dept Med,Vanderbilt Epidemiol Ctr,Vanderbilt Ingr, Nashville, TN 37212 USA.
[Thibodeau, Stephen N.; Schaid, Dan] Mayo Clin, Rochester, MN USA.
[Maier, Christiane; Vogel, Walther] Univ Hosp Ulm, Dept Urol, Ulm, Germany.
[Maier, Christiane; Vogel, Walther] Univ Hosp Ulm, Inst Human Genet, Ulm, Germany.
[Kibel, Adam S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Div Urol Surg, Boston, MA 02245 USA.
[Cybulski, Cezary; Lubinski, Jan] Pomeranian Med Univ, Int Hereditary Canc Ctr, Dept Genet & Pathol, Szczecin, Poland.
[Cannon-Albright, Lisa] Univ Utah, Sch Med, Div Genet Epidemiol, Dept Med, Salt Lake City, UT 84132 USA.
[Cannon-Albright, Lisa] George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA.
[Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Park, Jong Y.] Univ S Florida, H Lee Moffitt Canc Ctr, Div Canc Prevent & Control, Tampa, FL 33682 USA.
[Kaneva, Radka] Med Univ Sofia, Mol Med Ctr, Sofia 1531, Bulgaria.
[Kaneva, Radka] Med Univ Sofia, Dept Med Chem & Biochem, Sofia 1531, Bulgaria.
[Batra, Jyotsna; Clements, Judith A.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Qld, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia.
[Batra, Jyotsna; Clements, Judith A.] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld 4001, Australia.
[Spurdle, Amanda] Queensland Inst Med Res, Mol Canc Epidemiol Lab, Brisbane, Qld 4006, Australia.
[Teixeira, Manuel R.] Portuguese Oncol Inst, Dept Genet, Oporto, Portugal.
[Teixeira, Manuel R.] Univ Porto, P-4100 Oporto, Portugal.
[Teixeira, Manuel R.] Univ Porto, Biomed Sci Inst ICBAS, P-4100 Oporto, Portugal.
[Vincent, Daniel; Bacot, Francois; Tessier, Daniel C.] Ctr Innovat Genome Quebec, Montreal, PQ H3A 0G1, Canada.
[Vincent, Daniel; Bacot, Francois; Tessier, Daniel C.] McGill Univ, Montreal, PQ H3A 0G1, Canada.
RP Kote-Jarai, Z (reprint author), Inst Canc Res, Oncogenet Team, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.
EM zsofia.kote-jarai@icr.ac.uk
RI Batra, Jyotsna/B-4130-2011; Spurdle, Amanda/A-4978-2011; Albanes,
Demetrius/B-9749-2015; Teixeira, Manuel/E-4885-2011; Campa,
Daniele/K-1617-2016; Brenner, Hermann/B-4627-2017;
OI Leongamornlert, Daniel/0000-0002-3486-3168; Hayes,
Richard/0000-0002-0918-661X; albright, lisa/0000-0003-2602-3668;
Dunning, Alison Margaret/0000-0001-6651-7166; Giles,
Graham/0000-0003-4946-9099; Clements, Judith/0000-0001-6026-1964;
Ostrander, Elaine/0000-0001-6075-9738; Saunders, Ed/0000-0003-4343-3570;
Eeles, Rosalind/0000-0002-3698-6241; Spurdle,
Amanda/0000-0003-1337-7897; Dennis, Joe/0000-0003-4591-1214; Neal,
David/0000-0002-6033-5086; Teixeira, Manuel/0000-0002-4896-5982; Campa,
Daniele/0000-0003-3220-9944; Brenner, Hermann/0000-0002-6129-1572;
Dadaev, Tokhir/0000-0002-8268-0438
FU European Commission [223175 (HEALTH-F2-2009-223175)]; Cancer Research UK
[C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692, C16913/A6135];
National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative [1
U19 CA 148537-01]; Institute of Cancer Research and The Everyman
Campaign; Prostate Action; Orchid Cancer Appeal; National Cancer
Research Network, UK; National Cancer Research Institute (NCRI), UK;
NIHR; Royal Marsden NHS Foundation Trust
FX This work was supported by European Commission's Seventh Framework
Programme grant agreement No. 223175 (HEALTH-F2-2009-223175), Cancer
Research UK Grants C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692,
C16913/A6135 and The National Institute of Health (NIH) Cancer
Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON
initiative). We would like to thank the following for funding support:
The Institute of Cancer Research and The Everyman Campaign, The Prostate
Cancer Research Foundation (now Prostate Action), Prostate Research
Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The
National Cancer Research Network, UK and The National Cancer Research
Institute (NCRI), UK. We are grateful for support of NIHR funding to the
NIHR Biomedical Research Centre at The Institute of Cancer Research and
The Royal Marsden NHS Foundation Trust. Funding to pay the Open Access
publication charges for this article was provided by European
Commission's Seventh Framework Programme grant agreement No. 223175
(HEALTH-F2-2009-223175).
NR 25
TC 58
Z9 59
U1 2
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2013
VL 22
IS 12
BP 2520
EP 2528
DI 10.1093/hmg/ddt086
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 151AK
UT WOS:000319432800017
PM 23535824
ER
PT J
AU Walsh, SR
Wilck, MB
Dominguez, DJ
Zablowsky, E
Bajimaya, S
Gagne, LS
Verrill, KA
Kleinjan, JA
Patel, A
Zhang, Y
Hill, H
Acharyya, A
Fisher, DC
Antin, JH
Seaman, MS
Dolin, R
Baden, LR
AF Walsh, Stephen R.
Wilck, Marissa B.
Dominguez, David J.
Zablowsky, Elise
Bajimaya, Shringkhala
Gagne, Lisa S.
Verrill, Kelly A.
Kleinjan, Jane A.
Patel, Alka
Zhang, Ying
Hill, Heather
Acharyya, Aruna
Fisher, David C.
Antin, Joseph H.
Seaman, Michael S.
Dolin, Raphael
Baden, Lindsey R.
TI Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic
Stem Cell Transplant Recipients: A Randomized, Controlled Trial
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE safety; immunogenicity; dose; stem cell transplant; modified vaccinia
ankara; clinical trial
ID SMALLPOX VACCINATION; VIRUS ANKARA; DRYVAX(R) CHALLENGE;
INFECTIOUS-DISEASES; GENOMIC SEQUENCE; MVA; CANCER; STRAIN;
IMMUNOTHERAPY; INDIVIDUALS
AB Background. Modified vaccinia Ankara (MVA-BN, IMVAMUNE) is emerging as a primary immunogen and as a delivery system to treat or prevent a wide range of diseases. Defining the safety and immunogenicity of MVA-BN in key populations is therefore important.
Methods. We performed a dose-escalation study of MVA-BN administered subcutaneously in 2 doses, one on day 0 and another on day 28. Twenty-four hematopoietic stem cell transplant recipients were enrolled sequentially into the study, and vaccine or placebo was administered under a randomized, double-blind allocation. Ten subjects received vaccine containing 10(7) median tissue culture infective doses (TCID50) of MVA-BN, 10 subjects received vaccine containing 10(8) TCID50 of MVA-BN, and 4 subjects received placebo.
Results. MVA-BN was generally well tolerated at both doses. No vaccine-related serious adverse events were identified. Transient local reactogenicity was more frequently seen at the higher dose. Neutralizing antibodies (NAb) to Vaccinia virus (VACV) were elicited by both doses of MVA-BN and were greater for the higher dose. Median peak anti-VACV NAb titers were 1:49 in the lower-dose group and 1:118 in the higher-dose group. T-cell immune responses to VACV were detected by an interferon gamma enzyme-linked immunosorbent spot assay and were higher in the higher-dose group.
Conclusions. MVA-BN is safe, well tolerated, and immunogenic in HSCT recipients. These data support the use of 10(8) TCID50 of MVA-BN in this population.
Clinical Trials Registration. NCT00565929.
C1 [Walsh, Stephen R.; Wilck, Marissa B.; Gagne, Lisa S.; Verrill, Kelly A.; Kleinjan, Jane A.; Patel, Alka; Dolin, Raphael; Baden, Lindsey R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Walsh, Stephen R.; Dominguez, David J.; Zablowsky, Elise; Bajimaya, Shringkhala; Seaman, Michael S.; Dolin, Raphael] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
[Walsh, Stephen R.; Wilck, Marissa B.; Seaman, Michael S.; Dolin, Raphael; Baden, Lindsey R.] Harvard Univ, Sch Med, Boston, MA USA.
[Fisher, David C.; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Zhang, Ying; Hill, Heather; Acharyya, Aruna] EMMES Corp, Rockville, MD USA.
RP Walsh, SR (reprint author), Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, 3 Blackfan Cir, Boston, MA 02115 USA.
EM srwalsh@bidmc.harvard.edu
FU National Institute of Allergy and Infectious Diseases; National Center
for Advancing Translational Sciences (US Public Health Service) [U54
AI057159, U19 AI057330, UL1 RR025758, K23 AI085181]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases and the National Center for Advancing Translational
Sciences (US Public Health Service grants U54 AI057159, U19 AI057330,
UL1 RR025758, and K23 AI085181).
NR 37
TC 11
Z9 12
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 15
PY 2013
VL 207
IS 12
BP 1888
EP 1897
DI 10.1093/infdis/jit105
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 151PI
UT WOS:000319472200014
PM 23482644
ER
PT J
AU Ashburner, J
Go, A
Reynolds, K
Chang, YC
Fang, M
Applebaum, K
Fredman, L
Singer, D
AF Ashburner, Jeffrey
Go, Alan
Reynolds, Kristi
Chang, Yuchiao
Fang, Margaret
Applebaum, Kate
Fredman, Lisa
Singer, Daniel
TI WARFARIN ANTICOAGULATION THERAPY AND MORTALITY FOLLOWING
GASTROINTESTINAL HEMORRHAGE IN PATIENTS WITH ATRIAL FIBRILLATION IN
CLINICAL CARE: THE ATRIA AND ATRIA-CVRN COHORTS.
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 Boston Univ, Sch Publ Hlth, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S127
EP S127
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300501
ER
PT J
AU Dunn, E
Richmond, T
Milliren, C
Subramanian, SV
AF Dunn, Erin
Richmond, Tracy
Milliren, Carly
Subramanian, S. V.
TI THE "MISSING LEVEL" PROBLEM IN MULTILEVEL STUDIES: EVIDENCE THAT
CROSS-CLASSIFIED MULTILEVEL MODELS ARE PREFERRED TO TRADITIONAL
MULTILEVEL MODELS.
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Dunn, Erin; Richmond, Tracy; Milliren, Carly; Subramanian, S. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S153
EP S153
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300602
ER
PT J
AU Dunn, E
McLaughlin, K
Slopen, N
Rosand, J
Smoller, J
AF Dunn, Erin
McLaughlin, Katie
Slopen, Natalie
Rosand, Jonathan
Smoller, Jordan
TI ASSOCIATION BETWEEN DEVELOPMENTAL TIMING OF EXPOSURE TO CHILD
MALTREATMENT AND SYMPTOMS OF DEPRESSION AND SUICIDALITY: EVIDENCE OF A
SENSITIVE PERIOD?
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Dunn, Erin; McLaughlin, Katie; Slopen, Natalie; Rosand, Jonathan; Smoller, Jordan] Massachusetts Gen Hosp, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S27
EP S27
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300108
ER
PT J
AU Fonda, J
Lippa, S
Fortier, C
Milberg, W
McGlinchey, R
AF Fonda, Jennifer
Lippa, Sara
Fortier, Catherine
Milberg, William
McGlinchey, Regina
TI POLYMORBIDITY: LOOKING BEYOND PTSD AND TBI IN RETURNING SERVICE MEMBERS
AND VETERANS
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Fonda, Jennifer; Lippa, Sara; Fortier, Catherine; Milberg, William; McGlinchey, Regina] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S29
EP S29
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300116
ER
PT J
AU Littman, AJ
Thompson, ML
Boyko, EJ
Arterburn, DE
AF Littman, Alyson J.
Thompson, Mary Lou
Boyko, Edward J.
Arterburn, David E.
TI USE OF BODY WEIGHTS FROM ELECTRONIC MEDICAL RECORDS: OPPORTUNITIES AND
CHALLENGES.
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Littman, Alyson J.; Thompson, Mary Lou; Boyko, Edward J.; Arterburn, David E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S72
EP S72
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300287
ER
PT J
AU Thwin, SS
Clough-Gorr, K
Raju, S
Kosik, N
Cho, K
Hermos, J
Gaziano, M
AF Thwin, Soe Soe
Clough-Gorr, Kerri
Raju, Sanjay
Kosik, Nicole
Cho, Kelly
Hermos, John
Gaziano, Michael
TI TREATMENT DECISION-MAKING IN VETERANS WITH EARLY STAGE PROSTATE CANCER.
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Thwin, Soe Soe; Clough-Gorr, Kerri; Raju, Sanjay; Kosik, Nicole; Cho, Kelly; Hermos, John; Gaziano, Michael] VA Boston Healthcare Syst, Boston, MA 02130 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S176
EP S176
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300695
ER
PT J
AU Winston, C
Lucero-Obusan, C
Schirmer, P
Holodniy, M
AF Winston, Carla
Lucero-Obusan, Cynthia
Schirmer, Patricia
Holodniy, Mark
TI PREDICTING INFLUENZA ADMISSIONS AMONG VETERANS FROM TELEPHONE TRIAGE
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Meeting Abstract
C1 [Winston, Carla; Lucero-Obusan, Cynthia; Schirmer, Patricia; Holodniy, Mark] US Dept Vet Affairs, Palo Alto, CA 94304 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 15
PY 2013
VL 177
SU 11
BP S111
EP S111
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 157BL
UT WOS:000319870300439
ER
PT J
AU Albadawi, H
Haurani, MJ
Oklu, R
Trubiano, JP
Laub, PJ
Yoo, HJ
Watkins, MT
AF Albadawi, Hassan
Haurani, Mounir J.
Oklu, Rahmi
Trubiano, Jordan P.
Laub, Peter J.
Yoo, Hyung-Jin
Watkins, Michael T.
TI Differential effect of zoledronic acid on human vascular smooth muscle
cells
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Vascular smooth muscle; Intimal hyperplasia; Bisphosphonates
ID INTIMAL HYPERPLASIA; POLY(ADP-RIBOSE) POLYMERASE; ATP ANALOG;
DNA-REPLICATION; CANCER-PATIENTS; BREAST-CANCER; IN-VITRO;
BISPHOSPHONATE; RABBITS; CLODRONATE
AB Introduction: The activation of human vascular smooth muscle cell proliferation, adhesion and migration is essential for intimal hyperplasia formation. These experiments were designed to test whether zoledronic acid (ZA) would modulate indices of human smooth muscle cell activation, exert differential effects on proliferating versus quiescent cells, and determine whether these effects were dependent on GTPase binding proteins prenylation. ZA was chosen for testing in these experiments because it is clinically used in humans with cancer, and has been shown to modulate rat smooth muscle cell proliferation and migration.
Methods: Human aortic smooth muscle cells (HASMC) were cultured under either proliferating or growth arrest (quiescent) conditions in the presence or absence of ZA for 48 hours, whereupon the effect of ZA on HASMC proliferation, cellular viability, metabolic activity, and membrane integrity were compared. In addition, the effect of ZA on adhesion and migration were assessed in proliferating cells. The effect of increased concentration of ZA on the mevalonate pathway and genomic/cellular stress related poly-adenosine diphosphate ribose polymerase enzyme activity were assessed using the relative prenylation of Rap-1A/B protein and the formation of poly adenosine diphosphate-ribosylated protein, respectively.
Results: There was a dose dependent inhibition of cellular proliferation, adhesion and migration following ZA treatment. ZA treatment decreased indices of cellular viability and significantly increased membrane injury in proliferating versus quiescent cells. This was correlated with the appearance of unprenylated Rap-1A protein and dose dependent down regulation of activity.
Conclusions: These data suggest that ZA is effective in inhibiting HASMC proliferation, adhesion, and migration, which coincide with the appearance of unprenylated RAP-1A/B protein, thereby suggesting that the mevalonate pathway may play a role in the inhibition of HASMC activation. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Albadawi, Hassan; Haurani, Mounir J.; Trubiano, Jordan P.; Laub, Peter J.; Yoo, Hyung-Jin; Watkins, Michael T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
[Oklu, Rahmi] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Vasc Intervent Radiol, Boston, MA 02114 USA.
RP Watkins, MT (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,Suite 440, Boston, MA 02114 USA.
EM mtwatkins@partners.org
RI Haurani, Mounir/F-5802-2012;
OI Haurani, Mounir/0000-0003-3984-3366
FU National Institutes of Health [1R01AR055843]; American Diabetes
Association; Pacific Vascular Research Foundation; Department of
Surgery, Division of Vascular and Endovascular Surgery, Massachusetts
General Hospital
FX The authors acknowledge funding from the National Institutes of Health
(1R01AR055843), the American Diabetes Association, the Pacific Vascular
Research Foundation and the Department of Surgery, Division of Vascular
and Endovascular Surgery, Massachusetts General Hospital (the Geneen
Fund). M.W. is a Ronnie Isenberg Scholar in Academic Surgery at the
Massachusetts General Hospital.
NR 48
TC 3
Z9 3
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUN 15
PY 2013
VL 182
IS 2
BP 339
EP 346
DI 10.1016/j.jss.2012.10.033
PG 8
WC Surgery
SC Surgery
GA 143ZI
UT WOS:000318907900030
PM 23164362
ER
PT J
AU Kuwahara, Y
Mora-Blanco, EL
Banine, F
Rogers, AB
Fletcher, C
Sherman, LS
Roberts, CWM
Weissman, BE
AF Kuwahara, Yasumichi
Mora-Blanco, E. Lorena
Banine, Fatima
Rogers, Arlin B.
Fletcher, Christopher
Sherman, Larry S.
Roberts, Charles W. M.
Weissman, Bernard E.
TI Establishment and characterization of MRT cell lines from genetically
engineered mouse models and the influence of genetic background on their
development
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE pediatric cancers; SWI; SNF complex; mouse models of cancer; SNF5/INI1
ID MALIGNANT RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; STEM-CELL; TARGETED
DISRUPTION; MUTATIONAL ANALYSIS; T-ANTIGEN; IN-VIVO; HSNF5/INI1; CANCER;
SNF5
AB Malignant rhabdoid tumors (MRTs) are rare, aggressive cancers occuring in young children primarily through inactivation of the SNF5(INI1, SMARCB1) tumor suppressor gene. We and others have demonstrated that mice heterozygous for a Snf5 null allele develop MRTs with partial penetrance. We have also shown that Snf5+/ mice that lack expression of the pRb family, due to TgT121 transgene expression, develop MRTs with increased penetrance and decreased latency. Here, we report that altering the genetic background has substantial effects upon MRT development in Snf5+/- and TgT121;Snf5+/ mice, with a mixed F1 background resulting in increased latency and the appearance of brain tumors. We also report the establishment of the first mouse MRT cell lines that recapitulate many features of their human counterparts. Our studies provide further insight into the genetic influences on MRT development as well as provide valuable new cell culture and genetically engineered mouse models for the study of CNS-MRT etiology.
C1 [Kuwahara, Yasumichi; Rogers, Arlin B.; Weissman, Bernard E.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Harvard Univ, Boston, MA 02115 USA.
[Banine, Fatima; Sherman, Larry S.] Oregon Hlth & Sci Univ, Natl Primate Res Ctr, Div Neurosci, Beaverton, OR USA.
[Rogers, Arlin B.; Weissman, Bernard E.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
[Fletcher, Christopher] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Weissman, BE (reprint author), Univ N Carolina, Lineberger Canc Ctr, Room 32-048, Chapel Hill, NC 27599 USA.
EM weissman@med.unc.edu
FU PHS [R01CA091048, R01CA113794, U01CA105423, RR00163]; Garrett B. Smith
Foundation; Cure AT/RT Now fund; Children's Tumor Foundation
FX We wish to thank Mr. Nisarg Desai for excellent help with the genotyping
studies and the UNC-Lineberger Animal Studies Core for their help with
the in vivo tumorigenicity studies. The work was supported by PHS awards
R01CA091048 (B. E. W.), R01CA113794 and U01CA105423 (C. W. M. R.) and
RR00163 (L. S. S.). Dr. Roberts also gratefully acknowledges support
from The Garrett B. Smith Foundation and the Cure AT/RT Now fund. Dr.
Sherman also gratefully acknowledges support from the Children's Tumor
Foundation.
NR 49
TC 0
Z9 0
U1 0
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 15
PY 2013
VL 132
IS 12
BP 2767
EP 2777
DI 10.1002/ijc.27976
PG 11
WC Oncology
SC Oncology
GA 126DV
UT WOS:000317593100006
PM 23197309
ER
PT J
AU Francis, SA
Daly, C
Heydari, B
Abbasi, S
Shah, RV
Kwong, RY
AF Francis, Sanjeev A.
Daly, Caroline
Heydari, Bobak
Abbasi, Siddique
Shah, Ravi V.
Kwong, Raymond Y.
TI Cost-effectiveness analysis for imaging techniques with a focus on
cardiovascular magnetic resonance
SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
LA English
DT Review
ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; HEART-DISEASE;
UNITED-STATES; CHEST-PAIN; STRESS MRI; CE-MARC; DIAGNOSIS; HEALTH;
ANGIOGRAPHY
AB With the need for healthcare cost-containment, increased scrutiny will be placed on new medical therapeutic or diagnostic technologies. Several challenges exist for a new diagnostic test to demonstrate cost-effectiveness. New diagnostic tests differ from therapeutic procedures due to the fact that diagnostic tests do not generally directly affect long-term patient outcomes. Instead, the results of diagnostic tests can influence management decisions for patients and by this route, diagnostic tests indirectly affect long-term outcomes. The benefits from a specific diagnostic technology depend therefore not only on its performance characteristics, but also on other factors such as prevalence of disease, and effectiveness of existing treatments for the disease of interest. We review the concepts and theories of cost-effectiveness analyses (CEA) as they apply to diagnostic tests in general. The limitations of CEA across different study designs and geographic regions are discussed, and we also examine the strengths and weakness of the existing publications where CMR was the focus of CEA compared to other diagnostic options.
C1 [Heydari, Bobak; Abbasi, Siddique; Shah, Ravi V.; Kwong, Raymond Y.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Francis, Sanjeev A.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Daly, Caroline] St James Hosp, Div Cardiol, Dublin 8, Ireland.
RP Kwong, RY (reprint author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
EM rykwong@partners.org
OI Abbasi, Siddique/0000-0002-9601-7565
NR 51
TC 11
Z9 11
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1097-6647
J9 J CARDIOVASC MAGN R
JI J. Cardiov. Magn. Reson.
PD JUN 14
PY 2013
VL 15
AR 52
DI 10.1186/1532-429X-15-52
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 180FK
UT WOS:000321578800001
PM 23767423
ER
PT J
AU Campbell, KN
Wong, JS
Gupta, R
Asanuma, K
Sudol, M
He, JC
Mundel, P
AF Campbell, Kirk N.
Wong, Jenny S.
Gupta, Ritu
Asanuma, Katsuhiko
Sudol, Marius
He, John Cijiang
Mundel, Peter
TI Yes-associated Protein (YAP) Promotes Cell Survival by Inhibiting
Proapoptotic Dendrin Signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DOMAIN-CONTAINING PROTEIN; WW DOMAIN; INDUCED APOPTOSIS; RAT-BRAIN;
HIPPO; PODOCYTES; PATHWAY; KIBRA; DROSOPHILA; GENE
AB Kidney podocytes are highly specialized terminally differentiated cells that form the final barrier to urinary protein loss. Podocytes are a target for injury by metabolic, autoimmune, hereditary, inflammatory, and other stressors. Persistence of podocyte injury leads to podocyte death and loss, which results in progressive kidney damage and ultimately kidney failure. Dendrin is a dual compartment protein with proapoptotic signaling properties. Nuclear relocation of dendrin in response to glomerular injury promotes podocyte apoptosis. Here we show that Yes-associated protein (YAP), a downstream target of Hippo kinases and an inhibitor of apoptosis, is expressed in the nucleus of podocytes. The WW domains of YAP mediate the interaction with the PPXY motifs of dendrin. This interaction is functionally relevant because YAP binding to dendrin reduces dendrin-dependent, staurosporine-induced apoptosis in co-transfected HEK293 cells. Moreover gene silencing of YAP in podocytes increases adriamycin-induced podocyte apoptosis. It also increases staurosporine-induced caspase-3/7 activity, which is rescued by dendrin depletion in YAP knockdown cells. Our findings elucidate YAP binding to dendrin as a prosurvival mechanism. The antiapoptotic signaling properties of YAP in podocytes could hold significance in the quest for targeted therapeutics aimed at preventing podocyte loss.
C1 [Campbell, Kirk N.; Wong, Jenny S.; Sudol, Marius; He, John Cijiang] Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA.
[Gupta, Ritu] Yale New Haven Med Ctr, Dept Med, New Haven, CT 06511 USA.
[Asanuma, Katsuhiko] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Lab Kidney Res,TMK Project, Kyoto 6068501, Japan.
[Sudol, Marius] Weis Ctr Res, Danville, PA 17822 USA.
[Mundel, Peter] Massachusetts Gen Hosp, Dept Med, Boston, MA 02129 USA.
[Mundel, Peter] Harvard Univ, Sch Med, Boston, MA 02129 USA.
RP Campbell, KN (reprint author), Mt Sinai Sch Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.
EM kirk.campbell@mssm.edu; mundel.peter@mgh.harvard.edu
FU National Institutes of Health [DK57683, DK062472, DK09368201, DK081617];
NephCure Young Investigator grant; PA Breast Cancer Coalition [60707,
920093]; Geisinger Clinic
FX This work was supported, in whole or in part, by National Institutes of
Health Grants DK57683, DK062472, and DK09368201 (to P. M.), National
Institutes of Health Grant DK081617 (to K. N. C.). This work was also
supported by a NephCure Young Investigator grant (to K. N. C.) and by PA
Breast Cancer Coalition Grants 60707 and 920093 and by a grant from the
Geisinger Clinic (to M. S.).
NR 38
TC 12
Z9 12
U1 1
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 14
PY 2013
VL 288
IS 24
BP 17057
EP 17062
DI 10.1074/jbc.C113.457390
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 164AH
UT WOS:000320380600002
PM 23667252
ER
PT J
AU Onal, M
Piemontese, M
Xiong, JH
Wang, YY
Han, L
Ye, SQ
Komatsu, M
Selig, M
Weinstein, RS
Zhao, HB
Jilka, RL
Almeida, M
Manolagas, SC
O'Brien, CA
AF Onal, Melda
Piemontese, Marilina
Xiong, Jinhu
Wang, Yiying
Han, Li
Ye, Shiqiao
Komatsu, Masaaki
Selig, Martin
Weinstein, Robert S.
Zhao, Haibo
Jilka, Robert L.
Almeida, Maria
Manolagas, Stavros C.
O'Brien, Charles A.
TI Suppression of Autophagy in Osteocytes Mimics Skeletal Aging
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRABECULAR BONE LOSS; OSTEOCLAST FORMATION; TARGETED DELETION; RANKL
EXPRESSION; OXIDATIVE STRESS; BMP ANTAGONIST; MICE; CELLS; GENE;
OSTEOPOROSIS
AB Bone mass declines with age but the mechanisms responsible remain unclear. Here we demonstrate that deletion of a conditional allele for Atg7, a gene essential for autophagy, from osteocytes caused low bone mass in 6-month-old male and female mice. Cancellous bone volume and cortical thickness were decreased, and cortical porosity increased, in conditional knock-out mice compared with control littermates. These changes were associated with low osteoclast number, osteoblast number, bone formation rate, and wall width in the cancellous bone of conditional knock-out mice. In addition, oxidative stress was higher in the bones of conditional knock-out mice as measured by reactive oxygen species levels in the bone marrow and by p66(shc) phosphorylation in L6 vertebra. Each of these changes has been previously demonstrated in the bones of old versus young adult mice. Thus, these results demonstrate that suppression of autophagy in osteocytes mimics, in many aspects, the impact of aging on the skeleton and suggest that a decline in autophagy with age may contribute to the low bone mass associated with aging.
C1 [Onal, Melda; Piemontese, Marilina; Xiong, Jinhu; Wang, Yiying; Han, Li; Ye, Shiqiao; Weinstein, Robert S.; Zhao, Haibo; Jilka, Robert L.; Almeida, Maria; Manolagas, Stavros C.; O'Brien, Charles A.] Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA.
[Onal, Melda; Piemontese, Marilina; Xiong, Jinhu; Wang, Yiying; Han, Li; Ye, Shiqiao; Weinstein, Robert S.; Zhao, Haibo; Jilka, Robert L.; Almeida, Maria; Manolagas, Stavros C.; O'Brien, Charles A.] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA.
[Komatsu, Masaaki] Tokyo Metropolitan Inst Med Sci, Prot Metab Project, Tokyo 1568506, Japan.
[Selig, Martin] Massachusetts Gen Hosp, Pathol Serv, Electron Microscopy Unit, Boston, MA 02114 USA.
[Selig, Martin] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP O'Brien, CA (reprint author), Univ Arkansas Med Sci, 4301 W Markham St,MS 587, Little Rock, AR 72205 USA.
EM caobrien@uams.edu
RI xiong, jinhu/E-1849-2011; Liu, Juan/J-5155-2015; Ye, Shiqiao/N-2873-2015
OI Ye, Shiqiao/0000-0003-1529-7102
FU National Institutes of Health [AG13918, AR049794]; Central Arkansas
Veteran's Healthcare System [1I01BX000294]; UAMS Translational Research
Institute [UL1RR029884]; UAMS tobacco settlement funds
FX This work was supported by National Institutes of Health Grants AG13918
(to S. C. M.) and AR049794 (to C. A. O.) and the Central Arkansas
Veteran's Healthcare System (Merit Review 1I01BX000294, to C. A. O.).
Additional support was provided by the UAMS Translational Research
Institute (UL1RR029884) and by UAMS tobacco settlement funds.
NR 53
TC 43
Z9 45
U1 1
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 14
PY 2013
VL 288
IS 24
BP 17432
EP 17440
DI 10.1074/jbc.M112.444190
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 164AH
UT WOS:000320380600035
PM 23645674
ER
PT J
AU Zhang, YY
Wang, JF
Wheat, J
Chen, X
Jin, S
Sadrzadeh, H
Fathi, AT
Peterson, RT
Kung, AL
Sweetser, DA
Yeh, JRJ
AF Zhang, Yiyun
Wang, Jianfeng
Wheat, Justin
Chen, Xi
Jin, Shan
Sadrzadeh, Hossein
Fathi, Amir T.
Peterson, Randall T.
Kung, Andrew L.
Sweetser, David A.
Yeh, Jing-Ruey Joanna
TI AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through
a COX/beta-catenin signaling pathway
SO BLOOD
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; NONSTEROIDAL ANTIINFLAMMATORY DRUG;
BETA-CATENIN; STEM-CELLS; REGULATES EXPRESSION; COLORECTAL-CANCER;
LONG-TERM; DIFFERENTIATION; TRANSLOCATION; DISEASE
AB Developing novel therapies that suppress self-renewal of leukemia stem cells may reduce the likelihood of relapses and extend long-term survival of patients with acute myelogenous leukemia (AML). AML1-ETO (AE) is an oncogene that plays an important role in inducing self-renewal of hematopoietic stem/progenitor cells (HSPCs), leading to the development of leukemia stem cells. Previously, using a zebrafish model of AE and a whole-organism chemical suppressor screen, we have discovered that AE induces specific hematopoietic phenotypes in embryonic zebrafish through a cyclooxygenase (COX)-2 and beta-catenin-dependent pathway. Here, we show that AE also induces expression of the Cox-2 gene and activates beta-catenin in mouse bone marrow cells. Inhibition of COX suppresses beta-catenin activation and serial replating of AE(+) mouse HSPCs. Genetic knockdown of beta-catenin also abrogates the clonogenic growth of AE(+) mouse HSPCs and human leukemia cells. In addition, treatment with nimesulide, a COX-2 selective inhibitor, dramatically suppresses xenograft tumor formation and inhibits in vivo progression of human leukemia cells. In summary, our data indicate an important role of a COX/beta-catenin-dependent signaling pathway in tumor initiation, growth, and self-renewal, and in providing the rationale for testing potential benefits from common COX inhibitors as a part of AML treatments.
C1 [Zhang, Yiyun; Jin, Shan; Peterson, Randall T.; Yeh, Jing-Ruey Joanna] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Zhang, Yiyun; Wang, Jianfeng; Jin, Shan; Fathi, Amir T.; Peterson, Randall T.; Sweetser, David A.; Yeh, Jing-Ruey Joanna] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Wang, Jianfeng; Wheat, Justin; Chen, Xi; Sweetser, David A.] Massachusetts Gen Hosp, Dept Pediat, Div Pediat Hematol Oncol, Boston, MA 02114 USA.
[Wang, Jianfeng; Wheat, Justin; Chen, Xi; Sweetser, David A.] Massachusetts Gen Hosp, Dept Pediat, Div Med Genet, Boston, MA 02114 USA.
[Sadrzadeh, Hossein; Fathi, Amir T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Peterson, Randall T.; Kung, Andrew L.] Broad Inst, Cambridge, MA USA.
[Kung, Andrew L.] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA.
RP Yeh, JRJ (reprint author), 149 13th St,149-4201, Charlestown, MA 02129 USA.
EM dsweetser@partners.org; jyeh1@partners.org
FU National Institutes of Health [K01 AG031300, R01 CA140188, R01 CA115772,
T32 CA071345]; Hundai Hope on Wheels; Mattina Proctor Foundation;
Massachusetts General Hospital Claflin Distinguished Scholar Award
FX This work was supported by grants from the National Institutes of Health
(K01 AG031300 [J.-R.J.Y.], R01 CA140188 [J.-R.J.Y., D. A. S., R. T. P.,
and Y.Z.], R01 CA115772 [D. A. S., X. C., and J.W.], and T32 CA071345
[J.W.]); Hundai Hope on Wheels (D. A. S.); the Mattina Proctor
Foundation (D. A. S.); and the Massachusetts General Hospital Claflin
Distinguished Scholar Award (J.-R.J.Y.).
NR 50
TC 17
Z9 19
U1 2
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 13
PY 2013
VL 121
IS 24
BP 4906
EP 4916
DI 10.1182/blood-2012-08-447763
PG 11
WC Hematology
SC Hematology
GA 184NB
UT WOS:000321896300018
PM 23645839
ER
PT J
AU DiNardo, CD
Propert, KJ
Loren, AW
Paietta, E
Sun, ZX
Levine, RL
Straley, KS
Yen, K
Patel, JP
Agresta, S
Abdel-Wahab, O
Perl, AE
Litzow, MR
Rowe, JM
Lazarus, HM
Fernandez, HF
Margolis, DJ
Tallman, MS
Luger, SM
Carroll, M
AF DiNardo, Courtney D.
Propert, Kathleen J.
Loren, Alison W.
Paietta, Elisabeth
Sun, Zhuoxin
Levine, Ross L.
Straley, Kimberly S.
Yen, Katharine
Patel, Jay P.
Agresta, Samuel
Abdel-Wahab, Omar
Perl, Alexander E.
Litzow, Mark R.
Rowe, Jacob M.
Lazarus, Hillard M.
Fernandez, Hugo F.
Margolis, David J.
Tallman, Martin S.
Luger, Selina M.
Carroll, Martin
TI Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase
mutations and clinical outcome in acute myeloid leukemia
SO BLOOD
LA English
DT Article
ID IDH2 MUTATIONS; PROGNOSTIC-SIGNIFICANCE; MOLECULAR ALTERATIONS;
ONCOLOGY-GROUP; AML; DIFFERENTIATION; PREVALENCE; FREQUENT; GROWTH;
GENES
AB Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the metabolite 2-hydroxyglutarate (2HG), but the clinical utility of 2HG has not been established. We studied whether 2HG measurements in acute myeloid leukemia (AML) patients correlate with IDH mutations, and whether diagnostic or remission 2HG measurements predict survival. Sera from 223 de novo AML patients were analyzed for 2HG concentration by reverse-phase liquid chromatography-mass spectrometry. Pretreatment 2HG levels ranged from 10 to 30 000 ng/mL and were elevated in IDH-mutants (median, 3004 ng/mL), compared to wild-type IDH (median, 61 ng/mL) (P < .0005). 2HG levels did not differ among IDH1 or IDH2 allelic variants. In receiver operating characteristic analysis, a discriminatory level of 700 ng/mL optimally segregated patients with and without IDH mutations, and on subsequent mutational analysis of the 13 IDH wild-type samples with 2HG levels >700 ng/mL, 9 were identified to have IDH mutations. IDH-mutant patients with 2HG levels >200 at complete remission had shorter overall survival compared to 2HG <= 200 ng/mL (hazard ratio, 3.9; P = .02). We establish a firm association between IDH mutations and serum 2HG concentration in AML, and confirm that serum oncometabolite measurements provide useful diagnostic and prognostic information that can improve patient selection for IDH-targeted therapies.
C1 [DiNardo, Courtney D.; Propert, Kathleen J.; Loren, Alison W.; Perl, Alexander E.; Margolis, David J.; Luger, Selina M.; Carroll, Martin] Univ Penn, Philadelphia, PA 19104 USA.
[Paietta, Elisabeth] Montefiore Med Ctr, Albert Einstein Coll Med, North Div, Bronx, NY 10467 USA.
[Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Levine, Ross L.; Patel, Jay P.; Abdel-Wahab, Omar; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Straley, Kimberly S.; Yen, Katharine; Agresta, Samuel] Agios, Cambridge, MA USA.
[Litzow, Mark R.] Mayo Clin, Rochester, MN USA.
[Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel.
[Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
[Fernandez, Hugo F.] H Lee Moffitt Canc Inst, Tampa, FL USA.
RP Carroll, M (reprint author), Hosp Univ Penn, Div Hematol Oncol, Rm 708 BRB 2-3, Philadelphia, PA 19146 USA.
EM carroll2@mail.med.upenn.edu
OI Abdel-Wahab, Omar/0000-0002-3907-6171
FU National Institutes of Health Cancer Clinical Epidemiology Training
Grant [T32 CA 009679]; National Institutes of Health National Cancer
Institute Grant [RO1 CA149566]; VA Merit Award [1I01BX000918]
FX This work was supported by the National Institutes of Health Cancer
Clinical Epidemiology Training Grant (T32 CA 009679) (C. D. D.) and by
the National Institutes of Health National Cancer Institute Grant (RO1
CA149566) and VA Merit Award 1I01BX000918 (M.C.).
NR 37
TC 55
Z9 57
U1 1
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 13
PY 2013
VL 121
IS 24
BP 4917
EP 4924
DI 10.1182/blood-2013-03-493197
PG 8
WC Hematology
SC Hematology
GA 184NB
UT WOS:000321896300019
PM 23641016
ER
PT J
AU Wharton, W
Gleason, CE
Miller, VM
Asthana, S
AF Wharton, Whitney
Gleason, Carey E.
Miller, Virginia M.
Asthana, Sanjay
TI Rationale and design of the Kronos Early Estrogen Prevention Study
(KEEPS) and the KEEPS cognitive and affective sub study (KEEPS Cog)
SO BRAIN RESEARCH
LA English
DT Article
DE Hormone therapy; Clinical trial; KEEPS; Estrogen; Alzheimer's disease;
Cognition; Menopause
ID CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; HEALTH
INITIATIVE MEMORY; ORAL MICRONIZED PROGESTERONE; RANDOMIZED
CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; PLUS
PROGESTIN; ALZHEIMER-DISEASE; CACHE COUNTY
AB This manuscript describes the study design and rationalle for the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective ancillary study (KEEPS Cog). KEEPS is a multicenter, randomized, double-blinded, placebo-controlled trial, designed to test the hypothesis that low-dose hormone therapy (HT) initiated in recently postmenopausal women will reduce the progression of subclinical atherosclerosis as measured by carotid artery intima-media thickness (CIMT) and coronary artery calcification (CAC) over four years. The KEEPS Cog ancillary study was designed to assess potential estrogenic treatment effects on cognition and mood. We present the KEEPS trial in the context of issues raised by the Women's Health Initiative (WHI) and the Women's Health Initiative Memory Study (WHIMS). Here we also describe the most recent results and ongoing HT-related research studies designed to address similar issues.
This article is part of a Special Issue entitled Hormone Therapy. (C) 2013 Published by Elsevier B.V.
C1 [Wharton, Whitney; Gleason, Carey E.; Asthana, Sanjay] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA.
[Gleason, Carey E.; Asthana, Sanjay] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
[Wharton, Whitney; Gleason, Carey E.; Asthana, Sanjay] Wisconsin Alzheimers Dis Res Ctr ADRC, Madison, WI 53792 USA.
[Miller, Virginia M.] Mayo Clin, Rochester, MN 55905 USA.
RP Wharton, W (reprint author), Univ Wisconsin, Dept Med & Publ Hlth, 2500 Overlook Terrace,VA Hosp GRECC D4243, Madison, WI 53705 USA.
EM wlwharto@medicine.wisc.edu
FU NIA NIH HHS [P50 AG033514]
NR 32
TC 20
Z9 21
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD JUN 13
PY 2013
VL 1514
SI SI
BP 12
EP 17
DI 10.1016/j.brainres.2013.04.011
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 180KV
UT WOS:000321595000003
PM 23603409
ER
PT J
AU Liu, Y
Quang, P
Braggio, E
Ngo, H
Badalian-Very, G
Flores, L
Zhang, Y
Sacco, A
Maiso, P
Azab, AK
Azab, F
Carrasco, R
Rollins, BJ
Roccaro, AM
Ghobrial, IM
AF Liu, Yang
Phong Quang
Braggio, Esteban
Hai Ngo
Badalian-Very, Gayane
Flores, Ludmila
Zhang, Yong
Sacco, Antonio
Maiso, Patricia
Azab, Abdel Kareem
Azab, Feda
Carrasco, Ruben
Rollins, Barrett J.
Roccaro, Aldo M.
Ghobrial, Irene M.
TI Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor
GITR in Multiple Myeloma
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; NK CELLS; T-CELLS; SUPERFAMILY; PATHWAY; ACTIVATION;
BIOLOGY; LIGAND; CANCER; NEUROBLASTOMA
AB Glucocorticoid-induced TNF receptor (GITR) plays a crucial role in modulating immune response and inflammation, however the role of GITR in human cancers is poorly understood. In this study, we demonstrated that GITR is inactivated during tumor progression in Multiple Myeloma (MM) through promoter CpG island methylation, mediating gene silencing in primary MM plasma cells and MM cell lines. Restoration of GITR expression in GITR deficient MM cells led to inhibition of MM proliferation in vitro and in vivo and induction of apoptosis. These findings were supported by the presence of induction of p21 and PUMA, two direct downstream targets of p53, together with modulation of NF-kappa B in GITR-overexpressing MM cells. Moreover, the unbalanced expression of GITR in clonal plasma cells correlated with MM disease progression, poor prognosis and survival. These findings provide novel insights into the pivotal role of GITR in MM pathogenesis and disease progression.
C1 [Liu, Yang; Phong Quang; Hai Ngo; Badalian-Very, Gayane; Flores, Ludmila; Zhang, Yong; Sacco, Antonio; Maiso, Patricia; Azab, Abdel Kareem; Azab, Feda; Carrasco, Ruben; Rollins, Barrett J.; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02114 USA.
[Braggio, Esteban] Mayo Clin, Coll Med, Div Haematol, Dept Med, Scottsdale, AZ USA.
RP Ghobrial, IM (reprint author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02114 USA.
EM irene_ghobrial@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016;
OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924;
Roccaro, Aldo/0000-0002-1872-5128
FU NIH [R01CA125690, R01CA133799]
FX This work was supported by NIHR01CA125690 and R01CA133799
NR 38
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 13
PY 2013
VL 8
IS 6
AR e66982
DI 10.1371/journal.pone.0066982
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 172XB
UT WOS:000321038800009
PM 23785514
ER
PT J
AU Elkins, JM
Wang, J
Deng, XM
Pattison, MJ
Arthur, JSC
Erazo, T
Gomez, N
Lizcano, JM
Gray, NS
Knapp, S
AF Elkins, Jonathan M.
Wang, Jing
Deng, Xianming
Pattison, Michael J.
Arthur, J. Simon C.
Erazo, Tatiana
Gomez, Nestor
Lizcano, Jose M.
Gray, Nathanael S.
Knapp, Stefan
TI X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific
Inhibitor
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; TARGETED DELETION; SIGNALING PATHWAY;
MEK5-ERK5 PATHWAY; PROSTATE-CANCER; BREAST-CANCER; GROWTH-FACTOR;
EXPRESSION; BMK1/ERK5; IDENTIFICATION
AB The protein kinase ERK5 (MAPK7) is an emerging drug target for a variety of indications, in particular for cancer where it plays a key role mediating cell proliferation, survival, epithelial-mesenchymal transition, and angiogenesis. To date, no three-dimensional structure has been published that would allow rational design of inhibitors. To address this, we determined the X-ray crystal structure of the human ERK5 kinase domain in complex with a highly specific benzo[e]pyrimido[5,4-b]diazepine-6(11H)-one inhibitor. The structure reveals that specific residue differences in the ATP-binding site, compared to the related ERKs p38s and JNKs, allow for the development of ERK5-specific inhibitors. The selectivity of previously observed ERK5 inhibitors can also be rationalized using this structure, which provides a template for future development of inhibitors with potential for treatment of disease.
C1 [Elkins, Jonathan M.; Wang, Jing; Knapp, Stefan] Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Oxford OX3 7DQ, England.
[Knapp, Stefan] Univ Oxford, TDI, Oxford OX3 7FZ, England.
[Deng, Xianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Deng, Xianming; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Pattison, Michael J.; Arthur, J. Simon C.] Univ Dundee, Coll Life Sci, MRC Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.
[Pattison, Michael J.; Arthur, J. Simon C.] Univ Dundee, Coll Life Sci, Div Cell Signaling & Immunol, Dundee DD1 5EH, Scotland.
[Erazo, Tatiana; Gomez, Nestor; Lizcano, Jose M.] Univ Autonoma Barcelona, Inst Neurociencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain.
RP Knapp, S (reprint author), Univ Oxford, Nuffield Dept Clin Med, Struct Genom Consortium, Old Rd Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
EM stefan.knapp@sgc.ox.ac.uk
RI Gomez, Nestor/I-2522-2015;
OI Gomez, Nestor/0000-0002-1348-2737; Pattison,
Michael/0000-0001-7588-2560; Elkins, Jon/0000-0003-2858-8929; Arthur,
Simon/0000-0002-8135-1958; lizcano, jose m/0000-0002-3154-5383; Knapp,
Stefan/0000-0001-5995-6494
FU SGC [1097737]; Canadian Institutes for Health Research; Canada
Foundation for Innovation; Genome Canada; GlaxoSmithKline; Pfizer; Eli
Lilly; Takeda; AbbVie; Novartis Research Foundation; Ontario Ministry of
Research and Innovation; Wellcome Trust [092809/Z/10/Z]
FX J.M.E., J.W., and S.K. are grateful for financial support by the SGC, a
registered charity (No. 1097737) that receives funds from the Canadian
Institutes for Health Research, the Canada Foundation for Innovation,
Genome Canada, GlaxoSmithKline, Pfizer, Eli Lilly, Takeda, AbbVie, the
Novartis Research Foundation, the Ontario Ministry of Research and
Innovation, and the Wellcome Trust (No. 092809/Z/10/Z).
NR 46
TC 9
Z9 9
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 13
PY 2013
VL 56
IS 11
BP 4413
EP 4421
DI 10.1021/jm4000837
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 167OI
UT WOS:000320640900017
PM 23656407
ER
PT J
AU Bartsch, P
Swenson, ER
AF Baertsch, Peter
Swenson, Erik R.
TI Acute High-Altitude Illnesses
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE MOUNTAIN-SICKNESS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED
TRIAL; PULMONARY-EDEMA; CEREBRAL EDEMA; EXERCISE PERFORMANCE; NORMOBARIC
HYPOXIA; DOUBLE-BLIND; PREVENTION; DEXAMETHASONE
AB A 45-year-old healthy man wishes to climb Mount Kilimanjaro (5895 m) in a 5-day period, starting at 1800 m. The results of a recent exercise stress test were normal; he runs 10 km 4 or 5 times per week and finished a marathon in less than 4 hours last year. He wants to know how he can prevent becoming ill at high altitude and whether training or sleeping under normobaric hypoxic conditions in the weeks before the ascent would be helpful. What would you advise?
C1 [Baertsch, Peter] Univ Clin, Dept Internal Med, Div Sports Med 7, D-69120 Heidelberg, Germany.
[Swenson, Erik R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98195 USA.
RP Bartsch, P (reprint author), Univ Clin, Dept Internal Med, Div Sports Med 7, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
EM peter.bartsch@med.uni-heidelberg.de
FU Merck Sharp Dohme; Bayer HealthCare; Linde Group
FX Dr. Bartsch reports receiving lecture fees from Merck Sharp & Dohme and
Bayer HealthCare and payment to his institution for meeting expenses
from the Linde Group. No other potential conflict of interest relevant
to this article was reported.
NR 50
TC 92
Z9 94
U1 8
U2 44
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 13
PY 2013
VL 368
IS 24
BP 2294
EP 2302
DI 10.1056/NEJMcp1214870
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 161YN
UT WOS:000320230500005
PM 23758234
ER
PT J
AU Cole, AJ
Eskandar, E
Mela, T
Noebels, JL
Gonzalez, RG
McGuone, D
AF Cole, Andrew J.
Eskandar, Emad
Mela, Theofanie
Noebels, Jeffrey L.
Gonzalez, R. Gilberto
McGuone, Declan
TI Case 18-2013: A 32-Year-Old Woman with Recurrent Episodes of Altered
Consciousness Oligoastrocytoma, WHO grade II of IV, associated with
temporal-lobe seizures and ictal asystole (arrhythmogenic epilepsy)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LONG-QT SYNDROME; BRADYCARDIA; SYNCOPE; IDENTIFICATION; STIMULATION;
LOBECTOMY; GENETICS; DEATH; TERM
C1 [Cole, Andrew J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Eskandar, Emad] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Mela, Theofanie] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[McGuone, Declan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Cole, Andrew J.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Eskandar, Emad] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
[Mela, Theofanie] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Gonzalez, R. Gilberto] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[McGuone, Declan] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Noebels, Jeffrey L.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
RP Cole, AJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
FU Clarus Ventures; Concert Pharmaceuticals; Sage Pharmaceuticals
FX Dr. Cole reports receiving consulting fees from Clarus Ventures, Concert
Pharmaceuticals, and Sage Pharmaceuticals. Dr. Eskandar reports payment
to his institution for a patent on a device for deep-brain stimulation
for enhancing learning, motivation, and memory. No other potential
conflict of interest relevant to this article was reported.
NR 32
TC 2
Z9 2
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 13
PY 2013
VL 368
IS 24
BP 2304
EP 2312
DI 10.1056/NEJMcpc1215969
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 161YN
UT WOS:000320230500008
PM 23758236
ER
PT J
AU Hunt, KA
Mistry, V
Bockett, NA
Ahmad, T
Ban, M
Barker, JN
Barrett, JC
Blackburn, H
Brand, O
Burren, O
Capon, F
Compston, A
Gough, SCL
Jostins, L
Kong, Y
Lee, JC
Lek, M
MacArthur, DG
Mansfield, JC
Mathew, CG
Mein, CA
Mirza, M
Nutland, S
Onengut-Gumuscu, S
Papouli, E
Parkes, M
Rich, SS
Sawcer, S
Satsangi, J
Simmonds, MJ
Trembath, RC
Walker, NM
Wozniak, E
Todd, JA
Simpson, MA
Plagnol, V
van Heel, DA
AF Hunt, Karen A.
Mistry, Vanisha
Bockett, Nicholas A.
Ahmad, Tariq
Ban, Maria
Barker, Jonathan N.
Barrett, Jeffrey C.
Blackburn, Hannah
Brand, Oliver
Burren, Oliver
Capon, Francesca
Compston, Alastair
Gough, Stephen C. L.
Jostins, Luke
Kong, Yong
Lee, James C.
Lek, Monkol
MacArthur, Daniel G.
Mansfield, John C.
Mathew, Christopher G.
Mein, Charles A.
Mirza, Muddassar
Nutland, Sarah
Onengut-Gumuscu, Suna
Papouli, Efterpi
Parkes, Miles
Rich, Stephen S.
Sawcer, Steven
Satsangi, Jack
Simmonds, Matthew J.
Trembath, Richard C.
Walker, Neil M.
Wozniak, Eva
Todd, John A.
Simpson, Michael A.
Plagnol, Vincent
van Heel, David A.
TI Negligible impact of rare autoimmune-locus coding-region variants on
missing heritability
SO NATURE
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; PSORIASIS
SUSCEPTIBILITY LOCI; RHEUMATOID-ARTHRITIS; COMMON VARIANTS;
LOW-FREQUENCY; GENES; RISK; ARCHITECTURE; REVEALS
AB Genome-wide association studies(GWAS) have identified common variants of modest-effect size at hundreds of loci for common autoimmune diseases; however, a substantial fraction of heritability remains unexplained, to which rare variants may contribute(1,2). To discover rare variants and test them for association with a phenotype, most studies re-sequence a small initial sample size and then genotype the discovered variants in a larger sample set(3-5). This approach fails to analyse a large fraction of the rare variants present in the entire sample set. Here we perform simultaneous amplicon-sequencing-based variant discovery and genotyping for coding exons of 25 GWAS risk genes in 41,911 UK residents of white European origin, comprising 24,892 subjects with six autoimmune disease phenotypes and 17,019 controls, and show that rare coding-region variants at known loci have a negligible role in common autoimmune disease susceptibility. These results do not support the rare-variant synthetic genome-wide-association hypothesis(6) (in which unobserved rare causal variants lead to association detected at common tag variants). Many known autoimmune disease risk loci contain multiple, independently associated, common and low-frequency variants, and so genes at these loci are a priori stronger candidates for harbouring rare coding-region variants than other genes. Our data indicate that the missing heritability for common autoimmune diseases may not be attributable to the rare coding-region variant portion of the allelic spectrum, but perhaps, as others have proposed, may be a result of many common-variant loci of weak effect(7-10).
C1 [Hunt, Karen A.; Mistry, Vanisha; Bockett, Nicholas A.; van Heel, David A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England.
[Ahmad, Tariq] Peninsula Coll Med & Dent, Exeter EX2 5DW, Devon, England.
[Ban, Maria; Compston, Alastair; Sawcer, Steven] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 0QQ, England.
[Barker, Jonathan N.; Capon, Francesca; Mathew, Christopher G.; Mirza, Muddassar; Papouli, Efterpi; Simpson, Michael A.] Kings Coll London, Sch Med, Div Genet & Mol Med, Guys Hosp, London SE1 9RT, England.
[Barrett, Jeffrey C.; Blackburn, Hannah] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Brand, Oliver; Gough, Stephen C. L.; Simmonds, Matthew J.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England.
[Burren, Oliver; Nutland, Sarah; Walker, Neil M.; Todd, John A.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Juvenile Diabet Res Fdn,Wellcome Trust Diabet & I, Cambridge CB2 0XY, England.
[Jostins, Luke] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
[Kong, Yong] Yale Univ, WM Keck Fdn Biotechnol Resource Lab, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA.
[Lee, James C.; Parkes, Miles] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 0QQ, England.
[Lek, Monkol; MacArthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Mansfield, John C.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
[Mein, Charles A.; Wozniak, Eva] Queen Mary Univ London, Barts & London Sch Med & Dent, John Vane Sci Ctr, Genome Ctr, London EC1M 6BQ, England.
[Onengut-Gumuscu, Suna; Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA.
[Satsangi, Jack] Univ Edinburgh, Western Gen Hosp, Mol Med Ctr, Gastrointestinal Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
[Trembath, Richard C.] Queen Mary Univ London, Barts & London Sch Med & Dent, London E1 2AT, England.
[Plagnol, Vincent] UCL, Genet Inst, London WC1E 6BT, England.
RP van Heel, DA (reprint author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London E1 2AT, England.
EM v.plagnol@ucl.ac.uk; d.vanheel@qmul.ac.uk
RI Capon, Francesca/F-4763-2011; Simpson, Michael/F-4737-2011; Todd,
John/A-3542-2010; Mathew, Christopher/G-3434-2015;
OI Barrett, Jeffrey/0000-0002-1152-370X; Trembath,
Richard/0000-0003-0550-3400; Lee, James/0000-0001-5711-9385; Capon,
Francesca/0000-0003-2432-5793; Simpson, Michael/0000-0002-8539-8753;
Mathew, Christopher/0000-0003-4178-1838; Walker,
Neil/0000-0001-9796-7688; Simmonds, Matt/0000-0003-3154-3510; van Heel,
David/0000-0002-0637-2265; Plagnol, Vincent/0000-0002-5597-9215; Kong,
Yong/0000-0002-2881-5274; Burren, Oliver/0000-0002-3388-5760
FU Medical Research Council [MRC G1001158]; Coeliac UK; MRC [G0601387];
National Institutes for Health Research (NIHR) Biomedical Research
Centre based at Guy's and St Thomas' NHS Foundation Trust; King's
College London; Cambridge NIHR Biomedical Research Centre; Wellcome
Trust [076113/C/04/Z, 068545/Z/02, 068181, JDRF 4-2001-1008, WT061858];
NIHR [RP-PG-0310-1002]; UK MRC [G0000934]; British Society for
Paediatric Endocrinology and Diabetes
FX The study was primarily funded by the Medical Research Council (MRC
G1001158 to D. A. v. H and V. P.), with further funding from Coeliac UK
(to D. A. v. H). We thank C. Wijmenga and G. Trynka for sharing
ImmunoChip data, and the International Multiple Sclerosis Genomics
Consortium for ImmunoChip data and samples. J.N.B. and R. C. T. are
supported by MRC grant G0601387. This research was supported by the
National Institutes for Health Research (NIHR) Biomedical Research
Centre based at Guy's and St Thomas' NHS Foundation Trust and King's
College London. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health. The
study was supported by the Cambridge NIHR Biomedical Research Centre. We
thank E. Gray and D. Jones (Wellcome Trust Sanger Institute) for sample
preparation. We acknowledge use of DNA from The UK Blood Services
collection of Common Controls (UKBS-CC collection), funded by the
Wellcome Trust grant 076113/C/04/Z and by NIHR programme grant to NHS
Blood and Transplant (RP-PG-0310-1002). The collection was established
as part of the Wellcome Trust Case Control Consortium(WTCCC). We
acknowledge use of DNA from the British 1958 Birth Cohort collection,
funded by the UK MRC grant G0000934 and the Wellcome Trust grant
068545/Z/02. We thank nurses and doctors for recruiting autoimmune
thyroid disease (AITD) subjects into the AITD National Collection,
funded by the Wellcome Trust grant 068181. We acknowledge use of DNA
from the Cambridge BioResource. We acknowledge use of DNA from the
Juvenile Diabetes Research Foundation (JDRF)/Wellcome Trust Case-Series
(GRID), funded by JDRF and the Wellcome Trust (grant references JDRF
4-2001-1008 and WT061858). The subjects were recruited in the UK by D.
Dunger and his team with support from the British Society for Paediatric
Endocrinology and Diabetes. The samples were prepared and provided by
the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, University
of Cambridge, UK. Psoriasis samples used were based on the WTCCC2 GWAS
clinical panel, for which we thank D. Burden, C. Griffiths, M. Cork and
R. McManus. Finally, we would like to thank all autoimmune disease and
control subjects for participating in this study.
NR 30
TC 98
Z9 98
U1 1
U2 46
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 13
PY 2013
VL 498
IS 7453
BP 232
EP +
DI 10.1038/nature12170
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 162RR
UT WOS:000320283400049
PM 23698362
ER
PT J
AU Shalek, AK
Satija, R
Adiconis, X
Gertner, RS
Gaublomme, JT
Raychowdhury, R
Schwartz, S
Yosef, N
Malboeuf, C
Lu, DN
Trombetta, JJ
Gennert, D
Gnirke, A
Goren, A
Hacohen, N
Levin, JZ
Park, H
Regev, A
AF Shalek, Alex K.
Satija, Rahul
Adiconis, Xian
Gertner, Rona S.
Gaublomme, Jellert T.
Raychowdhury, Raktima
Schwartz, Schraga
Yosef, Nir
Malboeuf, Christine
Lu, Diana
Trombetta, John J.
Gennert, Dave
Gnirke, Andreas
Goren, Alon
Hacohen, Nir
Levin, Joshua Z.
Park, Hongkun
Regev, Aviv
TI Single-cell transcriptomics reveals bimodality in expression and
splicing in immune cells
SO NATURE
LA English
DT Article
ID MESSENGER-RNA-SEQ; GENE-EXPRESSION; LEVEL; RESPONSES; PROTEINS; PATHWAY;
DRUG
AB Recent molecular studies have shown that, even when derived from a seemingly homogenous population, individual cells can exhibit substantial differences in gene expression, protein levels and phenotypic output(1-5), with important functional consequences(4,5). Existing studies of cellular heterogeneity, however, have typically measured only a few pre-selected RNAs1,2 or proteins(5,6) simultaneously, because genomic profiling methods(3) could not be applied to single cells until very recently(7-10). Here we use single-cell RNA sequencing to investigate heterogeneity in the response of mouse bone-marrow-derived dendritic cells (BMDCs) to lipopolysaccharide. We find extensive, and previously unobserved, bimodal variation in messenger RNA abundance and splicing patterns, which we validate by RNA-fluorescence in situ hybridization for select transcripts. In particular, hundreds of key immune genes are bimodally expressed across cells, surprisingly even for genes that are very highly expressed at the population average. Moreover, splicing patterns demonstrate previously unobserved levels of heterogeneity between cells. Some of the observed bimodality can be attributed to closely related, yet distinct, known maturity states of BMDCs; other portions reflect differences in the usage of key regulatory circuits. For example, we identify a module of 137 highly variable, yet co-regulated, antiviral response genes. Using cells from knockout mice, we show that variability in this module may be propagated through an interferon feedback circuit, involving the transcriptional regulators Stat2 and Irf7. Our study demonstrates the power and promise of single-cell genomics in uncovering functional diversity between cells and in deciphering cell states and circuits.
C1 [Shalek, Alex K.; Gertner, Rona S.; Gaublomme, Jellert T.; Park, Hongkun] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Shalek, Alex K.; Gertner, Rona S.; Gaublomme, Jellert T.; Park, Hongkun] Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.
[Satija, Rahul; Adiconis, Xian; Raychowdhury, Raktima; Schwartz, Schraga; Yosef, Nir; Malboeuf, Christine; Lu, Diana; Trombetta, John J.; Gennert, Dave; Gnirke, Andreas; Goren, Alon; Hacohen, Nir; Levin, Joshua Z.; Park, Hongkun; Regev, Aviv] Broad Inst MIT & Harvard, Cambridge Ctr 7, Cambridge, MA 02142 USA.
[Goren, Alon] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA.
[Goren, Alon] Massachusetts Gen Hosp, Ctr Syst Biol, Charlestown, MA 02129 USA.
[Goren, Alon] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA.
[Regev, Aviv] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02140 USA.
RP Park, H (reprint author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.
EM Hongkun_Park@harvard.edu; aregev@broad.mit.edu
OI Shalek, Alex K./0000-0001-5670-8778; Schwartz,
Schraga/0000-0002-3671-9709
FU National Institutes of Health (NIH) [1F32HD075541-01, U54 AI057159, DP2
OD002230, 5DP1OD003893-03, DP1OD003958-01]; Charles H. Hood Foundation;
NIH CEGS Award [1P50HG006193-01]; Broad Institute; HHMI; Klarman Cell
Observatory at the Broad Institute
FX We thank N. Chevrier, C. Villani, M. Jovanovic, M. Bray and J. Shuga for
scientific discussions; N. Friedman and E. Lander for comments on the
manuscript; B. Tilton, T. Rogers and M. Tam for assistance with cell
sorting; J. Bochicchio, E. Shefler and C. Guiducci for project
management; the Broad Genomics Platform for all sequencing work; K.
Fitzgerald for the Irf7-/- bone marrow; and L. Gaffney for
help with artwork. Work was supported by a National Institutes of Health
(NIH) Postdoctoral Fellowship (1F32HD075541-01, to R. S.), a Charles H.
Hood Foundation Postdoctoral Fellowship (to A. Goren), an NIH grant (U54
AI057159, to N. H.), an NIH New Innovator Award (DP2 OD002230, to N.
H.), an NIH CEGS Award (1P50HG006193-01, to H. P., A. R. and N. H.), NIH
Pioneer Awards (5DP1OD003893-03 to H. P., DP1OD003958-01 to A. R.), the
Broad Institute (to H. P. and A. R.), HHMI (to A. R.), and the Klarman
Cell Observatory at the Broad Institute (to A.R.).
NR 30
TC 309
Z9 315
U1 15
U2 165
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 13
PY 2013
VL 498
IS 7453
BP 236
EP 240
DI 10.1038/nature12172
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 162RR
UT WOS:000320283400050
PM 23685454
ER
PT J
AU Floyd, SR
Pacold, ME
Huang, QY
Clarke, SM
Lam, FC
Cannell, IG
Bryson, BD
Rameseder, J
Lee, MJ
Blake, EJ
Fydrych, A
Ho, R
Greenberger, BA
Chen, GC
Maffa, A
Del Rosario, AM
Root, DE
Carpenter, AE
Hahn, WC
Sabatini, DM
Chen, CC
White, FM
Bradner, JE
Yaffe, MB
AF Floyd, Scott R.
Pacold, Michael E.
Huang, Qiuying
Clarke, Scott M.
Lam, Fred C.
Cannell, Ian G.
Bryson, Bryan D.
Rameseder, Jonathan
Lee, Michael J.
Blake, Emily J.
Fydrych, Anna
Ho, Richard
Greenberger, Benjamin A.
Chen, Grace C.
Maffa, Amanda
Del Rosario, Amanda M.
Root, David E.
Carpenter, Anne E.
Hahn, William C.
Sabatini, David M.
Chen, Clark C.
White, Forest M.
Bradner, James E.
Yaffe, Michael B.
TI The bromodomain protein Brd4 insulates chromatin from DNA damage
signalling
SO NATURE
LA English
DT Article
ID P-TEFB; GAMMA-H2AX; ACTIVATION; TRANSCRIPTION; REPAIR; BREAKS
AB DNA damage activates a signalling network that blocks cell-cycle progression, recruits DNA repair factors and/or triggers senescence or programmed cell death(1). Alterations in chromatin structure are implicated in the initiation and propagation of the DNA damage response(2). Here we further investigate the role of chromatin structure in the DNA damage response by monitoring ionizing-radiation-induced signalling and response events with a high-content multiplex RNA-mediated interference screen of chromatin-modifying and -interacting genes. We discover that an isoform of Brd4, a bromodomain and extra-terminal (BET) family member, functions as an endogenous inhibitor of DNA damage response signalling by recruiting the condensin II chromatin remodelling complex to acetylated histones through bromodomain interactions. Loss of this isoform results in relaxed chromatin structure, rapid cell-cycle checkpoint recovery and enhanced survival after irradiation, whereas functional gain of this isoform compacted chromatin, attenuated DNA damage response signalling and enhanced radiation-induced lethality. These data implicate Brd4, previously known for its role in transcriptional control, as an insulator of chromatin that can modulate the signalling response to DNA damage.
C1 [Floyd, Scott R.; Pacold, Michael E.; Huang, Qiuying; Clarke, Scott M.; Lam, Fred C.; Cannell, Ian G.; Bryson, Bryan D.; Rameseder, Jonathan; Lee, Michael J.; Blake, Emily J.; Fydrych, Anna; Ho, Richard; Greenberger, Benjamin A.; Chen, Grace C.; Maffa, Amanda; Del Rosario, Amanda M.; White, Forest M.; Yaffe, Michael B.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Floyd, Scott R.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Pacold, Michael E.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA.
[Pacold, Michael E.; Sabatini, David M.] Whitehead Inst, Cambridge, MA 02139 USA.
[Root, David E.; Carpenter, Anne E.; Hahn, William C.; Sabatini, David M.; Bradner, James E.; Yaffe, Michael B.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Hahn, William C.; Chen, Clark C.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Chen, Clark C.; Yaffe, Michael B.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA.
[White, Forest M.; Yaffe, Michael B.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA.
[Yaffe, Michael B.] MIT, Dept Biol, Cambridge, MA 02139 USA.
RP Yaffe, MB (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM myaffe@mit.edu
OI Lee, Michael/0000-0003-3378-6196
FU Koch Institute; Center for Environmental Health Sciences National
Institutes of Health [P30-CA14051, ES-002109]; SPARC; Holman Pathway
Research Resident Seed Grant; American Society for Radiation Oncology
Junior Faculty Career Research Training Award; Burroughs Wellcome Career
Award for Medical Scientists; [R01-ES15339]; [1-U54-CA112967-04];
[R21-NS063917]
FX We thank H. Le, T. R. Jones and M. Vokes for assistance with screening
and image analysis. We thank C. Whittaker, S. Hoersch and M. Moran for
computing and data analysis assistance; C. Reinhardt, C. Ellson and A.
Gardino for manuscript editing; and P. Filippakopoulos and S. Knapp for
discussions. This work was partially supported by the Koch Institute and
Center for Environmental Health Sciences National Institutes of Health
Core Grants P30-CA14051 and ES-002109; and by grants R01-ES15339,
1-U54-CA112967-04 and R21-NS063917; a SPARC grant to M.B.Y.; and a
Holman Pathway Research Resident Seed Grant, American Society for
Radiation Oncology Junior Faculty Career Research Training Award,
Klarman Scholar, Koch Institute Clinical Investigator Award, and
Burroughs Wellcome Career Award for Medical Scientists to S.R.F.
NR 22
TC 74
Z9 78
U1 4
U2 49
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD JUN 13
PY 2013
VL 498
IS 7453
BP 246
EP +
DI 10.1038/nature12147
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 162RR
UT WOS:000320283400052
PM 23728299
ER
PT J
AU Cohen, NR
Lobritz, MA
Collins, JJ
AF Cohen, Nadia R
Lobritz, Michael A.
Collins, James J.
TI Microbial Persistence and the Road to Drug Resistance
SO CELL HOST & MICROBE
LA English
DT Review
ID MYCOBACTERIUM-TUBERCULOSIS PERSISTENCE; MEDIATE ANTIBIOTIC TOLERANCE;
SMALL-MOLECULE INHIBITORS; PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI;
PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; BACTERICIDAL ANTIBIOTICS;
BIOFILM FORMATION; STRESS-RESPONSE
AB Microbial drug persistence is a widespread phenomenon in which a subpopulation of microorganisms is able to survive antimicrobial treatment without acquiring resistance-conferring genetic changes. Microbial persisters can cause recurrent or intractable infections, and, like resistant mutants, they carry an increasing clinical burden. In contrast to heritable drug resistance, however, the biology of persistence is only beginning to be unraveled. Persisters have traditionally been thought of as metabolically dormant, nondividing cells. As discussed in this review, increasing evidence suggests that persistence is in fact an actively maintained state, triggered and enabled by a network of intracellular stress responses that can accelerate processes of adaptive evolution. Beyond shedding light on the basis of persistence, these findings raise the possibility that persisters behave as an evolutionary reservoir from which resistant organisms can emerge. As persistence and its consequences come into clearer focus, so too does the need for clinically useful persister-eradication strategies.
C1 [Cohen, Nadia R; Lobritz, Michael A.; Collins, James J.] Boston Univ, Howard Hughes Med Inst, Boston, MA 02215 USA.
[Cohen, Nadia R; Lobritz, Michael A.; Collins, James J.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
[Cohen, Nadia R; Lobritz, Michael A.; Collins, James J.] Boston Univ, Ctr Synthet Biol, Boston, MA 02215 USA.
[Cohen, Nadia R; Lobritz, Michael A.; Collins, James J.] Harvard Univ, Wyss Inst Biologically Inspired Engn, Boston, MA 02115 USA.
[Lobritz, Michael A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Collins, James J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Collins, JJ (reprint author), Boston Univ, Howard Hughes Med Inst, Boston, MA 02215 USA.
EM jcollins@bu.edu
FU Wyss Institute Clinical Fellowship program; Howard Hughes Medical
Institute
FX We thank Drs. Kara Lassen, Ahmad S. Khalil, Peter Belenky, and Rebecca
S. Shapiro for critical input and reading of the manuscript. This work
was supported by funding from the Wyss Institute Clinical Fellowship
program and the Howard Hughes Medical Institute.
NR 115
TC 68
Z9 71
U1 10
U2 56
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD JUN 12
PY 2013
VL 13
IS 6
BP 632
EP 642
DI 10.1016/j.chom.2013.05.009
PG 11
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AA1IY
UT WOS:000330851000004
PM 23768488
ER
PT J
AU Morfini, GA
Bosco, DA
Brown, H
Gatto, R
Kaminska, A
Song, YY
Molla, L
Baker, L
Marangoni, MN
Berth, S
Tavassoli, E
Bagnato, C
Tiwari, A
Hayward, LJ
Pigino, GF
Watterson, DM
Huang, CF
Banker, G
Brown, RH
Brady, ST
AF Morfini, Gerardo A.
Bosco, Daryl A.
Brown, Hannah
Gatto, Rodolfo
Kaminska, Agnieszka
Song, Yuyu
Molla, Linda
Baker, Lisa
Marangoni, M. Natalia
Berth, Sarah
Tavassoli, Ehsan
Bagnato, Carolina
Tiwari, Ashutosh
Hayward, Lawrence J.
Pigino, Gustavo F.
Watterson, D. Martin
Huang, Chun-Fang
Banker, Gary
Brown, Robert H., Jr.
Brady, Scott T.
TI Inhibition of Fast Axonal Transport by Pathogenic SOD1 Involves
Activation of p38 MAP Kinase
SO PLOS ONE
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DEGENERATION; ZINC
SUPEROXIDE-DISMUTASE; SQUID GIANT-AXON; PROTEIN-KINASE; MOUSE MODEL;
CYTOPLASMIC DYNEIN; IN-VIVO; NEUROFILAMENT PROTEIN; HEXANUCLEOTIDE
REPEAT
AB Dying-back degeneration of motor neuron axons represents an established feature of familial amyotrophic lateral sclerosis (FALS) associated with superoxide dismutase 1 (SOD1) mutations, but axon-autonomous effects of pathogenic SOD1 remained undefined. Characteristics of motor neurons affected in FALS include abnormal kinase activation, aberrant neurofilament phosphorylation, and fast axonal transport (FAT) deficits, but functional relationships among these pathogenic events were unclear. Experiments in isolated squid axoplasm reveal that FALS-related SOD1 mutant polypeptides inhibit FAT through a mechanism involving a p38 mitogen activated protein kinase pathway. Mutant SOD1 activated neuronal p38 in mouse spinal cord, neuroblastoma cells and squid axoplasm. Active p38 MAP kinase phosphorylated kinesin-1, and this phosphorylation event inhibited kinesin-1. Finally, vesicle motility assays revealed previously unrecognized, isoform-specific effects of p38 on FAT. Axon-autonomous activation of the p38 pathway represents a novel gain of toxic function for FALS-linked SOD1 proteins consistent with the dying-back pattern of neurodegeneration characteristic of ALS.
C1 [Morfini, Gerardo A.; Gatto, Rodolfo; Kaminska, Agnieszka; Song, Yuyu; Marangoni, M. Natalia; Berth, Sarah; Tavassoli, Ehsan; Pigino, Gustavo F.; Brady, Scott T.] Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60607 USA.
[Morfini, Gerardo A.; Brown, Hannah; Kaminska, Agnieszka; Song, Yuyu; Molla, Linda; Baker, Lisa; Marangoni, M. Natalia; Berth, Sarah; Pigino, Gustavo F.; Brady, Scott T.] Marine Biol Lab, Woods Hole, MA 02543 USA.
[Bosco, Daryl A.; Hayward, Lawrence J.; Brown, Robert H., Jr.] Univ Massachusetts, Med Ctr, Dept Neurol, Worcester, MA 01655 USA.
[Tiwari, Ashutosh] Michigan Technol Univ, Dept Chem, Houghton, MI 49931 USA.
[Brown, Hannah] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Watterson, D. Martin] Northwestern Univ, Ctr Mol Innovat & Drug Discovery, Chicago, IL 60611 USA.
[Watterson, D. Martin] Northwestern Univ, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA.
[Huang, Chun-Fang; Banker, Gary] Oregon Hlth & Sci Univ, Jungers Ctr Neurosci Res, Portland, OR 97201 USA.
[Bagnato, Carolina] Natl Univ Rio Negro, Dept Nat Sci & Engn, Rio Negro, Argentina.
RP Morfini, GA (reprint author), Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60607 USA.
EM gmorfini@uic.edu; stbrady@uic.edu
RI Tiwari, Ashutosh/A-7458-2008;
OI Tiwari, Ashutosh/0000-0001-7373-349X; Song, Yuyu/0000-0002-9196-1610;
Watterson, Daniel/0000-0001-7605-5866
FU Marine Biological Laboratory; NIH [NS066942A, R01NS44170, NS23868,
NS23320, NS41170, MH066179, R01AG031311, R01NS055951, U01NS05225,
R01NS050557, 1RC1NS068391, 1RC2NS070342, R01NS067206]; Howard Hughes
Medical Institute-USE [52006287]; Muscular Dystrophy Association (MDA);
ALS Association; ALS/CVS Therapy Alliance; Angel Fund; DeBourgknecht
Fund for ALS Research; P2ALS; Project ALS
FX Support was provided by 2007/2008 Marine Biological Laboratory summer
fellowships and NIH (NS066942A) grants to GM; Howard Hughes Medical
Institute-USE Grant #52006287 to Hunter College of CUNY (LM); Muscular
Dystrophy Association (MDA) and NIH (R01NS44170) grants to LJH; MDA and
NIH (NS23868, NS23320, NS41170) grants to STB; NIH grant MH066179 to GB;
NIH grants R01AG031311 and R01NS055951 to DMW; NIH (U01NS05225,
R01NS050557, 1RC1NS068391, 1RC2NS070342) grants to RHB; R01NS067206 to
DAB; ALS Association grants to GM, AT, RHB, and STB; and ALS/CVS Therapy
Alliance grants to RHB, GM, AT, LJH, and DAB. RHB and AT received
support from the Angel Fund. RHB also received support from the
DeBourgknecht Fund for ALS Research, P2ALS and Project ALS. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 90
TC 24
Z9 25
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2013
VL 8
IS 6
AR e65235
DI 10.1371/journal.pone.0065235
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163FW
UT WOS:000320322400010
PM 23776455
ER
PT J
AU Mehndiratta, MM
Singhal, AB
Chaturvedi, S
Sivakumar, MR
Moonis, M
AF Mehndiratta, Man Mohan
Singhal, Aneesh B.
Chaturvedi, Seemant
Sivakumar, M. R.
Moonis, Majaz
TI MEETING THE CHALLENGES OF STROKE IN INDIA
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Mehndiratta, Man Mohan] GB Pant Hosp, Dept Neurol, New Delhi, India.
[Singhal, Aneesh B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Chaturvedi, Seemant] Wayne State Univ, Dept Neurol, Detroit, MI USA.
[Moonis, Majaz] Univ Massachusetts, Dept Neurol, Worcester, MA 01605 USA.
RP Mehndiratta, MM (reprint author), GB Pant Hosp, Dept Neurol, New Delhi, India.
EM mmehndi@hotmail.com
NR 3
TC 7
Z9 8
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 11
PY 2013
VL 80
IS 24
BP 2246
EP 2247
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA 304FW
UT WOS:000330733500017
PM 23751917
ER
PT J
AU Giza, CC
Kutcher, JS
Ashwal, S
Barth, J
Getchius, TSD
Gioia, GA
Gronseth, GS
Guskiewicz, K
Mandel, S
Manley, G
McKeag, DB
Thurman, DJ
Zafonte, R
AF Giza, Christopher C.
Kutcher, Jeffrey S.
Ashwal, Stephen
Barth, Jeffrey
Getchius, Thomas S. D.
Gioia, Gerard A.
Gronseth, Gary S.
Guskiewicz, Kevin
Mandel, Steven
Manley, Geoffrey
McKeag, Douglas B.
Thurman, David J.
Zafonte, Ross
TI Summary of evidence-based guideline update: Evaluation and management of
concussion in sports Report of the Guideline Development Subcommittee of
the American Academy of Neurology
SO NEUROLOGY
LA English
DT Article
ID TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL;
STANDARDIZED ASSESSMENT; NCAA CONCUSSION; RUGBY PLAYERS; EPIDEMIOLOGY;
RECOVERY; RISK; PREDICTORS
AB Objective: To update the 1997 American Academy of Neurology (AAN) practice parameter regarding sports concussion, focusing on 4 questions: 1) What factors increase/decrease concussion risk? 2) What diagnostic tools identify those with concussion and those at increased risk for severe/prolonged early impairments, neurologic catastrophe, or chronic neurobehavioral impairment? 3) What clinical factors identify those at increased risk for severe/prolonged early postconcussion impairments, neurologic catastrophe, recurrent concussions, or chronic neurobehavioral impairment? 4) What interventions enhance recovery, reduce recurrent concussion risk, or diminish long-term sequelae? The complete guideline on which this summary is based is available as an online data supplement to this article.
Methods: We systematically reviewed the literature from 1955 to June 2012 for pertinent evidence. We assessed evidence for quality and synthesized into conclusions using a modified Grading of Recommendations Assessment, Development and Evaluation process. We used a modified Delphi process to develop recommendations.
Results: Specific risk factors can increase or decrease concussion risk. Diagnostic tools to help identify individuals with concussion include graded symptom checklists, the Standardized Assessment of Concussion, neuropsychological assessments, and the Balance Error Scoring System. Ongoing clinical symptoms, concussion history, and younger age identify those at risk for postconcussion impairments. Risk factors for recurrent concussion include history of multiple concussions, particularly within 10 days after initial concussion. Risk factors for chronic neurobehavioral impairment include concussion exposure and APOE epsilon 4 genotype. Data are insufficient to show that any intervention enhances recovery or diminishes long-term sequelae postconcussion. Practice recommendations are presented for preparticipation counseling, management of suspected concussion, and management of diagnosed concussion.
C1 [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA.
[Kutcher, Jeffrey S.] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA.
[Ashwal, Stephen] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA.
[Ashwal, Stephen] Loma Linda Univ, Dept Neurol, Loma Linda, CA 92350 USA.
[Barth, Jeffrey] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA.
[Getchius, Thomas S. D.] Amer Acad Neurol, Ctr Hlth Policy, Minneapolis, MN USA.
[Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat & Psychiat, Washington, DC USA.
[Gronseth, Gary S.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS USA.
[Guskiewicz, Kevin] Univ N Carolina, Matthew Geller Sport Related Traumat Brain Injury, Chapel Hill, NC USA.
[Mandel, Steven] Neurol & Neurophysiol Associates PC, Philadelphia, PA USA.
[Manley, Geoffrey] UCSF Med Ctr, San Francisco, CA USA.
[McKeag, Douglas B.] Indiana Univ, Ctr Sports Med, Dept Family Med, Indianapolis, IN 46204 USA.
[Thurman, David J.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Zafonte, Ross] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Phys Med & Rehabil,Spaulding Rehabil Hosp, Cambridge, MA 02138 USA.
RP Giza, CC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA.
FU American Academy of Neurology
FX This evidence-based guideline was funded by the American Academy of
Neurology. No author received honoraria or financial support to develop
this document.
NR 40
TC 237
Z9 240
U1 18
U2 59
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 11
PY 2013
VL 80
IS 24
BP 2250
EP 2257
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 304FW
UT WOS:000330733500019
PM 23508730
ER
PT J
AU Singhal, T
Venna, N
AF Singhal, Tarun
Venna, Nagagopal
TI Mystery Case: Frontal meningoencephalocele causing recurrent bacterial
meningitis
SO NEUROLOGY
LA English
DT Editorial Material
C1 [Singhal, Tarun; Venna, Nagagopal] Massachusetts Gen Hosp, Dept Neurol, Div Gen Neurol, Boston, MA 02114 USA.
RP Venna, N (reprint author), Massachusetts Gen Hosp, Dept Neurol, Div Gen Neurol, Boston, MA 02114 USA.
EM nvenna1@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD JUN 11
PY 2013
VL 80
IS 24
BP E250
EP E250
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA 304FW
UT WOS:000330733500001
PM 23751922
ER
PT J
AU Bouix, S
Pasternak, O
Rathi, Y
Pelavin, PE
Zafonte, R
Shenton, ME
AF Bouix, Sylvain
Pasternak, Ofer
Rathi, Yogesh
Pelavin, Paula E.
Zafonte, Ross
Shenton, Martha E.
TI Increased Gray Matter Diffusion Anisotropy in Patients with Persistent
Post-Concussive Symptoms following Mild Traumatic Brain Injury
SO PLOS ONE
LA English
DT Article
ID PRINCIPAL EIGENVECTOR MEASUREMENTS; TENSOR IMAGING FINDINGS; MINOR
HEAD-INJURY; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; MRI; DTI;
REPRODUCIBILITY; DEGENERATION; 1.5T
AB A significant percentage of individuals diagnosed with mild traumatic brain injury (mTBI) experience persistent post-concussive symptoms (PPCS). Little is known about the pathology of these symptoms and there is often no radiological evidence based on conventional clinical imaging. We aimed to utilize methods to evaluate microstructural tissue changes and to determine whether or not a link with PPCS was present. A novel analysis method was developed to identify abnormalities in high-resolution diffusion tensor imaging (DTI) when the location of brain injury is heterogeneous across subjects. A normative atlas with 145 brain regions of interest (ROI) was built from 47 normal controls. Comparing each subject's diffusion measures to the atlas generated subject-specific profiles of injury. Abnormal ROIs were defined by absolute z-score values above a given threshold. The method was applied to 11 PPCS patients following mTBI and 11 matched controls. Z-score information for each individual was summarized with two location-independent measures: "load'' (number of abnormal regions) and "severity'' (largest absolute z-score). Group differences were then computed using Wilcoxon rank sum tests. Results showed statistically significantly higher load (p = 0.018) and severity (p = 0.006) for fractional anisotropy (FA) in patients compared with controls. Subject-specific profiles of injury evinced abnormally high FA regions in gray matter (30 occurrences over 11 patients), and abnormally low FA in white matter (3 occurrences over 11 subjects). Subject-specific profiles provide important information regarding the pathology associated with PPCS. Increased gray matter (GM) anisotropy is a novel in-vivo finding, which is consistent with an animal model of brain trauma that associates increased FA in GM with pathologies such as gliosis. In addition, the individualized analysis shows promise for enhancing the clinical care of PPCS patients as it could play a role in the diagnosis of brain injury not revealed using conventional imaging.
C1 [Bouix, Sylvain; Pasternak, Ofer; Rathi, Yogesh; Pelavin, Paula E.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA.
[Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA.
RP Bouix, S (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
EM sylvain@bwh.harvard.edu
OI Bouix, Sylvain/0000-0003-1326-6054
FU Center for Integration of Medicine and Innovative Technology Soldier in
Medicine Award; National Institute of Health [R01 MH082918, R01
NS078337, NAMIC-U54 EB005149]; INTRuST Posttraumatic Stress Disorder and
Traumatic Brain Injury Clinical Consortium; Department of Defense
Psychological Health/Traumatic Brain Injury Research Program
[X81XWH-07-CC-CSDoD]
FX This work was supported in part by the Center for Integration of
Medicine and Innovative Technology Soldier in Medicine Award [to S.B.],
by the National Institute of Health [R01 MH082918 to S.B., R01 NS078337
to M.E.S., NAMIC-U54 EB005149 to M.E.S.] and by the INTRuST
Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical
Consortium funded by the Department of Defense Psychological
Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD to
M.E.S., S.B., O.P., Y.R. and R.Z.]. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 41
TC 30
Z9 30
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2013
VL 8
IS 6
AR e66205
DI 10.1371/journal.pone.0066205
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 169CU
UT WOS:000320755400120
PM 23776631
ER
PT J
AU Singh, JA
AF Singh, Jasvinder A.
TI Use of biologics in a patient with rheumatoid arthritis refractory to
methotrexate
SO CANADIAN MEDICAL ASSOCIATION JOURNAL
LA English
DT Editorial Material
ID THERAPY; RISK; MALIGNANCIES; METAANALYSIS; ABATACEPT; EFFICACY; AGENTS
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg & Med Acute care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Ctr Surg & Med Acute care Res & Transit C SMART, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
NR 15
TC 2
Z9 2
U1 0
U2 0
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0820-3946
J9 CAN MED ASSOC J
JI Can. Med. Assoc. J.
PD JUN 11
PY 2013
VL 185
IS 9
BP 793
EP 795
DI 10.1503/cmaj.121607
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 180YQ
UT WOS:000321635600036
PM 23460636
ER
PT J
AU Shah, RV
Goldfine, AB
AF Shah, Ravi V.
Goldfine, Allison B.
TI Response to Letter Regarding Article, "Statins and Risk of New-Onset
Diabetes Mellitus"
SO CIRCULATION
LA English
DT Letter
ID THERAPY; METAANALYSIS; TRIALS
C1 [Shah, Ravi V.] Harvard Univ, Sch Med, Dept Med, Cardiol Div,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Goldfine, Allison B.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Shah, RV (reprint author), Harvard Univ, Sch Med, Dept Med, Cardiol Div,Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD JUN 11
PY 2013
VL 127
IS 23
BP E838
EP E838
DI 10.1161/CIRCULATIONAHA.113.001664
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 160YR
UT WOS:000320156900006
PM 23905169
ER
PT J
AU Sun, L
Zhu, LL
Lu, P
Yuen, T
Li, JH
Ma, RS
Baliram, R
Moonga, SS
Liu, P
Zallone, A
New, MI
Davies, TF
Zaidi, M
AF Sun, Li
Zhu, Ling-Ling
Lu, Ping
Yuen, Tony
Li, Jianhua
Ma, Risheng
Baliram, Ramkumari
Moonga, Surinder S.
Liu, Peng
Zallone, Alberta
New, Maria I.
Davies, Terry F.
Zaidi, Mone
TI Genetic confirmation for a central role for TNF alpha in the direct
action of thyroid stimulating hormone on the skeleton
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE bone metabolism; thyroid disease; bone density
ID MARROW STROMAL CELLS; BONE LOSS; OSTEOCLAST PRECURSORS; THYROTROPIN
RECEPTOR; POSTMENOPAUSAL WOMEN; TRANSGENIC MICE; IN-VIVO; TSH;
EXPRESSION; OXYTOCIN
AB Clinical data showing correlations between low thyroid-stimulating hormone (TSH) levels and high bone turnover markers, low bone mineral density, and an increased risk of osteoporosis-related fractures are buttressed by mouse genetic and pharmacological studies identifying a direct action of TSH on the skeleton. Here we show that the skeletal actions of TSH deficiency are mediated, in part, through TNF alpha. Compound mouse mutants generated by genetically deleting the Tnf alpha gene on a Tshr(-/-) (homozygote) or Tshr(+/-) (heterozygote) background resulted in full rescue of the osteoporosis, low bone formation, and hyperresorption that accompany TSH deficiency. Studies using ex vivo bone marrow cell cultures showed that TSH inhibits and stimulates TNF alpha production from macrophages and osteoblasts, respectively. TNF alpha, in turn, stimulates osteoclastogenesis but also enhances the production in bone marrow of a variant TSH beta. This locally produced TSH suppresses osteoclast formation in a negative feedback loop. We speculate that TNF alpha elevations due to low TSH signaling in human hyperthyroidism contribute to the bone loss that has traditionally been attributed solely to high thyroid hormone levels.
C1 [Sun, Li; Zhu, Ling-Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
[Sun, Li; Zhu, Ling-Ling; Lu, Ping; Yuen, Tony; Li, Jianhua; Ma, Risheng; Baliram, Ramkumari; Moonga, Surinder S.; Liu, Peng; Zallone, Alberta; New, Maria I.; Davies, Terry F.; Zaidi, Mone] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
[Yuen, Tony; New, Maria I.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA.
[Ma, Risheng; Baliram, Ramkumari; Davies, Terry F.] James J Peters Vet Affairs Med Ctr, Thyroid Res Unit, Bronx, NY 10468 USA.
[Zallone, Alberta] Univ Bari, Dept Human Anat & Histol, I-70124 Bari, Italy.
RP New, MI (reprint author), Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10029 USA.
EM maria.new@mssm.edu; mone.zaidi@mssm.edu
FU National Institutes of Health [DK80459, AG23176, AG40132]; Department of
Veterans Affairs; Maria I. New Children's Hormone Research Foundation;
Chinese University of Hong Kong
FX We thank Dr. Jay Cao for help with microtomography measurements. This
work was supported by National Institutes of Health Grants DK80459 (to
L. S., T. F. D., and M.Z.), AG23176 (to M.Z.), and AG40132 (to M.Z.). T.
F. D. acknowledges support from the Department of Veterans Affairs
(Veterans Affairs Merit Award). M.I.N. is supported by the Maria I. New
Children's Hormone Research Foundation and the Chinese University of
Hong Kong.
NR 38
TC 8
Z9 10
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP 9891
EP 9896
DI 10.1073/pnas.1308336110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 171LM
UT WOS:000320930100068
PM 23716650
ER
PT J
AU Slater, LH
Hett, EC
Clatworthy, AE
Mark, KG
Hung, DT
AF Slater, Louise H.
Hett, Erik C.
Clatworthy, Anne E.
Mark, Kevin G.
Hung, Deborah T.
TI CCT chaperonin complex is required for efficient delivery of anthrax
toxin into the cytosol of host cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE TCP-1; TRiC
ID BOTULINUM C2 TOXIN; PROTECTIVE ANTIGEN; LETHAL FACTOR; MEMBRANE
TRANSLOCATION; PROTEIN TRANSLOCATION; DIPHTHERIA-TOXIN; MAMMALIAN-CELLS;
IN-VITRO; RECEPTOR; ACTIN
AB Bacterial toxins have evolved successful strategies for coopting host proteins to access the cytosol of host cells. Anthrax lethal factor (LF) enters the cytosol through pores in the endosomal membrane formed by anthrax protective antigen. Although in vitro models using planar lipid bilayers have shown that translocation can occur in the absence of cellular factors, recent studies using intact endosomes indicate that host factors are required for translocation in the cellular environment. In this study, we describe a high-throughput shRNA screen to identify host factors required for anthrax lethal toxin-induced cell death. The cytosolic chaperonin complex chaperonin containing t-complex protein 1 (CCT) was identified, and subsequent studies showed that CCT is required for efficient delivery of LF and related fusion proteins into the cytosol. We further show that knockdown of CCT inhibits the acid-induced delivery of LF and the fusion protein LFN-Bla (N terminal domain of LF fused to beta-lactamase) across the plasma membrane of intact cells. Together, these results suggest that CCT is required for efficient delivery of enzymatically active toxin to the cytosol and are consistent with a direct role for CCT in translocation of LF through the protective antigen pore.
C1 [Slater, Louise H.; Hett, Erik C.; Clatworthy, Anne E.; Mark, Kevin G.; Hung, Deborah T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Slater, Louise H.; Hett, Erik C.; Clatworthy, Anne E.; Mark, Kevin G.; Hung, Deborah T.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Slater, Louise H.; Hett, Erik C.; Clatworthy, Anne E.; Mark, Kevin G.; Hung, Deborah T.] Broad Inst, Infect Dis Initiat, Cambridge, MA 02142 USA.
[Slater, Louise H.; Hett, Erik C.; Clatworthy, Anne E.; Mark, Kevin G.; Hung, Deborah T.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
RP Hung, DT (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM hung@molbio.mgh.harvard.edu
FU National Institutes of Health (NIH) National Research Service
[F32AI084323]; NIH [U54 AI057159]
FX We thank A. Barker and A. McCluskey for help with production and
purification of PA, LF, and LFN-Bla; and the Broad Institute
RNAi screening platform for technical help. E. C. H. was supported by
National Institutes of Health (NIH) National Research Service Award
Fellowship F32AI084323. This work was supported, in part, by NIH Grant
U54 AI057159 to the New England Center of Excellence/Biodefense and
Emerging Infectious Diseases (D.T.H.).
NR 44
TC 7
Z9 7
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP 9932
EP 9937
DI 10.1073/pnas.1302257110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 171LM
UT WOS:000320930100075
PM 23716698
ER
PT J
AU Cywes-Bentley, C
Skurnik, D
Zaidi, T
Roux, D
DeOliveira, RB
Garrett, WS
Lu, X
O'Malley, J
Kinzel, K
Zaidi, T
Rey, A
Perrin, C
Fichorova, RN
Kayatani, AKK
Maira-Litran, T
Gening, ML
Tsvetkov, YE
Nifantiev, NE
Bakaletz, LO
Pelton, SI
Golenbock, DT
Pier, GB
AF Cywes-Bentley, Colette
Skurnik, David
Zaidi, Tanweer
Roux, Damien
DeOliveira, Rosane B.
Garrett, Wendy S.
Lu, Xi
O'Malley, Jennifer
Kinzel, Kathryn
Zaidi, Tauqeer
Rey, Astrid
Perrin, Christophe
Fichorova, Raina N.
Kayatani, Alexander K. K.
Maira-Litran, Tomas
Gening, Marina L.
Tsvetkov, Yury E.
Nifantiev, Nikolay E.
Bakaletz, Lauren O.
Pelton, Stephen I.
Golenbock, Douglas T.
Pier, Gerald B.
TI Antibody to a conserved antigenic target is protective against diverse
prokaryotic and eukaryotic pathogens
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE immunotherapy; infectious diseases; malaria; carbohydrates; animal
models
ID POLY-N-ACETYLGLUCOSAMINE; HUMAN MONOCLONAL-ANTIBODIES;
STAPHYLOCOCCUS-AUREUS; SURFACE POLYSACCHARIDE; CONJUGATE VACCINES;
UNITED-STATES; DISPERSIN-B; ACTINOBACILLUS-ACTINOMYCETEMCOMITANS;
STREPTOCOCCUS-PNEUMONIAE; NEISSERIA-MENINGITIDIS
AB Microbial capsular antigens are effective vaccines but are chemically and immunologically diverse, resulting in a major barrier to their use against multiple pathogens. A beta-(1 -> 6)-linked poly-N-acetyl-D-glucosamine (PNAG) surface capsule is synthesized by four proteins encoded in genetic loci designated intercellular adhesion in Staphylococcus aureus or polyglucosamine in selected Gram-negative bacterial pathogens. We report that many microbial pathogens lacking an identifiable intercellular adhesion or polyglucosamine locus produce PNAG, including Gram-positive, Gram-negative, and fungal pathogens, as well as protozoa, e. g., Trichomonas vaginalis, Plasmodium berghei, and sporozoites and blood-stage forms of Plasmodium falciparum. Natural antibody to PNAG is common in humans and animals and binds primarily to the highly acetylated glycoform of PNAG but is not protective against infection due to lack of deposition of complement opsonins. Polyclonal animal antibody raised to deacetylated glycoforms of PNAG and a fully human IgG1 monoclonal antibody that both bind to native and deacetylated glycoforms of PNAG mediated complement-dependent opsonic or bactericidal killing and protected mice against local and/or systemic infections by Streptococcus pyogenes, Streptococcus pneumoniae, Listeria monocytogenes, Neisseria meningitidis serogroup B, Candida albicans, and P. berghei ANKA, and against colonic pathology in a model of infectious colitis. PNAG is also a capsular polysaccharide for Neisseria gonorrhoeae and nontypable Hemophilus influenzae, and protects cells from environmental stress. Vaccination targeting PNAG could contribute to immunity against serious and diverse prokaryotic and eukaryotic pathogens, and the conserved production of PNAG suggests that it is a critical factor in microbial biology.
C1 [Cywes-Bentley, Colette; Skurnik, David; Zaidi, Tanweer; Roux, Damien; Lu, Xi; O'Malley, Jennifer; Kinzel, Kathryn; Zaidi, Tauqeer; Maira-Litran, Tomas; Pier, Gerald B.] Harvard Univ, Sch Med, Dept Med, Div Infect Dis,Brigham & Womens Hosp, Boston, MA 02115 USA.
[DeOliveira, Rosane B.; Golenbock, Douglas T.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.
[Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA.
[Garrett, Wendy S.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Complex Dis, Boston, MA 02115 USA.
[Rey, Astrid; Perrin, Christophe] Sanofi Res & Dev, Therapeut Strateg Unit, Infect Dis, F-31270 Toulouse, France.
[Fichorova, Raina N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Genital Tract Biol,Dept Obstet Gynecol & Repr, Boston, MA 02115 USA.
[Kayatani, Alexander K. K.] Walter Reed Army Inst Res, Mil Malaria Res Program, Vaccine Branch, Silver Spring, MD 20910 USA.
[Gening, Marina L.; Tsvetkov, Yury E.; Nifantiev, Nikolay E.] ND Zelinskii Inst Organ Chem, Lab Glycoconjugate Chem, Moscow 119991, Russia.
[Bakaletz, Lauren O.] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.
[Bakaletz, Lauren O.] Ohio State Univ, Coll Med, Columbus, OH 43205 USA.
[Pelton, Stephen I.] Boston Univ, Med Ctr, Dept Pediat Infect Dis, Boston, MA 02118 USA.
RP Pier, GB (reprint author), Harvard Univ, Sch Med, Dept Med, Div Infect Dis,Brigham & Womens Hosp, Boston, MA 02115 USA.
EM gpier@rics.bwh.harvard.edu
RI Roux, Damien/C-5618-2014; Fichorova, Raina/G-9969-2014; Roux,
Damien/L-3671-2014;
OI Roux, Damien/0000-0002-6103-6416; Roux, Damien/0000-0002-6103-6416;
Pier, Gerald/0000-0002-9112-2331; Pelton, Stephen/0000-0003-4862-5344
FU NIAID [AI46706, AI057159, U54 AI057159, 5R01AI079085-04, RO1AI079293]
FX We gratefully acknowledge the following individuals for supplying
microbial strains or tissue samples: Dr. Peter Rice (University of
Massachusetts Medical School); Dr. Lee Wetzler (Boston University
Medical School); Drs. Daniel Milner, Eric Rubin, and Marc Lipsitch
(Harvard School of Public Health), Drs. Richard Malley and Michael
Wessels (Children's Hospital, Harvard Medical School); Dr. Darren
Higgins (Harvard Medical School); Drs. Laurie Comstock, Maria
Chatzidaki-Livanis, Neeraj (Neil) Surana, and Lynn Bry (Brigham and
Women's Hospital, Harvard Medical School); Dr. Yung-Fu Chang (Cornell
College of Veterinary Medicine); Dr. Joanna Goldberg (University of
Virginia Medical School); Drs. Stanley Spinola and Margaret Bauer
(Indiana University Medical School); Dr. Darlene Miller (Bascom-Palmer
Eye Institute, University of Miami); Dr. Arturo Casadevall (Albert
Einstein College of Medicine); Dr. Janet Yother (University of Alabama,
Birmingham); Dr. Sandra Richter (University of Iowa); Dr. Janet Lindow
(University of Vermont); Dr. Alan Cross (University of Maryland School
of Medicine); Dr. Kwang Sik Kim (The Johns Hopkins University School of
Medicine); Dr. Rachel McLoughlin (University College Dublin); and Dr.
Johannes Huebner (Ludwig Maximilians University). We also gratefully
acknowledge the technical expertise and help of Ms. Maria Ericsson with
electron microscopy and Ms. Ariana Huebner with laboratory experiments.
This work was supported by NIAID Grants AI46706 and AI057159, a
component of Award U54 AI057159. The work with T. vaginalis was
supported by NIAID Grant 5R01AI079085-04 and the work with P. berghei
was supported by NIAID Grant RO1AI079293.
NR 58
TC 41
Z9 42
U1 0
U2 21
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 11
PY 2013
VL 110
IS 24
BP E2209
EP E2218
DI 10.1073/pnas.1303573110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 171LM
UT WOS:000320930100011
PM 23716675
ER
PT J
AU Yao, JK
Dougherty, GG
Reddy, RD
Matson, WR
Kaddurah-Daouk, R
Keshavan, MS
AF Yao, Jeffrey K.
Dougherty, George G.
Reddy, Ravinder D.
Matson, Wayne R.
Kaddurah-Daouk, Rima
Keshavan, Matcheri S.
TI Associations between purine metabolites and monoamine neurotransmitters
in first-episode psychosis
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Article
DE schizophrenia; first-episode psychosis; neuroleptic-naive; oxidative
stress; purine catabolism; monoamine neurotransmitters
ID SERUM URIC-ACID; NEUROLOGIC EXAMINATION ABNORMALITIES;
MULTIPLE-SCLEROSIS PATIENTS; NEUROLEPTIC-NAIVE PATIENTS; REDOX-ACTIVE
COMPOUNDS; SEROTONERGIC RESPONSIVITY; LIQUID-CHROMATOGRAPHY; PLASMA
ANTIOXIDANTS; CEREBROSPINAL-FLUID; PARKINSONS-DISEASE
AB Schizophrenia (SZ) is a biochemically complex disorder characterized by widespread defects in multiple metabolic pathways whose dynamic interactions, until recently, have been difficult to examine. Rather, evidence for these alterations has been collected piecemeal, limiting the potential to inform our understanding of the interactions amongst relevant biochemical pathways. We herein review perturbations in purine and neurotransmitter metabolism observed in early SZ using a metabolomic approach. Purine catabolism is an underappreciated, but important component of the homeostatic response of mitochondria to oxidant stress. We have observed a homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with SZ (FENNS). Precursor and product relationships within purine pathways are tightly correlated. Although some of these correlations persist across disease or medication status, others appear to be lost among FENNS suggesting that steady formation of the antioxidant uric acid (UA) via purine catabolism is altered early in the course of illness. As is the case for within-pathway correlations, there are also significant cross-pathway correlations between respective purine and tryptophan (TRP) pathway metabolites. By contrast, purine metabolites show significant cross-pathway correlation only with tyrosine, and not with its metabolites. Furthermore, several purine metabolites (UA, guanosine, or xanthine) are each significantly correlated with 5-hydroxyindoleacetic acid (5-HIAA) in healthy controls, but not in FENNS at baseline or 4-week after antipsychotic treatment. Taken together, the above findings suggest that purine catabolism strongly associates with the TRP pathways leading to serotonin (5-hydroxytryptamine, 5-HT) and kynurenine metabolites. The lack of a significant correlation between purine metabolites and 5-HIAA, suggests alterations in key 5-HT pathways that may both be modified by and contribute to oxidative stress via purine catabolism in FENNS.
C1 [Yao, Jeffrey K.; Dougherty, George G.] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA 15206 USA.
[Yao, Jeffrey K.; Dougherty, George G.; Reddy, Ravinder D.; Keshavan, Matcheri S.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Yao, Jeffrey K.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
[Matson, Wayne R.] Bedford VA Med Ctr, Med Res Serv, Bedford, MA USA.
[Kaddurah-Daouk, Rima] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA.
[Keshavan, Matcheri S.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Boston, MA 02215 USA.
[Keshavan, Matcheri S.] Harvard Univ, Boston, MA 02115 USA.
RP Yao, JK (reprint author), VA Pittsburgh Healthcare Syst, Med Res Serv, 7180 Highland Dr,151U-H, Pittsburgh, PA 15206 USA.
EM jkyao@pitt.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory RD; VA Pittsburgh
Healthcare System [MH58141, MH64118, MH45203, MH 45156, R24 GM078233, c
UL1 RR024153, M01 RR00056]; Metabolomics Research Network; Stanley
Medical Research Institute; NARSAD
FX This review is based upon work supported in part by the grants from the
Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Biomedical Laboratory R&D [Merit Reviews
(Jeffrey K. Yao) and Senior Research Career Scientist Award (Jeffrey K.
Yao)], VA Pittsburgh Healthcare System (Jeffrey K. Yao, George G.
Dougherty, Ravinder D. Reddy), National Institute of Health [MH58141
(Jeffrey K. Yao), MH64118 (Ravinder D. Reddy), MH45203 and MH 45156
(Matcheri S. Keshavan), R24 GM078233 (Rima Kaddurah-Daouk), c UL1
RR024153 and NIH/NCRR/GCRC Grant M01 RR00056], Metabolomics Research
Network (Rima Kaddurah-Daouk); Stanley Medical Research Institute (Rima
Kaddurah-Daouk), and NARSAD (Rima Kaddurah-Daouk). The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript. The contents of this article do not
represent the views of the Department of Veterans Affairs or the United
States Government.
NR 99
TC 10
Z9 10
U1 1
U2 14
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JUN 11
PY 2013
VL 7
AR 90
DI 10.3389/fncel.2013.00090
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 170JM
UT WOS:000320846200001
PM 23781173
ER
PT J
AU Bhat-Nakshatri, P
Song, EK
Collins, NR
Uversky, VN
Dunker, AK
O'Malley, BW
Geistlinger, TR
Carroll, JS
Brown, M
Nakshatri, H
AF Bhat-Nakshatri, Poornima
Song, Eun-Kyung
Collins, Nikail R.
Uversky, Vladimir N.
Dunker, A. Keith
O'Malley, Bert W.
Geistlinger, Tim R.
Carroll, Jason S.
Brown, Myles
Nakshatri, Harikrishna
TI Interplay between estrogen receptor and AKT in Estradiol-induced
alternative splicing
SO BMC MEDICAL GENOMICS
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR-2; GENOME-WIDE ASSOCIATION; BREAST-CANCER;
MESSENGER-RNA; GENE-EXPRESSION; BINDING-SITES; ALPHA BINDING; SR
PROTEINS; FAS LIGAND; ACTIVATION
AB Background: Alternative splicing is critical for generating complex proteomes in response to extracellular signals. Nuclear receptors including estrogen receptor alpha (ERa) and their ligands promote alternative splicing. The endogenous targets of ERa: estradiol (E2)-mediated alternative splicing and the influence of extracellular kinases that phosphorylate ERa on E2-induced splicing are unknown.
Methods: MCF-7 and its anti-estrogen derivatives were used for the majority of the assays. CD44 mini gene was used to measure the effect of E2 and AKT on alternative splicing. ExonHit array analysis was performed to identify E2 and AKT-regulated endogenous alternatively spliced apoptosis-related genes. Quantitative reverse transcription polymerase chain reaction was performed to verify alternative splicing. ERa binding to alternatively spliced genes was verified by chromatin immunoprecipitation assay. Bromodeoxyuridine incorporation-ELISA and Annexin V labeling assays were done to measure cell proliferation and apoptosis, respectively.
Results: We identified the targets of E2-induced alternative splicing and deconstructed some of the mechanisms surrounding E2-induced splicing by combining splice array with ERa cistrome and gene expression array. E2-induced alternatively spliced genes fall into at least two subgroups: coupled to E2-regulated transcription and ERa binding to the gene without an effect on rate of transcription. Further, AKT, which phosphorylates both ERa and splicing factors, influenced ERa: E2 dependent splicing in a gene-specific manner. Genes that are alternatively spliced include FAS/CD95, FGFR2, and AXIN-1. E2 increased the expression of FGFR2 C1 isoform but reduced C3 isoform at mRNA level. E2-induced alternative splicing of FAS and FGFR2 in MCF-7 cells correlated with resistance to FAS activation-induced apoptosis and response to keratinocyte growth factor (KGF), respectively. Resistance of MCF-7 breast cancer cells to the anti-estrogen tamoxifen was associated with ERa-dependent overexpression of FGFR2, whereas resistance to fulvestrant was associated with ERa-dependent isoform switching, which correlated with altered response to KGF.
Conclusion: E2 may partly alter cellular proteome through alternative splicing uncoupled to its effects on transcription initiation and aberration in E2-induced alternative splicing events may influence response to anti-estrogens.
C1 [Bhat-Nakshatri, Poornima; Song, Eun-Kyung; Collins, Nikail R.; Nakshatri, Harikrishna] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
[Nakshatri, Harikrishna] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Uversky, Vladimir N.; Dunker, A. Keith] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.
[Dunker, A. Keith] Indiana Univ, Sch Informat, Sch Med Program Bioinformat, Dept Mol & Cellular Biol, Indianapolis, IN 46202 USA.
[O'Malley, Bert W.] Baylor Coll Med, Dept Med Oncol, Houston, TX 77030 USA.
[Geistlinger, Tim R.; Carroll, Jason S.; Brown, Myles] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Geistlinger, Tim R.] Amyris, Emeryville, CA 94608 USA.
[Carroll, Jason S.] Univ Cambridge, Cambridge Res Inst, Cambridge CB2 0RE, England.
[Carroll, Jason S.] Univ Cambridge, Canc Res UK, Dept Oncol, Cambridge CB2 0RE, England.
RP Nakshatri, H (reprint author), Indiana Univ Sch Med, Dept Surg, 980 West Walnut St, Indianapolis, IN 46202 USA.
EM hnakshat@iupui.edu
RI Uversky, Vladimir/F-4515-2011;
OI Uversky, Vladimir/0000-0002-4037-5857; Brown, Myles/0000-0002-8213-1658
FU National Institutes of Health [CA89153]; Susan G. Komen for the Cure
grant [SAC110025]; Korea Science & Engineering Foundation
FX This work is supported by a grant from the National Institutes of Health
(CA89153) and Susan G. Komen for the Cure grant SAC110025. E-K. Song was
supported by a post-doctoral fellowship from the Korea Science &
Engineering Foundation.
NR 61
TC 8
Z9 8
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JUN 11
PY 2013
VL 6
AR 21
DI 10.1186/1755-8794-6-21
PG 18
WC Genetics & Heredity
SC Genetics & Heredity
GA 166RT
UT WOS:000320575500001
PM 23758675
ER
PT J
AU Stirman, SW
Miller, CJ
Toder, K
Calloway, A
AF Stirman, Shannon Wiltsey
Miller, Christopher J.
Toder, Katherine
Calloway, Amber
TI Development of a framework and coding system for modifications and
adaptations of evidence-based interventions
SO IMPLEMENTATION SCIENCE
LA English
DT Article
DE Implementation; Modification; Adaptation; Sustainability
ID COGNITIVE PROCESSING THERAPY; HIV PREVENTION INTERVENTIONS; PROGRAM
FIDELITY; HEALTH-PROGRAMS; SUSTAINABILITY; MODEL; IMPLEMENTATION;
ADHERENCE; PTSD; FACILITATORS
AB Background: Evidence-based interventions are frequently modified or adapted during the implementation process. Changes may be made to protocols to meet the needs of the target population or address differences between the context in which the intervention was originally designed and the one into which it is implemented [Addict Behav 2011, 36(6):630-635]. However, whether modification compromises or enhances the desired benefits of the intervention is not well understood. A challenge to understanding the impact of specific types of modifications is a lack of attention to characterizing the different types of changes that may occur. A system for classifying the types of modifications that are made when interventions and programs are implemented can facilitate efforts to understand the nature of modifications that are made in particular contexts as well as the impact of these modifications on outcomes of interest.
Methods: We developed a system for classifying modifications made to interventions and programs across a variety of fields and settings. We then coded 258 modifications identified in 32 published articles that described interventions implemented in routine care or community settings.
Results: We identified modifications made to the content of interventions, as well as to the context in which interventions are delivered. We identified 12 different types of content modifications, and our coding scheme also included ratings for the level at which these modifications were made (ranging from the individual patient level up to a hospital network or community). We identified five types of contextual modifications (changes to the format, setting, or patient population that do not in and of themselves alter the actual content of the intervention). We also developed codes to indicate who made the modifications and identified a smaller subset of modifications made to the ways that training or evaluations occur when evidence-based interventions are implemented. Rater agreement analyses indicated that the coding scheme can be used to reliably classify modifications described in research articles without overly burdensome training.
Conclusions: This coding system can complement research on fidelity and may advance research with the goal of understanding the impact of modifications made when evidence-based interventions are implemented. Such findings can further inform efforts to implement such interventions while preserving desired levels of program or intervention effectiveness.
C1 [Stirman, Shannon Wiltsey] Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
[Stirman, Shannon Wiltsey; Miller, Christopher J.] VA Boston Healthcare Syst, Boston, MA USA.
[Stirman, Shannon Wiltsey] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Toder, Katherine] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Miller, Christopher J.] VA Ctr Org Leadership & Management Res, Boston, MA USA.
[Calloway, Amber] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
RP Stirman, SW (reprint author), Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA USA.
EM sws@bu.edu
FU National Institute of Mental Health [R00 MH 01800, R25 MH080916-01A2];
Department of Veterans Affairs, Health Services Research & Development
Service, Quality Enhancement Research Initiative (QUERI)
FX The preparation of this article was supported through funding from the
National Institute of Mental Health (R00 MH 01800) [Dr. Stirman]. At the
time that this study was being conducted, Dr. Stirman was a Fellow at
the Implementation Research Institute (IRI), at the George Warren Brown
School of Social Work, Washington University in St. Louis, which is
funded through an award from the National Institute of Mental Health
(R25 MH080916-01A2) and the Department of Veterans Affairs, Health
Services Research & Development Service, Quality Enhancement Research
Initiative (QUERI). We wish to thank Jennifer Gamarra and Andrea DeVito
for their assistance with the preparation of this manuscript. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Mental Health, the National Institutes of Health, or the Department of
Veterans Affairs.
NR 55
TC 41
Z9 41
U1 3
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1748-5908
J9 IMPLEMENT SCI
JI Implement. Sci.
PD JUN 10
PY 2013
VL 8
AR 65
DI 10.1186/1748-5908-8-65
PG 12
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 168OH
UT WOS:000320714900001
PM 23758995
ER
PT J
AU Watanabe, H
Meyerson, M
AF Watanabe, Hideo
Meyerson, Matthew
TI Hopping between Differentiation States in Lung Adenocarcinoma
SO CANCER CELL
LA English
DT Editorial Material
ID NKX2-1; GATA6
AB The work by Cheung and colleagues, in this issue of Cancer Cell, demonstrates another example of how lineage-specific transcriptional regulators of differentiation, GATA6 and HOPX, can control the fate of lung adenocarcinoma progression.
C1 [Watanabe, Hideo; Meyerson, Matthew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Watanabe, Hideo; Meyerson, Matthew] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Watanabe, Hideo; Meyerson, Matthew] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA 02142 USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Meyerson, Matthew] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Watanabe, H (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM hideo_watanabe@dfci.harvard.edu
FU NCI NIH HHS [R01 CA109038]
NR 11
TC 5
Z9 5
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD JUN 10
PY 2013
VL 23
IS 6
BP 707
EP 709
DI 10.1016/j.ccr.2013.05.013
PG 3
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 163QB
UT WOS:000320350900001
PM 23763994
ER
PT J
AU Buchwalter, G
Hickey, MM
Cromer, A
Selfors, LM
Gunawardane, RN
Frishman, J
Jeselsohn, R
Lim, E
Chi, D
Fu, XY
Schiff, R
Brown, M
Brugge, JS
AF Buchwalter, Gilles
Hickey, Michele M.
Cromer, Anne
Selfors, Laura M.
Gunawardane, Ruwanthi N.
Frishman, Jason
Jeselsohn, Rinath
Lim, Elgene
Chi, David
Fu, Xiaoyong
Schiff, Rachel
Brown, Myles
Brugge, Joan S.
TI PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for
ER-Positive Breast Cancer Cells
SO CANCER CELL
LA English
DT Article
ID ETS TRANSCRIPTION FACTOR; GENE-EXPRESSION PATTERNS; GENOME-WIDE
ANALYSIS; FACTOR MESSENGER-RNA; MAMMARY-GLAND; IN-VIVO; RECEPTOR;
TUMORS; EPITHELIUM; INVASION
AB Breast cancer is a heterogeneous disease and can be classified based on gene expression profiles that reflect distinct epithelial subtypes. We identify prostate-derived ETS factor (PDEF) as a mediator of mammary luminal epithelial lineage-specific gene expression and as a factor required for tumorigenesis in a subset of breast cancers. PDEF levels strongly correlate with estrogen receptor (ER)-positive luminal breast cancer, and PDEF transcription is inversely regulated by ER and GATA3. Furthermore, PDEF is essential for luminal breast cancer cell survival and is required in models of endocrine resistance. These results offer insights into the function of this ETS factor that are clinically relevant and may be of therapeutic value for patients with breast cancer treated with endocrine therapy.
C1 [Buchwalter, Gilles; Frishman, Jason; Jeselsohn, Rinath; Lim, Elgene; Chi, David; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA.
[Buchwalter, Gilles; Frishman, Jason; Jeselsohn, Rinath; Lim, Elgene; Chi, David; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Buchwalter, Gilles; Frishman, Jason; Jeselsohn, Rinath; Lim, Elgene; Chi, David; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Hickey, Michele M.; Cromer, Anne; Selfors, Laura M.; Gunawardane, Ruwanthi N.; Brugge, Joan S.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA.
[Fu, Xiaoyong; Schiff, Rachel] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77054 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA 02215 USA.
EM myles_brown@dfci.harvard.edu; joan_brugge@hms.harvard.edu
OI Lim, Elgene/0000-0001-8065-8838; Brown, Myles/0000-0002-8213-1658
FU DOD Breast Cancer Research Program Postdoctoral Fellowship
[W81XWH-10-1-0029]; Association pour la Recherche contre le Cancer;
Susan G. Komen for the Cure [KG080737]; Breast Cancer Research
Foundation; NCI [P01 CA080111]; NIDDK [R01 DK074967]
FX We are grateful to Housheng Hansen He for help with gene expression
analysis and the Nikon Imaging Center at Harvard Medical School, the
DF/HCC Rodent Histopathology Core, the Developmental Studies Hybridoma
Bank at the University of Iowa, and members of the Brugge and Brown
laboratories for technical assistance and helpful discussions. This work
was supported by a DOD Breast Cancer Research Program Postdoctoral
Fellowship (W81XWH-10-1-0029 to M.M.H.), fellowships from the
Association pour la Recherche contre le Cancer (to G.B.) and Susan G.
Komen for the Cure (KG080737 to G.B.), and grants from the Breast Cancer
Research Foundation (to J.S.B.), the NCI (P01 CA080111 to M.B.), and
NIDDK (R01 DK074967 to M.B.).
NR 49
TC 18
Z9 19
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD JUN 10
PY 2013
VL 23
IS 6
BP 753
EP 767
DI 10.1016/j.ccr.2013.04.026
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 163QB
UT WOS:000320350900009
PM 23764000
ER
PT J
AU Chen, LF
Monti, S
Juszczynski, P
Ouyang, J
Chapuy, B
Neuberg, D
Doench, JG
Bogusz, AM
Habermann, TM
Dogan, A
Witzig, TE
Kutok, JL
Rodig, SJ
Golub, T
Shipp, MA
AF Chen, Linfeng
Monti, Stefano
Juszczynski, Przemyslaw
Ouyang, Jing
Chapuy, Bjoern
Neuberg, Donna
Doench, John G.
Bogusz, Agata M.
Habermann, Thomas M.
Dogan, Ahmet
Witzig, Thomas E.
Kutok, Jeffery L.
Rodig, Scott J.
Golub, Todd
Shipp, Margaret A.
TI SYK Inhibition Modulates Distinct PI3K/AKT-Dependent Survival Pathways
and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas
SO CANCER CELL
LA English
DT Article
ID NF-KAPPA-B; HEMATOPOIETIC PROGENITOR CELLS; CHRONIC
LYMPHOCYTIC-LEUKEMIA; NON-HODGKIN-LYMPHOMA; THERAPEUTIC TARGET;
GENE-EXPRESSION; LIPID RAFTS; PRE-BCR; DEREGULATION; ACTIVATION
AB B cell receptor (BCR) signaling pathway components represent promising treatment targets in diffuse large B cell lymphoma (DLBCL) and additional B cell tumors. BCR signaling activates spleen tyrosine kinase (SYK) and downstream pathways including PI3K/AKT and NF-kappa B. In previous studies, chemical SYK blockade selectively decreased BCR signaling and induced apoptosis of BCR-dependent DLBCLs. Herein, we characterize distinct SYK/PI3K-dependent survival pathways in DLBCLs with high or low baseline NF-KB activity including selective repression of the pro-apoptotic HRK protein in NF-kappa B-low tumors. We also define SYK/PI3K-dependent cholesterol biosynthesis as a feed-forward mechanism of maintaining the integrity of BCRs in lipid rafts in DLBCLs with low or high NF-kappa B. In addition, SYK amplification and PTEN deletion are identified as selective genetic alterations in primary "BCR"-type DLBCLs.
C1 [Chen, Linfeng; Juszczynski, Przemyslaw; Ouyang, Jing; Chapuy, Bjoern; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02215 USA.
[Monti, Stefano; Doench, John G.; Golub, Todd] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02142 USA.
[Bogusz, Agata M.; Kutok, Jeffery L.; Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Habermann, Thomas M.; Witzig, Thomas E.] Mayo Clin, Dept Med, Rochester, MN 55905 USA.
[Dogan, Ahmet] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA.
RP Shipp, MA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM margaret_shipp@dfci.harvard.edu
OI Monti, Stefano/0000-0002-9376-0660; Doench, John/0000-0002-3707-9889
FU NIH [P01CA092625, LLS SCOR 7391, LLS SCOR 7009]
FX This work was supported by NIH grants P01CA092625, LLS SCOR 7391, and
LLS SCOR 7009.
NR 49
TC 37
Z9 44
U1 3
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD JUN 10
PY 2013
VL 23
IS 6
BP 826
EP 838
DI 10.1016/j.ccr.2013.05.002
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 163QB
UT WOS:000320350900014
PM 23764004
ER
PT J
AU Bekelman, JE
Kim, M
Emanuel, EJ
AF Bekelman, Justin E.
Kim, Miranda
Emanuel, Ezekiel J.
TI Toward Accountable Cancer Care
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID MEDICARE
C1 [Bekelman, Justin E.] Univ Penn, Abramson Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Emanuel, Ezekiel J.] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA.
[Bekelman, Justin E.; Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Emanuel, Ezekiel J.] Univ Penn, Wharton Sch Business, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Kim, Miranda] Dana Farber Harvard Canc Ctr, Harvard Joint Ctr Radiat Therapy, Boston, MA USA.
RP Bekelman, JE (reprint author), Univ Penn, Perelman Sch Med, Perelman Ctr Adv Med, Abramson Canc Ctr, 4 West,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA.
EM bekelman@uphs.upenn.edu
FU NCI NIH HHS [K07 CA163616]
NR 7
TC 7
Z9 7
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 10
PY 2013
VL 173
IS 11
BP 958
EP 959
DI 10.1001/jamainternmed.2013.635
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159MT
UT WOS:000320050200005
PM 23699890
ER
PT J
AU Flood, KL
MacLennan, PA
McGrew, D
Green, D
Dodd, C
Brown, CJ
AF Flood, Kellie L.
MacLennan, Paul A.
McGrew, Deborah
Green, Darlene
Dodd, Cindy
Brown, Cynthia J.
TI Effects of an Acute Care for Elders Unit on Costs and 30-Day
Readmissions
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID HOSPITALIZED OLDER PATIENTS; ONCOLOGY-ACUTE CARE; FUNCTIONAL DECLINE;
CONTROLLED TRIAL; HEALTH-CARE; HIGH-RISK; OUTCOMES; ADULTS;
INTERVENTION; MOBILITY
AB Importance: Providing high-quality care while containing cost is essential for the economic stability of our health care system. The United States is experiencing a rapidly growing elderly population. The Acute Care for Elders (ACE) unit interdisciplinary team model of care has been shown to improve outcomes in hospitalized older adults. The University of Alabama at Birmingham ACE unit incorporates evidence-based care processes. We hypothesized that the ACE model would also reduce costs.
Objective: To examine variable direct costs from an interdisciplinary ACE compared with a multidisciplinary usual care (UC) unit.
Design: Retrospective cohort study.
Setting: Tertiary care academic medical center.
Participants: Hospitalists' patients aged 70 years or older spending the entirety of their hospitalization in either the ACE or UC unit in fiscal year 2010.
Main Outcome Measures: Using administrative data, we analyzed variable direct costs for ACE and UC patients. We also conducted a subset analysis restricted to the 25 most common diagnosis related groups (DRGs) shared by ACE and UC patients. Generalized linear regression was used to estimate cost ratios and 95% confidence intervals adjusted for age, sex, comorbidity score, and case mix index (CMI).
Results: A total of 818 hospitalists' patients met inclusion criteria: 428 from the ACE and 390 from the UC unit. For this study group (all DRGs), the mean (SD) variable direct cost per patient was $2109 ($1870) for ACE and $2480 ($2113) for UC (P=.009). Adjusted cost ratios revealed significant cost savings for patients with low (0.82; 95% CI, 0.72-0.94) or moderate (0.74; 95% CI, 0.620.89) CMI scores; care was cost neutral for patients with high CMI scores (1.13; 95% CI, 0.93-1.37). Significantly fewer ACE patients than UC patients were readmitted within 30 days of discharge (7.9% vs 12.8%; P=.02). Subset analysis of the 25 most common DRGs revealed a significantly reduced mean (SD) variable direct cost per patient for ACE compared with UC patients ($1693 [$1063] vs $2138 [$1431]; P<.001); cost ratios for total (0.78; 95% CI, 0.70-0.87) and daily (0.89; 95% CI, 0.85-0.94) variable direct costs remained significant after adjustment.
Conclusions and Relevance: The ACE unit team model reduces costs and 30-day readmissions. In an era when improving care processes while reducing costs is a vital objective for the Medicare program and our nation as a whole, the ACE model meets these goals.
C1 [Flood, Kellie L.; Brown, Cynthia J.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA.
[MacLennan, Paul A.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[McGrew, Deborah; Green, Darlene; Dodd, Cindy] Univ Alabama Birmingham, Birmingham Hosp, Birmingham, AL 35294 USA.
[Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Flood, KL (reprint author), Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, 1720 2nd Ave S,CH-19,Room 219, Birmingham, AL 35294 USA.
EM kflood@uabmc.edu
NR 33
TC 21
Z9 22
U1 2
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 10
PY 2013
VL 173
IS 11
BP 981
EP 987
DI 10.1001/jamainternmed.2013.524
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159MT
UT WOS:000320050200010
PM 23609002
ER
PT J
AU Hung, WW
Ross, JS
Farber, J
Siu, AL
AF Hung, William W.
Ross, Joseph S.
Farber, Jeffrey
Siu, Albert L.
TI Evaluation of the Mobile Acute Care of the Elderly (MACE) Service
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID HOSPITALIZED OLDER PATIENTS; UNITED-STATES; MULTICOMPONENT INTERVENTION;
FUNCTIONAL OUTCOMES; MEDICAL UNIT; SYSTEM; VALIDATION; COMMUNITY;
DELIRIUM; SCORES
AB Importance: Older adults are particularly vulnerable to adverse events during hospitalization for acute medical problems. The Mobile Acute Care of the Elderly (MACE) service is a novel model of care delivered by an interdisciplinary team, designed to deliver specialized care to hospitalized older adults to improve patient outcomes.
Objective: To evaluate the impact of the MACE service when compared with general medical service (usual care).
Design: Prospective, matched cohort study.
Setting: The Mount Sinai Hospital, an urban tertiary acute care hospital.
Participants: Patients aged 75 years or older admitted because of an acute illness to either the MACE service or usual care. Patients were matched for age, diagnosis, and ability to ambulate independently.
Exposures: Admission to the MACE service when compared with admission to usual care.
Main Outcome Measures: Patient outcomes included incidence of adverse events, including falls, pressure ulcers, restraint use, and catheter-associated urinary tract infections, along with length of stay, rehospitalization within 30 days, functional status at 30 days, and patient satisfaction during care transitions, measured with the 3-item Care Transition Measure.
Results: A total of 173 matched pairs of patients were recruited. The mean (SD) age was 85.2 (5.3) and 84.7 (5.4) years in the MACE and usual-care groups, respectively. After adjustment for confounders, patients in the MACE group were less likely to experience adverse events (9.5% vs 17.0%; adjusted odds ratio, 0.11; 95% CI, 0.01-0.88; P=.04) and had shorter hospital stays (0.8 days, 95% CI, 0.7-0.9; P=.001) than patients receiving usual care. Patients in the MACE group were not less likely to have a lower rate of rehospitalization within 30 days than those in the usual-care group (odds ratio, 0.91; 95% CI, 0.39-2.10; P=.83). Functional status did not differ between the 2 groups. Care Transition Measure scores were 7.4 points (95% CI, 2.9-11.9; P=.001) higher in the MACE group.
Conclusions and Relevance: Admission to the MACE service was associated with lower rates of adverse events, shorter hospital stays, and better satisfaction. This model has the potential to improve care outcomes among hospitalized older adults.
C1 [Hung, William W.; Farber, Jeffrey; Siu, Albert L.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA.
[Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Hlth Serv Res & Dev Serv, Bronx, NY USA.
[Hung, William W.; Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ Clin Ctr, Bronx, NY USA.
[Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA.
[Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
RP Hung, WW (reprint author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,POB 1070, New York, NY 10029 USA.
EM william.hung@mssm.edu
FU Medtronic, Inc; National Institute on Aging [K08 AG032886]; American
Federation for Aging Research through the Paul B. Beeson Career
Development Award Program; John A. Hartford Center of Excellence; Claude
D. Pepper Older Americans Independence Center at Mount Sinai School of
Medicine [P30-AG028741]; Centers for Medicare & Medicaid Services; Pew
Charitable Trusts
FX Dr Ross reports that he is a member of a scientific advisory board for
FAIR Health, Inc, and receives grant funding from Medtronic, Inc, to
develop methods of clinical trial data sharing, from the Centers for
Medicare & Medicaid Services to develop and maintain performance
measures used for public reporting, and from the Pew Charitable Trusts
to examine regulatory issues at the US Food and Drug Administration. Dr
Ross is supported by the National Institute on Aging (grant K08
AG032886) and by the American Federation for Aging Research through the
Paul B. Beeson Career Development Award Program.; Support for this
project was provided by the John A. Hartford Center of Excellence and in
part by the Claude D. Pepper Older Americans Independence Center at
Mount Sinai School of Medicine (grant P30-AG028741).
NR 28
TC 9
Z9 9
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 10
PY 2013
VL 173
IS 11
BP 990
EP 996
DI 10.1001/jamainternmed.2013.478
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159MT
UT WOS:000320050200012
PM 23608775
ER
PT J
AU Linos, E
Parvataneni, R
Stuart, SE
Boscardin, WJ
Landefeld, CS
Chren, MM
AF Linos, Eleni
Parvataneni, Rupa
Stuart, Sarah E.
Boscardin, W. John
Landefeld, C. Seth
Chren, Mary-Margaret
TI Treatment of Nonfatal Conditions at the End of Life Nonmelanoma Skin
Cancer
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID MOHS MICROGRAPHIC SURGERY; BASAL-CELL CARCINOMA; UNITED-STATES; CARE;
COHORT
AB Importance: Nonmelanoma skin cancer (NMSC) is the most common cancer and predominantly affects older patients. Because NMSCs do not typically affect survival or short-term quality of life, the decision about whether and how to treat patients with limited life expectancy (LLE) is challenging, especially for asymptomatic tumors.
Objective: To compare treatment patterns and clinical outcomes of patients with NMSC with and without LLE.
Design, Setting, and Participants: A prospective cohort study of 1536 consecutive patients diagnosed with NMSC at 2 dermatology clinics: a university-based private practice and a Veterans Affairs Medical Center in San Francisco, California. Patients were recruited in 1999 through 2000 and followed up for a median of 9 years. A total of 1360 patients with 1739 tumors (90%) were included in the final analysis. Limited life expectancy was defined as patients either 85 years or older at the time of diagnosis or patients with multiple comorbidities (Charlson Comorbidity Index of >= 3). Treatment options included no treatment, destruction, or 2 types of surgery-elliptical excision or Mohs surgery.
Main Outcomes and Measures: Treatment type.
Results: Most NMSCs (69%) were treated surgically, regardless of patient life expectancy. The choice of surgery was not influenced by patient prognosis in univariate or multivariable models adjusted for tumor and patient characteristics. Many patients with LLE (43%) died within 5 years, none of NMSC. Tumor recurrence was rare (3.7% at 5 years [95% CI, 2.6%-4.7%]) in all patients. Although serious complications were unusual, approximately 20% of patients with LLE reported complications of therapy, compared with 15% of other patients.
Conclusions and Relevance: Most NMSCs are treated surgically, regardless of the patient's life expectancy. Given the very low tumor recurrence rates and high mortality from causes unrelated to NMSC in patients with LLE, clinicians should consider whether these patients would prefer less invasive treatment strategies.
C1 [Linos, Eleni; Parvataneni, Rupa; Stuart, Sarah E.; Chren, Mary-Margaret] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Landefeld, C. Seth] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA.
[Chren, Mary-Margaret] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,Room N421,Mail Code Box 0808, San Francisco, CA 94143 USA.
EM linose@derm.ucsf.edu
RI Linos, Eleni/C-4392-2014;
OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700
FU National Center for Research Resources [KL2RR024130]; National Institute
of Arthritis and Musculoskeletal and Skin Diseases, National Institutes
of Health [R01 AR 054983, K24 AR052667]; American Skin Association;
Dermatology Foundation
FX This study was supported in part by Award KL2RR024130 from the National
Center for Research Resources (Dr Linos), by grants R01 AR 054983 and
K24 AR052667 from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, National Institutes of Health (Dr
Chren), and by a Career Development Award from the American Skin
Association and Dermatology Foundation (Dr Linos).
NR 23
TC 17
Z9 17
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD JUN 10
PY 2013
VL 173
IS 11
BP 1006
EP 1012
DI 10.1001/jamainternmed.2013.639
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159MT
UT WOS:000320050200016
PM 23699934
ER
PT J
AU Stone, RM
AF Stone, Richard M.
TI Consolidation Chemotherapy for Adults With AML in First Remission: Is
There a Best Choice?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; HIGH-DOSE CYTARABINE; GROUP-B; THERAPY;
MUTATIONS; CANCER; INTENSIFICATION; YOUNGER; AGE
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Stone, RM (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.
FU Novartis
FX Research Funding: Richard M. Stone, Novartis
NR 22
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2067
EP 2069
DI 10.1200/JCO.2013.48.6886
PG 3
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400009
PM 23630213
ER
PT J
AU Marcucci, G
Maharry, KS
Metzeler, KH
Volinia, S
Wu, YZ
Mrozek, K
Nicolet, D
Kohlschmidt, J
Whitman, SP
Mendler, JH
Schwind, S
Becker, H
Eisfeld, AK
Carroll, AJ
Powell, BL
Kolitz, JE
Garzon, R
Caligiuri, MA
Stone, RM
Bloomfield, CD
AF Marcucci, Guido
Maharry, Kati S.
Metzeler, Klaus H.
Volinia, Stefano
Wu, Yue-Zhong
Mrozek, Krzysztof
Nicolet, Deedra
Kohlschmidt, Jessica
Whitman, Susan P.
Mendler, Jason H.
Schwind, Sebastian
Becker, Heiko
Eisfeld, Ann-Kathrin
Carroll, Andrew J.
Powell, Bayard L.
Kolitz, Jonathan E.
Garzon, Ramiro
Caligiuri, Michael A.
Stone, Richard M.
Bloomfield, Clara D.
TI Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid
Leukemia: miR-155 Upregulation Independently Identifies High-Risk
Patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID RESISTANCE MODULATOR PSC-833; PARTIAL TANDEM DUPLICATION; AGE 60 YEARS;
GROUP-B; OLDER PATIENTS; EXPRESSION SIGNATURES; PROGNOSTIC-SIGNIFICANCE;
DISTINCT GENE; EUROPEAN LEUKEMIANET; CANCER
AB Purpose
To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other clinical and molecular prognosticators and to gain insight into the leukemogenic role of this microRNA.
Patients and Methods
We evaluated 363 patients with primary CN-AML. miR-155 levels were measured in pretreatment marrow and blood by NanoString nCounter assays that quantified the expression of the encoding gene MIR155HG. All molecular prognosticators were assessed centrally. miR-155-associated gene and microRNA expression profiles were derived using microarrays.
Results
Considering all patients, high miR-155 expression was associated with a lower complete remission (CR) rate (P < .001) and shorter disease-free survival (P = .001) and overall survival (OS; P < .001) after adjusting for age. In multivariable analyses, high miR-155 expression remained an independent predictor for a lower CR rate (P = .007) and shorter OS (P < .001). High miR-155 expressers had approximately 50% reduction in the odds of achieving CR and 60% increase in the risk of death compared with low miR-155 expressers. Although high miR-155 expression was not associated with a distinct microRNA expression profile, it was associated with a gene expression profile enriched for genes involved in cellular mechanisms deregulated in AML (eg, apoptosis, nuclear factor-kappa B activation, and inflammation), thereby supporting a pivotal and unique role of this microRNA in myeloid leukemogenesis.
Conclusion
miR-155 expression levels are associated with clinical outcome independently of other strong clinical and molecular predictors. The availability of emerging compounds with antagonistic activity to microRNAs in the clinic provides the opportunity for future therapeutic targeting of miR-155 in AML. (C) 2013 by American Society of Clinical Oncology
C1 [Marcucci, Guido; Maharry, Kati S.; Metzeler, Klaus H.; Volinia, Stefano; Wu, Yue-Zhong; Mrozek, Krzysztof; Nicolet, Deedra; Kohlschmidt, Jessica; Whitman, Susan P.; Mendler, Jason H.; Schwind, Sebastian; Becker, Heiko; Eisfeld, Ann-Kathrin; Garzon, Ramiro; Caligiuri, Michael A.; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Maharry, Kati S.; Nicolet, Deedra; Kohlschmidt, Jessica] Mayo Clin, Alliance Clin Trials Oncol Stat & Data Ctr, Rochester, MN USA.
[Carroll, Andrew J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA.
[Kolitz, Jonathan E.] Monter Canc Ctr, Lake Success, NY USA.
[Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Marcucci, G (reprint author), Ohio State Univ, Ctr Comprehens Canc, Biomed Res Tower 460 W 12th Ave, Columbus, OH 43210 USA.
EM guido.marcucci@osumc.edu
RI Metzeler, Klaus/C-2118-2009; Garzon, Ramiro/E-3104-2011; Mrozek,
Krzysztof/A-3142-2008;
OI Metzeler, Klaus/0000-0003-3920-7490; Mendler, Jason/0000-0001-5605-5324;
Volinia, Stefano/0000-0003-0910-3893
FU National Cancer Institute (Bethesda, MD) [CA101140, CA114725, CA31946,
CA33601, CA16058, CA77658, CA129657, CA140158]; Coleman Leukemia
Research Foundation; Deutsche Krebshilfe-Dr Mildred Scheel Cancer
Foundation; Pelotonia Fellowship Program; Conquer Cancer Foundation
FX Supported in part by National Cancer Institute (Bethesda, MD) Grants No.
CA101140, CA114725, CA31946, CA33601, CA16058, CA77658, CA129657, and
CA140158; the Coleman Leukemia Research Foundation; the Deutsche
Krebshilfe-Dr Mildred Scheel Cancer Foundation (H.B.); the Pelotonia
Fellowship Program (A.-K.E.); and the Conquer Cancer Foundation
(J.H.M.).
NR 48
TC 75
Z9 80
U1 0
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2086
EP 2093
DI 10.1200/JCO.2012.45.6228
PG 8
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400014
PM 23650424
ER
PT J
AU Shepherd, FA
Domerg, C
Hainaut, P
Janne, PA
Pignon, JP
Graziano, S
Douillard, JY
Brambilla, E
Le Chevalier, T
Seymour, L
Bourredjem, A
Teuff, G
Pirker, R
Filipits, M
Rosell, R
Kratzke, R
Bandarchi, B
Ma, XL
Capelletti, M
Soria, JC
Tsao, MS
AF Shepherd, Frances A.
Domerg, Caroline
Hainaut, Pierre
Jaenne, Pasi A.
Pignon, Jean-Pierre
Graziano, Stephen
Douillard, Jean-Yves
Brambilla, Elizabeth
Le Chevalier, Thierry
Seymour, Lesley
Bourredjem, Abderrahmane
Le Teuff, Gwenael
Pirker, Robert
Filipits, Martin
Rosell, Rafael
Kratzke, Robert
Bandarchi, Bizhan
Ma, Xiaoli
Capelletti, Marzia
Soria, Jean-Charles
Tsao, Ming-Sound
TI Pooled Analysis of the Prognostic and Predictive Effects of KRAS
Mutation Status and KRAS Mutation Subtype in Early-Stage Resected
Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID K-RAS ONCOGENE; METASTATIC COLORECTAL-CANCER; VINORELBINE PLUS
CISPLATIN; GROWTH-FACTOR RECEPTOR; MOLECULAR BIOMARKERS; PHASE-III;
ADENOCARCINOMA; ACTIVATION; EGFR; RESISTANCE
AB Purpose
We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles of KRAS in non-small-cell lung cancer (NSCLC).
Methods
KRAS mutation was determined in blinded fashion. Exploratory analyses were performed to characterize relationships between mutation status and subtype and survival outcomes using a multivariable Cox model.
Results
Among 1,543 patients (763 OBS, 780 ACT), 300 had KRAS mutations (codon 12, n = 275; codon 13, n = 24; codon 14, n = 1). In OBS patients, there was no prognostic difference for overall survival for codon-12 (mutation v wild type [WT] hazard ratio [HR] = 1.04; 95% CI, 0.77 to 1.40) or codon-13 (HR = 1.01; 95% CI, 0.47 to 2.17) mutations. No significant benefit from ACT was observed for WT-KRAS (ACT v OBS HR = 0.89; 95% CI, 0.76 to 1.04; P = .15) or codon-12 mutations (HR = 0.95; 95% CI, 0.67 to 1.35; P = .77); with codon-13 mutations, ACT was deleterious (HR = 5.78; 95% CI, 2.06 to 16.2; P < .001; interaction P = .002). There was no prognostic effect for specific codon-12 amino acid substitution. The effect of ACT was variable among patients with codon-12 mutations: G12A or G12R (HR = 0.66; P = .48), G12C or G12V (HR = 0.94; P = .77) and G12D or G12S (HR = 1.39; P = .48; comparison of four HRs, including WT, interaction P = .76). OBS patients with KRAS-mutated tumors were more likely to develop second primary cancers (HR = 2.76, 95% CI, 1.34 to 5.70; P = .005) but not ACT patients (HR = 0.66; 95% CI, 0.25 to 1.75; P = .40; interaction, P = .02).
Conclusion
KRAS mutation status is not significantly prognostic. The potential interaction in patients with codon-13 mutations requires validation. At this time, KRAS status cannot be recommended to select patients with NSCLC for ACT. (C) 2013 by American Society of Clinical Oncology
C1 [Shepherd, Frances A.; Bandarchi, Bizhan; Tsao, Ming-Sound] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.
[Shepherd, Frances A.; Bandarchi, Bizhan; Tsao, Ming-Sound] Univ Toronto, Toronto, ON, Canada.
[Seymour, Lesley] Queens Univ, Natl Canc Inst, Canada Clin Trials Grp, Kingston, ON, Canada.
[Domerg, Caroline; Pignon, Jean-Pierre; Le Chevalier, Thierry; Bourredjem, Abderrahmane; Le Teuff, Gwenael; Soria, Jean-Charles] Inst Gustave Roussy, Paris, France.
[Domerg, Caroline; Pignon, Jean-Pierre; Le Chevalier, Thierry; Bourredjem, Abderrahmane; Le Teuff, Gwenael; Soria, Jean-Charles] Univ Paris 11, Paris, France.
[Hainaut, Pierre; Ma, Xiaoli] Int Agcy Res Canc, F-69372 Lyon, France.
[Douillard, Jean-Yves] Inst Cancerol Ouest, St Herblain, France.
[Brambilla, Elizabeth] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France.
[Jaenne, Pasi A.; Capelletti, Marzia] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Graziano, Stephen] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[Pirker, Robert; Filipits, Martin] Med Univ Vienna, Vienna, Austria.
[Rosell, Rafael] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain.
[Kratzke, Robert] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
RP Shepherd, FA (reprint author), Princess Margaret Hosp, Dept Med Oncol & Hematol, Room 5-103,610 Univ Ave, Toronto, ON M5G 2M9, Canada.
EM frances.shepherd@uhn.on.ca
RI Brambilla, Elisabeth/L-8796-2013; Hainaut, Pierre /B-6018-2012
OI Hainaut, Pierre /0000-0002-1303-1610
FU Ligue Nationale Contre le Cancer (France); Programme National
d'Excellence Spe'cialise cancer du poumon de l'Institut National du
Cancer (INCa) (France); National Cancer Institute (United States);
Canadian Cancer Society Research Institute (Canada)
FX Supported by la Ligue Nationale Contre le Cancer (France), le Programme
National d'Excellence Spe'cialise cancer du poumon de l'Institut
National du Cancer (INCa) (France), the National Cancer Institute
(United States), the Canadian Cancer Society Research Institute
(Canada), and an unrestricted grant from Sanofi.
NR 40
TC 76
Z9 76
U1 0
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2173
EP U168
DI 10.1200/JCO.2012.48.1390
PG 10
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400026
PM 23630215
ER
PT J
AU Jain, RK
AF Jain, Rakesh K.
TI Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to
Biomarkers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTERSTITIAL FLUID PRESSURE; METASTATIC
BREAST-CANCER; FACTOR RECEPTOR-2 BLOCKADE; ANTI-ANGIOGENIC THERAPY;
PHASE-I TRIAL; SOLID TUMORS; ANTIANGIOGENIC THERAPY; BLOOD-FLOW;
VASCULAR NORMALIZATION
AB For almost four decades, my work has focused on one challenge: improving the delivery and efficacy of anticancer therapeutics. Working on the hypothesis that the abnormal tumor microenvironment-characterized by hypoxia and high interstitial fluid pressure-fuels tumor progression and treatment resistance, we developed an array of sophisticated imaging technologies and animal models as well as mathematic models to unravel the complex biology of tumors. Using these tools, we demonstrated that the blood and lymphatic vasculature, fibroblasts, immune cells, and extracellular matrix associated with tumors are abnormal, which together create a hostile tumor microenvironment. We next hypothesized that agents that induce normalization of the microenvironment can improve treatment outcome. Indeed, we demonstrated that judicious use of antiangiogenic agents-originally designed to starve tumors-could transiently normalize tumor vasculature, alleviate hypoxia, increase delivery of drugs and antitumor immune cells, and improve the outcome of various therapies. Our trials of antiangiogenics in patients with newly diagnosed and recurrent glioblastoma supported this concept. They revealed that patients whose tumor blood perfusion increased in response to cediranib survived 6 to 9 months longer than those whose blood perfusion did not increase. The normalization hypothesis also opened doors to treating various nonmalignant diseases characterized by abnormal vasculature, such as neurofibromatosis type 2. More recently, we discovered that antifibrosis drugs capable of normalizing the tumor microenvironment can improve the delivery and efficacy of nano-and molecular medicines. Our current efforts are directed at identifying predictive biomarkers and more-effective strategies to normalize the tumor microenvironment for enhancing anticancer therapies. (C) 2013 by American Society of Clinical Oncology
C1 [Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA USA.
[Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Jain, RK (reprint author), Harvard Univ, Sch Med, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, 100 Blossom St,Cox 7, Boston, MA 02115 USA.
EM jain@steele.mgh.harvard.edu
RI Arumugam, Thirumagal/C-3408-2014
FU National Cancer Institute; National Science Foundation; Department of
Defense Breast Cancer Research; American Cancer Society; National
Foundation for Cancer Research; Goldhirsh Foundation; Brain Tumor
Society; AstraZeneca; DuPont-Merck; Enzon; Genentech; Hybritech;
ImClone; Medimmune; Miravant; Roche
FX Supported by grants from the National Cancer Institute (1980 to
present), National Science Foundation (1976-1999), Department of Defense
Breast Cancer Research Program (1996-2002; 2010 to present), American
Cancer Society (1980-1992), National Foundation for Cancer Research
(1998 to present), Goldhirsh Foundation (2002-2006), and Brain Tumor
Society (2006-2008) and by grants from AstraZeneca, DuPont-Merck, Enzon,
Genentech, Hybritech, ImClone, Medimmune, Miravant, Roche.
NR 173
TC 239
Z9 246
U1 18
U2 138
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2205
EP U210
DI 10.1200/JCO.2012.46.3653
PG 15
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400029
PM 23669226
ER
PT J
AU Joyce, CE
Novina, CD
AF Joyce, Cailin E.
Novina, Carl D.
TI miR-155 in Acute Myeloid Leukemia: Not Merely a Prognostic Marker?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
ID MICRORNA EXPRESSION; TRANSCRIPTION FACTOR; TARGETS; SIGNATURE; CANCER;
PU.1
C1 [Joyce, Cailin E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA.
RP Joyce, CE (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 23
TC 4
Z9 4
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2219
EP 2221
DI 10.1200/JCO.2012.48.3180
PG 3
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400030
PM 23650419
ER
PT J
AU Mayer, EL
Lin, NU
AF Mayer, Erica L.
Lin, Nancy U.
TI Questionable Validity of Cardiac Risk Score on the Basis of the NSABP
B-31 Model Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID BREAST-CANCER; TRASTUZUMAB
C1 [Mayer, Erica L.; Lin, Nancy U.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
RP Mayer, EL (reprint author), Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUN 10
PY 2013
VL 31
IS 17
BP 2225
EP 2226
DI 10.1200/JCO.2012.48.3719
PG 2
WC Oncology
SC Oncology
GA 160FZ
UT WOS:000320104400036
PM 23901420
ER
PT J
AU McDavid, A
Crane, PK
Newton, KM
Crosslin, DR
McCormick, W
Weston, N
Ehrlich, K
Hart, E
Harrison, R
Kukull, WA
Rottscheit, C
Peissig, P
Stefanski, E
McCarty, CA
Zuvich, RL
Ritchie, MD
Haines, JL
Denny, JC
Schellenberg, GD
de Andrade, M
Kullo, I
Li, RL
Mirel, D
Crenshaw, A
Bowen, JD
Li, G
Tsuang, D
McCurry, S
Teri, L
Larson, EB
Jarvik, GP
Carlson, CS
AF McDavid, Andrew
Crane, Paul K.
Newton, Katherine M.
Crosslin, David R.
McCormick, Wayne
Weston, Noah
Ehrlich, Kelly
Hart, Eugene
Harrison, Robert
Kukull, Walter A.
Rottscheit, Carla
Peissig, Peggy
Stefanski, Elisha
McCarty, Catherine A.
Zuvich, Rebecca Lynn
Ritchie, Marylyn D.
Haines, Jonathan L.
Denny, Joshua C.
Schellenberg, Gerard D.
de Andrade, Mariza
Kullo, Iftikhar
Li, Rongling
Mirel, Daniel
Crenshaw, Andrew
Bowen, James D.
Li, Ge
Tsuang, Debby
McCurry, Susan
Teri, Linda
Larson, Eric B.
Jarvik, Gail P.
Carlson, Chris S.
TI Enhancing the Power of Genetic Association Studies through the Use of
Silver Standard Cases Derived from Electronic Medical Records
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA;
CATEGORICAL-DATA; COMMON VARIANTS; MISCLASSIFICATION; DIAGNOSIS;
CRITERIA; LINKAGE; CD2AP
AB The feasibility of using imperfectly phenotyped "silver standard" samples identified from electronic medical record diagnoses is considered in genetic association studies when these samples might be combined with an existing set of samples phenotyped with a gold standard technique. An analytic expression is derived for the power of a chi-square test of independence using either research-quality case/control samples alone, or augmented with silver standard data. The subset of the parameter space where inclusion of silver standard samples increases statistical power is identified. A case study of dementia subjects identified from electronic medical records from the Electronic Medical Records and Genomics (eMERGE) network, combined with subjects from two studies specifically targeting dementia, verifies these results.
C1 [McDavid, Andrew; Carlson, Chris S.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Crane, Paul K.; McCormick, Wayne; Larson, Eric B.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Newton, Katherine M.; Weston, Noah; Ehrlich, Kelly; Hart, Eugene; Harrison, Robert; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA.
[Crosslin, David R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Kukull, Walter A.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Rottscheit, Carla; Peissig, Peggy] Marshfield Clin Res Fdn, Biomed Informat Res Ctr, Marshfield, WI USA.
[Stefanski, Elisha] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
[McCarty, Catherine A.] Essentia Inst Rural Hlth, Duluth, MN USA.
[Zuvich, Rebecca Lynn; Haines, Jonathan L.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
[Ritchie, Marylyn D.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
[Denny, Joshua C.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37212 USA.
[Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA.
[de Andrade, Mariza] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA.
[Kullo, Iftikhar] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA.
[Li, Rongling] NHGRI, NIH, Bethesda, MD 20892 USA.
[Mirel, Daniel; Crenshaw, Andrew] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Bowen, James D.] Swedish Med Ctr, Dept Neurol, Seattle, WA USA.
[Li, Ge; Tsuang, Debby] Univ Washington, Dept Psychiat, Sch Med, Seattle, WA 98195 USA.
[Tsuang, Debby] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[McCurry, Susan; Teri, Linda] Univ Washington, Sch Nursing, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA.
[Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA.
RP McDavid, A (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
EM amcdavid@fhcrc.org
RI Crane, Paul/C-8623-2014; Jarvik, Gail/N-6476-2014; Tsuang,
Debby/L-7234-2016;
OI Jarvik, Gail/0000-0002-6710-8708; Tsuang, Debby/0000-0002-4716-1894;
Kukull, Walter/0000-0001-8761-9014; Crane, Paul/0000-0003-4278-7465;
McDavid, Andrew/0000-0002-6581-1213
FU National Institutes of Health (NIH) [HG004610, AG06781, U01HG004438]
FX This study was funded by National Institutes of Health (NIH) award
HG004610, AG06781 (Group Health Cooperative) and U01HG004438. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 40
TC 7
Z9 7
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2013
VL 8
IS 6
AR e63481
DI 10.1371/journal.pone.0063481
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 164VY
UT WOS:000320440500003
PM 23762230
ER
PT J
AU Rao, VR
Neogi, U
Talboom, JS
Padilla, L
Rahman, M
Fritz-French, C
Gonzalez-Ramirez, S
Verma, A
Wood, C
Ruprecht, RM
Ranga, U
Azim, T
Joska, J
Eugenin, E
Shet, A
Bimonte-Nelson, H
Tyor, WR
Prasad, VR
AF Rao, Vasudev R.
Neogi, Ujjwal
Talboom, Joshua S.
Padilla, Ligia
Rahman, Mustafizur
Fritz-French, Cari
Gonzalez-Ramirez, Sandra
Verma, Anjali
Wood, Charles
Ruprecht, Ruth M.
Ranga, Udaykumar
Azim, Tasnim
Joska, John
Eugenin, Eliseo
Shet, Anita
Bimonte-Nelson, Heather
Tyor, William R.
Prasad, Vinayaka R.
TI Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater
frequency of dicysteine motif-containing Tat variants than those in
Southeast Asia and cause increased neurovirulence
SO RETROVIROLOGY
LA English
DT Article
DE Clade C HIV-1; Subtype C HIV-1; HIV-1 Tat; Tat dicysteine;
Neuropathogenesis; SCID-HIVE mouse model; HIV-1 Tat C31S polymorphism;
Neuroaids; HIV dementia
ID TYPE-1 SUBTYPE-C; IMMUNODEFICIENCY-VIRUS ENCEPHALITIS; MONOCYTE
CHEMOATTRACTANT PROTEIN-1; RADIAL-ARM MAZE; MOLECULAR CLONE; SCID MICE;
NEUROCOGNITIVE DISORDERS; CHEMOTACTIC PROTEIN-1; NEURONAL INJURY;
WORKING-MEMORY
AB Background: HIV-1 Clade C (Subtype C; HIV-1C) is responsible for greater than 50% of infections worldwide. Unlike clade B HIV-1 (Subtype B; HIV-1B), which is known to cause HIV associated dementia (HAD) in approximately 15% to 30% of the infected individuals, HIV-1C has been linked with lower prevalence of HAD (0 to 6%) in India and Ethiopia. However, recent studies report a higher prevalence of HAD in South Africa, Zambia and Botswana, where HIV-1C infections predominate. Therefore, we examined whether Southern African HIV-1C is genetically distinct and investigated its neurovirulence. HIV-1 Tat protein is a viral determinant of neurocognitive dysfunction. Therefore, we focused our study on the variations seen in tat gene and its contribution to HIV associated neuropathogenesis.
Results: A phylogenetic analysis of tat sequences of Southern African (South Africa and Zambia) HIV isolates with those from the geographically distant Southeast Asian (India and Bangladesh) isolates revealed that Southern African tat sequences are distinct from Southeast Asian isolates. The proportion of HIV - 1C variants with an intact dicysteine motif in Tat protein (C30C31) was significantly higher in the Southern African countries compared to Southeast Asia and broadly paralleled the high incidence of HAD in these countries. Neuropathogenic potential of a Southern African HIV-1C isolate (from Zambia; HIV-1C(1084i)), a HIV-1C isolate (HIV-1(IndieC1)) from Southeast Asia and a HIV-1B isolate (HIV-1(ADA)) from the US were tested using in vitro assays to measure neurovirulence and a SCID mouse HIV encephalitis model to measure cognitive deficits. In vitro assays revealed that the Southern African isolate, HIV-1C(1084i) exhibited increased monocyte chemotaxis and greater neurotoxicity compared to Southeast Asian HIV-1C. In neurocognitive tests, SCID mice injected with MDM infected with Southern African HIV-1C(1084i) showed greater cognitive dysfunction similar to HIV-1B but much higher than those exposed to Southeast Asian HIV - 1C.
Conclusions: We report here, for the first time, that HIV-1C from Southern African countries is genetically distinct from Southeast Asian HIV-1C and that it exhibits a high frequency of variants with dicysteine motif in a key neurotoxic HIV protein, Tat. Our results indicate that Tat dicysteine motif determines neurovirulence. If confirmed in population studies, it may be possible to predict neurocognitive outcomes of individuals infected with HIV-1C by genotyping Tat.
C1 [Rao, Vasudev R.; Prasad, Vinayaka R.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
[Neogi, Ujjwal; Shet, Anita] St Johns Med Coll & Hosp, Dept Microbiol & Pediat, Div Clin Virol, Bangalore, Karnataka, India.
[Talboom, Joshua S.; Bimonte-Nelson, Heather] Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA.
[Talboom, Joshua S.; Bimonte-Nelson, Heather] Arizona Alzheimers Consortium, Phoenix, AZ USA.
[Padilla, Ligia; Tyor, William R.] Atlanta VA Med Ctr, Decatur, GA USA.
[Rahman, Mustafizur; Azim, Tasnim] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh.
[Fritz-French, Cari; Tyor, William R.] Emory Univ, Grad Div Biol & Biomed Sci, Immunol & Mol Pathol Program, Atlanta, GA 30322 USA.
[Gonzalez-Ramirez, Sandra; Wood, Charles; Tyor, William R.] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE USA.
[Gonzalez-Ramirez, Sandra; Wood, Charles; Tyor, William R.] Univ Nebraska, Sch Biol Sci, Lincoln, NE USA.
[Ruprecht, Ruth M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA USA.
[Verma, Anjali; Ranga, Udaykumar] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560012, Karnataka, India.
[Joska, John] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa.
[Eugenin, Eliseo] Publ Hlth Res Inst, Newark, NJ USA.
[Eugenin, Eliseo] UMDNJ, Dept Microbiol & Mol Genet, Newark, NJ USA.
[Tyor, William R.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
RP Prasad, VR (reprint author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM vinayaka.prasad@einstein.yu.edu
RI rahman, mustafizur/E-6918-2010; Neogi, Ujjwal/E-4274-2012;
OI Neogi, Ujjwal/0000-0002-0844-3338; Shet, Anita/0000-0002-7204-8164
FU NIH [R01 MH083579, D43 TW001403, P01 AI048240, NS74903, GM103509, R01
MH096625, T32 AI060547]
FX This work was mainly supported by NIH R01 MH083579 (V. R. P.) and NIH
D43 TW001403 (V. R. P.). The work was also supported by NIH P01 AI048240
(R. M. R.), NIH NS74903 & NIH GM103509 (to C. W.), NIH R01 MH096625 (to
E. E.) and NIH T32 AI060547 (to S. G.). The authors wish to thank the
Einstein/Montefiore Center for AIDS Research (P30 AI051519) for the use
of BSL3/Clinical Virology Core services; Jasmeen Dara and Arthur Ruiz
for reading the manuscript, Milka Rodriguez and Jayashree Nandi for
technical assistance and Susan Engelbrecht for help with sequencing the
Cape Town samples.
NR 61
TC 20
Z9 20
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD JUN 8
PY 2013
VL 10
AR 61
DI 10.1186/1742-4690-10-61
PG 16
WC Virology
SC Virology
GA 167BE
UT WOS:000320604400001
PM 23758766
ER
PT J
AU Nahrendorf, M
Swirski, FK
AF Nahrendorf, Matthias
Swirski, Filip K.
TI Monocyte and Macrophage Heterogeneity in the Heart
SO CIRCULATION RESEARCH
LA English
DT Review
DE healing; heart failure; macrophages; monocytes; myocardial infarction
ID ACUTE MYOCARDIAL-INFARCTION; PREDICT CARDIOVASCULAR EVENTS;
GENE-EXPRESSION PROFILES; HEMATOPOIETIC STEM-CELLS; DENDRITIC CELLS;
BONE-MARROW; IN-VIVO; ATHEROSCLEROTIC LESIONS; INFLAMMATORY MONOCYTES;
RHEUMATOID-ARTHRITIS
AB Monocytes and macrophages are innate immune cells that reside and accumulate in the healthy and injured heart. The cells and their subsets pursue distinct functions in steady-state and disease, and their tenure may range between hours and months. Some subsets are highly inflammatory, whereas others support tissue repair. This review discusses current concepts of lineage relationships and crosstalk of systems, highlights open questions, and describes tools for studying monocyte and macrophage subsets in the murine and human heart.
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Nahrendorf, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM mnahrendorf@mgh.harvard.edu; fswirski@mgh.harvard.edu
FU National Heart, Lung, and Blood Institute; National Institutes of
Health; Department of Health and Human Services [R01HL095612,
R01HL095629, R01HL096576, HHSN268201000044C]
FX This work has been funded in whole or in part with federal funds from
the National Heart, Lung, and Blood Institute, the National Institutes
of Health, and the Department of Health and Human Services (R01HL095612,
R01HL095629, R01HL096576, Contract No. HHSN268201000044C).
NR 95
TC 94
Z9 99
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD JUN 7
PY 2013
VL 112
IS 12
BP 1624
EP 1633
DI 10.1161/CIRCRESAHA.113.300890
PG 10
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA 298UV
UT WOS:000330350900019
PM 23743228
ER
PT J
AU Miyamoto, DT
Viswanathan, AN
AF Miyamoto, David T.
Viswanathan, Akila N.
TI Concurrent Chemoradiation for Vaginal Cancer
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; HIGH-DOSE-RATE;
CERVICAL-CANCER; PREOPERATIVE CHEMORADIATION; INTERSTITIAL
BRACHYTHERAPY; RADIATION-THERAPY; CHEMOTHERAPY; VULVA; OUTCOMES
AB Background: It is not known whether the addition of chemotherapy to radiation therapy improves outcomes in primary vaginal cancer. Here, we review clinical outcomes in patients with primary vaginal cancer treated with radiation therapy (RT) or concurrent chemoradiation therapy (CRT).
Methods: Seventy-one patients with primary vaginal cancer treated with definitive RT with or without concurrent chemotherapy at a single institution were identified and their records reviewed. A total of 51 patients were treated with RT alone; 20 patients were treated with CRT. Recurrences were analyzed. Overall survival (OS) and disease-free survival (DFS) rates were estimated using the Kaplan-Meier method. Cox regression analysis was performed.
Results: The median age at diagnosis was 61 years (range, 18-92 years) and the median follow-up time among survivors was 3.0 years. Kaplan-Meier estimates for OS and DFS differed significantly between the RT and CRT groups (3-yr OS = 56% vs. 79%, log-rank p=0.037; 3-yr DFS = 43% vs. 73%, log-rank p=0.011). Twenty-three patients (45%) in the RT group had a relapse at any site compared to 3 (15%) in the CRT group (p=0.027). With regard to the sites of first relapse, 10 patients (14%) had local only, 4 (6%) had local and regional, 9 (13%) had regional only, 1 (1%) had regional and distant, and 2 (3%) had distant only relapse. On univariate analysis, the use of concurrent chemotherapy, FIGO stage, tumor size, and date of diagnosis were significant predictors of DFS. On multivariate analysis, the use of concurrent chemotherapy remained a significant predictor of DFS (hazard ratio 0.31 (95% CI, 0.10-0.97; p = 0.04)).
Conclusions: Vaginal cancer results in poor outcomes. Adequate radiation dose is essential to ensure curative management. Concurrent chemotherapy should be considered for vaginal cancer patients.
C1 [Miyamoto, David T.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA.
[Viswanathan, Akila N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvard.edu
FU St. Laurent Family Fund
FX This research was supported by a donation to Dr Viswanathan by the St.
Laurent Family Fund. The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 22
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 7
PY 2013
VL 8
IS 6
AR e65048
DI 10.1371/journal.pone.0065048
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173QU
UT WOS:000321094800016
PM 23762284
ER
PT J
AU Adams, SV
Ahnen, DJ
Baron, JA
Campbell, PT
Gallinger, S
Grady, WM
LeMarchand, L
Lindor, NM
Potter, JD
Newcomb, PA
AF Adams, Scott V.
Ahnen, Dennis J.
Baron, John A.
Campbell, Peter T.
Gallinger, Steven
Grady, William M.
LeMarchand, Loic
Lindor, Noralane M.
Potter, John D.
Newcomb, Polly A.
TI Survival after inflammatory bowel disease-associated colorectal cancer
in the Colon Cancer Family Registry
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Colorectal cancer; Inflammatory bowel disease; Outcomes research; Cancer
survival; Inflammation
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POPULATION-BASED DANISH; C-REACTIVE
PROTEIN; ULCERATIVE-COLITIS; CROHNS-DISEASE; MICROSATELLITE INSTABILITY;
5-AMINOSALICYLATE USE; INTESTINAL CANCER; RISK; PROGNOSIS
AB AIM: To investigate the survival of individuals with colorectal cancer (CRC) with inflammatory bowel disease (IBD-associated CRC) compared to that of individuals without IBD diagnosed with CRC.
METHODS: Epidemiologic, clinical, and follow-up data were obtained from the Colon Cancer Family Registry (Colon CFR). IBD-associated cases were identified from self-report of physician diagnosis. For a subset of participants, medical records were examined to confirm self-report of IBD. Cox proportional hazards regression was applied to estimate adjusted hazard ratios (aHR) and 95%CI of mortality, comparing IBD-associated to non-IBD- associated CRC, adjusted for age at CRC diagnosis, sex, Colon CFR phase, and number of prior endoscopies. Following imputation to complete CRC stage information, adjustment for CRC stage was examined.
RESULTS: A total of 7202 CRC cases, including 250 cases of IBD-associated CRC, were analyzed. Over a twelve year follow-up period following CRC diagnosis, 2013 and 74 deaths occurred among non-IBD associated CRC and IBD-associated CRC patients, respectively. The difference in survival between IBD-associated and non-IBD CRC cases was not statistically significant (aHR = 1.08; 95%CI: 0.85-1.36). However, the assumption of proportional hazards necessary for valid inference from Cox regression was not met over the entire follow-up period, and we therefore limited analyses to within five years after CRC diagnosis when the assumption of proportional hazards was met. Over this period, there was evidence of worse prognosis for IBD-associated CRC (aHR = 1.36; 95%CI: 1.05-1.76). Results were similar when adjusted for CRC stage, or restricted to IBD confirmed in medical records.
CONCLUSION: These results support the hypothesis that IBD-associated CRC has a worse prognosis than non-IBD-associated CRC. (C) 2013 Baishideng. All rights reserved.
C1 [Adams, Scott V.; Grady, William M.; Potter, John D.; Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
[Ahnen, Dennis J.] Denver VA Med Ctr, Dept Med, Denver, CO 80045 USA.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Denver, CO 80045 USA.
[Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
[Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Dept Intramural Res, Atlanta, GA 30303 USA.
[Gallinger, Steven] Univ Toronto, Div Gen Surg, Toronto, ON M5G 2C4, Canada.
[LeMarchand, Loic] Univ Hawaii, Canc Res Ctr Hawaii, Honolulu, HI 96813 USA.
[Lindor, Noralane M.] Mayo Clin Arizona, Dept Hlth Sci Res, Scottsdale, AZ 85259 USA.
RP Adams, SV (reprint author), Fred Hutchinson Canc Res Ctr, M3-B232,POB 19024, Seattle, WA 98109 USA.
EM sadams@fhcrc.org
RI Gallinger, Steven/E-4575-2013;
OI Potter, John/0000-0001-5439-1500
FU The American Society of Preventive Oncology/Prevent Cancer
Foundation/American Society for Clinical Oncology Cancer Prevention
Research Fellowship; Australasian Colorectal Cancer Family Registry [U01
CA097735]; Familial Colorectal Neoplasia Collaborative Group [U01
CA074799]; Mayo Clinic Cooperative Family Registry for Colon Cancer
Studies [U01 CA074800]; Ontario Registry for Studies of Familial
Colorectal Cancer [U01 CA074783]; Seattle Colorectal Cancer Family
Registry [U01 CA074794]; University of Hawaii Colorectal Cancer Family
Registry [U01 CA074806]; University of California, Irvine Informatics
Center [U01 CA078296]
FX Supported by The American Society of Preventive Oncology/Prevent Cancer
Foundation/American Society for Clinical Oncology Cancer Prevention
Research Fellowship to SVA; the Australasian Colorectal Cancer Family
Registry, No. U01 CA097735; the Familial Colorectal Neoplasia
Collaborative Group, No. U01 CA074799; the Mayo Clinic Cooperative
Family Registry for Colon Cancer Studies, No. U01 CA074800; the Ontario
Registry for Studies of Familial Colorectal Cancer, No. U01 CA074783;
the Seattle Colorectal Cancer Family Registry, No. U01 CA074794; the
University of Hawaii Colorectal Cancer Family Registry, No. U01
CA074806; and the University of California, Irvine Informatics Center,
No. U01 CA078296
NR 45
TC 7
Z9 7
U1 0
U2 6
PU BAISHIDENG PUBL GRP CO LTD
PI WANCHAI
PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG
100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUN 7
PY 2013
VL 19
IS 21
BP 3241
EP 3248
DI 10.3748/wjg.v19.i21.3241
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 163YQ
UT WOS:000320375000007
PM 23745025
ER
PT J
AU Cho, J
Ibbott, G
Gillin, M
Gonzalez-Lepera, C
Min, CH
Zhu, XP
El Fakhri, G
Paganetti, H
Mawlawi, O
AF Cho, Jongmin
Ibbott, Geoffrey
Gillin, Michael
Gonzalez-Lepera, Carlos
Min, Chul Hee
Zhu, Xuping
El Fakhri, Georges
Paganetti, Harald
Mawlawi, Osama
TI Determination of elemental tissue composition following proton treatment
using positron emission tomography
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID BEAM RANGE VERIFICATION; MONTE-CARLO SIMULATIONS; CT NUMBERS; IN-BEAM;
THERAPY; PET; DISTRIBUTIONS; RADIOTHERAPY; IRRADIATION; UNCERTAINTIES
AB Positron emission tomography (PET) has been suggested as an imaging technique for in vivo proton dose and range verification after proton induced-tissue activation. During proton treatment, irradiated tissue is activated and decays while emitting positrons. In this paper, we assessed the feasibility of using PET imaging after proton treatment to determine tissue elemental composition by evaluating the resultant composite decay curve of activated tissue. A phantom consisting of sections composed of different combinations of H-1, C-12, N-14, and O-16 was irradiated using a pristine Bragg peak and a 6 cm spread-out Bragg-peak (SOBP) proton beam. The beam ranges defined at 90% distal dose were 10 cm; the delivered dose was 1.6 Gy for the near monoenergetic beam and 2 Gy for the SOBP beam. After irradiation, activated phantom decay was measured using an in-room PET scanner for 30 min in list mode. Decay curves from the activated C-12 and O-16 sections were first decomposed into multiple simple exponential decay curves, each curve corresponding to a constituent radioisotope, using a least-squares method. The relative radioisotope fractions from each section were determined. These fractions were used to guide the decay curve decomposition from the section consisting mainly of C-12 + O-16 and calculate the relative elemental composition of C-12 and O-16. A Monte Carlo simulation was also used to determine the elemental composition of the C-12 + O-16 section. The calculated compositions of the C-12 + O-16 section using both approaches (PET and Monte Carlo) were compared with the true known phantom composition. Finally, two patients were imaged using an in-room PET scanner after proton therapy of the head. Their PET data and the technique described above were used to construct elemental composition (C-12 and O-16) maps that corresponded to the proton-activated regions. We compared the C-12 and O-16 compositions of seven ROIs that corresponded to the vitreous humor, adipose/face mask, adipose tissue, and brain tissue with ICRU 46 elemental composition data. The C-12 and O-16 compositions of the C-12 + O-16 phantom section were estimated to within a maximum difference of 3.6% for the near monoenergetic and SOBP beams over an 8 cm depth range. On the other hand, the Monte Carlo simulation estimated the corresponding C-12 and O-16 compositions in the C-12 + O-16 section to within a maximum difference of 3.4%. For the patients, the C-12 and O-16 compositions in the seven ROIs agreed with the ICRU elemental composition data, with a mean (maximum) difference of 9.4% (15.2%). The C-12 and O-16 compositions of the phantom and patients were estimated with relatively small differences. PET imaging may be useful for determining the tissue elemental composition and thereby improving proton treatment planning and verification.
C1 [Cho, Jongmin] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
[Cho, Jongmin] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Cho, Jongmin; Ibbott, Geoffrey; Gillin, Michael] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
[Gonzalez-Lepera, Carlos] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA.
[Min, Chul Hee] Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Wonju 220710, Kangwon Do, South Korea.
[Zhu, Xuping; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Zhu, Xuping; El Fakhri, Georges; Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Mawlawi, Osama] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA.
RP Cho, J (reprint author), Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA.
EM jcho2@mdanderson.org
FU National Institutes of Health through MD Anderson's Cancer Center
Support Grant [CA016672]
FX The authors thank Pablo Yepes at Rice University and Uwe Titt in the
Department of Radiation Physics, Tinsu Pan in the Department of Imaging
Physics, Francesco Stingo in the Department of Biostatistics, and the
Department of Scientific Publications at the MD Anderson Cancer Center.
This research is supported in part by the National Institutes of Health
through MD Anderson's Cancer Center Support Grant (CA016672).
NR 35
TC 6
Z9 6
U1 0
U2 6
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD JUN 7
PY 2013
VL 58
IS 11
BP 3815
EP 3835
DI 10.1088/0031-9155/58/11/3815
PG 21
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 144UN
UT WOS:000318966200021
PM 23681070
ER
PT J
AU Apostolou, E
Ferrari, F
Walsh, RM
Bar-Nur, O
Stadtfeld, M
Cheloufi, S
Stuart, HT
Polo, JM
Ohsumi, TK
Borowsky, ML
Kharchenko, PV
Park, PJ
Hochedlinger, K
AF Apostolou, Effie
Ferrari, Francesco
Walsh, Ryan M.
Bar-Nur, Ori
Stadtfeld, Matthias
Cheloufi, Sihem
Stuart, Hannah T.
Polo, Jose M.
Ohsumi, Toshiro K.
Borowsky, Mark L.
Kharchenko, Peter V.
Park, Peter J.
Hochedlinger, Konrad
TI Genome-wide Chromatin Interactions of the Nanog Locus in Pluripotency,
Differentiation, and Reprogramming
SO CELL STEM CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; CHROMOSOMAL REARRANGEMENTS; TRANSCRIPTIONAL
NETWORK; GENE-EXPRESSION; GROUND-STATE; ES CELLS; MOUSE; ORGANIZATION;
MEDIATOR; COMPLEX
AB The chromatin state of pluripotency genes has been studied extensively in embryonic stem cells (ESCs) and differentiated cells, but their potential interactions with other parts of the genome remain largely unexplored. Here, we identified a genome-wide, pluripotency-specific interaction network around the Nanog promoter by adapting circular chromosome conformation capture sequencing. This network was rearranged during differentiation and restored in induced pluripotent stem cells. A large fraction of Nanog-interacting loci were bound by Mediator or cohesin in pluripotent cells. Depletion of these proteins from ESCs resulted in a disruption of contacts and the acquisition of a differentiation-specific interaction pattern prior to obvious transcriptional and phenotypic changes. Similarly, the establishment of Nanog interactions during reprogramming often preceded transcriptional upregulation of associated genes, suggesting a causative link. Our results document a complex, pluripotency-specific chromatin "interactome'' for Nanog and suggest a functional role for long-range genomic interactions in the maintenance and induction of pluripotency.
C1 [Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Ctr Regenerat Med, Boston, MA 02114 USA.
[Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA.
[Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Apostolou, Effie; Walsh, Ryan M.; Bar-Nur, Ori; Stadtfeld, Matthias; Cheloufi, Sihem; Stuart, Hannah T.; Polo, Jose M.; Hochedlinger, Konrad] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Ferrari, Francesco; Kharchenko, Peter V.; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Ohsumi, Toshiro K.; Borowsky, Mark L.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Ohsumi, Toshiro K.; Borowsky, Mark L.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Kharchenko, Peter V.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA.
[Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
RP Park, PJ (reprint author), Harvard Univ, Sch Med, Ctr Biomed Informat, 10 Shattuck St, Boston, MA 02115 USA.
EM peter_park@harvard.edu; khochedlinger@helix.mgh.harvard.edu
RI Ferrari, Francesco/H-5007-2012;
OI Ferrari, Francesco/0000-0002-9811-3753; Stadtfeld,
Matthias/0000-0002-5852-9906
FU JCCF; HHMI; NIH [RC2HL102815, K25AG037596, DP2OD003266, R01HD058013]
FX We acknowledge Peter Fraser, Frank Grosveld, Jane Skok, and Job Dekker
for comments and suggestions. We thank Mariann Miscinai and
Triantiafyllos Paparountas for discussing bioinformatics analysis, Eda
Yildirim and Berni Peyer for advice about FISH experiments, and all
members of the Hochedlinger and Park groups for suggestions. E.A. was
supported by post-doctoral fellowships from JCCF and HHMI. P.J.P. was
supported by a Sloan Research Fellowship and NIH (RC2HL102815), P.V.K
was supported by NIH (K25AG037596), and K.H. was supported by NIH
(DP2OD003266 and R01HD058013).
NR 62
TC 79
Z9 80
U1 1
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUN 6
PY 2013
VL 12
IS 6
BP 699
EP 712
DI 10.1016/j.stem.2013.04.013
PG 14
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VH
UT WOS:000329569900013
PM 23665121
ER
PT J
AU Yang, YM
Gupta, SK
Kim, KJ
Powers, BE
Cerqueira, A
Wainger, BJ
Ngo, HD
Rosowski, KA
Schein, PA
Ackeifi, CA
Arvanites, AC
Davidow, LS
Woolf, CJ
Rubin, LL
AF Yang, Yin M.
Gupta, Shailesh K.
Kim, Kevin J.
Powers, Berit E.
Cerqueira, Antonio
Wainger, Brian J.
Ngo, Hien D.
Rosowski, Kathryn A.
Schein, Pamela A.
Ackeifi, Courtney A.
Arvanites, Anthony C.
Davidow, Lance S.
Woolf, Clifford J.
Rubin, Lee L.
TI A Small Molecule Screen in Stem-Cell-Derived Motor Neurons Identifies a
Kinase Inhibitor as a Candidate Therapeutic for ALS
SO CELL STEM CELL
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; MOUSE
MODEL; C-JUN; MATRIX METALLOPROTEINASES; DISEASE PROGRESSION; SIGNALING
PATHWAY; PROTEIN-KINASE; SURVIVAL; DEATH
AB Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative disease, characterized by motor neuron (MN) death, for which there are no truly effective treatments. Here, we describe a new small molecule survival screen carried out using MNs from both wild-type and mutant SOD1 mouse embryonic stem cells. Among the hits we found, kenpaullone had a particularly impressive ability to prolong the healthy survival of both types of MNs that can be attributed to its dual inhibition of GSK-3 and HGK kinases. Furthermore, kenpaullone also strongly improved the survival of human MNs derived from ALS-patient-induced pluripotent stem cells and was more active than either of two compounds, olesoxime and dexpramipexole, that recently failed in ALS clinical trials. Our studies demonstrate the value of a stem cell approach to drug discovery and point to a new paradigm for identification and preclinical testing of future ALS therapeutics.
C1 [Yang, Yin M.; Gupta, Shailesh K.; Kim, Kevin J.; Powers, Berit E.; Cerqueira, Antonio; Ngo, Hien D.; Rosowski, Kathryn A.; Schein, Pamela A.; Ackeifi, Courtney A.; Rubin, Lee L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Yang, Yin M.; Gupta, Shailesh K.; Kim, Kevin J.; Powers, Berit E.; Cerqueira, Antonio; Ngo, Hien D.; Rosowski, Kathryn A.; Schein, Pamela A.; Ackeifi, Courtney A.; Arvanites, Anthony C.; Davidow, Lance S.; Rubin, Lee L.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Rosowski, Kathryn A.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.
[Wainger, Brian J.; Woolf, Clifford J.] Childrens Hosp, Program Neurobiol, Boston, MA 02115 USA.
[Wainger, Brian J.; Woolf, Clifford J.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.
[Wainger, Brian J.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP Rubin, LL (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM lee_rubin@harvard.edu
OI Kim, Kevin/0000-0002-7015-5871
FU ALS Association; New York Stem Cell Foundation; NINDS [P01NS066888]
FX We are grateful to K. Eggan for providing mouse ESCs and human ESCs and
iPSCs, G. Daley for providing the TDP-43 human iPSCs, and B. Doble and
J. Woodgett for providing mouse GSK-KO ESC lines. We would also like to
thank B. Tilton and P. Rogers for assistance with FACS; K. Kotkow, A. D.
Sinor-Anderson, N. Makhortova, M. Hayhurst, K. Krumholz, G. Boulting, J.
Ichida, E. Kiskinis, and A. Blumenstein for providing reagents and
helpful discussions; and J. LaLonde for editorial assistance. This work
was supported by the ALS Association, the New York Stem Cell Foundation,
NINDS (P01NS066888), and the Harvard Stem Cell Institute. L.L.R. is a
founder of iPierian Inc. and a member of its Scientific Advisory Board.
NR 58
TC 109
Z9 114
U1 1
U2 28
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUN 6
PY 2013
VL 12
IS 6
BP 713
EP 726
DI 10.1016/j.stem.2013.04.003
PG 14
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VH
UT WOS:000329569900014
PM 23602540
ER
PT J
AU Tulpule, A
Kelley, JM
Lensch, MW
McPherson, J
Park, IH
Hartung, O
Nakamura, T
Schlaeger, TM
Shimamura, A
Daley, GQ
AF Tulpule, Asmin
Kelley, James M.
Lensch, M. William
McPherson, Jade
Park, In Hyun
Hartung, Odelya
Nakamura, Tomoka
Schlaeger, Thorsten M.
Shimamura, Akiko
Daley, George Q.
TI Pluripotent Stem Cell Models of Shwachman-Diamond Syndrome Reveal a
Common Mechanism for Pancreatic and Hematopoietic Dysfunction
SO CELL STEM CELL
LA English
DT Article
ID MARROW FAILURE SYNDROMES; SBDS GENE; MUTATIONS; DIFFERENTIATION;
GENERATION; FEATURES; PROTEIN; DEATH; RNA
AB Shwachman-Diamond syndrome (SDS), a rare autosomal- recessive disorder characterized by exocrine pancreatic insufficiency and hematopoietic dysfunction, is caused by mutations in the Shwachman-Bodian- Diamond syndrome (SBDS) gene. We created human pluripotent stem cell models of SDS through knockdown of SBDS in human embryonic stem cells (hESCs) and generation of induced pluripotent stem cell (iPSC) lines from two patients with SDS. SBDS-deficient hESCs and iPSCs manifest deficits in exocrine pancreatic and hematopoietic differentiation in vitro, enhanced apoptosis, and elevated protease levels in culture supernatants, which could be reversed by restoring SBDS protein expression through transgene rescue or by supplementing culture media with protease inhibitors. Protease-mediated autodigestion provides a mechanistic link between the pancreatic and hematopoietic phenotypes in SDS, highlighting the utility of hESCs and iPSCs in obtaining novel insights into human disease.
C1 [Tulpule, Asmin; Lensch, M. William; McPherson, Jade; Hartung, Odelya; Schlaeger, Thorsten M.; Shimamura, Akiko; Daley, George Q.] Boston Childrens Hosp, Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
[Tulpule, Asmin; Daley, George Q.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Kelley, James M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Tulpule, Asmin; Lensch, M. William; McPherson, Jade; Hartung, Odelya; Schlaeger, Thorsten M.; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Lensch, M. William; Daley, George Q.] Howard Hughes Med Inst, New Haven, CT 06520 USA.
[Park, In Hyun] Yale Stem Cell Ctr, New Haven, CT 06520 USA.
[Nakamura, Tomoka; Shimamura, Akiko] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA.
[Shimamura, Akiko] Seattle Childrens Hosp, Seattle, WA 98105 USA.
[Shimamura, Akiko] Univ Washington, Seattle, WA 98105 USA.
RP Daley, GQ (reprint author), Boston Childrens Hosp, Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA.
EM george.daley@childrens.harvard.edu
FU Manton Center for Orphan Disease Research (BCH); NIH [P30 DK056465-10,
R01 HL079582-11, R24 DK092760, RC4 DK09091, U01 HL100001, UL1 DE019582];
Roche Foundation for Anemia Research
FX We thank Shuibing Chen (Weill Cornell Medical College) and Doug Melton
(Harvard University) for their help with pancreatic differentiation
protocols and Roderick Bronson (Harvard University) for his
histopathological expertise. Harry Kozakewich (Boston Children's
Hospital [BCH]) provided SDS patient slides. This work was supported by
the Manton Center for Orphan Disease Research (BCH); NIH grants P30
DK056465-10, R01 HL079582-11, R24 DK092760, RC4 DK09091, U01 HL100001,
and UL1 DE019582; and the Roche Foundation for Anemia Research. G.Q.D.
is an investigator of the Howard Hughes Medical Institute.
NR 32
TC 29
Z9 30
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD JUN 6
PY 2013
VL 12
IS 6
BP 727
EP 736
DI 10.1016/j.stem.2013.04.002
PG 10
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VH
UT WOS:000329569900015
PM 23602541
ER
PT J
AU Wan, YZ
Wu, CJ
AF Wan, Youzhong
Wu, Catherine J.
TI SF3B1 mutations in chronic lymphocytic leukemia
SO BLOOD
LA English
DT Review
ID SPLICING FACTOR SF3B; PRE-MESSENGER-RNA; MYELODYSPLASTIC SYNDROMES;
CLINICAL-SIGNIFICANCE; RING SIDEROBLASTS; RECURRENT MUTATIONS; CLONAL
EVOLUTION; CANCER GENES; MACHINERY; PATHWAY
AB SF3B1 is a critical component of the splicing machinery, which catalyzes the removal of introns from precursor messenger RNA (mRNA). Next-generation sequencing studies have identified mutations in SF3B1 in chronic lymphocytic leukemia (CLL) at high frequency. In CLL, SF3B1 mutation is associated with more aggressive disease and shorter survival, and recent studies suggest that it can be incorporated into prognostic schema to improve the prediction of disease progression. Mutations in SF3B1 are predominantly subclonal genetic events in CLL, and hence are likely later events in the progression of CLL. Evidence of altered pre-mRNA splicing has been detected in CLL cases with SF3B1 mutations. Although the causative link between SF3B1 mutation and CLL pathogenesis remains unclear, several lines of evidence suggest SF3B1 mutation might be linked to genomic stability and epigenetic modification.
C1 [Wan, Youzhong; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Wan, Youzhong; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Wu, CJ (reprint author), Harvard Inst Med, Dana Farber Canc Inst, Room 420,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM cwu@partners.org
FU Leukemia and Lymphoma Society; Blavatnik Family Foundation; Lymphoma
Research Foundation; National Institutes of Health National Heart, Lung,
and Blood Institute [1RO1HL103532-01, 1RO1HL116452-01]; National Cancer
Institute [1R01CA155010-01A1]; Leukemia Lymphoma Translational Research
Program Award; American Association of Cancer Research: Stand Up To
Cancer Innovative Research Grant
FX Y.W. is supported by a fellowship from the Leukemia and Lymphoma
Society. C.J.W. acknowledges support from the Blavatnik Family
Foundation, the Lymphoma Research Foundation, and the National
Institutes of Health National Heart, Lung, and Blood Institute
(1RO1HL103532-01, 1RO1HL116452-01) and National Cancer Institute
(1R01CA155010-01A1), and is a recipient of a Leukemia Lymphoma
Translational Research Program Award and an American Association of
Cancer Research: Stand Up To Cancer Innovative Research Grant.
NR 49
TC 32
Z9 32
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD JUN 6
PY 2013
VL 121
IS 23
BP 4627
EP 4634
DI 10.1182/blood-2013-02-427641
PG 8
WC Hematology
SC Hematology
GA 184MW
UT WOS:000321895700006
PM 23568491
ER
PT J
AU Higgins, PC
Prigerson, HG
AF Higgins, Philip C.
Prigerson, Holly G.
TI Caregiver Evaluation of the Quality of End-Of-Life Care (CEQUEL) Scale:
The Caregiver's Perception of Patient Care Near Death
SO PLOS ONE
LA English
DT Article
ID EXPLORATORY FACTOR-ANALYSIS; BEREAVED FAMILY-MEMBERS; INITIAL
VALIDATION; TERMINAL ILLNESS; CANCER-PATIENTS; MENTAL-HEALTH;
MEDICAL-CARE; COMMUNICATION; PROVIDERS; PERSPECTIVES
AB Purpose: End-of-life (EOL) measures are limited in capturing caregiver assessment of the quality of EOL care. Because none include caregiver perception of patient suffering or prolongation of death, we sought to develop and validate the Caregiver Evaluation of Quality of End-of-Life Care (CEQUEL) scale to include these dimensions of caregiver-perceived quality of EOL care.
Patients and Methods: Data were derived from Coping with Cancer (CwC), a multisite, prospective, longitudinal study of advanced cancer patients and their caregivers (N = 275 dyads). Caregivers were assessed before and after patient deaths. CEQUEL's factor structure was examined; reliability was evaluated using Cronbach's alpha, and convergent validity by the strength of associations between CEQUEL scores and key EOL outcomes.
Results: Factor analysis revealed four distinct factors: Prolongation of Death, Perceived Suffering, Shared Decision-Making, and Preparation for the Death. Each item loaded strongly on only a single factor. The 13-item CEQUEL and its subscales showed moderate to acceptable Cronbach's alpha (range: 0.52-0.78). 53% of caregivers reported patients suffering more than expected. Higher CEQUEL scores were positively associated with therapeutic alliance (rho =. 13; p <=.05) and hospice enrollment (z = -2.09; p <=.05), and negatively associated with bereaved caregiver regret (rho = -.36, p <=.001) and a diagnosis of Posttraumatic Stress Disorder (z = -2.06; p <=.05).
Conclusion: CEQUEL is a brief, valid measure of quality of EOL care from the caregiver's perspective. It is the first scale to include perceived suffering and prolongation of death. If validated in future work, it may prove a useful quality indicator for the delivery of EOL care and a risk indicator for poor bereavement adjustment.
C1 [Higgins, Philip C.] Boston Coll, Grad Sch Social Work, Chestnut Hill, MA 02167 USA.
[Higgins, Philip C.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
[Higgins, Philip C.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.
[Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02115 USA.
[Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA.
RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.
EM holly_prigerson@dfci.harvard.edu
FU American Cancer Society [DSW1009403SW]; National Institute of Mental
Health [MH63892]; National Cancer Institute [CA106370, CA156732]; Center
for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer
Institute
FX This research was supported in part by the following grants to PCH:
DSW1009403SW from the American Cancer Society; and to HGP: MH63892 from
the National Institute of Mental Health and CA106370 and CA156732 from
the National Cancer Institute; and the Center for Psychosocial
Epidemiology and Outcomes Research, Dana-Farber Cancer Institute. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 62
TC 6
Z9 6
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2013
VL 8
IS 6
AR e66066
DI 10.1371/journal.pone.0066066
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173SK
UT WOS:000321099000125
PM 23762467
ER
PT J
AU Zhang, Y
Schuff, N
Camacho, M
Chao, LL
Fletcher, TP
Yaffe, K
Woolley, SC
Madison, C
Rosen, HJ
Miller, BL
Weiner, MW
AF Zhang, Yu
Schuff, Norbert
Camacho, Monica
Chao, Linda L.
Fletcher, Thomas P.
Yaffe, Kristine
Woolley, Susan C.
Madison, Catherine
Rosen, Howard J.
Miller, Bruce L.
Weiner, Michael W.
TI MRI Markers for Mild Cognitive Impairment: Comparisons between White
Matter Integrity and Gray Matter Volume Measurements
SO PLOS ONE
LA English
DT Article
ID MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; POSTERIOR
CINGULATE; ENTORHINAL CORTEX; ABNORMAL INTEGRITY; DIAGNOSTIC UTILITY;
STRUCTURAL MRI; FIBER TRACTS; DIFFUSION
AB The aim of the study was to evaluate the value of assessing white matter integrity using diffusion tensor imaging (DTI) for classification of mild cognitive impairment (MCI) and prediction of cognitive impairments in comparison to brain atrophy measurements using structural MRI. Fifty-one patients with MCI and 66 cognitive normal controls (CN) underwent DTI and T1-weighted structural MRI. DTI measures included fractional anisotropy (FA) and radial diffusivity (DR) from 20 predetermined regions-of-interest (ROIs) in the commissural, limbic and association tracts, which are thought to be involved in Alzheimer's disease; measures of regional gray matter (GM) volume included 21 ROIs in medial temporal lobe, parietal cortex, and subcortical regions. Significant group differences between MCI and CN were detected by each MRI modality: In particular, reduced FA was found in splenium, left isthmus cingulum and fornix; increased DR was found in splenium, left isthmus cingulum and bilateral uncinate fasciculi; reduced GM volume was found in bilateral hippocampi, left entorhinal cortex, right amygdala and bilateral thalamus; and thinner cortex was found in the left entorhinal cortex. Group classifications based on FA or DR was significant and better than classifications based on GM volume. Using either DR or FA together with GM volume improved classification accuracy. Furthermore, all three measures, FA, DR and GM volume were similarly accurate in predicting cognitive performance in MCI patients. Taken together, the results imply that DTI measures are as accurate as measures of GM volume in detecting brain alterations that are associated with cognitive impairment. Furthermore, a combination of DTI and structural MRI measurements improves classification accuracy.
C1 [Zhang, Yu; Schuff, Norbert; Camacho, Monica; Chao, Linda L.; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
[Zhang, Yu; Schuff, Norbert; Camacho, Monica; Chao, Linda L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
[Fletcher, Thomas P.] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA.
[Yaffe, Kristine] San Francisco VA Med Ctr, Dept Psychiat Neurol & Epidemiol, San Francisco, CA USA.
[Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Woolley, Susan C.; Madison, Catherine] Calif Pacific Med Ctr, Dept Neurol, San Francisco, CA USA.
[Rosen, Howard J.; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Zhang, Y (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
EM Yu.Zhang@ucsf.edu
FU National Institutes of Health/National Institute on Aging [P01AG19724,
P01AG12435]; NIH/National Center for Research Resources [P41RR023953]
FX This research was supported in part by National Institutes of
Health/National Institute on Aging grants P01AG19724, P01AG12435 and
grant from NIH/National Center for Research Resources P41RR023953, which
were administered by the Northern California Institute for Research and
Education, and with resources of the Veterans Affairs Medical Center,
San Francisco, California. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 79
TC 22
Z9 23
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 6
PY 2013
VL 8
IS 6
AR e66367
DI 10.1371/journal.pone.0066367
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 173SK
UT WOS:000321099000132
PM 23762488
ER
PT J
AU Callen, E
Di Virgilio, M
Kruhlak, MJ
Nieto-Soler, M
Wong, N
Chen, HT
Faryabi, RB
Polato, F
Santos, M
Starnes, LM
Wesemann, DR
Lee, JE
Tubbs, A
Sleckman, BP
Daniel, JA
Ge, K
Alt, FW
Fernandez-Capetillo, O
Nussenzweig, MC
Nussenzweig, A
AF Callen, Elsa
Di Virgilio, Michela
Kruhlak, Michael J.
Nieto-Soler, Maria
Wong, Nancy
Chen, Hua-Tang
Faryabi, Robert B.
Polato, Federica
Santos, Margarida
Starnes, Linda M.
Wesemann, Duane R.
Lee, Ji-Eun
Tubbs, Anthony
Sleckman, Barry P.
Daniel, Jeremy A.
Ge, Kai
Alt, Frederick W.
Fernandez-Capetillo, Oscar
Nussenzweig, Michel C.
Nussenzweig, Andre
TI 53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct
Phosphoprotein Interactions
SO CELL
LA English
DT Article
ID CLASS SWITCH RECOMBINATION; LYSINE-4 METHYLTRANSFERASE COMPLEX; STRAND
BREAK REPAIR; HOMOLOGOUS RECOMBINATION; END RESECTION; BRCT-DOMAIN;
DYSFUNCTIONAL TELOMERES; B-CELLS; PTIP; RIF1
AB The DNA damage response (DDR) protein 53BP1 protects DNA ends from excessive resection in G1, and thereby favors repair by nonhomologous end-joining (NHEJ) as opposed to homologous recombination (HR). During S phase, BRCA1 antagonizes 53BP1 to promote HR. The pro-NHEJ and antirecombinase functions of 53BP1 are mediated in part by RIF1, the only known factor that requires 53BP1 phosphorylation for its recruitment to double-strand breaks (DSBs). Here, we show that a 53BP1 phosphomutant, 53BP1(8A), comprising alanine substitutions of the eight most N-terminal S/TQ phosphorylation sites, mimics 53BP1 deficiency by restoring genome stability in BRCA1-deficient cells yet behaves like wild-type 53BP1 with respect to immunoglobulin class switch recombination (CSR). 53BP1(8A) recruits RIF1 but fails to recruit the DDR protein PTIP to DSBs, and disruption of PTIP phenocopies 53BP1(8A). We conclude that 53BP1 promotes productive CSR and suppresses mutagenic DNA repair through distinct phosphodependent interactions with RIF1 and PTIP.
C1 [Callen, Elsa; Wong, Nancy; Chen, Hua-Tang; Faryabi, Robert B.; Polato, Federica; Santos, Margarida; Nussenzweig, Andre] NCI, Lab Genome Integr, NIH, Bethesda, MD 20892 USA.
[Kruhlak, Michael J.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Di Virgilio, Michela; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.
[Di Virgilio, Michela; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA.
[Nieto-Soler, Maria; Fernandez-Capetillo, Oscar] Spanish Natl Canc Res Ctr CNIO, Gen Instabil Grp, Madrid 28029, Spain.
[Santos, Margarida; Daniel, Jeremy A.] Univ Copenhagen, Novo Nordisk Fdn Ctr Prot Res, Fac Hlth & Med Sci, Copenhagen, Denmark.
[Wesemann, Duane R.; Alt, Frederick W.] Childrens Hosp, Program Cellular & Mol Med, Immune Dis Inst, Boston, MA 02115 USA.
[Wesemann, Duane R.; Alt, Frederick W.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Lee, Ji-Eun; Ge, Kai] NIDDKD, Lab Endocrinol & Receptor Biol, NIH, Bethesda, MD 20892 USA.
[Tubbs, Anthony; Sleckman, Barry P.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
RP Nussenzweig, A (reprint author), NCI, Lab Genome Integr, NIH, Bethesda, MD 20892 USA.
EM andre_nussenzweig@nih.gov
RI Lee, Ji-Eun/F-7891-2011; Faryabi, Robert/H-3544-2015;
Fernandez-Capetillo, Oscar/H-3508-2015; Daniel, Jeremy/S-4729-2016;
OI Lee, Ji-Eun/0000-0002-3768-7016; Faryabi, Robert/0000-0002-7931-2175;
Fernandez-Capetillo, Oscar/0000-0002-2690-6885; Daniel,
Jeremy/0000-0002-1981-5571; Tubbs, Anthony/0000-0002-5605-8231; Ge,
Kai/0000-0002-7442-5138
FU NIH [AI89972]; American Association of Allergy Asthma and Immunology and
CSL Behring; Career Award for Medical Scientists (Burroughs Wellcome
Fund); Intramural Research Program of the NIH; National Cancer
Institute; Center for Cancer Research; Department of Defense grant
[BC102335]
FX We thank all members of the A. Nussenzweig lab and Davide Robbiani for
discussions; Titia de Lange for RIF1f/f mice; Susan Sharrow for flow
cytometry; and Sandy Chang for the TRF2 shRNA construct. M.C.N., F.W.A
and O.F.-C. are HHMI investigators. D.R.W. was supported by NIH grants
AI89972, the American Association of Allergy Asthma and Immunology and
CSL Behring, and a Career Award for Medical Scientists (Burroughs
Wellcome Fund). This work was supported by the Intramural Research
Program of the NIH, the National Cancer Institute, and the Center for
Cancer Research, and by a Department of Defense grant to A.N.
(BC102335).
NR 53
TC 109
Z9 112
U1 2
U2 33
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUN 6
PY 2013
VL 153
IS 6
BP 1266
EP 1280
DI 10.1016/j.cell.2013.05.023
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 158NQ
UT WOS:000319979200012
PM 23727112
ER
PT J
AU Galbraith, MD
Allen, MA
Bensard, CL
Wang, XX
Schwinn, MK
Qin, B
Long, HW
Daniels, DL
Hahn, WC
Dowell, RD
Espinosa, JM
AF Galbraith, Matthew D.
Allen, Mary A.
Bensard, Claire L.
Wang, Xiaoxing
Schwinn, Marie K.
Qin, Bo
Long, Henry W.
Daniels, Danette L.
Hahn, William C.
Dowell, Robin D.
Espinosa, Joaquin M.
TI HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response
to Hypoxia
SO CELL
LA English
DT Article
ID BROMODOMAIN PROTEIN BRD4; POLYMERASE-II CTD; TRANSCRIPTION ELONGATION;
P-TEFB; COMPLEX; CDK8; RECRUITMENT; COACTIVATOR; INITIATION; BINDING
AB The transcription factor HIF1A is a key mediator of the cellular response to hypoxia. Despite the importance of HIF1A in homeostasis and various pathologies, little is known about how it regulates RNA polymerase II (RNAPII). We report here that HIF1A employs a specific variant of the Mediator complex to stimulate RNAPII elongation. The Mediator-associated kinase CDK8, but not the paralog CDK19, is required for induction of many HIF1A target genes. HIF1A induces binding of CDK8-Mediator and the super elongation complex (SEC), containing AFF4 and CDK9, to alleviate RNAPII pausing. CDK8 is dispensable for HIF1A chromatin binding and histone acetylation, but it is essential for binding of SEC and RNAPII elongation. Global analysis of active RNAPII reveals that hypoxia-inducible genes are paused and active prior to their induction. Our results provide a mechanistic link between HIF1A and CDK8, two potent oncogenes, in the cellular response to hypoxia.
C1 [Galbraith, Matthew D.; Allen, Mary A.; Bensard, Claire L.; Espinosa, Joaquin M.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
[Galbraith, Matthew D.; Allen, Mary A.; Bensard, Claire L.; Dowell, Robin D.; Espinosa, Joaquin M.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
[Allen, Mary A.; Dowell, Robin D.] Univ Colorado, Biofrontiers Inst, Boulder, CO 80309 USA.
[Wang, Xiaoxing; Qin, Bo; Long, Henry W.; Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Wang, Xiaoxing; Hahn, William C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Schwinn, Marie K.; Daniels, Danette L.] Promega Corp, Madison, WI 53711 USA.
[Qin, Bo] Tongji Univ, Dept Bioinformat, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
RP Espinosa, JM (reprint author), Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
EM joaquin.espinosa@colorado.edu
OI DOWELL, ROBIN/0000-0001-7665-9985
FU NSF [MCB-0842974, MCB-1243522]; NIH [RO1CA117907, RO1CA140545]; Butcher
Seed Grant; Boettcher Foundation's Webb-Waring Biomedical Research
program; DoD Breast Cancer Postdoctoral Fellowship [W81XWH-10-1-0062,
2T15LM009451]
FX We thank Dr. Shilatifard for AFF4 antibody, Dr. Taatjes and Dr. Lin for
HeLa nuclear extracts and MED15 antibody, and Edward Head for helpful
discussions. This work was supported primarily by NSF grants MCB-0842974
and MCB-1243522, and also by NIH RO1CA117907 grant (J.M.E.), a Butcher
Seed Grant (J.M.E, R.D.D.), the Boettcher Foundation's Webb-Waring
Biomedical Research program (R.D.D.), DoD Breast Cancer Postdoctoral
Fellowship W81XWH-10-1-0062 (X.W.), 2T15LM009451 (M.A.A.), and NIH
RO1CA140545 (W.C.H.). J.M.E. is an HHMI Early Career Scientist. W.C.H.
is a consultant for Novartis. Promega Corporation is the commercial
owner by assignment of patents of the HaloTag technology and its
applications.
NR 40
TC 67
Z9 68
U1 1
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD JUN 6
PY 2013
VL 153
IS 6
BP 1327
EP 1339
DI 10.1016/j.cell.2013.04.048
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 158NQ
UT WOS:000319979200016
PM 23746844
ER
PT J
AU Oates, EC
Rossor, AM
Hafezparast, M
Gonzalez, M
Speziani, F
MacArthur, DG
Lek, M
Cottenie, E
Scoto, M
Foley, AR
Hurles, M
Houlden, H
Greensmith, L
Auer-Grumbach, M
Pieber, TR
Strom, TM
Schule, R
Herrmann, DN
Sowden, JE
Acsadi, G
Menezes, MP
Clarke, NF
Zuchner, S
Muntoni, F
North, KN
Reilly, MM
AF Oates, Emily C.
Rossor, Alexander M.
Hafezparast, Majid
Gonzalez, Michael
Speziani, Fiorella
MacArthur, Daniel G.
Lek, Monkol
Cottenie, Ellen
Scoto, Mariacristina
Foley, A. Reghan
Hurles, Matthew
Houlden, Henry
Greensmith, Linda
Auer-Grumbach, Michaela
Pieber, Thomas R.
Strom, Tim M.
Schule, Rebecca
Herrmann, David N.
Sowden, Janet E.
Acsadi, Gyula
Menezes, Manoj P.
Clarke, Nigel F.
Zuechner, Stephan
Muntoni, Francesco
North, Kathryn N.
Reilly, Mary M.
CA UK10K
TI Mutations in BICD2 Cause Dominant Congenital Spinal Muscular Atrophy and
Hereditary Spastic Paraplegia
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID BICAUDAL-D; TRANSPORT; OOGENESIS; NEURONS; GENOME; FORM
AB Dominant congenital spinal muscular atrophy (DCSMA) is a disorder of developing anterior horn cells and shows lower-limb predominance and clinical overlap with hereditary spastic paraplegia (HSP), a lower-limb-predominant disorder of corticospinal motor neurons. We have identified four mutations in bicaudal D homolog 2 (Drosophila) (BICD2) in six kindreds affected by DCSMA, DCSMA with upper motor neuron features, or HSP. BICD2 encodes BICD2, a key adaptor protein that interacts with the dynein-dynactin motor complex, which facilitates trafficking of cellular cargos that are critical to motor neuron development and maintenance. We demonstrate that mutations resulting in amino acid substitutions in two binding regions of BICD2 increase its binding affinity for the cytoplasmic dynein-dynactin complex, which might result in the perturbation of BICD2-dynein-dynactin-mediated trafficking, and impair neurite outgrowth. These findings provide insight into the mechanism underlying both the static and the slowly progressive clinical features and the motor neuron pathology that characterize BICD2-associated diseases, and underscore the importance of the dynein-dynactin transport pathway in the development and survival of both lower and upper motor neurons.
C1 [Oates, Emily C.; Menezes, Manoj P.; Clarke, Nigel F.; North, Kathryn N.] Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
[Oates, Emily C.; Menezes, Manoj P.; Clarke, Nigel F.] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
[Rossor, Alexander M.; Cottenie, Ellen; Houlden, Henry; Greensmith, Linda; Reilly, Mary M.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
[Hafezparast, Majid] Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.
[Gonzalez, Michael; Speziani, Fiorella; Zuechner, Stephan] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL 33136 USA.
[Gonzalez, Michael; Speziani, Fiorella; Zuechner, Stephan] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
[MacArthur, Daniel G.; Lek, Monkol] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[MacArthur, Daniel G.; Lek, Monkol] Broad Inst Harvard & MIT, Boston, MA 02142 USA.
[Scoto, Mariacristina; Foley, A. Reghan; Muntoni, Francesco] UCL Inst Child Hlth, Dubowitz Neuromuscular Ctr, London WC1N 1EH, England.
[Hurles, Matthew] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England.
[Houlden, Henry] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
[Houlden, Henry] UCL Inst Neurol, Neurogenet Lab, London WC1N 3BG, England.
[Greensmith, Linda] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England.
[Auer-Grumbach, Michaela] Med Univ Vienna, Div Orthopaed, A-1090 Vienna, Austria.
[Pieber, Thomas R.] Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, A-8036 Graz, Austria.
[Strom, Tim M.] Helmholtz Zentrum Munchen, Inst Human Genet, D-85764 Neuherberg, Germany.
[Strom, Tim M.] Tech Univ Munich, Inst Human Genet, D-85748 Garching, Germany.
[Schule, Rebecca] Univ Tubingen, Hertie Inst Clin Brain Res, D-72074 Tubingen, Germany.
[Schule, Rebecca] Univ Tubingen, Ctr Neurol, Dept Neurodegenerat Dis, D-72074 Tubingen, Germany.
[Herrmann, David N.; Sowden, Janet E.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Herrmann, David N.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.
[Acsadi, Gyula] Connecticut Childrens Med Ctr, Dept Neurol, Hartford, CT 06106 USA.
[North, Kathryn N.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
[North, Kathryn N.] Univ Melbourne, Dept Paediat, Parkville, Vic 3010, Australia.
RP North, KN (reprint author), Childrens Hosp Westmead, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
EM kathryn.north@mcri.edu.au
RI Houlden, Henry/C-1532-2008; North, Kathryn/K-6476-2012
OI Houlden, Henry/0000-0002-2866-7777; North, Kathryn/0000-0003-0841-8009
FU National Human Genome Research Institute, National Institutes of Health
[U54 HG003067]; Inherited Neuropathies Consortium (Rare Disease Clinical
Research Network, National Institute of Neurological Disorders and
Stroke) [1U54NS0657]; Wellcome Trust [WT091310]
FX We would like to thank Leigh Waddell for coordination of AUS1 exome
samples, Katy Eichinger for research evaluation of USA1, and Garth
Nicholson, Marina Kennerson, Giovanni Stevanin, and Matthew Harms for
further investigating additional BICD2 variants that ultimately did not
segregate with the disease phenotype in their kindreds. AUS1 exome
sequencing was supported by a grant from the National Human Genome
Research Institute, National Institutes of Health (Medical Sequencing
Program grant U54 HG003067 to E.S. Lander, the principal investigator at
the Broad Institute of Harvard and MIT). Genetic testing of AUSTRAI1,
UK1, USA1, and GERMANY1 was supported by the Inherited Neuropathies
Consortium (Rare Disease Clinical Research Network, National Institute
of Neurological Disorders and Stroke 1U54NS0657). The study makes use of
data (from sample set NM5061932 [UK2]) generated by the UK10K Consortium
with funding from the Wellcome Trust (award WT091310). Investigators who
contributed to the generation of these data are listed at www.UK10K.org.
Funding sources for individual authors are summarized in the
Supplemental Acknowledgments.
NR 21
TC 51
Z9 53
U1 0
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN 6
PY 2013
VL 92
IS 6
BP 965
EP 973
DI 10.1016/j.ajhg.2013.04.018
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA 164MX
UT WOS:000320415300013
PM 23664120
ER
PT J
AU Lapenta, OM
Minati, L
Fregni, F
Boggio, PS
AF Lapenta, Olivia M.
Minati, Ludovico
Fregni, Felipe
Boggio, Paulo S.
TI Je pense donc je fais: transcranial direct current stimulation modulates
brain oscillations associated with motor imagery and movement
observation
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Article
DE tDCS; EEG; mu rhythm; motor imagery; action observation; primary motor
cortex
ID MU-RHYTHM; MAGNETIC STIMULATION; CORTICOSPINAL EXCITABILITY; HOMEOSTATIC
PLASTICITY; STROKE PATIENTS; EEG EVIDENCE; CORTEX; SIMULATION; HUMANS;
TASK
AB Motor system neural networks are activated during movement imagery, observation and execution, with a neural signature characterized by suppression of the Mu rhythm. In order to investigate the origin of this neurophysiological marker, we tested whether transcranial direct current stimulation (tDCS) modifies Mu rhythm oscillations during tasks involving observation and imagery of biological and non-biological movements. We applied tDCS (anodal, cathodal, and sham) in 21 male participants (mean age 23.8 +/- 3.06), over the left M1 with a current of 2 mA for 20 min. Following this, we recorded the EEG at C3, C4, and Cz and surrounding C3 and C4 electrodes. Analyses of C3 and C4 showed significant effects for biological vs. non-biological movement (p = 0.005), and differential hemisphere effects according to the type of stimulation (p = 0.04) and type of movement (p = 0.02). Analyses of surrounding electrodes revealed significant interaction effects considering type of stimulation and imagery or observation of biological or non-biological movement (p = 0.03). The main findings of this study were (1) Mu desynchronization during biological movement of the hand region in the contralateral hemisphere after sham tDCS; (2) polarity-dependent modulation effects of tDCS on the Mu rhythm, i.e., anodal tDCS led to Mu synchronization while cathodal tDCS led to Mu desynchronization during movement observation and imagery (3) specific focal and opposite inter-hemispheric effects, i.e., contrary effects for the surrounding electrodes during imagery condition and also for inter-hemispheric electrodes (C3 vs. C4). These findings provide insights into the cortical oscillations during movement observation and imagery. Furthermore, it shows that tDCS can be highly focal when guided by a behavioral task.
C1 [Lapenta, Olivia M.; Boggio, Paulo S.] Univ Prebiteriana Mackenzie, Social & Cognit Neurosci Lab, Ctr Hlth & Biol Sci, BR-01241001 Sao Paulo, Brazil.
[Minati, Ludovico] Fdn IRCCS Ist Neurol Carlo Besta, UO Direz Sci, Milan, Italy.
[Fregni, Felipe] Harvard Univ, Lab Neuromodulat, Sch Med, Spaulding Rehabil Hosp,Massachusetts Gen Hosp, Boston, MA USA.
RP Boggio, PS (reprint author), Univ Prebiteriana Mackenzie, Social & Cognit Neurosci Lab, Rua Piaui,181,10 Andar, BR-01241001 Sao Paulo, Brazil.
EM boggio@mackenzie.br
RI Boggio, Paulo/K-6272-2012
OI Boggio, Paulo/0000-0002-6109-0447
FU CNPq researcher grant [304164/2012-7]; Master grant (CAPES-PROSUP-IES
modality I)
FX Paulo S. Boggio is supported by a CNPq researcher grant (304164/2012-7).
Olivia M. Lapenta was supported by a Master grant (CAPES-PROSUP-IES
modality I).
NR 57
TC 13
Z9 13
U1 1
U2 10
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUN 6
PY 2013
VL 7
AR 256
DI 10.3389/fnhum.2013.00256
PG 9
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 158TP
UT WOS:000319996400001
PM 23761755
ER
PT J
AU Hoo, GWS
AF Hoo, Guy W. Soo
TI In Prone Ventilation, One Good Turn Deserves Another
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; FAILURE
C1 [Hoo, Guy W. Soo] Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect 111Q, Los Angeles, CA USA.
[Hoo, Guy W. Soo] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Hoo, GWS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, West Los Angeles Vet Affairs Healthcare Ctr, Pulm & Crit Care Sect 111Q, Los Angeles, CA USA.
NR 10
TC 3
Z9 3
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 6
PY 2013
VL 368
IS 23
BP 2227
EP 2228
DI 10.1056/NEJMe1304349
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 158DN
UT WOS:000319948900012
ER
PT J
AU Greka, A
Dekker, JP
Calderwood, SB
AF Greka, Anna
Dekker, John P.
Calderwood, Stephen B.
TI Case 4-2013: A Man with Acute Flank Pain
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Greka, Anna; Dekker, John P.; Calderwood, Stephen B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Greka, A (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD JUN 6
PY 2013
VL 368
IS 23
BP 2237
EP 2237
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 158DN
UT WOS:000319948900026
PM 23738559
ER
PT J
AU Bagci-Onder, T
Agarwal, A
Flusberg, D
Wanningen, S
Sorger, P
Shah, K
AF Bagci-Onder, T.
Agarwal, A.
Flusberg, D.
Wanningen, S.
Sorger, P.
Shah, K.
TI Real-time imaging of the dynamics of death receptors and therapeutics
that overcome TRAIL resistance in tumors
SO ONCOGENE
LA English
DT Article
DE live-cell imaging; DR4/5; TRAIL; GBM; neural stem cell; dual luciferase
imaging
ID HISTONE DEACETYLASE INHIBITORS; PHASE-II TRIAL; INDUCED APOPTOSIS;
CANCER-CELLS; UP-REGULATION; DOWN-REGULATION; STEM-CELLS; IN-VIVO;
S-TRAIL; GLIOMA
AB Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis specifically in tumor cells and its efficacy has been tested in pre-clinical models by delivering it systemically as a purified ligand or via engineered stem cells (SC). However, about 50% of tumor lines are resistant to TRAIL and overcoming TRAIL resistance in aggressive tumors, such as glioblastoma-multiforme (GBM), and understanding the molecular dynamics of TRAIL-based combination therapies are critical to broadly use TRAIL as a therapeutic agent. In this study, we developed death receptor (DR)4/5-reporters that offer an imaging-based platform to identify agents that act in concert with a potent, secretable variant of TRAIL (S-TRAIL) by monitoring changes in DR4/5 expression. Utilizing these reporters, we show a differential regulation of DR4/5 when exposed to a panel of clinically relevant agents. A histone deacetylase inhibitor, MS-275, resulted in upregulation of DR4/5 in all GBM cell lines, and these changes could be followed in real time both in vitro and in vivo in mice bearing tumors and they correlated with increased TRAIL sensitivity. To further assess the dynamics of combinatorial strategies that overcome resistance of tumors to SC released S-TRAIL, we also engineered tumor cells to express live-cell caspase-reporters and SCs to express S-TRAIL. Utilizing DR4/5 and caspase reporters in parallel, we show that MS-275 sensitizes TRAIL-resistant GBM cells to stem cell (SC) delivered S-TRAIL by changing the time-to-death in vitro and in vivo. This study demonstrates the effectiveness of a combination of real-time reporters of TRAIL-induced apoptosis pathway in evaluating the efficacy of SC-TRAIL-based therapeutics and may have implications in targeting a broad range of cancers.
C1 [Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA.
[Bagci-Onder, T.; Agarwal, A.; Wanningen, S.; Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Flusberg, D.; Sorger, P.] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02114 USA.
[Shah, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA.
[Shah, K.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Shah, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA.
EM kshah@mgh.harvard.edu
FU American Cancer Society; NIH [CA138922, NS071197, CA139980]; James
McDonnell Foundation
FX We thank Dr Shi-Yon Sun for providing pDR4 and pDR5 basic constructs;
real-time PCR core facility of Neuroscience Department, Massachusetts
General Hospital; flow cytometry core facility of Ragon Institute,
Massachusetts General Hospital; and Nikon Imaging Center, Harvard
Medical School for technical help and equipments. This work was
supported by American Cancer Society (KS), NIH grants CA138922, NS071197
(KS), CA139980 (PKS) and the James McDonnell Foundation (KS). There are
no competing financial interests to disclose.
NR 39
TC 14
Z9 14
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD JUN 6
PY 2013
VL 32
IS 23
BP 2818
EP 2827
DI 10.1038/onc.2012.304
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 163WR
UT WOS:000320369100002
PM 22824792
ER
PT J
AU Choi, S
Chatzigeorgiou, M
Taylor, KP
Schafer, WR
Kaplan, JM
AF Choi, Seungwon
Chatzigeorgiou, Marios
Taylor, Kelsey P.
Schafer, William R.
Kaplan, Joshua M.
TI Analysis of NPR-1 Reveals a Circuit Mechanism for Behavioral Quiescence
in C. elegans
SO NEURON
LA English
DT Article
ID PIGMENT-DISPERSING FACTOR; SLEEP-LIKE STATE; CAENORHABDITIS-ELEGANS;
SOCIAL-BEHAVIOR; DROSOPHILA-MELANOGASTER; NEURAL CIRCUIT; NEUROPEPTIDE;
NEURONS; SYSTEM; GENE
AB Animals undergo periods of behavioral quiescence and arousal in response to environmental, circadian, or developmental cues. During larval molts, C. elegans undergoes a period of profound behavioral quiescence termed lethargus. Locomotion quiescence during lethargus was abolished in mutants lacking a neuropeptide receptor (NPR-1) and was reduced in mutants lacking NPR-1 ligands (FLP-18 and FLP-21). Wild-type strains are polymorphic for the npr-1 gene, and their lethargus behavior varies correspondingly. Locomotion quiescence and arousal were mediated by decreased and increased secretion of an arousal neuropeptide (PDF-1) from central neurons. PDF receptors (PDFR-1) expressed in peripheral mechanosensory neurons enhanced touch-evoked calcium transients. Thus, a central circuit stimulates arousal from lethargus by enhancing the sensitivity of peripheral mechanosensory neurons in the body. These results define a circuit mechanism controlling a developmentally programmed form of quiescence.
C1 [Choi, Seungwon; Taylor, Kelsey P.; Kaplan, Joshua M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Choi, Seungwon; Taylor, Kelsey P.; Kaplan, Joshua M.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
[Choi, Seungwon; Taylor, Kelsey P.; Kaplan, Joshua M.] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA 02115 USA.
[Chatzigeorgiou, Marios; Schafer, William R.] MRC, Mol Biol Lab, Div Cell Biol, Cambridge CB2 0QH, England.
RP Kaplan, JM (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM kaplan@molbio.mgh.harvard.edu
FU Kwanjeong Educational Foundation; [NIH DK80215]; [MRC MC-A022-5PB9]
FX We thank the following for strains, advice, reagents, and comments on
the manuscript: Cori Bargmann for NPR-1 sensory rescue and rat TRPV1
transgenes, Mario de Bono for flp-18 mutants, the Caenorhabditis
Genetics Center (CGC) and S. Mitani for strains, and members of the
Kaplan lab for comments on the manuscript. This work was supported by a
Kwanjeong Educational Foundation Predoctoral Fellowship (S.C.), and by
research grants to J.K. (NIH DK80215), and to W.S. (MRC MC-A022-5PB9).
NR 51
TC 31
Z9 35
U1 0
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD JUN 5
PY 2013
VL 78
IS 5
BP 869
EP 880
DI 10.1016/j.neuron.2013.04.002
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 168YH
UT WOS:000320743400013
PM 23764289
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Ipsilateral lower extremity joint involvement increases the risk of poor
pain and function outcomes after hip or knee arthroplasty
SO BMC MEDICINE
LA English
DT Article
DE Arthroplasty; Ipsilateral; Joint replacement; Outcomes; Risk factors;
Total hip replacement; Total knee replacement
ID CLINICAL RATING SYSTEM; REPLACEMENT; PREDICTORS; TRENDS
AB Background: Poor pain and function outcomes are undesirable after an elective surgery such as total hip or knee arthroplasty (THA/TKA). Recent studies have indicated that the presence of contralateral joint influences outcomes of THA/TKA, however the impact of ipsilateral knee/hip involvement on THA/TKA outcomes has not been explored. The objective of this study was to assess the association of ipsilateral knee/hip joint involvement on short-term and medium-term pain and function outcomes after THA/TKA.
Methods: In this retrospective study of prospectively collected data, we used the data from the Mayo Clinic Total Joint Registry to assess the association of ipsilateral knee or hip joint involvement with moderate to severe pain and moderate to severe activity limitation at 2-year and 5-year follow-up after primary and revision THA and TKA using multivariable-adjusted logistic regression analyses.
Results: At 2 years, 3,823 primary THA, 4,701 primary TKA, 1,218 revision THA and 725 revision TKA procedures were studied. After adjusting for multiple covariates, ipsilateral knee pain was significantly associated with outcomes after primary THA (all P values <0.01): (1) moderate to severe pain: at 2 years, odds ratio (OR), 2.3 (95% confidence interval (CI) 1.5 to 3.6); at 5 years, OR 1.8 (95% CI 1.1 to 2.7); (2) moderate to severe activity limitation: at 2 years, OR 3.1 (95% CI 2.3 to 4.3); at 5 years, OR 3.6 (95% CI 2.6 to 5.0). Ipsilateral hip pain was significantly associated with outcomes after primary TKA (all P values <0.01): (1) moderate to severe pain: at 2 years, OR 3.3 (95% CI 2.3 to 4.7); at 5 years, OR 1.8 (95% CI 1.1 to 2.7); (2) moderate to severe activity limitation: at 2 years, OR 3.6 (95% CI 2.6 to 4.9); at 5 years, OR 2.2 (95% CI 1.6 to 3.2). Similar associations were noted for revision THA and TKA patients.
Conclusions: To the best of our knowledge, this is the first study showing that the presence of ipsilateral joint involvement after THA or TKA is strongly associated with poor pain and function outcomes. A potential way to improve outcomes is to address ipsilateral lower extremity joint involvement.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds; National Institutes of
Health (NIH) Clinical Translational Science Award [1 KL2 RR024151-01];
Agency for Health Quality and Research Center for Education and Research
on Therapeutics (CERTs); National Institute of Aging and National Cancer
Institute
FX This study was supported by research funds from the Mayo Clinic
Orthopedic Surgery research funds, National Institutes of Health (NIH)
Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic
Center for Clinical and Translational Research) and the resources and
use of facilities at the Birmingham VA Medical Center, Alabama, USA. JAS
is also supported by grants from the Agency for Health Quality and
Research Center for Education and Research on Therapeutics (CERTs),
National Institute of Aging and National Cancer Institute. The funding
agencies played no role in the design, in the collection, analysis, and
interpretation of data; in the writing of the manuscript; and in the
decision to submit the manuscript for publication. This study was
presented as an oral abstract presentation at the 2012 American College
of Rheumatology Annual meeting in Washington, DC in November 2012.
NR 22
TC 7
Z9 7
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD JUN 5
PY 2013
VL 11
AR 144
DI 10.1186/1741-7015-11-144
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 163GF
UT WOS:000320323300001
PM 23738845
ER
PT J
AU Iannotti, JP
Deutsch, A
Green, A
Rudicel, S
Christensen, J
Marraffino, S
Rodeo, S
AF Iannotti, Joseph P.
Deutsch, Allen
Green, Andrew
Rudicel, Sally
Christensen, Jared
Marraffino, Shannon
Rodeo, Scott
TI Time to Failure After Rotator Cuff Repair A Prospective Imaging Study
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article
ID ARTHROSCOPIC REPAIR; FUNCTIONAL OUTCOMES; FATTY DEGENERATION; SHOULDER;
TEARS; ROW; ULTRASOUND; INTEGRITY; TRENDS; MODEL
AB Background: Failure of tendon healing after a rotator cuff repair is demonstrated by magnetic resonance imaging (MRI) as a fluid-filled defect within the tendon. The frequency of, and factors associated with, failure of the tendon repair to heal have been the focus of many clinical studies. The timing of when these defects occur has not been previously studied in a large prospectively defined patient population, to our knowledge. It was our hypothesis that the majority of failures occur within twelve weeks after surgery.
Methods: One hundred and thirteen patients were enrolled in a multi-institutional prospective study. All patients had a standardized arthroscopic repair of a full-thickness tear of 1 to 4 cm as well as sequential MRI studies at six intervals from two weeks to fifty-two weeks. MRIs were reviewed at the time of imaging by the treating surgeon. Standardized patient-oriented clinical data were collected, physical examination was performed, and strength measurements were made preoperatively and postoperatively.
Results: The treating surgeons diagnosed a recurrent tear with MRI in nineteen (17%) of the 113 patients within one year after surgery. The mean time to the retear was 19.2 weeks. There was a linear increase in retears over the first twenty-six weeks after surgery, and one additional tear was diagnosed between twenty-six and fifty-two weeks after repair.
Conclusions: Retears primarily occur between six and twenty-six weeks after arthroscopic rotator cuff repair, and few additional tears occur thereafter. A substantial number of retears occur between twelve and twenty-six weeks after repair.
C1 [Iannotti, Joseph P.] Cleveland Clin, Cleveland, OH 44195 USA.
Kelsey Seabold Clin, Houston, TX 77025 USA.
Univ Orthoped, Providence, RI USA.
Hosp Special Surg, New York, NY 10021 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
CORE Inst, Phoenix, AZ USA.
Everett Clin, Everett, WA USA.
Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
Texas Orthoped Specialists, Bedford, TX USA.
UCSF, San Francisco, CA USA.
Yale Univ, New Haven, CT USA.
RP Iannotti, JP (reprint author), Cleveland Clin, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM iannotj@ccf.org
FU Pfizer Pharmaceuticals
FX This study was funded by Pfizer Pharmaceuticals. They provided support
for defining the study protocol and provided all resources for
monitoring data collection from each enrollment site, monitoring study
data, central data collection, and analysis. No support was provided to
any author for review of data or for preparation of this manuscript.
NR 26
TC 46
Z9 48
U1 0
U2 3
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD JUN 5
PY 2013
VL 95A
IS 11
BP 965
EP 971
DI 10.2106/JBJS.L.00708
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 161TU
UT WOS:000320217000002
PM 23780533
ER
PT J
AU Harms, AS
Cao, SW
Rowse, AL
Thome, AD
Li, XR
Mangieri, LR
Cron, RQ
Shacka, JJ
Raman, C
Standaert, DG
AF Harms, Ashley S.
Cao, Shuwen
Rowse, Amber L.
Thome, Aaron D.
Li, Xinru
Mangieri, Leandra R.
Cron, Randy Q.
Shacka, John J.
Raman, Chander
Standaert, David G.
TI MHCII Is Required for alpha-Synuclein-Induced Activation of Microglia,
CD4 T Cell Proliferation, and Dopaminergic Neurodegeneratione
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; MOUSE MODEL; CEREBROSPINAL-FLUID;
BRAIN; GAMMA; CHAIN; INTERLEUKIN-1-BETA; INFLAMMATION; EXPRESSION
AB Accumulation of alpha-synuclein (alpha-syn) in the brain is a core feature of Parkinson disease (PD) and leads to microglial activation, production of inflammatory cytokines and chemokines, T-cell infiltration, and neurodegeneration. Here, we have used both an in vivo mouse model induced by viral overexpression of alpha-syn as well as in vitro systems to study the role of the MHCII complex in alpha-syn-induced neuroinflammation and neurodegeneration. We find that in vivo, expression of full-length human alpha-syncauses striking induction of MHCII expression by microglia, while knock-out of MHCII prevents alpha-syn-induced microglial activation, antigen presentation, IgG deposition, and the degeneration of dopaminergic neurons. In vitro, treatment of microglia with aggregated alpha-syn leads to activation of antigen processing and presentation of antigen sufficient to drive CD4 T-cell proliferation and to trigger cytokine release. These results indicate a central role for microglial MHCII in the activation of both the innate and adaptive immune responses to alpha-syn in PD and suggest that the MHCII signaling complex may be a target of neuroprotective therapies for the disease.
C1 [Harms, Ashley S.; Cao, Shuwen; Thome, Aaron D.; Li, Xinru; Standaert, David G.] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL 35294 USA.
[Rowse, Amber L.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA.
[Mangieri, Leandra R.; Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.
[Cron, Randy Q.] Childrens Hosp Alabama, Dept Pediat, Div Rheumatol, Birmingham, AL 35294 USA.
[Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA.
[Raman, Chander] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
RP Standaert, DG (reprint author), Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, 1719 6th Ave South,CIRC 516, Birmingham, AL 35294 USA.
EM dstandaert@uab.edu
RI Cao, Shuwen/E-1924-2016
FU RJG Foundation; University of Alabama (UAB) Comprehensive Arthritis,
Musculoskeletal, and Autoimmunity Center (CAMAC) Comprehensive Flow
Cytometry Core (NIH) [P30 AR48311]; UAB Animal Resources Program (NIH)
[G20 RR025858, G20 RR022807-01]; NIH [T32 AR007450-30]
FX The work from these studies is generously supported by the RJG
Foundation, the University of Alabama (UAB) Comprehensive Arthritis,
Musculoskeletal, and Autoimmunity Center (CAMAC) Comprehensive Flow
Cytometry Core (NIH Grant P30 AR48311), the UAB Animal Resources Program
(NIH Grants G20 RR025858 and G20 RR022807-01), and NIH Grant T32
AR007450-30. We thank Dr. Chad Steele for his help with the multiplex
ELISA assay at University of Alabama at Birmingham.
NR 39
TC 56
Z9 58
U1 3
U2 19
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD JUN 5
PY 2013
VL 33
IS 23
BP 9592
EP 9600
DI 10.1523/JNEUROSCI.5610-12.2013
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 158IS
UT WOS:000319963300003
PM 23739956
ER
PT J
AU Seal, KH
Stein, MB
AF Seal, Karen H.
Stein, Murray B.
TI Preventing the Pain of PTSD
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; MORPHINE; OPIOIDS; FEAR;
IRAQ
AB A selective opioid receptor agonist prevents fear memory consolidation in the amygdala in a mouse model of posttraumatic stress disorder (Andero et al.).
C1 [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Seal, Karen H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA 92103 USA.
RP Stein, MB (reprint author), Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
EM mstein@ucsd.edu
NR 10
TC 2
Z9 2
U1 1
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 5
PY 2013
VL 5
IS 188
AR 188fs22
DI 10.1126/scitranslmed.3006635
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 158LK
UT WOS:000319972300002
PM 23740896
ER
PT J
AU Maggard-Gibbons, M
Maglione, M
Livhits, M
Ewing, B
Maher, AR
Hu, JH
Li, ZP
Shekelle, PG
AF Maggard-Gibbons, Melinda
Maglione, Margaret
Livhits, Masha
Ewing, Brett
Maher, Alicia Ruelaz
Hu, Jianhui
Li, Zhaoping
Shekelle, Paul G.
TI Bariatric Surgery for Weight Loss and Glycemic Control in Nonmorbidly
Obese Adults With Diabetes A Systematic Review
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID Y GASTRIC BYPASS; BODY-MASS INDEX; RANDOMIZED-CONTROLLED-TRIAL;
LIFE-STYLE INTERVENTIONS; BMI LESS-THAN-35 KG/M(2); LONG-TERM
EFFECTIVENESS; GLUCAGON-LIKE PEPTIDE-1; 10-YEAR FOLLOW-UP; THAN 35
KG/M(2); SLEEVE GASTRECTOMY
AB Importance Bariatric surgery is beneficial in persons with a body mass index (BMI) of 35 or greater with obesity-related comorbidities. There is interest in using these procedures in persons with lower BMI and diabetes.
Objective To assess the association between bariatric surgery vs nonsurgical treatments and weight loss and glycemic control among patients with diabetes or impaired glucose tolerance and BMI of 30 to 35.
Evidence Review PubMed, EMBASE, and Cochrane Library databases were searched from January 1985 through September 2012. Of 1291 screened articles, we included 32 surgical studies, 11 systematic reviews on nonsurgical treatments, and 11 large nonsurgical studies published after those reviews. Weight loss, metabolic outcomes, and adverse events were abstracted by 2 independent reviewers.
Findings Three randomized clinical trials (RCTs) (N=290; including 1 trial of 150 patients with type 2 diabetes and mean BMI of 37, 1 trial of 80 patients without diabetes [38% with metabolic syndrome] and BMI of 30 to 35, and 1 trial of 60 patients with diabetes and BMI of 30 to 40 [13 patients with BMI <35]) found that surgery was associated with greater weight loss (range, 14.4-24 kg) and glycemic control (range, 0.9-1.43 point improvements in hemoglobin A(1c) levels) during 1 to 2 years of follow-up than nonsurgical treatment. Indirect comparisons of evidence from observational studies of bariatric procedures (n approximate to 600 patients) and meta-analyses of nonsurgical therapies (containing more than 300 RCTs) support this finding at 1 or 2 years of follow-up. However, there are no robust surgical data beyond 5 years of follow-up on outcomes of diabetes, glucose control, or macrovascular and microvascular outcomes. In contrast, some RCT data of nonsurgical therapies show benefits at 10 years of follow-up or more. Surgeon-reported adverse events were low (eg, hospital deaths of 0.3%-1.0%), but data were from select centers and surgeons. Long-term adverse events are unknown.
Conclusions and Relevance Current evidence suggests that, when compared with nonsurgical treatments, bariatric surgical procedures in patients with a BMI of 30 to 35 and diabetes are associated with greater short-term weight loss and better intermediate glucose outcomes. Evidence is insufficient to reach conclusions about the appropriate use of bariatric surgery in this population until more data are available about long-term outcomes and complications of surgery.
C1 [Maggard-Gibbons, Melinda; Maglione, Margaret; Ewing, Brett; Maher, Alicia Ruelaz; Hu, Jianhui; Shekelle, Paul G.] Rand Hlth, Santa Monica, CA USA.
[Maggard-Gibbons, Melinda; Livhits, Masha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Maggard-Gibbons, Melinda; Livhits, Masha; Li, Zhaoping; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Maggard-Gibbons, Melinda] Olive View UCLA Med Ctr, Dept Surg, Sylmar, CA 91342 USA.
[Maher, Alicia Ruelaz] Akasha Ctr Integrat Med, Santa Monica, CA USA.
RP Maggard-Gibbons, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, CHS 72-215,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mmaggard@mednet.ucla.edu
FU AHRQ [290-2007-10062I]; US Department of Health and Human Services
FX This project was funded under the contract 290-2007-10062I from the AHRQ
and US Department of Health and Human Services.
NR 84
TC 97
Z9 99
U1 2
U2 34
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 5
PY 2013
VL 309
IS 21
BP 2250
EP 2261
DI 10.1001/jama.2013.4851
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 156YC
UT WOS:000319859200029
PM 23736734
ER
PT J
AU Demberg, T
Brocca-Cofano, E
Kuate, S
Aladi, S
Vargas-Inchaustegui, DA
Venzon, D
Kalisz, I
Kalyanaraman, VS
Lee, EM
Pal, R
DiPasquale, J
Ruprecht, RM
Montefiori, DC
Srivastava, I
Barnett, SW
Robert-Guroff, M
AF Demberg, Thorsten
Brocca-Cofano, Egidio
Kuate, Seraphin
Aladi, Stanley
Vargas-Inchaustegui, Diego A.
Venzon, David
Kalisz, Irene
Kalyanaraman, V. S.
Lee, Eun Mi
Pal, Ranajit
DiPasquale, Janet
Ruprecht, Ruth M.
Montefiori, David C.
Srivastava, Indresh
Barnett, Susan W.
Robert-Guroff, Marjorie
TI Impact of antibody quality and anamnestic response on viremia control
post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques
SO VIROLOGY
LA English
DT Article
DE HIV vaccine; HIV Tat; HIV Envelope; Rhesus macaque; SHIV challenge; ADCC
ID VIRUS SHIV89.6P CHALLENGE; CELLS IN-VITRO; PROTECTIVE EFFICACY;
IMMUNE-RESPONSES; DENDRITIC CELLS; REPLICATION-COMPETENT; ANTIRETROVIRAL
THERAPY; RECOMBINANT VACCINES; HIV-1 INFECTION; MESSENGER-RNA
AB Previously, priming rhesus macaques with Adenovirus type 5 host range mutant-recombinants encoding Tat and Env and boosting with Tat and Env protein in MPL-SE controlled chronic viremia by 4 logs following homologous intravenous SHIV89.6P, challenge. Here we evaluated Tat, Env, and Tat/Env regimens for immunogenicity and protective efficacy using clade C Env, alum adjuvant, and a heterologous intrarectal SHIV1157ipd3N4 challenge. Despite induction of strong cellular and humoral immunity, Tat/Env group T and B-cell memory responses were not significantly enhanced over Tat- or Env-only groups. Lack of viremia control post-challenge was attributed to lower avidity Env antibodies and no anamnestic ADCC response or SHIV1157ipd3N4 neutralizing antibody development post-challenge. Poor biologic activity of the Tat immunogen may have impaired Tat immunity. In the absence of sterilizing immunity, strong anamnestic responses to heterologous virus can help control viremia. Both antibody breadth and optimal adjuvanticity are needed to elicit high-quality antibody for protective efficacy. Published by Elsevier Inc.
C1 [Demberg, Thorsten; Brocca-Cofano, Egidio; Kuate, Seraphin; Aladi, Stanley; Vargas-Inchaustegui, Diego A.; DiPasquale, Janet; Robert-Guroff, Marjorie] NCI, Vaccine Branch, Bethesda, MD 20892 USA.
[Venzon, David] NCI, Biostat & Data Management Sect, Bethesda, MD 20892 USA.
[Kalisz, Irene; Kalyanaraman, V. S.; Lee, Eun Mi; Pal, Ranajit] Adv BioSci Labs Inc, Kensington, MD 20895 USA.
[Ruprecht, Ruth M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Montefiori, David C.] Duke Univ, Med Ctr, Durham, NC 27705 USA.
[Srivastava, Indresh; Barnett, Susan W.] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA.
RP Robert-Guroff, M (reprint author), NCI, NIH, Vaccine Branch, 41 Medlars Dr,Bldg 41,Room D804, Bethesda, MD 20892 USA.
EM guroffm@mail.nih.gov
FU NIH [P01AI048240]; Intramural Research Program of the National
Institutes of Health; National Cancer Institute
FX We thank Dr. Deborah Weiss, James Treece and all the veterinary staff at
ABL for excellent care of our animals and performance of all animal
technical procedures. The following reagent was obtained from the AIDS
Research and Reference Reagent program, DAIDS, NIAID, NIH: HIV Tat clade
B consensus peptides, complete set. This work was supported in part by
NIH grant P01AI048240 to R.M.R and by the Intramural Research Program of
the National Institutes of Health, National Cancer Institute.
NR 46
TC 7
Z9 7
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN 5
PY 2013
VL 440
IS 2
BP 210
EP 221
DI 10.1016/j.virol.2013.02.024
PG 12
WC Virology
SC Virology
GA 141VT
UT WOS:000318755300012
PM 23528732
ER
PT J
AU Chaudhuri, D
Sancak, Y
Mootha, VK
Clapham, DE
AF Chaudhuri, Dipayan
Sancak, Yasemin
Mootha, Vamsi K.
Clapham, David E.
TI MCU encodes the pore conducting mitochondrial calcium currents
SO ELIFE
LA English
DT Article
ID ESSENTIAL COMPONENT; CA2+ UPTAKE; UNIPORTER; CHANNELS; PROTEIN
AB Mitochondrial calcium (Ca2+) import is a well-described phenomenon regulating cell survival and ATP production. Of multiple pathways allowing such entry, the mitochondrial Ca2+ uniporter is a highly Ca2+-selective channel complex encoded by several recently-discovered genes. However, the identity of the pore-forming subunit remains to be established, since knockdown of all the candidate uniporter genes inhibit Ca2+ uptake in imaging assays, and reconstitution experiments have been equivocal. To definitively identify the channel, we use whole-mitoplast voltage-clamping, the technique that originally established the uniporter as a Ca2+ channel. We show that RNAi-mediated knockdown of the mitochondrial calcium uniporter (MCU) gene reduces mitochondrial Ca2+ current (I-MiCa), whereas overexpression increases it. Additionally, a classic feature of I-MiCa, its sensitivity to ruthenium red inhibition, can be abolished by a point mutation in the putative pore domain without altering current magnitude. These analyses establish that MCU encodes the pore-forming subunit of the uniporter channel.
C1 [Chaudhuri, Dipayan] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Chaudhuri, Dipayan; Clapham, David E.] Boston Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA USA.
[Sancak, Yasemin; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sancak, Yasemin; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Sancak, Yasemin; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Clapham, David E.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
RP Clapham, DE (reprint author), Boston Childrens Hosp, Howard Hughes Med Inst, Dept Cardiol, Boston, MA USA.
EM dclapham@enders.tch.harvard.edu
FU National Institutes of Health [F32HL107021, R24DK080261]; Helen Hay
Whitney Foundation; Howard Hughes Medical Institute
FX National Institutes of Health F32HL107021 Dipayan Chaudhuri; National
Institutes of Health R24DK080261 Vamsi K Mootha; Helen Hay Whitney
Foundation Yasemin Sancak; Howard Hughes Medical Institute David E
Clapham
NR 14
TC 51
Z9 52
U1 0
U2 3
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD JUN 4
PY 2013
VL 2
AR e00704
DI 10.7554/eLife.00704
PG 8
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 274OP
UT WOS:000328616200004
PM 23755363
ER
PT J
AU Tilly, JL
Sinclair, DA
AF Tilly, Jonathan L.
Sinclair, David A.
TI Germline Energetics, Aging, and Female Infertility
SO CELL METABOLISM
LA English
DT Review
ID ASSISTED REPRODUCTIVE TECHNOLOGIES; MUSCLE MITOCHONDRIAL-FUNCTION;
CALORIE RESTRICTION; STEM-CELLS; HUMAN OOCYTES; MATERNAL AGE; LIFE-SPAN;
CHROMOSOME-ABNORMALITIES; MOUSE OOCYTES; HUMAN EMBRYOS
AB The role of metabolism in ovarian aging is poorly described, despite the fact that ovaries fail earlier than most other organs. Growing interest in ovarian function is being driven by recent evidence that mammalian females routinely generate new oocytes during adult life through the activity of germline stem cells. In this perspective, we overview the female reproductive system as a powerful and clinically relevant model to understand links between aging and metabolism, and we discuss new concepts for how oocytes and their precursor cells might be altered metabolically to sustain or increase ovarian function and fertility in women.
C1 [Tilly, Jonathan L.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.
[Tilly, Jonathan L.] Harvard Univ, Dept Obstet Gynecol & Reprod Biol, Sch Med, Boston, MA 02115 USA.
[Sinclair, David A.] Harvard Univ, Glenn Labs Biol Mech Aging, Sch Med, Boston, MA 02115 USA.
[Sinclair, David A.] Harvard Univ, Dept Genet, Sch Med, Boston, MA 02115 USA.
[Sinclair, David A.] Univ New S Wales, Sydney, NSW 2052, Australia.
RP Tilly, JL (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.
EM jtilly@partners.org; david_sinclair@hms.harvard.edu
OI Sinclair, David/0000-0002-9936-436X
FU Method to Extend Research in Time (MERIT) Award from the National
Institute on Aging [NIH R37-AG012279]; Glenn Foundation for Medical
Research; Henry and Vivian Rosenberg Philanthropic Fund; NIH
[R01-AG028730]; Ellison Medical Foundation; Juvenile Diabetes
Foundation; United Mitochondrial Disease Foundation
FX Work conducted by the lab of J.L.T. was supported by a Method to Extend
Research in Time (MERIT) Award from the National Institute on Aging (NIH
R37-AG012279), the Glenn Foundation for Medical Research, and the Henry
and Vivian Rosenberg Philanthropic Fund. Work conducted by the lab of D.
A. S. was supported by NIH grant R01-AG028730, the Ellison Medical
Foundation, the Glenn Foundation for Medical Research, the Juvenile
Diabetes Foundation, the United Mitochondrial Disease Foundation, and a
philanthropic gift from R. Shulsky-David. The authors thank D. C. Woods
for helpful discussions and citation of work from preliminary studies
conducted with J.L.T. Interest is declared by J.L.T. in intellectual
property described in U. S. Patent 7,955,846, related to work discussed
herein; J.L.T. and D. A. S. are cofounders of OvaScience, Inc.
(Cambridge, MA); D. A. S. is a cofounder of and consultant to Cohbar
(Washington, DC) and Sirtris, a GlaxoSmithKline company (Cambridge, MA).
NR 158
TC 32
Z9 35
U1 1
U2 27
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JUN 4
PY 2013
VL 17
IS 6
BP 838
EP 850
DI 10.1016/j.cmet.2013.05.007
PG 13
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 242UC
UT WOS:000326266900008
PM 23747243
ER
PT J
AU Ezzat, S
Zheng, L
Florez, JC
Stefan, N
Mayr, T
Hliang, MM
Jablonski, K
Harden, M
Stancakova, A
Laakso, M
Haring, HU
Ullrich, A
Asa, SL
AF Ezzat, Shereen
Zheng, Lei
Florez, Jose C.
Stefan, Norbert
Mayr, Thomas
Hliang, Maw Maw
Jablonski, Kathleen
Harden, Maegan
Stancakova, Alena
Laakso, Markku
Haring, Hans-Ulrich
Ullrich, Axel
Asa, Sylvia L.
TI The Cancer-Associated FGFR4-G388R Polymorphism Enhances Pancreatic
Insulin Secretion and Modifies the Risk of Diabetes
SO CELL METABOLISM
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR-4; ADAPTER PROTEIN GRB14; FGFR4 ARG388 ALLELE;
BETA-CELL FUNCTION; BREAST-CANCER; SUSCEPTIBILITY LOCI; ARG(388) ALLELE;
FACTOR-I; PROGRESSION; ACTIVATION
AB The fibroblast growth factor receptor 4 (FGFR4)-R388 single-nucleotide polymorphism has been associated with cancer risk and prognosis. Here we show that the FGFR4-R388 allele yields a receptor variant that preferentially promotes STAT3/5 signaling. This STAT activation transcriptionally induces Grb14 in pancreatic endocrine cells to promote insulin secretion. Knockin mice with the FGFR4 variant allele develop pancreatic islets that secrete more insulin, a feature that is reversed through Grb14 deletion and enhanced with FGF19 administration. We also show in humans that the FGFR4-R388 allele enhances islet function and may protect against type 2 diabetes. These data support a common genetic link underlying cancer and hyperinsulinemia.
C1 [Ezzat, Shereen; Zheng, Lei; Hliang, Maw Maw; Asa, Sylvia L.] Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res & Diabet, Res Ctr, Diabet Unit, Boston, MA 02114 USA.
[Florez, Jose C.; Harden, Maegan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02142 USA.
[Stefan, Norbert; Haring, Hans-Ulrich] Univ Tubingen, D-72076 Tubingen, Germany.
[Mayr, Thomas; Ullrich, Axel] Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.
[Jablonski, Kathleen] George Washington Univ, Biostat Ctr, Rockville, MD 20852 USA.
[Stancakova, Alena; Laakso, Markku] Univ Eastern Finland, Dept Med, Kuopio 70210, Finland.
RP Ezzat, S (reprint author), Univ Hlth Network, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
EM shereen.ezzat@utoronto.ca
OI Stefan, Norbert/0000-0002-2186-9595
FU Canadian Institutes of Health Research [CIHR-MOP-125981]; Raymond and
Beverly Sackler Foundation; Ontario Ministry of Health and Long-Term
Care (OMHLTC); Heisenberg-Grant from the Deutsche Forschungsgemeinschaft
[STE 1096/1-1]; Academy of Finland; Finnish Diabetes Research
Foundation; Finnish Cardiovascular Research Foundation; EVO grant from
the Kuopio University Hospital [5263]; [R01 DK072041]
FX The authors would like to thank Anastasia Diamandis for technical
assistance and Vuk Stambolic for helpful discussions. This work was
supported by the Canadian Institutes of Health Research
(CIHR-MOP-125981), the Raymond and Beverly Sackler Foundation, and the
Ontario Ministry of Health and Long-Term Care (OMHLTC). The views
expressed do not necessarily reflect those of the OMHLTC. N.S. is
supported by a Heisenberg-Grant from the Deutsche Forschungsgemeinschaft
(STE 1096/1-1). M. L. is supported by the Academy of Finland, the
Finnish Diabetes Research Foundation, The Finnish Cardiovascular
Research Foundation, and an EVO grant from the Kuopio University
Hospital (5263). Genetic studies in the DPP are funded by R01 DK072041
to J.C.F. J.C.F. has received consulting honoraria from Novartis, Lilly,
and Pfizer.
NR 57
TC 8
Z9 10
U1 4
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JUN 4
PY 2013
VL 17
IS 6
BP 929
EP 940
DI 10.1016/j.cmet.2013.05.002
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 242UC
UT WOS:000326266900016
PM 23747250
ER
PT J
AU Csordas, G
Golenar, T
Seifert, EL
Kamer, KJ
Sancak, Y
Perocchi, F
Moffat, C
Weaver, D
Perez, SD
Bogorad, R
Koteliansky, V
Adijanto, J
Mootha, VK
Hajnoczky, GR
AF Csordas, Gyoergy
Golenar, Tuende
Seifert, Erin L.
Kamer, Kimberli J.
Sancak, Yasemin
Perocchi, Fabiana
Moffat, Cynthia
Weaver, David
Perez, Sergio de la Fuente
Bogorad, Roman
Koteliansky, Victor
Adijanto, Jeffrey
Mootha, Vamsi K.
Hajnoczky, Gyoergy
TI MICU1 Controls Both the Threshold and Cooperative Activation of the
Mitochondrial Ca2+ Uniporter
SO CELL METABOLISM
LA English
DT Article
ID RAT-LIVER MITOCHONDRIA; ENDOPLASMIC-RETICULUM; CALCIUM UNIPORTER;
ESSENTIAL COMPONENT; INNER MEMBRANE; CHANNELS; SIGNALS; METABOLISM;
PROTEIN; MECHANISMS
AB Mitochondrial Ca2+ uptake via the uniporter is central to cell metabolism, signaling, and survival. Recent studies identified MCU as the uniporter's likely pore and MICU1, an EF-hand protein, as its critical regulator. How this complex decodes dynamic cytoplasmic [Ca2+] ([Ca2+](c)) signals, to tune out small [Ca2+](c) increases yet permit pulse transmission, remains unknown. We report that loss of MICU1 in mouse liver and cultured cells causes mitochondrial Ca2+ accumulation during small [Ca2+](c) elevations but an attenuated response to agonist-induced [Ca2+](c) pulses. The latter reflects loss of positive cooperativity, likely via the EF-hands. MICU1 faces the intermembrane space and responds to [Ca2+](c) changes. Prolonged MICU1 loss leads to an adaptive increase in matrix Ca2+ binding, yet cells show impaired oxidative metabolism and sensitization to Ca2+ overload. Collectively, the data indicate that MICU1 senses the [Ca2+](c) to establish the uniporter's threshold and gain, thereby allowing mitochondria to properly decode different inputs.
C1 [Csordas, Gyoergy; Golenar, Tuende; Seifert, Erin L.; Moffat, Cynthia; Weaver, David; Perez, Sergio de la Fuente; Adijanto, Jeffrey; Hajnoczky, Gyoergy] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.
[Kamer, Kimberli J.; Sancak, Yasemin; Perocchi, Fabiana; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sancak, Yasemin; Perocchi, Fabiana; Mootha, Vamsi K.] Harvard Univ, Dept Syst Biol, Med Sch &, Cambridge, MA 02142 USA.
[Sancak, Yasemin; Perocchi, Fabiana; Mootha, Vamsi K.] Broad Inst, Cambridge, MA 02142 USA.
[Bogorad, Roman] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Koteliansky, Victor] Alnylam Pharmaceut Inc, Cambridge, MA 02142 USA.
[Perocchi, Fabiana] Univ Munich, Gene Ctr, D-81377 Munich, Germany.
RP Mootha, VK (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM vamsi@hms.harvard.edu; gyorgy.hajnoczky@jefferson.edu
OI Kamer, Kimberli/0000-0001-8728-7793
FU NIH [DK080261, DK051526]
FX We thank Olga Goldberger for technical assistance, and B. R.
Bettencourt, K. Charisse, S. Kuchimanchi, and A. Akinc of Alnylam
Pharmaceuticals for siRNA design, synthesis, and formulation. This work
was supported by NIH grants DK080261 (to V. K. M.) and DK051526 (to G.
H.). V. K. was formerly an employee at and received compensation from
Alnylam Pharmaceuticals.
NR 48
TC 104
Z9 107
U1 1
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD JUN 4
PY 2013
VL 17
IS 6
BP 976
EP 987
DI 10.1016/j.cmet.2013.04.020
PG 12
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 242UC
UT WOS:000326266900020
PM 23747253
ER
PT J
AU DesRoches, CM
Audet, AM
Painter, M
Donelan, K
AF DesRoches, Catherine M.
Audet, Anne-Marie
Painter, Michael
Donelan, Karen
TI Meeting Meaningful Use Criteria and Managing Patient Populations A
National Survey of Practicing Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID ELECTRONIC HEALTH RECORD; CARE; INCENTIVES; SYSTEMS
AB Background: Meaningful use, as defined by the Centers for Medicare & Medicaid Services, will require the aggregation of patient data to enable population assessment. Little is known about the proportion of physicians who are able to meet meaningful use criteria or their use of electronic health records (EHRs) to manage patient populations.
Objective: To evaluate physicians' reports of EHR adoption and ease of use and their ability to use EHRs for patient panel management.
Design: National mailed survey of practicing physicians (response rate of 60%).
Setting: Late 2011 and early 2012.
Participants: 1820 primary care physicians and specialists in office-based practices.
Measurements: Proportion of physicians who have a basic EHR and meet meaningful use criteria and ease of use of computerized systems designed for patient population management tasks.
Results: A total of 43.5% of physicians reported having a basic EHR, and 9.8% met meaningful use criteria. Computerized systems for managing patient populations were not widespread; fewer than one half of respondents reported the presence of computerized systems for any of the patient population management tasks included in the survey. Physicians with such functionalities reported that these systems varied in ease of use. Physicians with an EHR that met meaningful use criteria were significantly more likely than those not meeting the standard to rate panel management tasks as easy.
Limitation: Ease-of-use measures are subjective.
Conclusion: Few physicians could meet meaningful use criteria in early 2012 and using computerized systems for the panel management tasks was difficult. Results support the growing evidence that using the basic data input capabilities of an EHR does not translate into the greater opportunity that these technologies promise.
C1 [DesRoches, Catherine M.] Mathemat Policy Res, Cambridge, MA 02139 USA.
Commonwealth Fund, New York, NY USA.
Robert Wood Johnson Fdn, Princeton, NJ 08540 USA.
Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
RP DesRoches, CM (reprint author), Mathemat Policy Res, 955 Massachusetts Ave,Suite 800, Cambridge, MA 02139 USA.
EM cdesroches@mathematica-mpr.com
FU Robert Wood Johnson Foundation [68812]; Commonwealth Fund [20110087]
FX By the Robert Wood Johnson Foundation (grant 68812) and the Commonwealth
Fund (grant 20110087).
NR 22
TC 29
Z9 29
U1 1
U2 7
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 4
PY 2013
VL 158
IS 11
BP 791
EP +
DI 10.7326/0003-4819-158-11-201306040-00003
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 164AA
UT WOS:000320379800002
PM 23732712
ER
PT J
AU Kalantarian, S
Ruskin, JN
AF Kalantarian, Shadi
Ruskin, Jeremy N.
TI Cognitive Impairment Associated With Atrial Fibrillation RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Kalantarian, Shadi; Ruskin, Jeremy N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kalantarian, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 3
TC 1
Z9 1
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUN 4
PY 2013
VL 158
IS 11
BP 849
EP 849
DI 10.7326/0003-4819-158-11-201306040-00016
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 164AA
UT WOS:000320379800012
PM 23732721
ER
PT J
AU Hsu, JC
Li, YM
Marcus, GM
Hsue, PY
Scherzer, R
Grunfeld, C
Shlipak, MG
AF Hsu, Jonathan C.
Li, Yongmei
Marcus, Gregory M.
Hsue, Priscilla Y.
Scherzer, Rebecca
Grunfeld, Carl
Shlipak, Michael G.
TI Atrial Fibrillation and Atrial Flutter in Human Immunodeficiency
Virus-Infected Persons Incidence, Risk Factors, and Association With
Markers of HIV Disease Severity
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE arrhythmia; atrial fibrillation; epidemiology; HIV infection; risk
factors
ID ANTIRETROVIRAL THERAPY ERA; CARDIOVASCULAR EVENTS; KIDNEY-FUNCTION;
LIFETIME RISK; HEART; INFLAMMATION; PREVALENCE; VETERANS; COHORT;
ATHEROSCLEROSIS
AB Objectives The purpose of this study was to investigate the associations of traditional risk factors and longitudinal measures of human immunodeficiency virus (HIV) disease severity with risk of incident atrial fibrillation (AF) in a contemporary cohort of HIV-infected individuals.
Background Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhythmia, AF, has not been adequately studied in this population.
Methods We studied a national sample of 30,533 HIV-infected veterans followed in the Veterans Affairs HIV Clinical Case Registry from 1996 to 2011. We examined the independent associations of demographic characteristics, time-updated comorbidities, and time-updated clinical measurements including CD4(+) cell count and viral load with the outcome of incident AF using proportional hazards regression for multivariable analysis.
Results Over a median follow-up of 6.8 years, 780 (2.6%) patients developed AF. After multivariable adjustment for traditional risk factors, a lower CD4(+) cell count (<200 compared with >350 cells/mm(3); hazard ratio [HR]: 1.4; 95% confidence interval [CI]: 1.1 to 1.8; p = 0.018) and higher viral load (>100,000 compared with <500 copies/ml; HR: 1.7; 95% CI: 1.2 to 2.4; p = 0.002) were independently associated with increased risk of incident AF. Additional risk factors independently associated with risk of AF included older age, White race, coronary artery disease, congestive heart failure, alcoholism, proteinuria, reduced kidney function, and hypothyroidism.
Conclusions In a large HIV-infected cohort, markers of HIV disease severity represented by low CD4(+) cell count and high viral load, assessed by multiple time-updated measures, were independently associated with development of AF. (C) 2013 by the American College of Cardiology Foundation
C1 [Hsu, Jonathan C.; Marcus, Gregory M.] Univ Calif San Francisco, Sect Cardiac Electrophysiol, Div Cardiol, Dept Med, San Francisco, CA 94143 USA.
[Li, Yongmei; Scherzer, Rebecca; Grunfeld, Carl; Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
[Li, Yongmei; Scherzer, Rebecca; Grunfeld, Carl; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hsue, Priscilla Y.] San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94110 USA.
RP Hsu, JC (reprint author), Univ Calif San Francisco, Sect Cardiac Electrophysiol, Div Cardiol, Dept Med, 500 Parnassus Ave,MUE 434,Box 1354, San Francisco, CA 94143 USA.
EM jonhsumd@gmail.com
OI Hsu, Jonathan/0000-0002-1523-573X
FU National Institutes of Health, University of California, San
Francisco-Gladstone Institute of Virology & Immunology Center for AIDS
Research [P30-AI027763]; St. Jude Medical; Baylis; Medical, Gilead;
SentreHeart Inc; Tobira
FX This research was supported by a grant from the National Institutes of
Health, University of California, San Francisco-Gladstone Institute of
Virology & Immunology Center for AIDS Research, P30-AI027763. Dr. Marcus
receives speaker's fees from St. Jude Medical; is a consultant for
InCarda; and receives research support from Baylis; Medical, Gilead, and
SentreHeart Inc. Dr. Hsue is an advisor for Gilead and Pfizer; and has
received research support from Tobira. All other authors have reported
that they have no relationships relevant to the contents of this paper
to disclose.
NR 33
TC 20
Z9 20
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD JUN 4
PY 2013
VL 61
IS 22
BP 2288
EP 2295
DI 10.1016/j.jacc.2013.03.022
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 166ZV
UT WOS:000320600700010
PM 23563125
ER
PT J
AU Zhao, LB
Lu, YT
Li, FQ
Wu, K
Hou, S
Yu, JH
Shen, QL
Wu, DX
Song, M
OuYang, WH
Luo, Z
Lee, T
Fang, XH
Shao, C
Xu, X
Garcia, MA
Chung, LWK
Rettig, M
Tseng, HR
Posadas, EM
AF Zhao, Libo
Lu, Yi-Tsung
Li, Fuqiang
Wu, Kui
Hou, Shuang
Yu, Juehua
Shen, Qinglin
Wu, Dongxia
Song, Min
OuYang, Wei-Han
Luo, Zheng
Lee, Tom
Fang, Xiaohong
Shao, Chen
Xu, Xun
Garcia, Mitch A.
Chung, Leland W. K.
Rettig, Matthew
Tseng, Hsian-Rong
Posadas, Edwin M.
TI High-Purity Prostate Circulating Tumor Cell Isolation by a Polymer
Nanofiber-Embedded Microchip for Whole Exome Sequencing
SO ADVANCED MATERIALS
LA English
DT Article
DE electrospun nanomaterials; microfluidics; circulating tumor cell; whole
exome sequencing; prostate cancer
ID CANCER PATIENTS; BREAST-CANCER; CAPTURE; PROGRESSION; ENRICHMENT; BLOOD
C1 [Zhao, Libo; Fang, Xiaohong] Chinese Acad Sci, Key Lab Mol Nanostruct & Nanotechnol, Inst Chem, Beijing 100190, Peoples R China.
[Lu, Yi-Tsung; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urol Oncol Program, Los Angeles, CA 90048 USA.
[Lu, Yi-Tsung; Chung, Leland W. K.; Posadas, Edwin M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA.
[Zhao, Libo; Hou, Shuang; Yu, Juehua; Shen, Qinglin; Wu, Dongxia; Song, Min; Luo, Zheng; Lee, Tom; Tseng, Hsian-Rong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, CIMI, CNSI, Los Angeles, CA 90095 USA.
[Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA.
[Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90095 USA.
[Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA USA.
[Li, Fuqiang; Wu, Kui; Xu, Xun] BGI ShenZhen, Shenzhen 518083, Peoples R China.
[OuYang, Wei-Han; Garcia, Mitch A.] CytoLumina Technol Corp, Walnut, CA 91789 USA.
[Shao, Chen] Fourth Mil Med Univ, Dept Urol, Xijing Hosp, Xian 710032, Peoples R China.
RP Xu, X (reprint author), BGI ShenZhen, 2nd F,Bldg 11, Shenzhen 518083, Peoples R China.
EM xuxun@genomics.cn; mgarcia@cytolumina.com; Leland.Chung@cshs.org;
MRettig@mednet.ucla.edu; HRTseng@mednet.ucla.edu; Edwin.Posadas@csmc.edu
RI Tseng, Hsian-Rong/G-2222-2010; Zhao, Libo/G-2421-2010
FU NIH/NCI [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422];
PCF Young Investigator Award; Prostate Cancer Foundation (PCF)
FX The research endeavors at UCLA were supported by a Creativity Award from
Prostate Cancer Foundation (PCF), and research grants (R21 CA151159 and
R33 CA157396) from NIH/NCI Innovative Molecular Analysis Technologies
(IMAT) Program. The research endeavors at Cedars Sinai Medical Center
were supported by DoD Idea Award (W81XWH-11-1-0422) and PCF Young
Investigator Award.
NR 26
TC 58
Z9 59
U1 14
U2 160
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD JUN 4
PY 2013
VL 25
IS 21
BP 2897
EP 2902
DI 10.1002/adma.201205237
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA 157MG
UT WOS:000319899700002
PM 23529932
ER
PT J
AU Viswanathan, J
Haapasalo, A
Kurkinen, KMA
Natunen, T
Makinen, P
Bertram, L
Soininen, H
Tanzi, RE
Hiltunen, M
AF Viswanathan, Jayashree
Haapasalo, Annakaisa
Kurkinen, Kaisa M. A.
Natunen, Teemu
Makinen, Petra
Bertram, Lars
Soininen, Hilkka
Tanzi, Rudolph E.
Hiltunen, Mikko
TI Ubiquilin-1 Modulates gamma-Secretase-Mediated epsilon-Site Cleavage in
Neuronal Cells
SO BIOCHEMISTRY
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; PRESENILIN/GAMMA-SECRETASE; TRANSMEMBRANE
DOMAIN; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; NOTCH; APP; FE65;
PROTEASOME; INTERACTS
AB Ubiquilin-1 is an Alzheimer's disease-associated protein, which is known to modulate amyloid precursor protein (APP) processing, amyloid-beta (A beta) secretion, and presenilin-1 (PS1) accumulation. Here, we aim to elucidate the molecular mechanisms by which full-length transcript variant 1 of ubiquilin-1 (TV1) affects APP processing and gamma-secretase function in human neuroblastoma cells stably overexpressing APP (SH-SY5Y-APP751). We found that TV1 overexpressing significant increased the level of APP intracellular domain (AICD) generation. However, there was no increase in the levels of secreted A beta 40, A beta 42, or total A beta, suggesting that ubiquilin-1 in particular enhances gamma-secretase-mediated epsilon-site cleavage. This is supported by the finding that TV1 also significantly increased the level of intracellular domain generation of another gamma-secretase substrate, leukocyte common antigen-related (LAR) phosphatase. However, in these cells, the increase in AICD levels was abolished, suggesting a preference of the gamma-secretase for LAR over APP. TV2, another ubiquilin-1 variant that lacks the protein fragment encoded by exon 8, did not increase the level of AICD generation like TV1 did. The subcellular and plasma membrane localization of APP or gamma-secretase complex components PS1 and nicastrin was not altered in TV1-overexpressing cells. Moreover, the effects of TV1 were not mediated by altered expression or APP binding of FE6S, an adaptor protein thought to regulate AICD generation and stability. These data suggest that ubiquilin-1 modulates gamma-secretase-mediated epsilon-site cleave and thus may play role in regulating gamma-secretase cleavage of various substrates.
C1 [Viswanathan, Jayashree; Haapasalo, Annakaisa; Kurkinen, Kaisa M. A.; Natunen, Teemu; Makinen, Petra; Soininen, Hilkka; Hiltunen, Mikko] Univ Eastern Finland, Inst Clin Med Neurol, Kuopio 70211, Finland.
[Viswanathan, Jayashree; Haapasalo, Annakaisa; Kurkinen, Kaisa M. A.; Natunen, Teemu; Makinen, Petra; Soininen, Hilkka; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
[Bertram, Lars] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany.
[Tanzi, Rudolph E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
RP Hiltunen, M (reprint author), Univ Eastern Finland, Inst Clin Med Neurol, POB 1627, Kuopio 70211, Finland.
EM mikko.hiltunen@uef.fi
RI Bertram, Lars/K-3889-2015
OI Bertram, Lars/0000-0002-0108-124X
FU EC FP6; Health Research Council of the Academy of Finland; EVO of Kuopio
University Hospital [5772708]; Cure Alzheimer's Fund; Sigrid Juselius
Foundation; strategic funding of the University of Eastern Finland
(UEF-Brain); [MEST-CT-2005-019217]
FX This study was supported by EC FP6, MEST-CT-2005-019217, the Health
Research Council of the Academy of Finland, EVO Grant 5772708 of Kuopio
University Hospital, Cure Alzheimer's Fund, Sigrid Juselius Foundation,
and the strategic funding of the University of Eastern Finland
(UEF-Brain).
NR 48
TC 6
Z9 6
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUN 4
PY 2013
VL 52
IS 22
BP 3899
EP 3912
DI 10.1021/bi400138p
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 160DM
UT WOS:000320097200012
PM 23663107
ER
PT J
AU Wylie, BJ
Kalilani-Phiri, L
Madanitsa, M
Membe, G
Nyirenda, O
Mawindo, P
Kuyenda, R
Malenga, A
Masonbrink, A
Makanani, B
Thesing, P
Laufer, MK
AF Wylie, Blair J.
Kalilani-Phiri, Linda
Madanitsa, Mwayi
Membe, Gladys
Nyirenda, Osward
Mawindo, Patricia
Kuyenda, Redson
Malenga, Albert
Masonbrink, Abbey
Makanani, Bonus
Thesing, Phillip
Laufer, Miriam K.
TI Gestational age assessment in malaria pregnancy cohorts: a prospective
ultrasound demonstration project in Malawi
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria in pregnancy; Ultrasound; Foetal biometry; Preterm delivery;
Small for gestational age; Ballard examination
ID LOCAL HEALTH-WORKERS; THAI-BURMESE BORDER; FALCIPARUM-MALARIA;
BIRTH-WEIGHT; DIAMETER MEASUREMENT; NEWBORN-INFANT; BALLARD SCORE;
MENSTRUAL AGE; FETAL-GROWTH; REFUGEE CAMP
AB Background: Malaria during pregnancy is associated with an increased risk for low birth weight (< 2500 grams). Distinguishing infants that are born premature (< 37 weeks) from those that are growth-restricted (less than the 10th percentile at birth) requires accurate assessment of gestational age. Where ultrasound is accessible, sonographic confirmation of gestational age is more accurate than menstrual dating. The goal was to pilot the feasibility and utility of adding ultrasound to an observational pregnancy malaria cohort.
Methods: In July 2009, research staff (three mid-level clinical providers, one nurse) from The Blantyre Malaria Project underwent an intensive one-week ultrasound training to perform foetal biometry. Following an additional four months of practice and remote image review, subjects from an ongoing cohort were recruited for ultrasound to determine gestational age. Gestational age at delivery established by ultrasound was compared with postnatal gestational age assessment (Ballard examination).
Results: One hundred and seventy-eight women were enrolled. The majority of images were of good quality (94.3%, 509/540) although a learning curve was apparent with 17.5% (24/135) images of unacceptable quality in the first 25% of scans. Ultrasound was used to date 13% of the pregnancies when menstrual dates were unknown and changed the estimated gestational age for an additional 25%. There was poor agreement between the gestational age at delivery as established by the ultrasound protocol compared to that determined by the Ballard examination (bias 0.8 weeks, limits of agreement -3.5 weeks to 5.1 weeks). The distribution of gestational ages by Ballard suggested a clustering of gestational age around the mean with 87% of the values falling between 39 and 41 weeks. The distribution of gestational age by ultrasound confirmed menstrual dates was more typical. Using ultrasound confirmed dates as the gold standard, 78.5% of preterm infants were misclassified as term and 26.8% of small-for gestational age infants misclassified as appropriately grown by Ballard.
Conclusion: Ultrasound should be strongly considered in prospective malaria studies with obstetric endpoints to confirm gestational age and avoid misclassification of infants as premature or growth-restricted. The use of ultrasound does require a significant investment of time to maintain quality image acquisition.
C1 [Wylie, Blair J.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA 02114 USA.
[Kalilani-Phiri, Linda; Madanitsa, Mwayi; Membe, Gladys; Makanani, Bonus] Univ Malawi, Coll Med, Blantyre, Malawi.
[Nyirenda, Osward; Mawindo, Patricia; Kuyenda, Redson; Malenga, Albert; Thesing, Phillip] Queen Elizabeth Cent Hosp, Blantyre Malaria Project, Blantyre 3, Malawi.
[Masonbrink, Abbey; Thesing, Phillip] New York Dept Hlth, New York, NY USA.
[Thesing, Phillip] City Cincinnati Hlth Dept, Cincinnati, OH USA.
[Masonbrink, Abbey; Laufer, Miriam K.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
RP Wylie, BJ (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Massachusetts 55 Fruit St Boston, Boston, MA 02114 USA.
EM bwylie@partners.org
FU Doris Duke Charitable Foundation [2008042]; National Institutes of
Health [K23 ES021471]; SoundCaring Program (Sonosite(TM), Inc, Bothell,
Washington, USA)
FX The ultrasound machine used during the project was donated by the
Vincent Department of Obstetrics and Gynecology at the Massachusetts
General Hospital with a matching grant from the SoundCaring Program
(Sonosite (TM), Inc, Bothell, Washington, USA). Research was supported
by the Doris Duke Charitable Foundation grant number 2008042 (to MKL)
and by the National Institutes of Health grant number K23 ES021471 (to
BJW). We are especially grateful to the pregnant women who participated
in this trial and have supported our work at the Ndirande research
clinic for over a decade.
NR 42
TC 8
Z9 8
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 4
PY 2013
VL 12
AR 183
DI 10.1186/1475-2875-12-183
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 160LO
UT WOS:000320121200001
PM 23734718
ER
PT J
AU Hamilton, RT
Bhattacharya, A
Walsh, ME
Shi, Y
Wei, R
Zhang, YQ
Rodriguez, KA
Buffenstein, R
Chaudhuri, AR
Van Remmen, H
AF Hamilton, Ryan T.
Bhattacharya, Arunabh
Walsh, Michael E.
Shi, Yun
Wei, Rochelle
Zhang, Yiqiang
Rodriguez, Karl A.
Buffenstein, Rochelle
Chaudhuri, Asish R.
Van Remmen, Holly
TI Elevated Protein Carbonylation, and Misfolding in Sciatic Nerve from
db/db and Sod1(-/-) Mice: Plausible Link between Oxidative Stress and
Demyelination
SO PLOS ONE
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; PERIPHERAL MYELIN PROTEIN-22; ALDOSE
REDUCTASE INHIBITION; ALZHEIMERS-DISEASE BRAIN; DIABETIC-NEUROPATHY;
LIPID-PEROXIDATION; SKELETAL-MUSCLE; CONDUCTION-VELOCITY; NITROSATIVE
STRESS; ADVANCED GLYCATION
AB Diabetic peripheral polyneuropathy is associated with decrements in motor/sensory neuron myelination, nerve conduction and muscle function; however, the mechanisms of reduced myelination in diabetes are poorly understood. Chronic elevation of oxidative stress may be one of the potential determinants for demyelination as lipids and proteins are important structural constituents of myelin and highly susceptible to oxidation. The goal of the current study was to determine whether there is a link between protein oxidation/misfolding and demyelination. We chose two distinct models to test our hypothesis: 1) the leptin receptor deficient mouse (dbdb) model of diabetic polyneuropathy and 2) superoxide dismutase 1 knockout (Sod1 2/2) mouse model of in vivo oxidative stress. Both experimental models displayed a significant decrement in nerve conduction, increase in tail distal motor latency as well as reduced myelin thickness and fiber/axon diameter. Further biochemical studies demonstrated that oxidative stress is likely to be a potential key player in the demyelination process as both models exhibited significant elevation in protein carbonylation and alterations in protein conformation. Since peripheral myelin protein 22 (PMP22) is a key component of myelin sheath and has been found mutated and aggregated in several peripheral neuropathies, we predicted that an increase in carbonylation and aggregation of PMP22 may be associated with demyelination in dbdb mice. Indeed, PMP22 was found to be carbonylated and aggregated in sciatic nerves of dbdb mice. Sequence-driven hydropathy plot analysis and in vitro oxidation-induced aggregation of purified PMP22 protein supported the premise for oxidation-dependent aggregation of PMP22 in dbdb mice. Collectively, these data strongly suggest for the first time that oxidation-mediated protein misfolding and aggregation of key myelin proteins may be linked to demyelination and reduced nerve conduction in peripheral neuropathies.
C1 [Hamilton, Ryan T.; Bhattacharya, Arunabh; Walsh, Michael E.; Shi, Yun; Zhang, Yiqiang; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Rodriguez, Karl A.; Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Chaudhuri, Asish R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hamilton, Ryan T.; Bhattacharya, Arunabh; Shi, Yun; Wei, Rochelle; Zhang, Yiqiang; Rodriguez, Karl A.; Buffenstein, Rochelle; Chaudhuri, Asish R.; Van Remmen, Holly] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX USA.
[Chaudhuri, Asish R.; Van Remmen, Holly] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Chaudhuri, AR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM chaudhuria@uthscsa.edu; vanremmen@uthscsa.edu
FU National Service Research Award; Program project at the National
Institute of Aging [AG20591]; University of Michigan Grant; Go Grant at
the National institute of Aging project [RCA2AG036613]; Glenn Award
(Research in Biological Mechanisms of Aging); Ellison Medical Foundation
[AGSS-178006]; Glenn Foundation for Medical Research
FX Funding provided by T32 AG021890-08 (NIA) National Service Research
Award to Postdoctoral Fellow Training Grant on the Biology of Aging to
Steven N. Austad for trainees (RTH, KAR) AG20591 Program project at the
National Institute of Aging (HV) (Project 2: Does Superoxide-Induced
Mitochondrial Dysfunction Lead to Muscle Atrophy?) University of
Michigan Grant (Subcontract), RCA2AG036613 Go Grant at the National
institute of Aging project 8 (WW and HV) (Effect of rapa on removal of
protein by the autophagic and/or proteasomal pathways) under (AR) (Can
rapamycin retard aging?), Glenn Award (Research in Biological Mechanisms
of Aging) (http://glennfoundation.org/), AGSS-178006 (RB is PI) Ellison
Medical Foundation (Genomic Stability in the Naked Mole-Rat: A Role for
Cancer Resistance and Extended Longevity)
(http://www.ellisonfoundation.org/), and Glenn Foundation for Medical
Research (RB is PI). (Comparative biological mechanisms of aging,
insights from the longest lived rodent, the naked mole-rat)
(http://glennfoundation.org/). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 53
TC 17
Z9 17
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2013
VL 8
IS 6
AR e65725
DI 10.1371/journal.pone.0065725
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 158IE
UT WOS:000319961900075
PM 23750273
ER
PT J
AU Jiang, W
Zhang, DH
Bursac, N
Zhang, Y
AF Jiang, Wei
Zhang, Donghui
Bursac, Nenad
Zhang, Yi
TI WNT3 Is a Biomarker Capable of Predicting the Definitive Endoderm
Differentiation Potential of hESCs
SO STEM CELL REPORTS
LA English
DT Article
ID EMBRYONIC STEM-CELLS; INSULIN-PRODUCING CELLS; EFFICIENT
DIFFERENTIATION; PROGENITORS; PROPENSITY; EXPRESSION; LINES
AB Generation of functional cells from human pluripotent stem cells (PSCs) through in vitro differentiation is a promising approach for drug screening and cell therapy. However, the observed large and unavoidable variation in the differentiation potential of different human embryonic stem cell (hESC)/induced PSC (iPSC) lines makes the selection of an appropriate cell line for the differentiation of a particular cell lineage difficult. Here, we report identification of WNT3 as a biomarker capable of predicting definitive endoderm (DE) differentiation potential of hESCs. We show that the mRNA level of WNT3 in hESCs correlates with their DE differentiation efficiency. In addition, manipulations of hESCs through WNT3 knockdown or overexpression can respectively inhibit or promote DE differentiation in a WNT3 level-dependent manner. Finally, analysis of several hESC lines based on their WNT3expression levels allowed accurate prediction of their DE differentiation potential. Collectively, our study supports the notion that WNT3 can serve as a biomarker for predicting DE differentiation potential of hESCs.
C1 [Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Jiang, Wei; Zhang, Yi] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pediat,Div Hematol Oncol, Boston, MA 02115 USA.
[Zhang, Yi] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Zhang, Yi] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Zhang, Donghui; Bursac, Nenad] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
RP Jiang, W (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 25 Shattuck St, Boston, MA 02115 USA.
EM wei.jiang@childrens.harvard.edu; yzhang@genetics.med.harvard.edu
RI Jiang, Wei/J-7993-2012; zhang, donghui/I-5130-2013
OI Jiang, Wei/0000-0002-6463-7356;
FU NIH [U01-DK089565, R01-HL104326, R21-HL095069]; JDRF postdoctoral
fellowship
FX We thank Dr. Edouard Stanley (Monash University) for the MEL-1 (MG3) and
HES3 cell lines, Dr. Sean Wu (Stanford University) for the iPSC JT16
line, and Mr. Damian Sendler for a critical reading of the manuscript.
This work was supported by NIH grants U01-DK089565 to Y.Z. and
R01-HL104326 and R21-HL095069 to N.B. W.J. is supported by a JDRF
postdoctoral fellowship. Y.Z. is an investigator of the Howard Hughes
Medical Institute. The authors declare no competing financial interests.
NR 20
TC 20
Z9 21
U1 1
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD JUN 4
PY 2013
VL 1
IS 1
BP 46
EP 52
DI 10.1016/j.stemcr.2013.03.003
PG 7
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AI1SI
UT WOS:000336632000007
PM 24052941
ER
PT J
AU Ascierto, PA
Grimaldi, AM
Acquavella, N
Borgognoni, L
Calabro, L
Cascinelli, N
Cesano, A
Del Vecchio, M
Eggermont, AM
Faries, M
Ferrone, S
Fox, BA
Gajewski, TF
Galon, J
Gnjatic, S
Gogas, H
Kashani-Sabet, M
Kaufman, HL
Larkin, J
Lo, RS
Mantovani, A
Margolin, K
Melief, C
McArthur, G
Palmieri, G
Puzanov, I
Ribas, A
Seliger, B
Sosman, J
Suenaert, P
Tarhini, AA
Trinchieri, G
Vidal-Vanaclocha, F
Wang, E
Ciliberto, G
Mozzillo, N
Marincola, FM
Thurin, M
AF Ascierto, Paolo A.
Grimaldi, Antonio M.
Acquavella, Nicolas
Borgognoni, Lorenzo
Calabro, Luana
Cascinelli, Natale
Cesano, Alessandra
Del Vecchio, Michele
Eggermont, Alexander M.
Faries, Mark
Ferrone, Soldano
Fox, Bernard A.
Gajewski, Thomas F.
Galon, Jerome
Gnjatic, Sacha
Gogas, Helen
Kashani-Sabet, Mohammed
Kaufman, Howard L.
Larkin, James
Lo, Roger S.
Mantovani, Alberto
Margolin, Kim
Melief, Cornelis
McArthur, Grant
Palmieri, Giuseppe
Puzanov, Igor
Ribas, Antoni
Seliger, Barbara
Sosman, Jeff
Suenaert, Peter
Tarhini, Ahmad A.
Trinchieri, Giorgio
Vidal-Vanaclocha, Fernando
Wang, Ena
Ciliberto, Gennaro
Mozzillo, Nicola
Marincola, Francesco M.
Thurin, Magdalena
TI Future perspectives in melanoma research. Meeting report from the
"Melanoma Bridge. Napoli, December 2nd-4th 2012"
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
ID ADJUVANT INTERFERON THERAPY; SENTINEL LYMPH-NODES; HIGH-RISK MELANOMA;
RANDOMIZED CONTROLLED-TRIAL; STAGE-III MELANOMA; T-CELL RESPONSES;
METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; PEGYLATED INTERFERON-ALPHA-2B;
BRAF(V600E) INHIBITION
AB Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third "Melanoma Research: " A bridge from Naples to the World" meeting, shortened as " Bridge Melanoma Meeting" took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.
C1 [Ascierto, Paolo A.; Grimaldi, Antonio M.; Ciliberto, Gennaro; Mozzillo, Nicola] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy.
[Acquavella, Nicolas] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Borgognoni, Lorenzo] SM Annunziata Hosp, Reg Melanoma Refferral Ctr, Florence, Italy.
[Calabro, Luana] Univ Hosp Siena, Ist Toscano Tumori, Siena, Italy.
[Cascinelli, Natale] WHO, Melanoma Program, Milan, Italy.
[Cesano, Alessandra] Nodality Inc, San Francisco, CA USA.
[Del Vecchio, Michele] Ist Nazl Tumori, Fdn IRCCS, Dept Med Oncol, I-20133 Milan, Italy.
[Eggermont, Alexander M.] Canc Inst Gustave Roussy, Paris, France.
[Faries, Mark] John Wayne Canc Inst, Santa Monica, CA USA.
[Ferrone, Soldano] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
[Fox, Bernard A.] Providence Portland Med Ctr, Robert W Franz Canc Ctr, Earle A Chiles Res Inst, Lab Mol & Tumor Immunol, Portland, OR USA.
[Fox, Bernard A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Gajewski, Thomas F.] Univ Chicago, Chicago, IL 60637 USA.
[Galon, Jerome] INSERM, Lab Integrat Canc Immunol, U872, F-75006 Paris, France.
[Galon, Jerome] Univ Paris 05, Paris, France.
[Galon, Jerome] Univ Paris 06, Ctr Rech Cordeliers, Paris, France.
[Gnjatic, Sacha] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
[Gogas, Helen] Univ Athens, Sch Med, Dept Med 1, GR-11527 Athens, Greece.
[Kashani-Sabet, Mohammed] Calif Pacific Med Ctr, Res Inst, Ctr Melanoma Res & Treatment, San Francisco, CA USA.
[Kaufman, Howard L.] Rush Univ, Chicago, IL 60612 USA.
[Larkin, James] Royal Marsden NHS Fdn Trust, London, England.
[Lo, Roger S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Lo, Roger S.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA.
[Mantovani, Alberto] Humanitas Clin & Res Inst, Rozzano, Italy.
[Margolin, Kim] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Melief, Cornelis] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Melief, Cornelis] ISA Pharmaceut, Leiden, Netherlands.
[McArthur, Grant] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia.
[Palmieri, Giuseppe] CNR, Inst Biomol Chem, Unit Canc Genet, Sassari, Italy.
[Puzanov, Igor] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Ribas, Antoni] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Tumor Immunol Programme, Los Angeles, CA 90095 USA.
[Seliger, Barbara] Univ Halle Wittenberg, Inst Med Immunol, D-06108 Halle, Germany.
[Sosman, Jeff] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA.
[Suenaert, Peter] GlaxoSmithKline Vaccines, Global Early Clin Dev, Clin Immunotherapeut, Immunotherapeut, Rixensart, Belgium.
[Tarhini, Ahmad A.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
[Trinchieri, Giorgio] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
[Vidal-Vanaclocha, Fernando] CEU San Pablo Univ, Inst Appl Mol Med IMMA, Madrid 28668, Spain.
[Vidal-Vanaclocha, Fernando] HM Hosp, Sch Med, Madrid 28668, Spain.
[Wang, Ena] NIH, Infect Dis & Immunogenet Sect, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Wang, Ena] NIH, Ctr Human Immunol, Bethesda, MD 20892 USA.
[Marincola, Francesco M.] Sidra Med & Res Ctr, Doha, Qatar.
[Thurin, Magdalena] NCI, Canc Diag Program, NIH, Bethesda, MD 20892 USA.
RP Ascierto, PA (reprint author), Fdn G Pascale, Ist Nazl Tumori, Naples, Italy.
EM paolo.ascierto@gmail.com
RI Del Vecchio, Michele/K-1584-2016;
OI Palmieri, Giuseppe/0000-0002-4350-2276; Del Vecchio,
Michele/0000-0001-9060-2512; Ciliberto, Gennaro/0000-0003-2851-8605;
Mantovani, Alberto/0000-0001-5578-236X
FU Cancer Research Institute/Ludwig Institute for Cancer Research Cancer
Vaccine Collaborative
FX The meeting was supported by Fondazione Melanoma Onlus and the Society
of ImmunoTherapy of Cancer (SITC). A special thanks to 3P Solution of
Napoli for their support and cooperation in organizing the meeting and
to Michael Hoetzel for providing us with the group picture from the
meeting. Sacha Gnjatic would like to acknowledge the Cancer Research
Institute/Ludwig Institute for Cancer Research Cancer Vaccine
Collaborative for grant support. All Authors would like to dedicate this
manuscript to the memory of Natale Cascinelli who devoted his life to
the research and care of melanoma patients and was an example for all of
us.
NR 115
TC 12
Z9 12
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD JUN 3
PY 2013
VL 11
AR 137
DI 10.1186/1479-5876-11-137
PG 28
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 162ZQ
UT WOS:000320305200001
PM 23731854
ER
PT J
AU Menzaghi, C
Bacci, S
Salvemini, L
Mendonca, C
Palladino, G
Fontana, A
De Bonis, C
Marucci, A
Goheen, E
Prudente, S
Morini, E
Rizza, S
Kanagaki, A
Fini, G
Mangiacotti, D
Federici, M
De Cosmo, S
Pellegrini, F
Doria, A
Trischitta, V
AF Menzaghi, Claudia
Bacci, Simonetta
Salvemini, Lucia
Mendonca, Christine
Palladino, Giuseppe
Fontana, Andrea
De Bonis, Concetta
Marucci, Antonella
Goheen, Elizabeth
Prudente, Sabrina
Morini, Eleonora
Rizza, Stefano
Kanagaki, Alyssa
Fini, Grazia
Mangiacotti, Davide
Federici, Massimo
De Cosmo, Salvatore
Pellegrini, Fabio
Doria, Alessandro
Trischitta, Vincenzo
TI Serum Resistin, Cardiovascular Disease and All-Cause Mortality in
Patients with Type 2 Diabetes
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; MYOCARDIAL-INFARCTION;
ADIPOSE-TISSUE; INSULIN-RESISTANCE; HORMONE RESISTIN; RISK; MARKER;
ASSOCIATION; ADIPONECTIN
AB Background: High serum resistin has been associated with increased risk of cardiovascular disease in the general population, Only sparse and conflicting results, limited to Asian individuals, have been reported, so far, in type 2 diabetes. We studied the role of serum resistin on coronary artery disease, major cardiovascular events and all-cause mortality in type 2 diabetes.
Methods: We tested the association of circulating resistin concentrations with coronary artery disease, major cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and all-cause mortality in 2,313 diabetic patients of European ancestry from two cross-sectional and two prospective studies. In addition, the expression of resistin gene (RETN) was measured in blood cells of 68 diabetic patients and correlated with their serum resistin levels.
Results: In a model comprising age, sex, smoking habits, BMI, HbA1c, and insulin, antihypertensive and antidyslipidemic therapies, serum resistin was associated with coronary artery disease in both cross-sectional studies: OR (95%CI) per SD increment = 1.35 (1.101.64) and 1.99 (1.552.55). Additionally, serum resistin predicted incident major cardiovascular events (HR per SD increment = 1.31; 1.101.56) and all-cause mortality (HR per SD increment = 1.16; 1.061.26). Adjusting also for fibrinogen levels affected the association with coronary artery disease and incident cardiovascular events, but not that with all cause-mortality. Finally, serum resistin was positively correlated with RETN mRNA expression (rho = 0.343).
Conclusions: This is the first study showing that high serum resistin (a likely consequence, at least partly, of increased RETN expression) is a risk factor for cardiovascular disease and all-cause mortality in diabetic patients of European ancestry.
C1 [Menzaghi, Claudia; Salvemini, Lucia; Palladino, Giuseppe; De Bonis, Concetta; Marucci, Antonella; Morini, Eleonora; Fini, Grazia; Mangiacotti, Davide; Trischitta, Vincenzo] IRCCS Casa Sollievo Sofferenza, Res Unit Diabet & Endocrine Dis, San Giovanni Rotondo, Italy.
[Bacci, Simonetta; De Cosmo, Salvatore] IRCCS Casa Sollievo Sofferenza, Unit Endocrinol, San Giovanni Rotondo, Italy.
[Mendonca, Christine; Goheen, Elizabeth; Kanagaki, Alyssa; Doria, Alessandro] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
[Fontana, Andrea; Pellegrini, Fabio] IRCCS Casa Sollievo Sofferenza, Unit Biostat, San Giovanni Rotondo, Italy.
[Prudente, Sabrina; Trischitta, Vincenzo] IRCSS Casa Sollievo Sofferenza, Mendel Lab, Rome, Italy.
[Rizza, Stefano; Federici, Massimo] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy.
[Pellegrini, Fabio] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Biostat, I-66030 Santa Maria Imbaro, Italy.
[Doria, Alessandro] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Trischitta, Vincenzo] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy.
RP Menzaghi, C (reprint author), IRCCS Casa Sollievo Sofferenza, Res Unit Diabet & Endocrine Dis, San Giovanni Rotondo, Italy.
EM c.menzaghi@operapadrepio.it; v.trischitta@operapadrepio.it
RI Prudente, Sabrina/H-2886-2016; Fontana, Andrea/J-8584-2016; Trischitta,
Vincenzo/K-1487-2016; Salvemini, Lucia/K-2121-2016; Federici,
Massimo/G-9940-2012; marucci, antonella/B-8722-2017
OI Prudente, Sabrina/0000-0001-9220-8981; Menzaghi,
Claudia/0000-0002-7438-8955; Fontana, Andrea/0000-0002-6660-5315; De
Cosmo, Salvatore/0000-0001-8787-8286; Trischitta,
Vincenzo/0000-0003-1174-127X; Salvemini, Lucia/0000-0001-8776-9477;
Federici, Massimo/0000-0003-4989-5194; marucci,
antonella/0000-0001-8131-8317
FU Accordo Programma Quadro in Materia di Ricerca Scientifica nella Regione
Puglia-PST; PO Puglia FESR; Italian Ministry of Health [RC2011, RC2012];
European Foundation for the Study of Diabetes/Pfizer; National
Institutes of Health [HL073168]; EFSD/Pfizer
FX This research was supported by Accordo Programma Quadro in Materia di
Ricerca Scientifica nella Regione Puglia-PST 2006 and PO Puglia FESR
2007-2013, Italian Ministry of Health grants RC2011, RC2012, European
Foundation for the Study of Diabetes/Pfizer grant (CM) and National
Institutes of Health grant HL073168 (AD). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.; CM received funding from the
EFSD/Pfizer. MF is a PLOS ONE Editorial Board member. There are no
patents, products in development or marketed products to declare. This
does not alter the authors adherence to all the PLOS ONE policies on
sharing data and materials.
NR 40
TC 27
Z9 27
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2013
VL 8
IS 6
AR UNSP e64729
DI 10.1371/journal.pone.0064729
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 157CD
UT WOS:000319872300025
ER
PT J
AU Price, JC
Pollock, LM
Rudd, ML
Fogoros, SK
Mohamed, H
Hanigan, CL
Le Gallo, M
Zhang, SY
Cruz, P
Cherukuri, PF
Hansen, NF
McManus, KJ
Godwin, AK
Sgroi, DC
Mullikin, JC
Merino, MJ
Hieter, P
Bell, DW
AF Price, Jessica C.
Pollock, Lana M.
Rudd, Meghan L.
Fogoros, Sarah K.
Mohamed, Hassan
Hanigan, Christin L.
Le Gallo, Matthieu
Zhang, Suiyuan
Cruz, Pedro
Cherukuri, Praveen F.
Hansen, Nancy F.
McManus, Kirk J.
Godwin, Andrew K.
Sgroi, Dennis C.
Mullikin, James C.
Merino, Maria J.
Hieter, Philip
Bell, Daphne W.
CA NIH Intramural Sequencing Ctr NISC
TI Sequencing of Candidate Chromosome Instability Genes in Endometrial
Cancers Cancers Reveals Somatic Mutations in ESCO1, CHTF18, and MRE11A
SO PLOS ONE
LA English
DT Article
ID SISTER-CHROMATID COHESION; CTF18-REPLICATION FACTOR-C; ANTIGEN LOADER
COMPLEX; DNA MISMATCH REPAIR; MICROSATELLITE INSTABILITY; S-PHASE;
SACCHAROMYCES-CEREVISIAE; COLORECTAL CANCERS; CONSERVED PROTEIN;
HUMAN-CELLS
AB Most endometrial cancers can be classified histologically as endometrioid, serous, or clear cell. Non-endometrioid endometrial cancers (NEECs; serous and clear cell) are the most clinically aggressive of the three major histotypes and are characterized by aneuploidy, a feature of chromosome instability. The genetic alterations that underlie chromosome instability in endometrial cancer are poorly understood. In the present study, we used Sanger sequencing to search for nucleotide variants in the coding exons and splice junctions of 21 candidate chromosome instability genes, including 19 genes implicated in sister chromatid cohesion, from 24 primary, microsatellite-stable NEECs. Somatic mutations were verified by sequencing matched normal DNAs. We subsequently resequenced mutated genes from 41 additional NEECs as well as 42 endometrioid ECs (EECs). We uncovered nonsynonymous somatic mutations in ESCO1, CHTF18, and MRE11A in, respectively, 3.7% (4 of 107), 1.9% (2 of 107), and 1.9% (2 of 107) of endometrial tumors. Overall, 7.7% (5 of 65) of NEECs and 2.4% (1 of 42) of EECs had somatically mutated one or more of the three genes. A subset of mutations are predicted to impact protein function. The co-occurrence of somatic mutations in ESCO1 and CHTF18 was statistically significant (P = 0.0011, two-tailed Fisher's exact test). This is the first report of somatic mutations within ESCO1 and CHTF18 in endometrial tumors and of MRE11A mutations in microsatellite-stable endometrial tumors. Our findings warrant future studies to determine whether these mutations are driver events that contribute to the pathogenesis of endometrial cancer.
C1 [Price, Jessica C.; Pollock, Lana M.; Rudd, Meghan L.; Fogoros, Sarah K.; Mohamed, Hassan; Hanigan, Christin L.; Le Gallo, Matthieu; Bell, Daphne W.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
[Mullikin, James C.; NIH Intramural Sequencing Ctr NISC] NIH, Intramural Sequencing Ctr, Bethesda, MD 20892 USA.
[Zhang, Suiyuan; Cruz, Pedro; Cherukuri, Praveen F.; Hansen, Nancy F.; Mullikin, James C.] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.
[McManus, Kirk J.] Univ Manitoba, Manitoba Inst Cell Biol, Dept Biochem & Med Genet, Winnipeg, MB, Canada.
[Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA.
[Godwin, Andrew K.] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66103 USA.
[Sgroi, Dennis C.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA USA.
[Sgroi, Dennis C.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
[Merino, Maria J.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Hieter, Philip] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada.
RP Bell, DW (reprint author), NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
EM belldaph@mail.nih.gov
FU National Human Genome Research Institute at NIH; NIH [CA016519,
RO1-1CA112021-01]; Canadian Institutes of Health Research (CIHR)
[MOP-38096]; Manitoba Health Research Council (MHRC); CIHR/MHRC RPP New
Investigator award; NCI SPORE in breast cancer at Massachusetts General
Hospital; Avon Foundation; [U01 CA113916]; [R01 CA140323]
FX This work was funded, in part, by the Intramural Research Program of the
National Human Genome Research Institute at NIH (DWB, JCM); NIH grant
CA016519 (PH); Canadian Institutes of Health Research (CIHR) grant
MOP-38096 (PH); Manitoba Health Research Council (MHRC) grant (KJM);
CIHR/MHRC RPP New Investigator award (KJM); U01 CA113916 and R01
CA140323 (AKG); NIH RO1-1CA112021-01 (DCS); the NCI SPORE in breast
cancer at Massachusetts General Hospital (DCS); and the Avon Foundation
(DCS). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 67
TC 7
Z9 7
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2013
VL 8
IS 6
AR e63313
DI 10.1371/journal.pone.0063313
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 157CD
UT WOS:000319872300008
ER
PT J
AU Rehman, H
Krishnasamy, Y
Haque, K
Thurman, RG
Lemasters, JJ
Schnellmann, RG
Zhong, Z
AF Rehman, Hasibur
Krishnasamy, Yasodha
Haque, Khujista
Thurman, Ronald G.
Lemasters, John J.
Schnellmann, Rick G.
Zhong, Zhi
TI Green Tea Polyphenols Stimulate Mitochondrial Biogenesis and Improve
Renal Function after Chronic Cyclosporin A Treatment in Rats
SO PLOS ONE
LA English
DT Article
ID PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTIONAL COACTIVATOR
PGC-1-ALPHA; PROXIMAL TUBULE CELLS; HUMAN SKELETAL-MUSCLE; ACUTE KIDNEY
INJURY; MAMMALIAN-CELLS; DIETARY GLYCINE; PROTEIN-KINASE; PERMEABILITY
TRANSITION; METABOLIC REGULATOR
AB Our previous studies showed that an extract from Camellia sinenesis (green tea), which contains several polyphenols, attenuates nephrotoxicity caused by cyclosporine A (CsA). Since polyphenols are stimulators of mitochondrial biogenesis (MB), this study investigated whether stimulation of MB plays a role in green tea polyphenol protection against CsA renal toxicity. Rats were fed a powdered diet containing green tea polyphenolic extract (0.1%) starting 3 days prior to CsA treatment (25 mg/kg, i.g. daily for 3 weeks). CsA alone decreased renal nuclear DNA-encoded oxidative phosphorylation (OXPHOS) protein ATP synthase-beta (AS-beta) by 42%, mitochondrial DNA (mtDNA)-encoded OXPHOS protein NADH dehydrogenase-3 (ND3) by 87% and their associated mRNAs. Mitochondrial DNA copy number was also decreased by 78% by CsA. Immunohistochemical analysis showed decreased cytochrome c oxidase subunit IV (COX-IV), an OXPHOS protein, in tubular cells. Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1 alpha, the master regulator of MB, and mitochondrial transcription factor-A (Tfam), the transcription factor that regulates mtDNA replication and transcription, were 42% and 90% lower, respectively, in the kidneys of CsA-treated than in untreated rats. These results indicate suppression of MB by chronic CsA treatment. Green tea polyphenols alone and following CsA increased AS-beta, ND3, COX-IV, mtDNA copy number, PGC-1 alpha mRNA and protein, decreased acetylated PGC-1 alpha, and increased Tfam mRNA and protein. In association with suppressed MB, CsA increased serum creatinine, caused loss of brush border and dilatation of proximal tubules, tubular atrophy, vacuolization, apoptosis, calcification, and increased neutrophil gelatinase-associated lipocalin expression, leukocyte infiltration, and renal fibrosis. Green tea polyphenols markedly attenuated CsA-induced renal injury and improved renal function. Together, these results demonstrate that green tea polyphenols attenuate CsA-induced kidney injury, at least in part, through the stimulation of MB.
C1 [Rehman, Hasibur; Krishnasamy, Yasodha; Haque, Khujista; Lemasters, John J.; Schnellmann, Rick G.; Zhong, Zhi] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
[Lemasters, John J.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Lemasters, John J.; Schnellmann, Rick G.; Zhong, Zhi] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
[Thurman, Ronald G.; Zhong, Zhi] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA.
[Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Zhong, Z (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
EM zhong@musc.edu
FU National Institutes of Health [DK70844, DK37034, GM 084147]; South
Carolina COBRE in Oxidants, Redox Balance and Stress Signaling [P20
GM103542]
FX This study was supported, in part, by Grants DK70844, DK37034, and GM
084147 from the National Institutes of Health and South Carolina COBRE
in Oxidants, Redox Balance and Stress Signaling [P20 GM103542]. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 97
TC 13
Z9 13
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 3
PY 2013
VL 8
IS 6
AR e65029
DI 10.1371/journal.pone.0065029
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 157CD
UT WOS:000319872300044
ER
PT J
AU Garfin, PM
Min, D
Bryson, JL
Serwold, T
Edris, B
Blackburn, CC
Richie, ER
Weinberg, KI
Manley, NR
Sage, J
Viatour, P
AF Garfin, Phillip M.
Min, Dullei
Bryson, Jerrod L.
Serwold, Thomas
Edris, Badreddin
Blackburn, Clare C.
Richie, Ellen R.
Weinberg, Kenneth I.
Manley, Nancy R.
Sage, Julien
Viatour, Patrick
TI Inactivation of the RB family prevents thymus involution and promotes
thymic function by direct control of Foxn1 expression
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID T-CELL DEVELOPMENT; RETINOBLASTOMA GENE FAMILY; CORTICAL
EPITHELIAL-CELLS; TRANSGENIC MICE; CYCLIN D1; TRANSCRIPTIONAL
REGULATION; POSITIVE SELECTION; IN-VIVO; DIFFERENTIATION; PROLIFERATION
AB Thymic involution during aging is a major cause of decreased production of T cells and reduced immunity. Here we show that inactivation of Rb family genes in young mice prevents thymic involution and results in an enlarged thymus competent for increased production of naive T cells. This phenotype originates from the expansion of functional thymic epithelial cells (TECs). In RB family mutant TECs, increased activity of E2F transcription factors drives increased expression of Foxn1, a central regulator of the thymic epithelium. Increased Foxn1 expression is required for the thymic expansion observed in Rb family mutant mice. Thus, the RB family promotes thymic involution and controls T cell production via a bone marrow-independent mechanism, identifying a novel pathway to target to increase thymic function in patients.
C1 [Garfin, Phillip M.; Min, Dullei; Weinberg, Kenneth I.; Sage, Julien; Viatour, Patrick] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
[Edris, Badreddin; Sage, Julien; Viatour, Patrick] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
[Bryson, Jerrod L.; Manley, Nancy R.] Univ Georgia, Dept Genet, Athens, GA 30602 USA.
[Serwold, Thomas] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Blackburn, Clare C.] Univ Edinburgh, Sch Biol Sci, Inst Stem Cell Res, Med Res Council Ctr Regenerat Med, Edinburgh EH16 4UU, Midlothian, Scotland.
[Richie, Ellen R.] Univ Texas MD Anderson Canc Ctr, Depat Mol Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA.
RP Sage, J (reprint author), Stanford Univ, Dept Pediat, Stanford, CA 94305 USA.
EM julsage@stanford.edu
RI Blackburn, Clare/B-2847-2009
OI Blackburn, Clare/0000-0002-6326-640X
FU Lucile Packard Foundation for Children's Health; Leukemia and Lymphoma
Society; Human Frontier Science Program; European Molecular Biology
Organization; Fonds de la Recherche Scientifique; Leon Fredericq
Foundation; California Institute of Regenerative Medicine grant
[TG2-01159]; Alex's Lemonade Stand Foundation for Childhood Cancer; Paul
F. Glenn Laboratories for the Biology of Aging at Stanford University
FX This work was supported by the Lucile Packard Foundation for Children's
Health and the Leukemia and Lymphoma Society (to J. Sage), as well as
fellowships from Human Frontier Science Program, the European Molecular
Biology Organization, the Fonds de la Recherche Scientifique, the Leon
Fredericq Foundation (to P. Viatour), and the California Institute of
Regenerative Medicine grant number TG2-01159 (to P.M. Garfin). This work
was also supported by the Alex's Lemonade Stand Foundation for Childhood
Cancer and the Paul F. Glenn Laboratories for the Biology of Aging at
Stanford University.
NR 63
TC 17
Z9 18
U1 1
U2 10
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD JUN 3
PY 2013
VL 210
IS 6
BP 1087
EP 1097
DI 10.1084/jem.20121716
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 156FS
UT WOS:000319807800004
PM 23669396
ER
PT J
AU Ferree, S
Neuhaus, V
Mudgal, CS
AF Ferree, S.
Neuhaus, V.
Mudgal, C. S.
TI Mouse wrist
SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME
LA English
DT Letter
ID TENOSYNOVITIS
C1 [Ferree, S.; Neuhaus, V.; Mudgal, C. S.] Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA.
RP Ferree, S (reprint author), Massachusetts Gen Hosp, Orthopaed Hand Serv, Boston, MA 02114 USA.
EM cmudgal@partners.org
NR 4
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-1934
EI 2043-6289
J9 J HAND SURG-EUR VOL
JI J. Hand Surg.-Eur. Vol.
PD JUN
PY 2013
VL 38
IS 5
BP 568
EP 569
DI 10.1177/1753193412453427
PG 2
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AF3DY
UT WOS:000334592900028
PM 22976874
ER
PT J
AU Cordeiro, CA
Moreira, PR
Bessa, TF
Costa, GC
Dutra, WO
Campos, WR
Orefice, F
Young, LH
Teixeira, AL
AF Cordeiro, Cynthia A.
Moreira, Paula R.
Bessa, Thais F.
Costa, Germano C.
Dutra, Walderez O.
Campos, Wesley R.
Orefice, Fernando
Young, Lucy H.
Teixeira, Antonio L.
TI Interleukin-6 gene polymorphism (-174 G/C) is associated with
toxoplasmic retinochoroiditis
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE uveitis; toxoplasmosis; polymorphism; interleukin-6
ID OCULAR TOXOPLASMOSIS; PERIODONTAL-DISEASE; ALZHEIMERS-DISEASE;
PROTECTIVE ROLE; AQUEOUS-HUMOR; PLASMA-LEVELS; IL-6 GENE; TNF-ALPHA;
UVEITIS; GONDII
AB Abstract.
Purpose: Experimental data have demonstrated a relevant role for IL-6 in the modulation of acute ocular toxoplasmosis. Therefore, we aim to investigate the possible association between the IL-6 gene polymorphism at position -174 and toxoplasmic retinochoroiditis (TR) in humans.
Methods: Ninety-seven patients with diagnosed TR were recruited from the Uveitis Section, Federal University of Minas Gerais. For comparison, 83 healthy blood donors with positive serology for toxoplasmosis and without retinal signs of previous TR were included in the study. Genomic DNA was obtained from oral swabs of individuals and amplified using polymerase chain reaction (PCR) with specific primers flanking the locus -174 of IL-6 (-174G/C). PCR products were submitted to restriction endonuclease digestion and analysed by polyacrylamide gel electrophoresis to distinguish allele G and C of the IL-6 gene, allowing the detection of the polymorphism and determination of genotypes.
Results: There was a significant difference in the genotype (chi(2) = 12.9, p = 0.001) and allele (chi(2) = 6.62, p = 0.01) distribution between TR patients and control subjects. In a subgroup analysis, there was no significant difference in genotypes and allele frequencies regarding TR recurrence.
Conclusions: This study suggests that the genotypes related with a lower production of IL-6 may be associated with the occurrence of TR.
C1 [Cordeiro, Cynthia A.; Teixeira, Antonio L.] Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Belo Horizonte, MG, Brazil.
[Cordeiro, Cynthia A.; Young, Lucy H.] Massachusetts Eye & Ear Infirm, Retina Dept, Boston, MA 02114 USA.
[Cordeiro, Cynthia A.; Orefice, Fernando] Brazilian Ctr Visual Sci, Belo Horizonte, MG, Brazil.
[Moreira, Paula R.; Bessa, Thais F.; Costa, Germano C.; Dutra, Walderez O.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Belo Horizonte, MG, Brazil.
[Dutra, Walderez O.] SRI Int, Ctr Infect Dis Res, Biosci Div, Trop Dis Res Program, Menlo Pk, CA 94025 USA.
[Campos, Wesley R.] Univ Fed Minas Gerais, Sch Med, Dept Ophthalmol, Belo Horizonte, MG, Brazil.
RP Cordeiro, CA (reprint author), Rua Espirito Santo 2701 Apt 801, BR-30160032 Belo Horizonte, MG, Brazil.
EM cordeiro.cy@gmail.com
FU CNPq, Brazil [163183/20112]
FX This work was supported by grant from CNPq (163183/20112), Brazil. The
funding sources did not have any role in the data collection, analysis,
and manuscript writing.
NR 38
TC 7
Z9 7
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2013
VL 91
IS 4
BP E311
EP E314
DI 10.1111/aos.12046
PG 4
WC Ophthalmology
SC Ophthalmology
GA AF0FE
UT WOS:000334387500013
PM 23336844
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI EFFECT OF N ACETYLCYSTEINE (NAC) IN HYPOXIA INDUCED LIVER INJURY
(HILI)-A RANDOMIZED PLACEBO CONTROL CLINICAL TRIAL
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
[Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A184
EP A184
DI 10.1136/gutjnl-2013-304907.418
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600312
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI ROMIPLOSTIM'S EFFECT TO OPTIMIZE SVR WITH TELAPRAVIR, RIBAVIRIN, AND PEG
INTERFERON-ALFA 2A IN THROMBOCYTOPENIC CIRRHOTICS WITH CHRONIC HEPATITIS
C. A PLACEBO CONTROLLED PROSPECTIVE CLINICAL TRIAL: RESTRAINT C TRIAL
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A183
EP A183
DI 10.1136/gutjnl-2013-304907.416
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600310
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND
TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A182
EP A182
DI 10.1136/gutjnl-2013-304907.414
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600308
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Atluri, S
Rahaman, M
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Atluri, S.
Rahaman, M.
TI CURCUMIN, ANTI-OXIDANT, AND PIOGLITAZONE THERAPY WITH INCLUSION OF
VITAMIN E IN NON ALCOHOLIC FATTY LIVER DISEASE-A RANDOMIZED OPEN LABEL
PLACEBO CONTROLLED CLINICAL PROSPECTIVE TRIAL (CAPTIVE)
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Atluri, S.; Rahaman, M.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Shah, N. J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A23
EP A23
DI 10.1136/gutjnl-2013-304907.052
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600047
ER
PT J
AU Canavan, C
Corey, K
Hur, C
AF Canavan, C.
Corey, K.
Hur, C.
TI DEFINING CIRRHOSIS WITH FIBROSCAN FOR ENTRY TO HEPATOCELLULAR CARCINOMA
SURVEILLANCE IN CHRONIC HEPATITIS C: A UK COST EFFECTIVENESS ANALYSIS
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Canavan, C.] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England.
[Corey, K.; Hur, C.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Hur, C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A35
EP A35
DI 10.1136/gutjnl-2013-304907.080
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600070
ER
PT J
AU Pai, M
Yang, J
Zhang, X
Jin, Z
Wang, D
Senturk, H
Lakhtakia, S
Reddy, DN
Kahaleh, M
Habib, N
Brugge, WR
AF Pai, M.
Yang, J.
Zhang, X.
Jin, Z.
Wang, D.
Senturk, H.
Lakhtakia, S.
Reddy, D. N.
Kahaleh, M.
Habib, N.
Brugge, W. R.
TI ENDOSCOPIC ULTRASOUND GUIDED RADIOFREQUENCY ABLATION (EUS-RFA) FOR
PANCREATIC DUCTAL ADENOCARCINOMA
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Pai, M.; Habib, N.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, HPB Unit, London, England.
[Yang, J.; Zhang, X.] Hangzhou First Peoples Hosp, GI Dept, Hangzhou, Zhejiang, Peoples R China.
[Jin, Z.; Wang, D.] Second Mil Med Univ, Changhai Hosp, Digest Endoscopy Ctr, Shanghai, Peoples R China.
[Senturk, H.] Bezmi Alem Univ, Istanbul, Turkey.
[Lakhtakia, S.; Reddy, D. N.] Asian Inst Gastroenterol, Hyderabad, Andhra Pradesh, India.
[Kahaleh, M.] Weill Cornell Med Coll, Dept Med, Div Gastroenterol & Hepatol, New York, NY 10065 USA.
[Habib, N.] EMcision Ltd, London, England.
[Brugge, W. R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 6
Z9 6
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A153
EP A153
DI 10.1136/gutjnl-2013-304907.344
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600276
ER
PT J
AU Ahluwalia, S
Bekelman, D
Prendergast, TJ
Huynh, AK
Lorenz, K
AF Ahluwalia, Sangeeta
Bekelman, David
Prendergast, Thomas J.
Huynh, Alexis K.
Lorenz, Karl
TI CROSSING BOUNDARIES: WHAT IS NEEDED TO REALIZE A COMPREHENSIVE MODEL OF
ADVANCE CARE PLANNING?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ahluwalia, Sangeeta; Huynh, Alexis K.; Lorenz, Karl] Vet Adm Greater Los Angeles, Los Angeles, CA USA.
[Ahluwalia, Sangeeta] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA.
[Bekelman, David] VA Denver, Denver, CO USA.
[Bekelman, David] Univ Colorado, Denver, CO 80202 USA.
[Prendergast, Thomas J.] VA Portland, Portland, OR USA.
[Lorenz, Karl] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S56
EP S57
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300133
ER
PT J
AU Arora, V
Kumar, R
Farnan, JM
Levy, A
Shah, N
AF Arora, Vineet
Kumar, Rupali
Farnan, Jeanne M.
Levy, Andrew
Shah, Neel
TI GOTMEDS? DESIGNING AND PILOTING AN INTERACTIVE MODULE FOR TRAINEES ON
REDUCING DRUG COSTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Arora, Vineet; Kumar, Rupali; Farnan, Jeanne M.; Levy, Andrew] Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
[Shah, Neel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S464
EP S465
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302417
ER
PT J
AU Arreola-Owen, OA
Warde, CM
Gomez, AG
AF Arreola-Owen, Olivia A.
Warde, Carole M.
Gomez, Arthur G.
TI A PILOT PRIMARY CARE RESIDENCY TRACK: EDUCATION AND LEADERSHIP IN
PATIENT-ALIGNED CARE TEAMS (ELPACT)
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Arreola-Owen, Olivia A.] Cedars Sinai Internal Med Residency, Los Angeles, CA USA.
[Warde, Carole M.; Gomez, Arthur G.] Greater Los Angeles VA Hlth Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S452
EP S452
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302389
ER
PT J
AU Ashburner, JM
Grant, RW
Jernigan, M
Borowsky, LH
Atlas, SJ
AF Ashburner, Jeffrey M.
Grant, Richard W.
Jernigan, Michael
Borowsky, Leila H.
Atlas, Steven J.
TI THE MEDICATION METRONOME: A HEALTH IT SYSTEM TO IMPROVE MEDICATION
MANAGEMENT AND LABORATORY MONITORING FOR CHRONIC DISEASES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ashburner, Jeffrey M.; Grant, Richard W.; Jernigan, Michael; Borowsky, Leila H.; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S447
EP S447
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302378
ER
PT J
AU Ashburner, JM
Go, AS
Reynolds, K
Chang, YC
Fang, M
Fredman, L
Singer, DE
AF Ashburner, Jeffrey M.
Go, Alan S.
Reynolds, Kristi
Chang, Yuchiao
Fang, Margaret
Fredman, Lisa
Singer, Daniel E.
TI WARFARIN ANTICOAGULATION THERAPY AND MORTALITY FOLLOWING
GASTROINTESTINAL HEMORRHAGE IN PATIENTS WITH ATRIAL FIBRILLATION IN
CLINICAL CARE: THE ATRIA AND ATRIA-CVRN COHORTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ashburner, Jeffrey M.; Chang, Yuchiao; Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Go, Alan S.] Kaiser Permanente No Calif, Oakland, CA USA.
[Reynolds, Kristi] Kaiser Permanente So Calif, Pasadena, CA 91101 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ashburner, Jeffrey M.; Fang, Margaret; Fredman, Lisa] Boston Univ, Sch Publ Hlth, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S240
EP S240
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301326
ER
PT J
AU Ashburner, JM
Ward, CE
Levy, D
Zai, A
Grant, RW
Atlas, SJ
AF Ashburner, Jeffrey M.
Ward, Charlotte E.
Levy, Douglas
Zai, Adrian
Grant, Richard W.
Atlas, Steven J.
TI IMPACT OF A POPULATION MANAGEMENT SYSTEM ON PHYSICIAN PERCEIVED TIME
DEVOTED TO PREVENTIVE CANCER SCREENING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ashburner, Jeffrey M.; Ward, Charlotte E.; Levy, Douglas; Zai, Adrian; Grant, Richard W.; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S100
EP S100
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300239
ER
PT J
AU Atlas, SJ
Estey, G
Ashburner, JM
Rao, P
He, W
Chueh, H
AF Atlas, Steven J.
Estey, Gregory
Ashburner, Jeffrey M.
Rao, Priya
He, Wei
Chueh, Henry
TI PATIENT ATTRIBUTION TO CARE PROVIDERS IN A PRIMARY CARE NETWORK:
COMPARING RETROSPECTIVE AND PROSPECTIVE ALGORITHMS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Atlas, Steven J.; Estey, Gregory; Ashburner, Jeffrey M.; Rao, Priya; He, Wei; Chueh, Henry] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S444
EP S444
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302372
ER
PT J
AU Atlas, SJ
Ashburner, JM
Zai, A
Chang, YC
Percac-Lima, S
Levy, D
Grant, RW
AF Atlas, Steven J.
Ashburner, Jeffrey M.
Zai, Adrian
Chang, Yuchiao
Percac-Lima, Sanja
Levy, Douglas
Grant, Richard W.
TI THE ROLE OF THE PCP IN PREVENTIVE CANCER SCREENING USING A NOVEL
POPULATION MANAGEMENT SYSTEM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Atlas, Steven J.; Ashburner, Jeffrey M.; Zai, Adrian; Chang, Yuchiao; Percac-Lima, Sanja; Levy, Douglas; Grant, Richard W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S212
EP S212
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301263
ER
PT J
AU Bachhuber, M
Patel, S
O'Brien, B
AF Bachhuber, Melissa
Patel, Shalini
O'Brien, Bridget
TI A HOME VISIT CURRICULUM TO FOSTER INTERPROFESSIONAL LEARNING AND IMPROVE
CARE COORDINATION FOR HIGH-RISK PATIENTS IN TRAINEE PRIMARY CARE
CONTINUITY CLINICS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Bachhuber, Melissa; Patel, Shalini; O'Brien, Bridget] UCSF, San Francisco, CA USA.
[Bachhuber, Melissa; Patel, Shalini; O'Brien, Bridget] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S451
EP S451
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302386
ER
PT J
AU Baggett, TP
Rigotti, NA
AF Baggett, Travis P.
Rigotti, Nancy A.
TI SMOKING-ATTRIBUTABLE MORTALITY AMONG HOMELESS ADULTS IN BOSTON
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Baggett, Travis P.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Baggett, Travis P.] Boston Hlth Care Homeless Program, Boston, MA USA.
[Rigotti, Nancy A.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S182
EP S183
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301194
ER
PT J
AU Baggett, TP
Lebrun-Harris, LA
Rigotti, NA
AF Baggett, Travis P.
Lebrun-Harris, Lydie A.
Rigotti, Nancy A.
TI HOMELESSNESS, CIGARETTE SMOKING, AND DESIRE TO QUIT: A NATIONAL STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Baggett, Travis P.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Baggett, Travis P.] Boston Hlth Care Homeless Program, Boston, MA USA.
[Lebrun-Harris, Lydie A.] Hlth Resources & Serv Adm, Rockville, MD USA.
[Rigotti, Nancy A.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S89
EP S89
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300212
ER
PT J
AU Barocas, J
Brennan, M
Crnich, C
Hess, T
Sethi, A
Sosman, JM
AF Barocas, Joshua
Brennan, Meghan
Crnich, Christopher
Hess, Timothy
Sethi, Ajay
Sosman, James M.
TI SELF-AUDIT INCREASES CLINICIAN-DRIVEN UNIVERSAL HIV SCREENING AMONG
INTERNAL MEDICINE RESIDENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Barocas, Joshua; Brennan, Meghan; Crnich, Christopher; Hess, Timothy; Sethi, Ajay; Sosman, James M.] Univ Wisconsin, Madison, WI USA.
[Brennan, Meghan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S178
EP S178
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301183
ER
PT J
AU Bekelman, D
Nowels, CT
Main, D
Heidenreich, P
Hattler, B
Lorenz, K
Meek, P
McBryde, C
Hooker, S
AF Bekelman, David
Nowels, Carolyn T.
Main, Debbi
Heidenreich, Paul
Hattler, Brack
Lorenz, Karl
Meek, Paula
McBryde, Connor
Hooker, Stephanie
TI PILOT CLINICAL TRIAL OF A COLLABORATIVE CARE INTERVENTION TO IMPROVE
SYMPTOMS AND QUALITY OF LIFE IN CHRONIC HEART FAILURE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Bekelman, David; Hattler, Brack; McBryde, Connor] VA Eastern Colorado Heath Care Syst, Denver, CO USA.
[Bekelman, David; Nowels, Carolyn T.; Hattler, Brack; McBryde, Connor] Univ Colorado, Sch Med, Aurora, CO USA.
[Main, Debbi; Hooker, Stephanie] Univ Colorado, Denver, CO 80202 USA.
[Meek, Paula] Univ Colorado, Coll Nursing, Aurora, CO USA.
[Heidenreich, Paul] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Lorenz, Karl] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S149
EP S149
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301113
ER
PT J
AU Bokhour, BG
Solomon, J
Laws, MB
Gifford, AL
Goetz, MB
AF Bokhour, Barbara G.
Solomon, Jeffrey
Laws, Michael B.
Gifford, Allen L.
Goetz, Matthew B.
TI THE IMPACT OF AN HIV ADHERENCE INFORMATICS INTERVENTION ON
PATIENT-PROVIDER COMMUNICATION ABOUT ART ADHERENCE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Bokhour, Barbara G.; Solomon, Jeffrey; Gifford, Allen L.] ENRM Vet Affairs Med Ctr, Bedford, MA USA.
[Bokhour, Barbara G.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Goetz, Matthew B.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
Brown Univ, Providence, RI 02912 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S217
EP S217
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301274
ER
PT J
AU Bradley, K
Rubinsky, AD
Au, D
Bryson, CL
Achtmeyer, C
Williams, E
Lapham, G
Chavez, L
Kivlahan, D
AF Bradley, Katharine
Rubinsky, Anna D.
Au, David
Bryson, Christopher L.
Achtmeyer, Carol
Williams, Emily
Lapham, Gwendolyn
Chavez, Laura
Kivlahan, Daniel
TI VALIDATING ALCOHOL SCREENING SCORES AS PATIENT-REPORTED OUTCOME MEASURES
- RESULTS OF THE MONITOR STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Bradley, Katharine; Rubinsky, Anna D.; Au, David; Bryson, Christopher L.; Achtmeyer, Carol; Williams, Emily; Lapham, Gwendolyn; Chavez, Laura] VA Puget Sound, Seattle, WA USA.
[Bradley, Katharine] Grp Hlth Cooperat Puget Sound, Seattle, WA USA.
[Au, David; Bryson, Christopher L.; Williams, Emily] Univ Washington, Seattle, WA 98195 USA.
[Kivlahan, Daniel] Vet Hlth Adm, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S236
EP S236
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301317
ER
PT J
AU Brown, RT
Ahalt, C
Steinman, MA
Williams, B
AF Brown, Rebecca T.
Ahalt, Cyrus
Steinman, Michael A.
Williams, Brie
TI HANDS ON THE HOOD, GRANDPA: ASSESSING THE NEED FOR GERIATRICS HEALTH
TRAINING AMONG POLICE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Brown, Rebecca T.; Ahalt, Cyrus; Steinman, Michael A.; Williams, Brie] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S84
EP S84
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300199
ER
PT J
AU Burke, R
Guo, RX
Misky, GJ
AF Burke, Robert
Guo, Ruixin
Misky, Gregory J.
TI IDENTIFYING KEYS TO SUCCESS FOR REDUCING READMISSIONS: USING THE IDEAL
TRANSITION IN CARE FRAMEWORK
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Burke, Robert] Denver VA Med Ctr, Denver, CO USA.
[Burke, Robert; Guo, Ruixin; Misky, Gregory J.] Univ Colorado, Sch Med, Denver, CO USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S94
EP S94
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300225
ER
PT J
AU Burke, R
Whitfield, E
Prochazka, AV
AF Burke, Robert
Whitfield, Emily
Prochazka, Allan V.
TI EFFECT OF A HOSPITALIST-RUN POST-DISCHARGE CLINIC ON ADVERSE
POST-DISCHARGE OUTCOMES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Burke, Robert; Whitfield, Emily; Prochazka, Allan V.] Denver VA Med Ctr, Denver, CO USA.
[Burke, Robert; Prochazka, Allan V.] Univ Colorado, Sch Med, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S69
EP S69
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300162
ER
PT J
AU Carlini, SV
Klinger, E
Gonzalez, I
Linder, JA
Park, ER
Kontos, E
Rigotti, NA
Haas, J
AF Carlini, Sara V.
Klinger, Elissa
Gonzalez, Irina
Linder, Jeffrey A.
Park, Elyse R.
Kontos, Emily
Rigotti, Nancy A.
Haas, Jennifer
TI ACCURACY OF RACE/ETHNICITY AND LANGUAGE PREFERENCE IN AN ELECTRONIC
HEALTH RECORD
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Carlini, Sara V.; Klinger, Elissa; Gonzalez, Irina; Linder, Jeffrey A.; Haas, Jennifer] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Park, Elyse R.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kontos, Emily; Haas, Jennifer] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S16
EP S16
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300036
ER
PT J
AU Chang, E
Chung, B
Gilmore, J
Tang, LQ
Morgan, A
Wells, KB
AF Chang, Evelyn
Chung, Bowen
Gilmore, James
Tang, Lingqi
Morgan, Anna
Wells, Kenneth B.
TI COMORBID DEPRESSION AND SUBSTANCE ABUSE IN SAFETY-NET CLIENTS OF HEALTH
AND COMMUNITY-BASED AGENCIES IN LOS ANGELES: CLINICAL NEEDS AND SERVICE
USE PATTERNS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Chang, Evelyn] VA Greater Los Angeles, Los Angeles, CA USA.
[Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA.
[Chung, Bowen; Tang, Lingqi; Wells, Kenneth B.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Gilmore, James] Behav Hlth Serv Inc, Los Angeles, CA USA.
[Morgan, Anna] Harbor UCLA, Torrance, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S48
EP S49
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300115
ER
PT J
AU Chang, E
Wells, KB
Young, AS
Stockdale, SE
Fickel, J
Johnson, M
Jou, K
Rubenstein, LV
AF Chang, Evelyn
Wells, Kenneth B.
Young, Alexander S.
Stockdale, Susan E.
Fickel, Jacqueline
Johnson, Megan
Jou, Kevin
Rubenstein, Lisa V.
TI ACHIEVING COMMUNICATION BETWEEN PRIMARY CARE AND MENTAL HEALTH: WHY IS
IT SO DIFFICULT, EVEN IN THE VA? A QUALITY IMPROVEMENT APPROACH
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Chang, Evelyn] VA Greater Los Angeles, Los Angeles, CA USA.
[Young, Alexander S.; Stockdale, Susan E.; Fickel, Jacqueline; Johnson, Megan; Jou, Kevin; Rubenstein, Lisa V.] VA Greater Los Angeles, North Hills, CA USA.
[Wells, Kenneth B.; Rubenstein, Lisa V.] RAND Corp, Santa Monica, CA USA.
[Wells, Kenneth B.] Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S17
EP S17
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300039
ER
PT J
AU Cohen, B
Shi, Y
Neylan, T
Seal, KH
AF Cohen, Beth
Shi, Ying
Neylan, Thomas
Seal, Karen H.
TI OFF-LABEL ANTIPSYCHOTIC PRESCRIPTIONS IN IRAQ AND AFGHANISTAN VETERANS
WITH POSTTRAUMATIC STRESS DISORDER IN VA HEALTHCARE, 2001-2011
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Cohen, Beth; Shi, Ying; Neylan, Thomas; Seal, Karen H.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cohen, Beth; Neylan, Thomas; Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S131
EP S132
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301072
ER
PT J
AU Cohen, B
Neylan, T
Bertenthal, D
Yaffe, K
AF Cohen, Beth
Neylan, Thomas
Bertenthal, Daniel
Yaffe, Kristine
TI ASSOCIATION OF POSTTRAUMATIC STRESS DISORDER AND INCIDENT
CEREBROVASCULAR DISEASE IN A VETERANS ADMINISTRATION POPULATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Cohen, Beth; Neylan, Thomas; Bertenthal, Daniel; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA.
[Cohen, Beth; Neylan, Thomas; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S28
EP S28
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300066
ER
PT J
AU Darby, A
Ahalt, C
Cenzer, IS
Sudore, RL
Williams, B
AF Darby, Anna
Ahalt, Cyrus
Cenzer, Irena Stijacic
Sudore, Rebecca L.
Williams, Brie
TI EVALUATING A MODIFIED INFORMED CONSENT FOR OLDER ADULTS IN CORRECTIONAL
RESEARCH
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Darby, Anna] Mt Sinai Sch Med, New York, NY USA.
[Ahalt, Cyrus; Cenzer, Irena Stijacic; Sudore, Rebecca L.; Williams, Brie] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Cenzer, Irena Stijacic; Sudore, Rebecca L.; Williams, Brie] San Francisco VA Med Ctr, San Francisco, CA USA.
RI Darby, Alistair/I-6485-2012
OI Darby, Alistair/0000-0002-3786-6209
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S74
EP S74
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300174
ER
PT J
AU DeBiasi, R
Adusumalli, S
Schainfeld, R
Jaff, MR
AF DeBiasi, Ralph
Adusumalli, Srinath
Schainfeld, Robert
Jaff, Michael R.
TI ATHEROSCLEROTIC RENAL ARTERY STENOSIS (ARAS): WHO SHOULD BE SCREENED AND
BY WHOM?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [DeBiasi, Ralph; Adusumalli, Srinath; Schainfeld, Robert; Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S30
EP S30
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300072
ER
PT J
AU Edelman, EJ
Gordon, KS
Lo Re, V
Skanderson, M
Fiellin, DA
Justice, AC
AF Edelman, E. J.
Gordon, Kirsha S.
Lo Re, Vincent
Skanderson, Melissa
Fiellin, David A.
Justice, Amy C.
TI ACETAMINOPHEN RECEIPT AMONG HIV-INFECTED PATIENTS WITH ADVANCED HEPATIC
FIBROSIS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Edelman, E. J.; Fiellin, David A.; Justice, Amy C.] Yale Univ, New Haven, CT USA.
[Gordon, Kirsha S.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Lo Re, Vincent] Univ Penn, Philadelphia, PA 19104 USA.
[Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RI Lo Re, Vincent/N-7817-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S16
EP S17
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300038
ER
PT J
AU Edwards, ST
Mafi, JN
Landon, BE
AF Edwards, Samuel T.
Mafi, John N.
Landon, Bruce E.
TI SPECIALISTS AS PRIMARY CARE PHYSICIANS: PATIENT CHARACTERISTICS AND
QUALITY OF CARE OF VISITS TO GENERALIST AND SPECIALIST PHYSICIANS
SELF-IDENTIFIED AS PRIMARY CARE PHYSICIANS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Edwards, Samuel T.] Boston VA Healthcare Syst, Boston, MA USA.
[Edwards, Samuel T.; Mafi, John N.] Harvard Univ, Sch Med, Boston, MA USA.
[Mafi, John N.; Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Landon, Bruce E.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S184
EP S185
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301198
ER
PT J
AU Edwards, ST
Prentice, J
Li, DL
Simon, SR
Cooper, D
Edes, T
Pizer, SD
AF Edwards, Samuel T.
Prentice, Julia
Li, Donglin
Simon, Steven R.
Cooper, Dayna
Edes, Thomas
Pizer, Steven D.
TI PREDICTORS OF EARLY ENROLLMENT IN HOME BASED PRIMARY CARE AMONG VETERANS
WITH DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Edwards, Samuel T.; Prentice, Julia; Li, Donglin; Simon, Steven R.; Pizer, Steven D.] Boston VA Healthcare Syst, Boston, MA USA.
[Edwards, Samuel T.] Harvard Univ, Sch Med, Boston, MA USA.
[Prentice, Julia; Pizer, Steven D.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Prentice, Julia; Pizer, Steven D.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Cooper, Dayna; Edes, Thomas] Vet Hlth Adm, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S151
EP S152
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301119
ER
PT J
AU Edwards, ST
Neri, PM
Volk, LA
Schiff, GD
Bates, DW
AF Edwards, Samuel T.
Neri, Pamela M.
Volk, Lynn A.
Schiff, Gordon D.
Bates, David W.
TI NOTE QUALITY AND QUALITY OF CARE: IS THERE AN ASSOCIATION?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Edwards, Samuel T.] VA Boston Healthcare Syst, Boston, MA USA.
[Edwards, Samuel T.; Schiff, Gordon D.; Bates, David W.] Harvard Univ, Sch Med, Boston, MA USA.
[Neri, Pamela M.; Volk, Lynn A.] Partners Healthcare Syst, Wellesley, MA USA.
[Schiff, Gordon D.; Bates, David W.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S130
EP S130
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301070
ER
PT J
AU Elman, SA
Wang, LD
Bachorik, AE
Huppert, LA
Palaniappa, NC
Simchoni, N
Spinelli, MA
Thomas, DC
Berman, R
Meah, YS
AF Elman, Scott A.
Wang, Linda
Bachorik, Alexandra E.
Huppert, Laura A.
Palaniappa, Nandini C.
Simchoni, Noa
Spinelli, Matthew A.
Thomas, David C.
Berman, Rebecca
Meah, Yasmin S.
TI STUDENT-RUN CLINICS AS MEDICAL STUDENT SCHOLARLY HOMES FOR GENERAL
INTERNAL MEDICINE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Elman, Scott A.; Huppert, Laura A.; Berman, Rebecca] Harvard Univ, Sch Med, Boston, MA USA.
[Wang, Linda; Bachorik, Alexandra E.; Palaniappa, Nandini C.; Simchoni, Noa; Spinelli, Matthew A.; Thomas, David C.; Meah, Yasmin S.] Icahn Sch Med Mt Sinai, New York, NY USA.
[Berman, Rebecca] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S188
EP S188
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301206
ER
PT J
AU Eng, JA
Hatoun, J
Liu, C
Blum-Smith, L
Shea, S
Suen, W
AF Eng, Jessica A.
Hatoun, Jonathan
Liu, Constance
Blum-Smith, Laura
Shea, Sandra
Suen, Winnie
TI RESIDENT ATTITUDES, KNOWLEDGE AND BEHAVIORS REGARDING AN ELECTRONIC
INCIDENT REPORTING SYSTEM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Eng, Jessica A.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Hatoun, Jonathan; Liu, Constance; Suen, Winnie] Boston Med Ctr, Boston, MA USA.
[Hatoun, Jonathan] Boston Childrens Hosp, Boston, MA USA.
[Blum-Smith, Laura; Shea, Sandra] Comm Interns & Residents, New York, NY USA.
[Suen, Winnie] Boston Univ, Sch Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S171
EP S171
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301166
ER
PT J
AU Eng, JA
Hunter, CJ
Cantino, LB
Yuan, C
Lai, S
Kalmar, E
Boscardin, CK
Handley, MA
Gonzales, R
Ackerman, S
AF Eng, Jessica A.
Hunter, Cecily J.
Cantino, Laura B.
Yuan, Caterina
Lai, Sunny
Kalmar, Evie
Boscardin, Christy K.
Handley, Margaret A.
Gonzales, Ralph
Ackerman, Sara
TI LET'S TALK! PATIENT ATTITUDES ABOUT TELEPHONE-BASED ALTERNATIVES TO
FOLLOW-UP OFFICE VISITS WITH SPECIALISTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Eng, Jessica A.; Hunter, Cecily J.; Cantino, Laura B.; Yuan, Caterina; Lai, Sunny; Kalmar, Evie; Boscardin, Christy K.; Handley, Margaret A.; Gonzales, Ralph] UCSF Sch Med, San Francisco, CA USA.
[Eng, Jessica A.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Ackerman, Sara] UCSF Sch Nursing, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S114
EP S115
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301034
ER
PT J
AU Fairfield, K
Gerstein, B
Levin, CA
McNaughton-Collins, M
AF Fairfield, Kathleen
Gerstein, Bethany
Levin, Carrie A.
McNaughton-Collins, Mary
TI DECISIONS ABOUT MEDICATION USE AND CANCER SCREENING AMONG ELDERLY ADULTS
IN THE UNITED STATES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Fairfield, Kathleen] Maine Med Ctr, Portland, ME 04102 USA.
[McNaughton-Collins, Mary] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gerstein, Bethany; Levin, Carrie A.; McNaughton-Collins, Mary] Informed Med Decis Fdn, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S57
EP S57
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300134
ER
PT J
AU Flickinger, TE
Saha, S
Moore, RD
Beach, MC
AF Flickinger, Tabor E.
Saha, Somnath
Moore, Richard D.
Beach, Mary Catherine
TI HIGHER QUALITY COMMUNICATION AND RELATIONSHIPS ARE ASSOCIATED WITH
IMPROVED PATIENT ENGAGEMENT IN HIV CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Flickinger, Tabor E.; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S88
EP S88
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300210
ER
PT J
AU Fraser, T
Strom, JB
Park, L
AF Fraser, Traci
Strom, Jordan B.
Park, Lee
TI EXUDATIVE PLEURAL EFFUSION IN A HAITIAN MAN
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Fraser, Traci; Strom, Jordan B.; Park, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S325
EP S325
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302072
ER
PT J
AU Fu, S
Roth, C
Battaglia, C
Nelson, D
Farmer, M
Do, T
Goldstein, M
Kavathekar, R
Widome, R
Hagedorne, H
Zillich, A
AF Fu, Steven
Roth, Craig
Battaglia, Catherine
Nelson, David
Farmer, Melissa
Do, Tam
Goldstein, Michael
Kavathekar, Rahul
Widome, Rachel
Hagedorne, Hildi
Zillich, Alan
TI A RANDOMIZED TRIAL OF TWO APPROACHES TO TRAINING VETERANS AFFAIRS (VA)
MEDICAL HOME HEALTHCARE PROVIDERS ON MOTIVATIONAL INTERVIEWING FOR
TOBACCO CESSATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Fu, Steven; Roth, Craig; Nelson, David; Do, Tam; Kavathekar, Rahul; Widome, Rachel; Hagedorne, Hildi] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA.
[Zillich, Alan] Roudebush VA Med Ctr, Indianapolis, IN USA.
[Battaglia, Catherine] VA Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Farmer, Melissa] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA.
[Goldstein, Michael] VHA Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S7
EP S8
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300017
ER
PT J
AU Gerber, MR
Pineles, S
Japuntich, S
Bean-Mayberry, B
King, M
Haskell, SG
AF Gerber, Megan R.
Pineles, Suzanne
Japuntich, Sandra
Bean-Mayberry, Bevanne
King, Matthew
Haskell, Sally G.
TI HORMONE THERAPY USE IN WOMEN VETERANS ACCESSING VA CARE: A NATIONAL
CROSS-SECTIONAL STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Gerber, Megan R.; Pineles, Suzanne; Japuntich, Sandra; King, Matthew] VA Boston Healthcare Syst, Jamaica Plain, MA USA.
[Gerber, Megan R.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Bean-Mayberry, Bevanne] VA Greater Los Angeles Healthcare Sys, Los Angeles, CA USA.
[Haskell, Sally G.] VA Connecticut Healthcare Syst West Haven Campus, West Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S89
EP S90
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300213
ER
PT J
AU Gopalan, A
Tahirovic, E
Moss, H
Troxel, AB
Zhu, JS
Volpp, KG
AF Gopalan, Anjali
Tahirovic, Emin
Moss, Haley
Troxel, Andrea B.
Zhu, Jingsan
Volpp, Kevin G.
TI A RANDOMIZED, CONTROLLED TRIAL OF ALTERNATIVE FORMS OF FEEDBACK ON
GLYCEMIC CONTROL IN PATIENTS WITH POORLY CONTROLLED DIABETES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Gopalan, Anjali; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Tahirovic, Emin; Moss, Haley; Troxel, Andrea B.; Zhu, Jingsan; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gopalan, Anjali] Robert Wood Johnson Clin Scholars Program, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S13
EP S13
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300030
ER
PT J
AU Halm, E
Tiro, J
Nelson, C
Batchelor, K
Xuan, L
Cosenza, C
Sepucha, KR
AF Halm, Ethan
Tiro, Jasmin
Nelson, Colin
Batchelor, Kim
Xuan, Lei
Cosenza, Carol
Sepucha, Karen R.
TI DEVELOPMENT OF AN INSTRUMENT TO MEASURE THE QUALITY OF TREATMENT
DECISIONS FOR ASYMPTOMATIC CAROTID ARTERY DISEASE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Halm, Ethan; Tiro, Jasmin; Batchelor, Kim; Xuan, Lei] Univ TX Southwestern Med Ctr, Dallas, TX USA.
[Nelson, Colin] Informed Med Decis Fdn, Boston, MA USA.
[Cosenza, Carol] Univ Massachusetts, Boston, MA 02125 USA.
[Sepucha, Karen R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S60
EP S61
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300142
ER
PT J
AU Hebert, P
Liu, CF
Wong, E
Hernandez, S
Batten, A
Lo, S
Lemon, J
AF Hebert, Paul
Liu, Chuan-Fen
Wong, Edwin
Hernandez, Susan
Batten, Adam
Lo, Sophie
Lemon, Jackie
TI NATIONAL EVALUATION OF THE EFFECTS ON HEALTHCARE UTILIZATION AND COSTS
OF THE VA PATIENT CENTERED MEDICAL HOME INITIATIVE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Hebert, Paul; Liu, Chuan-Fen; Wong, Edwin; Hernandez, Susan; Batten, Adam; Lo, Sophie; Lemon, Jackie] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S124
EP S124
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301057
ER
PT J
AU Heyworth, L
Paquin, AM
Clark, J
Orlov, VJ
Stewart, MD
Martin, TL
Simon, SR
AF Heyworth, Leonie
Paquin, Allison M.
Clark, Justice
Orlov, Victor J.
Stewart, Max D.
Martin, Tracey L.
Simon, Steven R.
TI VIRTUAL MEDICATION RECONCILIATION: A PILOT STUDY OF INTERACTIVE
MEDICATION RECONCILIATION BY SECURE MESSAGING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Heyworth, Leonie; Paquin, Allison M.; Clark, Justice; Orlov, Victor J.; Stewart, Max D.; Martin, Tracey L.; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S239
EP S239
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301323
ER
PT J
AU Heyworth, L
Bitton, A
Lipsitz, SR
Schilling, T
Schiff, GD
Bates, DW
Simon, SR
AF Heyworth, Leonie
Bitton, Asaf
Lipsitz, Stuart R.
Schilling, Thad
Schiff, Gordon D.
Bates, David W.
Simon, Steven R.
TI THE EFFECT OF PATIENT-CENTERED MEDICAL HOME TRANSFORMATION COUPLED WITH
PAYMENT REFORM: PATIENT EXPERIENCE OUTCOMES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Heyworth, Leonie; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Heyworth, Leonie; Bitton, Asaf; Lipsitz, Stuart R.; Schiff, Gordon D.; Bates, David W.; Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Schilling, Thad] Atrius Hlth, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S216
EP S216
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301272
ER
PT J
AU Ho, M
Aron, D
Sales, AE
Au, D
Helfrich, C
Fagan, K
Lambert-Kerzner, A
Lowery, J
Battaglia, C
Pogach, L
Graham, GD
Ellington, V
Kirsh, S
AF Ho, Michael
Aron, David
Sales, Anne E.
Au, David
Helfrich, Christian
Fagan, Katherine
Lambert-Kerzner, Anne
Lowery, Julie
Battaglia, Catherine
Pogach, Leonard
Graham, Glenn D.
Ellington, Vaness
Kirsh, Susan
TI THE VA'S SPECIALTY CARE TRANSFORMATIONAL INITIATIVES TO IMPROVE ACCESS
AND DELIVERY OF SPECIALTY CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ho, Michael; Fagan, Katherine; Lambert-Kerzner, Anne; Battaglia, Catherine] Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Sales, Anne E.; Lowery, Julie] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA.
[Pogach, Leonard; Graham, Glenn D.; Ellington, Vaness] Washington DC VA Med Ctr, Washington, DC USA.
[Aron, David; Kirsh, Susan] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Au, David; Helfrich, Christian] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S447
EP S448
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302379
ER
PT J
AU Hong, CS
Grant, RW
Chang, YC
Ashburner, JM
He, W
Ferris, T
Atlas, SJ
AF Hong, Clemens S.
Grant, Richard W.
Chang, Yuchiao
Ashburner, Jeffrey M.
He, Wei
Ferris, Timothy
Atlas, Steven J.
TI PRIMARY CARE PHYSICIAN-DEFINED COMPLEXITY AND OUTPATIENT CHARLSON SCORE
AS PREDICTORS OF HEALTH CARE UTILIZATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Hong, Clemens S.; Chang, Yuchiao; Ashburner, Jeffrey M.; He, Wei; Ferris, Timothy; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Grant, Richard W.] Kaiser Permanent, Div Res, Oakland, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S156
EP S157
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301131
ER
PT J
AU Jarvie, JL
Regan, MC
Cohen, B
AF Jarvie, Jennifer L.
Regan, Mathilda C.
Cohen, Beth
TI PROSPECTIVE ASSOCIATION OF PHYSICAL ACTIVITY AND MARKERS OF INFLAMMATION
AND INSULIN RESISTANCE IN OUTPATIENTS WITH CORONARY HEART DISEASE: DATA
FROM THE HEART AND SOUL STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Jarvie, Jennifer L.; Cohen, Beth] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Regan, Mathilda C.; Cohen, Beth] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S160
EP S161
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301140
ER
PT J
AU Jubelt, LE
Graham, J
Maeng, DD
Metlay, J
Epstein, A
AF Jubelt, Lindsay E.
Graham, Jove
Maeng, Daniel D.
Metlay, Joshua
Epstein, Andrew
TI CASE MANAGEMENT PERFORMANCE IN A MEDICAL HOME AND ASSOCIATIONS WITH
PATIENT SATISFACTION AND HEALTHCARE UTILIZATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Jubelt, Lindsay E.; Metlay, Joshua; Epstein, Andrew] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Jubelt, Lindsay E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Graham, Jove] Geisinger Ctr Hlth Res, Danville, PA USA.
[Maeng, Daniel D.] Geisinger Hlth Syst, Danville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S40
EP S41
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300096
ER
PT J
AU Justice, AC
Tate, JP
Brown, ST
Gibert, C
Rodriguez-Barradas, M
Rimland, D
Akgun, KM
Bryant, K
AF Justice, Amy C.
Tate, Janet P.
Brown, Sheldon T.
Gibert, Cynthia
Rodriguez-Barradas, Maria
Rimland, David
Akguen, Kathleen M.
Bryant, Kendall
TI CAN THE VETERANS AGING COHORT STUDY INDEX IMPROVE CLINICAL JUDGMENT FOR
BOTH HIV INFECTED AND UNINFECTED VETERANS?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Justice, Amy C.; Tate, Janet P.; Akguen, Kathleen M.] Yale Univ, West Haven, CT USA.
[Justice, Amy C.; Tate, Janet P.; Akguen, Kathleen M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, New York, NY USA.
[Brown, Sheldon T.] Mt Sinai Sch Med, New York, NY USA.
[Gibert, Cynthia] George Washington Univ, Sch Med, Washington, DC USA.
[Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Rodriguez-Barradas, Maria] Baylor Coll Med, Houston, TX 77030 USA.
[Rodriguez-Barradas, Maria] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Rimland, David] Emory Sch Med, Atlanta, GA USA.
[Rimland, David] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Bryant, Kendall] NIAAA, Bethesda, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S39
EP S39
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300093
ER
PT J
AU Kaminetzky, CP
Keedy, JR
Evans, GA
Poppe, AP
Wipf, JE
AF Kaminetzky, Catherine P.
Keedy, Jacqueline R.
Evans, Ginger A.
Poppe, Anne P.
Wipf, Joyce E.
TI INTERPROFESSIONAL PANEL MANAGEMENT: TEACHING RESIDENTS DATA-DRIVEN
LONGITUDINAL AND CONTINUOUS CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kaminetzky, Catherine P.; Keedy, Jacqueline R.; Evans, Ginger A.; Poppe, Anne P.; Wipf, Joyce E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Kaminetzky, Catherine P.; Keedy, Jacqueline R.; Evans, Ginger A.; Poppe, Anne P.; Wipf, Joyce E.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S469
EP S470
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302429
ER
PT J
AU Kangovi, S
Grande, D
Mitra, N
Sellman, J
White, ML
McCollum, S
Shannon, R
Long, JA
AF Kangovi, Shreya
Grande, David
Mitra, Nandita
Sellman, Jeffrey
White, Mary L.
McCollum, Sharon
Shannon, Richard
Long, Judith A.
TI A RANDOMIZED CONTROLLED TRIAL OF A COMMUNITY HEALTH WORKER POST-HOSPITAL
CARE TRANSITIONS INTERVENTION FOR LOW SOCIOECONOMIC STATUS PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kangovi, Shreya; Sellman, Jeffrey; Long, Judith A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Grande, David; Shannon, Richard; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Grande, David; Mitra, Nandita] Univ Penn, Philadelphia, PA 19104 USA.
[Kangovi, Shreya; White, Mary L.; McCollum, Sharon] Spectrum Hlth Serv Inc, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S11
EP S12
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300026
ER
PT J
AU Kaplan-Lewis, ER
Cronin, PR
Percac-Lima, S
AF Kaplan-Lewis, Emma R.
Cronin, Patrick R.
Percac-Lima, Sanja
TI NO-SHOW TO PRIMARY CARE APPOINTMENTS: WHY PATIENTS DO NOT COME?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kaplan-Lewis, Emma R.; Cronin, Patrick R.; Percac-Lima, Sanja] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S130
EP S130
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301069
ER
PT J
AU Karwowski, E
Cheng, T
Orlander, JD
AF Karwowski, Elizabeth
Cheng, Teresa
Orlander, Jay D.
TI EXAMINING THE INFLUENCE OF A BEHAVIORAL CHANGE ACTIVITY ON SENIOR
MEDICAL STUDENT ATTITUDES ABOUT MOTIVATIONAL INTERVIEWING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Karwowski, Elizabeth; Cheng, Teresa; Orlander, Jay D.] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA.
[Karwowski, Elizabeth; Orlander, Jay D.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S75
EP S75
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300178
ER
PT J
AU Kertesz, S
Kim, TW
Gordon, A
Young, AS
Pollio, DE
Jones, RN
Holt, CL
Austin, EL
Roth, D
AF Kertesz, Stefan
Kim, Theresa W.
Gordon, Adam
Young, Alexander S.
Pollio, David E.
Jones, Richard N.
Holt, Cheryl L.
Austin, Erika L.
Roth, David
TI COMPARING HOMELESS PERSONS' CARE EXPERIENCES IN TAILORED VERSUS
NON-TAILORED PRIMARY CARE SETTINGS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kertesz, Stefan; Austin, Erika L.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Kertesz, Stefan; Austin, Erika L.] U Alabama Birmingham, Birmingham, AL USA.
[Kim, Theresa W.] Boston Univ, Boston, MA 02215 USA.
[Gordon, Adam] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
[Gordon, Adam] U Pittsburgh, Pittsburgh, PA USA.
[Pollio, David E.] U Alabama, Tuscaloosa, AL USA.
[Young, Alexander S.] VA Greater Los Angeles, Los Angeles, CA USA.
[Holt, Cheryl L.] U Maryland, Baltimore, MD USA.
[Roth, David] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Jones, Richard N.] Hebrew SeniorLife, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S49
EP S50
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300117
ER
PT J
AU Kolehmainen, CJ
Brennan, M
Filut, A
Isaac, C
Carnes, M
AF Kolehmainen, Christine J.
Brennan, Meghan
Filut, Amarette
Isaac, Carol
Carnes, Molly
TI GENDER AND LEADERSHIP IN CARDIOPULMONARY RESUSCITATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kolehmainen, Christine J.; Brennan, Meghan; Filut, Amarette; Isaac, Carol; Carnes, Molly] Univ Wisconsin, Madison, WI USA.
[Kolehmainen, Christine J.; Brennan, Meghan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S81
EP S81
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300191
ER
PT J
AU Krug, MF
Davidson, HL
Wander, PL
Wipf, JE
AF Krug, Michael F.
Davidson, Heather L.
Wander, P. L.
Wipf, Joyce E.
TI THE EFFECTS OF A DECADE OF PROGRESSIVE DUTY HOUR LIMITATIONS AT A
MULTI-HOSPITAL INTERNAL MEDICINE RESIDENCY PROGRAM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Krug, Michael F.; Davidson, Heather L.; Wander, P. L.; Wipf, Joyce E.] Univ Washington, Seattle, WA 98195 USA.
[Davidson, Heather L.; Wipf, Joyce E.] VA Puget Sound HCS, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S201
EP S202
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301237
ER
PT J
AU Kruse, GR
Khan, SM
Zaslavsky, AM
Ayanian, JZ
Sequist, TD
AF Kruse, Gina R.
Khan, Sami M.
Zaslavsky, Alan M.
Ayanian, John Z.
Sequist, Thomas D.
TI OVERUSE, UNDERUSE, AND MISUSE OF COLORECTAL CANCER SCREENING TESTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kruse, Gina R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Khan, Sami M.; Ayanian, John Z.; Sequist, Thomas D.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Zaslavsky, Alan M.; Ayanian, John Z.] Harvard Univ, Sch Med, Boston, MA USA.
[Sequist, Thomas D.] Harvard Vanguard Med Associates, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S133
EP S134
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301076
ER
PT J
AU Kullgren, JT
Troxel, AB
Loewenstein, G
Norton, L
Gatto, D
Tao, YY
Zhu, JS
Schofield, H
Shea, JA
Asch, DA
Pellathy, T
Driggers, J
Volpp, KG
AF Kullgren, Jeffrey T.
Troxel, Andrea B.
Loewenstein, George
Norton, Laurie
Gatto, Dana
Tao, Yuanyuan
Zhu, Jingsan
Schofield, Heather
Shea, Judy A.
Asch, David A.
Pellathy, Thomas
Driggers, Jay
Volpp, Kevin G.
TI A MIXED-METHODS RANDOMIZED CONTROLLED TRIAL OF EMPLOYER MATCHING OF
DEPOSIT CONTRACTS TO PROMOTE WEIGHT LOSS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kullgren, Jeffrey T.] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA.
[Kullgren, Jeffrey T.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Troxel, Andrea B.; Norton, Laurie; Gatto, Dana; Tao, Yuanyuan; Zhu, Jingsan; Shea, Judy A.; Asch, David A.; Volpp, Kevin G.] Univ Penn, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
[Schofield, Heather] Harvard Univ, Cambridge, MA 02138 USA.
[Asch, David A.; Volpp, Kevin G.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Pellathy, Thomas] McKinsey & Co Inc, Pittsburgh, PA USA.
[Driggers, Jay] Horizon Healthcare Innovat, Newark, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S5
EP S5
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300011
ER
PT J
AU Kullgren, JT
Duey, KA
Werner, RM
AF Kullgren, Jeffrey T.
Duey, Katia A.
Werner, Rachel M.
TI A CENSUS OF STATE-BASED CONSUMER HEALTH CARE PRICE WEBSITES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Kullgren, Jeffrey T.] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA.
[Kullgren, Jeffrey T.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Duey, Katia A.; Werner, Rachel M.] Univ Penn, Philadelphia, PA 19104 USA.
[Werner, Rachel M.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S4
EP S4
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300008
ER
PT J
AU Lee, JS
Nsa, W
Hausmann, LR
Trivedi, AN
Bratzler, DW
Auden, D
Goodrich, K
Larbi, FM
Fine, MJ
AF Lee, Jonathan S.
Nsa, Wato
Hausmann, Leslie R.
Trivedi, Amal N.
Bratzler, Dale W.
Auden, Dana
Goodrich, Kate
Larbi, Fiona M.
Fine, Michael J.
TI NATIONAL TRENDS IN PROCESSES AND OUTCOMES OF CARE FOR ELDERLY PATIENTS
HOSPITALIZED FOR PNEUMONIA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Lee, Jonathan S.; Hausmann, Leslie R.; Fine, Michael J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Nsa, Wato; Auden, Dana] Oklahoma Fdn Med Qual, Oklahoma City, OK USA.
[Hausmann, Leslie R.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S126
EP S127
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301062
ER
PT J
AU Lee, JS
Nsa, W
Hausmann, LR
Trivedi, AN
Bratzler, DW
Auden, D
Goodrich, K
Larbi, FM
Fine, MJ
AF Lee, Jonathan S.
Nsa, Wato
Hausmann, Leslie R.
Trivedi, Amal N.
Bratzler, Dale W.
Auden, Dana
Goodrich, Kate
Larbi, Fiona M.
Fine, Michael J.
TI ASSOCIATIONS BETWEEN PROCESSES OF CARE AND MORTALITY IN A NATIONAL
COHORT OF ELDERLY PATIENTS HOSPITALIZED FOR PNEUMONIA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Lee, Jonathan S.; Hausmann, Leslie R.; Fine, Michael J.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Nsa, Wato; Auden, Dana] Univ Pittsburgh, Med Ctr, Oklahoma City, OK USA.
[Hausmann, Leslie R.; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Bratzler, Dale W.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
[Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S28
EP S28
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300067
ER
PT J
AU Lee, PT
Cunningham, E
Munson, D
Joyner, J
Wakeman, S
Tipirneni, R
Dunkle, A
Paterniti, D
Stone, VE
AF Lee, Patrick T.
Cunningham, Elizabeth
Munson, David
Joyner, Joseph
Wakeman, Sarah
Tipirneni, Renuka
Dunkle, Ashley
Paterniti, Debora
Stone, Valerie E.
TI MIXED-METHODS EVALUATION OF THE MGH GLOBAL PRIMARY CARE CURRICULUM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Lee, Patrick T.; Cunningham, Elizabeth; Munson, David; Joyner, Joseph; Wakeman, Sarah; Tipirneni, Renuka; Dunkle, Ashley; Stone, Valerie E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lee, Patrick T.] Cambridge Hlth Alliance, Cambridge, MA USA.
[Paterniti, Debora] Univ Calif Davis, Davis, CA 95616 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S472
EP S473
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302437
ER
PT J
AU Levy, D
Munshi, V
Ashburner, JM
Zai, A
Grant, RW
Atlas, SJ
AF Levy, Douglas
Munshi, Vidit
Ashburner, Jeffrey M.
Zai, Adrian
Grant, Richard W.
Atlas, Steven J.
TI THE EFFECTIVENESS AND COSTS OF TWO POPULATION-BASED CANCER SCREENING
PROGRAMS: THE VALUE OF PCP INPUT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Levy, Douglas; Munshi, Vidit; Ashburner, Jeffrey M.; Grant, Richard W.; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S216
EP S217
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301273
ER
PT J
AU Linsky, A
Simon, SR
Bokhour, BG
AF Linsky, Amy
Simon, Steven R.
Bokhour, Barbara G.
TI PROVIDER PERCEPTIONS OF INTENTIONAL MEDICATION DISCONTINUATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Linsky, Amy] Boston Univ Sch Med, Boston, MA USA.
[Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bokhour, Barbara G.] ENRM VA Med Ctr, Bedford, MA USA.
[Bokhour, Barbara G.] Boston Univ Sch Publ Hlth, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S161
EP S161
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301141
ER
PT J
AU Linsky, A
Maniam, N
Volk, LA
Simon, SR
AF Linsky, Amy
Maniam, Nivethietha
Volk, Lynn A.
Simon, Steven R.
TI EFFECT OF COMPUTERIZED CLINICAL DECISION SUPPORT ON APPROPRIATE
LABORATORY MONITORING OF MEDICATIONS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Linsky, Amy; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
[Linsky, Amy] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Maniam, Nivethietha; Volk, Lynn A.] Partners Healthcare Syst, Wellesley, MA USA.
[Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S67
EP S68
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300159
ER
PT J
AU Liu, MPH
Landrum, MB
Weeks, JC
Huskamp, HA
Kahn, KL
He, YL
Mack, JW
Keating, NL
AF Liu, Michael Pang-Hsiang
Landrum, Mary Beth
Weeks, Jane C.
Huskamp, Haiden A.
Kahn, Katherine L.
He, Yulei
Mack, Jennifer W.
Keating, Nancy L.
TI PHYSICIANS' PROPENSITY TO DISCUSS PROGNOSIS ON PATIENTS' PROGNOSIS
AWARENESS FOR METASTATIC LUNG OR COLORECTAL CANCER
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Liu, Michael Pang-Hsiang; Landrum, Mary Beth; Huskamp, Haiden A.; He, Yulei; Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA.
[Weeks, Jane C.; Mack, Jennifer W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kahn, Katherine L.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Liu, Michael Pang-Hsiang/B-9903-2015
OI Liu, Michael Pang-Hsiang/0000-0001-8842-2264
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S147
EP S148
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301110
ER
PT J
AU Liu, MPH
Chinn, GM
Keating, NL
AF Liu, Michael Pang-Hsiang
Chinn, Garrett M.
Keating, Nancy L.
TI HOSPICE ENROLLMENT PREFERENCES AMONG PHYSICIANS AND THE TIMING OF THEIR
END-OF-LIFE CARE DISCUSSIONS WITH TERMINALLY-ILL CANCER PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Chinn, Garrett M.] VA Boston Healthcare Syst, Boston, MA USA.
[Liu, Michael Pang-Hsiang; Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA.
[Chinn, Garrett M.; Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Liu, Michael Pang-Hsiang/B-9903-2015
OI Liu, Michael Pang-Hsiang/0000-0001-8842-2264
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S90
EP S90
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300214
ER
PT J
AU Makam, AN
Boscardin, WJ
Miao, YH
Steinman, M
AF Makam, Anil N.
Boscardin, W. John
Miao, Yinghui
Steinman, Michael
TI THE RISK OF THIAZIDE-INDUCED ADVERSE EFFECTS IN OLDER ADULTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Makam, Anil N.; Boscardin, W. John; Miao, Yinghui; Steinman, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Boscardin, W. John; Miao, Yinghui; Steinman, Michael] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S209
EP S209
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301257
ER
PT J
AU Maniam, N
Chinn, GM
Volk, LA
Williams, DH
Bates, DW
Simon, SR
AF Maniam, Nive
Chinn, Garrett M.
Volk, Lynn A.
Williams, Deborah H.
Bates, David W.
Simon, Steven R.
TI IMPLEMENTATION OF A WEB-BASED PATIENT PORTAL TO IMPROVE TEST RESULT
NOTIFICATION IN A COMMUNITY-BASED PEDIATRIC PRIMARY CARE PRACTICE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Maniam, Nive; Volk, Lynn A.; Williams, Deborah H.; Bates, David W.] Partners HealthCare, Wellesley, MA USA.
[Maniam, Nive; Chinn, Garrett M.; Volk, Lynn A.; Bates, David W.; Simon, Steven R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chinn, Garrett M.; Simon, Steven R.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S438
EP S438
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302360
ER
PT J
AU Mann, EA
Kinsosian, B
Miller, RK
Mary-Ann, H
Hammond, J
Feinberg, A
AF Mann, Elizabeth A.
Kinsosian, Bruce
Miller, Rachel K.
Mary-Ann, Haggerty
Hammond, James
Feinberg, Ariel
TI HOSPITAL AT HOME AS AN INTERAGENCY COLLABORATIVE AT THE PHILADELPHIA VA
MEDICAL CENTER
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Mann, Elizabeth A.; Kinsosian, Bruce; Miller, Rachel K.] Univ Penn, Philadelphia, PA 19104 USA.
[Kinsosian, Bruce; Miller, Rachel K.; Mary-Ann, Haggerty; Hammond, James; Feinberg, Ariel] Philadelphia VA Med Ctr, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S437
EP S437
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302357
ER
PT J
AU McCormick, D
Hanchate, AD
Lasser, KE
Lin, MY
D'Amore, M
Kressin, NR
AF McCormick, Danny
Hanchate, Amresh D.
Lasser, Karen E.
Lin, Mengyun
D'Amore, Meredith
Kressin, Nancy R.
TI IMPACT OF MASSACHUSETTS HEALTH CARE REFORM ON INSURANCE COVERAGE, ACCESS
TO AND RECEIPT OF CARE AND HEALTH STATUS AMONG PATIENTS WITH
CARDIOVASCULAR DISEASE OR RISK FACTORS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [McCormick, Danny] Cambridge Hlth Alliance, Cambridge, MA USA.
[McCormick, Danny] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Hanchate, Amresh D.; Kressin, Nancy R.] VA Boston Healthcare Syst, Boston, MA USA.
[Hanchate, Amresh D.; Lasser, Karen E.; Lin, Mengyun; D'Amore, Meredith; Kressin, Nancy R.] Boston Univ, Sch Med, Boston, MA 02118 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S98
EP S98
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300234
ER
PT J
AU Nall, R
Vanka, A
Ford, K
Libman, H
AF Nall, Ryan
Vanka, Anita
Ford, Kelly
Libman, Howard
TI OUTPATIENT INTENSIVE ORIENTATION PROGRAM
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Nall, Ryan; Vanka, Anita; Ford, Kelly; Libman, Howard] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S474
EP S475
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302441
ER
PT J
AU Nall, R
Comstock, P
AF Nall, Ryan
Comstock, Paige
TI FATIGUE AND SECOND DEGREE AV BLOCK IN A YOUNG HEALTHY MALE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Nall, Ryan; Comstock, Paige] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S326
EP S326
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302075
ER
PT J
AU Nasir, S
Bates, JT
AF Nasir, Saifullah
Bates, Jeffrey T.
TI CLOPIDOGREL HYPERSENSITIVITY REACTION AFTER PLACEMENT OF A DRUG-ELUTING
STENT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Nasir, Saifullah; Bates, Jeffrey T.] Baylor Coll Med, Houston, TX 77030 USA.
[Nasir, Saifullah; Bates, Jeffrey T.] Houston VAMC, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S309
EP S309
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302030
ER
PT J
AU Neugarten, C
Saha, S
Roter, D
Korthuis, PT
Cohn, JA
Sharp, VL
Moore, RD
Beach, MC
AF Neugarten, Carter
Saha, Somnath
Roter, Deborah
Korthuis, Philip T.
Cohn, Jonathan A.
Sharp, Victoria L.
Moore, Richard D.
Beach, Mary Catherine
TI AT EASE AND DIS-EASE: PATIENT REQUESTS FOR REASSURANCE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Neugarten, Carter; Roter, Deborah; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA.
[Saha, Somnath] Portland VA Med Ctr, Portland, OR USA.
[Saha, Somnath; Korthuis, Philip T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Sharp, Victoria L.] St Lukes Roosevelt, New York, NY USA.
[Cohn, Jonathan A.] Wayne State Univ, Detroit, MI USA.
RI Roter, Debra/N-8830-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S30
EP S30
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300071
ER
PT J
AU Ong, M
Wells, KB
Jones, L
Chung, B
Dixon, E
Tang, LQ
Gilmore, J
Sherbourne, C
Ngo, VK
Stockdale, SE
Ramos, E
Belin, TR
Miranda, J
AF Ong, Michael
Wells, Kenneth B.
Jones, Loretta
Chung, Bowen
Dixon, Elizabeth
Tang, Lingqi
Gilmore, James
Sherbourne, Cathy
Ngo, Victoria K.
Stockdale, Susan E.
Ramos, Esmeralda
Belin, Thomas R.
Miranda, Jeanne
TI COMMUNITY-PARTNERED CLUSTER-RANDOMIZED COMPARATIVE EFFECTIVENESS TRIAL
OF COMMUNITY ENGAGEMENT AND PLANNING OR PROGRAM TECHNICAL ASSISTANCE TO
ADDRESS DEPRESSION DISPARITIES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wells, Kenneth B.; Chung, Bowen; Sherbourne, Cathy; Ngo, Victoria K.] RAND Corp, Santa Monica, CA USA.
[Ong, Michael; Wells, Kenneth B.; Tang, Lingqi; Stockdale, Susan E.; Ramos, Esmeralda; Belin, Thomas R.; Miranda, Jeanne] Univ Calif Los Angeles, Los Angeles, CA USA.
[Jones, Loretta] Hlth African Amer Families II, Los Angeles, CA USA.
[Jones, Loretta] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
[Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Dixon, Elizabeth] QueensCare Hlth & Faith Partnership, Los Angeles, CA USA.
[Gilmore, James] Behav Hlth Serv, Gardena, CA USA.
[Stockdale, Susan E.] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S47
EP S47
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300112
ER
PT J
AU Ong, M
Miranda, J
Jones, L
Chung, B
Dixon, E
Tang, LQ
Gilmore, J
Sherbourne, C
Ngo, VK
Stockdale, SE
Ramos, E
Belin, TR
Wells, KB
AF Ong, Michael
Miranda, Jeanne
Jones, Loretta
Chung, Bowen
Dixon, Elizabeth
Tang, Lingqi
Gilmore, James
Sherbourne, Cathy
Ngo, Victoria K.
Stockdale, Susan E.
Ramos, Esmeralda
Belin, Thomas R.
Wells, Kenneth B.
TI COMMUNITY-PARTNERED EVALUATION OF DEPRESSION SERVICES FOR CLIENTS OF
COMMUNITY-BASED AGENCIES IN UNDER-RESOURCED COMMUNITIES IN LOS ANGELES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ong, Michael; Miranda, Jeanne; Tang, Lingqi; Ramos, Esmeralda; Belin, Thomas R.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Jones, Loretta] Hlth African Amer Families II, Los Angeles, CA USA.
[Jones, Loretta] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
[Chung, Bowen; Sherbourne, Cathy; Ngo, Victoria K.; Wells, Kenneth B.] RAND Corp, Santa Monica, CA USA.
[Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Dixon, Elizabeth] QueensCare Hlth & Faith Partnership, Los Angeles, CA USA.
[Gilmore, James] Behav Hlth Serv, Gardena, CA USA.
[Stockdale, Susan E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S48
EP S48
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300113
ER
PT J
AU Percac-Lima, S
Bond, B
Saadi, A
AF Percac-Lima, Sanja
Bond, Barbara
Saadi, Altaf
TI BOSNIAN, IRAQI, AND SOMALI REFUGEE WOMEN SPEAK: A COMPARATIVE STUDY OF
REFUGEE HEALTH BELIEFS ON PREVENTIVE HEALTH AND BREAST CANCER SCREENING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Percac-Lima, Sanja] Massachussetts Gen Hosp, Chelsea, MA USA.
[Bond, Barbara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Percac-Lima, Sanja; Saadi, Altaf] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S35
EP S35
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300083
ER
PT J
AU Reddy, SM
Dick, AM
Gerber, MR
Mitchell, KS
AF Reddy, Shivani M.
Dick, Alexandra M.
Gerber, Megan R.
Mitchell, Karen S.
TI TREATMENT SEEKING CHARACTERISTICS OF WOMEN PARTICIPATING IN A YOGA
INTERVENTION FOR PTSD
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Reddy, Shivani M.; Gerber, Megan R.; Mitchell, Karen S.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Reddy, Shivani M.; Dick, Alexandra M.; Gerber, Megan R.; Mitchell, Karen S.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S225
EP S226
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301292
ER
PT J
AU Reddy, SM
Gerber, MR
Mitchell, KS
AF Reddy, Shivani M.
Gerber, Megan R.
Mitchell, Karen S.
TI THE EFFECT OF A YOGA INTERVENTION ON ALCOHOL AND DRUG ABUSE RISK IN
VETERAN AND CIVILIAN WOMEN WITH PTSD
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Reddy, Shivani M.; Gerber, Megan R.; Mitchell, Karen S.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Reddy, Shivani M.; Gerber, Megan R.; Mitchell, Karen S.] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S200
EP S200
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301234
ER
PT J
AU Redmond, N
Litaker, MS
Conner, M
Kertesz, S
AF Redmond, Nicole
Litaker, Mark S.
Conner, Michael
Kertesz, Stefan
TI DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF VETERANS WITH A HISTORY OF
INCARCERATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Redmond, Nicole; Litaker, Mark S.; Kertesz, Stefan] Univ Alabama Birmingham, Birmingham, AL USA.
[Litaker, Mark S.; Conner, Michael; Kertesz, Stefan] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S58
EP S59
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300137
ER
PT J
AU Rigotti, NA
Japuntich, S
Regan, S
Kelley, JH
Chang, YC
Reyen, M
Viana, JC
Park, ER
Levy, D
Korotkin, M
Streck, J
Singer, DE
AF Rigotti, Nancy A.
Japuntich, Sandra
Regan, Susan
Kelley, Jennifer H.
Chang, Yuchiao
Reyen, Michele
Viana, Joseph C.
Park, Elyse R.
Levy, Douglas
Korotkin, Molly
Streck, Joanna
Singer, Daniel E.
TI PROMOTING SMOKING CESSATION AFTER HOSPITAL DISCHARGE: THE HELPING HAND
RANDOMIZED CONTROLLED COMPARATIVE EFFECTIVENESS TRIAL
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Rigotti, Nancy A.; Regan, Susan; Kelley, Jennifer H.; Chang, Yuchiao; Reyen, Michele; Viana, Joseph C.; Park, Elyse R.; Levy, Douglas; Korotkin, Molly; Streck, Joanna; Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Japuntich, Sandra] Boston VA Hlth Care Syst, Boston, MA USA.
NR 0
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S160
EP S160
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301139
ER
PT J
AU Ripp, J
Fallar, R
Katz, JT
Bazari, H
Bellini, L
Korenstein, D
AF Ripp, Jonathan
Fallar, Robert
Katz, Joel T.
Bazari, Hasan
Bellini, Lisa
Korenstein, Deborah
TI THE IMPACT OF DUTY HOUR RESTRICTIONS ON JOB BURNOUT IN INTERNAL MEDICINE
RESIDENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ripp, Jonathan; Fallar, Robert; Korenstein, Deborah] Mt Sinai Sch Med, New York, NY USA.
[Katz, Joel T.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bazari, Hasan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bellini, Lisa] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S204
EP S204
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301243
ER
PT J
AU Seal, KH
Samuelson, K
McCamish, N
Koenig, CJ
Bertenthal, D
Tarasovsky, G
Choucroun, G
AF Seal, Karen H.
Samuelson, Kristin
McCamish, Nicole
Koenig, Christopher J.
Bertenthal, Daniel
Tarasovsky, Gary
Choucroun, Gerard
TI OUTCOMES OF A NEW WEB-BASED PTSD TRAINING FOR PRIMARY CARE PROVIDERS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Seal, Karen H.; Samuelson, Kristin; McCamish, Nicole; Koenig, Christopher J.; Bertenthal, Daniel; Tarasovsky, Gary; Choucroun, Gerard] San Francisco VA Med Ctr, San Francisco, CA USA.
[Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Samuelson, Kristin] Alliant Int Univ, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S473
EP S474
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302439
ER
PT J
AU Silverman, JB
Compton, N
AF Silverman, Julie B.
Compton, Nicholas
TI AN UNCOMMON CAUSE OF DYSASTHESIA AND PRURITUS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Silverman, Julie B.; Compton, Nicholas] VA Puget Sound, Seattle, WA USA.
[Silverman, Julie B.; Compton, Nicholas] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S286
EP S286
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301443
ER
PT J
AU Simmons, LH
Sepucha, KR
Leavitt, L
AF Simmons, Leigh H.
Sepucha, Karen R.
Leavitt, Lauren
TI LETTING PATIENTS DECIDE: A NOVEL STRATEGY FOR INCREASING USE OF PATIENT
DECISION AIDS IN PRIMARY CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Simmons, Leigh H.; Sepucha, Karen R.; Leavitt, Lauren] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S441
EP S442
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302367
ER
PT J
AU Simmons, LH
Welch, LC
Pober, DM
Trachtenberg, FL
McKinlay, JB
AF Simmons, Leigh H.
Welch, Lisa C.
Pober, David M.
Trachtenberg, Felicia L.
McKinlay, John B.
TI IN THE PRESENCE OF A MENTAL HEALTH COMORBIDITY, WHAT PREDICTS GUIDELINE
ADHERENCE FOR A CHRONIC CONDITION (TYPE 2 DIABETES)?
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Welch, Lisa C.; Pober, David M.; Trachtenberg, Felicia L.; McKinlay, John B.] New England Res Inst, Watertown, MA 02172 USA.
[Simmons, Leigh H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S107
EP S107
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301016
ER
PT J
AU Simon, SR
Checchi, K
McNair, SS
Rubin, A
Marcello, T
Bickmore, T
AF Simon, Steven R.
Checchi, Kyle
McNair, Sarah S.
Rubin, Amy
Marcello, Thomas
Bickmore, Timothy
TI A PILOT STUDY OF A COMPUTER-BASED RELATIONAL AGENT TO SCREEN FOR
SUBSTANCE-USE PROBLEMS IN PRIMARY CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Simon, Steven R.; Checchi, Kyle; McNair, Sarah S.; Marcello, Thomas] VA Boston, Boston, MA USA.
[Checchi, Kyle; McNair, Sarah S.] Harvard Univ, Sch Med, Boston, MA USA.
[Rubin, Amy] Boston Univ, Boston, MA 02215 USA.
[Rubin, Amy] VA Boston Healthcare Syst, Boston, MA USA.
[Simon, Steven R.; Marcello, Thomas] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bickmore, Timothy] Northeastern Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S6
EP S7
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300015
ER
PT J
AU Sudore, RL
Knight, SJ
Stewart, AL
McMahan, RD
Feuz, M
Miao, YH
Barnes, DE
AF Sudore, Rebecca L.
Knight, Sara J.
Stewart, Anita L.
McMahan, Ryan D.
Feuz, Mariko
Miao, Yinghui
Barnes, Deborah E.
TI A NOVEL WEBSITE TO PREPARE DIVERSE OLDER ADULTS FOR DECISION MAKING AND
ADVANCE CARE PLANNING: A PILOT STUDY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Sudore, Rebecca L.; Stewart, Anita L.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui; Barnes, Deborah E.] UCSF, San Francisco, CA USA.
[Sudore, Rebecca L.; Knight, Sara J.; McMahan, Ryan D.; Feuz, Mariko; Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA USA.
[Knight, Sara J.] Vet Hlth Adm, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S6
EP S6
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300013
ER
PT J
AU Sugiyama, T
Zingmond, D
Lorenz, K
Diamant, A
O'Malley, K
Citko, J
Gonzalez, V
Wenger, N
AF Sugiyama, Takehiro
Zingmond, David
Lorenz, Karl
Diamant, Allison
O'Malley, Kate
Citko, Judy
Gonzalez, Victor
Wenger, Neil
TI IMPLICATIONS OF POVERTY, HOSPITAL TYPE, AND A GRASSROOTS COMMUNITY
INTERVENTION ON DISSEMINATION OF PHYSICIAN ORDERS FOR LIFE SUSTAINING
TREATMENT IN CALIFORNIA HOSPITALS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Sugiyama, Takehiro; Zingmond, David; Diamant, Allison; Gonzalez, Victor; Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA USA.
[Sugiyama, Takehiro] Univ Tokyo, Tokyo, Japan.
[Lorenz, Karl] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA.
[O'Malley, Kate] Calif HealthCare Fdn, Oakland, CA USA.
[Citko, Judy] Coalit Compassionate Care Calif, Sacramento, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S104
EP S104
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301009
ER
PT J
AU Takahashi, TA
Berger, DB
Wipf, JE
Shannon, SE
Zierler, BK
AF Takahashi, Traci A.
Berger, Douglas B.
Wipf, Joyce E.
Shannon, Sarah E.
Zierler, Brenda K.
TI "MEET YOUR COLLEAGUES": ENHANCING THE APPEAL OF EDUCATION IN
COLLABORATIVE CARE
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Takahashi, Traci A.; Berger, Douglas B.; Wipf, Joyce E.] VA Puget Sound, Seattle, WA USA.
[Takahashi, Traci A.; Berger, Douglas B.; Wipf, Joyce E.; Shannon, Sarah E.; Zierler, Brenda K.] Univ Washington, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S488
EP S488
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302473
ER
PT J
AU Taksler, G
Cutler, DM
Giovannucci, E
Smith, MR
Keating, NL
AF Taksler, Glen
Cutler, David M.
Giovannucci, Edward
Smith, Matthew R.
Keating, Nancy L.
TI VITAMIN D AND RACIAL DIFFERENCES IN PROSTATE CANCER INCIDENCE AND
MORTALITY
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Taksler, Glen] NYU, Sch Med, New York, NY USA.
[Cutler, David M.] Harvard Univ, Cambridge, MA 02138 USA.
[Cutler, David M.] Natl Bur Econ Res, Cambridge, MA 02138 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Giovannucci, Edward; Smith, Matthew R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Smith, Matthew R.; Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S239
EP S240
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301325
ER
PT J
AU Talamantes, E
Moreno, G
Guerrero, LR
Mangione, C
Morales, L
AF Talamantes, Efrain
Moreno, Gerardo
Guerrero, Lourdes R.
Mangione, Carol
Morales, Leo
TI HABLAMOS JUNTOS (TOGETHER WE SPEAK): A BRIEF PATIENT-REPORTED MEASURE OF
THE QUALITY OF INTERPRETERS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Talamantes, Efrain; Moreno, Gerardo; Guerrero, Lourdes R.; Mangione, Carol] Univ Calif Los Angeles, Los Angeles, CA USA.
[Talamantes, Efrain] US Dept Vet Affairs, Los Angeles, CA USA.
[Morales, Leo] Univ Washington, Seattle, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S83
EP S83
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300197
ER
PT J
AU Thorndike, AN
Mills, S
Sonnenberg, L
Palakshappa, D
Gao, T
Pau, CT
Regan, S
AF Thorndike, Anne N.
Mills, Sarah
Sonnenberg, Lillian
Palakshappa, Deepak
Gao, Tian
Pau, Cindy T.
Regan, Susan
TI RANDOMIZED INTERVENTION TO PROMOTE PHYSICAL ACTIVITY OF INTERNAL
MEDICINE RESIDENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Thorndike, Anne N.; Mills, Sarah; Sonnenberg, Lillian; Palakshappa, Deepak; Gao, Tian; Pau, Cindy T.; Regan, Susan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S165
EP S165
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301151
ER
PT J
AU Trivedi, AN
Nsa, W
Hausmann, LR
Lee, JS
Ma, A
Bratzler, DW
Goodrich, K
Larbi, FM
Fine, MJ
AF Trivedi, Amal N.
Nsa, Wato
Hausmann, Leslie R.
Lee, Jonathan S.
Ma, Allen
Bratzler, Dale W.
Goodrich, Kate
Larbi, Fiona M.
Fine, Michael J.
TI TRENDS IN THE QUALITY OF CARE AND RACIAL/ETHNIC DISPARITIES IN US
HOSPITALS, 2005-2010
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Trivedi, Amal N.] Providence VA Med Ctr, Providence, RI USA.
[Trivedi, Amal N.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Nsa, Wato; Ma, Allen; Bratzler, Dale W.] Oklahoma Fdn Med Qual, Oklahoma City, OK USA.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hausmann, Leslie R.; Lee, Jonathan S.; Goodrich, Kate; Larbi, Fiona M.] Ctr Medicare Serv, Baltimore, MD USA.
[Hausmann, Leslie R.; Lee, Jonathan S.; Goodrich, Kate; Larbi, Fiona M.] Ctr Medicaid Serv, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S228
EP S228
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301298
ER
PT J
AU Trivedi, R
Kivlahan, D
McCarthy, J
Post, EP
Saxon, AJ
Pomerantz, A
Sun, H
Piette, JD
Fihn, SD
Nelson, KM
AF Trivedi, Ranak
Kivlahan, Dan
McCarthy, John
Post, Edward P.
Saxon, Andrew J.
Pomerantz, Andrew
Sun, Haili
Piette, John D.
Fihn, Stephan D.
Nelson, Karin M.
TI BURDEN OF MENTAL ILLNESS AMONG VA PRIMARY CARE PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Trivedi, Ranak; Saxon, Andrew J.; Sun, Haili; Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Trivedi, Ranak; Saxon, Andrew J.; Fihn, Stephan D.; Nelson, Karin M.] Univ Washington, Seattle, WA 98195 USA.
[McCarthy, John; Post, Edward P.; Piette, John D.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA.
[McCarthy, John; Post, Edward P.; Piette, John D.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Kivlahan, Dan; Pomerantz, Andrew] VA Off Mental Hlth Serv, White River, VT USA.
[Pomerantz, Andrew] Dartmouth Coll, Hanover, NH 03755 USA.
[Fihn, Stephan D.] VA Off Analyt & Business Intelligence, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S37
EP S38
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300089
ER
PT J
AU Turner, BJ
Finley, E
Garza, DR
Vale, S
Simmonds, MJ
Pugh, MJ
AF Turner, Barbara J.
Finley, Erin
Garza, Diandrea R.
Vale, Shruthi
Simmonds, Maureen J.
Pugh, Mary Jo
TI THEMES FROM FOCUS GROUPS OF VETERANS WITH CHRONIC NON-CANCER PAIN ON
HIGH DOSE OPIOID ANALGESICS: LOVE/HATE OF OPIOIDS AND CHALLENGES WITH
ALTERNATIVE PAIN CARE STRATEGIES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Turner, Barbara J.; Finley, Erin; Garza, Diandrea R.; Vale, Shruthi; Simmonds, Maureen J.; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Finley, Erin; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S221
EP S222
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301284
ER
PT J
AU Varkey, AB
Manwell, LB
Ibrahim, SA
Brown, R
Laiteerapong, N
Schwartz, MD
Williams, E
Burgess, D
Wiltshire, J
Montague, E
Poplau, S
Linzer, M
AF Varkey, Anita B.
Manwell, Linda Baier
Ibrahim, Said A.
Brown, Roger
Laiteerapong, Neda
Schwartz, Mark D.
Williams, Eric
Burgess, Diana
Wiltshire, Jacqueline
Montague, Enid
Poplau, Sara
Linzer, Mark
TI IMPACT OF WORK CONDITIONS ON ERRORS AND QUALITY: A COMPARISON OF PRIMARY
CARE CLINICS SERVING LARGE PROPORTIONS OF MINORITY PATIENTS TO THOSE
THAT DO NOT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Varkey, Anita B.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
[Manwell, Linda Baier; Brown, Roger] Univ Wisconsin, Madison, WI USA.
[Ibrahim, Said A.] VA Philadelphia Med Ctr, Philadelphia, PA USA.
[Ibrahim, Said A.] Perelman Univ Penn, Sch Med, Philadelphia, PA USA.
[Laiteerapong, Neda] Univ Chicago, Chicago, IL 60637 USA.
[Schwartz, Mark D.] NYU, Sch Med, New York, NY USA.
[Schwartz, Mark D.] VA New York Harbor Hlth Care Syst, New York, NY USA.
[Williams, Eric] Univ Alabama, Tuscaloosa, AL USA.
[Burgess, Diana] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
[Burgess, Diana] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA.
[Wiltshire, Jacqueline] Univ S Florida, Tampa, FL USA.
[Montague, Enid] Northwestern Univ, Chicago, IL 60611 USA.
[Poplau, Sara; Linzer, Mark] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
RI Burgess, Diana/A-1946-2016
NR 0
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S100
EP S100
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300238
ER
PT J
AU Wachterman, MW
Simon, SR
Lipsitz, SR
Keating, NL
AF Wachterman, Melissa W.
Simon, Steven R.
Lipsitz, Stuart R.
Keating, Nancy L.
TI PATTERNS OF HOSPICE CARE AMONG VETERANS AND NON-VETERANS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wachterman, Melissa W.; Simon, Steven R.] VA Boston Healthcare Syst, Jamaica Plain, MA USA.
[Wachterman, Melissa W.; Simon, Steven R.; Lipsitz, Stuart R.; Keating, Nancy L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Keating, Nancy L.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S142
EP S143
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301098
ER
PT J
AU Wakeman, S
Baggett, M
Campbell, E
Pham-Kanter, G
AF Wakeman, Sarah
Baggett, Meridale
Campbell, Eric
Pham-Kanter, Genevieve
TI INTERNAL MEDICINE RESIDENTS' TRAINING IN SUBSTANCE USE DISORDERS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wakeman, Sarah; Baggett, Meridale] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wakeman, Sarah; Campbell, Eric] Harvard Univ, Sch Med, Boston, MA USA.
[Campbell, Eric; Pham-Kanter, Genevieve] Mongan Inst Hlth Policy, Boston, MA USA.
[Pham-Kanter, Genevieve] Univ Colorado Anschutz Med Campus, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S109
EP S110
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301022
ER
PT J
AU Wang, EA
McGinnis, KA
Akgun, KM
Edelman, J
Justice, AC
Rimland, D
Wang, KR
Fiellin, DA
AF Wang, Emily A.
McGinnis, Kathleen A.
Akguen, Kathleen M.
Edelman, Jennifer
Justice, Amy C.
Rimland, David
Wang, Karen
Fiellin, David A.
TI INCARCERATION IS ASSOCIATED WITH WORSE HEALTH OUTCOMES AND
ANTIRETROVIRAL ADHERENCE AMONG HIV-INFECTED PATIENTS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wang, Emily A.; Akguen, Kathleen M.; Edelman, Jennifer; Justice, Amy C.; Fiellin, David A.] Yale Univ, New Haven, CT USA.
[McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Justice, Amy C.; Wang, Karen] VA CT Healthcare Syst, West Haven, CT USA.
[Rimland, David] Atlanta VAMC, Atlanta, GA USA.
[Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S107
EP S108
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301017
ER
PT J
AU Wang, ES
Conde, M
Simon, B
Leykum, L
AF Wang, Emily S.
Conde, Michelle
Simon, Bret
Leykum, Luci
TI KNOWLEDGE AND PERCEPTIONS OF NON-PHYSICIAN PRIMARY CARE TEAM MEMBERS
REGARDING END OF YEAR PCP TRANSITIONS IN A RESIDENT CONTINUITY CLINIC
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wang, Emily S.; Conde, Michelle; Leykum, Luci] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Wang, Emily S.; Conde, Michelle; Simon, Bret; Leykum, Luci] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S112
EP S112
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301028
ER
PT J
AU Ward, CE
He, W
Ashburner, JM
Atlas, SJ
AF Ward, Charlotte E.
He, Wei
Ashburner, Jeffrey M.
Atlas, Steven J.
TI DEVELOPMENT OF AN INTERACTIVE, WEB-BASED COMPREHENSIVE PERFORMANCE
DASHBOARD FOR USE IN PRIMARY CARE PRACTICE NETWORKS
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ward, Charlotte E.; He, Wei; Ashburner, Jeffrey M.; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S434
EP S434
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302352
ER
PT J
AU Ward, CE
Edgman-Levitan, S
Cohen, MJ
Berman, R
AF Ward, Charlotte E.
Edgman-Levitan, Susan
Cohen, Marya J.
Berman, Rebecca
TI THE ASSOCIATION BETWEEN MEDICAL STUDENT CAREER INTERESTS AND ATTITUDES
TOWARD PRIMARY CARE, FACULTY MENTORSHIP, AND INSTITUTIONAL SUPPORT
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ward, Charlotte E.; Edgman-Levitan, Susan; Cohen, Marya J.; Berman, Rebecca] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S195
EP S196
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301223
ER
PT J
AU Ward, CE
Ashburner, JM
He, W
Atlas, SJ
AF Ward, Charlotte E.
Ashburner, Jeffrey M.
He, Wei
Atlas, Steven J.
TI THE ASSOCIATION BETWEEN PATIENT EXPERIENCE OF CARE AND SUBSEQUENT CANCER
PREVENTION AND CHRONIC DISEASE OUTCOMES
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ward, Charlotte E.; Ashburner, Jeffrey M.; He, Wei; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S196
EP S197
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301225
ER
PT J
AU Ward, CE
Ashburner, J
He, W
Atlas, SJ
AF Ward, Charlotte E.
Ashburner, JeffreyM.
He, Wei
Atlas, Steven J.
TI THE ASSOCIATION BETWEEN OUTPATIENT EXPERIENCE OF CARE AND SUBSEQUENT
RESOURCE UTILIZATION IN A PRIMARY CARE NETWORK
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Ward, Charlotte E.; Ashburner, JeffreyM.; He, Wei; Atlas, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S196
EP S196
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301224
ER
PT J
AU Warde, CM
Pearson, M
AF Warde, Carole M.
Pearson, Marjorie
TI A CURRICULUM TO IMPROVE AND TEACH PRIMARY CARE TEAM FUNCTION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Warde, Carole M.] Greater Los Angeles VA Hlth Syst, North Hills, CA USA.
[Pearson, Marjorie] RAND Corp, Santa Monica, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S450
EP S451
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302385
ER
PT J
AU Wu, CA
Mulder, AL
Costa, MV
Zai, A
Tishler, L
Saltzman, JR
Bitton, A
Ellner, AL
AF Wu, Charlotte A.
Mulder, Amara L.
Costa, Manuela V.
Zai, Adrian
Tishler, Lori
Saltzman, John R.
Bitton, Asaf
Ellner, Andrew L.
TI A POPULATION MANAGEMENT SYSTEM FOR IMPROVING COLORECTAL SCREENING RATES
IN A PRIMARY CARE SETTING
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Wu, Charlotte A.; Mulder, Amara L.; Costa, Manuela V.; Tishler, Lori; Saltzman, John R.; Bitton, Asaf; Ellner, Andrew L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Wu, Charlotte A.; Bitton, Asaf; Ellner, Andrew L.] Harvard Univ, Sch Med, Boston, MA USA.
[Zai, Adrian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S428
EP S429
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939302340
ER
PT J
AU Young, EA
Stratton, KA
Brin, M
AF Young, Eric A.
Stratton, Kristin A.
Brin, Michael
TI DECLINE IN INTERNAL MEDICINE RESIDENTS' ACLS EXPERIENCE IN THE MODERN
TRAINING ERA
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Young, Eric A.; Stratton, Kristin A.; Brin, Michael] Denver VA Med Ctr, Denver, CO USA.
[Young, Eric A.; Stratton, Kristin A.] Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S57
EP S58
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939300135
ER
PT J
AU Zulman, D
Yoon, J
Cohen, DM
Wagner, TH
Ritchie, C
Asch, S
AF Zulman, Donna
Yoon, Jean
Cohen, Danielle M.
Wagner, Todd H.
Ritchie, Christine
Asch, Steven
TI MULTIMORBIDITY AND HEALTH CARE UTILIZATION AMONG HIGH-COST PATIENTS:
IMPLICATIONS FOR CARE COORDINATION
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Meeting Abstract
CT 36th Annual Meeting of the Society-of-General-Internal-Medicine
CY APR 24-27, 2013
CL Denver, CO
SP Soc Gen Internal Med
C1 [Zulman, Donna; Yoon, Jean; Cohen, Danielle M.; Wagner, Todd H.; Asch, Steven] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Zulman, Donna; Cohen, Danielle M.; Wagner, Todd H.; Asch, Steven] Stanford Univ, Stanford, CA 94305 USA.
[Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Ritchie, Christine] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2013
VL 28
SU 1
BP S123
EP S124
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AB6ZP
UT WOS:000331939301055
ER
PT J
AU Maguire, CA
Bovenberg, MS
Crommentuijn, MHW
Niers, JM
Kerami, M
Teng, J
Sena-Esteves, M
Badr, CE
Tannous, BA
AF Maguire, Casey A.
Bovenberg, M. Sarah
Crommentuijn, Matheus H. W.
Niers, Johanna M.
Kerami, Mariam
Teng, Jian
Sena-Esteves, Miguel
Badr, Christian E.
Tannous, Bakhos A.
TI Triple Bioluminescence Imaging for In Vivo Monitoring of Cellular
Processes
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
DE bioluminescence imaging; firefly luciferase; Gaussia luciferase; Vargula
luciferase
ID VARGULA-HILGENDORFII LUCIFERASE; FIREFLY LUCIFERASE; GENE-EXPRESSION;
REPORTER APPLICATIONS; SECRETED LUCIFERASE; RENILLA LUCIFERASE;
MOUSE-BRAIN; STEM-CELLS; T-CELLS; APOPTOSIS
AB Bioluminescence imaging (BLI) has shown to be crucial for monitoring in vivo biological processes. So far, only dual bioluminescence imaging using firefly (Fluc) and Renilla or Gaussia (Gluc) luciferase has been achieved due to the lack of availability of other efficiently expressed luciferases using different substrates. Here, we characterized a codon-optimized luciferase from Vargula hilgendorfii (Vluc) as a reporter for mammalian gene expression. We showed that Vluc can be multiplexed with Gluc and Fluc for sequential imaging of three distinct cellular phenomena in the same biological system using vargulin, coelenterazine, and D-luciferin substrates, respectively. We applied this triple imaging system to monitor the effect of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) delivered using an adeno-associated viral vector (AAV) on brain tumors in mice. Vluc imaging showed efficient sTRAIL gene delivery to the brain, while Fluc imaging revealed a robust antiglioma therapy. Further, nuclear factor-kappa B (NF-kappa B) activation in response to sTRAIL binding to glioma cells death receptors was monitored by Gluc imaging. This work is the first demonstration of trimodal in vivo bioluminescence imaging and will have a broad applicability in many different fields including immunology, oncology, virology, and neuroscience.
C1 [Maguire, Casey A.; Bovenberg, M. Sarah; Crommentuijn, Matheus H. W.; Niers, Johanna M.; Kerami, Mariam; Teng, Jian; Badr, Christian E.; Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Neurol, Neurosci Ctr, Expt Therapeut & Mol Imaging Lab, Boston, MA 02114 USA.
[Maguire, Casey A.; Bovenberg, M. Sarah; Crommentuijn, Matheus H. W.; Niers, Johanna M.; Kerami, Mariam; Teng, Jian; Badr, Christian E.; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA.
[Bovenberg, M. Sarah] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
[Crommentuijn, Matheus H. W.; Niers, Johanna M.; Kerami, Mariam] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Neurosurg, Neurooncol Res Grp, Amsterdam, Netherlands.
[Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA.
[Tannous, Bakhos A.] Massachusetts Gen Hosp, Dept Radiol, Ctr Mol Imaging Res, Boston, MA 02114 USA.
RP Tannous, BA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Neurosci Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM btannous@hms.harvard.edu
OI Crommentuijn, Matheus/0000-0001-8217-5370
FU National Institutes of Health/National Institute of Neurological
Disorders and Stroke (NINDS) [P30NS045776, 1R01NS064983]; American Brain
Tumor Association; Fulbright scholarship; Huygens Scholarship Program;
VSB fonds; Saal van Zwanenberg Foundation; NINDS [P30NS045776]
FX This work was supported by grant from National Institutes of
Health/National Institute of Neurological Disorders and Stroke (NINDS)
P30NS045776 and 1R01NS064983 (B. A. T.) and by a Fellowship from the
American Brain Tumor Association (C. A. M.). M. S. B. was supported by a
Fulbright scholarship, the Huygens Scholarship Program, VSB fonds, and
the Saal van Zwanenberg Foundation. We thank Hiroaki Wakimoto for the
GBM8 cells. We acknowledge the Neuroscience Center Nucleic Acid
Quantitation Core and Image Analysis Core (supported by NINDS
P30NS045776). The authors declared no conflict of interest.
NR 38
TC 22
Z9 23
U1 1
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD JUN
PY 2013
VL 2
AR e99
DI 10.1038/mtna.2013.25
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AC4BV
UT WOS:000332466500004
PM 23778500
ER
PT J
AU Singh, JA
Wells, G
Christensen, R
Ghogomu, E
Macdonald, J
Maxwell, L
Tarp, S
Buchbinder, R
Tugwell, P
AF Singh, J. A.
Wells, G.
Christensen, R.
Ghogomu, E.
Macdonald, J.
Maxwell, L.
Tarp, S.
Buchbinder, R.
Tugwell, P.
CA Cochrane Biol Study Grp
TI RISK OF CANCER, SERIOUS LUNG INFECTIONS AND DEATH WITH BIOLOGICS: A
SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED
TRIALS (RCTS)
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Wells, G.; Ghogomu, E.; Maxwell, L.; Tugwell, P.] Univ Ottawa, Ottawa, ON, Canada.
[Christensen, R.] Copenhagen Univ Hosp, Frederiksberg, Denmark.
[Macdonald, J.] Robarts Res Inst, London, ON N6A 5C1, Canada.
[Tarp, S.] Copenhagen Univ Hosp, Frederiksberg, Denmark.
[Buchbinder, R.] Monash Univ, Malvern, Australia.
RI Buchbinder, Rachelle/G-2952-2011
NR 1
TC 0
Z9 1
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 74
EP 74
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901274
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI INCOME AND PATIENT-REPORTED OUTCOMES (PROS) AFTER PRIMARY TOTAL KNEE
ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 81
EP 82
PG 2
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901296
ER
PT J
AU Khanna, D
Gladue, H
Fitzgerald, J
Channick, R
Chung, L
Distler, O
Furst, D
Hachulla, E
Humbert, M
Langelben, D
Mathai, S
Saggar, R
Visovatti, S
McLaughlin, V
AF Khanna, D.
Gladue, H.
Fitzgerald, J.
Channick, R.
Chung, L.
Distler, O.
Furst, D.
Hachulla, E.
Humbert, M.
Langelben, D.
Mathai, S.
Saggar, R.
Visovatti, S.
McLaughlin, V.
TI RECOMMENDATIONS FOR SCREENING AND DETECTION OF CONNECTIVE-TISSUE DISEASE
ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Khanna, D.; Gladue, H.; Visovatti, S.; McLaughlin, V.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Fitzgerald, J.; Furst, D.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Channick, R.] Mass Gen Hosp, Boston, MA USA.
[Chung, L.] Stanford Univ, Stanford, CA 94305 USA.
[Distler, O.] Univ Zurich, Zurich, Switzerland.
[Hachulla, E.] Univ Hosp Lille, Lille, France.
[Humbert, M.] Univ S Paris, Paris, France.
[Langelben, D.] McGill Univ, Montreal, PQ, Canada.
[Mathai, S.] Johns Hopkins Univ, Baltimore, MD USA.
[Saggar, R.] St Joseph Hosp, Phoenix, AZ USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 146
EP 146
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901477
ER
PT J
AU Hirsh, JM
Quinzanos, I
Keniston, A
Caplan, L
AF Hirsh, J. M.
Quinzanos, I.
Keniston, A.
Caplan, L.
TI VERBALLY ADMINISTERED PATIENT GLOBAL ASSESSMENTS AND ASSESSMENTS OF
DISEASE ACTIVITY DEMONSTRATE GOOD CORRELATION WITH TRADITIONAL WRITTEN
VERSIONS: THE TALK-THE-LINE OBSERVATIONAL STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Hirsh, J. M.; Keniston, A.] Denver Hlth, Denver, CO USA.
[Quinzanos, I.; Caplan, L.] Denver Vet Affairs Med Ctr, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 149
EP 149
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587901485
ER
PT J
AU O'Dell, JR
Mikuls, TR
Taylor, T
Ahluwalia, V
Brophy, M
Warren, S
Lew, R
Phibbs, C
Anis, AH
Cannella, AC
Kunkel, GA
Keystone, E
AF O'Dell, J. R.
Mikuls, T. R.
Taylor, T.
Ahluwalia, V.
Brophy, M.
Warren, S.
Lew, R.
Phibbs, C.
Anis, A. H.
Cannella, A. C.
Kunkel, G. A.
Keystone, E.
CA CSP551 RACAT Res Grp
TI RANDOMIZED DOUBLE-BLIND COMPARATIVE EFFECTIVENESS IN RA PATIENTS WITH
ACTIVE DISEASE DESPITE METHOTREXATE (MTX): A COMPARISON OF CONVENTIONAL
DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS WITH A BIOLOGICAL
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [O'Dell, J. R.; Mikuls, T. R.; Cannella, A. C.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Taylor, T.] VA Med Ctr, White River Jct, VT USA.
[Ahluwalia, V.] Osler Hlth Ctr, Mississauga, ON, Canada.
[Brophy, M.; Lew, R.] VA Boston Healthcare Syst, Boston, MA USA.
[Warren, S.] VA CSP Clin Res Pharm Coordinating Ctr, Albuquerque, NM USA.
[Phibbs, C.] Palo Alto VA Hlth Care Syst, Hearth Econ Resource Ctr 152, Palo Alto, CA USA.
[Anis, A. H.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Kunkel, G. A.] George Wahlen Vet Affairs Med Ctr, Div Rheumatol, Salt Lake City, UT USA.
[Keystone, E.] Univ Toronto, Toronto, ON, Canada.
NR 0
TC 0
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 240
EP 240
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587902143
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI PATIENTS WITH OSTEOARTHRITIS HAVE BETTER FUNCTIONAL OUTCOMES COMPARED TO
RHEUMATOID ARTHRITIS AFTER PRIMARY HIP ARTHROPLASTY: A COHORT STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 351
EP 351
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587902471
ER
PT J
AU Caplan, L
Luong, PT
Richards, JS
Majithia, V
Bobba, S
Qaiyumi, S
Davis, LA
AF Caplan, L.
Luong, P. T.
Richards, J. S.
Majithia, V.
Bobba, S.
Qaiyumi, S.
Davis, L. A.
TI VALIDATION OF MODIFIED DISEASE ACTIVITY AND FUNCTIONAL STATUS
QUESTIONNAIRES IN SPONDYLOARTHRITIS
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Caplan, L.; Luong, P. T.; Bobba, S.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Richards, J. S.; Qaiyumi, S.] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Majithia, V.] Montgomery Vet Affairs Med Ctr, Jackson, MS USA.
[Davis, L. A.] Denver Hlth, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 534
EP 534
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903361
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI IPSILATERAL LOWER EXTREMITY JOINT INVOLVEMENT INCREASES THE RISK OF POOR
PAIN AND FUNCTION OUTCOMES AFTER HIP OR KNEE ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 552
EP 553
PG 2
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903418
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI UNDERLYING DIAGNOSIS PREDICTS PATIENT-REPORTED OUTCOMES AFTER REVISION
TOTAL HIP ARTHROPLASTY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 553
EP 553
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587903419
ER
PT J
AU Singh, JA
Lewallen, D
AF Singh, J. A.
Lewallen, D.
TI MEDICAL COMORBIDITY IS ASSOCIATED WITH PERSISTENT INDEX HIP PAIN AFTER
PRIMARY THA
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Lewallen, D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2013
VL 72
SU 3
BP 696
EP 696
PG 1
WC Rheumatology
SC Rheumatology
GA AB1XT
UT WOS:000331587904154
ER
PT J
AU Brown, RT
Steinman, MA
AF Brown, Rebecca T.
Steinman, Michael A.
TI Characteristics of Emergency Department Visits by Older Versus Younger
Homeless Adults in the United States
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HEALTH-CARE; SUBSTANCE USE; GERIATRIC SYNDROMES; ALCOHOL-PROBLEMS;
FREQUENT USERS; SAN-FRANCISCO; POPULATION; EPIDEMIOLOGY; PEOPLE; URBAN
AB Objectives. We compared the characteristics of emergency department (ED) visits of older versus younger homeless adults.
Methods. We analyzed 2005-2009 data from the National Hospital Ambulatory Medical Care Survey, a nationally representative survey of visits to hospitals and EDs, and used sampling weights, strata, and clustering variables to obtain nationally representative estimates.
Results. The ED visits of homeless adults aged 50 years and older accounted for 36% of annual visits by homeless patients. Although demographic characteristics of ED visits were similar in older and younger homeless adults, clinical and health services characteristics differed. Older homeless adults had fewer discharge diagnoses related to psychiatric conditions (10% vs 20%; P = .002) and drug abuse (7% vs 15%; P = .003) but more diagnoses related to alcohol abuse (31% vs 23%; P = .03) and were more likely to arrive by ambulance (48% vs 36%; P = .02) and to be admitted to the hospital (20% vs 11%; P = .003).
Conclusions. Older homeless adults' patterns of ED care differ from those of younger homeless adults. Health care systems need to account for these differences to meet the needs of the aging homeless population.
C1 [Brown, Rebecca T.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Brown, Rebecca T.; Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94112 USA.
RP Brown, RT (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,UCSF Box VA-181G, San Francisco, CA 94112 USA.
EM rebecca.brown@ucsf.edu
FU National Institute on Aging [T32 AG000212]; American Federation for
Aging Research [1K23 AG030999]
FX R.T. Brown was supported by the National Institute on Aging (grant T32
AG000212). M. A. Steinman was supported by the National Institute on
Aging, and the American Federation for Aging Research (grant 1K23
AG030999).
NR 44
TC 8
Z9 9
U1 1
U2 7
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2013
VL 103
IS 6
BP 1046
EP 1051
DI 10.2105/AJPH.2012.301006
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3FI
UT WOS:000330977900036
PM 23597348
ER
PT J
AU Tsai, AC
AF Tsai, Alexander C.
TI ACHIEVING CONSENSUS ON TERMINOLOGY DESCRIBING MULTIVARIABLE ANALYSES
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Harvard Univ, Sch Med, Boston, MA USA.
RP Tsai, AC (reprint author), 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM actsai@partners.org
FU NIMH NIH HHS [MH-096620, K23 MH096620]
NR 4
TC 1
Z9 1
U1 0
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2013
VL 103
IS 6
BP E1
EP E1
DI 10.2105/AJPH.2013.301234
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3FI
UT WOS:000330977900001
PM 23597350
ER
PT J
AU Wang, EA
Hong, CS
Shavat, S
Kessell, ER
Sanders, R
Kushel, MB
AF Wang, Emily A.
Hong, Clemens S.
Shavat, Shira
Kessell, Eric R.
Sanders, Ronald
Kushel, Margot B.
TI EXCLUSION OF NON-ENGLISH-SPEAKING, RECENTLY RELEASED PRISONERS RESPONSE
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
C1 [Wang, Emily A.] Yale Univ, Sch Med, Sect Gen Med, New Haven, CT USA.
[Hong, Clemens S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA.
[Shavat, Shira; Sanders, Ronald] San Francisco Dept Publ Hlth, Transit Clin, Southeast Hlth Ctr, San Francisco, CA USA.
[Shavat, Shira] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA.
[Kessell, Eric R.] Univ Calif San Francisco, Div Hosp Med, Dept Med, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
[Kushel, Margot B.] Univ Calif San Francisco, Dept Internal Med, Div Gen Internal Med, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
RP Wang, EA (reprint author), Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, 367 Cedar St,Harkness Bldg A,Suite 410A, New Haven, CT 06510 USA.
EM emily.wang@yale.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUN
PY 2013
VL 103
IS 6
BP E6
EP E7
DI 10.2105/AJPH.2013.301363
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA3FI
UT WOS:000330977900007
PM 23597355
ER
PT J
AU Duggan, M
Rago, A
Sharma, U
Zugates, G
Freyman, T
Busold, R
Caulkins, J
Pham, Q
Chang, YC
Mejaddam, A
Beagle, J
Velmahos, G
deMoya, M
Zukerberg, L
Ng, TF
King, LTCDR
AF Duggan, Michael
Rago, Adam
Sharma, Upma
Zugates, Greg
Freyman, Toby
Busold, Rany
Caulkins, John
Quynh Pham
Chang, Yuchaio
Mejaddam, Ali
Beagle, John
Velmahos, George
deMoya, Marc
Zukerberg, Lawrence
Tat Fong Ng
King, L. T. C. David R.
TI Self-expanding polyurethane polymer improves survival in a model of
noncompressible massive abdominal hemorrhage
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Combat; battlefield; noncompressible; hemorrhage; prehospital
ID OPERATION-IRAQI-FREEDOM; FIBRIN SEALANT FOAM; HEMOSTATIC AGENT;
LIVER-INJURIES; BLOOD-LOSS; DRESSINGS; TRAUMA; SWINE; BANDAGE; CARE
AB BACKGROUND: Intracavitary noncompressible hemorrhage remains a significant cause of preventable death on the battlefield. Two dynamically mixed and percutaneously injected liquids were engineered to create an in situ self-expanding polymer foam to facilitate hemostasis in massive bleeding. We hypothesized that intraperitoneal injection of the polymer could achieve conformal contact with sites of injury and improve survival in swine with lethal hepatoportal injury.
METHODS: High grade hepatoportal injury was created in a closed abdominal cavity, resulting in massive noncoagulopathic, noncompressible hemorrhage. Animals received either standard battlefield fluid resuscitation (control, n = 12) or fluid resuscitation plus intraperitoneal injection of hemostatic foam(polymer, n = 15) and were monitored for 3 hours. Blood loss was quantified, and all hepatoportal injuries were inspected for consistency.
RESULTS: Before intervention, all animals initially experienced severe, profound hypotension and near-arrest (mean arterial pressure at 10 minutes, 21 [5.3] mm Hg). Overall survival at 3 hours was 73% in the polymer group and 8% in the control group (p = 0.001). Median survival time was more than 150 minutes in the polymer group versus 23 minutes (19-41.5 minutes) in the control group (p < 0.001), and normalized blood loss in the polymer group was 0.47 (0.30) g/kg per minute versus 3.0 (1.3) g/kg per minute in the controls (p = < 0.001). All hepatoportal injuries were anatomically similar, and the polymer had conformal contact with injured tissues.
CONCLUSION: Intraperitoneal polymer injection during massive noncompressible hemorrhage reduces blood loss and improves survival in a lethal, closed-cavity, hepatoportal injury model. Chronic safety and additional efficacy studies in other models are needed. (Copyright (C) 2013 by Lippincott Williams & Wilkins)
C1 [Duggan, Michael; Chang, Yuchaio; Mejaddam, Ali; Beagle, John; Velmahos, George; deMoya, Marc; Zukerberg, Lawrence; King, L. T. C. David R.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02141 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Rago, Adam; Sharma, Upma; Zugates, Greg; Freyman, Toby; Busold, Rany; Caulkins, John; Quynh Pham; Tat Fong Ng] Arsenal Med Inc, Watertown, MA USA.
RP King, LTCDR (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02141 USA.
EM dking3@partners.org
OI King, David/0000-0003-1028-1478
FU DARPA; ARO [W911NF-10-C-0089]
FX This work was supported by DARPA and ARO contract W911NF-10-C-0089.
NR 22
TC 17
Z9 19
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD JUN
PY 2013
VL 74
IS 6
BP 1462
EP 1467
DI 10.1097/TA.0b013e31828da937
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA AB4DO
UT WOS:000331739800012
PM 23694873
ER
PT J
AU Borczuk, P
Penn, J
Peak, D
Chang, YC
AF Borczuk, Pierre
Penn, Joshua
Peak, David
Chang, Yuchiao
TI Patients with traumatic subarachnoid hemorrhage are at low risk for
deterioration or neurosurgical intervention
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Mild head trauma; subarachnoid hemorrhage; neurosurgical consultation
ID MINOR HEAD-INJURY; BRAIN-INJURY; COMPUTED-TOMOGRAPHY; UTILITY;
CONSULTATION; MANAGEMENT; RULE
AB BACKGROUND: Current standard of care for patients with traumatic intracranial hemorrhage (TIH) includes neurosurgical consultation and/or transfer to a trauma center with neurosurgical backup. We hypothesize that a set of low-risk criteria can be applied to such patients to identify those who may not require neurosurgical evaluation.
METHODS: This is a cross-sectional study of consecutive emergency department patients in 2009 and 2010 with TIH on computerized tomographic scan owing to blunt head trauma. Patients presented to an urban academic Level I trauma center (volume, 92,000) were older than 15 years and had a Glasgow Coma Scale (GCS) score of 13 or greater. Charts were abstracted using a standardized data form by two emergency physicians. Our principal outcome was deterioration represented by a composite of neurosurgical intervention, clinical deterioration, or worsening computerized tomographic scan result.
RESULTS: During the study period, 404 patients were seen with TIH and met our inclusion criteria, and 48 of those patients (11.8%) deteriorated. Patients with isolated subarachnoid hemorrhage, were less likely to deteriorate (odds ratio [OR], 0.08; 95% confidence interval [CI], 0.011-0.58). Characteristics associated with deterioration were subdural hematomas (OR, 2.63; 95% CI, 1.198-5.81) or presenting GCS of less than 15 (OR, 2.12; 95% CI, 1.01-4.43). The use of anticoagulant medications or antiplatelet agents were not associated with deterioration for warfarin, aspirin, or clopidogrel; however bleeding diatheses were corrected with vitamin K, fresh frozen plasma, and platelets as necessary.
CONCLUSION: Patients with isolated traumatic subarachnoid hemorrhage are at low risk for deterioration. These individuals may not need neurosurgical consultation or transfer to a trauma center where neurosurgical backup is available. Those patients with subdural hematoma or a GCS of less than 15 have a higher risk of deterioration and require neurosurgical evaluation. (Copyright (C) 2013 by Lippincott Williams & Wilkins)
C1 [Borczuk, Pierre; Peak, David] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Chang, Yuchiao] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Borczuk, Pierre; Penn, Joshua; Peak, David] Harvard Univ, Sch Med, Div Emergency Med, Boston, MA USA.
[Penn, Joshua] Winchester Hosp, Dept Emergency Med, Boston, MA USA.
RP Borczuk, P (reprint author), Massachusetts Gen Hosp, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA.
EM pborczuk@partners.org
NR 19
TC 14
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD JUN
PY 2013
VL 74
IS 6
BP 1504
EP 1509
DI 10.1097/TA.0b013e31829215cf
PG 6
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA AB4DO
UT WOS:000331739800018
PM 23694879
ER
PT J
AU Varshney, N
Jain, A
Chan, V
Yu, L
Sarraf, D
AF Varshney, Neeta
Jain, Atul
Chan, Vicki
Yu, Le
Sarraf, David
TI Anti-VEGF response in macular hemorrhage and incidence of retinal
pigment epithelial tears
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; INTRAVITREAL BEVACIZUMAB INJECTION;
CARDIOVASCULAR RISK-FACTORS; SUBMACULAR HEMORRHAGE; CHOROIDAL
NEOVASCULARIZATION; PNEUMATIC DISPLACEMENT; RANIBIZUMAB INJECTION;
DEGENERATION; MANAGEMENT; DISEASE
AB Objective: To study the visual and anatomic outcomes of serial anti-vascular endothelial growth factor (anti-VEGF) therapy for severe macular hemorrhage in eyes with exudative age-related macular degeneration (AMD).
Design: Consecutive retrospective analysis.
Participants: Twenty eyes from 20 patients with severe macular hemorrhage (greater than 50% blockage with formal fluorescein angiography [FA]) secondary to wet AMD were studied.
Methods: We performed a chart review of patients at a single centre from May 2006 to September 2009. Presenting visual acuity and diameter of hemorrhage were recorded as well as number of injections, time by which no hemorrhage was remaining, and final anatomic outcome. Cardiovascular risk factors and use of antiplatelet medication or anticoagulation were noted.
Results: Average presenting visual acuity was 1.55 (20/710), and number of injections needed for resolution of hemorrhage was 4. Visual acuity significantly improved from 1.55 (20/710) to 0.70 (20/100) after injections. Thirty-five percent of eyes were found to have an associated retinal pigment epithelial (RPE) tear, and these eyes were found to have received more injections. Final visual acuity was not significantly different in eyes with RPE tears compared with nontear eyes. Eighty-one percent of patients had associated cardiovascular risk factors; antiplatelet therapy and anticoagulation were not found to play a role in hemorrhage size.
Conclusions: RPE tears are found in a significant number of individuals with large macular hemorrhages secondary to exudative macular degeneration, but with continued treatment with anti-VEGF therapy, visual acuity can significantly improve even in the presence of these tears. Eyes with severe macular hemorrhage thus should be considered candidates for anti-VEGF therapy.
C1 [Varshney, Neeta; Chan, Vicki; Yu, Le; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
[Jain, Atul] San Diego Retina Associates, San Diego, CA USA.
[Sarraf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Sarraf, David] Kaiser Permanente, Woodland Hills, CA USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
FU Karl Kirchgessner Foundation
FX This work was supported by grants from Karl Kirchgessner Foundation
(D.S.).
NR 39
TC 1
Z9 1
U1 1
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2013
VL 48
IS 3
BP 210
EP 215
DI 10.1016/j.jcjo.2013.01.023
PG 6
WC Ophthalmology
SC Ophthalmology
GA AA5OD
UT WOS:000331148400025
PM 23769784
ER
PT J
AU Yonekawa, Y
AF Yonekawa, Yoshihiro
TI Aflibercept for the treatment of refractory polypoidal choroidal
vasculopathy
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Letter
ID RANIBIZUMAB; BEVACIZUMAB; EFFICACY
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
RP Yonekawa, Y (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
EM yoshihiro_yonekawa@meei.harvard.edu
NR 8
TC 6
Z9 6
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2013
VL 48
IS 3
BP E59
EP E60
DI 10.1016/j.jcjo.2012.12.015
PG 2
WC Ophthalmology
SC Ophthalmology
GA AA5OD
UT WOS:000331148400011
PM 23769799
ER
PT J
AU Kane, JM
Perlis, RH
DiCarlo, LA
Au-Yeung, K
Duong, J
Petrides, G
AF Kane, John M.
Perlis, Roy H.
DiCarlo, Lorenzo A.
Au-Yeung, Kityee
Duong, Jessie
Petrides, Georgios
TI First Experience With a Wireless System Incorporating Physiologic
Assessments and Direct Confirmation of Digital Tablet Ingestions in
Ambulatory Patients With Schizophrenia or Bipolar Disorder
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID RATING-SCALE; ADHERENCE; RELIABILITY; MEDICATION
AB Objective: To characterize the feasibility and safety of a wireless networked system incorporating physiologic assessments and direct confirmation of digital tablet ingestions in ambulatory patients with schizophrenia or bipolar disorder.
Method: In this 4-week observational study conducted between May 2010 and May 2011 at 2 US academic clinical study sites, 12 adults with bipolar disorder and 16 adults with schizophrenia (all diagnosed according to DSM-IV criteria) utilized a digital health feedback system (DHFS). All subjects were on a stable regimen of oral medication. The DHFS utilized a digital tablet, consisting of an ingestion sensor that was embedded in a tablet containing nonpharmacologic excipients, which subjects coingested with their regularly prescribed medication. The formulation of this digital tablet allowed ingestion sensor separation and activation by stomach fluids after ingestion, followed by communication of a unique identifying signal from the ingestion sensor to an adhesive sensor worn on the torso, which automatically logged the date and time of each digital tablet ingestion. The wearable sensor also collected physiologic measures including activity and heart rate. The primary study objective was to compare the accuracy of DHFS in confirming digital tablet ingestion versus a method of directly observed ingestion; secondary aims included characterization of adherence and physiologic measures longitudinally in these cohorts.
Results: 27 of 28 subjects (96%) completed the study. The mean adherence rate was 74% (95% CI, 64%-86%), and 67% (95% CI, 55%-79%) of doses were taken within 2 hours of the prescribed dosing time. Activity consisted of 847 to 15,930 steps daily, and sleep duration ranged from 3.2 to 15.2 hours daily. For individual subjects, mean sleep disruption, defined as the amount of brief arousals and postural changes during sleep events (eg, subject sitting up during the night), was as low as 5% and as high as 43% for the entire study period. The most common adverse event was minor skin irritation that occurred at the site of the wearable sensor in 5 subjects (18%), which did not lead to early discontinuation. No adverse events occurred due to the ingestion sensor. No subjects developed worsening of psychosis attributable to use of the DHFS. Of the 27 subjects who completed the study, 19 (70%) found the DHFS concept easy to understand, 21 (78%) said they would like to receive reminders on their cell phone if they forgot to take their medications, and 24 (89%) thought the DHFS could be useful to them.
Conclusions: The DHFS provided a novel means of confirming medication ingestion and tracking selected physiologic parameters, and it was generally well tolerated by patients.
C1 [Kane, John M.; Petrides, Georgios] Zucker Hillside Hosp, Glen Oaks, NY USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[DiCarlo, Lorenzo A.; Au-Yeung, Kityee; Duong, Jessie] Proteus Digital Hlth Inc, Redwood City, CA USA.
RP DiCarlo, LA (reprint author), 2600 Bridge Pkwy,Ste 101, Redwood City, CA 94065 USA.
EM ldicarlo@proteusdh.com
FU Proteus Digital Health, Inc, Redwood City, California
FX This study was funded by Proteus Digital Health, Inc, Redwood City,
California.
NR 17
TC 16
Z9 16
U1 1
U2 7
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2013
VL 74
IS 6
BP E533
EP E540
DI 10.4088/JCP.12m08222
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AA5DE
UT WOS:000331115200003
PM 23842023
ER
PT J
AU Purohit, MP
Wells, RE
Zafonte, R
Davis, RB
Yeh, GY
Phillips, RS
AF Purohit, Maulik P.
Wells, Rebecca Erwin
Zafonte, Ross
Davis, Roger B.
Yeh, Gloria Y.
Phillips, Russell S.
TI Neuropsychiatric Symptoms and the Use of Mind-Body Therapies
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID COMMON NEUROLOGICAL CONDITIONS; ALTERNATIVE MEDICINE USE; TRAUMATIC
BRAIN-INJURY; STRESS REDUCTION; COMPLEMENTARY; ADULTS; METAANALYSIS;
ASSOCIATION; DEPRESSION; DISORDERS
AB Objective: Neuropsychiatric symptoms affect 37% of US adults and present in many important diagnoses including posttraumatic stress disorder, traumatic brain injury, and chronic pain. However, these symptoms are difficult to treat with standard treatments, and patients may seek alternative options. In this study, we examined the use of mind-body therapies by adults with neuropsychiatric symptoms.
Method: We compared mind-body therapy use (biofeedback, energy healing, meditation, guided imagery, yoga, deep-breathing exercises, hypnosis, progressive relaxation therapy, qigong, and tai chi) between adults with and without neuropsychiatric symptoms (anxiety, depression, insomnia, headaches, memory deficits, attention deficits, and excessive daytime sleepiness) in the 2007 National Health Interview Survey (N = 23,393). Use of >= 1 of these therapies in the prior 12 months was the primary outcome of interest. We also examined prevalence and reasons for mind-body therapy use in adults with neuropsychiatric symptoms. We performed logistic regression to examine the association between neuropsychiatric symptoms and mind-body therapy use to adjust for sociodemographic and clinical factors.
Results: Adults with >= 1 neuropsychiatric symptom used mind-body therapies more than adults without symptoms (25.3% vs 15.0%, P<.001). Prevalence increased with increasing number of symptoms (21.5% for 1 symptom, 32.4% for >= 3 symptoms, P<.001); differences persisted after adjustment for potential confounders (odds ratios, 1.39 [95% CI, 1.26-1.53] and 2.48 [95% CI, 2.18-2.82]). Reasons for mind-body therapy use among adults with >= 1 symptom included the ineffectiveness or expense of conventional medicine (30.2%). Most adults (nearly 70%) with >= 1 symptom did not discuss their mind-body therapy use with a conventional provider.
Conclusions: Adults with >= 1 neuropsychiatric symptom use mind-body therapies frequently; more symptoms are associated with increased use. Future research is needed to understand the efficacy of these therapies.
C1 [Purohit, Maulik P.; Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Purohit, Maulik P.; Zafonte, Ross] Harvard Univ, Spaulding Rehabil Hosp, Sch Med, Boston, MA USA.
[Purohit, Maulik P.; Davis, Roger B.; Yeh, Gloria Y.; Phillips, Russell S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Wells, Rebecca Erwin] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Wells, Rebecca Erwin] Harvard Univ, Faulkner Hosp, Sch Med, Boston, MA USA.
[Phillips, Russell S.] Harvard Univ, Ctr Primary Care, Sch Med, Boston, MA USA.
RP Purohit, MP (reprint author), Spaulding Rehabil Hosp Network, 125 Nashua St,720, Boston, MA 02114 USA.
EM mpurohit1@partners.org
FU institutional National Research Service Award from the National Center
for Complementary and Alternative Medicine (NCCAM), National Institutes
of Health [T32AT000051]; American Headache Society; National Institute
of Child Health and Human Development Investigator Award
[5R24HD065688-02]; Spaulding-Harvard Spinal Cord Injury Model System, US
Department of Education, National Institute on Disability and
Rehabilitation Research, Traumatic Brain Injury Model Systems grant
[H133N110010]; Department of Defense Insight; Harvard Clinical
Consortium PTSD/TBI study site (INTRuST), Department of Defense, US Army
Medical Research and Materiel Command grant [W81XWH-08-2-0159];
Mid-Career Investigator Award from NCCAM, National Institutes of Health
[K24AT000589]
FX Drs Purohit and Wells were supported by an institutional National
Research Service Award Number T32AT000051 from the National Center for
Complementary and Alternative Medicine (NCCAM), National Institutes of
Health. Dr Wells was supported by a headache fellowship from the
American Headache Society. Dr Zafonte was supported by National
Institute of Child Health and Human Development Investigator Award
5R24HD065688-02; Spaulding-Harvard Spinal Cord Injury Model System, US
Department of Education, National Institute on Disability and
Rehabilitation Research, Traumatic Brain Injury Model Systems grant
H133N110010; Department of Defense Insight; and Harvard Clinical
Consortium PTSD/TBI study site (INTRuST), Department of Defense, US Army
Medical Research and Materiel Command grant W81XWH-08-2-0159. Drs
Phillips and Davis were supported by Mid-Career Investigator Award
K24AT000589 from NCCAM, National Institutes of Health.
NR 26
TC 8
Z9 8
U1 2
U2 24
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2013
VL 74
IS 6
BP E520
EP +
DI 10.4088/JCP.12m08246
PG 11
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AA5DE
UT WOS:000331115200001
PM 23842021
ER
PT J
AU Storch, EA
Goddard, AW
Grant, JE
Nadai, AS
Goodman, WK
Mutch, PJ
Medlock, C
Odlaug, B
McDougle, CJ
Murphy, TK
AF Storch, Eric A.
Goddard, Andrew W.
Grant, Jon E.
De Nadai, Alessandro S.
Goodman, Wayne K.
Mutch, P. Jane
Medlock, Carla
Odlaug, Brian
McDougle, Christopher J.
Murphy, Tanya K.
TI Double-Blind, Placebo-Controlled, Pilot Trial of Paliperidone
Augmentation in Serotonin Reuptake Inhibitor-Resistant
Obsessive-Compulsive Disorder
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID RISPERIDONE AUGMENTATION; SCALE
AB Objective: This pilot study explored the efficacy and tolerability of paliperidone augmentation of serotonin reuptake inhibitors (SRIs) in adults with treatment-resistant obsessive-compulsive disorder (OCD).
Method: Thirty-four patients aged 24-67 years (mean = 43.7 years, SD = 11.4) who met DSM IV criteria for OCD and remained symptomatic following 2 or more past adequate SRI trials (including their current medication) were enrolled from May 2008 to March 2012. Participants were treated for 8 weeks in a double-blind study with either paliperidone (up to 9 mg/d) or matching placebo in addition to their SRI. Blinded raters conducted outcome assessments. The primary outcome, obsessive-compulsive symptom severity, was assessed using the Yale-Brown Obsessive Compulsive Scale (YBOCS). Secondary outcomes included the Clinical Global Impressions-Severity of Illness and -Improvement scales.
Results: Paliperidone administration resulted in significant baseline-to-posttreatment reductions in obsessive-compulsive symptoms as measured by the YBOCS (P<.01, d = 0.66), although placebo administration also resulted in medium-sized, trend-level significant YBOCS changes (P = .05, d = 0.53). In exploratory analyses examining between-group differences, tests for paliperidone superiority relative to placebo were not significant (P = .14, d = 0.34); however, a numerical trend toward significant between-group differences was found, with a reduction of 7.98 points on the YBOCS for the paliperidone group compared to a reduction of 4.02 points for the placebo group. Paliperidone was generally well tolerated and not associated with significant weight gain (mean [SD] weight: paliperidone, pretreatment 84.70 [27.08] kg, posttreatment 84.84 [18.99] kg; vs placebo, pretreatment 77.50 [25.33] kg, posttreatment 77.43 [19.90] kg; P = .21).
Conclusions: These results suggest that paliperidone augmentation is well tolerated and has potential efficacy in the short-term treatment of some patients with SRI-resistant OCD. Well-powered, randomized, controlled studies are necessary to more definitively address the efficacy of this treatment strategy.
C1 [Storch, Eric A.; De Nadai, Alessandro S.; Mutch, P. Jane; Murphy, Tanya K.] Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA.
[Goddard, Andrew W.; Medlock, Carla] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA.
[Grant, Jon E.; Odlaug, Brian] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA.
[Goodman, Wayne K.] Mt Sinai Hosp, Dept Psychiat, New York, NY 10029 USA.
[Odlaug, Brian] Univ Copenhagen, Dept Publ Hlth, Fac Hlth & Med Sci, Copenhagen, Denmark.
[McDougle, Christopher J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[McDougle, Christopher J.] Massachusetts Gen Hosp, Lurie Ctr Autism, Boston, MA 02114 USA.
RP Storch, EA (reprint author), Univ S Florida, Dept Pediat, Rothman Ctr Neuropsychiat, Box 7523,880 6th St South, St Petersburg, FL 33701 USA.
EM estorch@health.usf.edu
RI Murphy, Tanya/J-7079-2013;
OI Odlaug, Brian/0000-0001-5407-0686
FU Janssen Scientific Affairs, LLC
FX This work was supported by Janssen Scientific Affairs, LLC, who provided
funding and study medication.
NR 28
TC 8
Z9 9
U1 0
U2 2
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2013
VL 74
IS 6
BP E527
EP E532
DI 10.4088/JCP.12m08278
PG 6
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AA5DE
UT WOS:000331115200002
PM 23842022
ER
PT J
AU Siedner, MJ
Lankowski, A
Tsai, AC
Muzoora, C
Martin, JN
Hunt, PW
Haberer, JE
Bangsberg, DR
AF Siedner, Mark J.
Lankowski, Alexander
Tsai, Alexander C.
Muzoora, Conrad
Martin, Jeffrey N.
Hunt, Peter W.
Haberer, Jessica E.
Bangsberg, David R.
TI GPS-measured distance to clinic, but not self-reported transportation
factors, are associated with missed HIV clinic visits in rural Uganda
SO AIDS
LA English
DT Article
DE distance to clinic; global positioning systems; HIV/AIDS; linkage to
care; sub-Saharan Africa; transportation; Uganda
ID RECEIVING ANTIRETROVIRAL THERAPY; FOLLOW-UP; INFECTED PATIENTS; WESTERN
KENYA; RISK-FACTORS; ADHERENCE; MORTALITY; PROGRAM; AFRICA; ADULTS
AB Objective: Studies of the association between transportation barriers and HIV-related health outcomes have shown both positive and negative effects, possibly because a reliable, validated measure of transportation barriers has not been identified.
Design: Prospective cohort study of HIV-infected patients in rural Uganda.
Methods: Participants were enrolled from the HIV clinic at the regional referral hospital in Mbarara, Uganda as part of the Uganda AIDS Rural Treatment Outcomes (UARTO) Study. We collected the following measures of transportation barriers to HIV clinic: global positioning systems (GPS)-tracked distance measured by driving participants to their homes along their typical route; straight-line GPS distance from clinic to home, calculated with the Great Circle Formula; self-reported travel time; and self-reported travel cost. We assessed inter-measure agreement using linear regression, correlation coefficients and kappa statistics (by measure quartile) and validated measures by fitting linear regression models to estimate associations with days late for clinic visits.
Results: One hundred and eighty-eight participants were tracked with GPS. Seventy-six percent were women, with a median age of 40 years and median CD4 cell count of 193 cells/ml. We found a high correlation between GPS-based distance measures (beta = 0.74, P < 0.001, R-2 = 0.92, kappa = 0.73), but little correlation between GPS-based and self-reported measures (all R-2 <= 0.4). GPS-based measures were associated with days late to clinic (P < 0.001); but neither self-reported measure was associated (P > 0.85).
Conclusion: GPS-measured distance to clinic is associated with HIV clinic absenteeism and should be prioritized over self-reported measures to optimally risk-stratify patients accessing care in rural, resource-limited settings. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Siedner, Mark J.; Lankowski, Alexander; Tsai, Alexander C.; Haberer, Jessica E.; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Dept Psychiat, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA.
[Muzoora, Conrad; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Martin, Jeffrey N.; Hunt, Peter W.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Ragon Inst, Massachusetts Gen Hosp MIT & Harvard, Boston, MA 02114 USA.
[Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA.
RP Siedner, MJ (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,GRJ 5, Boston, MA 02114 USA.
EM msiedner@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU U.S. National Institutes of Health [R01 MH54907, P30 AI27763]; NIH [K23
MH087228, K23 MH096620, K24 MH87227, T32 AI007433]; Harvard Institute
for Global Health; Fogarty International Clinical Research Scholars and
Fellows Program at Vanderbilt University [R24TW007988]; Doris Duke
Charitable Foundation through Harvard Medical School; Mark and Lisa
Schwartz Family Foundation; Sullivan Family Foundation; Bacca Foundation
FX the Uganda AIDS Rural Treatment Outcomes Study is funded by U.S.
National Institutes of Health R01 MH54907 and P30 AI27763. The authors
also acknowledge the following additional sources of salary support: NIH
K23 MH087228 (Haberer); NIH K23 MH096620 (Tsai); NIH K24 MH87227
(Bangsberg); the Harvard Institute for Global Health, the Fogarty
International Clinical Research Scholars and Fellows Program at
Vanderbilt University (R24TW007988), and NIH T32 AI007433 (M.J.S.); and
the Doris Duke Charitable Foundation through Harvard Medical School (A.
L.). Additional study funding was provided by the Mark and Lisa Schwartz
Family Foundation, the Sullivan Family Foundation, and the Bacca
Foundation.
NR 35
TC 29
Z9 29
U1 3
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2013
VL 27
IS 9
BP 1503
EP 1508
DI 10.1097/QAD.0b013e32835fd873
PG 6
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 301FV
UT WOS:000330519100016
PM 23435294
ER
PT J
AU Parrinello, CM
Landay, AL
Hodis, HN
Gange, SJ
Norris, PJ
Young, M
Anastos, K
Tien, PC
Xue, XN
Lazar, J
Benning, L
Tracy, RP
Kaplan, RC
AF Parrinello, Christina M.
Landay, Alan L.
Hodis, Howard N.
Gange, Stephen J.
Norris, Philip J.
Young, Mary
Anastos, Kathryn
Tien, Phyllis C.
Xue, Xiaonan
Lazar, Jason
Benning, Lorie
Tracy, Russell P.
Kaplan, Robert C.
TI Treatment-related changes in serum lipids and inflammation: clinical
relevance remains unclear. Analyses from the Women's Interagency HIV
study
SO AIDS
LA English
DT Article
ID INFECTED WOMEN; DISEASE RISK; ATHEROSCLEROSIS
AB Among 127 HIV-infected women, the magnitude of high-density lipoprotein cholesterol (HDLc) increases after HAART initiation predicted the magnitude of concurrent decreases in inflammation biomarkers. After HAART initiation, changes in low-density lipoprotein cholesterol (LDLc) and inflammation were unrelated. In the same population, predicted risk of coronary heart disease, based upon levels of standard clinical risk factors, was similar before and after HAART. Thus, it remains unknown whether short-term treatment-related changes in standard risk factors may appreciably change risk of cardiovascular disease (CVD).
C1 [Parrinello, Christina M.; Anastos, Kathryn; Xue, Xiaonan; Kaplan, Robert C.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Landay, Alan L.] Rush Univ, Dept Immunol Microbiol, Med Ctr, Chicago, IL 60612 USA.
[Hodis, Howard N.] Univ So Calif, Atherosclerosis Res Unit, Los Angeles, CA USA.
[Gange, Stephen J.; Benning, Lorie] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Lab Med, Blood Syst Res Inst, San Francisco, CA 94143 USA.
[Norris, Philip J.] Univ Calif San Francisco, Dept Med, Blood Syst Res Inst, San Francisco, CA USA.
[Young, Mary] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA.
[Anastos, Kathryn] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Lazar, Jason] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.
[Tracy, Russell P.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
RP Kaplan, RC (reprint author), 1300 Morris Pk Ave,Belfer 1306C, Bronx, NY 10461 USA.
EM robert.kaplan@einstein.yu.edu
OI Gange, Stephen/0000-0001-7842-512X
FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004,
UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI42590];
Eunice Kennedy Shriver National Institute of Child Health and Human
Development [UO1-HD-32632]; National Cancer Institute, the National
Institute on Drug Abuse; National Institute on Deafness and Other
Communication Disorders; National Center for Research Resources
(UCSF-CTSI) [UL1 RR024131]; National Heart, Lung and Blood Institute
[1R01HL095140, 1R01HL083760]; University of Washington's CVD and
Metabolic Complications of HIV/AIDS Data Coordinating Center
[5R01HL095126]
FX Data in this manuscript were collected by the WIHS Collaborative Study
Group with centres (Principal Investigators) at New York City/Bronx
Consortium (Kathryn Anastos); Brooklyn, New York (Howard Minkoff);
Washington, District of Columbia Metropolitan Consortium (Mary Young);
The Connie Wofsy Study Consortium of Northern California (Ruth
Greenblatt); Los Angeles County/Southern California Consortium
(Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating
Center (Stephen Gange). The WIHS is funded by the National Institute of
Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834,
UO1-AI-34994, UO1-AI-34989, UO1-AI-34993 and UO1-AI42590) and by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (UO1-HD-32632). The study is cofunded by the National Cancer
Institute, the National Institute on Drug Abuse, and the National
Institute on Deafness and Other Communication Disorders. Funding is also
provided by the National Center for Research Resources (UCSF-CTSI Grant
Number UL1 RR024131). Additional cofunding is provided by the National
Heart, Lung and Blood Institute (1R01HL095140, 1R01HL083760 to R. C.
K.). Partial funding for laboratory and work as well as assistance with
general study coordination was provided by the University of
Washington's CVD and Metabolic Complications of HIV/AIDS Data
Coordinating Center (5R01HL095126).
NR 6
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2013
VL 27
IS 9
BP 1516
EP 1519
DI 10.1097/QAD.0b013e32835fd8a9
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 301FV
UT WOS:000330519100019
PM 23435295
ER
PT J
AU Watkins, JD
Sholukh, AM
Mukhtar, MM
Siddappa, NB
Lakhashe, SK
Kim, M
Reinherz, EL
Gupta, S
Forthal, DN
Sattentau, QJ
Villinger, F
Corti, D
Ruprecht, RM
AF Watkins, Jennifer D.
Sholukh, Anton M.
Mukhtar, Muhammad M.
Siddappa, Nagadenahalli B.
Lakhashe, Samir K.
Kim, Mikyung
Reinherz, Ellis L.
Gupta, Sandeep
Forthal, Donald N.
Sattentau, Quentin J.
Villinger, Francois
Corti, Davide
Ruprecht, Ruth M.
CA CAVD Project Grp
TI Anti-HIV IgA isotypes: differential virion capture and inhibition of
transcytosis are linked to prevention of mucosal R5 SHIV transmission
SO AIDS
LA English
DT Article
DE HIV neutralization; immunoglobulin A isotypes; mucosal transmission; R5
SHIV; transcytosis; virion capture
ID NEUTRALIZING MONOCLONAL-ANTIBODIES; VIRUS; IMMUNIZATION; INDIVIDUALS;
PROTECTION; LOAD; AIDS
AB Objective: Although passive immunization with anti-HIV-1 Env IgG1 neutralizing monoclonal antibodies (nmAbs) prevented simian-human immunodeficiency virus (SHIV) infection in rhesus monkeys, IgA nmAbs have not been tested. Here, we sought to determine whether human anti-HIV-1 dimeric (d) IgA1, dIgA2, and IgG1 differ in their ability to prevent mucosal R5 SHIV acquisition in rhesus monkeys.
Design: DIgA1, dIgA2, and IgG1 versions of nmAb HGN194 were applied intrarectally in three rhesus monkey groups 30 min before intrarectal SHIV challenge.
Methods: After a control pharmacokinetic study confirmed that nmAb concentrations in rectal fluids over time were similar for all HGN194 isotypes, control and nmAb-treated animals were challenged intrarectally with an R5 SHIV, and viral loads were monitored.
Results: Unexpectedly, dIgA1 provided the best protection in vivo - although all nmAbs showed similar neutralizing activity in vitro. Five out of the six dIgA1-treated rhesus monkeys remained virus-free compared to only one out of six animals given dIgA2 (P = 0.045 by log-rank test) and two out of six rhesus monkeys treated with IgG1 forms of the nmAb (P = 0.12). Protection correlated significantly with virion capture activity by a given nmAb form, as well as inhibition of transcytosis of cell-free virus across an epithelial cell layer in vitro.
Conclusions: Our data imply that dIgA1-mediated capturing of virions in mucosal secretions and inhibition of transcytosis can provide significant prevention of lentiviral acquisition - over and above direct virus neutralization. Vaccine strategies that induce mucosal IgA, especially IgA1, should be developed as a first line of defense against HIV-1, a virus predominantly transmitted mucosally. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
C1 [Watkins, Jennifer D.; Sholukh, Anton M.; Mukhtar, Muhammad M.; Siddappa, Nagadenahalli B.; Lakhashe, Samir K.; Kim, Mikyung; Reinherz, Ellis L.; Ruprecht, Ruth M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Watkins, Jennifer D.; Sholukh, Anton M.; Mukhtar, Muhammad M.; Siddappa, Nagadenahalli B.; Lakhashe, Samir K.; Kim, Mikyung; Reinherz, Ellis L.; Ruprecht, Ruth M.] Harvard Univ, Sch Med, Boston, MA USA.
[Gupta, Sandeep; Forthal, Donald N.] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine Sch Med, Irvine, CA 92717 USA.
[Sattentau, Quentin J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
[Villinger, Francois] Emory Univ, Div Pathol, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
[Villinger, Francois] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
[Corti, Davide] Humabs SAGL, Bellinzona, Switzerland.
RP Ruprecht, RM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,JFB 809, Boston, MA 02215 USA.
EM ruth_ruprecht@dfci.harvard.edu
RI Lakhashe, Samir/F-1150-2014;
OI Heeney, Jonathan/0000-0003-2702-1621; Byrareddy, Siddappa
/0000-0002-7423-1763
FU Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine
Discovery (CAVD) [UCL-VDC 38637, CAVD 50314]; NIH [R37 AI34266, R01
DE023049, P01 AI48240]; ORIP [P51 000165]; [R24OD010947]
FX This work was supported by the Bill and Melinda Gates Foundation
Collaboration for AIDS Vaccine Discovery (CAVD) UCL-VDC grant 38637 (R.
A. W.) and CAVD 50314 (E. L. R.), by NIH grants R37 AI34266 and R01
DE023049 (R. M. R.), P01 AI48240 (R. M. R. and S.-L. H.) and by ORIP P51
000165 awarded to the YNPRC and R24OD010947 (F. V.).
NR 22
TC 44
Z9 45
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD JUN 1
PY 2013
VL 27
IS 9
BP F13
EP F20
DI 10.1097/QAD.0b013e328360eac6
PG 8
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 301FV
UT WOS:000330519100001
PM 23775002
ER
PT J
AU Weintraub, D
AF Weintraub, Daniel
TI Neuropsychiatric Symptoms in Parkinson Disease and Dementia with Lewy
Bodies: What Geriatric Psychiatry Can Learn
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
ID DISORDER
C1 [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Weintraub, D (reprint author), 3615 Chestnut St,330, Philadelphia, PA 19104 USA.
EM Daniel.Weintraub@uphs.upenn.edu
FU NINDS NIH HHS [P50 NS053488]
NR 8
TC 6
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2013
VL 21
IS 6
BP 497
EP 500
DI 10.1016/j.jagp.2013.02.020
PG 4
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298XV
UT WOS:000330358900001
PM 23668226
ER
PT J
AU Drye, LT
Scherer, RW
Lanctot, KL
Rosenberg, PB
Herrmann, N
Bachman, D
Mintzer, JE
AF Drye, Lea T.
Scherer, Roberta W.
Lanctot, Krista L.
Rosenberg, Paul B.
Herrmann, Nathan
Bachman, David
Mintzer, Jacobo E.
CA ADMET Res Grp
TI Designing a Trial to Evaluate Potential Treatments for Apathy in
Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET)
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Alzheimer dementia; apathy; methylphenidate; randomized trial
ID SEVERE ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC SYMPTOMS; CACHE COUNTY;
DOUBLE-BLIND; PSYCHOLOGICAL SYMPTOMS; BEHAVIORAL SYMPTOMS;
DIAGNOSTIC-CRITERIA; CLINICAL-PRACTICE; DEPRESSION; PREVALENCE
AB Background: Research on efficacious treatments for apathy in Alzheimer disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes. Methods: In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. Conclusion: The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer disease.
C1 [Drye, Lea T.; Scherer, Roberta W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Lanctot, Krista L.; Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
[Lanctot, Krista L.; Herrmann, Nathan] Univ Toronto, Toronto, ON M5S 1A1, Canada.
[Rosenberg, Paul B.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Rosenberg, Paul B.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA.
[Bachman, David; Mintzer, Jacobo E.] Med Univ S Carolina, Charleston, SC USA.
[Bachman, David; Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Drye, LT (reprint author), 615 North Wolfe St,W5010, Baltimore, MD 21205 USA.
EM ldrye@jhsph.edu
OI Drye, Lea/0000-0002-2964-1878; Lanctot, Krista L./0000-0001-7024-6637
FU National Institute on Aging; National Institute of Mental Health [R01
AG033032-01]
FX This study was supported by the National Institute on Aging and National
Institute of Mental Health, R01 AG033032-01.
NR 70
TC 6
Z9 6
U1 2
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD JUN
PY 2013
VL 21
IS 6
BP 549
EP 559
DI 10.1016/j.jagp.2012.12.018
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA 298XV
UT WOS:000330358900007
PM 23567407
ER
PT J
AU Lawlor, RT
Sluss, PM
Langer, R
Sughayer, MA
Igbe, MA
Siddiqui, K
De Blasio, P
Duma, B
Mendy, M
Chabannon, C
Ibrahim, M
AF Lawlor, Rita T.
Sluss, Patrick M.
Langer, Rupert
Sughayer, Maher A.
Igbe, Michael A.
Siddiqui, Khalid
De Blasio, Pasquale
Duma, Bonginkosi
Mendy, Maimuna
Chabannon, Christian
Ibrahim, Muntaser
TI European, Middle Eastern, and African Society for Biopreservation and
Biobanking (ESBB). 2012 Conference Session on Biobanking in Emerging
Countries
SO BIOPRESERVATION AND BIOBANKING
LA English
DT Article
C1 [Lawlor, Rita T.] Univ Verona, ARC Net Appl Res Canc Ctr, I-37100 Verona, Italy.
[Sluss, Patrick M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA.
[Langer, Rupert] Univ Bern, Inst Pathol, Bern, Switzerland.
[Sughayer, Maher A.] King Hussein Canc Ctr, Dept Pathol, Amman, Jordan.
[Igbe, Michael A.] Fed Minist Hlth, Dept Publ Hlth, Neglected Trop Dis NTDs Div, Natl Onchocerciasis Control Lymphat Filariasis El, Abuja, Nigeria.
[Siddiqui, Khalid] King Saud Univ, Strateg Ctr Diabet Res, Riyadh, Saudi Arabia.
[De Blasio, Pasquale] Integrated Syst Engn Srl, R&D Milano, Milan, Italy.
[Duma, Bonginkosi] Natl Hlth Lab Serv, Johannesburg, South Africa.
[Mendy, Maimuna] Int Agcy Res Canc, Lab Serv & Biobank Grp, F-69372 Lyon, France.
[Chabannon, Christian] Inst J Paoli I Calmettes, Dept Canc Biol, Ctr Ressources Biol, Marseille, France.
[Chabannon, Christian] Inserm Marseille, Marseille, France.
[Ibrahim, Muntaser] Univ Khartoum, Inst Endem Dis, Dept Mol Biol, Khartoum, Sudan.
RP Lawlor, RT (reprint author), Univ Verona, Dept Pathol & Diagnost, Policlin GB Rossi, ARC NET Res Ctr, 2 Floor,Piazzale LA Scuro 10, I-37100 Verona, Italy.
EM rita.lawlor@arc-net.it
RI Siddiqui, Khalid/B-4424-2010;
OI Siddiqui, Khalid/0000-0003-4860-1262; Sughayer,
Maher/0000-0002-9185-9616; lawlor, Rita/0000-0003-3160-0634
FU EC [FP7-INCO-2011-6, 295010]
FX Dr. M. Sughayer's work has been partially supported by the EC within the
7th framework program FP7-INCO-2011-6 under grant agreement no. 295010
(KHCCBIO).
NR 11
TC 3
Z9 3
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1947-5535
EI 1947-5543
J9 BIOPRESERV BIOBANK
JI Biopreserv. Biobank.
PD JUN
PY 2013
VL 11
IS 3
BP 176
EP 181
DI 10.1089/bio.2013.0017
PG 6
WC Cell Biology; Chemistry, Applied; Medical Laboratory Technology
SC Cell Biology; Chemistry; Medical Laboratory Technology
GA 300GT
UT WOS:000330453100010
PM 24850095
ER
PT J
AU Khodyakov, D
Stockdale, S
Jones, A
Mango, J
Jones, F
Lizaola, E
AF Khodyakov, Dmitry
Stockdale, Susan
Jones, Andrea
Mango, Joseph
Jones, Felica
Lizaola, Elizabeth
TI On Measuring Community Participation in Research
SO HEALTH EDUCATION & BEHAVIOR
LA English
DT Article
DE community-academic partnerships; community-based participatory research;
community participation in research; evaluation; mixed methods
ID HEALTH
AB Active participation of community partners in research aspects of community-academic partnered projects is often assumed to have a positive impact on the outcomes of such projects. The value of community engagement in research, however, cannot be empirically determined without good measures of the level of community participation in research activities. Based on our recent evaluation of community-academic partnered projects centered around behavioral health issues, this article uses semistructured interview and survey data to outline two complementary approaches to measuring the level of community participation in research-a "three-model" approach that differentiates between the levels of community participation and a Community Engagement in Research Index (CERI) that offers a multidimensional view of community engagement in the research process. The primary goal of this article is to present and compare these approaches, discuss their strengths and limitations, summarize the lessons learned, and offer directions for future research. We find that whereas the three-model approach is a simple measure of the perception of community participation in research activities, CERI allows for a more nuanced understanding by capturing multiple aspects of such participation. Although additional research is needed to validate these measures, our study makes a significant contribution by illustrating the complexity of measuring community participation in research and the lack of reliability in simple scores offered by the three-model approach.
C1 [Khodyakov, Dmitry] RAND Corp, Santa Monica, CA 90401 USA.
[Stockdale, Susan] VA Greater Los Angeles Healthcare Syst, HSR&D Ctr Study Healthcare Provider Behav, Sepulveda, CA USA.
[Stockdale, Susan; Mango, Joseph; Lizaola, Elizabeth] Univ Calif Los Angeles, Ctr Hlth Serv & Soc, Semel Inst, Los Angeles, CA USA.
[Jones, Andrea; Jones, Felica] Hlth African Amer Families, Los Angeles, CA USA.
[Jones, Andrea] Charles R Drew Univ Med & Sci, Los Angeles, CA 90059 USA.
RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St,POB 2138, Santa Monica, CA 90401 USA.
EM dmitry_khodyakov@rand.org
FU NIMH NIH HHS [P30MH082760, P30 MH082760, P30MH068639]
NR 13
TC 12
Z9 12
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1090-1981
EI 1552-6127
J9 HEALTH EDUC BEHAV
JI Health Educ. Behav.
PD JUN
PY 2013
VL 40
IS 3
BP 346
EP 354
DI 10.1177/1090198112459050
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 298AC
UT WOS:000330295200011
PM 23041704
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Hypoxic Pulmonary Vasoconstriction
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article
ID RED-BLOOD-CELLS; STRESS DOPPLER-ECHOCARDIOGRAPHY; MICE PARTIALLY
DEFICIENT; HIGH-ALTITUDE EXPOSURE; HEALTHY-HUMAN LUNG;
VASCULAR-RESPONSE; ARTERY PRESSURE; GAS-EXCHANGE; NITRIC-OXIDE;
TIME-COURSE
AB Hypoxic pulmonary vasoconstriction (HPV) continues to fascinate cardiopulmonary physiologists and clinicians since its definitive description in 1946. Hypoxic vasoconstriction exists in all vertebrate gas exchanging organs. This fundamental response of the pulmonary vasculature in air breathing animals has relevance to successful fetal transition to air breathing at birth and as a mechanism of ventilation-perfusion matching in health and disease. It is a complex process intrinsic to the vascular smooth muscle, but with in vivo modulation by a host of factors including the vascular endothelium, erythrocytes, pulmonary innervation, circulating hormones and acid-base status to name only a few. This review will provide a broad overview of HPV and its mechansms and discuss the advantages and disadvantages of HPV in normal physiology, disease and high altitude.
C1 [Swenson, Erik R.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Swenson, Erik R.] Univ Washington, Dept Physiol & Biophys, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
NR 136
TC 29
Z9 31
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
EI 1557-8682
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
PD JUN
PY 2013
VL 14
IS 2
BP 101
EP 110
DI 10.1089/ham.2013.1010
PG 10
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA 302BL
UT WOS:000330576200003
PM 23795729
ER
PT J
AU Counter, SA
Buchanan, LH
Ortega, F
AF Counter, S. Allen
Buchanan, Leo H.
Ortega, Fernando
TI Brainstem Auditory Evoked Responses in Children Living at High Altitude
in the Andes Mountains
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article
DE altitude; auditory evoked responses; brainstem; hearing; hypoxia
ID HYPOBARIC HYPOXIA; DEPRESSION; LATENCY; ABR
AB Objectives: This neurophysiological study compared brainstem auditory evoked responses (BAER) in children living at high elevations (2800 to 3000 meters) in the Andes Mountains of Ecuador with a reference group of children living at sea level in the U.S. Methods: BAER absolute latencies of waves I through V; interpeak latencies I-III, III-V, and I-V; amplitudes of waves I and V; and the V/I amplitude ratio were measured by scalp electrodes at acoustic click stimulus rates of 10 and 50 pulses per second (pps). Results: Statistical analysis showed that the high-altitude group had significantly longer absolute and interpeak BAER latencies than the sea-level reference group at both the 10 and 50 pps stimulus rates for most wave peaks. The amplitudes of waves I and V were significantly reduced for the high-altitude group at 10 and 50 pps, suggesting blood O-2 saturation effects. Conclusions: The BAER of children in the high-altitude group suggested physiological anomalies in auditory neural conduction and summation compared with the sea-level group. The results further suggest that small physiological effects of altitude on BAER, especially at elevations near 3000 meters and higher, should be taken into consideration in the evaluation of brainstem auditory function.
C1 [Counter, S. Allen] Harvard Univ, Sch Med, Biol Labs, Dept Neurol, Cambridge, MA 02138 USA.
[Counter, S. Allen] Massachusetts Gen Hosp, Dept Neurol Neurophysiol, Boston, MA 02114 USA.
[Buchanan, Leo H.] Univ Massachusetts, Sch Med, Dept Pediat, Eunice Kenn